

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

01 September 2022 (01.09.2022)



(10) International Publication Number

WO 2022/182574 A1

(51) International Patent Classification:

CI2N 15/113 (2010.01) A61P 3/08 (2006.01)
A61K 31/713 (2006.01) A61P 13/12 (2006.01)
A61P 3/06 (2006.01)

(21) International Application Number:

PCT/US2022/016890

(22) International Filing Date:

18 February 2022 (18.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/154,005 26 February 2021 (26.02.2021) US
63/223,581 20 July 2021 (20.07.2021) US
63/280,668 18 November 2021 (18.11.2021) US

(71) Applicant: ALNYLAM PHARMACEUTICALS, INC.

[US/US]; 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (US).

(72) Inventors; and

(71) Applicants: NOETZLI, Leila [US/US]; 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (US). MCININCH, James, D. [US/US]; 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (US). TREMBLAY, Frederic [CA/US]; 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (US). SCHLEGEL, Mark, K. [US/US]; 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (US). CASTORENO, Adam [US/US]; 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (US).

(74) Agent: ZACHARAKIS, Maria, Laccotripe et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

(57) Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the ketohexokinase (KHK) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a KHK gene and to methods of treating or preventing a KHK-associated disorder in a subject.

WO 2022/182574 A1

KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF**RELATED APPLICATIONS**

This application claims the benefit of priority to U.S. Provisional Application No.

- 5 63/154,005, filed on February 26, 2021, U.S. Provisional Application No. 63/223,581, filed on July 20, 2021, and U.S. Provisional Application No. 63/280,668, filed on November 18, 2021. The entire contents of each of the foregoing applications are incorporated herein by reference.

SEQUENCE LISTING

- 10 The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on February 16, 2022, is named 121301_14720_SL.txt and is 572,214 bytes in size.

BACKGROUND OF THE INVENTION

- 15 Epidemiological studies have shown that a western diet is one of the leading causes of the modern obesity pandemic. Increase in fructose uptake, associated with the use of enriched soft drinks and processed food, is proposed to be a major contributing factor to the epidemic. High fructose corn sweeteners started gaining widespread use in the food industry by 1967. Although glucose and fructose have the same caloric value per molecule, the two sugars are metabolized differently and utilize different
- 20 GLUT transporters. Fructose is almost exclusively metabolized in the liver, and unlike the glucose metabolism pathway, the fructose metabolism pathway is not regulated by feedback inhibition by the product (Khaitan Z *et al.*, (2013) *J. Nutr. Metab.* 2013, Article ID 682673, 1-12). While hexokinase and phosphofructokinase (PFK) regulate the production of glyceraldehyde-3-P from glucose, fructokinase or ketohexokinase (KHK), which is responsible for phosphorylation of fructose to fructose-1-phosphate in
- 25 the liver, it is not down regulated by increasing concentrations of fructose-1-phosphate. As a result, all fructose entering the cell is rapidly phosphorylated. (Cirillo P. *et al.*, (2009) *J. Am. Soc. Nephrol.* 20: 545-553). Continued utilization of ATP to phosphorylate the fructose to fructose-1-phosphate results in intracellular phosphate depletion, ATP depletion, activation of AMP deaminase and formation of uric acid (Khaitan Z. *et al.*, (2013) *J. Nutr. Metab.* Article ID 682673, 1-12). Increased uric acid further stimulates
- 30 the up-regulation of KHK (Lanaspa M.A. *et al.*, (2012) *PLOS ONE* 7(10): 1-11) and causes endothelial cell and adipocyte dysfunction. Fructose-1-phosphate is subsequently converted to glyceraldehyde by the action of aldolase B and is phosphorylated to glyceraldehyde-3-phosphate. The latter proceeds downstream to the glycolysis pathway to form pyruvate, which enters the citric acid cycle, wherefrom, under well-fed conditions, citrate is exported to the cytosol from the mitochondria, providing Acetyl
- 35 Coenzyme A for lipogenesis (Figure 1).

The phosphorylation of fructose by KHK, and subsequent activation of lipogenesis leads to, for example, fatty liver, hypertriglyceridemia, dyslipidemia, and insulin resistance. Proinflammatory changes in renal proximal tubular cells have also been shown to be induced by

KHK activity (Cirillo P. *et al.*, (2009) *J. Am. Soc. Nephrol.* 20: 545-553). The phosphorylation of fructose by KHK is associated with diseases, disorders or conditions such as liver disease (*e.g.*, fatty liver, steatohepatitis), dyslipidemia (*e.g.*, hyperlipidemia, high LDL cholesterol, low HDL cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (*e.g.*, insulin resistance, type 2 diabetes), cardiovascular disease (*e.g.*, hypertension, endothelial cell dysfunction), kidney disease (*e.g.*, acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, chronic kidney disease), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving. Accordingly, there is a need in the art for compositions and methods for treating diseases, disorders, and conditions associated with KHK activity.

SUMMARY OF THE INVENTION

The present invention provides iRNA compositions which affect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of a gene encoding ketohexokinase (KHK).

The KHK gene may be within a cell, *e.g.*, a cell within a subject, such as a human subject.

In an aspect, the invention provides a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of ketohexokinase (KHK) in a cell, wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, or 21, contiguous nucleotides differing by no more than 0, 1, 2, or 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 and the antisense strand comprises at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, 21, 22 or 23, contiguous nucleotides differing by no more than 1, 2, or 3 nucleotides from the nucleotide sequence of SEQ ID NO:2. In one embodiment, the dsRNA agent comprises at least one thermally destabilizing nucleotide modification, *e.g.*, an abasic modification; a mismatch with the opposing nucleotide in the duplex; and destabilizing sugar modification, a 2'-deoxy modification, an acyclic nucleotide, an unlocked nucleic acids (UNA), or a glycerol nucleic acid (GNA), *e.g.*, the antisense strand comprises at least one thermally destabilizing nucleotide modification.

In another aspect, the present invention provides a double stranded ribonucleic acid (dsRNA) for inhibiting expression of ketohexokinase (KHK) in a cell, wherein said dsRNA comprises a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises a region of complementarity to an mRNA encoding KHK, and wherein the region of complementarity comprises at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, 21, 22 or 23, contiguous nucleotides differing by no more than 0, 1, 2, or 3 nucleotides from any one of the antisense nucleotide sequences in any one of Tables 2, 3, 5, 6, and 8-13.

In one embodiment, the dsRNA agent comprises a sense strand comprising a contiguous nucleotide sequence which has at least 85%, *e.g.*, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, nucleotide sequence identity over its entire length to any one of the nucleotide sequences of the sense strands in any one of Tables 2, 3, 5, 6 and 8-13 and an antisense strand

comprising a contiguous nucleotide sequence which has at least 85%, e.g., 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, nucleotide sequence identity over its entire length to any one of the nucleotide sequences of the antisense strands in any one of Tables 2, 3, 5, 6 and 8-13.

5 In one embodiment, the dsRNA agent comprises a sense strand comprising at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, or 21, contiguous nucleotides differing by no more than three nucleotides from any one of the nucleotide sequences of the sense strands in any one of Tables 2, 3, 5, 6 and 8-13 and an antisense strand comprising at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, 21, 22 or 23, contiguous nucleotides differing by no more than three nucleotides from any one of the nucleotide sequences of the antisense strands in any one of Tables 2, 3, 5, 6 and 8-13.

10 In one embodiment, the dsRNA agent comprises a sense strand comprising at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, or 21, contiguous nucleotides differing by no more than two nucleotides from any one of the nucleotide sequences of the sense strands in any one of Tables 2, 3, 5, 6 and 8-13 and an antisense strand comprising at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, 21, 22 or 23, contiguous nucleotides differing by no more than two nucleotides from any one of the nucleotide sequences of the antisense strands in any one of Tables 2, 3, 5, 6 and 8-13.

15 In one embodiment, the dsRNA agent comprises a sense strand comprising at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, or 21, contiguous nucleotides differing by no more than one nucleotide from any one of the nucleotide sequences of the sense strands in any one of Tables 2, 3, 5, 6 and 8-13 and an antisense strand comprising at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, 21, 22 or 23, contiguous nucleotides differing by no more than one nucleotide from any one of the nucleotide sequences of the antisense strands in any one of Tables 2, 3, 5, 6 and 8-13.

20 In one embodiment, the dsRNA agent comprises a sense strand comprising or consisting of a nucleotide sequence selected from the group consisting of any one of the nucleotide sequences of the sense strands in any one of Tables 2, 3, 5, 6 and 8-13 and an antisense strand comprising or consisting of a nucleotide sequence selected from the group consisting of any one of the nucleotide sequences of the antisense strands in any one of Tables 2, 3, 5, 6 and 8-13.

25 In one aspect, the present invention provides a double stranded ribonucleic acid (dsRNA) for inhibiting expression of ketohexokinase (KHK) in a cell, wherein said dsRNA comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, or 21, contiguous nucleotides differing by no more than 0, 1, 2, or 3 nucleotides from any one of the nucleotide sequence of nucleotides 120-162; 164-188; 181-207; 193-217; 209-231; 283-306; 508-546; 568-603; 596-632; 640-674; 746-806; 806-835; 917-942; 936-084; 1016-1041; 1100-1123; 1149-1175; 1160-1193; 1205-1229; 1252-1283; 1334-1356; 1407-1429; 1472-1497; 1506-1533; 1539-1561; 1704-1727; 1747-1787; 1850-1873; 1936-1964; 1960-1990; 2015-2048; 2060-2095; 2090-2118; 2124-2160; 2181-2200; 2221-2262 of SEQ ID NO: 1, and the antisense strand comprises at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, 21, 22 or 23, contiguous nucleotides

differing by no more than three, *e.g.*, 3, 2, 1, or 0, from the corresponding nucleotide sequence of SEQ ID NO:2.

In one aspect, the present invention provides a double stranded ribonucleic acid (dsRNA) for inhibiting expression of ketohexokinase (KHK) in a cell, wherein said dsRNA comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, or 21, contiguous nucleotides differing by no more than 0, 1, 2, or 3 nucleotides from any one of the nucleotide sequence of nucleotides 517-539; 521-543; 524-546; 517-546; 581-603; 610-632; 747-769; 749-771; 752-774; 755-777; 757-779; 758-780; 764-786; 776-798; 781-803; 747-803; 920-942; 941-963; 944-966; 950-972; 962-984; 920-984; 1149-1171; 1161-1183; 1165-1187; 1171-1193; 1149-1193; 1205-1227; 1206-1228; 1205-1228; 1334-1356; 1472-1494; 1475-1497; 1472-1497 of SEQ ID NO: 1, and the antisense strand comprises at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, 21, 22 or 23, contiguous nucleotides differing by no more than three, *e.g.*, 3, 2, 1, or 0, from the corresponding nucleotide sequence of SEQ ID NO:2.

In one aspect, the present invention provides a double stranded ribonucleic acid (dsRNA) for inhibiting expression of ketohexokinase (KHK) in a cell, wherein said dsRNA comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, or 21, contiguous nucleotides differing by no more than 0, 1, 2, or 3 nucleotides from any one of the nucleotide sequence of nucleotides 517-539; 524-546; 517-546; 753-775; 757-779; 753-779; 764-786; 767-789; 768-790; 769-791; 764-791; 773-795; 781-803; 773-803; 753-803; 808-830; 937-959; 941-963; 944-966; 941-966; 948-970; 950-972; 948-972; 1160-1182; 1161-1183; 1160-1183; and 1207-1229 of SEQ ID NO: 1, and the antisense strand comprises at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, 21, 22 or 23, contiguous nucleotides differing by no more than three, *e.g.*, 3, 2, 1, or 0, from the corresponding nucleotide sequence of SEQ ID NO:2.

In one embodiment, the antisense strand comprises at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, 21, 22 or 23, contiguous nucleotides differing by no more than 0, 1, 2, or 3 nucleotides from any one of the antisense strand nucleotide sequences of a duplex selected from the group consisting of AD-1613400; AD-1613243; AD-1290757.3; AD-1290878.3; AD-1290969.3; AD-1423317.2; AD-1423327.2; AD-1423336.2; AD-1290599.3; AD-1523172.1; AD-1290837.3; AD-1523173.1; AD-1290884.3; AD-1523174.1; AD-1290959.3; AD-1523175.1; AD-1423311.2; AD-1423324.2; AD-1523176.1; AD-1423329.2; AD-1423333.2; AD-1423330.2; AD-1523177.1; AD-1290885.3; AD-1523178.1; AD-1423334.2; AD-1523179.1; AD-1523180.1; AD-1290539.3; and AD-1523181.1.

In another aspect, the present invention provides a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of ketohexokinase (KHK) in a cell, wherein said dsRNA comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, or 21, contiguous nucleotides differing by no more than three, *e.g.*, 3, 2, 1, or 0, nucleotides from any one of the nucleotide sequence of nucleotides 495-517, 492-517, 500-529, 514-551, 517-539, 524-546, 517-548, 614-643, 625-647, 625-660, 642-664, 642-672, 753-811, 754-780, 762-791, 764-786, 772-800, 781-803, 805-827, 808-830, 809-831, 792-

838, 931-982, 944-966, 947-969, 948-970, 948-982, 1011-1035, 1021-1043, 1019-1050, 1063-1091, 1150-1192, 1152-1176, 1160-1192, 1160-1182, 1162-1184, 1198-1230, 1198-1221, and 1202-1230 of SEQ ID NO: 1, and the antisense strand comprises at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, 21, 22 or 23, contiguous nucleotides differing by no more than 3, *e.g.*, 3, 2, 1, or 0, nucleotides from the corresponding nucleotide sequence of SEQ ID NO:2.

In one aspect, the present invention provides a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of ketohexokinase (KHK) in a cell, wherein said dsRNA comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, or 21, contiguous nucleotides differing by no more than three, *e.g.*, 3, 2, 1, or 0, nucleotides from any one of the nucleotide sequence of nucleotides 513-556, 753-813, 936-981, 1155-1193, 1200-1229, 1704-1727, 1747-1787, 1850-1873, 1936-1964, 1960-1990, 1936-1990, 2015-2048, 2060-2095, 2090-2118, 2060-2118, 2124-2160, 2181-2220, 2221-2249, 2181-2249, 2240-2262, 2221-2262, and 2181-2262 of SEQ ID NO: 1, and the antisense strand comprises at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, 21, 22 or 23, contiguous nucleotides differing by no more than 3, *e.g.*, 3, 2, 1, or 0, nucleotides from the corresponding nucleotide sequence of SEQ ID NO:2.

In one aspect, the present invention provides a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of ketohexokinase (KHK) in a cell, wherein said dsRNA comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, or 21, contiguous nucleotides differing by no more than 3, *e.g.*, 3, 2, 1, or 0, nucleotides from the nucleotide sequence of nucleotides 1207-1229 or 937-959 of SEQ ID NO: 1, and the antisense strand comprises at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, 21, 22, or 23, contiguous nucleotides differing by no more than 3, *e.g.*, 3, 2, 1, or 0, from the corresponding nucleotide sequence of SEQ ID NO:2.

In one embodiment, the sense strand comprises at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, or 21, contiguous nucleotides differing by no more than three, *e.g.*, 3, 2, 1, or 0, nucleotides from the nucleotide sequence of nucleotides 1207-1229 of SEQ ID NO: 1, and the antisense strand comprises at least 15, *e.g.*, 15, 16, 17, 18, 19, 20, 21, 22, or 23, contiguous nucleotides differing by no more than 3, *e.g.*, 3, 2, 1, or 0, from the corresponding nucleotide sequence of SEQ ID NO:2.

In one embodiment, the dsRNA agent comprises at least one modified nucleotide.

In one embodiment, substantially all of the nucleotides of the sense strand; substantially all of the nucleotides of the antisense strand comprise a modification; or substantially all of the nucleotides of the sense strand and substantially all of the nucleotides of the antisense strand comprise a modification.

In one embodiment, all of the nucleotides of the sense strand comprise a modification; all of the nucleotides of the antisense strand comprise a modification; or all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand comprise a modification.

In one embodiment, at least one of the modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3'-terminal deoxythymidine (dT) nucleotide, a 2'-O-methyl modified nucleotide, a 2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2'-amino-modified nucleotide, a 2'-O-allyl-modified nucleotide, 2'-C-alkyl-modified nucleotide, 2'-hydroxly-modified nucleotide, a 2'-methoxyethyl modified nucleotide, a 2'-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5'-phosphate, a nucleotide comprising a 5'-phosphate mimic, a thermally destabilizing nucleotide, a glycol modified nucleotide (GNA), a nucleotide comprising a 2' phosphate, and a 2-O-(N-methylacetamide) modified nucleotide; and combinations thereof.

In one embodiment, the modifications on the nucleotides are selected from the group consisting of LNA, HNA, CeNA, 2'-methoxyethyl, 2'-O-alkyl, 2'-O-allyl, 2'-C-allyl, 2'-fluoro, 2'-deoxy, 2'-hydroxyl, and glycol; and combinations thereof.

In one embodiment, at least one of the modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 2'-O-methyl modified nucleotide, a 2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, a glycol modified nucleotide (GNA), *e.g.*, Ggn, Cgn, Tgn, or Agn, a nucleotide comprising a 2' phosphate, *e.g.*, G2p, C2p, A2p, U2p, a vinyl-phosphonate nucleotide; and combinations thereof.

In another embodiment, at least one of the modifications on the nucleotides is a thermally destabilizing nucleotide modification.

In one embodiment, the thermally destabilizing nucleotide modification is selected from the group consisting of an abasic modification; a mismatch with the opposing nucleotide in the duplex; and destabilizing sugar modification, a 2'-deoxy modification, an acyclic nucleotide, an unlocked nucleic acids (UNA), and a glycerol nucleic acid (GNA).

In some embodiments, the modified nucleotide comprises a short sequence of 3'-terminal deoxythymidine nucleotides (dT).

In some embodiments, the modifications on the nucleotides are 2'-O-methyl, GNA and 2'-fluoro modifications.

In some embodiments, the dsRNA agent further comprises at least one phosphorothioate internucleotide linkage. In some embodiments, the dsRNA agent comprises 6-8 phosphorothioate internucleotide linkages. In one embodiment, the phosphorothioate or methylphosphonate internucleotide linkage is at the 3'-terminus of one strand. Optionally, the strand is the antisense strand. In another embodiment, the strand is the sense strand. In a related embodiment, the phosphorothioate or methylphosphonate internucleotide linkage is at the 5'-terminus of one strand. Optionally, the strand is the antisense strand. In another embodiment, the strand is the sense strand.

In another embodiment, the phosphorothioate or methylphosphonate internucleotide linkage is at the both the 5'- and 3'-terminus of one strand. Optionally, the strand is the antisense strand. In another embodiment, the strand is the sense strand.

The double stranded region may be 19-30 nucleotide pairs in length; 19-25 nucleotide pairs in length; 19-23 nucleotide pairs in length; 23-27 nucleotide pairs in length; or 21-23 nucleotide pairs in length.

In one embodiment, each strand is independently no more than 30 nucleotides in length.

In one embodiment, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

The region of complementarity may be at least 17 nucleotides in length; between 19 and 23 nucleotides in length; or 19 nucleotides in length.

In one embodiment, at least one strand comprises a 3' overhang of at least 1 nucleotide. In another embodiment, at least one strand comprises a 3' overhang of at least 2 nucleotides.


In one embodiment, the dsRNA agent further comprises a ligand.

In one embodiment, the ligand is conjugated to the 3' end of the sense strand of the dsRNA agent.


In one embodiment, the ligand is an N-acetylgalactosamine (GalNAc) derivative.

In one embodiment, the ligand is one or more GalNAc derivatives attached through a monovalent, bivalent, or trivalent branched linker.

In one embodiment, the ligand is



In one embodiment, the dsRNA agent is conjugated to the ligand as shown in the following schematic



and, wherein X is O or S.

5 In one embodiment, the X is O.

In one embodiment, the dsRNA agent further comprises at least one phosphorothioate or methylphosphonate internucleotide linkage.

In one embodiment, the phosphorothioate or methylphosphonate internucleotide linkage is at the 3'-terminus of one strand, *e.g.*, the antisense strand or the sense strand.

10 In another embodiment, the phosphorothioate or methylphosphonate internucleotide linkage is at the 5'-terminus of one strand, *e.g.*, the antisense strand or the sense strand.

In one embodiment, the phosphorothioate or methylphosphonate internucleotide linkage is at the both the 5'- and 3'-terminus of one strand. In one embodiment, the strand is the antisense strand.

15 In one embodiment, the base pair at the 1 position of the 5'-end of the antisense strand of the duplex is an AU base pair.

In one aspect, the present invention provides a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of ketohexokinase (KHK) in a cell, or a pharmaceutically acceptable salt thereof, comprising a sense strand and an antisense strand forming a double stranded region, wherein

20 a) the nucleotide sequence of the sense strand differs by no more than 4 bases from the nucleotide sequence 5'-gscsaggaagCfAfCfugagauucgu-3' and the nucleotide sequence of the antisense strand differs by no more than 4 bases from the nucleotide sequence 5'-asdCsgadAudCucagdTgCfuuccugcsasc-3', wherein a, g, c and u are 2'-O-methyl (2'-OMe) A, G, C, and U; Cf and Uf are 2'-deoxy-2'-fluoro (2'-F) C and U; dC, dA, and dT are 2'-deoxy C, A, and T;
25 and s is a phosphorothioate linkage; or

b) the nucleotide sequence of the sense strand differs by no more than 4 bases from the nucleotide sequence 5'-csusacggagAfCfGfugguguuugu-3' and the nucleotide sequence of the antisense strand differs by no more than 4 bases from the nucleotide sequence 5'-asdCsaadAc dAccacdGuCfuccguagscsc -3', wherein a, g, c and u are 2'-O-methyl (2'-OMe) A, G, C,

and U; Cf and Uf are 2'-deoxy-2'-fluoro (2'-F) C and U; dC, dA, and dG are 2'-deoxy C, A, and G; and s is a phosphorothioate linkage.

In one embodiment,

- 5 a) the nucleotide sequence of the sense strand differs by no more than 3 bases from the nucleotide sequence 5'-gscsaggaagCfAfCfugagauucgu-3' and the nucleotide sequence of the antisense strand differs by no more than 3 bases from the nucleotide sequence 5'-
asdCsgadAudCucagdTgCfuuccugcsasc-3', wherein a, g, c and u are 2'-O-methyl (2'-OMe) A, G, C,
and U; Cf and Uf are 2'-deoxy-2'-fluoro (2'-F) C and U; dC, dA, and dT are 2'-deoxy C, A, and T;
and s is a phosphorothioate linkage; or
- 10 b) the nucleotide sequence of the sense strand differs by no more than 3 bases from the nucleotide sequence 5'-csusacggagAfCfGfugguguuugu-3' and the nucleotide sequence of the antisense strand differs by no more than 3 bases from the nucleotide sequence 5'-
asdCsaadAcdAccacdGuCfuccguagscsc -3', wherein a, g, c and u are 2'-O-methyl (2'-OMe) A, G, C,
and U; Cf and Uf are 2'-deoxy-2'-fluoro (2'-F) C and U; dC, dA, and dG are 2'-deoxy C, A, and G;
15 and s is a phosphorothioate linkage.

In one embodiment,

- a) the nucleotide sequence of the sense strand differs by no more than 2 bases from the nucleotide sequence 5'-gscsaggaagCfAfCfugagauucgu-3' and the nucleotide sequence of the antisense strand differs by no more than 2 bases from the nucleotide sequence 5'-
20 asdCsgadAudCucagdTgCfuuccugcsasc-3', wherein a, g, c and u are 2'-O-methyl (2'-OMe) A, G, C,
and U; Cf and Uf are 2'-deoxy-2'-fluoro (2'-F) C and U; dC, dA, and dT are 2'-deoxy C, A, and T;
and s is a phosphorothioate linkage; or
- b) the nucleotide sequence of the sense strand differs by no more than 2 bases from the nucleotide sequence 5'-csusacggagAfCfGfugguguuugu-3' and the nucleotide sequence of the
25 antisense strand differs by no more than 2 bases from the nucleotide sequence 5'-
asdCsaadAcdAccacdGuCfuccguagscsc -3', wherein a, g, c and u are 2'-O-methyl (2'-OMe) A, G, C,
and U; Cf and Uf are 2'-deoxy-2'-fluoro (2'-F) C and U; dC, dA, and dG are 2'-deoxy C, A, and G;
and s is a phosphorothioate linkage.

In one embodiment,

- 30 a) the nucleotide sequence of the sense strand differs by no more than 1 base from the nucleotide sequence 5'-gscsaggaagCfAfCfugagauucgu-3' and the nucleotide sequence of the antisense strand differs by no more than 1 base from the nucleotide sequence 5'-
asdCsgadAudCucagdTgCfuuccugcsasc-3', wherein a, g, c and u are 2'-O-methyl (2'-OMe) A, G, C,
and U; Cf and Uf are 2'-deoxy-2'-fluoro (2'-F) C and U; dC, dA, and dT are 2'-deoxy C, A, and T;
35 and s is a phosphorothioate linkage; or
- b) the nucleotide sequence of the sense strand differs by no more than 1 base from the nucleotide sequence 5'-csusacggagAfCfGfugguguuugu-3' and the nucleotide sequence of the

antisense strand differs by no more than 1 base from the nucleotide sequence 5'-
asdCsaadAc dAccacdGuCfuccguagscsc -3', wherein a, g, c and u are 2'-O-methyl (2'-OMe) A, G, C,
and U; Cf and Uf are 2'-deoxy-2'-fluoro (2'-F) C and U; dC, dA, and dG are 2'-deoxy C, A, and G;
and s is a phosphorothioate linkage.

5 In one embodiment,

a) the nucleotide sequence of the sense strand comprises the nucleotide sequence 5'-
gscsaggaagCfAfCfugagauucgu-3' and the nucleotide sequence of the antisense strand comprises the
nucleotide sequence 5'- asdCsgadAudCucagdTgCfuuccugcsasc-3', wherein a, g, c and u are 2'-O-
methyl (2'-OMe) A, G, C, and U; Cf and Uf are 2'-deoxy-2'-fluoro (2'-F) C and U; dC, dA, and dT
10 are 2'-deoxy C, A, and T; and s is a phosphorothioate linkage; or

b) the nucleotide sequence of the sense strand comprises the nucleotide sequence 5'-
csusacggagAfCfGfugguguuugu-3' and the nucleotide sequence of the antisense strand comprises the
nucleotide sequence 5'- asdCsaadAc dAccacdGuCfuccguagscsc -3', wherein a, g, c and u are 2'-O-
methyl (2'-OMe) A, G, C, and U; Cf and Uf are 2'-deoxy-2'-fluoro (2'-F) C and U; dC, dA, and dG
15 are 2'-deoxy C, A, and G; and s is a phosphorothioate linkage.


In one embodiment, the dsRNA agent further comprises a ligand.

In one embodiment, the ligand is conjugated to the 3' end of the sense strand of the dsRNA
agent.


In one embodiment, the ligand is an N-acetylgalactosamine (GalNAc) derivative.

20 In one embodiment, the ligand is one or more GalNAc derivatives attached through a
monovalent, bivalent, or trivalent branched linker.

In one embodiment, the ligand is



In one embodiment, the dsRNA agent is conjugated to the ligand as shown in the following schematic



and, wherein X is O or S.

5 In one embodiment, X is O.

The present invention also provides cells containing any of the dsRNA agents of the invention and pharmaceutical compositions comprising any of the dsRNA agents of the invention.

The pharmaceutical composition of the invention may include dsRNA agent in an unbuffered solution, *e.g.*, saline or water, or the pharmaceutical composition of the invention may include the dsRNA agent is in a buffer solution, *e.g.*, a buffer solution comprising acetate, citrate, 10 prolamine, carbonate, or phosphate or any combination thereof; or phosphate buffered saline (PBS).

In one aspect, the present invention provides a method of inhibiting expression of a ketohexokinase (KHK) gene in a cell. The method includes contacting the cell with any of the dsRNAs of the invention or any of the pharmaceutical compositions of the invention, thereby 15 inhibiting expression of the KHK gene in the cell.

In one embodiment, the cell is within a subject, *e.g.*, a human subject, *e.g.*, a subject having a ketohexokinase (KHK)-associated disorder, such as a KHK-associate disorder selected from the group consisting of liver disease (*e.g.*, fatty liver, steatohepatitis, non-alcoholic steatohepatitis (NASH)), dyslipidemia (*e.g.*, hyperlipidemia, high LDL cholesterol, low HDL cholesterol, 20 hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (*e.g.*, insulin resistance, type 2 diabetes), cardiovascular disease (*e.g.*, hypertension, endothelial cell dysfunction), kidney disease (*e.g.*, acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, chronic kidney disease), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving.

25 In one embodiment, contacting the cell with the dsRNA agent inhibits the expression of KHK by at least 50%, 60%, 70%, 80%, 90%, or 95%.

In one embodiment, inhibiting expression of KHK decreases KHK protein level in serum of the subject by at least 50%, 60%, 70%, 80%, 90%, or 95%.

In one aspect, the present invention provides a method of treating a subject having a disorder that would benefit from reduction in ketohexokinase (KHK) expression. The method includes administering to the subject a therapeutically effective amount of any of the dsRNAs of the invention or any of the pharmaceutical compositions of the invention, thereby treating the subject having the disorder that would benefit from reduction in KHK expression.

In another aspect, the present invention provides a method of preventing at least one symptom in a subject having a disorder that would benefit from reduction in ketohexokinase (KHK) expression. The method includes administering to the subject a prophylactically effective amount of any of the dsRNAs of the invention or any of the pharmaceutical compositions of the invention, thereby preventing at least one symptom in the subject having the disorder that would benefit from reduction in KHK expression.

In certain embodiments, the KHK-associated disorder is a liver disease, *e.g.*, fatty liver disease such as NAFLD or NASH. In certain embodiments, the KHK-associated disorder is dyslipidemia, *e.g.*, elevated serum triglycerides, elevated serum LDL, elevated serum cholesterol, lowered serum HDL, postprandial hypertriglyceridemia. In another embodiment, the KHK-associated disorder is a disorder of glycemic control, *e.g.*, insulin resistance not resulting from an immune response against insulin, glucose resistance, type 2 diabetes. In certain embodiments, the KHK-associated disorder is a cardiovascular disease, *e.g.*, hypertension, endothelial cell dysfunction. In certain embodiments, the KHK-associated disorder is a kidney disease, *e.g.*, acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, chronic kidney disease. In certain embodiments, the disease is metabolic syndrome. In certain embodiments, the KHK-associated disorder is a disease of lipid deposition or dysfunction, *e.g.*, visceral adipose deposition, fatty liver, obesity. In certain embodiments, the KHK-associated disorder is a disease of elevated uric acid, *e.g.*, gout, hyperuricemia. In certain embodiments the KHK-associated disorder is an eating disorder such as excessive sugar craving.

In certain embodiments, the administration of the dsRNA to the subject causes a decrease in fructose metabolism. In certain embodiments, the administration of the dsRNA causes a decrease in the level of KHK in the subject, especially hepatic KHK, especially KHK-C in a subject with elevated KHK. In certain embodiments, the administration of the dsRNA causes a decrease in fructose metabolism in the subject. In certain embodiments, the administration of the dsRNA causes a decrease in the level of uric acid, *e.g.*, serum uric acid, in a subject with elevated serum uric acid, *e.g.*, elevated serum uric acid associated with gout. In certain embodiments, the administration of the dsRNA causes a normalization of serum lipids, *e.g.*, triglycerides including postprandial triglycerides, LDL, HDL, or cholesterol, in a subject with at least one abnormal serum lipid level. In certain embodiments, the administration of the dsRNA causes a normalization of lipid deposition, *e.g.*, a decrease of lipid deposition in the liver (*e.g.*, decrease of NAFLD or NASH), a decrease of visceral fat deposition, a decrease in body weight. In certain embodiments, the administration of the dsRNA causes a normalization of insulin or glucose response in a subject with abnormal insulin response not

related to an immune response to insulin, or abnormal glucose response. In certain embodiments, the administration of the dsRNA results in an improvement of kidney function, or a stoppage or reduction of the rate of loss of kidney function. In certain embodiments, the dsRNA causes a reduction of hypertension, *i.e.*, elevated blood pressure.

5 In certain embodiments, the invention further comprises administering an additional agent to a subject with a KHK-associated disease. In certain embodiments, treatments known in the art for the various KHK-associated diseases are used in combination with the RNAi agents of the invention. Such treatments are discussed below.

In one embodiment, the subject is human.

10 In one embodiment, the dsRNA agent is administered to the subject at a dose of about 0.01 mg/kg to about 50 mg/kg.

In one embodiment, the dsRNA agent is administered to the subject subcutaneously.

In one embodiment, the methods of the invention include further determining the level of KHK in a sample(s) from the subject.

15 In one embodiment, the level of KHK in the subject sample(s) is a KHK protein level in a blood or serum sample(s).

In one embodiment, the methods of the invention further comprise measuring the uric acid level, especially serum uric acid level, in the subject. In one embodiment, the methods of the invention further comprise measuring the urine fructose level in the subject. In one embodiment, the methods of the invention further comprise measuring a serum lipid level in a subject. In certain
20 embodiments, the methods of the invention further include measuring insulin or glucose sensitivity in a subject. In certain embodiments, a decrease in the levels of expression or activity of fructose metabolism indicates that the KHK-associated disease is being treated or prevented.

The present invention also provides kits comprising any of the dsRNAs of the invention or
25 any of the pharmaceutical compositions of the invention, and optionally, instructions for use.

The present invention further provides an RNA-induced silencing complex (RISC) comprising an antisense strand of any of the dsRNA agents of the invention.

In another embodiment, the RNAi agent is a pharmaceutically acceptable salt thereof. “Pharmaceutically acceptable salts” of each of RNAi agents herein include, but are not limited to, a
30 sodium salt, a calcium salt, a lithium salt, a potassium salt, an ammonium salt, a magnesium salt, and mixtures thereof. One skilled in the art will appreciate that the RNAi agent, when provided as a polycationic salt having one cation per free acid group of the optionally modified phosphodiester backbone and/or any other acidic modifications (e.g., 5'-terminal phosphonate groups). For example, an oligonucleotide of “n” nucleotides in length contains n-1 optionally modified phosphodiesters, so
35 that an oligonucleotide of 21 nt in length may be provided as a salt having up to 20 cations (e.g., 20 sodium cations). Similarly, an RNAi agent having a sense strand of 21 nt in length and an antisense strand of 23 nt in length may be provided as a salt having up to 42 cations (e.g., 42 sodium cations). In the preceding example, where the RNAi agent also includes a 5'-terminal phosphate or a 5'-

terminal vinylphosphonate group, the RNAi agent may be provided as a salt having up to 44 cations (e.g, 44 sodium cations).

The present invention is further illustrated by the following detailed description and drawings.

5

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the classic and alternative lipogenic pathways of fructose. In the classical pathway, triglycerides (TG) are a direct product of fructose metabolism by the action of multiple enzymes including aldolase B (Aldo B) and fatty acid synthase (FAS). In an alternative pathway, uric acid produced from the nucleotide turnover that occurs during the phosphorylation of fructose to fructose-1-phosphate (F-1-P) results in the generation of mitochondrial oxidative stress (mtROS), which causes a decrease in the activity of aconitase (ACO2) in the Krebs cycle. As a consequence, the ACO2 substrate, citrate, accumulates and is released to the cytosol where it acts as substrate for TG synthesis through the activation of ATP citrate lyase (ACL) and fatty acid synthase. AMPD2, AMP deaminase 2; IMP, inosine monophosphate; PO₄, phosphate (from Johnson *et al.* (2013) *Diabetes*. 62:3307-3315).

Figure 2 is a graph depicting the effect of administration of a single 3 mg/kg dose of the indicated duplexes on the level of KHK mRNA and KHK protein at Day 29 post-dose. The level of mRNA and protein are depicted as % remaining normalized to the pre-dose level of mRNA and protein.

Figure 3 is a graph depicting the effect of administration of a single 3 mg/kg dose of the indicated duplexes on the level of KHK mRNA at Day 50 post-dose. The level of mRNA is depicted as % remaining normalized to the pre-dose level of mRNA.

Figure 4 is a graph depicting the effect of administration of a single 3 mg/kg dose of the indicated duplexes on the level of KHK mRNA at Day 78 post-dose. The level of mRNA is depicted as % remaining normalized to the pre-dose level of mRNA.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides iRNA compositions which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of a ketohexokinase (KHK) gene. The gene may be within a cell, *e.g.*, a cell within a subject, such as a human. The use of these iRNAs enables the targeted degradation of mRNAs of the corresponding gene (KHK gene) in mammals.

The iRNAs of the invention have been designed to target the human ketohexokinase (KHK) gene, including portions of the gene that are conserved in the ketohexokinase (KHK) orthologs of other mammalian species. Without intending to be limited by theory, it is believed that a combination or sub-combination of the foregoing properties and the specific target sites or the specific modifications in these iRNAs confer to the iRNAs of the invention improved efficacy, stability, potency, durability, and safety.

Accordingly, the present invention provides methods for treating and preventing a ketohexokinase (KHK)-associated disorder, *e.g.*, liver disease (*e.g.*, fatty liver, steatohepatitis, non-alcoholic steatohepatitis (NASH)), dyslipidemia (*e.g.*, hyperlipidemia, high LDL cholesterol, low HDL cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (*e.g.*, insulin resistance, type 2 diabetes), cardiovascular disease (*e.g.*, hypertension, endothelial cell dysfunction), kidney disease (*e.g.*, acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, chronic kidney disease), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving, using iRNA compositions which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of a KHK gene.

The iRNAs of the invention include an RNA strand (the antisense strand) having a region which is up to about 30 nucleotides or less in length, *e.g.*, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length, which region is substantially complementary to at least part of an mRNA transcript of a KHK gene.

In certain embodiments, one or both of the strands of the double stranded RNAi agents of the invention is up to 66 nucleotides in length, *e.g.*, 36-66, 26-36, 25-36, 31-60, 22-43, 27-53 nucleotides in length, with a region of at least 19 contiguous nucleotides that is substantially complementary to at least a part of an mRNA transcript of a KHK gene. In some embodiments, such iRNA agents having longer length antisense strands can, for example, include a second RNA strand (the sense strand) of 20-60 nucleotides in length wherein the sense and antisense strands form a duplex of 18-30 contiguous nucleotides.

The use of iRNAs of the invention enables the targeted degradation of mRNAs of the corresponding gene (KHK gene) in mammals. Using *in vitro* assays, the present inventors have demonstrated that iRNAs targeting a KHK gene can potently mediate RNAi, resulting in significant inhibition of expression of a KHK gene. Thus, methods and compositions including these iRNAs are useful for treating a subject having a KHK-associated disorder, *e.g.*, liver disease (*e.g.*, fatty liver, steatohepatitis, non-alcoholic steatohepatitis (NASH)), dyslipidemia (*e.g.*, hyperlipidemia, high LDL cholesterol, low HDL cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (*e.g.*, insulin resistance, type 2 diabetes), cardiovascular disease (*e.g.*, hypertension, endothelial cell dysfunction), kidney disease (*e.g.*, acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, chronic kidney disease), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving.

Accordingly, the present invention provides methods and combination therapies for treating a subject having a disorder that would benefit from inhibiting or reducing the expression of a KHK gene, *e.g.*, a KHK-associated disorder, such as liver disease (*e.g.*, fatty liver, steatohepatitis, non-alcoholic steatohepatitis (NASH)), dyslipidemia (*e.g.*, hyperlipidemia, high LDL cholesterol, low

HDL cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (*e.g.*, insulin resistance, type 2 diabetes), cardiovascular disease (*e.g.*, hypertension, endothelial cell dysfunction), kidney disease (*e.g.*, acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, chronic kidney disease), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving, using iRNA compositions which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of a KHK gene.

The present invention also provides methods for preventing at least one symptom in a subject having a disorder that would benefit from inhibiting or reducing the expression of a KHK gene, *e.g.*, liver disease (*e.g.*, fatty liver, steatohepatitis, non-alcoholic steatohepatitis (NASH)), dyslipidemia (*e.g.*, hyperlipidemia, high LDL cholesterol, low HDL cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (*e.g.*, insulin resistance, type 2 diabetes), cardiovascular disease (*e.g.*, hypertension, endothelial cell dysfunction), kidney disease (*e.g.*, acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, chronic kidney disease), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving.

The following detailed description discloses how to make and use compositions containing iRNAs to inhibit the expression of a KHK gene as well as compositions, uses, and methods for treating subjects that would benefit from inhibition and/or reduction of the expression of a KHK gene, *e.g.*, subjects susceptible to or diagnosed with a KHK-associated disorder.

I. Definitions

In order that the present invention may be more readily understood, certain terms are first defined. In addition, it should be noted that whenever a value or range of values of a parameter are recited, it is intended that values and ranges intermediate to the recited values are also intended to be part of this invention.

The articles “a” and “an” are used herein to refer to one or to more than one (*i.e.*, to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element, *e.g.*, a plurality of elements.

The term “including” is used herein to mean, and is used interchangeably with, the phrase “including but not limited to”.

The term “or” is used herein to mean, and is used interchangeably with, the term “and/or,” unless context clearly indicates otherwise. For example, “sense strand or antisense strand” is understood as “sense strand or antisense strand or sense strand and antisense strand.”

The term “about” is used herein to mean within the typical ranges of tolerances in the art. For example, “about” can be understood as about 2 standard deviations from the mean. In certain embodiments, about means $\pm 10\%$. In certain embodiments, about means $\pm 5\%$. When about is

present before a series of numbers or a range, it is understood that “about” can modify each of the numbers in the series or range.

The term “at least”, “no less than”, or “or more” prior to a number or series of numbers is understood to include the number adjacent to the term “at least”, and all subsequent numbers or integers that could logically be included, as clear from context. For example, the number of nucleotides in a nucleic acid molecule must be an integer. For example, “at least 19 nucleotides of a 21 nucleotide nucleic acid molecule” means that 19, 20, or 21 nucleotides have the indicated property. When at least is present before a series of numbers or a range, it is understood that “at least” can modify each of the numbers in the series or range.

As used herein, “no more than” or “or less” is understood as the value adjacent to the phrase and logical lower values or integers, as logical from context, to zero. For example, a duplex with an overhang of “no more than 2 nucleotides” has a 2, 1, or 0 nucleotide overhang. When “no more than” is present before a series of numbers or a range, it is understood that “no more than” can modify each of the numbers in the series or range. As used herein, ranges include both the upper and lower limit.

As used herein, methods of detection can include determination that the amount of analyte present is below the level of detection of the method.

In the event of a conflict between an indicated target site and the nucleotide sequence for a sense or antisense strand, the indicated sequence takes precedence.

In the event of a conflict between a sequence and its indicated site on a transcript or other sequence, the nucleotide sequence recited in the specification takes precedence.

As used herein, “ketohexokinase,” used interchangeably with the term “KHK,” refers to the naturally occurring gene that encodes an enzyme that catalyzes conversion of fructose to fructose-1-phosphate. The product of this gene is the first enzyme in the pathway that catabolizes dietary fructose. Alternatively spliced transcript variants encoding different isoforms have been identified.

The gene is also known as fructokinase.

Exemplary nucleotide and amino acid sequences of KHK can be found, for example, at GenBank Accession No. XM_017004061.1 (Homo sapiens KHK; SEQ ID NO:1; reverse complement, SEQ ID NO:2); NM_006488.3 (Homo sapiens KHK; SEQ ID NO:3; reverse complement, SEQ ID NO:4); NM_000221.3 (Homo sapiens KHK; SEQ ID NO:5; reverse complement, SEQ ID NO:6); GenBank Accession No. NM_001310524.1 (Mus musculus KHK; SEQ ID NO:7; reverse complement, SEQ ID NO:8); GenBank Accession No. NM_031855.3 (Rattus norvegicus KHK; SEQ ID NO:9; reverse complement, SEQ ID NO:10); GenBank Accession No. XM_005576322.2 (Macaca fascicularis KHK, SEQ ID NO:11; reverse complement, SEQ ID NO:12).

The KHK (Ketohexokinase) gene is located on chromosome 2p23 and encodes ketohexokinase, also known as fructokinase. KHK is a phosphotransferase enzyme with an alcohol as the phosphate acceptor. KHK belongs to the ribokinase family of carbohydrate kinases (Trinh *et al.* , *ACTA Cryst.*, D65: 201-211). Two isoforms of ketohexokinase have been identified, KHK-A and

KHK-C, that result from alternative splicing of the full length mRNA. These isoforms differ by inclusion of either exon 3a or 3c, and differ by 32 amino acids between positions 72 and 115. KHK-C mRNA is expressed at high levels, predominantly in the liver, kidney and small intestine. KHK-C has a much lower K_m for fructose binding than KHK-A, and as a result, is highly effective in phosphorylating dietary fructose. The sequence of a human KHK-C mRNA transcript may be found at, for example, GenBank Accession No. NM_006488.3 (Homo sapiens KHK; SEQ ID NO:3). The sequence of a human KHK-A mRNA transcript may be found at, for example GenBank Accession No. NM_000221.3; SEQ ID NO:5). The sequence of full-length human KHK mRNA is provided in GenBank Accession No. GI: XM_017004061.1 (SEQ ID NO:1).

The iRNA agents provided herein can be capable of silencing one or both KHK isoforms. Additional examples of KHK mRNA sequences are readily available through publicly available databases, *e.g.*, GenBank, UniProt, OMIM, and the Macaca genome project web site. Further information on KHK can be found, for example, at www.ncbi.nlm.nih.gov/gene/?term=khk.

The entire contents of each of the foregoing GenBank Accession numbers and the Gene database numbers are incorporated herein by reference as of the date of filing this application.

The term KHK, as used herein, also refers to variations of the KHK gene including variants provided in the SNP database. Numerous sequence variations within the KHK gene have been identified and may be found at, for example, NCBI dbSNP and UniProt (see, *e.g.*, www.ncbi.nlm.nih.gov/snp/?term=KHK, the entire contents of which is incorporated herein by reference as of the date of filing this application.

As used herein, “target sequence” refers to a contiguous portion of the nucleotide sequence of an mRNA molecule formed during the transcription of a KHK gene, including mRNA that is a product of RNA processing of a primary transcription product. The target portion of the sequence will be at least long enough to serve as a substrate for iRNA-directed cleavage at or near that portion of the nucleotide sequence of an mRNA molecule formed during the transcription of a KHK gene. In one embodiment, the target sequence is within the protein coding region of KHK.

The target sequence may be from about 19-36 nucleotides in length, *e.g.*, about 19-30 nucleotides in length. For example, the target sequence can be about 19-30 nucleotides, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length. In certain embodiments, the target sequence is 19-23 nucleotides in length, optionally 21-23 nucleotides in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the disclosure.

As used herein, the term “strand comprising a sequence” refers to an oligonucleotide comprising a chain of nucleotides that is described by the sequence referred to using the standard nucleotide nomenclature.

“G,” “C,” “A,” “T,” and “U” each generally stand for a nucleotide that contains guanine, cytosine, adenine, thymidine, and uracil as a base, respectively. However, it will be understood that the term “ribonucleotide” or “nucleotide” can also refer to a modified nucleotide, as further detailed below, or a surrogate replacement moiety (see, *e.g.*, Table 1). The skilled person is well aware that

5 guanine, cytosine, adenine, and uracil can be replaced by other moieties without substantially altering the base pairing properties of an oligonucleotide comprising a nucleotide bearing such replacement moiety. For example, without limitation, a nucleotide comprising inosine as its base can base pair with nucleotides containing adenine, cytosine, or uracil. Hence, nucleotides containing uracil, guanine, or adenine can be replaced in the nucleotide sequences of dsRNA featured in the invention

10 by a nucleotide containing, for example, inosine. In another example, adenine and cytosine anywhere in the oligonucleotide can be replaced with guanine and uracil, respectively to form G-U Wobble base pairing with the target mRNA. Sequences containing such replacement moieties are suitable for the compositions and methods featured in the invention.

The terms “iRNA”, “RNAi agent,” “iRNA agent,” “RNA interference agent” as used

15 interchangeably herein, refer to an agent that contains RNA as that term is defined herein, and which mediates the targeted cleavage of an RNA transcript *via* an RNA-induced silencing complex (RISC) pathway. iRNA directs the sequence-specific degradation of mRNA through a process known as RNA interference (RNAi). The iRNA modulates, *e.g.*, inhibits, the expression of a KHK gene in a cell, *e.g.*, a cell within a subject, such as a mammalian subject.

20 In one embodiment, an RNAi agent of the invention includes a single stranded RNA that interacts with a target RNA sequence, *e.g.*, a KHK target mRNA sequence, to direct the cleavage of the target RNA. Without wishing to be bound by theory it is believed that long double stranded RNA introduced into cells is broken down into siRNA by a Type III endonuclease known as Dicer (Sharp *et al.* (2001) *Genes Dev.* 15:485). Dicer, a ribonuclease-III-like enzyme, processes the dsRNA into 19-

25 23 base pair short interfering RNAs with characteristic two base 3' overhangs (Bernstein, *et al.*, (2001) *Nature* 409:363). The siRNAs are then incorporated into an RNA-induced silencing complex (RISC) where one or more helicases unwind the siRNA duplex, enabling the complementary antisense strand to guide target recognition (Nykanen, *et al.*, (2001) *Cell* 107:309). Upon binding to the appropriate target mRNA, one or more endonucleases within the RISC cleave the target to induce

30 silencing (Elbashir, *et al.*, (2001) *Genes Dev.* 15:188). Thus, in one aspect the invention relates to a single stranded RNA (siRNA) generated within a cell and which promotes the formation of a RISC complex to effect silencing of the target gene, *i.e.*, a KHK gene. Accordingly, the term “siRNA” is also used herein to refer to an iRNA as described above.

In certain embodiments, the RNAi agent may be a single-stranded siRNA (ssRNAi) that is

35 introduced into a cell or organism to inhibit a target mRNA. Single-stranded RNAi agents bind to the RISC endonuclease, Argonaute 2, which then cleaves the target mRNA. The single-stranded siRNAs are generally 15-30 nucleotides and are chemically modified. The design and testing of single-stranded siRNAs are described in U.S. Patent No. 8,101,348 and in Lima *et al.*, (2012) *Cell* 150:883-

894, the entire contents of each of which are hereby incorporated herein by reference. Any of the antisense nucleotide sequences described herein may be used as a single-stranded siRNA as described herein or as chemically modified by the methods described in Lima *et al.*, (2012) *Cell* 150:883-894.

In certain embodiments, an “iRNA” for use in the compositions, uses, and methods of the invention is a double stranded RNA and is referred to herein as a “double stranded RNA agent,” “double stranded RNA (dsRNA) molecule,” “dsRNA agent,” or “dsRNA”. The term “dsRNA”, refers to a complex of ribonucleic acid molecules, having a duplex structure comprising two anti-parallel and substantially complementary nucleic acid strands, referred to as having “sense” and “antisense” orientations with respect to a target RNA, *i.e.*, a KHK gene. In some embodiments of the invention, a double stranded RNA (dsRNA) triggers the degradation of a target RNA, *e.g.*, an mRNA, through a post-transcriptional gene-silencing mechanism referred to herein as RNA interference or RNAi.

In general, the majority of nucleotides of each strand of a dsRNA molecule are ribonucleotides, but as described in detail herein, each or both strands can also include one or more non-ribonucleotides, *e.g.*, a deoxyribonucleotide or a modified nucleotide. In addition, as used in this specification, an “iRNA” may include ribonucleotides with chemical modifications; an iRNA may include substantial modifications at multiple nucleotides. As used herein, the term “modified nucleotide” refers to a nucleotide having, independently, a modified sugar moiety, a modified internucleotide linkage, or modified nucleobase, or any combination thereof. Thus, the term modified nucleotide encompasses substitutions, additions or removal of, *e.g.*, a functional group or atom, to internucleoside linkages, sugar moieties, or nucleobases. The modifications suitable for use in the agents of the invention include all types of modifications disclosed herein or known in the art. Any such modifications, as used in a siRNA type molecule, are encompassed by “iRNA” or “RNAi agent” for the purposes of this specification and claims.

In certain embodiments of the instant disclosure, inclusion of a deoxy-nucleotide if present within an RNAi agent can be considered to constitute a modified nucleotide.

The duplex region may be of any length that permits specific degradation of a desired target RNA through a RISC pathway, and may range from about 19 to 36 base pairs in length, *e.g.*, about 19-30 base pairs in length, for example, about 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 base pairs in length, such as about 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs in length. In certain embodiments, the duplex region is 19-21 base pairs in length, *e.g.*, 21 base pairs in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the disclosure.

The two strands forming the duplex structure may be different portions of one larger RNA molecule, or they may be separate RNA molecules. Where the two strands are part of one larger molecule, and therefore are connected by an uninterrupted chain of nucleotides between the 3'-end of one strand and the 5'-end of the respective other strand forming the duplex structure, the connecting

RNA chain is referred to as a “hairpin loop.” A hairpin loop can comprise at least one unpaired nucleotide. In some embodiments, the hairpin loop can comprise at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 23 or more unpaired nucleotides. In some embodiments, the hairpin loop can be 10 or fewer nucleotides. In some embodiments, the hairpin loop can be 8 or fewer unpaired nucleotides. In some
 5 embodiments, the hairpin loop can be 4-10 unpaired nucleotides. In some embodiments, the hairpin loop can be 4-8 nucleotides.

Where the two substantially complementary strands of a dsRNA are comprised by separate RNA molecules, those molecules need not be, but can be covalently connected. Where the two strands are connected covalently by means other than an uninterrupted chain of nucleotides between
 10 the 3'-end of one strand and the 5'-end of the respective other strand forming the duplex structure, the connecting structure is referred to as a “linker.” The RNA strands may have the same or a different number of nucleotides. The maximum number of base pairs is the number of nucleotides in the shortest strand of the dsRNA minus any overhangs that are present in the duplex. In addition to the duplex structure, an RNAi may comprise one or more nucleotide overhangs. In one embodiment of
 15 the RNAi agent, at least one strand comprises a 3' overhang of at least 1 nucleotide. In another embodiment, at least one strand comprises a 3' overhang of at least 2 nucleotides, *e.g.*, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, or 15 nucleotides. In other embodiments, at least one strand of the RNAi agent comprises a 5' overhang of at least 1 nucleotide. In certain embodiments, at least one strand
 20 comprises a 5' overhang of at least 2 nucleotides, *e.g.*, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, or 15 nucleotides. In still other embodiments, both the 3' and the 5' end of one strand of the RNAi agent comprise an overhang of at least 1 nucleotide.

In certain embodiments, an iRNA agent of the invention is a dsRNA, each strand of which comprises 19-23 nucleotides, that interacts with a target RNA sequence, *e.g.*, a KHK gene, to direct cleavage of the target RNA.

25 In some embodiments, an iRNA of the invention is a dsRNA of 24-30 nucleotides that interacts with a target RNA sequence, *e.g.*, a KHK target mRNA sequence, to direct the cleavage of the target RNA.

As used herein, the term “nucleotide overhang” refers to at least one unpaired nucleotide that protrudes from the duplex structure of a double stranded iRNA. For example, when a 3'-end of one
 30 strand of a dsRNA extends beyond the 5'-end of the other strand, or *vice versa*, there is a nucleotide overhang. A dsRNA can comprise an overhang of at least one nucleotide; alternatively the overhang can comprise at least two nucleotides, at least three nucleotides, at least four nucleotides, at least five nucleotides or more. A nucleotide overhang can comprise or consist of a nucleotide/nucleoside analog, including a deoxynucleotide/nucleoside. The overhang(s) can be on the sense strand, the
 35 antisense strand, or any combination thereof. Furthermore, the nucleotide(s) of an overhang can be present on the 5'-end, 3'-end, or both ends of either an antisense or sense strand of a dsRNA.

In one embodiment, the antisense strand of a dsRNA has a 1-10 nucleotide, *e.g.*, a 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide, overhang at the 3'-end or the 5'-end. In one embodiment, the sense

strand of a dsRNA has a 1-10 nucleotide, *e.g.*, a 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide, overhang at the 3'-end or the 5'-end. In another embodiment, one or more of the nucleotides in the overhang is replaced with a nucleoside thiophosphate.

In certain embodiments, the antisense strand of a dsRNA has a 1-10 nucleotide, *e.g.*, 0-3, 1-3, 2-4, 2-5, 4-10, 5-10, *e.g.*, a 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide, overhang at the 3'-end or the 5'-end. In one embodiment, the sense strand of a dsRNA has a 1-10 nucleotide, *e.g.*, a 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide, overhang at the 3'-end or the 5'-end. In another embodiment, one or more of the nucleotides in the overhang is replaced with a nucleoside thiophosphate.

In certain embodiments, the antisense strand of a dsRNA has a 1-10 nucleotides, *e.g.*, a 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide, overhang at the 3'-end or the 5'-end. In certain embodiments, the overhang on the sense strand or the antisense strand, or both, can include extended lengths longer than 10 nucleotides, *e.g.*, 1-30 nucleotides, 2-30 nucleotides, 10-30 nucleotides, 10-25 nucleotides, 10-20 nucleotides, or 10-15 nucleotides in length. In certain embodiments, an extended overhang is on the sense strand of the duplex. In certain embodiments, an extended overhang is present on the 3' end of the sense strand of the duplex. In certain embodiments, an extended overhang is present on the 5' end of the sense strand of the duplex. In certain embodiments, an extended overhang is on the antisense strand of the duplex. In certain embodiments, an extended overhang is present on the 3' end of the antisense strand of the duplex. In certain embodiments, an extended overhang is present on the 5' end of the antisense strand of the duplex. In certain embodiments, one or more of the nucleotides in the extended overhang is replaced with a nucleoside thiophosphate. In certain embodiments, the overhang includes a self-complementary portion such that the overhang is capable of forming a hairpin structure that is stable under physiological conditions.

“Blunt” or “blunt end” means that there are no unpaired nucleotides at that end of the double stranded RNA agent, *i.e.*, no nucleotide overhang. A “blunt ended” double stranded RNA agent is double stranded over its entire length, *i.e.*, no nucleotide overhang at either end of the molecule. The RNAi agents of the invention include RNAi agents with no nucleotide overhang at one end (*i.e.*, agents with one overhang and one blunt end) or with no nucleotide overhangs at either end. Most often such a molecule will be double-stranded over its entire length.

The term “antisense strand” or “guide strand” refers to the strand of an iRNA, *e.g.*, a dsRNA, which includes a region that is substantially complementary to a target sequence, *e.g.*, a KHK mRNA.

As used herein, the term “region of complementarity” refers to the region on the antisense strand that is substantially complementary to a sequence, for example a target sequence, *e.g.*, a KHK nucleotide sequence, as defined herein. Where the region of complementarity is not fully complementary to the target sequence, the mismatches can be in the internal or terminal regions of the molecule. Generally, the most tolerated mismatches are in the terminal regions, *e.g.*, within 5, 4, or 3 nucleotides of the 5'- or 3'-end of the iRNA. In some embodiments, a double stranded RNA agent of the invention includes a nucleotide mismatch in the antisense strand. In some embodiments, the antisense strand of the double stranded RNA agent of the invention includes no more than 4

mismatches with the target mRNA, *e.g.*, the antisense strand includes 4, 3, 2, 1, or 0 mismatches with the target mRNA. In some embodiments, the antisense strand double stranded RNA agent of the invention includes no more than 4 mismatches with the sense strand, *e.g.*, the antisense strand includes 4, 3, 2, 1, or 0 mismatches with the sense strand. In some embodiments, a double stranded
 5 RNA agent of the invention includes a nucleotide mismatch in the sense strand. In some embodiments, the sense strand of the double stranded RNA agent of the invention includes no more than 4 mismatches with the antisense strand, *e.g.*, the sense strand includes 4, 3, 2, 1, or 0 mismatches with the antisense strand. In some embodiments, the nucleotide mismatch is, for example, within 5, 4, 3 nucleotides from the 3'-end of the iRNA. In another embodiment, the nucleotide mismatch is, for
 10 example, in the 3'-terminal nucleotide of the iRNA agent. In some embodiments, the mismatch(s) is not in the seed region.

Thus, an RNAi agent as described herein can contain one or more mismatches to the target sequence. In one embodiment, an RNAi agent as described herein contains no more than 3 mismatches (*i.e.*, 3, 2, 1, or 0 mismatches). In one embodiment, an RNAi agent as described herein
 15 contains no more than 2 mismatches. In one embodiment, an RNAi agent as described herein contains no more than 1 mismatch. In one embodiment, an RNAi agent as described herein contains 0 mismatches. In certain embodiments, if the antisense strand of the RNAi agent contains mismatches to the target sequence, the mismatch can optionally be restricted to be within the last 5 nucleotides from either the 5'- or 3'-end of the region of complementarity. For example, in such embodiments, for
 20 a 23 nucleotide RNAi agent, the strand which is complementary to a region of a KHK gene, generally does not contain any mismatch within the central 13 nucleotides. The methods described herein or methods known in the art can be used to determine whether an RNAi agent containing a mismatch to a target sequence is effective in inhibiting the expression of a KHK gene. Consideration of the efficacy of RNAi agents with mismatches in inhibiting expression of a KHK gene is important,
 25 especially if the particular region of complementarity in a KHK gene is known to have polymorphic sequence variation within the population.

The term "sense strand" or "passenger strand" as used herein, refers to the strand of an iRNA that includes a region that is substantially complementary to a region of the antisense strand as that term is defined herein.

30 As used herein, "substantially all of the nucleotides are modified" are largely but not wholly modified and can include not more than 5, 4, 3, 2, or 1 unmodified nucleotides.

As used herein, the term "cleavage region" refers to a region that is located immediately adjacent to the cleavage site. The cleavage site is the site on the target at which cleavage occurs. In some embodiments, the cleavage region comprises three bases on either end of, and immediately
 35 adjacent to, the cleavage site. In some embodiments, the cleavage region comprises two bases on either end of, and immediately adjacent to, the cleavage site. In some embodiments, the cleavage site specifically occurs at the site bound by nucleotides 10 and 11 of the antisense strand, and the cleavage region comprises nucleotides 11, 12 and 13.

As used herein, and unless otherwise indicated, the term “complementary,” when used to describe a first nucleotide sequence in relation to a second nucleotide sequence, refers to the ability of an oligonucleotide or polynucleotide comprising the first nucleotide sequence to hybridize and form a duplex structure under certain conditions with an oligonucleotide or polynucleotide comprising the second nucleotide sequence, as will be understood by the skilled person. Such conditions can, for example, be stringent conditions, where stringent conditions can include: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50°C or 70°C for 12-16 hours followed by washing (see, *e.g.*, “Molecular Cloning: A Laboratory Manual, Sambrook, *et al.* (1989) Cold Spring Harbor Laboratory Press). Such conditions can be, for example, “stringent conditions”, where stringent conditions can include: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50 oC or 70 oC for 12-16 hours followed by washing (see, *e.g.*, “Molecular Cloning: A Laboratory Manual, Sambrook, *et al.* (1989) Cold Spring Harbor Laboratory Press). Other conditions, such as physiologically relevant conditions as can be encountered inside an organism, can apply. The skilled person will be able to determine the set of conditions most appropriate for a test of complementarity of two sequences in accordance with the ultimate application of the hybridized nucleotides.

Complementary sequences within an iRNA, *e.g.*, within a dsRNA as described herein, include base-pairing of the oligonucleotide or polynucleotide comprising a first nucleotide sequence to an oligonucleotide or polynucleotide comprising a second nucleotide sequence over the entire length of one or both nucleotide sequences. Such sequences can be referred to as “fully complementary” with respect to each other herein. However, where a first sequence is referred to as “substantially complementary” with respect to a second sequence herein, the two sequences can be fully complementary, or they can form one or more, but generally not more than 5, 4, 3, or 2 mismatched base pairs upon hybridization for a duplex up to 30 base pairs, while retaining the ability to hybridize under the conditions most relevant to their ultimate application, *e.g.*, inhibition of gene expression, in vitro or in vivo. However, where two oligonucleotides are designed to form, upon hybridization, one or more single stranded overhangs, such overhangs shall not be regarded as mismatches with regard to the determination of complementarity. For example, a dsRNA comprising one oligonucleotide 21 nucleotides in length and another oligonucleotide 23 nucleotides in length, wherein the longer oligonucleotide comprises a sequence of 21 nucleotides that is fully complementary to the shorter oligonucleotide, can yet be referred to as “fully complementary” for the purposes described herein.

“Complementary” sequences, as used herein, can also include, or be formed entirely from, non-Watson-Crick base pairs or base pairs formed from non-natural and modified nucleotides, in so far as the above requirements with respect to their ability to hybridize are fulfilled. Such non-Watson-Crick base pairs include, but are not limited to, G:U Wobble or Hoogsteen base pairing.

The terms “complementary,” “fully complementary” and “substantially complementary” herein can be used with respect to the base matching between the sense strand and the antisense strand of a dsRNA, or between two oligonucleotides or polynucleotides, such as the antisense strand of a double stranded RNA agent and a target sequence, as will be understood from the context of their use.

As used herein, a polynucleotide that is “substantially complementary to at least part of” a messenger RNA (mRNA) refers to a polynucleotide that is substantially complementary to a contiguous portion of the mRNA of interest (*e.g.*, an mRNA encoding a KHK gene). For example, a polynucleotide is complementary to at least a part of a KHK mRNA if the sequence is substantially complementary to a non-interrupted portion of an mRNA encoding a KHK gene.

Accordingly, in some embodiments, the antisense polynucleotides disclosed herein are fully complementary to the target KHK sequence. In other embodiments, the antisense polynucleotides disclosed herein are substantially complementary to the target KHK sequence and comprise a contiguous nucleotide sequence which is at least 80% complementary over its entire length to the equivalent region of the nucleotide sequence of any one of SEQ ID NOs:1, 3, 5, 7, 9, or 11, or a fragment of any one of SEQ ID NOs:1, 3, 5, 7, 9, or 11, such as about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% complementary.

In some embodiments, the antisense polynucleotides disclosed herein are substantially complementary to a fragment of a target KHK sequence and comprise a contiguous nucleotide sequence which is at least 80% complementary over its entire length to a fragment of SEQ ID NO: 1 selected from the group of nucleotides 120-162; 164-188; 181-207; 193-217; 209-231; 283-306; 508-546; 568-603; 596-632; 640-674; 746-806; 806-835; 917-942; 936-084; 1016-1041; 1100-1123; 1149-1175; 1160-1193; 1205-1229; 1252-1283; 1334-1356; 1407-1429; 1472-1497; 1506-1533; 1539-1561; 1704-1727; 1747-1787; 1850-1873; 1936-1964; 1960-1990; 2015-2048; 2060-2095; 2090-2118; 2124-2160; 2181-2200; 2221-2262 of SEQ ID NO: 1, such as about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% complementary.

In some embodiments, the antisense polynucleotides disclosed herein are substantially complementary to a fragment of a target KHK sequence and comprise a contiguous nucleotide sequence which is at least 80% complementary over its entire length to a fragment of SEQ ID NO: 1 selected from the group of nucleotides 517-539; 521-543; 524-546; 517-546; 581-603; 610-632; 747-769; 749-771; 752-774; 755-777; 757-779; 758-780; 764-786; 776-798; 781-803; 747-803; 920-942; 941-963; 944-966; 950-972; 962-984; 920-984; 1149-1171; 1161-1183; 1165-1187; 1171-1193; 1149-1193; 1205-1227; 1206-1228; 1205-1228; 1334-1356; 1472-1494; 1475-1497; 1472-1497 of SEQ ID NO: 1, such as about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% complementary.

In some embodiments, the antisense polynucleotides disclosed herein are substantially complementary to a fragment of a target KHK sequence and comprise a contiguous nucleotide sequence which is at least 80% complementary over its entire length to a fragment of SEQ ID NO: 1 selected from the group of nucleotides 517-539; 524-546; 517-546; 753-775; 757-779; 753-779; 764-786; 767-789; 768-790; 769-791; 764-791; 773-795; 781-803; 773-803; 753-803; 808-830; 937-959; 941-963; 944-966; 941-966; 948-970; 950-972; 948-972; 1160-1182; 1161-1183; 1160-1183; and

1207-1229 of SEQ ID NO: 1, such as about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% complementary.

In some embodiments, the antisense polynucleotides disclosed herein are substantially complementary to a fragment of a target KHK sequence and comprise a contiguous nucleotide

sequence which is at least 80% complementary over its entire length to a fragment of SEQ ID NO: 1 selected from the group of nucleotides 495-517, 492-517, 500-529, 514-551, 517-539, 524-546, 517-548, 614-643, 625-647, 625-660, 642-664, 642-672, 753-811, 754-780, 762-791, 764-786, 772-800, 781-803, 805-827, 808-830, 809-831, 792-838, 931-982, 944-966, 947-969, 948-970, 948-982, 1011-1035, 1021-1043, 1019-1050, 1063-1091, 1150-1192, 1152-1176, 1160-1192, 1160-1182, 1162-1184, 1198-1230, 1198-1221, and 1202-1230 of SEQ ID NO: 1, such as about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% complementary.

In some embodiments, the antisense polynucleotides disclosed herein are substantially complementary to a fragment of a target KHK sequence and comprise a contiguous nucleotide

sequence which is at least 80% complementary over its entire length to a fragment of SEQ ID NO: 1 selected from the group of nucleotides 513-556, 753-813, 936-981, 1155-1193, 1200-1229, 1704-1727, 1747-1787, 1850-1873, 1936-1964, 1960-1990, 1936-1990, 2015-2048, 2060-2095, 2090-2118, 2060-2118, 2124-2160, 2181-2220, 2221-2249, 2181-2249, 2240-2262, 2221-2262, and 2181-2262 of SEQ ID NO: 1, such as about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% complementary.

In other embodiments, the antisense polynucleotides disclosed herein are substantially complementary to the target KHK sequence and comprise a contiguous nucleotide sequence which is at least about 80% complementary over its entire length to any one of the sense strand nucleotide sequences in any one of any one of Tables 2, 3, 5, 6, and 8-13, or a fragment of any one of the sense strand nucleotide sequences in any one of Tables 2, 3, 5, 6, and 8-13, such as about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% complementary.

In one embodiment, an RNAi agent of the disclosure includes a sense strand that is substantially complementary to an antisense polynucleotide which, in turn, is the same as a target KHK sequence, and wherein the sense strand polynucleotide comprises a contiguous nucleotide sequence which is at least about 80% complementary over its entire length to the equivalent region of the nucleotide sequence of SEQ ID NOs: 2, 4, 6, 8, 10, or 12, or a fragment of any one of SEQ ID NOs: 2, 4, 6, 8, 10, or 12, such as about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% complementary.

In some embodiments, an iRNA of the invention includes a sense strand that is substantially complementary to an antisense polynucleotide which, in turn, is complementary to a target KHK sequence, and wherein the sense strand polynucleotide comprises a contiguous nucleotide sequence which is at least about 80% complementary over its entire length to any one of the antisense strand

nucleotide sequences in any one of any one of Tables 2, 3, 5, 6, and 8-13, or a fragment of any one of the antisense strand nucleotide sequences in any one of Tables 2, 3, 5, 6, and 8-13, such as about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% complementary.

5 In certain embodiments, the sense and antisense strands are selected from any one of duplexes AD-1613400; AD-1613243; AD-1290757.3; AD-1290878.3; AD-1290969.3; AD-1423317.2; AD-1423327.2; AD-1423336.2; AD-1290599.3; AD-1523172.1; AD-1290837.3; AD-1523173.1; AD-1290884.3; AD-1523174.1; AD-1290959.3; AD-1523175.1; AD-1423311.2; AD-1423324.2; AD-1523176.1; AD-1423329.2; AD-1423333.2; AD-1423330.2; AD-1523177.1; AD-10 1290885.3; AD-1523178.1; AD-1423334.2; AD-1523179.1; AD-1523180.1; AD-1290539.3; and AD-1523181.1.

In general, an “iRNA” includes ribonucleotides with chemical modifications. Such modifications may include all types of modifications disclosed herein or known in the art. Any such modifications, as used in a dsRNA molecule, are encompassed by “iRNA” for the purposes of this 15 specification and claims.

In certain embodiments of the instant disclosure, inclusion of a deoxy-nucleotide if present within an RNAi agent can be considered to constitute a modified nucleotide.

In an aspect of the invention, an agent for use in the methods and compositions of the invention is a single-stranded antisense oligonucleotide molecule that inhibits a target mRNA *via* an 20 antisense inhibition mechanism. The single-stranded antisense oligonucleotide molecule is complementary to a sequence within the target mRNA. The single-stranded antisense oligonucleotides can inhibit translation in a stoichiometric manner by base pairing to the mRNA and physically obstructing the translation machinery, see Dias, N. *et al.*, (2002) *Mol Cancer Ther* 1:347-355. The single-stranded antisense oligonucleotide molecule may be about 14 to about 30 nucleotides 25 in length and have a sequence that is complementary to a target sequence. For example, the single-stranded antisense oligonucleotide molecule may comprise a sequence that is at least about 14, 15, 16, 17, 18, 19, 20, or more contiguous nucleotides from any one of the antisense sequences described herein.

The phrase “contacting a cell with an iRNA,” such as a dsRNA, as used herein, includes 30 contacting a cell by any possible means. Contacting a cell with an iRNA includes contacting a cell *in vitro* with the iRNA or contacting a cell *in vivo* with the iRNA. The contacting may be done directly or indirectly. Thus, for example, the iRNA may be put into physical contact with the cell by the individual performing the method, or alternatively, the iRNA may be put into a situation that will permit or cause it to subsequently come into contact with the cell.

35 Contacting a cell *in vitro* may be done, for example, by incubating the cell with the iRNA. Contacting a cell *in vivo* may be done, for example, by injecting the iRNA into or near the tissue where the cell is located, or by injecting the iRNA into another area, *e.g.*, the bloodstream or the subcutaneous space, such that the agent will subsequently reach the tissue where the cell to be

contacted is located. For example, the iRNA may contain or be coupled to a ligand, *e.g.*, GalNAc, that directs the iRNA to a site of interest, *e.g.*, the liver. Combinations of *in vitro* and *in vivo* methods of contacting are also possible. For example, a cell may also be contacted *in vitro* with an iRNA and subsequently transplanted into a subject.

5 In certain embodiments, contacting a cell with an iRNA includes “introducing” or “delivering the iRNA into the cell” by facilitating or effecting uptake or absorption into the cell. Absorption or uptake of an iRNA can occur through unaided diffusion or active cellular processes, or by auxiliary agents or devices. Introducing an iRNA into a cell may be *in vitro* or *in vivo*. For example, for *in vivo* introduction, iRNA can be injected into a tissue site or administered systemically. *In vitro* introduction into a cell includes methods known in the art such as electroporation and lipofection. Further approaches are described herein below or are known in the art.

The term “lipid nanoparticle” or “LNP” is a vesicle comprising a lipid layer encapsulating a pharmaceutically active molecule, such as a nucleic acid molecule, *e.g.*, an iRNA or a plasmid from which an iRNA is transcribed. LNPs are described in, for example, U.S. Patent Nos. 6,858,225, 6,815,432, 8,158,601, and 8,058,069, the entire contents of which are hereby incorporated herein by reference.

As used herein, a “subject” is an animal, such as a mammal, including a primate (such as a human, a non-human primate, *e.g.*, a monkey, and a chimpanzee), a non-primate (such as a cow, a pig, a horse, a goat, a rabbit, a sheep, a hamster, a guinea pig, a cat, a dog, a rat, or a mouse), or a bird that expresses the target gene, either endogenously or heterologously. In an embodiment, the subject is a human, such as a human being treated or assessed for a disease or disorder that would benefit from reduction in KHK expression; a human at risk for a disease or disorder that would benefit from reduction in KHK expression; a human having a disease or disorder that would benefit from reduction in KHK expression; or human being treated for a disease or disorder that would benefit from reduction in KHK expression as described herein. In some embodiments, the subject is a female human. In other embodiments, the subject is a male human. In one embodiment, the subject is an adult subject. In another embodiment, the subject is a pediatric subject.

As used herein, the terms “treating” or “treatment” refer to a beneficial or desired result, such as reducing at least one sign or symptom of a KHK-associated disorder in a subject. Treatment also includes a reduction of one or more sign or symptoms associated with unwanted KHK expression; diminishing the extent of unwanted KHK activation or stabilization; amelioration or palliation of unwanted KHK activation or stabilization. “Treatment” can also mean prolonging survival as compared to expected survival in the absence of treatment. The term “lower” in the context of the level of KHK in a subject or a disease marker or symptom refers to a statistically significant decrease in such level. The decrease can be, for example, at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more. In certain embodiments, a decrease is at least 20%. In certain embodiments, the decrease is at least 50% in a disease marker, *e.g.*, protein or gene expression level. “Lower” in the context of the level of KHK in a subject is a

decrease to a level accepted as within the range of normal for an individual without such disorder. In certain embodiments, “lower” is the decrease in the difference between the level of a marker or symptom for a subject suffering from a disease and a level accepted within the range of normal for an individual, *e.g.*, the level of decrease in bodyweight between an obese individual and an individual having a weight accepted within the range of normal.

As used herein, “prevention” or “preventing,” when used in reference to a disease, disorder or condition thereof, may be treated or ameliorated by a reduction in expression of a KHK gene, refers to a reduction in the likelihood that a subject will develop a symptom associated with such a disease, disorder, or condition, *e.g.*, a symptom of unwanted or excessive KHK expression and/or activity, *e.g.*, increased fructose metabolism, elevated uric acid and lipid levels. Without being bound by mechanism, it is known that fructose phosphorylation catalyzed by KHK to form fructose-1-phosphate is not regulated by feedback inhibition which can result in depletion of ATP and intracellular phosphate, and increased AMP levels, which results in the production of uric acid. Further, the fructose-1-phosphate is metabolized to glyceraldehyde which feeds into the citric acid cycle increasing the production of acetyl Co-A stimulating fatty acid synthesis. Diseases and conditions associated with elevated uric acid and fatty acid synthesis include, *e.g.*, liver disease (*e.g.*, fatty liver, steatohepatitis including non-alcoholic steatohepatitis (NASH)), dyslipidemia (*e.g.*, hyperlipidemia, high LDL cholesterol, low HDL cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (*e.g.*, insulin resistance not related to immune response to insulin, type 2 diabetes), cardiovascular disease (*e.g.*, hypertension, endothelial cell dysfunction), kidney disease (*e.g.*, acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, chronic kidney disease), metabolic syndrome, disease of lipid deposition or dysfunction (*e.g.*, adipocyte dysfunction, visceral adipose deposition, obesity), disease of elevated uric acid (*e.g.*, hyperuricemia, gout), and eating disorders such as excessive sugar craving. The failure to develop a disease, disorder or condition, or the reduction in the development of a symptom or comorbidity associated with such a disease, disorder or condition (*e.g.*, by at least about 10% on a clinically accepted scale for that disease or disorder), or the exhibition of delayed signs or symptoms or disease progression by days, weeks, months or years is considered effective prevention.

As used herein, the term “ketohexokinase (KHK)-associated disease” or “KHK-associated disorder,” is a disease or disorder that is caused by, or associated with KHK gene expression or KHK protein production. The term “KHK-associated disease” includes a disease, disorder or condition that would benefit from a decrease in KHK gene expression, replication, or protein activity. Non-limiting examples of KHK-associated diseases include, for example, liver disease (*e.g.*, fatty liver, steatohepatitis including non-alcoholic steatohepatitis (NASH)), dyslipidemia (*e.g.*, hyperlipidemia, high LDL cholesterol, low HDL cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (*e.g.*, insulin resistance not related to immune response to insulin, type 2 diabetes), cardiovascular disease (*e.g.*, hypertension, endothelial cell dysfunction), kidney disease (*e.g.*, acute kidney disorder, tubular dysfunction, proinflammatory

changes to the proximal tubules, chronic kidney disease), metabolic syndrome, disease of lipid deposition or dysfunction (*e.g.*, adipocyte dysfunction, visceral adipose deposition, obesity), disease of elevated uric acid (*e.g.*, hyperuricemia, gout), and eating disorders such as excessive sugar craving.

In certain embodiments, a KHK-associated disease is associated with elevated uric acid (*e.g.* hyperuricemia, gout).

In certain embodiments, a KHK-associated disease is associated with elevated lipid levels (*e.g.*, fatty liver, steatohepatitis including non-alcoholic steatohepatitis (NASH), dyslipidemia).

"Therapeutically effective amount," as used herein, is intended to include the amount of an RNAi agent that, when administered to a subject having a KHK-associated disease, is sufficient to effect treatment of the disease (*e.g.*, by diminishing, ameliorating, or maintaining the existing disease or one or more symptoms of disease). The "therapeutically effective amount" may vary depending on the RNAi agent, how the agent is administered, the disease and its severity and the history, age, weight, family history, genetic makeup, the types of preceding or concomitant treatments, if any, and other individual characteristics of the subject to be treated.

"Prophylactically effective amount," as used herein, is intended to include the amount of an RNAi agent that, when administered to a subject having a KHK-associated disorder, is sufficient to prevent or ameliorate the disease or one or more symptoms of the disease. Ameliorating the disease includes slowing the course of the disease or reducing the severity of later-developing disease. The "prophylactically effective amount" may vary depending on the RNAi agent, how the agent is administered, the degree of risk of disease, and the history, age, weight, family history, genetic makeup, the types of preceding or concomitant treatments, if any, and other individual characteristics of the patient to be treated.

A "therapeutically-effective amount" or "prophylactically effective amount" also includes an amount of an RNAi agent that produces some desired effect at a reasonable benefit/risk ratio applicable to any treatment. The iRNA employed in the methods of the present invention may be administered in a sufficient amount to produce a reasonable benefit/risk ratio applicable to such treatment.

The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds (including salts), materials, compositions, or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human subjects and animal subjects without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

The phrase "pharmaceutically-acceptable carrier" as used herein means a pharmaceutically-acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (*e.g.*, lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the

subject being treated. Such carriers are known in the art. Pharmaceutically acceptable carriers include carriers for administration by injection.

The term “lower” in the context of the level of KHK gene expression or KHK protein production in a subject, or a disease marker or symptom refers to a statistically significant decrease in such level. The decrease can be, for example, at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or below the level of detection for the detection method. In certain embodiments, the expression of the target is normalized, *i.e.*, decreased towards or to a level accepted as within the range of normal for an individual without such disorder, *e.g.*, normalization of body weight, blood pressure, or a serum lipid level. As used here, “lower” in a subject can refer to lowering of gene expression or protein production in a cell in a subject does not require lowering of expression in all cells or tissues of a subject. For example, as used herein, lowering in a subject can include lowering of gene expression or protein production in the liver of a subject.

The term “lower” can also be used in association with normalizing a symptom of a disease or condition, *i.e.* decreasing the difference between a level in a subject suffering from a KHK-associated disease towards or to a level in a normal subject not suffering from a KHK-associated disease. For example, if a subject with a normal weight of 70 kg weighs 90 kg prior to treatment (20 kg overweight) and 80 kg after treatment (10 kg overweight), the subject’s weight is lowered towards a normal weight by 50% ($10/20 \times 100\%$). Similarly, if the HDL level of a woman is increased from 50 mg/dL (poor) to 57 mg/dL, with a normal level being 60 mg/dL, the difference between the prior level of the subject and the normal level is decreased by 70% (difference of 10 mg/dL between subject level and normal is decreased by 7 mg/dL, $7/10 \times 100\%$). As used herein, if a disease is associated with an elevated value for a symptom, “normal” is considered to be the upper limit of normal. If a disease is associated with a decreased value for a symptom, “normal” is considered to be the lower limit of normal.

The term “sample,” as used herein, includes a collection of similar fluids, cells, or tissues isolated from a subject, as well as fluids, cells, or tissues present within a subject. Examples of biological fluids include blood, serum and serosal fluids, plasma, cerebrospinal fluid, ocular fluids, lymph, urine, saliva, and the like. Tissue samples may include samples from tissues, organs, or localized regions. For example, samples may be derived from particular organs, parts of organs, or fluids or cells within those organs. In certain embodiments, samples may be derived from the liver (*e.g.*, whole liver or certain segments of liver or certain types of cells in the liver, such as, *e.g.*, hepatocytes). In some embodiments, a “sample derived from a subject” refers to urine obtained from the subject. A “sample derived from a subject” can refer to blood (which can be readily converted to plasma or serum) drawn from the subject.

II. iRNAs of the Invention

The present invention provides iRNAs which inhibit the expression of a KHK gene. In certain embodiments, the iRNA includes double stranded ribonucleic acid (dsRNA) molecules for inhibiting the expression of a KHK gene in a cell, such as a cell within a subject, *e.g.*, a mammal, such as a human having or susceptible to developing a KHK-associated disease. The dsRNAi agent includes an antisense strand having a region of complementarity which is complementary to at least a part of an mRNA formed in the expression of a KHK gene. The region of complementarity is about 30 nucleotides or less in length (*e.g.*, about 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, or 18 nucleotides or less in length). Upon contact with a cell expressing the KHK gene, the iRNA inhibits the expression of the KHK gene (*e.g.*, a human, a primate, a non-primate, or a rat KHK gene) by at least about 50% as assayed by, for example, a PCR or branched DNA (bDNA)-based method, or by a protein-based method, such as by immunofluorescence analysis, using, for example, western blotting or flow cytometric techniques. In certain embodiments, inhibition of expression is determined by the qPCR method provided in the examples herein with the siRNA at, *e.g.*, a 10 nM concentration, in an appropriate organism cell line provided therein. In certain embodiments, inhibition of expression in vivo is determined by knockdown of the human gene in a rodent expressing the human gene, *e.g.*, a mouse or an AAV-infected mouse expressing the human target gene, *e.g.*, when administered as single dose, *e.g.*, at 3 mg/kg at the nadir of RNA expression.

A dsRNA includes two RNA strands that are complementary and hybridize to form a duplex structure under conditions in which the dsRNA will be used. One strand of a dsRNA (the antisense strand) includes a region of complementarity that is substantially complementary, and generally fully complementary, to a target sequence. The target sequence can be derived from the sequence of an mRNA formed during the expression of a KHK gene. The other strand (the sense strand) includes a region that is complementary to the antisense strand, such that the two strands hybridize and form a duplex structure when combined under suitable conditions. As described elsewhere herein and as known in the art, the complementary sequences of a dsRNA can also be contained as self-complementary regions of a single nucleic acid molecule, as opposed to being on separate oligonucleotides.

Generally, the duplex structure is 15 to 30 base pairs in length, *e.g.*, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs in length. In certain embodiments, the duplex structure is 18 to 25 base pairs in length, *e.g.*, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-25, 20-24, 20-23, 20-22, 20-21, 21-25, 21-24, 21-23, 21-22, 22-25, 22-24, 22-23, 23-25, 23-24 or 24-25 base pairs in length, for example, 19-21 basepairs in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the disclosure.

Similarly, the region of complementarity to the target sequence is 15 to 30 nucleotides in length, *e.g.*, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length, for example 19-23 nucleotides in length or 21-23 nucleotides in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the disclosure. In some embodiments, the duplex structure is 19 to 30 base pairs in length. Similarly, the region of complementarity to the target sequence is 19 to 30 nucleotides in length.

In some embodiments, the dsRNA is about 19 to about 23 nucleotides in length, or about 25 to about 30 nucleotides in length. In general, the dsRNA is long enough to serve as a substrate for the Dicer enzyme. For example, it is well-known in the art that dsRNAs longer than about 21-23 nucleotides in length may serve as substrates for Dicer. As the ordinarily skilled person will also recognize, the region of an RNA targeted for cleavage will most often be part of a larger RNA molecule, often an mRNA molecule. Where relevant, a “part” of an mRNA target is a contiguous sequence of an mRNA target of sufficient length to allow it to be a substrate for RNAi-directed cleavage (*i.e.*, cleavage through a RISC pathway).

One of skill in the art will also recognize that the duplex region is a primary functional portion of a dsRNA, *e.g.*, a duplex region of about 19 to about 30 base pairs, *e.g.*, about 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs. Thus, in one embodiment, to the extent that it becomes processed to a functional duplex, of *e.g.*, 15-30 base pairs, that targets a desired RNA for cleavage, an RNA molecule or complex of RNA molecules having a duplex region greater than 30 base pairs is a dsRNA. Thus, an ordinarily skilled artisan will recognize that in one embodiment, a miRNA is a dsRNA. In another embodiment, a dsRNA is not a naturally occurring miRNA. In another embodiment, an iRNA agent useful to target KHK gene expression is not generated in the target cell by cleavage of a larger dsRNA.

A dsRNA as described herein can further include one or more single-stranded nucleotide overhangs *e.g.*, 1-4, 2-4, 1-3, 2-3, 1, 2, 3, or 4 nucleotides. dsRNAs having at least one nucleotide overhang can have superior inhibitory properties relative to their blunt-ended counterparts. A nucleotide overhang can comprise or consist of a nucleotide/nucleoside analog, including a deoxynucleotide/nucleoside. The overhang(s) can be on the sense strand, the antisense strand, or any combination thereof. Furthermore, the nucleotide(s) of an overhang can be present on the 5'-end, 3'-end, or both ends of an antisense or sense strand of a dsRNA.

A dsRNA can be synthesized by standard methods known in the art. Double stranded RNAi compounds of the invention may be prepared using a two-step procedure. First, the individual strands of the double stranded RNA molecule are prepared separately. Then, the component strands are annealed. The individual strands of the siRNA compound can be prepared using solution-phase or

solid-phase organic synthesis or both. Organic synthesis offers the advantage that the oligonucleotide strands comprising unnatural or modified nucleotides can be easily prepared. Similarly, single-stranded oligonucleotides of the invention can be prepared using solution-phase or solid-phase organic synthesis or both.

5 In an aspect, a dsRNA of the invention includes at least two nucleotide sequences, a sense sequence and an anti-sense sequence. The sense strand is selected from the group of sequences provided in any one of Tables 2, 3, 5, 6, and 8-13, and the corresponding antisense strand of the sense strand is selected from the group of sequences of any one of Tables 2, 3, 5, 6, and 8-13. In this aspect, one of the two sequences is complementary to the other of the two sequences, with one of the
10 sequences being substantially complementary to a sequence of an mRNA generated in the expression of a KHK gene. As such, in this aspect, a dsRNA will include two oligonucleotides, where one oligonucleotide is described as the sense strand in any one of Tables 2, 3, 5, 6, and 8-13, and the second oligonucleotide is described as the corresponding antisense strand of the sense strand in any one of Tables 2, 3, 5, 6, and 8-13.

15 In certain embodiments, the substantially complementary sequences of the dsRNA are contained on separate oligonucleotides. In other embodiments, the substantially complementary sequences of the dsRNA are contained on a single oligonucleotide.

In certain embodiments, the sense or antisense strand is selected from the sense or antisense strand of any one of duplexes AD-517197.2; AD-517258.2; AD-516748.2; AD-516851.2; AD-
20 519351.2; AD-519754.2; AD-519828.2; AD-520018.2; AD-520035.2; AD-520062.2; AD-520064.2; AD-520065.2; AD-520067.2; AD-75289.2; AD-520069.2; AD-520099.2; AD-67575.7; AD-520101.2; AD-1193323.1; AD-1193344.1; AD-1193350.1; AD-1193365.1; AD-1193379.1; AD-1193407.1; AD-1193421.1; AD-1193422.1; AD-1193429.1; AD-1193437.1; AD-1193443.1; AD-1193471.1; AD-1193481.1 or AD-67605.7.

25 In some embodiments, the sense or antisense strand is selected from the sense or antisense strand of any one of duplexes AD-519345.1, AD-519346.1, AD-519347.1, AD-67554.7, AD-519752.3, AD-1010731.1, AD-1010732.1, AD-519343.1, AD-519344.1, AD-519349.1, AD-519350.1, AD-519753.2, AD-519932.1, AD-519935.2, AD-520018.6, AD-517837.2, AD-805635.2, AD-519329.2, AD-520063.2, AD-519757.2, AD-805631.2, AD-516917.2, AD-516828.2, AD-
30 518983.2, AD-805636.2, AD-519754.7, AD-520062.2, AD-67575.9, AD-518923.3, AD-520053.4, AD-519667.2, AD-519773.2, AD-519354.2, AD-520060.4, AD-520061.4, AD-1010733.2, AD-1010735.2, AD-1193323.1; AD-1193344.1; AD-1193350.1; AD-1193365.1; AD-1193379.1; AD-1193407.1; AD-1193421.1; AD-1193422.1; AD-1193429.1; AD-1193437.1; AD-1193443.1; AD-1193471.1; or AD-1193481.1.

35 In some embodiments, the sense or antisense strand is selected from the sense or antisense strand of duplex AD-519351.

It will be understood that, although the sequences in, for example, Tables 2, 5, 8 and 10 are not described as modified or conjugated sequences, the RNA of the iRNA of the invention *e.g.*, a

dsRNA of the invention, may comprise any one of the sequences set forth in any one of Tables 2, 3, 5, 6, and 8-13 that is un-modified, un-conjugated, or modified or conjugated differently than described therein. In other words, the invention encompasses dsRNA of Tables 2, 3, 5, 6, and 8-13 which are un-modified, un-conjugated, modified, or conjugated, as described herein.

5 The skilled person is well aware that dsRNAs having a duplex structure of about 20 to 23 base pairs, *e.g.*, 21, base pairs have been hailed as particularly effective in inducing RNA interference (Elbashir *et al.*, EMBO 2001, 20:6877-6888). However, others have found that shorter or longer RNA duplex structures can also be effective (Chu and Rana (2007) RNA 14:1714-1719; Kim *et al.* (2005) Nat Biotech 23:222-226). In the embodiments described above, by virtue of the nature of the
10 oligonucleotide sequences provided in any one of Tables 2, 3, 5, 6, and 8-13. dsRNAs described herein can include at least one strand of a length of minimally 21 nucleotides. It can be reasonably expected that shorter duplexes having any one of the sequences in any one of Tables 2, 3, 5, 6, and 8-13 minus only a few nucleotides on one or both ends can be similarly effective as compared to the dsRNAs described above. Hence, dsRNAs having a sequence of at least 19, 20, 21, 22, 23 or more
15 contiguous nucleotides derived from any one of the sequences of any one of Tables 2, 3, 5, 6, and 8-13, and differing in their ability to inhibit the expression of a KHK gene by not more than about 5, 10, 15, 20, 25, or 30 % inhibition from a dsRNA comprising the full sequence, are contemplated to be within the scope of the present invention.

In addition, the RNAs provided in Tables 2, 3, 5, 6, and 8-13 identify a site(s) in a KHK
20 transcript that is susceptible to RISC-mediated cleavage. As such, the present invention further features iRNAs that target within one of these sites. As used herein, an iRNA is said to target within a particular site of an RNA transcript if the iRNA promotes cleavage of the transcript anywhere within that particular site. Such an iRNA will generally include at least about 19 contiguous nucleotides from any one of the sequences provided in any one of Tables 2, 3, 5, 6, and 8-13 coupled to additional
25 nucleotide sequences taken from the region contiguous to the selected sequence in a KHK gene.

III. Modified iRNAs of the Invention

In certain embodiments, the RNA of the iRNA of the invention *e.g.*, a dsRNA, is un-modified, and does not comprise, *e.g.*, chemical modifications or conjugations known in the art and
30 described herein. In other embodiments, the RNA of an iRNA of the invention, *e.g.*, a dsRNA, is chemically modified to enhance stability or other beneficial characteristics. In certain embodiments of the invention, substantially all of the nucleotides of an iRNA of the invention are modified. In other embodiments of the invention, all of the nucleotides of an iRNA or substantially all of the nucleotides of an iRNA are modified, *i.e.*, not more than 5, 4, 3, 2, or 1 unmodified nucleotides are present in a
35 strand of the iRNA.

The nucleic acids featured in the invention can be synthesized or modified by methods well established in the art, such as those described in "Current protocols in nucleic acid chemistry," Beaucage, S.L. *et al.* (Edrs.), John Wiley & Sons, Inc., New York, NY, USA, which is hereby

incorporated herein by reference. Modifications include, for example, end modifications, *e.g.*, 5'-end modifications (phosphorylation, conjugation, inverted linkages) or 3'-end modifications (conjugation, DNA nucleotides, inverted linkages, *etc.*); base modifications, *e.g.*, replacement with stabilizing bases, destabilizing bases, or bases that base pair with an expanded repertoire of partners, removal of bases (abasic nucleotides), or conjugated bases; sugar modifications (*e.g.*, at the 2'-position or 4'-position) or replacement of the sugar; or backbone modifications, including modification or replacement of the phosphodiester linkages. Specific examples of iRNA compounds useful in the embodiments described herein include, but are not limited to RNAs containing modified backbones or no natural internucleoside linkages. RNAs having modified backbones include, among others, those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified RNAs that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides. In some embodiments, a modified iRNA will have a phosphorus atom in its internucleoside backbone.

Modified RNA backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5'-linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included. In some embodiments of the invention, the dsRNA agents of the invention are in a free acid form. In other embodiments of the invention, the dsRNA agents of the invention are in a salt form. In one embodiment, the dsRNA agents of the invention are in a sodium salt form. In certain embodiments, when the dsRNA agents of the invention are in the sodium salt form, sodium ions are present in the agent as counterions for substantially all of the phosphodiester and/or phosphorothioate groups present in the agent. Agents in which substantially all of the phosphodiester and/or phosphorothioate linkages have a sodium counterion include not more than 5, 4, 3, 2, or 1 phosphodiester and/or phosphorothioate linkages without a sodium counterion. In some embodiments, when the dsRNA agents of the invention are in the sodium salt form, sodium ions are present in the agent as counterions for all of the phosphodiester and/or phosphorothioate groups present in the agent.

Representative U.S. Patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Patent Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,195; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,316; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,625,050; 6,028,188; 6,124,445; 6,160,109; 6,169,170; 6,172,209; 6,239,265; 6,277,603; 6,326,199; 6,346,614; 6,444,423; 6,531,590; 6,534,639; 6,608,035; 6,683,167; 6,858,715;

6,867,294; 6,878,805; 7,015,315; 7,041,816; 7,273,933; 7,321,029; and U.S. Pat RE39464, the entire contents of each of which are hereby incorporated herein by reference.

Modified RNA backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatoms and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S, and CH₂ component parts.

Representative U.S. Patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Patent Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,64,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, the entire contents of each of which are hereby incorporated herein by reference.

Suitable RNA mimetics are contemplated for use in iRNAs provided herein, in which both the sugar and the internucleoside linkage, *i.e.*, the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound in which an RNA mimetic that has been shown to have excellent hybridization properties is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar backbone of an RNA is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to nitrogen atoms of the amide portion of the backbone. Representative US patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Patent Nos. 5,539,082; 5,714,331; and 5,719,262, the entire contents of each of which are hereby incorporated herein by reference. Additional PNA compounds suitable for use in the iRNAs of the invention are described in, for example, in Nielsen *et al.*, *Science*, 1991, 254, 1497-1500.

Some embodiments featured in the invention include RNAs with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular --CH₂--NH--CH₂--, --CH₂--N(CH₃)--O--CH₂--[known as a methylene (methylimino) or MMI backbone], --CH₂--O--N(CH₃)--CH₂--, --CH₂--N(CH₃)--N(CH₃)--CH₂-- and --N(CH₃)--CH₂--CH₂-- of the above-referenced U.S. Patent No. 5,489,677, and the amide backbones of the above-referenced U.S. Patent No. 5,602,240. In some embodiments, the RNAs featured herein have morpholino backbone structures of the above-referenced U.S. Patent No. 5,034,506. The native phosphodiester backbone can be represented as O-P(O)(OH)-OCH₂-.

Modified RNAs can also contain one or more substituted sugar moieties. The iRNAs, *e.g.*, dsRNAs, featured herein can include one of the following at the 2'-position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl can be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Exemplary suitable modifications include O[(CH₂)_nO]_mCH₃, O(CH₂)_nOCH₃, O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nONH₂, and O(CH₂)_nON[(CH₂)_nCH₃]₂, where n and m are from 1 to about 10. In other embodiments, dsRNAs include one of the following at the 2' position: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an iRNA, or a group for improving the pharmacodynamic properties of an iRNA, and other substituents having similar properties. In some embodiments, the modification includes a 2'-methoxyethoxy (2'-O--CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin *et al.*, *Helv. Chim. Acta*, 1995, 78:486-504) *i.e.*, an alkoxy-alkoxy group. Another exemplary modification is 2'-dimethylaminoethoxy, *i.e.*, a O(CH₂)₂ON(CH₃)₂ group, also known as 2'-DMAOE, as described in examples herein below, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), *i.e.*, 2'-O--CH₂--O--CH₂--N(CH₃)₂. Further exemplary modifications include : 5'-Me-2'-F nucleotides, 5'-Me-2'-OMe nucleotides, 5'-Me-2'-deoxynucleotides, (both R and S isomers in these three families); 2'-alkoxyalkyl; and 2'-NMA (N-methylacetamide).

Other modifications include 2'-methoxy (2'-OCH₃), 2'-aminopropoxy (2'-OCH₂CH₂CH₂NH₂) and 2'-fluoro (2'-F). Similar modifications can also be made at other positions on the RNA of an iRNA, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked dsRNAs and the 5' position of 5' terminal nucleotide. iRNAs can also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative US patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Patent Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, certain of which are commonly owned with the instant application,. The entire contents of each of the foregoing are hereby incorporated herein by reference.

An iRNA can also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C), and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as deoxythymidine (dT), 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil

and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo, particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-


5 deazaguanine and 7-daazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in *Modified Nucleosides in Biochemistry, Biotechnology and Medicine*, Herdewijn, P. ed. Wiley-VCH, 2008; those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J. L., ed. John Wiley & Sons, 1990, these disclosed by Englisch *et al.*, *Angewandte Chemie, International*
 10 *Edition*, 1991, 30, 613, and those disclosed by Sanghvi, Y S., Chapter 15, *dsRNA Research and Applications*, pages 289-302, Crooke, S. T. and Lebleu, B., Ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds featured in the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-
 15 methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., Eds., *dsRNA Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are exemplary base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative U.S. Patents that teach the preparation of certain of the above noted modified
 20 nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Patent Nos. 3,687,808, 4,845,205; 5,130,30; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,681,941; 5,750,692; 6,015,886; 6,147,200; 6,166,197; 6,222,025; 6,235,887; 6,380,368; 6,528,640; 6,639,062; 6,617,438; 7,045,610; 7,427,672; and 7,495,088, the entire contents of each of
 25 which are hereby incorporated herein by reference.

An iRNA agent of the disclosure can also be modified to include one or more bicyclic sugar moieties. A "bicyclic sugar" is a furanosyl ring modified by a ring formed by the bridging of two carbons, whether adjacent or non-adjacent. A "bicyclic nucleoside" ("BNA") is a nucleoside having a sugar moiety comprising a ring formed by bridging two carbons, whether adjacent or non-adjacent, of
 30 the sugar ring, thereby forming a bicyclic ring system. In certain embodiments, the bridge connects the 4'-carbon and the 2'-carbon of the sugar ring, optionally, via the 2'-acyclic oxygen atom. Thus, in some embodiments an agent of the invention may include one or more locked nucleic acids (LNA). A locked nucleic acid is a nucleotide having a modified ribose moiety in which the ribose moiety comprises an extra bridge connecting the 2' and 4' carbons. In other words, an LNA is a nucleotide
 35 comprising a bicyclic sugar moiety comprising a 4'-CH₂-O-2' bridge. This structure effectively "locks" the ribose in the 3'-endo structural conformation. The addition of locked nucleic acids to siRNAs has been shown to increase siRNA stability in serum, and to reduce off-target effects (Elmen, J. *et al.*, (2005) *Nucleic Acids Research* 33(1):439-447; Mook, OR. *et al.*, (2007) *Mol Canc Ther*

6(3):833-843; Grunweller, A. *et al.*, (2003) *Nucleic Acids Research* 31(12):3185-3193). Examples of bicyclic nucleosides for use in the polynucleotides of the invention include without limitation nucleosides comprising a bridge between the 4' and the 2' ribosyl ring atoms. In certain embodiments, the antisense polynucleotide agents of the invention include one or more bicyclic nucleosides comprising a 4' to 2' bridge.

A locked nucleoside can be represented by the structure (omitting stereochemistry),



wherein B is a nucleobase or modified nucleobase and L is the linking group that joins the 2'-carbon to the 4'-carbon of the ribose ring. Examples of such 4' to 2' bridged bicyclic nucleosides, include but are not limited to 4'-(CH₂)—O-2' (LNA); 4'-(CH₂)—S-2'; 4'-(CH₂)₂—O-2' (ENA); 4'-CH(CH₃)—O-2' (also referred to as "constrained ethyl" or "cEt") and 4'-CH(CH₂OCH₃)—O-2' (and analogs thereof; see, *e.g.*, U.S. Patent No. 7,399,845); 4'-C(CH₃)(CH₃)—O-2' (and analogs thereof; see *e.g.*, U.S. Patent No. 8,278,283); 4'-CH₂—N(OCH₃)-2' (and analogs thereof; see *e.g.*, U.S. Patent No. 8,278,425); 4'-CH₂—O—N(CH₃)-2' (see, *e.g.*, U.S. Patent Publication No. 2004/0171570); 4'-CH₂—N(R)—O-2', wherein R is H, C1-C12 alkyl, or a nitrogen protecting group (see, *e.g.*, U.S. Patent No. 7,427,672); 4'-CH₂—C(H)(CH₃)-2' (see, *e.g.*, Chattopadhyaya *et al.*, *J. Org. Chem.*, 2009, 74, 118-134); and 4'-CH₂—C(=CH₂)-2' (and analogs thereof; see, *e.g.*, U.S. Patent No. 8,278,426). The entire contents of each of the foregoing are hereby incorporated herein by reference.

Additional representative U.S. Patents and U.S. Patent Publications that teach the preparation of locked nucleic acid nucleotides include, but are not limited to, the following: U.S. Patent Nos. 6,268,490; 6,525,191; 6,670,461; 6,770,748; 6,794,499; 6,998,484; 7,053,207; 7,034,133; 7,084,125; 7,399,845; 7,427,672; 7,569,686; 7,741,457; 8,022,193; 8,030,467; 8,278,425; 8,278,426; 8,278,283; US 2008/0039618; and US 2009/0012281, the entire contents of each of which are hereby incorporated herein by reference.

Any of the foregoing bicyclic nucleosides can be prepared having one or more stereochemical sugar configurations including for example α -L-ribofuranose and β -D-ribofuranose (see WO 99/14226).

The RNA of an iRNA can also be modified to include one or more constrained ethyl nucleotides. As used herein, a "constrained ethyl nucleotide" or "cEt" is a locked nucleic acid comprising a bicyclic sugar moiety comprising a 4'-CH(CH₃)-O-2' bridge (*i.e.*, L in the preceding structure). In one embodiment, a constrained ethyl nucleotide is in the S conformation referred to herein as "S-cEt."

An iRNA of the invention may also include one or more “conformationally restricted nucleotides” (“CRN”). CRN are nucleotide analogs with a linker connecting the C2' and C4' carbons of ribose or the C3 and -C5' carbons of ribose. CRN lock the ribose ring into a stable conformation and increase the hybridization affinity to mRNA. The linker is of sufficient length to place the oxygen in an optimal position for stability and affinity resulting in less ribose ring puckering.

Representative publications that teach the preparation of certain of the above noted CRN include, but are not limited to, U.S. Patent Publication No. 2013/0190383; and PCT publication WO 2013/036868, the entire contents of each of which are hereby incorporated herein by reference.

In some embodiments, an iRNA of the invention comprises one or more monomers that are UNA (unlocked nucleic acid) nucleotides. UNA is unlocked acyclic nucleic acid, wherein any of the bonds of the sugar has been removed, forming an unlocked "sugar" residue. In one example, UNA also encompasses monomer with bonds between C1'-C4' have been removed (*i.e.* the covalent carbon-oxygen-carbon bond between the C1' and C4' carbons). In another example, the C2'-C3' bond (*i.e.* the covalent carbon-carbon bond between the C2' and C3' carbons) of the sugar has been removed (see *Nuc. Acids Symp. Series*, 52, 133-134 (2008) and Fluiter *et al.*, *Mol. Biosyst.*, 2009, 10, 1039 hereby incorporated by reference).

Representative U.S. publications that teach the preparation of UNA include, but are not limited to, U.S. Patent No. 8,314,227; and U.S. Patent Publication Nos. 2013/0096289; 2013/0011922; and 2011/0313020, the entire contents of each of which are hereby incorporated herein by reference.

Potentially stabilizing modifications to the ends of RNA molecules can include N-(acetylaminocaproyl)-4-hydroxyprolinol (Hyp-C6-NHAc), N-(caproyl-4-hydroxyprolinol (Hyp-C6), N-(acetyl-4-hydroxyprolinol (Hyp-NHAc), thymidine-2'-O-deoxythymidine (ether), N-(aminocaproyl)-4-hydroxyprolinol (Hyp-C6-amino), 2-docosanoyl-uridine-3'-phosphate, inverted 2'-deoxy-modified ribonucleotide, such as inverted dT(idT), inverted dA (idA), and inverted abasic 2'-deoxyribonucleotide (iAb) and others. Disclosure of this modification can be found in WO 2011/005861.

In one example, the 3' or 5' terminal end of an oligonucleotide is linked to an inverted 2'-deoxy-modified ribonucleotide, such as inverted dT(idT), inverted dA (idA), or an inverted abasic 2'-deoxyribonucleotide (iAb). In one particular example, the inverted 2'-deoxy-modified ribonucleotide is linked to the 3' end of an oligonucleotide, such as the 3' end of a sense strand described herein, where the linking is via a 3'-3' phosphodiester linkage or a 3'-3'-phosphorothioate linkage.

In another example, the 3' end of a sense strand is linked via a 3'-3'-phosphorothioate linkage to an inverted abasic ribonucleotide (iAb). In another example, the 3' end of a sense strand is linked via a 3'-3'-phosphorothioate linkage to an inverted dA (idA).

In one particular example, the inverted 2'-deoxy-modified ribonucleotide is linked to the 3' end of an oligonucleotide, such as the 3' end of a sense strand described herein, where the linking is via a 3'-3' phosphodiester linkage or a 3'-3'-phosphorothioate linkage.

In another example, the 3'-terminal nucleotides of a sense strand is an inverted dA (idA) and is linked to the preceding nucleotide via a 3'-3'- linkage (e.g., 3'-3'-phosphorothioate linkage).

Other modifications of the nucleotides of an iRNA of the invention include a 5' phosphate or 5' phosphate mimic, e.g., a 5'-terminal phosphate or phosphate mimic on the antisense strand of an iRNA. Suitable phosphate mimics are disclosed in, for example U.S. Patent Publication No. 2012/0157511, the entire contents of which are incorporated herein by reference.

A. Modified iRNAs Comprising Motifs of the Invention

In certain aspects of the invention, the double stranded RNA agents of the invention include agents with chemical modifications as disclosed, for example, in WO2013/075035, the entire contents of each of which are incorporated herein by reference. As shown herein and in WO2013/075035, one or more motifs of three identical modifications on three consecutive nucleotides may be introduced into a sense strand or antisense strand of a dsRNAi agent, particularly at or near the cleavage site. In some embodiments, the sense strand and antisense strand of the dsRNAi agent may otherwise be completely modified. The introduction of these motifs interrupts the modification pattern, if present, of the sense or antisense strand. The dsRNAi agent may be optionally conjugated with a GalNAc derivative ligand, for instance on the sense strand.

More specifically, when the sense strand and antisense strand of the double stranded RNA agent are completely modified to have one or more motifs of three identical modifications on three consecutive nucleotides at or near the cleavage site of at least one strand of a dsRNAi agent, the gene silencing activity of the dsRNAi agent was observed.

Accordingly, the invention provides double stranded RNA agents capable of inhibiting the expression of a target gene (i.e., KHK gene) *in vivo*. The RNAi agent comprises a sense strand and an antisense strand. Each strand of the RNAi agent may be, for example, 17-30 nucleotides in length, 25-30 nucleotides in length, 27-30 nucleotides in length, 19-25 nucleotides in length, 19-23 nucleotides in length, 19-21 nucleotides in length, 21-25 nucleotides in length, or 21-23 nucleotides in length.

The sense strand and antisense strand typically form a duplex double stranded RNA ("dsRNA"), also referred to herein as "dsRNAi agent." The duplex region of a dsRNAi agent may be, for example, the duplex region can be 27-30 nucleotide pairs in length, 19-25 nucleotide pairs in length, 19-23 nucleotide pairs in length, 19-21 nucleotide pairs in length, 21-25 nucleotide pairs in length, or 21-23 nucleotide pairs in length. In another example, the duplex region is selected from 19, 20, 21, 22, 23, 24, 25, 26, and 27 nucleotides in length.

In certain embodiments, the dsRNAi agent may contain one or more overhang regions or capping groups at the 3'-end, 5'-end, or both ends of one or both strands. The overhang can be, independently, 1-6 nucleotides in length, for instance 2-6 nucleotides in length, 1-5 nucleotides in length, 2-5 nucleotides in length, 1-4 nucleotides in length, 2-4 nucleotides in length, 1-3 nucleotides in length, 2-3 nucleotides in length, or 1-2 nucleotides in length. In certain embodiments, the

overhang regions can include extended overhang regions as provided above. The overhangs can be the result of one strand being longer than the other, or the result of two strands of the same length being staggered. The overhang can form a mismatch with the target mRNA or it can be complementary to the gene sequences being targeted or can be another sequence. The first and second strands can also be joined, *e.g.*, by additional bases to form a hairpin, or by other non-base linkers.

In certain embodiments, the nucleotides in the overhang region of the dsRNAi agent can each independently be a modified or unmodified nucleotide including, but not limited to 2'-sugar modified, such as, 2'-F, 2'-O-methyl, thymidine (T), 2'-O-methoxyethyl-5-methyluridine (Teo), 2'-O-methoxyethyladenosine (Aeo), 2'-O-methoxyethyl-5-methylcytidine (m5Ceo), and any combinations thereof.

For example, TT can be an overhang sequence for either end on either strand. The overhang can form a mismatch with the target mRNA or it can be complementary to the gene sequences being targeted or can be another sequence.

The 5'- or 3'- overhangs at the sense strand, antisense strand, or both strands of the dsRNAi agent may be phosphorylated. In some embodiments, the overhang region(s) contains two nucleotides having a phosphorothioate between the two nucleotides, where the two nucleotides can be the same or different. In some embodiments, the overhang is present at the 3'-end of the sense strand, antisense strand, or both strands. In some embodiments, this 3'-overhang is present in the antisense strand. In some embodiments, this 3'-overhang is present in the sense strand.

The dsRNAi agent may contain only a single overhang, which can strengthen the interference activity of the RNAi, without affecting its overall stability. For example, the single-stranded overhang may be located at the 3'-end of the sense strand or, alternatively, at the 3'-end of the antisense strand. The RNAi may also have a blunt end, located at the 5'-end of the antisense strand (or the 3'-end of the sense strand) or *vice versa*. Generally, the antisense strand of the dsRNAi agent has a nucleotide overhang at the 3'-end, and the 5'-end is blunt. While not wishing to be bound by theory, the asymmetric blunt end at the 5'-end of the antisense strand and 3'-end overhang of the antisense strand favor the guide strand loading into RISC process.

In certain embodiments, the dsRNAi agent is a double blunt-ended of 19 nucleotides in length, wherein the sense strand contains at least one motif of three 2'-F modifications on three consecutive nucleotides at positions 7, 8, and 9 from the 5' end. The antisense strand contains at least one motif of three 2'-O-methyl modifications on three consecutive nucleotides at positions 11, 12, and 13 from the 5' end.

In other embodiments, the dsRNAi agent is a double blunt-ended of 20 nucleotides in length, wherein the sense strand contains at least one motif of three 2'-F modifications on three consecutive nucleotides at positions 8, 9, and 10 from the 5' end. The antisense strand contains at least one motif of three 2'-O-methyl modifications on three consecutive nucleotides at positions 11, 12, and 13 from the 5' end.

In yet other embodiments, the dsRNAi agent is a double blunt-ended of 21 nucleotides in length, wherein the sense strand contains at least one motif of three 2'-F modifications on three consecutive nucleotides at positions 9, 10, and 11 from the 5' end. The antisense strand contains at least one motif of three 2'-O-methyl modifications on three consecutive nucleotides at positions 11, 12, and 13 from the 5' end.

In certain embodiments, the dsRNAi agent comprises a 21 nucleotide sense strand and a 23 nucleotide antisense strand, wherein the sense strand contains at least one motif of three 2'-F modifications on three consecutive nucleotides at positions 9, 10, and 11 from the 5' end; the antisense strand contains at least one motif of three 2'-O-methyl modifications on three consecutive nucleotides at positions 11, 12, and 13 from the 5' end, wherein one end of the RNAi agent is blunt, while the other end comprises a two nucleotide overhang. In some embodiments, the two nucleotide overhang is at the 3'-end of the antisense strand.

When the two nucleotide overhang is at the 3'-end of the antisense strand, there may be two phosphorothioate internucleotide linkages between the terminal three nucleotides, wherein two of the three nucleotides are the overhang nucleotides, and the third nucleotide is a paired nucleotide next to the overhang nucleotide. In one embodiment, the RNAi agent additionally has two phosphorothioate internucleotide linkages between the terminal three nucleotides at both the 5'-end of the sense strand and at the 5'-end of the antisense strand. In certain embodiments, every nucleotide in the sense strand and the antisense strand of the dsRNAi agent, including the nucleotides that are part of the motifs are modified nucleotides. In certain embodiments each residue is independently modified with a 2'-O-methyl or 2'-fluoro, *e.g.*, in an alternating motif. Optionally, the dsRNAi agent further comprises a ligand (such as, GalNAc₃).

In certain embodiments, the dsRNAi agent comprises a sense and an antisense strand, wherein the sense strand is 25-30 nucleotide residues in length, wherein starting from the 5' terminal nucleotide (position 1) positions 1 to 23 of the first strand comprise at least 8 ribonucleotides; the antisense strand is 36-66 nucleotide residues in length and, starting from the 3' terminal nucleotide, comprises at least 8 ribonucleotides in the positions paired with positions 1-23 of sense strand to form a duplex; wherein at least the 3' terminal nucleotide of antisense strand is unpaired with sense strand, and up to 6 consecutive 3' terminal nucleotides are unpaired with sense strand, thereby forming a 3' single stranded overhang of 1-6 nucleotides; wherein the 5' terminus of antisense strand comprises from 10-30 consecutive nucleotides which are unpaired with sense strand, thereby forming a 10-30 nucleotide single stranded 5' overhang; wherein at least the sense strand 5' terminal and 3' terminal nucleotides are base paired with nucleotides of antisense strand when sense and antisense strands are aligned for maximum complementarity, thereby forming a substantially duplexed region between sense and antisense strands; and antisense strand is sufficiently complementary to a target RNA along at least 19 ribonucleotides of antisense strand length to reduce target gene expression when the double stranded nucleic acid is introduced into a mammalian cell; and wherein the sense strand contains at least one motif of three 2'-F modifications on three consecutive nucleotides, where at least one of the

motifs occurs at or near the cleavage site. The antisense strand contains at least one motif of three 2'-O-methyl modifications on three consecutive nucleotides at or near the cleavage site.

In certain embodiments, the dsRNAi agent comprises sense and antisense strands, wherein the dsRNAi agent comprises a first strand having a length which is at least 25 and at most 29 nucleotides and a second strand having a length which is at most 30 nucleotides with at least one motif of three 2'-O-methyl modifications on three consecutive nucleotides at position 11, 12, 13 from the 5' end; wherein the 3' end of the first strand and the 5' end of the second strand form a blunt end and the second strand is 1-4 nucleotides longer at its 3' end than the first strand, wherein the duplex region which is at least 25 nucleotides in length, and the second strand is sufficiently complementary to a target mRNA along at least 19 nucleotide of the second strand length to reduce target gene expression when the RNAi agent is introduced into a mammalian cell, and wherein Dicer cleavage of the dsRNAi agent results in an siRNA comprising the 3'-end of the second strand, thereby reducing expression of the target gene in the mammal. Optionally, the dsRNAi agent further comprises a ligand.

In certain embodiments, the sense strand of the dsRNAi agent contains at least one motif of three identical modifications on three consecutive nucleotides, where one of the motifs occurs at the cleavage site in the sense strand.

In certain embodiments, the antisense strand of the dsRNAi agent can also contain at least one motif of three identical modifications on three consecutive nucleotides, where one of the motifs occurs at or near the cleavage site in the antisense strand.

For a dsRNAi agent having a duplex region of 19-23 nucleotides in length, the cleavage site of the antisense strand is typically around the 10, 11, and 12 positions from the 5'-end. Thus the motifs of three identical modifications may occur at the 9, 10, and 11 positions; the 10, 11, and 12 positions; the 11, 12, and 13 positions; the 12, 13, and 14 positions; or the 13, 14, and 15 positions of the antisense strand, the count starting from the first nucleotide from the 5'-end of the antisense strand, or, the count starting from the first paired nucleotide within the duplex region from the 5'-end of the antisense strand. The cleavage site in the antisense strand may also change according to the length of the duplex region of the dsRNAi agent from the 5'-end.

The sense strand of the dsRNAi agent may contain at least one motif of three identical modifications on three consecutive nucleotides at the cleavage site of the strand; and the antisense strand may have at least one motif of three identical modifications on three consecutive nucleotides at or near the cleavage site of the strand. When the sense strand and the antisense strand form a dsRNA duplex, the sense strand and the antisense strand can be so aligned that one motif of the three nucleotides on the sense strand and one motif of the three nucleotides on the antisense strand have at least one nucleotide overlap, *i.e.*, at least one of the three nucleotides of the motif in the sense strand forms a base pair with at least one of the three nucleotides of the motif in the antisense strand. Alternatively, at least two nucleotides may overlap, or all three nucleotides may overlap.

In some embodiments, the sense strand of the dsRNAi agent may contain more than one motif of three identical modifications on three consecutive nucleotides. The first motif may occur at or near

the cleavage site of the strand and the other motifs may be a wing modification. The term “wing modification” herein refers to a motif occurring at another portion of the strand that is separated from the motif at or near the cleavage site of the same strand. The wing modification is either adjacent to the first motif or is separated by at least one or more nucleotides. When the motifs are immediately adjacent to each other then the chemistries of the motifs are distinct from each other, and when the motifs are separated by one or more nucleotide then the chemistries can be the same or different. Two or more wing modifications may be present. For instance, when two wing modifications are present, each wing modification may occur at one end relative to the first motif which is at or near cleavage site or on either side of the lead motif.

Like the sense strand, the antisense strand of the dsRNAi agent may contain more than one motif of three identical modifications on three consecutive nucleotides, with at least one of the motifs occurring at or near the cleavage site of the strand. This antisense strand may also contain one or more wing modifications in an alignment similar to the wing modifications that may be present on the sense strand.

In some embodiments, the wing modification on the sense strand or antisense strand of the dsRNAi agent typically does not include the first one or two terminal nucleotides at the 3'-end, 5'-end, or both ends of the strand.

In other embodiments, the wing modification on the sense strand or antisense strand of the dsRNAi agent typically does not include the first one or two paired nucleotides within the duplex region at the 3'-end, 5'-end, or both ends of the strand.

When the sense strand and the antisense strand of the dsRNAi agent each contain at least one wing modification, the wing modifications may fall on the same end of the duplex region, and have an overlap of one, two, or three nucleotides.

When the sense strand and the antisense strand of the dsRNAi agent each contain at least two wing modifications, the sense strand and the antisense strand can be so aligned that two modifications each from one strand fall on one end of the duplex region, having an overlap of one, two, or three nucleotides; two modifications each from one strand fall on the other end of the duplex region, having an overlap of one, two or three nucleotides; two modifications one strand fall on each side of the lead motif, having an overlap of one, two or three nucleotides in the duplex region.

In some embodiments, every nucleotide in the sense strand and antisense strand of the dsRNAi agent, including the nucleotides that are part of the motifs, may be modified. Each nucleotide may be modified with the same or different modification which can include one or more alteration of one or both of the non-linking phosphate oxygens or of one or more of the linking phosphate oxygens; alteration of a constituent of the ribose sugar, *e.g.*, of the 2'-hydroxyl on the ribose sugar; wholesale replacement of the phosphate moiety with “dephospho” linkers; modification or replacement of a naturally occurring base; and replacement or modification of the ribose-phosphate backbone.

As nucleic acids are polymers of subunits, many of the modifications occur at a position which is repeated within a nucleic acid, *e.g.*, a modification of a base, or a phosphate moiety, or a non-linking O of a phosphate moiety. In some cases the modification will occur at all of the subject positions in the nucleic acid but in many cases it will not. By way of example, a modification may only occur at a 3'- or 5' terminal position, may only occur in a terminal region, *e.g.*, at a position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of a strand. A modification may occur in a double strand region, a single strand region, or in both. A modification may occur only in the double strand region of an RNA or may only occur in a single strand region of a RNA. For example, a phosphorothioate modification at a non-linking O position may only occur at one or both termini, may only occur in a terminal region, *e.g.*, at a position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of a strand, or may occur in double strand and single strand regions, particularly at termini. The 5'-end or ends can be phosphorylated.

It may be possible, *e.g.*, to enhance stability, to include particular bases in overhangs, or to include modified nucleotides or nucleotide surrogates, in single strand overhangs, *e.g.*, in a 5'- or 3'-overhang, or in both. For example, it can be desirable to include purine nucleotides in overhangs. In some embodiments all or some of the bases in a 3'- or 5'-overhang may be modified, *e.g.*, with a modification described herein. Modifications can include, *e.g.*, the use of modifications at the 2' position of the ribose sugar with modifications that are known in the art, *e.g.*, the use of deoxyribonucleotides, 2'-deoxy-2'-fluoro (2'-F) or 2'-O-methyl modified instead of the ribosugar of the nucleobase, and modifications in the phosphate group, *e.g.*, phosphorothioate modifications. Overhangs need not be homologous with the target sequence.

In some embodiments, each residue of the sense strand and antisense strand is independently modified with LNA, CRN, cET, UNA, HNA, CeNA, 2'-methoxyethyl, 2'-O-methyl, 2'-O-allyl, 2'-C-allyl, 2'-deoxy, 2'-hydroxyl, or 2'-fluoro. The strands can contain more than one modification. In one embodiment, each residue of the sense strand and antisense strand is independently modified with 2'-O-methyl or 2'-fluoro.

At least two different modifications are typically present on the sense strand and antisense strand. Those two modifications may be the 2'-O-methyl or 2'-fluoro modifications, or others.

In certain embodiments, the N_a or N_b comprise modifications of an alternating pattern. The term "alternating motif" as used herein refers to a motif having one or more modifications, each modification occurring on alternating nucleotides of one strand. The alternating nucleotide may refer to one per every other nucleotide or one per every three nucleotides, or a similar pattern. For example, if A, B and C each represent one type of modification to the nucleotide, the alternating motif can be "ABABABABABAB...", "AABBBAABBBAABB...", "AABAABAABAABA...", "AAABAAABAAAB...", "AAABBBAAABBB...", or "ABCABCABCABC...", *etc.*

The type of modifications contained in the alternating motif may be the same or different. For example, if A, B, C, D each represent one type of modification on the nucleotide, the alternating pattern, *i.e.*, modifications on every other nucleotide, may be the same, but each of the sense strand or

antisense strand can be selected from several possibilities of modifications within the alternating motif such as “ABABAB...”, “ACACAC...” “BDBDBD...” or “CDCDCD...,” *etc.*

In some embodiments, the dsRNAi agent of the invention comprises the modification pattern for the alternating motif on the sense strand relative to the modification pattern for the alternating motif on the antisense strand is shifted. The shift may be such that the modified group of nucleotides of the sense strand corresponds to a differently modified group of nucleotides of the antisense strand and *vice versa*. For example, the sense strand when paired with the antisense strand in the dsRNA duplex, the alternating motif in the sense strand may start with “ABABAB” from 5’ to 3’ of the strand and the alternating motif in the antisense strand may start with “BABABA” from 5’ to 3’ of the strand within the duplex region. As another example, the alternating motif in the sense strand may start with “AABBAABB” from 5’ to 3’ of the strand and the alternating motif in the antisense strand may start with “BBAABBAA” from 5’ to 3’ of the strand within the duplex region, so that there is a complete or partial shift of the modification patterns between the sense strand and the antisense strand.

In one particular example, the alternating motif in the sense strand is “ABABAB” from 5’ to 3’ of the strand, where each A is an unmodified ribonucleotide and each B is a 2’-O-methyl modified nucleotide.

In one particular example, the alternating motif in the sense strand is “ABABAB” from 5’ to 3’ of the strand, where each A is a 2’-deoxy-2’-fluoro modified nucleotide and each B is a 2’-O-methyl modified nucleotide.

In another particular example, the alternating motif in the antisense strand is “BABABA” from 3’-5’ of the strand, where each A is a 2’-deoxy-2’-fluoro modified nucleotide and each B is a 2’-O-methyl modified nucleotide.

In one particular example, the alternating motif in the sense strand is “ABABAB” from 5’ to 3’ of the strand and the alternating motif in the antisense strand is “BABABA” from 3’-5’ of the strand, where each A is an unmodified ribonucleotide and each B is a 2’-O-methyl modified nucleotide.

In one particular example, the alternating motif in the sense strand is “ABABAB” from 5’ to 3’ of the strand and the alternating motif in the antisense strand is “BABABA” from 3’-5’ of the strand, where each A is a 2’-deoxy-2’-fluoro modified nucleotide and each B is a 2’-O-methyl modified nucleotide.

In some embodiments, the dsRNAi agent comprises the pattern of the alternating motif of 2’-O-methyl modification and 2’-F modification on the sense strand initially has a shift relative to the pattern of the alternating motif of 2’-O-methyl modification and 2’-F modification on the antisense strand initially, *i.e.*, the 2’-O-methyl modified nucleotide on the sense strand base pairs with a 2’-F modified nucleotide on the antisense strand and *vice versa*. The 1 position of the sense strand may start with the 2’-F modification, and the 1 position of the antisense strand may start with the 2’-O-methyl modification.

The introduction of one or more motifs of three identical modifications on three consecutive nucleotides to the sense strand or antisense strand interrupts the initial modification pattern present in

the sense strand or antisense strand. This interruption of the modification pattern of the sense or antisense strand by introducing one or more motifs of three identical modifications on three consecutive nucleotides to the sense or antisense strand may enhance the gene silencing activity against the target gene.

In some embodiments, when the motif of three identical modifications on three consecutive nucleotides is introduced to any of the strands, the modification of the nucleotide next to the motif is a different modification than the modification of the motif. For example, the portion of the sequence containing the motif is "...N_aYYYN_b..." where "Y" represents the modification of the motif of three identical modifications on three consecutive nucleotide, and "N_a" and "N_b" represent a modification to the nucleotide next to the motif "YYY" that is different than the modification of Y, and where N_a and N_b can be the same or different modifications. Alternatively, N_a or N_b may be present or absent when there is a wing modification present.

The iRNA may further comprise at least one phosphorothioate or methylphosphonate internucleotide linkage. The phosphorothioate or methylphosphonate internucleotide linkage modification may occur on any nucleotide of the sense strand, antisense strand, or both strands in any position of the strand. For instance, the internucleotide linkage modification may occur on every nucleotide on the sense strand or antisense strand; each internucleotide linkage modification may occur in an alternating pattern on the sense strand or antisense strand; or the sense strand or antisense strand may contain both internucleotide linkage modifications in an alternating pattern. The alternating pattern of the internucleotide linkage modification on the sense strand may be the same or different from the antisense strand, and the alternating pattern of the internucleotide linkage modification on the sense strand may have a shift relative to the alternating pattern of the internucleotide linkage modification on the antisense strand. In one embodiment, a double-stranded RNAi agent comprises 6-8 phosphorothioate internucleotide linkages. In some embodiments, the antisense strand comprises two phosphorothioate internucleotide linkages at the 5'-end and two phosphorothioate internucleotide linkages at the 3'-end, and the sense strand comprises at least two phosphorothioate internucleotide linkages at either the 5'-end or the 3'-end.

In some embodiments, the dsRNAi agent comprises a phosphorothioate or methylphosphonate internucleotide linkage modification in the overhang region. For example, the overhang region may contain two nucleotides having a phosphorothioate or methylphosphonate internucleotide linkage between the two nucleotides. Internucleotide linkage modifications also may be made to link the overhang nucleotides with the terminal paired nucleotides within the duplex region. For example, at least 2, 3, 4, or all the overhang nucleotides may be linked through phosphorothioate or methylphosphonate internucleotide linkage, and optionally, there may be additional phosphorothioate or methylphosphonate internucleotide linkages linking the overhang nucleotide with a paired nucleotide that is next to the overhang nucleotide. For instance, there may be at least two phosphorothioate internucleotide linkages between the terminal three nucleotides, in which two of the three nucleotides are overhang nucleotides, and the third is a paired nucleotide next

to the overhang nucleotide. These terminal three nucleotides may be at the 3'-end of the antisense strand, the 3'-end of the sense strand, the 5'-end of the antisense strand, or the 5'-end of the antisense strand.

In some embodiments, the 2-nucleotide overhang is at the 3'-end of the antisense strand, and there are two phosphorothioate internucleotide linkages between the terminal three nucleotides, wherein two of the three nucleotides are the overhang nucleotides, and the third nucleotide is a paired nucleotide next to the overhang nucleotide. Optionally, the dsRNAi agent may additionally have two phosphorothioate internucleotide linkages between the terminal three nucleotides at both the 5'-end of the sense strand and at the 5'-end of the antisense strand.


In one embodiment, the dsRNAi agent comprises mismatch(es) with the target, within the duplex, or combinations thereof. The mismatch may occur in the overhang region or the duplex region. The base pair may be ranked on the basis of their propensity to promote dissociation or melting (*e.g.*, on the free energy of association or dissociation of a particular pairing, the simplest approach is to examine the pairs on an individual pair basis, though next neighbor or similar analysis can also be used). In terms of promoting dissociation: A:U is preferred over G:C; G:U is preferred over G:C; and I:C is preferred over G:C (I=inosine). Mismatches, *e.g.*, non-canonical or other than canonical pairings (as described elsewhere herein) are preferred over canonical (A:T, A:U, G:C) pairings; and pairings which include a universal base are preferred over canonical pairings.

In certain embodiments, the dsRNAi agent comprises at least one of the first 1, 2, 3, 4, or 5 base pairs within the duplex regions from the 5'-end of the antisense strand independently selected from the group of: A:U, G:U, I:C, and mismatched pairs, *e.g.*, non-canonical or other than canonical pairings or pairings which include a universal base, to promote the dissociation of the antisense strand at the 5'-end of the duplex.

In certain embodiments, the nucleotide at the 1 position within the duplex region from the 5'-end in the antisense strand is selected from A, dA, dU, U, and dT. Alternatively, at least one of the first 1, 2, or 3 base pair within the duplex region from the 5'-end of the antisense strand is an AU base pair. For example, the first base pair within the duplex region from the 5'-end of the antisense strand is an AU base pair.

In other embodiments, the nucleotide at the 3'-end of the sense strand is deoxythymidine (dT) or the nucleotide at the 3'-end of the antisense strand is deoxythymidine (dT). For example, there is a short sequence of deoxythymidine nucleotides, for example, two dT nucleotides on the 3'-end of the sense, antisense strand, or both strands.

In certain embodiments, the sense strand sequence may be represented by formula (I):



wherein:

i and j are each independently 0 or 1;

p and q are each independently 0-6;

each N_a independently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides;

each N_b independently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;

5 each n_p and n_q independently represent an overhang nucleotide;

wherein N_b and Y do not have the same modification; and

XXX, YYY, and ZZZ each independently represent one motif of three identical modifications on three consecutive nucleotides. In some embodiments, YYY is all 2'-F modified nucleotides.

In some embodiments, the N_a or N_b comprises modifications of alternating pattern.

10 In some embodiments, the YYY motif occurs at or near the cleavage site of the sense strand. For example, when the dsRNAi agent has a duplex region of 17-23 nucleotides in length, the YYY motif can occur at or the vicinity of the cleavage site (*e.g.*: can occur at positions 6, 7, 8; 7, 8, 9; 8, 9, 10; 9, 10, 11; 10, 11, 12; or 11, 12, 13) of the sense strand, the count starting from the first nucleotide, from the 5'-end; or optionally, the count starting at the first paired nucleotide within the duplex
15 region, from the 5'-end.

In one embodiment, i is 1 and j is 0, or i is 0 and j is 1, or both i and j are 1. The sense strand can therefore be represented by the following formulas:

5' n_p - N_a -YYY- N_b -ZZZ- N_a - n_q 3' (Ib);

5' n_p - N_a -XXX- N_b -YYY- N_a - n_q 3' (Ic); or

20 5' n_p - N_a -XXX- N_b -YYY- N_b -ZZZ- N_a - n_q 3' (Id).

When the sense strand is represented by formula (Ib), N_b represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides. Each N_a independently can represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the sense strand is represented as formula (Ic), N_b represents an oligonucleotide
25 sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides. Each N_a can independently represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the sense strand is represented as formula (Id), each N_b independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides. In some
30 embodiments, N_b is 0, 1, 2, 3, 4, 5, or 6. Each N_a can independently represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.


Each of X, Y and Z may be the same or different from each other.

In other embodiments, i is 0 and j is 0, and the sense strand may be represented by the
formula:

35 5' n_p - N_a -YYY- N_a - n_q 3' (Ia).

When the sense strand is represented by formula (Ia), each N_a independently can represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

In one embodiment, the antisense strand sequence of the RNAi may be represented by formula (II):



wherein:

k and l are each independently 0 or 1;

p' and q' are each independently 0-6;

each N_a' independently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides;

each N_b' independently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;

each n_p' and n_q' independently represent an overhang nucleotide;

wherein N_b' and Y' do not have the same modification; and

X'X'X', Y'Y'Y', and Z'Z'Z' each independently represent one motif of three identical modifications on three consecutive nucleotides.




In some embodiments, the N_a' or N_b' comprises modifications of alternating pattern.

The Y'Y'Y' motif occurs at or near the cleavage site of the antisense strand. For example, when the dsRNAi agent has a duplex region of 17-23 nucleotides in length, the Y'Y'Y' motif can occur at positions 9, 10, 11; 10, 11, 12; 11, 12, 13; 12, 13, 14; or 13, 14, 15 of the antisense strand, with the count starting from the first nucleotide, from the 5'-end; or optionally, the count starting at the first paired nucleotide within the duplex region, from the 5'-end. In some embodiments, the Y'Y'Y' motif occurs at positions 11, 12, 13.

In certain embodiments, Y'Y'Y' motif is all 2'-OMe modified nucleotides.

In certain embodiments, k is 1 and l is 0, or k is 0 and l is 1, or both k and l are 1.

The antisense strand can therefore be represented by the following formulas:




When the antisense strand is represented by formula (IIb), N_b' represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides. Each N_a' independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the antisense strand is represented as formula (IIc), N_b' represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides. Each N_a' independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the antisense strand is represented as formula (IId), each N_b' independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides.

Each N_a' independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides. In some embodiments, N_b is 0, 1, 2, 3, 4, 5, or 6.

In other embodiments, k is 0 and l is 0 and the antisense strand may be represented by the formula:



When the antisense strand is represented as formula (IIa), each N_a' independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

Each of X' , Y' and Z' may be the same or different from each other.


Each nucleotide of the sense strand and antisense strand may be independently modified with LNA, CRN, UNA, cEt, HNA, CeNA, 2'-methoxyethyl, 2'-O-methyl, 2'-O-allyl, 2'-C-allyl, 2'-hydroxyl, or 2'-fluoro. For example, each nucleotide of the sense strand and antisense strand is independently modified with 2'-O-methyl or 2'-fluoro. Each X , Y , Z , X' , Y' , and Z' , in particular, may represent a 2'-O-methyl modification or a 2'-fluoro modification.

In some embodiments, the sense strand of the dsRNAi agent may contain YYY motif occurring at 9, 10, and 11 positions of the strand when the duplex region is 21 nt, the count starting from the first nucleotide from the 5'-end, or optionally, the count starting at the first paired nucleotide within the duplex region, from the 5'-end; and Y represents 2'-F modification. The sense strand may additionally contain XXX motif or ZZZ motifs as wing modifications at the opposite end of the duplex region; and XXX and ZZZ each independently represents a 2'-OMe modification or 2'-F modification.

In some embodiments the antisense strand may contain $Y'Y'Y'$ motif occurring at positions 11, 12, 13 of the strand, the count starting from the first nucleotide from the 5'-end, or optionally, the count starting at the first paired nucleotide within the duplex region, from the 5'-end; and Y' represents 2'-O-methyl modification. The antisense strand may additionally contain $X'X'X'$ motif or $Z'Z'Z'$ motifs as wing modifications at the opposite end of the duplex region; and $X'X'X'$ and $Z'Z'Z'$ each independently represents a 2'-OMe modification or 2'-F modification.

The sense strand represented by any one of the above formulas (Ia), (Ib), (Ic), and (Id) forms a duplex with an antisense strand being represented by any one of formulas (IIa), (IIb), (IIc), and (IId), respectively.

Accordingly, the dsRNAi agents for use in the methods of the invention may comprise a sense strand and an antisense strand, each strand having 14 to 30 nucleotides, the iRNA duplex represented by formula (III):



wherein:

i , j , k , and l are each independently 0 or 1;

p , p' , q , and q' are each independently 0-6;

each N_a and N_a' independently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides;

each N_b and N_b' independently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;

5 wherein each n_p' , n_p , n_q' , and n_q , each of which may or may not be present, independently represents an overhang nucleotide; and

XXX, YYY, ZZZ, X'X'X', Y'Y'Y', and Z'Z'Z' each independently represent one motif of three identical modifications on three consecutive nucleotides.

10 In one embodiment, i is 0 and j is 0; or i is 1 and j is 0; or i is 0 and j is 1; or both i and j are 0; or both i and j are 1. In another embodiment, k is 0 and l is 0; or k is 1 and l is 0; k is 0 and l is 1; or both k and l are 0; or both k and l are 1.

Exemplary combinations of the sense strand and antisense strand forming an iRNA duplex include the formulas below:

15 5' n_p - N_a - Y Y Y - N_a - n_q 3'
3' n_p' - N_a' - Y'Y'Y' - N_a' - n_q' 5'
(IIIa)

5' n_p - N_a - Y Y Y - N_b - Z Z Z - N_a - n_q 3'
3' n_p' - N_a' - Y'Y'Y' - N_b' - Z'Z'Z' - N_a' - n_q' 5'
(IIIb)

20 5' n_p - N_a - X X X - N_b - Y Y Y - N_a - n_q 3'
3' n_p' - N_a' - X'X'X' - N_b' - Y'Y'Y' - N_a' - n_q' 5'
(IIIc)

5' n_p - N_a - X X X - N_b - Y Y Y - N_b - Z Z Z - N_a - n_q 3'
3' n_p' - N_a' - X'X'X' - N_b' - Y'Y'Y' - N_b' - Z'Z'Z' - N_a' - n_q' 5'
25 (IIId)

When the dsRNAi agent is represented by formula (IIIa), each N_a independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the dsRNAi agent is represented by formula (IIIb), each N_b independently represents an oligonucleotide sequence comprising 1-10, 1-7, 1-5, or 1-4 modified nucleotides. Each N_a
30 independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the dsRNAi agent is represented as formula (IIIc), each N_b , N_b' independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides. Each N_a independently represents an oligonucleotide sequence comprising 2-20, 2-15, or
35 2-10 modified nucleotides.

When the dsRNAi agent is represented as formula (IIId), each N_b , N_b' independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides. Each N_a , N_a' independently represents an oligonucleotide sequence comprising 2-20, 2-

15, or 2-10 modified nucleotides. Each of N_a , N_a' , N_b , and N_b' independently comprises modifications of alternating pattern.

Each of X, Y, and Z in formulas (III), (IIIa), (IIIb), (IIIc), and (IIId) may be the same or different from each other.

5 When the dsRNAi agent is represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId), at least one of the Y nucleotides may form a base pair with one of the Y' nucleotides. Alternatively, at least two of the Y nucleotides form base pairs with the corresponding Y' nucleotides; or all three of the Y nucleotides all form base pairs with the corresponding Y' nucleotides.

10 When the dsRNAi agent is represented by formula (IIIb) or (IIId), at least one of the Z nucleotides may form a base pair with one of the Z' nucleotides. Alternatively, at least two of the Z nucleotides form base pairs with the corresponding Z' nucleotides; or all three of the Z nucleotides all form base pairs with the corresponding Z' nucleotides.

15 When the dsRNAi agent is represented as formula (IIIc) or (IIId), at least one of the X nucleotides may form a base pair with one of the X' nucleotides. Alternatively, at least two of the X nucleotides form base pairs with the corresponding X' nucleotides; or all three of the X nucleotides all form base pairs with the corresponding X' nucleotides.

20 In certain embodiments, the modification on the Y nucleotide is different than the modification on the Y' nucleotide, the modification on the Z nucleotide is different than the modification on the Z' nucleotide, or the modification on the X nucleotide is different than the modification on the X' nucleotide.

In certain embodiments, when the dsRNAi agent is represented by formula (IIId), the N_a modifications are 2'-O-methyl or 2'-fluoro modifications. In other embodiments, when the RNAi agent is represented by formula (IIId), the N_a modifications are 2'-O-methyl or 2'-fluoro modifications and $n_p' > 0$ and at least one n_p' is linked to a neighboring nucleotide *via* phosphorothioate linkage. In yet other embodiments, when the RNAi agent is represented by formula (IIId), the N_a modifications are 2'-O-methyl or 2'-fluoro modifications, $n_p' > 0$ and at least one n_p' is linked to a neighboring nucleotide *via* phosphorothioate linkage, and the sense strand is conjugated to one or more GalNAc derivatives attached through a bivalent or trivalent branched linker (described below). In other embodiments, when the RNAi agent is represented by formula (IIId), the N_a modifications are 2'-O-methyl or 2'-fluoro modifications, $n_p' > 0$ and at least one n_p' is linked to a neighboring nucleotide *via* phosphorothioate linkage, the sense strand comprises at least one phosphorothioate linkage, and the sense strand is conjugated to one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.

35 In some embodiments, when the dsRNAi agent is represented by formula (IIIa), the N_a modifications are 2'-O-methyl or 2'-fluoro modifications, $n_p' > 0$ and at least one n_p' is linked to a neighboring nucleotide *via* phosphorothioate linkage, the sense strand comprises at least one phosphorothioate linkage, and the sense strand is conjugated to one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.

In some embodiments, the dsRNAi agent is a multimer containing at least two duplexes represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId), wherein the duplexes are connected by a linker. The linker can be cleavable or non-cleavable. Optionally, the multimer further comprises a ligand. Each of the duplexes can target the same gene or two different genes; or each of the duplexes can target same gene at two different target sites.

In some embodiments, the dsRNAi agent is a multimer containing three, four, five, six, or more duplexes represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId), wherein the duplexes are connected by a linker. The linker can be cleavable or non-cleavable. Optionally, the multimer further comprises a ligand. Each of the duplexes can target the same gene or two different genes; or each of the duplexes can target same gene at two different target sites.


In one embodiment, two dsRNAi agents represented by at least one of formulas (III), (IIIa), (IIIb), (IIIc), and (IIId) are linked to each other at the 5' end, and one or both of the 3' ends, and are optionally conjugated to a ligand. Each of the agents can target the same gene or two different genes; or each of the agents can target same gene at two different target sites.

In certain embodiments, an RNAi agent of the invention may contain a low number of nucleotides containing a 2'-fluoro modification, *e.g.*, 10 or fewer nucleotides with 2'-fluoro modification. For example, the RNAi agent may contain 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 nucleotides with a 2'-fluoro modification. In a specific embodiment, the RNAi agent of the invention contains 10 nucleotides with a 2'-fluoro modification, *e.g.*, 4 nucleotides with a 2'-fluoro modification in the sense strand and 6 nucleotides with a 2'-fluoro modification in the antisense strand. In another specific embodiment, the RNAi agent of the invention contains 6 nucleotides with a 2'-fluoro modification, *e.g.*, 4 nucleotides with a 2'-fluoro modification in the sense strand and 2 nucleotides with a 2'-fluoro modification in the antisense strand.

In other embodiments, an RNAi agent of the invention may contain an ultra low number of nucleotides containing a 2'-fluoro modification, *e.g.*, 2 or fewer nucleotides containing a 2'-fluoro modification. For example, the RNAi agent may contain 2, 1 or 0 nucleotides with a 2'-fluoro modification. In a specific embodiment, the RNAi agent may contain 2 nucleotides with a 2'-fluoro modification, *e.g.*, 0 nucleotides with a 2-fluoro modification in the sense strand and 2 nucleotides with a 2'-fluoro modification in the antisense strand.

Various publications describe multimeric iRNAs that can be used in the methods of the invention. Such publications include WO2007/091269, U.S. Patent No. 7,858,769, WO2010/141511, WO2007/117686, WO2009/014887, and WO2011/031520 the entire contents of each of which are hereby incorporated herein by reference.

In certain embodiments, the compositions and methods of the disclosure include a vinyl phosphonate (VP) modification of an RNAi agent as described herein. In exemplary embodiments, a 5'- vinyl phosphonate modified nucleotide of the disclosure has the structure:



wherein X is O or S;

R is hydrogen, hydroxy, fluoro, or C₁₋₂₀alkoxy (*e.g.*, methoxy or n-hexadecyloxy);

R^{5'} is =C(H)-P(O)(OH)₂ and the double bond between the C5' carbon and R^{5'} is in the *E* or *Z*

5 orientation (*e.g.*, *E* orientation); and

B is a nucleobase or a modified nucleobase, optionally where B is adenine, guanine, cytosine, thymine, or uracil.

A vinyl phosphonate of the instant disclosure may be attached to either the antisense or the sense strand of a dsRNA of the disclosure. In certain embodiments, a vinyl phosphonate of the instant disclosure is attached to the antisense strand of a dsRNA, optionally at the 5' end of the antisense strand of the dsRNA.

Vinyl phosphonate modifications are also contemplated for the compositions and methods of the instant disclosure. An exemplary vinyl phosphonate structure includes the preceding structure, where R^{5'} is =C(H)-OP(O)(OH)₂ and the double bond between the C5' carbon and R^{5'} is in the *E* or *Z* orientation (*e.g.*, *E* orientation).

As described in more detail below, the iRNA that contains conjugations of one or more carbohydrate moieties to an iRNA can optimize one or more properties of the iRNA. In many cases, the carbohydrate moiety will be attached to a modified subunit of the iRNA. For example, the ribose sugar of one or more ribonucleotide subunits of a iRNA can be replaced with another moiety, *e.g.*, a non-carbohydrate (such as, cyclic) carrier to which is attached a carbohydrate ligand. A ribonucleotide subunit in which the ribose sugar of the subunit has been so replaced is referred to herein as a ribose replacement modification subunit (RRMS). A cyclic carrier may be a carbocyclic ring system, *i.e.*, all ring atoms are carbon atoms, or a heterocyclic ring system, *i.e.*, one or more ring atoms may be a heteroatom, *e.g.*, nitrogen, oxygen, sulfur. The cyclic carrier may be a monocyclic ring system, or may contain two or more rings, *e.g.* fused rings. The cyclic carrier may be a fully saturated ring system, or it may contain one or more double bonds.

The ligand may be attached to the polynucleotide *via* a carrier. The carriers include (i) at least one "backbone attachment point," such as, two "backbone attachment points" and (ii) at least one "tethering attachment point." A "backbone attachment point" as used herein refers to a functional group, *e.g.* a hydroxyl group, or generally, a bond available for, and that is suitable for incorporation of the carrier into the backbone, *e.g.*, the phosphate, or modified phosphate, *e.g.*, sulfur containing, backbone, of a ribonucleic acid. A "tethering attachment point" (TAP) in some embodiments refers to a constituent ring atom of the cyclic carrier, *e.g.*, a carbon atom or a heteroatom (distinct from an atom

which provides a backbone attachment point), that connects a selected moiety. The moiety can be, *e.g.*, a carbohydrate, *e.g.* monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, or polysaccharide. Optionally, the selected moiety is connected by an intervening tether to the cyclic carrier. Thus, the cyclic carrier will often include a functional group, *e.g.*, an amino group, or generally, provide a bond, that is suitable for incorporation or tethering of another chemical entity, *e.g.*, a ligand to the constituent ring.

The iRNA may be conjugated to a ligand *via* a carrier, wherein the carrier can be cyclic group or acyclic group. In some embodiments, the cyclic group is selected from pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, [1,3]dioxolane, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, tetrahydrofuryl, and decalin. In some embodiments, the acyclic group is a serinol backbone or diethanolamine backbone.


i. Thermally Destabilizing Modifications

In certain embodiments, a dsRNA molecule can be optimized for RNA interference by incorporating thermally destabilizing modifications in the seed region of the antisense strand. As used herein “seed region” means at positions 2-9 of the 5'-end of the referenced strand or at positions 2-8 of the 5'-end of the referenced strand. For example, thermally destabilizing modifications can be incorporated in the seed region of the antisense strand to reduce or inhibit off-target gene silencing.

The term “thermally destabilizing modification(s)” includes modification(s) that would result with a dsRNA with a lower overall melting temperature (T_m) than the T_m of the dsRNA without having such modification(s). For example, the thermally destabilizing modification(s) can decrease the T_m of the dsRNA by 1 – 4 °C, such as one, two, three or four degrees Celcius. And, the term “thermally destabilizing nucleotide” refers to a nucleotide containing one or more thermally destabilizing modifications.


It has been discovered that dsRNAs with an antisense strand comprising at least one thermally destabilizing modification of the duplex within the first 9 nucleotide positions, counting from the 5' end, of the antisense strand have reduced off-target gene silencing activity. Accordingly, in some embodiments, the antisense strand comprises at least one (*e.g.*, one, two, three, four, five or more) thermally destabilizing modification of the duplex within the first 9 nucleotide positions of the 5' region of the antisense strand. In some embodiments, one or more thermally destabilizing modification(s) of the duplex is/are located in positions 2-9, such as, positions 4-8, from the 5'-end of the antisense strand. In some further embodiments, the thermally destabilizing modification(s) of the duplex is/are located at position 6, 7 or 8 from the 5'-end of the antisense strand. In still some further embodiments, the thermally destabilizing modification of the duplex is located at position 7 from the 5'-end of the antisense strand. In some embodiments, the thermally destabilizing modification of the duplex is located at position 2, 3, 4, 5 or 9 from the 5'-end of the antisense strand.

An iRNA agent comprises a sense strand and an antisense strand, each strand having 14 to 40 nucleotides. The RNAi agent may be represented by formula (L):




In formula (L), B1, B2, B3, B1', B2', B3', and B4' each are independently a nucleotide containing a modification selected from the group consisting of 2'-O-alkyl, 2'-substituted alkoxy, 2'-substituted alkyl, 2'-halo, ENA, and BNA/LNA. In one embodiment, B1, B2, B3, B1', B2', B3', and B4' each contain 2'-OMe modifications. In one embodiment, B1, B2, B3, B1', B2', B3', and B4' each contain 2'-OMe or 2'-F modifications. In one embodiment, at least one of B1, B2, B3, B1', B2', B3', and B4' contain 2'-O-N-methylacetamido (2'-O-NMA, 2'-O-CH₂C(O)N(Me)H) modification.

C1 is a thermally destabilizing nucleotide placed at a site opposite to the seed region of the antisense strand (*i.e.*, at positions 2-8 of the 5'-end of the antisense strand or at positions 2-9 of the 5'-end of the referenced strand). For example, C1 is at a position of the sense strand that pairs with a nucleotide at positions 2-8 of the 5'-end of the antisense strand. In one example, C1 is at position 15 from the 5'-end of the sense strand. C1 nucleotide bears the thermally destabilizing modification which can include abasic modification; mismatch with the opposing nucleotide in the duplex; and sugar modification such as 2'-deoxy modification or acyclic nucleotide *e.g.*, unlocked nucleic acids (UNA) or glycerol nucleic acid (GNA); and 2'-5'-linked ribonucleotides ("3'-RNA"). In one embodiment, C1 has thermally destabilizing modification selected from the group consisting of: i) mismatch with the opposing nucleotide in the antisense strand; ii) abasic modification selected from the group consisting of:




selected from the group consisting of:

; and iii) sugar modification



, wherein B is a modified or unmodified nucleobase, R^1 and R^2 independently are H, halogen, OR_3 , or alkyl; and R_3 is H, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or sugar. In one embodiment, the thermally destabilizing modification in C1 is a mismatch selected from the group consisting of G:G, G:A, G:U, G:T, A:A, A:C, C:C, C:U, C:T, U:U, T:T, and U:T; and optionally, at least one nucleobase in the mismatch pair is a 2'-deoxy nucleobase. In one example, the thermally

destabilizing modification in C1 is GNA or



T1, T1', T2', and T3' each independently represent a nucleotide comprising a modification providing the nucleotide a steric bulk that is less or equal to the steric bulk of a 2'-OMe modification. A steric bulk refers to the sum of steric effects of a modification. Methods for determining steric effects of a modification of a nucleotide are known to one skilled in the art. The modification can be at the 2' position of a ribose sugar of the nucleotide, or a modification to a non-ribose nucleotide, acyclic nucleotide, or the backbone of the nucleotide that is similar or equivalent to the 2' position of the ribose sugar, and provides the nucleotide a steric bulk that is less than or equal to the steric bulk of a 2'-OMe modification. For example, T1, T1', T2', and T3' are each independently selected from DNA, RNA, LNA, 2'-F, and 2'-F-5'-methyl. In one embodiment, T1 is DNA. In one embodiment, T1' is DNA, RNA or LNA. In one embodiment, T2' is DNA or RNA. In one embodiment, T3' is DNA or RNA.

n^1 , n^3 , and q^1 are independently 4 to 15 nucleotides in length.

n^5 , q^3 , and q^7 are independently 1-6 nucleotide(s) in length.

n^4 , q^2 , and q^6 are independently 1-3 nucleotide(s) in length; alternatively, n^4 is 0.

q^5 is independently 0-10 nucleotide(s) in length.

n^2 and q^4 are independently 0-3 nucleotide(s) in length.

Alternatively, n^4 is 0-3 nucleotide(s) in length.

In one embodiment, n^4 can be 0. In one example, n^4 is 0, and q^2 and q^6 are 1. In another example, n^4 is 0, and q^2 and q^6 are 1, with two phosphorothioate internucleotide linkage modifications

within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand).

5 In one embodiment, n^4 , q^2 , and q^6 are each 1.

In one embodiment, n^2 , n^4 , q^2 , q^4 , and q^6 are each 1.

In one embodiment, C1 is at position 14-17 of the 5'-end of the sense strand, when the sense strand is 19-22 nucleotides in length, and n^4 is 1. In one embodiment, C1 is at position 15 of the 5'-end of the sense strand

10 In one embodiment, T3' starts at position 2 from the 5' end of the antisense strand. In one example, T3' is at position 2 from the 5' end of the antisense strand and q^6 is equal to 1.

In one embodiment, T1' starts at position 14 from the 5' end of the antisense strand. In one example, T1' is at position 14 from the 5' end of the antisense strand and q^2 is equal to 1.

15 In an exemplary embodiment, T3' starts from position 2 from the 5' end of the antisense strand and T1' starts from position 14 from the 5' end of the antisense strand. In one example, T3' starts from position 2 from the 5' end of the antisense strand and q^6 is equal to 1 and T1' starts from position 14 from the 5' end of the antisense strand and q^2 is equal to 1.

In one embodiment, T1' and T3' are separated by 11 nucleotides in length (*i.e.* not counting the T1' and T3' nucleotides).

20 In one embodiment, T1' is at position 14 from the 5' end of the antisense strand. In one example, T1' is at position 14 from the 5' end of the antisense strand and q^2 is equal to 1, and the modification at the 2' position or positions in a non-ribose, acyclic or backbone that provide less steric bulk than a 2'-OMe ribose.

25 In one embodiment, T3' is at position 2 from the 5' end of the antisense strand. In one example, T3' is at position 2 from the 5' end of the antisense strand and q^6 is equal to 1, and the modification at the 2' position or positions in a non-ribose, acyclic or backbone that provide less than or equal to steric bulk than a 2'-OMe ribose.

30 In one embodiment, T1 is at the cleavage site of the sense strand. In one example, T1 is at position 11 from the 5' end of the sense strand, when the sense strand is 19-22 nucleotides in length, and n^2 is 1. In an exemplary embodiment, T1 is at the cleavage site of the sense strand at position 11 from the 5' end of the sense strand, when the sense strand is 19-22 nucleotides in length, and n^2 is 1,

In one embodiment, T2' starts at position 6 from the 5' end of the antisense strand. In one example, T2' is at positions 6-10 from the 5' end of the antisense strand, and q^4 is 1.

35 In an exemplary embodiment, T1 is at the cleavage site of the sense strand, for instance, at position 11 from the 5' end of the sense strand, when the sense strand is 19-22 nucleotides in length, and n^2 is 1; T1' is at position 14 from the 5' end of the antisense strand, and q^2 is equal to 1, and the modification to T1' is at the 2' position of a ribose sugar or at positions in a non-ribose, acyclic or backbone that provide less steric bulk than a 2'-OMe ribose; T2' is at positions 6-10 from the 5' end

of the antisense strand, and q^4 is 1; and T3' is at position 2 from the 5' end of the antisense strand, and q^6 is equal to 1, and the modification to T3' is at the 2' position or at positions in a non-ribose, acyclic or backbone that provide less than or equal to steric bulk than a 2'-OMe ribose.

In one embodiment, T2' starts at position 8 from the 5' end of the antisense strand. In one example,

5 T2' starts at position 8 from the 5' end of the antisense strand, and q^4 is 2.

In one embodiment, T2' starts at position 9 from the 5' end of the antisense strand. In one example, T2' is at position 9 from the 5' end of the antisense strand, and q^4 is 1.

In one embodiment, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, T2' is 2'-F, q^4 is 1, B3' is 2'-OMe or 2'-F, q^5 is 6, T3' is 2'-F, q^6 is 1, B4' is 2'-OMe, and q^7 is
10 1; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand).

15 In one embodiment, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, T2' is 2'-F, q^4 is 1, B3' is 2'-OMe or 2'-F, q^5 is 6, T3' is 2'-F, q^6 is 1, B4' is 2'-OMe, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate
20 internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand).

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, T2' is 2'-F, q^4 is 2, B3' is 2'-OMe or 2'-F, q^5 is 5, T3' is 2'-F, q^6 is 1, B4' is 2'-OMe, and q^7 is
25 1.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, T2' is 2'-F, q^4 is 2, B3' is 2'-OMe or 2'-F, q^5 is 5, T3' is 2'-F, q^6 is 1, B4' is 2'-OMe, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand
30 (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand).

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 6, T1 is 2'F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 7, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, T2' is 2'-F, q^4 is 2, B3' is 2'-OMe or 2'-F, q^5 is 5, T3' is 2'-F, q^6 is 1, B4' is 2'-OMe, and q^7 is
35 1.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 6, T1 is 2'F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 7, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4,

T2' is 2'-F, q⁴ is 2, B3' is 2'-OMe or 2'-F, q⁵ is 5, T3' is 2'-F, q⁶ is 1, B4' is 2'-OMe, and q⁷ is 1; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand).

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F, q³ is 4, T2' is 2'-F, q⁴ is 1, B3' is 2'-OMe or 2'-F, q⁵ is 6, T3' is 2'-F, q⁶ is 1, B4' is 2'-OMe, and q⁷ is 1.

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'-OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F, q³ is 4, T2' is 2'-F, q⁴ is 1, B3' is 2'-OMe or 2'-F, q⁵ is 6, T3' is 2'-F, q⁶ is 1, B4' is 2'-OMe, and q⁷ is 1; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand).

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F, q³ is 5, T2' is 2'-F, q⁴ is 1, B3' is 2'-OMe or 2'-F, q⁵ is 5, T3' is 2'-F, q⁶ is 1, B4' is 2'-OMe, and q⁷ is 1; optionally with at least 2 additional TT at the 3'-end of the antisense strand.

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'-OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F, q³ is 5, T2' is 2'-F, q⁴ is 1, B3' is 2'-OMe or 2'-F, q⁵ is 5, T3' is 2'-F, q⁶ is 1, B4' is 2'-OMe, and q⁷ is 1; optionally with at least 2 additional TT at the 3'-end of the antisense strand; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand).

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'-OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F, q³ is 4, q⁴ is 0, B3' is 2'-OMe or 2'-F, q⁵ is 7, T3' is 2'-F, q⁶ is 1, B4' is 2'-OMe, and q⁷ is 1.

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'-OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F, q³ is 4, q⁴ is 0, B3' is 2'-OMe or 2'-F, q⁵ is 7, T3' is 2'-F, q⁶ is 1, B4' is 2'-OMe, and q⁷ is 1; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modifications at

positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end).

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, T2' is 2'-F, q^4 is 2, B3' is 2'-OMe or 2'-F, q^5 is 5, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, T2' is 2'-F, q^4 is 2, B3' is 2'-OMe or 2'-F, q^5 is 5, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1; with


two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand).

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1.


In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1; with two

phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand).

The RNAi agent can comprise a phosphorus-containing group at the 5'-end of the sense strand or antisense strand. The 5'-end phosphorus-containing group can be 5'-end phosphate (5'-P), 5'-end phosphorothioate (5'-PS), 5'-end phosphorodithioate (5'-PS₂), 5'-end vinylphosphonate (5'-

VP), 5'-end methylphosphonate (MePhos), or 5'-deoxy-5'-C-malonyl (). When the 5'-end phosphorus-containing group is 5'-end vinylphosphonate (5'-VP), the 5'-VP can be either

5'-E-VP isomer (i.e., *trans*-vinylphosphonate,

vinylphosphonate, , or mixtures thereof.

In one embodiment, the RNAi agent comprises a phosphorus-containing group at the 5'-end of the sense strand. In one embodiment, the RNAi agent comprises a phosphorus-containing group at the 5'-end of the antisense strand.

In one embodiment, the RNAi agent comprises a 5'-P. In one embodiment, the RNAi agent comprises a 5'-P in the antisense strand.

In one embodiment, the RNAi agent comprises a 5'-PS. In one embodiment, the RNAi agent comprises a 5'-PS in the antisense strand.

In one embodiment, the RNAi agent comprises a 5'-VP. In one embodiment, the RNAi agent comprises a 5'-VP in the antisense strand. In one embodiment, the RNAi agent comprises a 5'-E-VP in the antisense strand. In one embodiment, the RNAi agent comprises a 5'-Z-VP in the antisense strand.

In one embodiment, the RNAi agent comprises a 5'-PS₂. In one embodiment, the RNAi agent comprises a 5'-PS₂ in the antisense strand.

In one embodiment, the RNAi agent comprises a 5'-PS₂. In one embodiment, the RNAi agent comprises a 5'-deoxy-5'-C-malonyl in the antisense strand.

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F, q³ is 4, T2' is 2'-F, q⁴ is 2, B3' is 2'-OMe or 2'-F, q⁵ is 5, T3' is 2'-F, q⁶ is 1, B4' is 2'-OMe, and q⁷ is 1. The RNAi agent also comprises a 5'-PS.

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F, q³ is 4, T2' is 2'-F, q⁴ is 2, B3' is 2'-OMe or 2'-F, q⁵ is 5, T3' is 2'-F, q⁶ is 1, B4' is 2'-OMe, and q⁷ is 1. The RNAi agent also comprises a 5'-P.

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F, q³ is 4, T2' is 2'-F, q⁴ is 2, B3' is 2'-OMe or 2'-F, q⁵ is 5, T3' is 2'-F, q⁶ is 1, B4' is 2'-OMe, and q⁷ is 1. The RNAi agent also comprises a 5'-VP. The 5'-VP may be 5'-E-VP, 5'-Z-VP, or combination thereof.

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F, q³ is 4, T2' is 2'-F, q⁴ is 2, B3' is 2'-OMe or 2'-F, q⁵ is 5, T3' is 2'-F, q⁶ is 1, B4' is 2'-OMe, and q⁷ is 1. The RNAi agent also comprises a 5'-PS₂.

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F, q³ is 4, T2' is 2'-F, q⁴ is 2, B3' is 2'-OMe or 2'-F, q⁵ is 5, T3' is 2'-F, q⁶ is 1, B4' is 2'-OMe, and q⁷ is 1. The RNAi agent also comprises a 5'-deoxy-5'-C-malonyl.

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'-OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F,

q³ is 4, T2' is 2'-F, q⁴ is 2, B3' is 2'-OMe or 2'-F, q⁵ is 5, T3' is 2'-F, q⁶ is 1, B4' is 2'-OMe, and q⁷ is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The RNAi agent also comprises a 5'-P.

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'-F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'-OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F, q³ is 4, T2' is 2'-F, q⁴ is 2, B3' is 2'-OMe or 2'-F, q⁵ is 5, T3' is 2'-F, q⁶ is 1, B4' is 2'-OMe, and q⁷ is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The RNAi agent also comprises a 5'-PS.

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'-F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'-OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F, q³ is 4, T2' is 2'-F, q⁴ is 2, B3' is 2'-OMe or 2'-F, q⁵ is 5, T3' is 2'-F, q⁶ is 1, B4' is 2'-OMe, and q⁷ is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The RNAi agent also comprises a 5'-VP. The 5'-VP may be 5'-E-VP, 5'-Z-VP, or combination thereof.

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'-F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'-OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F, q³ is 4, T2' is 2'-F, q⁴ is 2, B3' is 2'-OMe or 2'-F, q⁵ is 5, T3' is 2'-F, q⁶ is 1, B4' is 2'-OMe, and q⁷ is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The RNAi agent also comprises a 5'-PS₂.

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'-F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'-OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F, q³ is 4, T2' is 2'-F, q⁴ is 2, B3' is 2'-OMe or 2'-F, q⁵ is 5, T3' is 2'-F, q⁶ is 1, B4' is 2'-OMe, and q⁷ is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand).

strand). The RNAi agent also comprises a 5'-deoxy-5'-C-malonyl.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-OMe, and q^7 is 1. The

5 RNAi agent also comprises a 5'-P.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-OMe, and q^7 is 1. The dsRNA agent also comprises a 5'-PS.

10 In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-OMe, and q^7 is 1. The RNAi agent also comprises a 5'-VP. The 5'-VP may be 5'-E-VP, 5'-Z-VP, or combination thereof.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-OMe, and q^7 is 1. The RNAi agent also comprises a 5'-PS₂.

20 In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-OMe, and q^7 is 1. The RNAi agent also comprises a 5'-deoxy-5'-C-malonyl.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-OMe, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end). The RNAi agent also comprises a 5'-P.

30 In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-OMe, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end). The RNAi agent also comprises a 5'-PS.

35 In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-OMe, and q^7 is 1; with two

phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end). The RNAi agent also comprises a 5'-VP. The 5'-VP may be 5'-E-VP, 5'-Z-VP, or combination thereof.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-OMe, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end). The RNAi agent also comprises a 5'-PS₂.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-OMe, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end). The RNAi agent also comprises a 5'-deoxy-5'-C-malonyl.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, T2' is 2'-F, q^4 is 2, B3' is 2'-OMe or 2'-F, q^5 is 5, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1. The RNAi agent also comprises a 5'-P.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, T2' is 2'-F, q^4 is 2, B3' is 2'-OMe or 2'-F, q^5 is 5, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1. The RNAi agent also comprises a 5'-PS.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, T2' is 2'-F, q^4 is 2, B3' is 2'-OMe or 2'-F, q^5 is 5, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1. The RNAi agent also comprises a 5'-VP. The 5'-VP may be 5'-E-VP, 5'-Z-VP, or combination thereof.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, T2' is 2'-F, q^4 is 2, B3' is 2'-OMe or 2'-F, q^5 is 5, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1. The dsRNAi RNA agent also comprises a 5'-PS₂.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, T2' is 2'-F, q^4 is 2, B3' is 2'-OMe or 2'-F, q^5 is 5, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1. The RNAi agent also comprises a 5'-deoxy-5'-C-malonyl.

5 In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, T2' is 2'-F, q^4 is 2, B3' is 2'-OMe or 2'-F, q^5 is 5, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide
10 linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The RNAi agent also comprises a 5'-P.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F,
15 q^3 is 4, T2' is 2'-F, q^4 is 2, B3' is 2'-OMe or 2'-F, q^5 is 5, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense
20 strand). The RNAi agent also comprises a 5'-PS.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, T2' is 2'-F, q^4 is 2, B3' is 2'-OMe or 2'-F, q^5 is 5, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense
25 strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The RNAi agent also comprises a 5'-VP. The 5'-VP may be 5'-E-VP, 5'-Z-VP, or combination thereof.

30 In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, T2' is 2'-F, q^4 is 2, B3' is 2'-OMe or 2'-F, q^5 is 5, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide
35 linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The RNAi agent also comprises a 5'-PS₂.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, T2' is 2'-F, q^4 is 2, B3' is 2'-OMe or 2'-F, q^5 is 5, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The RNAi agent also comprises a 5'-deoxy-5'-C-malonyl.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1. The RNAi agent also comprises a 5'-P.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1. The RNAi agent also comprises a 5'-PS.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1. The RNAi agent also comprises a 5'-VP. The 5'-VP may be 5'-E-VP, 5'-Z-VP, or combination thereof.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1. The RNAi agent also comprises a 5'-PS₂.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1. The RNAi agent also comprises a 5'-deoxy-5'-C-malonyl.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The RNAi agent also comprises a 5'-P.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F,

q³ is 4, q⁴ is 0, B3' is 2'-OMe or 2'-F, q⁵ is 7, T3' is 2'-F, q⁶ is 1, B4' is 2'-F, and q⁷ is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The RNAi agent also comprises a 5'-PS.

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'-F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'-OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F, q³ is 4, q⁴ is 0, B3' is 2'-OMe or 2'-F, q⁵ is 7, T3' is 2'-F, q⁶ is 1, B4' is 2'-F, and q⁷ is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The RNAi agent also comprises a 5'-VP. The 5'-VP may be 5'-E-VP, 5'-Z-VP, or combination thereof.

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'-F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'-OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F, q³ is 4, q⁴ is 0, B3' is 2'-OMe or 2'-F, q⁵ is 7, T3' is 2'-F, q⁶ is 1, B4' is 2'-F, and q⁷ is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The RNAi agent also comprises a 5'-PS₂.

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'-F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'-OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F, q³ is 4, q⁴ is 0, B3' is 2'-OMe or 2'-F, q⁵ is 7, T3' is 2'-F, q⁶ is 1, B4' is 2'-F, and q⁷ is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The RNAi agent also comprises a 5'-deoxy-5'-C-malonyl.

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'-F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'-OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F, q³ is 4, T2' is 2'-F, q⁴ is 2, B3' is 2'-OMe or 2'-F, q⁵ is 5, T3' is 2'-F, q⁶ is 1, B4' is 2'-OMe, and q⁷ is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense

strand). The RNAi agent also comprises a 5'-P and a targeting ligand. In one embodiment, the 5'-P is at the 5'-end of the antisense strand, and the targeting ligand is at the 3'-end of the sense strand.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, T2' is 2'-F, q^4 is 2, B3' is 2'-OMe or 2'-F, q^5 is 5, T3' is 2'-F, q^6 is 1, B4' is 2'-OMe, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The RNAi agent also comprises a 5'-PS and a targeting ligand. In one embodiment, the 5'-PS is at the 5'-end of the antisense strand, and the targeting ligand is at the 3'-end of the sense strand.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, T2' is 2'-F, q^4 is 2, B3' is 2'-OMe or 2'-F, q^5 is 5, T3' is 2'-F, q^6 is 1, B4' is 2'-OMe, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The RNAi agent also comprises a 5'-VP (e.g., a 5'-E-VP, 5'-Z-VP, or combination thereof), and a targeting ligand.

In one embodiment, the 5'-VP is at the 5'-end of the antisense strand, and the targeting ligand is at the 3'-end of the sense strand.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, T2' is 2'-F, q^4 is 2, B3' is 2'-OMe or 2'-F, q^5 is 5, T3' is 2'-F, q^6 is 1, B4' is 2'-OMe, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The RNAi agent also comprises a 5'-PS₂ and a targeting ligand. In one embodiment, the 5'-PS₂ is at the 5'-end of the antisense strand, and the targeting ligand is at the 3'-end of the sense strand.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, T2' is 2'-F, q^4 is 2, B3' is 2'-OMe or 2'-F, q^5 is 5, T3' is 2'-F, q^6 is 1, B4' is 2'-OMe, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand).

strand). The RNAi agent also comprises a 5'-deoxy-5'-C-malonyl and a targeting ligand. In one embodiment, the 5'-deoxy-5'-C-malonyl is at the 5'-end of the antisense strand, and the targeting ligand is at the 3'-end of the sense strand.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-OMe, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end). The RNAi agent also comprises a 5'-P and a targeting ligand. In one embodiment, the 5'-P is at the 5'-end of the antisense strand, and the targeting ligand is at the 3'-end of the sense strand.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-OMe, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end). The RNAi agent also comprises a 5'-PS and a targeting ligand. In one embodiment, the 5'-PS is at the 5'-end of the antisense strand, and the targeting ligand is at the 3'-end of the sense strand.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-OMe, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end). The RNAi agent also comprises a 5'-VP (*e.g.*, a 5'-E-VP, 5'-Z-VP, or combination thereof) and a targeting ligand. In one embodiment, the 5'-VP is at the 5'-end of the antisense strand, and the targeting ligand is at the 3'-end of the sense strand.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-OMe, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end). The RNAi agent also comprises a 5'-PS₂ and a

targeting ligand. In one embodiment, the 5'-PS₂ is at the 5'-end of the antisense strand, and the targeting ligand is at the 3'-end of the sense strand.

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'-F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'-OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F, q³ is 4, q⁴ is 0, B3' is 2'-OMe or 2'-F, q⁵ is 7, T3' is 2'-F, q⁶ is 1, B4' is 2'-OMe, and q⁷ is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end). The RNAi agent also comprises a 5'-deoxy-5'-C-malonyl and a targeting ligand. In one embodiment, the 5'-deoxy-5'-C-malonyl is at the 5'-end of the antisense strand, and the targeting ligand is at the 3'-end of the sense strand.

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'-F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'-OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F, q³ is 4, T2' is 2'-F, q⁴ is 2, B3' is 2'-OMe or 2'-F, q⁵ is 5, T3' is 2'-F, q⁶ is 1, B4' is 2'-F, and q⁷ is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The RNAi agent also comprises a 5'-P and a targeting ligand. In one embodiment, the 5'-P is at the 5'-end of the antisense strand, and the targeting ligand is at the 3'-end of the sense strand.

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'-F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'-OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F, q³ is 4, T2' is 2'-F, q⁴ is 2, B3' is 2'-OMe or 2'-F, q⁵ is 5, T3' is 2'-F, q⁶ is 1, B4' is 2'-F, and q⁷ is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The RNAi agent also comprises a 5'-PS and a targeting ligand. In one embodiment, the 5'-PS is at the 5'-end of the antisense strand, and the targeting ligand is at the 3'-end of the sense strand.

In one embodiment, B1 is 2'-OMe or 2'-F, n¹ is 8, T1 is 2'-F, n² is 3, B2 is 2'-OMe, n³ is 7, n⁴ is 0, B3 is 2'-OMe, n⁵ is 3, B1' is 2'-OMe or 2'-F, q¹ is 9, T1' is 2'-F, q² is 1, B2' is 2'-OMe or 2'-F, q³ is 4, T2' is 2'-F, q⁴ is 2, B3' is 2'-OMe or 2'-F, q⁵ is 5, T3' is 2'-F, q⁶ is 1, B4' is 2'-F, and q⁷ is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The RNAi agent also comprises a 5'-VP (*e.g.*, a 5'-E-VP, 5'-Z-VP, or combination thereof)

and a targeting ligand. In one embodiment, the 5'-VP is at the 5'-end of the antisense strand, and the targeting ligand is at the 3'-end of the sense strand.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, T2' is 2'-F, q^4 is 2, B3' is 2'-OMe or 2'-F, q^5 is 5, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The RNAi agent also comprises a 5'-PS₂ and a targeting ligand. In one embodiment, the 5'-PS₂ is at the 5'-end of the antisense strand, and the targeting ligand is at the 3'-end of the sense strand.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, T2' is 2'-F, q^4 is 2, B3' is 2'-OMe or 2'-F, q^5 is 5, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The RNAi agent also comprises a 5'-deoxy-5'-C-malonyl and a targeting ligand. In one embodiment, the 5'-deoxy-5'-C-malonyl is at the 5'-end of the antisense strand, and the targeting ligand is at the 3'-end of the sense strand.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The RNAi agent also comprises a 5'-P and a targeting ligand. In one embodiment, the 5'-P is at the 5'-end of the antisense strand, and the targeting ligand is at the 3'-end of the sense strand.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The

RNAi agent also comprises a 5'-PS and a targeting ligand. In one embodiment, the 5'-PS is at the 5'-end of the antisense strand, and the targeting ligand is at the 3'-end of the sense strand.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The

RNAi agent also comprises a 5'-VP (*e.g.*, a 5'-E-VP, 5'-Z-VP, or combination thereof) and a targeting ligand. In one embodiment, the 5'-VP is at the 5'-end of the antisense strand, and the targeting ligand is at the 3'-end of the sense strand.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The

RNAi agent also comprises a 5'-PS₂ and a targeting ligand. In one embodiment, the 5'-PS₂ is at the 5'-end of the antisense strand, and the targeting ligand is at the 3'-end of the sense strand.

In one embodiment, B1 is 2'-OMe or 2'-F, n^1 is 8, T1 is 2'-F, n^2 is 3, B2 is 2'-OMe, n^3 is 7, n^4 is 0, B3 is 2'-OMe, n^5 is 3, B1' is 2'-OMe or 2'-F, q^1 is 9, T1' is 2'-F, q^2 is 1, B2' is 2'-OMe or 2'-F, q^3 is 4, q^4 is 0, B3' is 2'-OMe or 2'-F, q^5 is 7, T3' is 2'-F, q^6 is 1, B4' is 2'-F, and q^7 is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5'-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end of the antisense strand). The RNAi agent also comprises a 5'-deoxy-5'-C-malonyl and a targeting ligand. In one embodiment, the 5'-deoxy-5'-C-malonyl is at the 5'-end of the antisense strand, and the targeting ligand is at the 3'-end of the sense strand.

In a particular embodiment, an RNAi agent of the present invention comprises:

(a) a sense strand having:

(i) a length of 21 nucleotides;

(ii) an ASGPR ligand attached to the 3'-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker; and

(iii) 2'-F modifications at positions 1, 3, 5, 7, 9 to 11, 13, 17, 19, and 21, and 2'-OMe modifications at positions 2, 4, 6, 8, 12, 14 to 16, 18, and 20 (counting from the 5' end);

and

(b) an antisense strand having:

(i) a length of 23 nucleotides;

(ii) 2'-OMe modifications at positions 1, 3, 5, 9, 11 to 13, 15, 17, 19, 21, and 23, and 2'F modifications at positions 2, 4, 6 to 8, 10, 14, 16, 18, 20, and 22 (counting from the 5' end); and

(iii) phosphorothioate internucleotide linkages between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5' end);

wherein the dsRNA agents have a two nucleotide overhang at the 3'-end of the antisense strand, and a blunt end at the 5'-end of the antisense strand.

In another particular embodiment, an RNAi agent of the present invention comprises:

(a) a sense strand having:

(i) a length of 21 nucleotides;

(ii) an ASGPR ligand attached to the 3'-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;

(iii) 2'-F modifications at positions 1, 3, 5, 7, 9 to 11, 13, 15, 17, 19, and 21, and 2'-OMe modifications at positions 2, 4, 6, 8, 12, 14, 16, 18, and 20 (counting from the 5' end); and

(iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5' end);

and

(b) an antisense strand having:

(i) a length of 23 nucleotides;

(ii) 2'-OMe modifications at positions 1, 3, 5, 7, 9, 11 to 13, 15, 17, 19, and 21 to 23, and 2'F modifications at positions 2, 4, 6, 8, 10, 14, 16, 18, and 20 (counting from the 5' end); and

(iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5' end);

wherein the RNAi agents have a two nucleotide overhang at the 3'-end of the antisense strand, and a blunt end at the 5'-end of the antisense strand.

In another particular embodiment, a RNAi agent of the present invention comprises:

(a) a sense strand having:

(i) a length of 21 nucleotides;

(ii) an ASGPR ligand attached to the 3'-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;

(iii) 2'-OMe modifications at positions 1 to 6, 8, 10, and 12 to 21, 2'-F modifications at positions 7, and 9, and a deoxy-nucleotide (*e.g.* dT) at position 11 (counting from the 5' end); and

(iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5' end);

and

(b) an antisense strand having:

(i) a length of 23 nucleotides;

(ii) 2'-OMe modifications at positions 1, 3, 7, 9, 11, 13, 15, 17, and 19 to 23, and 2'-F modifications at positions 2, 4 to 6, 8, 10, 12, 14, 16, and 18 (counting from the 5' end);

and

(iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5' end);

wherein the RNAi agents have a two nucleotide overhang at the 3'-end of the antisense strand, and a blunt end at the 5'-end of the antisense strand.

In another particular embodiment, a RNAi agent of the present invention comprises:

(a) a sense strand having:

(i) a length of 21 nucleotides;

(ii) an ASGPR ligand attached to the 3'-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;

(iii) 2'-OMe modifications at positions 1 to 6, 8, 10, 12, 14, and 16 to 21, and 2'-F modifications at positions 7, 9, 11, 13, and 15; and

(iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5' end);

and

(b) an antisense strand having:

(i) a length of 23 nucleotides;

(ii) 2'-OMe modifications at positions 1, 5, 7, 9, 11, 13, 15, 17, 19, and 21 to 23, and 2'-F modifications at positions 2 to 4, 6, 8, 10, 12, 14, 16, 18, and 20 (counting from the 5' end); and

(iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5' end);

wherein the RNAi agents have a two nucleotide overhang at the 3'-end of the antisense strand, and a blunt end at the 5'-end of the antisense strand.

In another particular embodiment, a RNAi agent of the present invention comprises:

- (a) a sense strand having:
- (i) a length of 21 nucleotides;
 - (ii) an ASGPR ligand attached to the 3'-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;
 - (iii) 2'-OMe modifications at positions 1 to 9, and 12 to 21, and 2'-F modifications at positions 10, and 11; and
 - (iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5' end);

and

- (b) an antisense strand having:
- (i) a length of 23 nucleotides;
 - (ii) 2'-OMe modifications at positions 1, 3, 5, 7, 9, 11 to 13, 15, 17, 19, and 21 to 23, and 2'-F modifications at positions 2, 4, 6, 8, 10, 14, 16, 18, and 20 (counting from the 5' end); and
 - (iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5' end);

wherein the RNAi agents have a two nucleotide overhang at the 3'-end of the antisense strand, and a blunt end at the 5'-end of the antisense strand.

In another particular embodiment, a RNAi agent of the present invention comprises:

- (a) a sense strand having:
- (i) a length of 21 nucleotides;
 - (ii) an ASGPR ligand attached to the 3'-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;
 - (iii) 2'-F modifications at positions 1, 3, 5, 7, 9 to 11, and 13, and 2'-OMe modifications at positions 2, 4, 6, 8, 12, and 14 to 21; and
 - (iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5' end);

and

- (b) an antisense strand having:
- (i) a length of 23 nucleotides;
 - (ii) 2'-OMe modifications at positions 1, 3, 5 to 7, 9, 11 to 13, 15, 17 to 19, and 21 to 23, and 2'-F modifications at positions 2, 4, 8, 10, 14, 16, and 20 (counting from the 5' end); and
 - (iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5' end);

wherein the RNAi agents have a two nucleotide overhang at the 3'-end of the antisense strand, and a blunt end at the 5'-end of the antisense strand.

In another particular embodiment, a RNAi agent of the present invention comprises:

(a) a sense strand having:

- (i) a length of 21 nucleotides;
- (ii) an ASGPR ligand attached to the 3'-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;
- (iii) 2'-OMe modifications at positions 1, 2, 4, 6, 8, 12, 14, 15, 17, and 19 to 21, and 2'-F modifications at positions 3, 5, 7, 9 to 11, 13, 16, and 18; and
- (iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5' end);

and

(b) an antisense strand having:

- (i) a length of 25 nucleotides;
- (ii) 2'-OMe modifications at positions 1, 4, 6, 7, 9, 11 to 13, 15, 17, and 19 to 23, 2'-F modifications at positions 2, 3, 5, 8, 10, 14, 16, and 18, and desoxy-nucleotides (*e.g.* dT) at positions 24 and 25 (counting from the 5' end); and
- (iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5' end);

wherein the RNAi agents have a four nucleotide overhang at the 3'-end of the antisense strand, and a blunt end at the 5'-end of the antisense strand.

In another particular embodiment, a RNAi agent of the present invention comprises:

(a) a sense strand having:

- (i) a length of 21 nucleotides;
- (ii) an ASGPR ligand attached to the 3'-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;
- (iii) 2'-OMe modifications at positions 1 to 6, 8, and 12 to 21, and 2'-F modifications at positions 7, and 9 to 11; and
- (iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5' end);

and

(b) an antisense strand having:

- (i) a length of 23 nucleotides;
- (ii) 2'-OMe modifications at positions 1, 3 to 5, 7, 8, 10 to 13, 15, and 17 to 23, and 2'-F modifications at positions 2, 6, 9, 14, and 16 (counting from the 5' end); and

(iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5' end);

wherein the RNAi agents have a two nucleotide overhang at the 3'-end of the antisense strand, and a blunt end at the 5'-end of the antisense strand.

In another particular embodiment, a RNAi agent of the present invention comprises:

(a) a sense strand having:

(i) a length of 21 nucleotides;

(ii) an ASGPR ligand attached to the 3'-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;

(iii) 2'-OMe modifications at positions 1 to 6, 8, and 12 to 21, and 2'-F modifications at positions 7, and 9 to 11; and

(iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5' end);

and

(b) an antisense strand having:

(i) a length of 23 nucleotides;

(ii) 2'-OMe modifications at positions 1, 3 to 5, 7, 10 to 13, 15, and 17 to 23, and 2'-F modifications at positions 2, 6, 8, 9, 14, and 16 (counting from the 5' end); and

(iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5' end);

wherein the RNAi agents have a two nucleotide overhang at the 3'-end of the antisense strand, and a blunt end at the 5'-end of the antisense strand.

In another particular embodiment, a RNAi agent of the present invention comprises:

(a) a sense strand having:

(i) a length of 19 nucleotides;

(ii) an ASGPR ligand attached to the 3'-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;

(iii) 2'-OMe modifications at positions 1 to 4, 6, and 10 to 19, and 2'-F modifications at positions 5, and 7 to 9; and

(iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5' end);

and

(b) an antisense strand having:

(i) a length of 21 nucleotides;

(ii) 2'-OMe modifications at positions 1, 3 to 5, 7, 10 to 13, 15, and 17 to 21, and 2'-F modifications at positions 2, 6, 8, 9, 14, and 16 (counting from the 5' end); and

- (iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21 (counting from the 5' end);

wherein the RNAi agents have a two nucleotide overhang at the 3'-end of the antisense strand, and a blunt end at the 5'-end of the antisense strand.

In certain embodiments, the iRNA for use in the methods of the invention is an agent selected from agents listed in any one of Tables 2, 3, 5, 6, and 8-13. These agents may further comprise a ligand.

IV. iRNAs Conjugated to Ligands

Another modification of the RNA of an iRNA of the invention involves chemically linking to the iRNA one or more ligands, moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the iRNA *e.g.*, into a cell. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger *et al.*, *Proc. Natl. Acad. Sci. USA*, 1989, 86: 6553-6556). In other embodiments, the ligand is cholic acid (Manoharan *et al.*, *Biorg. Med. Chem. Lett.*, 1994, 4:1053-1060), a thioether, *e.g.*, beryl-S-tritylthiol (Manoharan *et al.*, *Ann. N.Y. Acad. Sci.*, 1992, 660:306-309; Manoharan *et al.*, *Biorg. Med. Chem. Lett.*, 1993, 3:2765-2770), a thiocholesterol (Oberhauser *et al.*, *Nucl. Acids Res.*, 1992, 20:533-538), an aliphatic chain, *e.g.*, dodecandiol or undecyl residues (Saison-Behmoaras *et al.*, *EMBO J*, 1991, 10:1111-1118; Kabanov *et al.*, *FEBS Lett.*, 1990, 259:327-330; Svinarchuk *et al.*, *Biochimie*, 1993, 75:49-54), a phospholipid, *e.g.*, di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-phosphonate (Manoharan *et al.*, *Tetrahedron Lett.*, 1995, 36:3651-3654; Shea *et al.*, *Nucl. Acids Res.*, 1990, 18:3777-3783), a polyamine or a polyethylene glycol chain (Manoharan *et al.*, *Nucleosides & Nucleotides*, 1995, 14:969-973), or adamantane acetic acid (Manoharan *et al.*, *Tetrahedron Lett.*, 1995, 36:3651-3654), a palmitoyl moiety (Mishra *et al.*, *Biochim. Biophys. Acta*, 1995, 1264:229-237), or an octadecylamine or hexylamino-carboxyloxycholesterol moiety (Crooke *et al.*, *J. Pharmacol. Exp. Ther.*, 1996, 277:923-937).

In certain embodiments, a ligand alters the distribution, targeting, or lifetime of an iRNA agent into which it is incorporated. In some embodiments a ligand provides an enhanced affinity for a selected target, *e.g.*, molecule, cell or cell type, compartment, *e.g.*, a cellular or organ compartment, tissue, organ or region of the body, as, *e.g.*, compared to a species absent such a ligand. In some embodiments, ligands do not take part in duplex pairing in a duplexed nucleic acid.

Ligands can include a naturally occurring substance, such as a protein (*e.g.*, human serum albumin (HSA), low-density lipoprotein (LDL), or globulin); carbohydrate (*e.g.*, a dextran, pullulan, chitin, chitosan, inulin, cyclodextrin, N-acetylglucosamine, N-acetylgalactosamine, or hyaluronic acid); or a lipid. The ligand can also be a recombinant or synthetic molecule, such as a synthetic polymer, *e.g.*, a synthetic polyamino acid. Examples of polyamino acids include polyamino acid is a polylysine (PLL), poly L-aspartic acid, poly L-glutamic acid, styrene-maleic acid anhydride

copolymer, poly(L-lactide-co-glycolide) copolymer, divinyl ether-maleic anhydride copolymer, N-(2-hydroxypropyl)methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly(2-ethylacrylic acid), N-isopropylacrylamide polymers, or polyphosphazene. Example of polyamines include: polyethylenimine, polylysine (PLL), spermine, spermidine, polyamine, pseudopeptide-polyamine, peptidomimetic polyamine, dendrimer polyamine, arginine, amidine, protamine, cationic lipid, cationic porphyrin, quaternary salt of a polyamine, or an alpha helical peptide.

Ligands can also include targeting groups, *e.g.*, a cell or tissue targeting agent, *e.g.*, a lectin, glycoprotein, lipid or protein, *e.g.*, an antibody, that binds to a specified cell type such as a kidney cell. A targeting group can be a thyrotropin, melanotropin, lectin, glycoprotein, surfactant protein A, Mucin carbohydrate, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine multivalent mannose, multivalent fucose, glycosylated polyaminoacids, multivalent galactose, transferrin, bisphosphonate, polyglutamate, polyaspartate, a lipid, cholesterol, a steroid, bile acid, folate, vitamin B12, vitamin A, biotin, or an RGD peptide or RGD peptide mimetic. In certain embodiments, the ligand is a multivalent galactose, *e.g.*, an N-acetyl-galactosamine.

Other examples of ligands include dyes, intercalating agents (*e.g.* acridines), cross-linkers (*e.g.* psoralene, mitomycin C), porphyrins (TPPC4, texaphyrin, Sapphyrin), polycyclic aromatic hydrocarbons (*e.g.*, phenazine, dihydrophenazine), artificial endonucleases (*e.g.* EDTA), lipophilic molecules, *e.g.*, cholesterol, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-Bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine) and peptide conjugates (*e.g.*, antennapedia peptide, Tat peptide), alkylating agents, phosphate, amino, mercapto, PEG (*e.g.*, PEG-40K), MPEG, [MPEG]₂, polyamino, alkyl, substituted alkyl, radiolabeled markers, enzymes, haptens (*e.g.* biotin), transport/absorption facilitators (*e.g.*, aspirin, vitamin E, folic acid), synthetic ribonucleases (*e.g.*, imidazole, bisimidazole, histamine, imidazole clusters, acridine-imidazole conjugates, Eu³⁺ complexes of tetraazamacrocycles), dinitrophenyl, HRP, or AP.

Ligands can be proteins, *e.g.*, glycoproteins, or peptides, *e.g.*, molecules having a specific affinity for a co-ligand, or antibodies *e.g.*, an antibody, that binds to a specified cell type such as a hepatic cell. Ligands can also include hormones and hormone receptors. They can also include non-peptidic species, such as lipids, lectins, carbohydrates, vitamins, cofactors, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine multivalent mannose, or multivalent fucose. The ligand can be, for example, a lipopolysaccharide, an activator of p38 MAP kinase, or an activator of NF- κ B.

The ligand can be a substance, *e.g.*, a drug, which can increase the uptake of the iRNA agent into the cell, for example, by disrupting the cell's cytoskeleton, *e.g.*, by disrupting the cell's microtubules, microfilaments, or intermediate filaments. The drug can be, for example, taxol,

vincristine, vinblastine, cytochalasin, nocodazole, japlakinolide, latrunculin A, phalloidin, swinholide A, indanocine, or myoservin.

In some embodiments, a ligand attached to an iRNA as described herein acts as a pharmacokinetic modulator (PK modulator). PK modulators include lipophiles, bile acids, steroids, phospholipid analogues, peptides, protein binding agents, PEG, vitamins, *etc.* Exemplary PK modulators include, but are not limited to, cholesterol, fatty acids, cholic acid, lithocholic acid, dialkylglycerides, diacylglyceride, phospholipids, sphingolipids, naproxen, ibuprofen, vitamin E, biotin. Oligonucleotides that comprise a number of phosphorothioate linkages are also known to bind to serum protein, thus short oligonucleotides, *e.g.*, oligonucleotides of about 5 bases, 10 bases, 15 bases, or 20 bases, comprising multiple of phosphorothioate linkages in the backbone are also amenable to the present invention as ligands (*e.g.* as PK modulating ligands). In addition, aptamers that bind serum components (*e.g.* serum proteins) are also suitable for use as PK modulating ligands in the embodiments described herein.

Ligand-conjugated iRNAs of the invention may be synthesized by the use of an oligonucleotide that bears a pendant reactive functionality, such as that derived from the attachment of a linking molecule onto the oligonucleotide (described below). This reactive oligonucleotide may be reacted directly with commercially-available ligands, ligands that are synthesized bearing any of a variety of protecting groups, or ligands that have a linking moiety attached thereto.

The oligonucleotides used in the conjugates of the present invention may be conveniently and routinely made through the well-known technique of solid-phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems® (Foster City, Calif.). Any other methods for such synthesis known in the art may additionally or alternatively be employed. It is also known to use similar techniques to prepare other oligonucleotides, such as the phosphorothioates and alkylated derivatives.

In the ligand-conjugated iRNAs and ligand-molecule bearing sequence-specific linked nucleosides of the present invention, the oligonucleotides and oligonucleosides may be assembled on a suitable DNA synthesizer utilizing standard nucleotide or nucleoside precursors, or nucleotide or nucleoside conjugate precursors that already bear the linking moiety, ligand-nucleotide or nucleoside-conjugate precursors that already bear the ligand molecule, or non-nucleoside ligand-bearing building blocks.

When using nucleotide-conjugate precursors that already bear a linking moiety, the synthesis of the sequence-specific linked nucleosides is typically completed, and the ligand molecule is then reacted with the linking moiety to form the ligand-conjugated oligonucleotide. In some embodiments, the oligonucleotides or linked nucleosides of the present invention are synthesized by an automated synthesizer using phosphoramidites derived from ligand-nucleoside conjugates in addition to the standard phosphoramidites and non-standard phosphoramidites that are commercially available and routinely used in oligonucleotide synthesis.

A. Lipid Conjugates

In certain embodiments, the ligand or conjugate is a lipid or lipid-based molecule. Such a lipid or lipid-based molecule may bind a serum protein, *e.g.*, human serum albumin (HSA). An HSA binding ligand allows for distribution of the conjugate to a target tissue, *e.g.*, a non-kidney target tissue of the body. For example, the target tissue can be the liver, including parenchymal cells of the liver. Other molecules that can bind HSA can also be used as ligands. For example, naproxen or aspirin can be used. A lipid or lipid-based ligand can (a) increase resistance to degradation of the conjugate, (b) increase targeting or transport into a target cell or cell membrane, or (c) can be used to adjust binding to a serum protein, *e.g.*, HSA.

A lipid based ligand can be used to inhibit, *e.g.*, control the binding of the conjugate to a target tissue. For example, a lipid or lipid-based ligand that binds to HSA more strongly will be less likely to be targeted to the kidney and therefore less likely to be cleared from the body. A lipid or lipid-based ligand that binds to HSA less strongly can be used to target the conjugate to the kidney.

In certain embodiments, the lipid based ligand binds HSA. In some embodiments, it binds HSA with a sufficient affinity such that the conjugate will be distributed to a non-kidney tissue. However, it is preferred that the affinity not be so strong that the HSA-ligand binding cannot be reversed.

In other embodiments, the lipid based ligand binds HSA weakly or not at all, such that the conjugate will be distributed to the kidney. Other moieties that target to kidney cells can also be used in place of, or in addition to, the lipid based ligand.

In another aspect, the ligand is a moiety, *e.g.*, a vitamin, which is taken up by a target cell, *e.g.*, a proliferating cell. These are particularly useful for treating disorders characterized by unwanted cell proliferation, *e.g.*, of the malignant or non-malignant type, *e.g.*, cancer cells. Exemplary vitamins include vitamin A, E, and K. Other exemplary vitamins include are B vitamin, *e.g.*, folic acid, B12, riboflavin, biotin, pyridoxal or other vitamins or nutrients taken up by target cells such as liver cells. Also included are HSA and low density lipoprotein (LDL).

B. Cell Permeation Agents

In another aspect, the ligand is a cell-permeation agent, such as, a helical cell-permeation agent. In some embodiments, the agent is amphipathic. An exemplary agent is a peptide such as tat or antennopodia. If the agent is a peptide, it can be modified, including a peptidylmimetic, invertomers, non-peptide or pseudo-peptide linkages, and use of D-amino acids. In some embodiments, the helical agent is an alpha-helical agent, which has a lipophilic and a lipophobic phase.

The ligand can be a peptide or peptidomimetic. A peptidomimetic (also referred to herein as an oligopeptidomimetic) is a molecule capable of folding into a defined three-dimensional structure similar to a natural peptide. The attachment of peptide and peptidomimetics to iRNA agents can affect pharmacokinetic distribution of the iRNA, such as by enhancing cellular recognition and

absorption. The peptide or peptidomimetic moiety can be about 5-50 amino acids long, *e.g.*, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids long.

A peptide or peptidomimetic can be, for example, a cell permeation peptide, cationic peptide, amphipathic peptide, or hydrophobic peptide (*e.g.*, consisting primarily of Tyr, Trp, or Phe). The peptide moiety can be a dendrimer peptide, constrained peptide or crosslinked peptide. In another alternative, the peptide moiety can include a hydrophobic membrane translocation sequence (MTS). An exemplary hydrophobic MTS-containing peptide is RFGF having the amino acid sequence AAVALLPAVLLALLAP (SEQ ID NO: 14). An RFGF analogue (*e.g.*, amino acid sequence AALLPVLLAAP (SEQ ID NO:15) containing a hydrophobic MTS can also be a targeting moiety.

The peptide moiety can be a “delivery” peptide, which can carry large polar molecules including peptides, oligonucleotides, and protein across cell membranes. For example, sequences from the HIV Tat protein (GRKKRRQRRRPPQ (SEQ ID NO:16) and the Drosophila Antennapedia protein (RQIKIWFQNRRMKWKK (SEQ ID NO:17) have been found to be capable of functioning as delivery peptides. A peptide or peptidomimetic can be encoded by a random sequence of DNA, such as a peptide identified from a phage-display library, or one-bead-one-compound (OBOC) combinatorial library (Lam *et al.*, Nature, 354:82-84, 1991). Examples of a peptide or peptidomimetic tethered to a dsRNA agent *via* an incorporated monomer unit for cell targeting purposes is an arginine-glycine-aspartic acid (RGD)-peptide, or RGD mimic. A peptide moiety can range in length from about 5 amino acids to about 40 amino acids. The peptide moieties can have a structural modification, such as to increase stability or direct conformational properties. Any of the structural modifications described below can be utilized.

An RGD peptide for use in the compositions and methods of the invention may be linear or cyclic, and may be modified, *e.g.*, glycosylated or methylated, to facilitate targeting to a specific tissue(s). RGD-containing peptides and peptidomimetics may include D-amino acids, as well as synthetic RGD mimics. In addition to RGD, one can use other moieties that target the integrin ligand, *e.g.*, PECAM-1 or VEGF.

A “cell permeation peptide” is capable of permeating a cell, *e.g.*, a microbial cell, such as a bacterial or fungal cell, or a mammalian cell, such as a human cell. A microbial cell-permeating peptide can be, for example, an α -helical linear peptide (*e.g.*, LL-37 or Ceropin P1), a disulfide bond-containing peptide (*e.g.*, α -defensin, β -defensin or bactenecin), or a peptide containing only one or two dominating amino acids (*e.g.*, PR-39 or indolicidin). A cell permeation peptide can also include a nuclear localization signal (NLS). For example, a cell permeation peptide can be a bipartite amphipathic peptide, such as MPG, which is derived from the fusion peptide domain of HIV-1 gp41 and the NLS of SV40 large T antigen (Simeoni *et al.*, Nucl. Acids Res. 31:2717-2724, 2003).

C. Carbohydrate Conjugates

In some embodiments of the compositions and methods of the invention, an iRNA further comprises a carbohydrate. The carbohydrate conjugated iRNA is advantageous for the *in vivo*

delivery of nucleic acids, as well as compositions suitable for *in vivo* therapeutic use, as described herein. As used herein, "carbohydrate" refers to a compound which is either a carbohydrate *per se* made up of one or more monosaccharide units having at least 6 carbon atoms (which can be linear, branched or cyclic) with an oxygen, nitrogen or sulfur atom bonded to each carbon atom; or a

5 compound having as a part thereof a carbohydrate moiety made up of one or more monosaccharide units each having at least six carbon atoms (which can be linear, branched or cyclic), with an oxygen, nitrogen or sulfur atom bonded to each carbon atom. Representative carbohydrates include the sugars (mono-, di-, tri-, and oligosaccharides containing from about 4, 5, 6, 7, 8, or 9 monosaccharide units), and polysaccharides such as starches, glycogen, cellulose and polysaccharide gums. Specific
10 monosaccharides include C5 and above (*e.g.*, C5, C6, C7, or C8) sugars; di- and trisaccharides include sugars having two or three monosaccharide units (*e.g.*, C5, C6, C7, or C8).

In certain embodiments, a carbohydrate conjugate for use in the compositions and methods of the invention is a monosaccharide.

In certain embodiments, the monosaccharide is an N-acetylgalactosamine (GalNAc). GalNAc
15 conjugates, which comprise one or more N-acetylgalactosamine (GalNAc) derivatives, are described, for example, in US 8,106,022, the entire content of which is hereby incorporated herein by reference. In some embodiments, the GalNAc conjugate serves as a ligand that targets the iRNA to particular cells. In some embodiments, the GalNAc conjugate targets the iRNA to liver cells, *e.g.*, by serving as a ligand for the asialoglycoprotein receptor of liver cells (*e.g.*, hepatocytes).

20 In some embodiments, the carbohydrate conjugate comprises one or more GalNAc derivatives. The GalNAc derivatives may be attached *via* a linker, *e.g.*, a bivalent or trivalent branched linker. In some embodiments the GalNAc conjugate is conjugated to the 3' end of the sense strand. In some embodiments, the GalNAc conjugate is conjugated to the iRNA agent (*e.g.*, to the 3' end of the sense strand) *via* a linker, *e.g.*, a linker as described herein. In some embodiments the
25 GalNAc conjugate is conjugated to the 5' end of the sense strand. In some embodiments, the GalNAc conjugate is conjugated to the iRNA agent (*e.g.*, to the 5' end of the sense strand) *via* a linker, *e.g.*, a linker as described herein.


In certain embodiments of the invention, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention *via* a monovalent linker. In some embodiments, the GalNAc or GalNAc
30 derivative is attached to an iRNA agent of the invention *via* a bivalent linker. In yet other embodiments of the invention, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention *via* a trivalent linker. In other embodiments of the invention, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention *via* a tetravalent linker.

In certain embodiments, the double stranded RNAi agents of the invention comprise one
35 GalNAc or GalNAc derivative attached to the iRNA agent. In certain embodiments, the double stranded RNAi agents of the invention comprise a plurality (*e.g.*, 2, 3, 4, 5, or 6) GalNAc or GalNAc derivatives, each independently attached to a plurality of nucleotides of the double stranded RNAi agent through a plurality of monovalent linkers.


In some embodiments, for example, when the two strands of an iRNA agent of the invention are part of one larger molecule connected by an uninterrupted chain of nucleotides between the 3'-end of one strand and the 5'-end of the respective other strand forming a hairpin loop comprising, a plurality of unpaired nucleotides, each unpaired nucleotide within the hairpin loop may independently
 5 comprise a GalNAc or GalNAc derivative attached *via* a monovalent linker. The hairpin loop may also be formed by an extended overhang in one strand of the duplex.

In some embodiments, for example, when the two strands of an iRNA agent of the invention are part of one larger molecule connected by an uninterrupted chain of nucleotides between the 3'-end of one strand and the 5'-end of the respective other strand forming a hairpin loop comprising, a
 10 plurality of unpaired nucleotides, each unpaired nucleotide within the hairpin loop may independently comprise a GalNAc or GalNAc derivative attached *via* a monovalent linker. The hairpin loop may also be formed by an extended overhang in one strand of the duplex.


In one embodiment, a carbohydrate conjugate for use in the compositions and methods of the invention is selected from the group consisting of:




Formula II,




Formula III,




Formula IV,




Formula V,




Formula VI,




Formula VII,




Formula VIII,




Formula IX,




Formula X,




Formula XI,




Formula XII,




Formula XIII,




Formula XIV,




Formula XV,




Formula XVI,




Formula XVII,




Formula XVIII,




Formula XIX,




Formula XX,




Formula XXI,




Formula XXII,




Formula XXIII;






, wherein Y is O or S and n is 3 -6 (Formula XXIV);





, wherein Y is O or S and n is 3-6 (Formula XXV);



Formula XXVI;




Formula XXVII; Formula XXIX;




Formula XXX;

Formula XXXI;




, and




Formula XXXII;

5 Formula XXXIII.




Formula XXXIV.

In another embodiment, a carbohydrate conjugate for use in the compositions and methods of the invention is a monosaccharide. In one embodiment, the monosaccharide is an N-acetylgalactosamine, such as




Formula II.


In some embodiments, the RNAi agent is attached to the carbohydrate conjugate *via* a linker as shown in the following schematic, wherein X is O or S



In some embodiments, the RNAi agent is conjugated to L96 as defined in Table 1 and shown below:




Another representative carbohydrate conjugate for use in the embodiments described herein includes, but is not limited to,



(Formula XXXVI), when one of X or Y is an oligonucleotide, the other is a hydrogen.

In some embodiments, a suitable ligand is a ligand disclosed in WO 2019/055633, the entire contents of which are incorporated herein by reference. In one embodiment the ligand comprises the structure below:



In certain embodiments of the invention, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention *via* a monovalent linker. In some embodiments, the GalNAc or GalNAc

derivative is attached to an iRNA agent of the invention *via* a bivalent linker. In yet other embodiments of the invention, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention *via* a trivalent linker.

In one embodiment, the double stranded RNAi agents of the invention comprise one or more GalNAc or GalNAc derivative attached to the iRNA agent. The GalNAc may be attached to any nucleotide *via* a linker on the sense strand or antisense strand. The GalNAc may be attached to the 5'-end of the sense strand, the 3' end of the sense strand, the 5'-end of the antisense strand, or the 3' – end of the antisense strand. In one embodiment, the GalNAc is attached to the 3' end of the sense strand, *e.g.*, *via* a trivalent linker.

In other embodiments, the double stranded RNAi agents of the invention comprise a plurality (*e.g.*, 2, 3, 4, 5, or 6) GalNAc or GalNAc derivatives, each independently attached to a plurality of nucleotides of the double stranded RNAi agent through a plurality of linkers, *e.g.*, monovalent linkers.

In some embodiments, for example, when the two strands of an iRNA agent of the invention is part of one larger molecule connected by an uninterrupted chain of nucleotides between the 3'-end of one strand and the 5'-end of the respective other strand forming a hairpin loop comprising, a plurality of unpaired nucleotides, each unpaired nucleotide within the hairpin loop may independently comprise a GalNAc or GalNAc derivative attached *via* a monovalent linker.

In some embodiments, the carbohydrate conjugate further comprises one or more additional ligands as described above, such as, but not limited to, a PK modulator or a cell permeation peptide.

Additional carbohydrate conjugates and linkers suitable for use in the present invention include those described in PCT Publication Nos. WO 2014/179620 and WO 2014/179627, the entire contents of each of which are incorporated herein by reference.

D. Linkers

In some embodiments, the conjugate or ligand described herein can be attached to an iRNA oligonucleotide with various linkers that can be cleavable or non-cleavable.

The term "linker" or "linking group" means an organic moiety that connects two parts of a compound, *e.g.*, covalently attaches two parts of a compound. Linkers typically comprise a direct bond or an atom such as oxygen or sulfur, a unit such as NR₈, C(O), C(O)NH, SO, SO₂, SO₂NH or a chain of atoms, such as, but not limited to, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclalkyl, heterocyclalkenyl, heterocyclalkynyl, aryl, heteroaryl, heterocycl, cycloalkyl, cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl, alkenylarylalkenyl, alkenylarylalkynyl, alkynylarylalkyl, alkynylarylalkenyl, alkynylarylalkynyl, alkylheteroarylalkyl, alkylheteroarylalkenyl, alkylheteroarylalkynyl, alkenylheteroarylalkyl, alkenylheteroarylalkenyl, alkenylheteroarylalkynyl, alkynylheteroarylalkyl, alkynylheteroarylalkenyl, alkynylheteroarylalkynyl, alkylheterocyclalkyl, alkylheterocyclalkenyl, alkylheterocyclalkynyl, alkenylheterocyclalkyl,

alkenylheterocyclalkenyl, alkenylheterocyclalkynyl, alkynylheterocyclalkyl, alkynylheterocyclalkenyl, alkynylheterocyclalkynyl, alkylaryl, alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl, alkynylheteroaryl, which one or more methylenes can be interrupted or terminated by O, S, S(O), SO₂, N(R₈), C(O), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclic; where R₈ is hydrogen, acyl, aliphatic, or substituted aliphatic. In one embodiment, the linker is about 1-24 atoms, 2-24, 3-24, 4-24, 5-24, 6-24, 6-18, 7-18, 8-18, 7-17, 8-17, 6-16, 7-17, or 8-16 atoms.

A cleavable linking group is one which is sufficiently stable outside the cell, but which upon entry into a target cell is cleaved to release the two parts the linker is holding together. In one embodiment, the cleavable linking group is cleaved at least about 10 times, 20, times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, or more, or at least 100 times faster in a target cell or under a first reference condition (which can, *e.g.*, be selected to mimic or represent intracellular conditions) than in the blood of a subject, or under a second reference condition (which can, *e.g.*, be selected to mimic or represent conditions found in the blood or serum).

Cleavable linking groups are susceptible to cleavage agents, *e.g.*, pH, redox potential, or the presence of degradative molecules. Generally, cleavage agents are more prevalent or found at higher levels or activities inside cells than in serum or blood. Examples of such degradative agents include: redox agents which are selected for particular substrates or which have no substrate specificity, including, *e.g.*, oxidative or reductive enzymes or reductive agents such as mercaptans, present in cells, that can degrade a redox cleavable linking group by reduction; esterases; endosomes or agents that can create an acidic environment, *e.g.*, those that result in a pH of five or lower; enzymes that can hydrolyze or degrade an acid cleavable linking group by acting as a general acid, peptidases (which can be substrate specific), and phosphatases.

A cleavable linkage group, such as a disulfide bond can be susceptible to pH. The pH of human serum is 7.4, while the average intracellular pH is slightly lower, ranging from about 7.1-7.3. Endosomes have a more acidic pH, in the range of 5.5-6.0, and lysosomes have an even more acidic pH at around 5.0. Some linkers will have a cleavable linking group that is cleaved at a selected pH, thereby releasing a cationic lipid from the ligand inside the cell, or into the desired compartment of the cell.

A linker can include a cleavable linking group that is cleavable by a particular enzyme. The type of cleavable linking group incorporated into a linker can depend on the cell to be targeted. For example, a liver-targeting ligand can be linked to a cationic lipid through a linker that includes an ester group. Liver cells are rich in esterases, and therefore the linker will be cleaved more efficiently in liver cells than in cell types that are not esterase-rich. Other cell-types rich in esterases include cells of the lung, renal cortex, and testis.

Linkers that contain peptide bonds can be used when targeting cell types rich in peptidases, such as liver cells and synoviocytes.

In general, the suitability of a candidate cleavable linking group can be evaluated by testing the ability of a degradative agent (or condition) to cleave the candidate linking group. It will also be desirable to also test the candidate cleavable linking group for the ability to resist cleavage in the blood or when in contact with other non-target tissue. Thus, one can determine the relative susceptibility to cleavage between a first and a second condition, where the first is selected to be indicative of cleavage in a target cell and the second is selected to be indicative of cleavage in other tissues or biological fluids, *e.g.*, blood or serum. The evaluations can be carried out in cell free systems, in cells, in cell culture, in organ or tissue culture, or in whole animals. It can be useful to make initial evaluations in cell-free or culture conditions and to confirm by further evaluations in whole animals. In some embodiments, useful candidate compounds are cleaved at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 times faster in the cell (or under *in vitro* conditions selected to mimic intracellular conditions) as compared to blood or serum (or under *in vitro* conditions selected to mimic extracellular conditions).

i. Redox cleavable linking groups

In certain embodiments, a cleavable linking group is a redox cleavable linking group that is cleaved upon reduction or oxidation. An example of reductively cleavable linking group is a disulphide linking group (-S-S-). To determine if a candidate cleavable linking group is a suitable “reductively cleavable linking group,” or for example is suitable for use with a particular iRNA moiety and particular targeting agent one can look to methods described herein. For example, a candidate can be evaluated by incubation with dithiothreitol (DTT), or other reducing agent using reagents known in the art, which mimic the rate of cleavage which would be observed in a cell, *e.g.*, a target cell. The candidates can also be evaluated under conditions which are selected to mimic blood or serum conditions. In one, candidate compounds are cleaved by at most about 10% in the blood. In other embodiments, useful candidate compounds are degraded at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster in the cell (or under *in vitro* conditions selected to mimic intracellular conditions) as compared to blood (or under *in vitro* conditions selected to mimic extracellular conditions). The rate of cleavage of candidate compounds can be determined using standard enzyme kinetics assays under conditions chosen to mimic intracellular media and compared to conditions chosen to mimic extracellular media.

ii. Phosphate-based cleavable linking groups

In other embodiments, a cleavable linker comprises a phosphate-based cleavable linking group. A phosphate-based cleavable linking group is cleaved by agents that degrade or hydrolyze the phosphate group. An example of an agent that cleaves phosphate groups in cells are enzymes such as phosphatases in cells. Examples of phosphate-based linking groups are -O-P(O)(ORk)-O-, -O-P(S)(ORk)-O-, -O-P(S)(SRk)-O-, -S-P(O)(ORk)-O-, -O-P(O)(ORk)-S-, -S-P(O)(ORk)-S-, -O-P(S)(ORk)-S-, -S-P(S)(ORk)-O-, -O-P(O)(Rk)-O-, -O-P(S)(Rk)-O-, -S-P(O)(Rk)-O-, -S-P(S)(Rk)-O-,

-S-P(O)(Rk)-S-, -O-P(S)(Rk)-S-, wherein Rk at each occurrence can be, independently, C1-C20 alkyl, C1-C20 haloalkyl, C6-C10 aryl, or C7-C12 aralkyl. Exemplary embodiments include -O-P(O)(OH)-O-, -O-P(S)(OH)-O-, -O-P(S)(SH)-O-, -S-P(O)(OH)-O-, -O-P(O)(OH)-S-, -S-P(O)(OH)-S-, -O-P(S)(OH)-S-, -S-P(S)(OH)-O-, -O-P(O)(H)-O-, -O-P(S)(H)-O-, -S-P(O)(H)-O-, -S-P(S)(H)-O-, -S-P(O)(H)-S-, and -O-P(S)(H)-S-. In certain embodiments, a phosphate-based linking group is -O-P(O)(OH)-O-. These candidates can be evaluated using methods analogous to those described above.

iii. Acid cleavable linking groups

In other embodiments, a cleavable linker comprises an acid cleavable linking group. An acid cleavable linking group is a linking group that is cleaved under acidic conditions. In some embodiments acid cleavable linking groups are cleaved in an acidic environment with a pH of about 6.5 or lower (*e.g.*, about 6.0, 5.5, 5.0, or lower), or by agents such as enzymes that can act as a general acid. In a cell, specific low pH organelles, such as endosomes and lysosomes can provide a cleaving environment for acid cleavable linking groups. Examples of acid cleavable linking groups include but are not limited to hydrazones, esters, and esters of amino acids. Acid cleavable groups can have the general formula -C=NN-, C(O)O, or -OC(O). An exemplary embodiment is when the carbon attached to the oxygen of the ester (the alkoxy group) is an aryl group, substituted alkyl group, or tertiary alkyl group such as dimethyl pentyl or t-butyl. These candidates can be evaluated using methods analogous to those described above.

iv. Ester-based linking groups


In other embodiments, a cleavable linker comprises an ester-based cleavable linking group. An ester-based cleavable linking group is cleaved by enzymes such as esterases and amidases in cells. Examples of ester-based cleavable linking groups include, but are not limited to, esters of alkylene, alkenylene and alkynylene groups. Ester cleavable linking groups have the general formula -C(O)O-, or -OC(O)-. These candidates can be evaluated using methods analogous to those described above.

v. Peptide-based cleaving groups


In yet other embodiments, a cleavable linker comprises a peptide-based cleavable linking group. A peptide-based cleavable linking group is cleaved by enzymes such as peptidases and proteases in cells. Peptide-based cleavable linking groups are peptide bonds formed between amino acids to yield oligopeptides (*e.g.*, dipeptides, tripeptides *etc.*) and polypeptides. Peptide-based cleavable groups do not include the amide group (-C(O)NH-). The amide group can be formed between any alkylene, alkenylene or alkynylene. A peptide bond is a special type of amide bond formed between amino acids to yield peptides and proteins. The peptide based cleavage group is generally limited to the peptide bond (*i.e.*, the amide bond) formed between amino acids yielding peptides and proteins and does not include the entire amide functional group. Peptide-based cleavable linking groups have the general formula -NHCHRAC(O)NHCHRBC(O)-, where RA and RB are the

R groups of the two adjacent amino acids. These candidates can be evaluated using methods analogous to those described above.


In some embodiments, an iRNA of the invention is conjugated to a carbohydrate through a linker. Non-limiting examples of iRNA carbohydrate conjugates with linkers of the compositions and methods of the invention include, but are not limited to,




(Formula XXXVII),




(Formula XXXVIII),




(Formula XXXIX),




(Formula XL),




(Formula XLI),



5 (Formula XLII),



(Formula XLIII), and




10

(Formula XLIV), when one of X or Y is an oligonucleotide, the other is a hydrogen.



In certain embodiments of the compositions and methods of the invention, a ligand is one or more “GalNAc” (N-acetylgalactosamine) derivatives attached through a bivalent or trivalent branched linker.

In one embodiment, a dsRNA of the invention is conjugated to a bivalent or trivalent branched linker selected from the group of structures shown in any of formula (XLV) – (XLVI):


Formula XXXXV



Formula XLVI



Formula (VII)




Formula (VIII)

Formula XLVII

wherein:


q_{2A}, q_{2B}, q_{3A}, q_{3B}, q_{4A}, q_{4B}, q_{5A}, q_{5B} and q_{5C} represent independently for each occurrence 0-20 and wherein the repeating unit can be the same or different;

- 10 P^{2A}, P^{2B}, P^{3A}, P^{3B}, P^{4A}, P^{4B}, P^{5A}, P^{5B}, P^{5C}, T^{2A}, T^{2B}, T^{3A}, T^{3B}, T^{4A}, T^{4B}, T^{4A}, T^{5B}, T^{5C} are each independently for each occurrence absent, CO, NH, O, S, OC(O), NHC(O), CH₂, CH₂NH or CH₂O; Q^{2A}, Q^{2B}, Q^{3A}, Q^{3B}, Q^{4A}, Q^{4B}, Q^{5A}, Q^{5B}, Q^{5C} are independently for each occurrence absent, alkylene, substituted alkylene wherein one or more methylenes can be interrupted or terminated by one or more of O, S, S(O), SO₂, N(R^N), C(R')=C(R''), C≡C or C(O);
- 15 R^{2A}, R^{2B}, R^{3A}, R^{3B}, R^{4A}, R^{4B}, R^{5A}, R^{5B}, R^{5C} are each independently for each occurrence absent, NH, O,



L^{2A}, L^{2B}, L^{3A}, L^{3B}, L^{4A}, L^{4B}, L^{5A}, L^{5B} and L^{5C} represent the ligand; *i.e.* each independently for each occurrence a monosaccharide (such as GalNAc), disaccharide, trisaccharide, tetrasaccharide,

- 20 oligosaccharide, or polysaccharide; and R^a is H or amino acid side chain. Trivalent conjugating GalNAc derivatives are particularly useful for use with RNAi agents for inhibiting the expression of a target gene, such as those of formula (XLIX):



Formula (VII)

wherein L^{5A} , L^{5B} and L^{5C} represent a monosaccharide, such as GalNAc derivative.

Examples of suitable bivalent and trivalent branched linker groups conjugating GalNAc derivatives include, but are not limited to, the structures recited above as formulas II, VII, XI, X, and XIII.

Representative U.S. Patents that teach the preparation of RNA conjugates include, but are not limited to, U.S. Patent Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928; 5,688,941; 6,294,664; 6,320,017; 6,576,752; 6,783,931; 6,900,297; 7,037,646; and 8,106,022, the entire contents of each of which are hereby incorporated herein by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications can be incorporated in a single compound or even at a single nucleoside within an iRNA. The present invention also includes iRNA compounds that are chimeric compounds.

“Chimeric” iRNA compounds or “chimeras,” in the context of this invention, are iRNA compounds, such as, dsRNAi agents, that contain two or more chemically distinct regions, each made up of at least one monomer unit, *i.e.*, a nucleotide in the case of a dsRNA compound. These iRNAs typically contain at least one region wherein the RNA is modified so as to confer upon the iRNA increased resistance to nuclease degradation, increased cellular uptake, or increased binding affinity for the target nucleic acid. An additional region of the iRNA can serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of iRNA inhibition of gene expression. Consequently, comparable results can often be obtained with shorter iRNAs when chimeric dsRNAs are used, compared to phosphorothioate deoxy dsRNAs hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

In certain instances, the RNA of an iRNA can be modified by a non-ligand group. A number of non-ligand molecules have been conjugated to iRNAs in order to enhance the activity, cellular distribution or cellular uptake of the iRNA, and procedures for performing such conjugations are available in the scientific literature. Such non-ligand moieties have included lipid moieties, such as cholesterol (Kubo, T. *et al.*, *Biochem. Biophys. Res. Comm.*, 2007, 365(1):54-61; Letsinger *et al.*, *Proc. Natl. Acad. Sci. USA*, 1989, 86:6553), cholic acid (Manoharan *et al.*, *Bioorg. Med. Chem. Lett.*, 1994, 4:1053), a thioether, *e.g.*, hexyl-S-tritylthiol (Manoharan *et al.*, *Ann. N.Y. Acad. Sci.*, 1992, 660:306; Manoharan *et al.*, *Bioorg. Med. Chem. Lett.*, 1993, 3:2765), a thiocholesterol (Oberhauser *et al.*, *Nucl. Acids Res.*, 1992, 20:533), an aliphatic chain, *e.g.*, dodecandiol or undecyl residues (Saison-Behmoaras *et al.*, *EMBO J.*, 1991, 10:111; Kabanov *et al.*, *FEBS Lett.*, 1990, 259:327; Svinarchuk *et al.*, *Biochimie*, 1993, 75:49), a phospholipid, *e.g.*, di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan *et al.*, *Tetrahedron Lett.*, 1995, 36:3651; Shea *et al.*, *Nucl. Acids Res.*, 1990, 18:3777), a polyamine or a polyethylene glycol chain (Manoharan *et al.*, *Nucleosides & Nucleotides*, 1995, 14:969), or adamantane acetic acid (Manoharan *et al.*, *Tetrahedron Lett.*, 1995, 36:3651), a palmityl moiety (Mishra *et al.*, *Biochim. Biophys. Acta*, 1995, 1264:229), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke *et al.*, *J. Pharmacol. Exp. Ther.*, 1996, 277:923). Representative United States patents that teach the preparation of such RNA conjugates have been listed above. Typical conjugation protocols involve the synthesis of RNAs bearing an aminolinker at one or more positions of the sequence. The amino group is then reacted with the molecule being conjugated using appropriate coupling or activating reagents. The conjugation reaction can be performed either with the RNA still bound to the solid support or following cleavage of the RNA, in solution phase. Purification of the RNA conjugate by HPLC typically affords the pure conjugate.

V. Delivery of an iRNA of the Invention

The delivery of an iRNA of the invention to a cell *e.g.*, a cell within a subject, such as a human subject (*e.g.*, a subject in need thereof, such as a subject susceptible to or diagnosed with a KHK-associated disorder, as described herein) can be achieved in a number of different ways. For example, delivery may be performed by contacting a cell with an iRNA of the invention either *in vitro* or *in vivo*. *In vivo* delivery may also be performed directly by administering a composition comprising an iRNA, *e.g.*, a dsRNA, to a subject. Alternatively, *in vivo* delivery may be performed indirectly by administering one or more vectors that encode and direct the expression of the iRNA. These alternatives are discussed further below.

In general, any method of delivering a nucleic acid molecule (*in vitro* or *in vivo*) can be adapted for use with an iRNA of the invention (see *e.g.*, Akhtar S. and Julian RL. (1992) *Trends Cell Biol.* 2(5):139-144 and WO94/02595, which are incorporated herein by reference in their entireties). For *in vivo* delivery, factors to consider in order to deliver an iRNA molecule include, for example, biological stability of the delivered molecule, prevention of non-specific effects, and accumulation of

the delivered molecule in the target tissue. RNA interference has also shown success with local delivery to the CNS by direct injection (Dorn, G., *et al.* (2004) *Nucleic Acids* 32:e49; Tan, PH., *et al.* (2005) *Gene Ther.* 12:59-66; Makimura, H., *et al.* (2002) *BMC Neurosci.* 3:18; Shishkina, GT., *et al.* (2004) *Neuroscience* 129:521-528; Thakker, ER., *et al.* (2004) *Proc. Natl. Acad. Sci. U.S.A.*

101:17270-17275; Akaneya, Y., *et al.* (2005) *J. Neurophysiol.* 93:594-602). Modification of the RNA or the pharmaceutical carrier can also permit targeting of the iRNA to the target tissue and avoid undesirable off-target effects. iRNA molecules can be modified by chemical conjugation to lipophilic groups such as cholesterol to enhance cellular uptake and prevent degradation. For example, an iRNA directed against ApoB conjugated to a lipophilic cholesterol moiety was injected systemically into mice and resulted in knockdown of apoB mRNA in both the liver and jejunum (Soutschek, J., *et al.* (2004) *Nature* 432:173-178).

In an alternative embodiment, the iRNA can be delivered using drug delivery systems such as a nanoparticle, a dendrimer, a polymer, liposomes, or a cationic delivery system. Positively charged cationic delivery systems facilitate binding of an iRNA molecule (negatively charged) and also enhance interactions at the negatively charged cell membrane to permit efficient uptake of an iRNA by the cell. Cationic lipids, dendrimers, or polymers can either be bound to an iRNA, or induced to form a vesicle or micelle (see *e.g.*, Kim SH, *et al.* (2008) *Journal of Controlled Release* 129(2):107-116) that encases an iRNA. The formation of vesicles or micelles further prevents degradation of the iRNA when administered systemically. Methods for making and administering cationic- iRNA complexes are well within the abilities of one skilled in the art (see *e.g.*, Sorensen, DR, *et al.* (2003) *J. Mol. Biol.* 327:761-766; Verma, UN, *et al.* (2003) *Clin. Cancer Res.* 9:1291-1300; Arnold, AS *et al.* (2007) *J. Hypertens.* 25:197-205, which are incorporated herein by reference in their entirety). Some non-limiting examples of drug delivery systems useful for systemic delivery of iRNAs include DOTAP (Sorensen, DR., *et al.* (2003), *supra*; Verma, UN, *et al.* (2003), *supra*), "solid nucleic acid lipid particles" (Zimmermann, TS, *et al.* (2006) *Nature* 441:111-114), cardiolipin (Chien, PY, *et al.* (2005) *Cancer Gene Ther.* 12:321-328; Pal, A, *et al.* (2005) *Int J. Oncol.* 26:1087-1091), polyethyleneimine (Bonnet ME, *et al.* (2008) *Pharm. Res.* Aug 16 Epub ahead of print; Aigner, A. (2006) *J. Biomed. Biotechnol.* 71659), Arg-Gly-Asp (RGD) peptides (Liu, S. (2006) *Mol. Pharm.* 3:472-487), and polyamidoamines (Tomalia, DA, *et al.* (2007) *Biochem. Soc. Trans.* 35:61-67; Yoo, H., *et al.* (1999) *Pharm. Res.* 16:1799-1804). In some embodiments, an iRNA forms a complex with cyclodextrin for systemic administration. Methods for administration and pharmaceutical compositions of iRNAs and cyclodextrins can be found in U.S. Patent No. 7,427,605, which is herein incorporated by reference in its entirety.

A. Vector encoded iRNAs of the Invention

iRNA targeting the KHK gene can be expressed from transcription units inserted into DNA or RNA vectors (see, *e.g.*, Couture, A, *et al.*, *TIG.* (1996), 12:5-10; Skillern, A, *et al.*, International PCT Publication No. WO 00/22113, Conrad, International PCT Publication No. WO 00/22114, and

Conrad, U.S. Patent No. 6,054,299). Expression can be transient (on the order of hours to weeks) or sustained (weeks to months or longer), depending upon the specific construct used and the target tissue or cell type. These transgenes can be introduced as a linear construct, a circular plasmid, or a viral vector, which can be an integrating or non-integrating vector. The transgene can also be constructed to permit it to be inherited as an extrachromosomal plasmid (Gassmann, *et al.*, *Proc. Natl. Acad. Sci. USA* (1995) 92:1292).

Viral vector systems which can be utilized with the methods and compositions described herein include, but are not limited to, (a) adenovirus vectors; (b) retrovirus vectors, including but not limited to lentiviral vectors, moloney murine leukemia virus, *etc.*; (c) adeno- associated virus vectors; (d) herpes simplex virus vectors; (e) SV 40 vectors; (f) polyoma virus vectors; (g) papilloma virus vectors; (h) picornavirus vectors; (i) pox virus vectors such as an orthopox, *e.g.*, vaccinia virus vectors or avipox, *e.g.* canary pox or fowl pox; and (j) a helper-dependent or gutless adenovirus. Replication-defective viruses can also be advantageous. Different vectors will or will not become incorporated into the cells' genome. The constructs can include viral sequences for transfection, if desired. Alternatively, the construct can be incorporated into vectors capable of episomal replication, *e.g.* EPV and EBV vectors. Constructs for the recombinant expression of an iRNA will generally require regulatory elements, *e.g.*, promoters, enhancers, *etc.*, to ensure the expression of the iRNA in target cells. Other aspects to consider for vectors and constructs are known in the art.

VI. Pharmaceutical Compositions of the Invention

The present invention also includes pharmaceutical compositions and formulations which include the iRNAs of the invention. In one embodiment, provided herein are pharmaceutical compositions containing an iRNA, as described herein, and a pharmaceutically acceptable carrier. The pharmaceutical compositions containing the iRNA are useful for treating a disease or disorder associated with the expression or activity of a KHK gene. Such pharmaceutical compositions are formulated based on the mode of delivery. One example is compositions that are formulated for systemic administration via parenteral delivery, *e.g.*, by subcutaneous (SC) or intravenous (IV) delivery. The pharmaceutical compositions of the invention may be administered in dosages sufficient to inhibit expression of a KHK gene.

In some embodiments, the pharmaceutical compositions of the invention are sterile. In another embodiment, the pharmaceutical compositions of the invention are pyrogen free.

The pharmaceutical compositions of the invention may be administered in dosages sufficient to inhibit expression of a KHK gene. In general, a suitable dose of an iRNA of the invention will be in the range of about 0.001 to about 200.0 milligrams per kilogram body weight of the recipient per day, generally in the range of about 1 to 50 mg per kilogram body weight per day. Typically, a suitable dose of an iRNA of the invention will be in the range of about 0.1 mg/kg to about 5.0 mg/kg, about 0.3 mg/kg and about 3.0 mg/kg. A repeat-dose regimen may include administration of a therapeutic amount of iRNA on a regular basis, such as every month, once every 3-6 months, or once

a year. In certain embodiments, the iRNA is administered about once per month to about once per six months.

After an initial treatment regimen, the treatments can be administered on a less frequent basis. Duration of treatment can be determined based on the severity of disease.

5 In other embodiments, a single dose of the pharmaceutical compositions can be long lasting, such that doses are administered at not more than 1, 2, 3, or 4 month intervals. In some embodiments of the invention, a single dose of the pharmaceutical compositions of the invention is administered about once per month. In other embodiments of the invention, a single dose of the pharmaceutical compositions of the invention is administered quarterly (*i.e.*, about every three months). In other
10 embodiments of the invention, a single dose of the pharmaceutical compositions of the invention is administered twice per year (*i.e.*, about once every six months).

The skilled artisan will appreciate that certain factors can influence the dosage and timing required to effectively treat a subject, including but not limited to mutations present in the subject, previous treatments, the general health or age of the subject, and other diseases present. Moreover,
15 treatment of a subject with a prophylactically or therapeutically effective amount, as appropriate, of a composition can include a single treatment or a series of treatments.

The iRNA can be delivered in a manner to target a particular tissue (*e.g.*, hepatocytes).

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions can be generated
20 from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids, and self-emulsifying semisolids. Formulations include those that target the liver.

The pharmaceutical formulations of the present invention, which can conveniently be presented in unit dosage form, can be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active
25 ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers.

A. Additional Formulations

i. Emulsions

30 The compositions of the present invention can be prepared and formulated as emulsions. Emulsions are typically heterogeneous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter (see *e.g.*, Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, LV., Popovich NG., and Ansel HC., 2004, Lippincott Williams & Wilkins (8th ed.), New York, NY; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in
35 Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in Pharmaceutical Dosage Forms, Lieberman, Rieger and

Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi *et al.*, in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1985, p. 301). Emulsions are often biphasic systems comprising two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions can be of either the water-in-oil (w/o) or the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase, the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase, the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions can contain additional components in addition to the dispersed phases, and the active drug which can be present as a solution either in the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants can also be present in emulsions as needed. Pharmaceutical emulsions can also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous phase provides an o/w/o emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Other means of stabilizing emulsions entail the use of emulsifiers that can be incorporated into either phase of the emulsion. Emulsifiers can broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (see *e.g.*, Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, LV., Popovich NG., and Ansel HC., 2004, Lippincott Williams & Wilkins (8th ed.), New York, NY; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (see *e.g.*, Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, LV., Popovich NG., and Ansel HC., 2004, Lippincott Williams & Wilkins (8th ed.), New York, NY; Rieger, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants can be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic,

cationic, and amphoteric (see *e.g.*, Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, LV., Popovich NG., and Ansel HC., 2004, Lippincott Williams & Wilkins (8th ed.), New York, NY; Rieger, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

5 A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives, and antioxidants (Block, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

10 The application of emulsion formulations *via* dermatological, oral, and parenteral routes, and methods for their manufacture have been reviewed in the literature (see *e.g.*, Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, LV., Popovich NG., and Ansel HC., 2004, Lippincott Williams & Wilkins (8th ed.), New York, NY; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

ii. Microemulsions

In one embodiment of the present invention, the compositions of iRNAs and nucleic acids are formulated as microemulsions. A microemulsion can be defined as a system of water, oil, and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (see 20 *e.g.*, Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, LV., Popovich NG., and Ansel HC., 2004, Lippincott Williams & Wilkins (8th ed.), New York, NY; Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first 25 dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: Controlled Release of Drugs: Polymers and Aggregate Systems, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215).

iii. Microparticles

An iRNA of the invention may be incorporated into a particle, *e.g.*, a microparticle. Microparticles can be produced by spray-drying, but may also be produced by other methods 35 including lyophilization, evaporation, fluid bed drying, vacuum drying, or a combination of these techniques.

iv. Penetration Enhancers

In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly iRNAs, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs can cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers can be classified as belonging to one of five broad categories, *i.e.*, surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (see *e.g.*, Malmsten, M. Surfactants and polymers in drug delivery, Informa Health Care, New York, NY, 2002; Lee *et al.*, Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p.92). Each of the above mentioned classes of penetration enhancers and their use in manufacture of pharmaceutical compositions and delivery of pharmaceutical agents are well known in the art.

v. Excipients

In contrast to a carrier compound, a “pharmaceutical carrier” or “excipient” is a pharmaceutically acceptable solvent, suspending agent, or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient can be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Such agent are well known in the art.

vi. Other Components

The compositions of the present invention can additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions can contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or can contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, *e.g.*, lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings, or aromatic substances, and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

Aqueous suspensions can contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol, or dextran. The suspension can also contain stabilizers.

In some embodiments, pharmaceutical compositions featured in the invention include (a) one or more iRNA and (b) one or more agents which function by a non-iRNA mechanism and which are useful in treating a KHK-associated disorder, *e.g.*, liver disease (*e.g.*, fatty liver, steatohepatitis, non-alcoholic steatohepatitis (NASH)), dyslipidemia (*e.g.*, hyperlipidemia, high LDL cholesterol, low HDL cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (*e.g.*, insulin resistance, type 2 diabetes), cardiovascular disease (*e.g.*, hypertension, endothelial cell dysfunction), kidney disease (*e.g.*, acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, chronic kidney disease), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving.

Toxicity and prophylactic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose prophylactically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compounds that exhibit high therapeutic indices are preferred.

The data obtained from cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of compositions featured herein in the invention lies generally within a range of circulating concentrations that include the ED50, such as, an ED80 or ED90, with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the methods featured in the invention, the prophylactically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range of the compound or, when appropriate, of the polypeptide product of a target sequence (*e.g.*, achieving a decreased concentration of the polypeptide) that includes the IC50 (*i.e.*, the concentration of the test compound which achieves a half-maximal inhibition of symptoms) or higher levels of inhibition as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma can be measured, for example, by high performance liquid chromatography.

In addition to their administration, as discussed above, the iRNAs featured in the invention can be administered in combination with other known agents used for the prevention or treatment of a KHK-associated disorder, *e.g.*, liver disease (*e.g.*, fatty liver, steatohepatitis, non-alcoholic steatohepatitis (NASH)), dyslipidemia (*e.g.*, hyperlipidemia, high LDL cholesterol, low HDL cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (*e.g.*, insulin resistance, type 2 diabetes), cardiovascular disease (*e.g.*, hypertension, endothelial cell

dysfunction), kidney disease (*e.g.*, acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, chronic kidney disease), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving. In any event, the administering physician can adjust the amount and timing of iRNA administration on the basis of results observed using standard measures of efficacy known in the art or described herein.

VII. Methods For Inhibiting KHK Expression

The present invention also provides methods of inhibiting expression of a KHK gene in a cell. The methods include contacting a cell with an RNAi agent, *e.g.*, double stranded RNAi agent, in an amount effective to inhibit expression of KHK in the cell, thereby inhibiting expression of KHK in the cell.

Contacting of a cell with an iRNA, *e.g.*, a double stranded RNA agent, may be done *in vitro* or *in vivo*. Contacting a cell *in vivo* with the iRNA includes contacting a cell or group of cells within a subject, *e.g.*, a human subject, with the iRNA. Combinations of *in vitro* and *in vivo* methods of contacting a cell are also possible. Contacting a cell may be direct or indirect, as discussed above. Furthermore, contacting a cell may be accomplished *via* a targeting ligand, including any ligand described herein or known in the art. In some embodiments, the targeting ligand is a carbohydrate moiety, *e.g.*, a GalNAc₃ ligand, or any other ligand that directs the RNAi agent to a site of interest.

The term “inhibiting,” as used herein, is used interchangeably with “reducing,” “silencing,” “downregulating,” “suppressing”, and other similar terms, and includes any level of inhibition.

The phrase “inhibiting expression of a KHK” is intended to refer to inhibition of expression of any KHK gene (such as, *e.g.*, a mouse KHK 3 gene, a rat KHK gene, a monkey KHK gene, or a human KHK gene) as well as variants or mutants of a KHK gene. Thus, the KHK gene may be a wild-type KHK gene, a mutant KHK gene, or a transgenic KHK gene in the context of a genetically manipulated cell, group of cells, or organism.

“Inhibiting expression of a KHK gene” includes any level of inhibition of a KHK gene, *e.g.*, at least partial suppression of the expression of a KHK gene. The expression of the KHK gene may be assessed based on the level, or the change in the level, of any variable associated with KHK gene expression, *e.g.*, KHK mRNA level or KHK protein level. This level may be assessed in an individual cell or in a group of cells, including, for example, a sample derived from a subject.

Inhibition may be assessed by a decrease in an absolute or relative level of one or more variables that are associated with KHK expression compared with a control level. The control level may be any type of control level that is utilized in the art, *e.g.*, a pre-dose baseline level, or a level determined from a similar subject, cell, or sample that is untreated or treated with a control (such as, *e.g.*, buffer only control or inactive agent control).

It is understood that the degree and duration of elevation of a sign of a KHK-associated disease will vary depending upon the sign. For example, lipid signs, *e.g.*, fasting lipid levels,

NAFLD, NASH, obesity; signs of liver and kidney function, and glucose or insulin response, are durable signs that will not vary in a clinically significant manner within a day or even within a week. Other markers, *e.g.*, serum uric acid and glucose levels, and urine fructose levels, will vary within and likely between days. Blood pressure can be elevated transiently and durably in response to fructose.

- 5 As fructose likely results in weight gain at least in part by reducing satiety, fructose consumption in conjunction with caloric limitation may not result in weight gain.

Further, depending on the disease state in the subject, as many as one third of adults and two thirds of children malabsorb fructose (Johnson *et al.* (2013) *Diabetes*. 62:3307-3315), *e.g.*, due to variations in expression of the GLUT5 transporter in the gut. However, repeated exposure to fructose
10 can increase fructose absorption. Fructose metabolism has demonstrated to be different depending on the source of fructose, *e.g.*, in high fructose corn syrup vs. in natural fruit, and at high concentrations, such as those provided by soft drinks, glucose can be converted to fructose by the polyol pathway. However, fructose will have more metabolic effects than glucose. Body composition, *e.g.*, lean body mass, has also been demonstrated to affect fructose metabolism. Therefore, both the timing of testing
15 and controls must be carefully selected.

In some embodiments of the methods of the invention, expression of a KHK gene is inhibited by at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or to below the level of detection of the assay. In some embodiments, expression of a KHK gene is inhibited by at least 70%. In some embodiments, expression level is determined using the assay method provided in Example 2
20 with a 10 nM siRNA concentration in the appropriate species matched cell line.

In certain embodiments, inhibition of expression *in vivo* is determined by knockdown of the human gene in a rodent expressing the human gene, *e.g.*, an AAV-infected mouse expressing the human target gene (*i.e.*, KHK), *e.g.*, when administered as a single dose, *e.g.*, at 3 mg/kg at the nadir of RNA expression. Knockdown of expression of an endogenous gene in a model animal system can
25 also be determined, *e.g.*, after administration of a single dose at, *e.g.*, 3 mg/kg at the nadir of RNA expression. Such systems are useful when the nucleic acid sequence of the human gene and the model animal gene are sufficiently close such that the human iRNA provides effective knockdown of the model animal gene. RNA expression in liver is determined using the PCR methods provided in Example 2.

30 Inhibition of the expression of a KHK gene may be manifested by a reduction of the amount of mRNA expressed by a first cell or group of cells (such cells may be present, for example, in a sample derived from a subject) in which a KHK gene is transcribed and which has or have been treated (*e.g.*, by contacting the cell or cells with an iRNA of the invention, or by administering an iRNA of the invention to a subject in which the cells are or were present) such that the expression of a
35 KHK gene is inhibited, as compared to a second cell or group of cells substantially identical to the first cell or group of cells but which has not or have not been so treated (control cell(s) not treated with an iRNA or not treated with an iRNA targeted to the gene of interest). In some embodiments, the inhibition is assessed by the method provided in Example 2 using a 10nM siRNA concentration in

the species matched cell line and expressing the level of mRNA in treated cells as a percentage of the level of mRNA in control cells, using the following formula:

$$\frac{(\text{mRNA in control cells}) - (\text{mRNA in treated cells})}{(\text{mRNA in control cells})} \bullet 100\%$$

In other embodiments, inhibition of the expression of a KHK gene may be assessed in terms of a reduction of a parameter that is functionally linked to KHK gene expression, *e.g.*, KHK protein level in blood or serum from a subject. KHK gene silencing may be determined in any cell expressing KHK, either endogenous or heterologous from an expression construct, and by any assay known in the art.

Inhibition of the expression of a KHK protein may be manifested by a reduction in the level of the KHK protein that is expressed by a cell or group of cells or in a subject sample (*e.g.*, the level of protein in a blood sample derived from a subject). As explained above, for the assessment of mRNA suppression, the inhibition of protein expression levels in a treated cell or group of cells may similarly be expressed as a percentage of the level of protein in a control cell or group of cells, or the change in the level of protein in a subject sample, *e.g.*, blood or serum derived therefrom.

A control cell, a group of cells, or subject sample that may be used to assess the inhibition of the expression of a KHK gene includes a cell, group of cells, or subject sample that has not yet been contacted with an RNAi agent of the invention. For example, the control cell, group of cells, or subject sample may be derived from an individual subject (*e.g.*, a human or animal subject) prior to treatment of the subject with an RNAi agent or an appropriately matched population control.

The level of KHK mRNA that is expressed by a cell or group of cells may be determined using any method known in the art for assessing mRNA expression. In one embodiment, the level of expression of KHK in a sample is determined by detecting a transcribed polynucleotide, or portion thereof, *e.g.*, mRNA of the KHK gene. RNA may be extracted from cells using RNA extraction techniques including, for example, using acid phenol/guanidine isothiocyanate extraction (RNAzol B; Biogenesis), RNeasyTM RNA preparation kits (Qiagen®) or PAXgeneTM (PreAnalytixTM, Switzerland). Typical assay formats utilizing ribonucleic acid hybridization include nuclear run-on assays, RT-PCR, RNase protection assays, northern blotting, *in situ* hybridization, and microarray analysis.

In some embodiments, the level of expression of KHK is determined using a nucleic acid probe. The term “probe”, as used herein, refers to any molecule that is capable of selectively binding to a specific KHK. Probes can be synthesized by one of skill in the art, or derived from appropriate biological preparations. Probes may be specifically designed to be labeled. Examples of molecules that can be utilized as probes include, but are not limited to, RNA, DNA, proteins, antibodies, and organic molecules.

Isolated mRNA can be used in hybridization or amplification assays that include, but are not limited to, Southern or northern analyses, polymerase chain reaction (PCR) analyses and probe arrays. One method for the determination of mRNA levels involves contacting the isolated mRNA with a

nucleic acid molecule (probe) that can hybridize to KHK mRNA. In one embodiment, the mRNA is immobilized on a solid surface and contacted with a probe, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose. In an alternative embodiment, the probe(s) are immobilized on a solid surface and the mRNA is contacted with the probe(s), for example, in an Affymetrix® gene chip array. A skilled artisan can readily adapt known mRNA detection methods for use in determining the level of KHK mRNA.

An alternative method for determining the level of expression of KHK in a sample involves the process of nucleic acid amplification or reverse transcriptase (to prepare cDNA) of for example mRNA in the sample, *e.g.*, by RT-PCR (the experimental embodiment set forth in Mullis, 1987, U.S. Patent No. 4,683,202), ligase chain reaction (Barany (1991) *Proc. Natl. Acad. Sci. USA* 88:189-193), self sustained sequence replication (Guatelli *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87:1874-1878), transcriptional amplification system (Kwoh *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:1173-1177), Q-Beta Replicase (Lizardi *et al.* (1988) *Bio/Technology* 6:1197), rolling circle replication (Lizardi *et al.*, U.S. Patent No. 5,854,033) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers. In particular aspects of the invention, the level of expression of KHK is determined by quantitative fluorogenic RT-PCR (*i.e.*, the TaqMan™ System). In some embodiments, expression level is determined by the method provided in Example 2 using, *e.g.*, a 10nM siRNA concentration, in the species matched cell line.

The expression levels of KHK mRNA may be monitored using a membrane blot (such as used in hybridization analysis such as northern, Southern, dot, and the like), or microwells, sample tubes, gels, beads or fibers (or any solid support comprising bound nucleic acids). See U.S. Patent Nos. 5,770,722, 5,874,219, 5,744,305, 5,677,195 and 5,445,934, which are incorporated herein by reference. The determination of KHK expression level may also comprise using nucleic acid probes in solution.

In some embodiments, the level of mRNA expression is assessed using branched DNA (bDNA) assays or real time PCR (qPCR). The use of these methods is described and exemplified in the Examples presented herein. In some embodiments, expression level is determined by the method provided in Example 2 using a 10nM siRNA concentration in the species matched cell line.

The level of KHK protein expression may be determined using any method known in the art for the measurement of protein levels. Such methods include, for example, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, fluid or gel precipitin reactions, absorption spectroscopy, a colorimetric assays, spectrophotometric assays, flow cytometry, immunodiffusion (single or double), immunoelectrophoresis, western blotting, radioimmunoassay (RIA), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, electrochemiluminescence assays, and the like.

In some embodiments, the efficacy of the methods of the invention are assessed by a decrease in KHK mRNA or protein level (*e.g.*, in a liver biopsy).

In some embodiments of the methods of the invention, the iRNA is administered to a subject such that the iRNA is delivered to a specific site within the subject. The inhibition of expression of KHK may be assessed using measurements of the level or change in the level of KHK mRNA or KHK protein in a sample derived from fluid or tissue from the specific site within the subject (*e.g.*, liver or blood).

As used herein, the terms detecting or determining a level of an analyte are understood to mean performing the steps to determine if a material, *e.g.*, protein, RNA, is present. As used herein, methods of detecting or determining include detection or determination of an analyte level that is below the level of detection for the method used.

VIII. Prophylactic and Treatment Methods of the Invention

The present invention also provides methods of using an iRNA of the invention or a composition containing an iRNA of the invention to inhibit expression of KHK, thereby preventing or treating an KHK-associated disorder, *e.g.*, liver disease (*e.g.*, fatty liver, steatohepatitis, non-alcoholic steatohepatitis (NASH)), dyslipidemia (*e.g.*, hyperlipidemia, high LDL cholesterol, low HDL cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (*e.g.*, insulin resistance, type 2 diabetes), cardiovascular disease (*e.g.*, hypertension, endothelial cell dysfunction), kidney disease (*e.g.*, acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, chronic kidney disease), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving. In the methods of the invention the cell may be contacted with the siRNA *in vitro* or *in vivo*, *i.e.*, the cell may be within a subject.

A cell suitable for treatment using the methods of the invention may be any cell that expresses a KHK gene, *e.g.*, a liver cell. A cell suitable for use in the methods of the invention may be a mammalian cell, *e.g.*, a primate cell (such as a human cell, including human cell in a chimeric non-human animal, or a non-human primate cell, *e.g.*, a monkey cell or a chimpanzee cell), or a non-primate cell. In certain embodiments, the cell is a human cell, *e.g.*, a human liver cell. In the methods of the invention, KHK expression is inhibited in the cell by at least 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95, or to a level below the level of detection of the assay.

The *in vivo* methods of the invention may include administering to a subject a composition containing an iRNA, where the iRNA includes a nucleotide sequence that is complementary to at least a part of an RNA transcript of the KHK gene of the mammal to which the RNAi agent is to be administered. The composition can be administered by any means known in the art including, but not limited to oral, intraperitoneal, or parenteral routes, including intracranial (*e.g.*, intraventricular, intraparenchymal, and intrathecal), intravenous, intramuscular, subcutaneous, transdermal, airway (aerosol), nasal, rectal, and topical (including buccal and sublingual) administration. In certain

embodiments, the compositions are administered by intravenous infusion or injection. In certain embodiments, the compositions are administered by subcutaneous injection. In certain embodiments, the compositions are administered by intramuscular injection.

In one aspect, the present invention also provides methods for inhibiting the expression of an KHK gene in a mammal. The methods include administering to the mammal a composition comprising a dsRNA that targets a KHK gene in a cell of the mammal and maintaining the mammal for a time sufficient to obtain degradation of the mRNA transcript of the KHK gene, thereby inhibiting expression of the KHK gene in the cell. Reduction in gene expression can be assessed by any methods known in the art and by methods, *e.g.* qRT-PCR, described herein, *e.g.*, in Example 2. Reduction in protein production can be assessed by any methods known in the art, *e.g.* ELISA. In certain embodiments, a puncture liver biopsy sample serves as the tissue material for monitoring the reduction in the KHK gene or protein expression. In other embodiments, a blood sample serves as the subject sample for monitoring the reduction in the KHK protein expression. A reduction in the expression of KHK may also be assessed indirectly by measuring a decrease in fructose metabolism by detecting one or more indicators of fructose metabolism, *e.g.*, the presence of fructose in the urine indicating lack of fructose metabolism.

The present invention further provides methods of treatment in a subject in need thereof, *e.g.*, a subject diagnosed with a KHK-associated disorder, such as, liver disease (*e.g.*, fatty liver, steatohepatitis, non-alcoholic steatohepatitis (NASH)), dyslipidemia (*e.g.*, hyperlipidemia, high LDL cholesterol, low HDL cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (*e.g.*, insulin resistance, type 2 diabetes), cardiovascular disease (*e.g.*, hypertension, endothelial cell dysfunction), kidney disease (*e.g.*, acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, chronic kidney disease), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving.

The present invention further provides methods of prophylaxis in a subject in need thereof. The treatment methods of the invention include administering an iRNA of the invention to a subject, *e.g.*, a subject that would benefit from a reduction of KHK expression, in a prophylactically effective amount of an iRNA targeting a KHK gene or a pharmaceutical composition comprising an iRNA targeting a KHK gene.

In one aspect, the present invention provides methods of treating a subject having a disorder that would benefit from reduction in KHK expression, *e.g.*, a KHK-associated disease, such as liver disease (*e.g.*, fatty liver, steatohepatitis, non-alcoholic steatohepatitis (NASH)), dyslipidemia (*e.g.*, hyperlipidemia, high LDL cholesterol, low HDL cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (*e.g.*, insulin resistance, type 2 diabetes), cardiovascular disease (*e.g.*, hypertension, endothelial cell dysfunction), kidney disease (*e.g.*, acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, chronic kidney disease), metabolic

syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving.

In certain embodiments, the KHK-associated disorder is a liver disease, *e.g.*, fatty liver disease such as NAFLD or NASH. In certain embodiments, the KHK-associated disorder is
 5 dyslipidemia, *e.g.*, elevated serum triglycerides, elevated serum LDL, elevated serum cholesterol, lowered serum HDL, postprandial hypertriglyceridemia. In another embodiment, the KHK-associated disorder is a disorder of glycemic control, *e.g.*, insulin resistance not resulting from an immune response against insulin, glucose resistance, type 2 diabetes. In certain embodiments, the KHK-associated disorder is a cardiovascular disease, *e.g.*, hypertension, endothelial cell dysfunction. In
 10 certain embodiments, the KHK-associated disorder is a kidney disease, *e.g.*, acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, chronic kidney disease. In certain embodiments, the disease is metabolic syndrome. In certain embodiments, the KHK-associated disorder is a disease of lipid deposition or dysfunction, *e.g.*, visceral adipose deposition, fatty liver, obesity. In certain embodiments, the KHK-associated disorder is a disease of elevated uric
 15 acid, *e.g.*, gout, hyperuricemia. In certain embodiments the KHK-associated disorder is an eating disorder such as excessive sugar craving.

An iRNA of the invention may be administered as a “free iRNA.” A free iRNA is administered in the absence of a pharmaceutical composition. The naked iRNA may be in a suitable buffer solution. The buffer solution may comprise acetate, citrate, prolamine, carbonate, or
 20 phosphate, or any combination thereof. In one embodiment, the buffer solution is phosphate buffered saline (PBS). The pH and osmolarity of the buffer solution containing the iRNA can be adjusted such that it is suitable for administering to a subject.

Alternatively, an iRNA of the invention may be administered as a pharmaceutical composition, such as a dsRNA liposomal formulation.

Subjects that would benefit from an inhibition of KHK gene expression are subjects
 25 susceptible to or diagnosed with an KHK-associated disorder, such as liver disease (*e.g.*, fatty liver, steatohepatitis, non-alcoholic steatohepatitis (NASH)), dyslipidemia (*e.g.*, hyperlipidemia, high LDL cholesterol, low HDL cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (*e.g.*, insulin resistance, type 2 diabetes), cardiovascular disease (*e.g.*,
 30 hypertension, endothelial cell dysfunction), kidney disease (*e.g.*, acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, chronic kidney disease), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving.

In an embodiment, the method includes administering a composition featured herein such that
 35 expression of the target a KHK gene is decreased, such as for about 1, 2, 3, 4, 5, 6, 1-6, 1-3, or 3-6 months per dose. In certain embodiments, the composition is administered once every 3-6 months.

In some embodiments, the iRNAs useful for the methods and compositions featured herein specifically target RNAs (primary or processed) of the target a KHK gene. Compositions and

methods for inhibiting the expression of these genes using iRNAs can be prepared and performed as described herein.

Administration of the iRNA according to the methods of the invention may result prevention or treatment of a KHK-associated disorder, *e.g.*, liver disease (*e.g.*, fatty liver, steatohepatitis, non-alcoholic steatohepatitis (NASH)), dyslipidemia (*e.g.*, hyperlipidemia, high LDL cholesterol, low HDL cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (*e.g.*, insulin resistance, type 2 diabetes), cardiovascular disease (*e.g.*, hypertension, endothelial cell dysfunction), kidney disease (*e.g.*, acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, chronic kidney disease), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving.

Subjects can be administered a therapeutic amount of iRNA, such as about 0.01 mg/kg to about 200 mg/kg.

In some embodiments, the iRNA is administered subcutaneously, *i.e.*, by subcutaneous injection. One or more injections may be used to deliver the desired dose of iRNA to a subject. The injections may be repeated over a period of time.

The administration may be repeated on a regular basis. In certain embodiments, after an initial treatment regimen, the treatments can be administered on a less frequent basis. A repeat-dose regimen may include administration of a therapeutic amount of iRNA on a regular basis, such as once per month to once a year. In certain embodiments, the iRNA is administered about once per month to about once every three months, or about once every three months to about once every six months.

The invention further provides methods and uses of an iRNA agent or a pharmaceutical composition thereof for treating a subject that would benefit from reduction and/or inhibition of KHK gene expression, *e.g.*, a subject having an KHK-associated disease, in combination with other pharmaceuticals and/or other therapeutic methods, *e.g.*, with known pharmaceuticals and/or known therapeutic methods, such as, for example, those which are currently employed for treating these disorders.

Accordingly, in some aspects of the invention, the methods which include either a single iRNA agent of the invention, further include administering to the subject one or more additional therapeutic agents.

The iRNA agent and an additional therapeutic agent and/or treatment may be administered at the same time and/or in the same combination, *e.g.*, parenterally, or the additional therapeutic agent can be administered as part of a separate composition or at separate times and/or by another method known in the art or described herein.

IX. Diagnostic Criteria and Treatment for KHK-Associated diseases

Diagnostic criteria, therapeutic agents, and considerations for treatment for various KHK-associated diseases are provided below.

A. Hyperuricemia

Serum uric acid levels are not routinely obtained as clinical lab values. However, hyperuricemia (elevated uric acid) is associated with a number of diseases and conditions including gout, NAFLD, NASH, metabolic disorder, insulin resistance (not resulting from an immune response to insulin), cardiovascular disease, hypertension, and type 2 diabetes. It is expected that decreasing KHK expression can be useful in the prevention or treatment of one or more conditions associated with elevated serum uric acid levels. Further, it is expected that a subject would derive clinical benefit from normalization of serum uric acid levels towards or to a normal serum uric acid level, *e.g.*, no more than 6.8 mg/dl, such as, no more than 6 mg/dl, even in the absence of overt signs or symptoms of one or more conditions associated with elevated uric acid.

Animal models of hyperuricemia include, for example, high fructose diet, *e.g.*, in rats and mice, which can induce one or more of fat accumulation including fatty liver, insulin resistance, type 2 diabetes, obesity including visceral obesity, metabolic syndrome, decreased adiponectin secretion, reduced renal function, and inflammation (see, *e.g.*, Johnson *et al.* (2013) Diabetes. 62:3307-3315). Administration of oxonic acid, a uricase inhibitor, can also be used to induce hyperuricemia (see, *e.g.*, Mazalli *et al.* (2001) Hypertens. 38:1101-1106). Genetic models of hyperuricemia include the B6;129S7-Uox^{tm1Bay}/J mouse available from Jackson Laboratory (jaxmice.jax.org/strain/002223.html) which develops hyperuricemia, with 10-fold higher levels of serum uric acid levels.

Various treatments for hyperuricemia are known in the art. However, some of the agents can only be used in limited populations. For example, allopurinol is a xanthine oxidase inhibitor that is used to reduce serum uric acid levels for the treatment of a number of conditions, *e.g.*, gout, cardiovascular disease including ischemia-reperfusion injury, hypertension, atherosclerosis, and stroke, and inflammatory diseases (Pacher *et al.*, (2006) Pharma. Rev. 58:87-114). However, the use of allopurinol is contraindicated in subjects with impaired renal function, *e.g.*, chronic kidney disease, hypothyroidism, hyperinsulinemia, or insulin resistance; or in subjects predisposed to kidney disease or impaired renal function, *e.g.*, subjects with hypertension, metabolic disorder, diabetes, and the elderly. Further, allopurinol should not be taken by subjects taking oral coagulants or probenecid as well as subjects taking diuretics, especially thiazide diuretics or other drugs that can reduce kidney function or have potential kidney toxicity.

In certain embodiments, the compositions and methods of the invention are used in combination with other compositions and methods to treat hyperuricemia, *e.g.*, allopurinol, oxypurinol, febuxostat. In certain embodiments, the compositions and methods of the invention are used for treatment of subjects with reduced kidney function or susceptible to reduced kidney function, *e.g.*, due to age, comorbidities, or drug interactions.

B. Gout

Gout affects approximately 1 in 40 adults, most commonly men between 30-60 years of age. Gout less commonly affects women. Gout is one of a few types of arthritis where future damage to

joints can be avoided by treatment. Gout is characterized by recurrent attacks of acute inflammatory arthritis caused by an inflammatory reaction to uric acid crystals in the joint due to hyperuricemia resulting from insufficient renal clearance of uric acid or excessive uric acid production. Fructose associated gout is sometimes associated with variants of transporters expressed in the kidney, intestine, and liver. Gout is characterized by the formation and deposition of tophi, monosodium urate (MSU) crystals, in the joints and subcutaneously. Pain associated with gout is not related to the size of the tophi, but is a result of an immune response against the MSU crystals. There is a linear inverse relation between serum uric acid and the rate of decrease in tophus size. For example, in one study of 18 patients with non-tophaceous gout, serum uric acid declined to 2.7–5.4 mg/dL (0.16–0.32 mM) in all subjects within 3 months of starting urate lowering therapy (Pascual and Sivera (2007) Ann. Rheum. Dis. 66:1056-1058). However, it took 12 months with normalized serum uric acid for MSU crystals to disappear from asymptomatic knee or first MTP joints in patients who had gout for less than 10 years, vs. 18 months in those with gout for more than 10 years. Therefore, effective treatment of gout does not require complete clearance of tophi or resolution of all symptoms, *e.g.*, joint pain and swelling, inflammation, but simply a reduction in at least one sign or symptom of gout, *e.g.*, reduction in severity or frequency of gout attacks, in conjunction with a reduction in serum urate levels.

Animal models of gout include oxonic acid- induced hyperuricemia (see, *e.g.*, Jang *et al.* (2014) Mycobiology. 42:296-300).

Currently available treatments for gout are contraindicated or ineffective in a number of subjects. Allopurinol, a common first line treatment to reduce uric acid levels in subjects with gout, is contraindicated in a number of populations, especially those with compromised renal function, as discussed above. Further, a number of subjects fail treatment with allopurinol, *e.g.*, subjects who suffer gout flares despite treatment, or subjects who suffer from rashes or hypersensitivity reactions associated with allopurinol.

In certain embodiments, the compositions and methods of the invention are used in combination with other agents to reduce serum uric acid. In certain embodiments, the compositions and methods of the invention are used in combination with agents for treatment of symptoms of gout, *e.g.*, analgesic or anti-inflammatory agents, *e.g.*, NSAIDS. In certain embodiments, the compositions and methods of the invention are used for treatment of subjects with reduced kidney function or susceptible to reduced kidney function, *e.g.*, due to age, comorbidities, or drug interactions.

C. Liver disease

NAFLD is associated with hyperuricemia (Xu *et al.* (2015) J. Hepatol. 62:1412-1419) which, in turn, is associated with elevated fructose metabolism. The definition of nonalcoholic fatty liver disease (NAFLD) requires that (a) there is evidence of hepatic steatosis, either by imaging or by histology and (b) there are no causes for secondary hepatic fat accumulation such as significant alcohol consumption, use of steatogenic medication or hereditary disorders. In the majority of

patients, NAFLD is associated with metabolic risk factors such as obesity, diabetes mellitus, and dyslipidemia. NAFLD is histologically further categorized into nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). NAFL is defined as the presence of hepatic steatosis with no evidence of hepatocellular injury in the form of ballooning of the hepatocytes. NASH is defined as the presence of hepatic steatosis and inflammation with hepatocyte injury (ballooning) with or without fibrosis (Chalasani *et al.* (2012) *Hepatology*. 55:2005-2023). It is generally agreed that patients with simple steatosis have very slow, if any, histological progression, while patients with NASH can exhibit histological progression to cirrhotic-stage disease. The long term outcomes of patients with NAFLD and NASH have been reported in several studies. Their findings can be summarized as follows; (a) patients with NAFLD have increased overall mortality compared to matched control populations, (b) the most common cause of death in patients with NAFLD, NAFL, and NASH is cardiovascular disease, and (c) patients with NASH (but not NAFL) have an increased liver-related mortality rate.

Animal models of NAFLD include various high fat- or high fructose-fed animal models. Genetic models of NAFLD include the B6.129S7-Ldlr^{tm1Her}/J and the B6.129S4-Pten^{tm1Hwu}/J mice available from The Jackson Laboratory.

Treatment of NAFLD is typically to manage the conditions that resulted in development of NAFLD. For example, patients with dyslipidemia are treated with agents to normalize cholesterol or triglycerides, as needed, to treat or prevent further progression of NAFLD. Patients with type 2 diabetes are treated with agents to normalize glucose or insulin sensitivity. Lifestyle changes, *e.g.*, changes in diet and exercise, are also used to treat NAFLD. In a mouse model of NAFLD, treatment with allopurinol both prevented the development of hepatic steatosis, but also significantly ameliorated established hepatic steatosis in mice (Xu *et al.*, *J. Hepatology*. 62:1412-1419, 2015).

In certain embodiments, the compositions and methods of the invention are used in combination with other agents to reduce serum uric acid. In certain embodiments, the compositions and methods of the invention are used in combination with agents for treatment of symptoms of NAFLD. In certain embodiments, the compositions and methods of the invention are used for treatment of subjects with reduced kidney function or susceptible to reduced kidney function, *e.g.*, due to age, comorbidities, or drug interactions.

D. Dyslipidemia, disorders of glycemic control, metabolic syndrome, and obesity

Dyslipidemia (*e.g.*, hyperlipidemia, high LDL cholesterol, low HDL cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (*e.g.*, insulin resistance, type 2 diabetes), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, and excessive sugar craving are associated with elevated fructose metabolism.

Characteristics or diagnostic criteria for the conditions are provided below. Animal models of metabolic disorder and the component features include various high fat- or high fructose-fed animal

models. Genetic models include leptin deficient B6.Cg-*Lep^{ob}*/J, commonly known as *ob* or *ob/ob* mice, which are available from The Jackson Laboratory.

Normal and abnormal fasting levels of the lipids are provided in the table below.

Lipid	Value	Interpretation
Total cholesterol	Below 200 mg/dL	Desirable
	200-239 mg/dL	Borderline high
	240 mg/dL and above	High
LDL cholesterol	Below 70 mg/dL	Best for people who have heart disease or diabetes.
	Below 100 mg/dL	Optimal for people at risk of heart disease.
	100-129 mg/dL	Near optimal if there is no heart disease. High if there is heart disease.
	130-159 mg/dL	Borderline high if there is no heart disease. High if there is heart disease.
	160-189 mg/dL	High if there is no heart disease. Very high if there is heart disease.
	190 mg/dL and above	Very high
HDL cholesterol	Below 40 mg/dL (men)	Poor
	Below 50 mg/dL (women)	
	50-59 mg/dL	Moderate
	60 mg/dL and above	Normal
Triglycerides	Below 150 mg/dL	Desirable
	150-199 mg/dL	Borderline high
	200-499 mg/dL	High
	500 mg/dL and above	Very High

Postprandial hypertriglyceridemia is principally initiated by overproduction or decreased catabolism of triglyceride-rich lipoproteins (TRLs) and is a consequence of predisposing genetic variations and medical conditions such as obesity and insulin resistance.

Insulin resistance is characterized by the presence of at least one of:

1. A fasting blood glucose level of 100-125 mg/dL taken at two different times; or
2. An oral glucose tolerance test with a result of a glucose level of 140-199 mg/dL at 2 hours after glucose consumption.

As used herein, insulin resistance does not include a lack of response to insulin as a result of an immune response to administered insulin as often occurs in late stages of insulin dependent diabetes, especially type 1 diabetes.

Type 2 diabetes is characterized by at least one of:

1. A fasting blood glucose level $\geq$ 126 mg/dL taken at two different times;

2. A hemoglobin A1c (A1C) test with a result of $\geq 6.5\%$ or higher; or
3. An oral glucose tolerance test with a result of a glucose level ≥ 200 mg/dL at 2 hours after glucose consumption.

Pharmacological treatments for type 2 diabetes and insulin resistance include treatment with agents to normalize blood sugar such as metformin (*e.g.*, glucophage, glumetza), sulfonylureas (*e.g.*, glyburide, glipizide, glimepiride), meglitinides (*e.g.*, repaglinide, nateglinide), thiazolidinediones (rosiglitazone, pioglitazone), DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin), GLP-1 receptor antagonists (exenatide, liraglutide), and SGLT2 inhibitors (*e.g.*, canagliflozin, dapagliflozin).

Obesity is characterized as disease of excess body fat. Body mass index (BMI), which is calculated by dividing body weight in kilograms (kg) by height in meters (m) squared, provides a reasonable estimate of body fat for most, but not all, people. Generally, a BMI below 18.5 is characterized as underweight, 18.5 to 24.9 is normal, 25.0-29.9 is overweight, 30.0-34.9 is obese (class I), 35-39.9 is obese (class II), and 40.0 and higher is extremely obese (class III).

Methods for assessment of subcutaneous vs. visceral fat are provided, for example, in Wajchenberg (2000) Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome, *Endocr Rev.* 21:697-738, which is incorporated herein by reference.

Metabolic syndrome is characterized by a cluster of conditions defined as at least three of the five following metabolic risk factors:

1. Large waistline (≥ 35 inches for women or ≥ 40 inches for men);
2. High triglyceride level (≥ 150 mg/dl);
3. Low HDL cholesterol (≤ 50 mg/dl for women or ≤ 40 mg/dl for men);
4. Elevated blood pressure ($\geq 130/85$) or on medicine to treat high blood pressure; and
5. High fasting blood sugar (≥ 100 mg/dl) or being in medicine to treat high blood sugar.

As with NAFLD, the agents for treatment of metabolic syndrome depend on the specific risk factors present, *e.g.*, normalize lipids when lipids are abnormal, normalize glucose or insulin sensitivity when they are abnormal.

Metabolic syndrome, insulin resistance, and type 2 diabetes are often associated with decreased renal function or the potential for decreased renal function.

In certain embodiments, the compositions and methods of the invention are for use in treatment of subjects with dyslipidemia, disorders of glycemic control, metabolic syndrome, and obesity. For example, in certain embodiments, the compositions and methods of the invention are for use in subjects with metabolic syndrome, insulin resistance, or type 2 diabetes and chronic kidney disease. In certain embodiments, the compositions and methods are for use in subjects with metabolic syndrome, insulin resistance, or type 2 diabetes who are suffering from one or more of cardiovascular disease, hypothyroidism, or inflammatory disease; or elderly subjects (*e.g.*, over 65). In certain embodiments, the compositions and methods are for use in subjects with metabolic syndrome, insulin resistance, or type 2 diabetes who are also taking a drug that can reduce kidney function as demonstrated by the drug label. For example, in certain embodiments the compositions and methods

of the invention are for use in subjects with metabolic syndrome, insulin resistance, or type 2 diabetes who are being treated with oral coagulants or probencid. For example, in certain embodiments the compositions and methods of the invention are for use in subjects with metabolic syndrome, insulin resistance, or type 2 diabetes who are being treated with diuretics, especially thiazide diuretics.

5 In certain embodiments, the compositions and methods of the invention are used in combination with other agents to reduce serum uric acid. In certain embodiments, the compositions and methods of the invention are used in combination with agents for treatment of symptoms of metabolic syndrome, insulin resistance, or type 2 diabetes. In certain embodiments, subjects are treated with *e.g.*, agents to decrease blood pressure, *e.g.*, diuretics, beta-blockers, ACE inhibitors, 10 angiotensin II receptor blockers, calcium channel blockers, alpha blockers, alpha-2 receptor antagonists, combined alpha- and beta-blockers, central agonists, peripheral adrenergic inhibitors, and blood vessel dilators; agents to decrease cholesterol, *e.g.*, statins, selective cholesterol absorption inhibitors, resins, or lipid lowering therapies; or agents to normalize blood sugar, *e.g.*, metformin, sulfonylureas, meglitinides, thiazolidinediones, DPP-4 inhibitors, GLP-1 receptor antagonists, and 15 SGLT2 inhibitors.

In certain embodiments, the compositions and methods of the invention are used for treatment of subjects with reduced kidney function or susceptible to reduced kidney function, *e.g.*, due to age, comorbidities, or drug interactions.

The iRNA and additional therapeutic agents may be administered at the same time or in the 20 same combination, *e.g.*, parenterally, or the additional therapeutic agent can be administered as part of a separate composition or at separate times or by another method known in the art or described herein.

E. Cardiovascular disease

In certain embodiments, the compositions and methods of the invention are for use in 25 treatment of subjects with cardiovascular disease. For example, in certain embodiments, the compositions and methods of the invention are for use in subjects with cardiovascular disease and chronic kidney disease. In certain embodiments, the compositions and methods are for use in subjects with cardiovascular disease who are suffering from one or more of metabolic disorder, insulin resistance, hyperinsulinemia, diabetes, hypothyroidism, or inflammatory disease. In certain 30 embodiments, the compositions and methods are for use in subjects with cardiovascular disease who are also taking a drug that can reduce kidney function as demonstrated by the drug label. For example, in certain embodiments the compositions and methods of the invention are for use in subjects with cardiovascular disease who are being treated with oral coagulants or probencid. For example, in certain embodiments the compositions and methods of the invention are for use in 35 subjects with cardiovascular disease who are being treated with diuretics, especially thiazide diuretics. For example, in certain embodiments the compositions and methods of the invention are for use in subjects with cardiovascular disease who have failed treatment with allopurinol.

In certain embodiments, the compositions and methods of the invention are used in combination with other agents to reduce serum uric acid. In certain embodiments, the compositions and methods of the invention are used in combination with agents for treatment of symptoms of cardiovascular disease, *e.g.*, agents to decrease blood pressure, *e.g.*, diuretics, beta-blockers, ACE inhibitors, angiotensin II receptor blockers, calcium channel blockers, alpha blockers, alpha-2 receptor antagonists, combined alpha- and beta-blockers, central agonists, peripheral adrenergic inhibitors, and blood vessel dilators; or agents to decrease cholesterol, *e.g.*, statins, selective cholesterol absorption inhibitors, resins, or lipid lowering therapies.

10 *F. Kidney disease*

Kidney disease includes, for example, acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, and chronic kidney disease.

Acute kidney (renal) failure occurs when the kidneys suddenly become unable to filter waste products from the blood resulting in accumulation of dangerous levels of wastes in serum and systemic chemical imbalance. Acute kidney failure can develop rapidly over a few hours or a few days, and is most common in individuals who are already hospitalized, particularly in critically ill individuals who need intensive care. Acute kidney failure can be fatal and requires intensive treatment. However, acute kidney failure may be reversible. If you're otherwise in good health, you may recover normal or nearly normal kidney function.

Chronic kidney disease, also called chronic kidney failure, describes the gradual loss of kidney function. When chronic kidney disease reaches an advanced stage, dangerous levels of fluid, electrolytes and wastes can accumulate in the body. Signs and symptoms of kidney disease may include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, changes in urine output, decreased mental sharpness, muscle twitches and cramps, hiccups, swelling of feet and ankles, persistent itching, chest pain, if fluid builds up around the lining of the heart, shortness of breath, if fluid builds up in the lungs, high blood pressure (hypertension) that's difficult to control. Signs and symptoms of chronic kidney disease are often nonspecific and can develop slowly, and may not appear until irreversible damage has occurred.

Kidney disease is treated by removing the damaging agent or condition that is causing kidney damage, *e.g.* normalize blood pressure to improve kidney function, end treatment with agents that can induce kidney damage, reduce inflammation that is causing kidney damage, or by providing renal support (*e.g.*, renal dialysis) to assist kidney function.

Renal function is typically determined using one or more routine laboratory tests, BUN (blood urea nitrogen), creatinine (blood), creatinine (urine), or creatinine clearance (see, *e.g.*, www.nlm.nih.gov/medlineplus/ency/article/003435.htm). The tests may also be diagnostic of conditions in other organs.

Generally, a BUN level of 6 to 20 mg/dL is considered normal, although normal values may vary among different laboratories. Elevated BUN level can be indicative of kidney disease, including glomerulonephritis, pyelonephritis, and acute tubular necrosis, or kidney failure.

A normal result for blood creatinine is 0.7 to 1.3 mg/dL for men and 0.6 to 1.1 mg/dL for women. Elevated blood creatinine can be indicative of compromised kidney function due to kidney damage or failure, infection, or reduced blood flow.

Urine creatinine (24-hour sample) values can range from 500 to 2000 mg/day. Results depend on age and amount of lean body mass. Normal results are 14 to 26 mg per kg of body mass per day for men and 11 to 20 mg per kg of body mass per day for women. Abnormal results can be indicative of kidney damage, such as damage to the tubule cells, kidney failure, decreased blood flow to the kidneys, or kidney infection (pyelonephritis).

The creatinine clearance test helps provide information regarding kidney function by comparing the creatinine level in urine with the creatinine level in blood. Clearance is often measured as milliliters per minute (ml/min). Normal values are 97 to 137 ml/min. for men and 88 to 128 ml/min. for women. Lower than normal creatinine clearance can be indicative of kidney damage, such as damage to the tubule cells, kidney failure, decreased blood flow to the kidneys, or reduced glomerular filtration in the kidneys.

In certain embodiments, the compositions and methods of the invention can be used for the treatment of kidney disease. It is expected that such agents would not cause damage to the kidney.

X. Kits

In certain aspects, the instant disclosure provides kits that include a suitable container containing a pharmaceutical formulation of a siRNA compound, *e.g.*, a double-stranded siRNA compound, or siRNA compound, (*e.g.*, a precursor, *e.g.*, a larger siRNA compound which can be processed into a siRNA compound, or a DNA which encodes an siRNA compound, *e.g.*, a double-stranded siRNA compound, or ssiRNA compound, or precursor thereof).

Such kits include one or more dsRNA agent(s) and instructions for use, *e.g.*, instructions for administering a prophylactically or therapeutically effective amount of a dsRNA agent(s). The dsRNA agent may be in a vial or a pre-filled syringe. The kits may optionally further comprise means for administering the dsRNA agent (*e.g.*, an injection device, such as a pre-filled syringe), or means for measuring the inhibition of KHK (*e.g.*, means for measuring the inhibition of KHK mRNA, KHK protein, and/or KHK activity). Such means for measuring the inhibition of KHK may comprise a means for obtaining a sample from a subject, such as, *e.g.*, a plasma sample. The kits of the invention may optionally further comprise means for determining the therapeutically effective or prophylactically effective amount.

In certain embodiments the individual components of the pharmaceutical formulation may be provided in one container, *e.g.*, a vial or a pre-filled syringe. Alternatively, it may be desirable to provide the components of the pharmaceutical formulation separately in two or more containers, *e.g.*,

one container for a siRNA compound preparation, and at least another for a carrier compound. The kit may be packaged in a number of different configurations such as one or more containers in a single box. The different components can be combined, *e.g.*, according to instructions provided with the kit. The components can be combined according to a method described herein, *e.g.*, to prepare and administer a pharmaceutical composition. The kit can also include a delivery device.

This invention is further illustrated by the following examples which should not be construed as limiting. The entire contents of all references, patents and published patent applications cited throughout this application, as well as the informal Sequence Listing, are hereby incorporated herein by reference.

EXAMPLES

Example 1. iRNA Synthesis

Source of reagents

Where the source of a reagent is not specifically given herein, such reagent can be obtained from any supplier of reagents for molecular biology at a quality/purity standard for application in molecular biology.

siRNA Design

siRNAs targeting the human KHK (human NCBI refseqID: XM_017004061.1; NCBI GeneID: 3795) were designed using custom R and Python scripts. The human KHK REFSEQ mRNA has a length of 2283 bases.

Detailed lists of the unmodified KHK sense and antisense strand nucleotide sequences are shown in Tables 2, 5 and 8. Detailed lists of the modified KHK sense and antisense strand nucleotide sequences are shown in Tables 3, 6 and 9.

It is to be understood that, throughout the application, a duplex name without a decimal is equivalent to a duplex name with a decimal which merely references the batch number of the duplex. For example, AD-959917 is equivalent to AD-959917.1.

siRNA Synthesis

siRNAs were designed, synthesized, and prepared using methods known in the art.

Briefly, siRNA sequences were synthesized on a 1 μ mol scale using a Mermade 192 synthesizer (BioAutomation) with phosphoramidite chemistry on solid supports. The solid support was controlled pore glass (500-1000 Å) loaded with a custom GalNAc ligand (3'-GalNAc conjugates), universal solid support (AM Chemicals), or the first nucleotide of interest. Ancillary synthesis reagents and standard 2-cyanoethyl phosphoramidite monomers (2'-deoxy-2'-fluoro, 2'-O-methyl, RNA, DNA) were obtained from Thermo-Fisher (Milwaukee, WI), Hongene (China), or

Chemgenes (Wilmington, MA, USA). Additional phosphoramidite monomers were procured from commercial suppliers, prepared in-house, or procured using custom synthesis from various CMOs. Phosphoramidites were prepared at a concentration of 100 mM in either acetonitrile or 9:1 acetonitrile:DMF and were coupled using 5-Ethylthio-1H-tetrazole (ETT, 0.25 M in acetonitrile) with a reaction time of 400 s. Phosphorothioate linkages were generated using a 100 mM solution of 3-((Dimethylamino-methylidene) amino)-3H-1,2,4-dithiazole-3-thione (DDTT, obtained from Chemgenes (Wilmington, MA, USA)) in anhydrous acetonitrile/pyridine (9:1 v/v). Oxidation time was 5 minutes. All sequences were synthesized with final removal of the DMT group ("DMT-Off").

Upon completion of the solid phase synthesis, solid-supported oligoribonucleotides were treated with 300 μ L of Methylamine (40% aqueous) at room temperature in 96 well plates for approximately 2 hours to afford cleavage from the solid support and subsequent removal of all additional base-labile protecting groups. For sequences containing any natural ribonucleotide linkages (2'-OH) protected with a tert-butyl dimethyl silyl (TBDMS) group, a second deprotection step was performed using TEA.3HF (triethylamine trihydrofluoride). To each oligonucleotide solution in aqueous methylamine was added 200 μ L of dimethyl sulfoxide (DMSO) and 300 μ L TEA.3HF and the solution was incubated for approximately 30 mins at 60 °C. After incubation, the plate was allowed to come to room temperature and crude oligonucleotides were precipitated by the addition of 1 mL of 9:1 acetonitrile:ethanol or 1:1 ethanol:isopropanol. The plates were then centrifuged at 4 °C for 45 mins and the supernatant carefully decanted with the aid of a multichannel pipette. The oligonucleotide pellet was resuspended in 20 mM NaOAc and subsequently desalted using a HiTrap size exclusion column (5 mL, GE Healthcare) on an Agilent LC system equipped with an autosampler, UV detector, conductivity meter, and fraction collector. Desalted samples were collected in 96 well plates and then analyzed by LC-MS and UV spectrometry to confirm identity and quantify the amount of material, respectively.

Duplexing of single strands was performed on a Tecan liquid handling robot. Sense and antisense single strands were combined in an equimolar ratio to a final concentration of 10 μ M in 1x PBS in 96 well plates, the plate sealed, incubated at 100 °C for 10 minutes, and subsequently allowed to return slowly to room temperature over a period of 2-3 hours. The concentration and identity of each duplex was confirmed and then subsequently utilized for in vitro screening assays.

Example 2. In vitro screening methods

HepG2 Cell culture and 96-well transfections

HepG2 cells were grown to near confluence at 37°C in an atmosphere of 5% CO₂ in Eagle's Minimum Essential Medium (Gibco) supplemented with 10% FBS (ATCC) before being released from the plate by trypsinization. Transfection was carried out by adding 18.5 μ L of Opti-MEM plus 0.25 μ L of Lipofectamine RNAiMax per well (Invitrogen, Carlsbad CA. cat # 13778-150) to 5 μ L of each siRNA duplex to an individual well in a 96-well plate. The mixture was then incubated at room temperature for 15 minutes. Eighty μ L of complete growth media without antibiotic containing ~2

$\times 10^4$ HepG2 cells were then added to the siRNA mixture. Cells were incubated for 24 hours prior to RNA purification. Dose experiments were performed at 10 nM, 1 nM and 0.1 nM final duplex concentration.

Total RNA isolation using DYNABEADS mRNA Isolation Kit (Invitrogen™, part #: 610-12)

Cells were lysed in 75µl of Lysis/Binding Buffer containing 3 µL of beads per well and mixed for 10 minutes on an electrostatic shaker. The washing steps were automated on a Biotek EL406, using a magnetic plate support. Beads were washed (in 90µL) once in Buffer A, once in Buffer B, and twice in Buffer E, with aspiration steps in between. Following a final aspiration, complete 10µL RT mixture was added to each well, as described below.

cDNA synthesis using ABI High capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, Cat #4368813)

A master mix of 1µl 10X Buffer, 0.4µl 25X dNTPs, 1µl Random primers, 0.5µl Reverse Transcriptase, 0.5µl RNase inhibitor and 6.6µl of H₂O per reaction were added per well. Plates were sealed, agitated for 10 minutes on an electrostatic shaker, and then incubated at 37 degrees C for 2 hours. Following this, the plates were agitated at 80 degrees C for 8 minutes.

Real time PCR

Two microlitre (µl) of cDNA were added to a master mix containing 0.5µl of human GAPDH TaqMan Probe (4326317E), 0.5µl human KHK, 2µl nuclease-free water and 5µl Lightcycler 480 probe master mix (Roche Cat # 04887301001) per well in a 384 well plates (Roche cat # 04887301001). Real time PCR was done in a LightCycler480 Real Time PCR system (Roche).

To calculate relative fold change, data were analyzed using the $\Delta\Delta C_t$ method and normalized to assays performed with cells transfected with 10nM AD-1955, or mock transfected cells. IC₅₀s were calculated using a 4 parameter fit model using XLFit and normalized to cells transfected with AD-1955 or mock-transfected. The sense and antisense sequences of AD-1955 are: sense: cuuAcGcuGAGuAcuucGAdTsdT (SEQ ID NO: 18) and antisense UCGAAGuACUcAGCGuAAGdTsdT (SEQ ID NO: 19).

The results of the transfection assays of the dsRNA agents listed in Tables 2 and 3 in HepG2 cells are shown in Table 4.

Table 1. Abbreviations of nucleotide monomers used in nucleic acid sequence representation. It will be understood that these monomers, when present in an oligonucleotide, are mutually linked by 5'-3'-phosphodiester bonds; and it is understood that when the nucleotide contains a 2'-fluoro modification,

then the fluoro replaces the hydroxy at that position in the parent nucleotide (*i.e.*, it is a 2'-deoxy-2'-fluoronucleotide).

Abbreviation	Nucleotide(s)
A	Adenosine-3'-phosphate
Ab	beta-L-adenosine-3'-phosphate
Abs	beta-L-adenosine-3'-phosphorothioate
Af	2'-fluoroadenosine-3'-phosphate
Afs	2'-fluoroadenosine-3'-phosphorothioate
As	adenosine-3'-phosphorothioate
C	cytidine-3'-phosphate
Cb	beta-L-cytidine-3'-phosphate
Cbs	beta-L-cytidine-3'-phosphorothioate
Cf	2'-fluorocytidine-3'-phosphate
Cfs	2'-fluorocytidine-3'-phosphorothioate
Cs	cytidine-3'-phosphorothioate
G	guanosine-3'-phosphate
Gb	beta-L-guanosine-3'-phosphate
Gbs	beta-L-guanosine-3'-phosphorothioate
Gf	2'-fluoroguanosine-3'-phosphate
Gfs	2'-fluoroguanosine-3'-phosphorothioate
Gs	guanosine-3'-phosphorothioate
T	5'-methyluridine-3'-phosphate
Tf	2'-fluoro-5-methyluridine-3'-phosphate
Tfs	2'-fluoro-5-methyluridine-3'-phosphorothioate
Ts	5-methyluridine-3'-phosphorothioate
U	Uridine-3'-phosphate
Uf	2'-fluorouridine-3'-phosphate
Ufs	2'-fluorouridine-3'-phosphorothioate
Us	uridine-3'-phosphorothioate
N	any nucleotide, modified or unmodified
a	2'-O-methyladenosine-3'-phosphate
as	2'-O-methyladenosine-3'-phosphorothioate
c	2'-O-methylcytidine-3'-phosphate
cs	2'-O-methylcytidine-3'-phosphorothioate
g	2'-O-methylguanosine-3'-phosphate
gs	2'-O-methylguanosine-3'-phosphorothioate
t	2'-O-methyl-5-methyluridine-3'-phosphate
ts	2'-O-methyl-5-methyluridine-3'-phosphorothioate
u	2'-O-methyluridine-3'-phosphate
us	2'-O-methyluridine-3'-phosphorothioate
s	phosphorothioate linkage
L10	N-(cholesterylcarboxamidocaproyl)-4-hydroxyprolinol (Hyp-C6-Chol)


Abbreviation	Nucleotide(s)
L96	N-[tris(GalNAc-alkyl)-amidodecanoyl]-4-hydroxyprolinol (Hyp-(GalNAc-alkyl)3) 
Y34	2-hydroxymethyl-tetrahydrofuran-4-methoxy-3-phosphate (abasic 2'-OMe furanose)
Y44	inverted abasic DNA (2-hydroxymethyl-tetrahydrofuran-5-phosphate)
(Agn)	Adenosine-glycol nucleic acid (GNA) S-Isomer
(Cgn)	Cytidine-glycol nucleic acid (GNA) S-Isomer
(Ggn)	Guanosine-glycol nucleic acid (GNA) S-Isomer
(Tgn)	Thymidine-glycol nucleic acid (GNA) S-Isomer
P	Phosphate
VP	Vinyl-phosphonate
dA	2'-deoxyadenosine-3'-phosphate
dAs	2'-deoxyadenosine-3'-phosphorothioate
dC	2'-deoxycytidine-3'-phosphate
dCs	2'-deoxycytidine-3'-phosphorothioate
dG	2'-deoxyguanosine-3'-phosphate
dGs	2'-deoxyguanosine-3'-phosphorothioate
dT	2'-deoxythymidine-3'-phosphate
dTs	2'-deoxythymidine-3'-phosphorothioate
dU	2'-deoxyuridine
dUs	2'-deoxyuridine-3'-phosphorothioate
(C2p)	cytidine-2'-phosphate
(G2p)	guanosine-2'-phosphate
(U2p)	uridine-2'-phosphate
(A2p)	adenosine-2'-phosphate
(Chd)	2'-O-hexadecyl-cytidine-3'-phosphate
(Ahd)	2'-O-hexadecyl-adenosine-3'-phosphate
(Ghd)	2'-O-hexadecyl-guanosine-3'-phosphate
(Uhd)	2'-O-hexadecyl-uridine-3'-phosphate
s	phosphorothioate

Table 2. Unmodified Sense and Antisense Strand Sequences of KHK dsRNAs

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1	Antisense sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1
AD-1290652	GUGGUGUUUGUCAGCAAAAGAU	20	810-830	AUCUUUGCUGACAAACACACACGU	244	808-830
AD-1290731	ACGUGGUGUUUGUCAGCAAAU	21	808-828	AUUUGCUGACAAACACACACGU	245	806-828
AD-1290560	UCAGAGCAAAUAAAUUCUCCU	22	1336-1356	AGGAAGAUUUUUUUGCUCUGAGG	246	1334-1356
AD-1290854	CAGUUCAGUGGAUCCACAUU	23	642-662	AAUGUGAUCCACUUUGAACUGGG	247	640-662
AD-1290629	AGUAGCGCAUUUUCUCUUUGU	24	122-142	ACAAAGAGAAAAUUGCGCUACUUG	248	120-142
AD-1290517	GCGCAUUUUUCUCUUUGCAUUU	25	126-146	AAUUGCAAAAGAGAAAAUUGCGCUA	249	124-146
AD-1290526	CGCAUUUUUCUCUUUGCAUUU	26	127-147	AGAAUGCAAAAGAGAAAAUUGCGCU	250	125-147
AD-1290559	GCAUUUUUCUCUUUGCAUUU	27	128-148	AAGAAUGCAAAAGAGAAAAUUGCGC	251	126-148
AD-1290548	CAUUUUUCUCUUUGCAUUUCU	28	129-149	AGAGAAUGCAAAAGAGAAAAUUGCG	252	127-149
AD-1290569	UUUUUCUUUGCAUUUCUCGAU	29	131-151	AUCGAGAAUGCAAAAGAGAAAAUUG	253	129-151
AD-1290547	UUCUCUUUGCAUUUCUCGAGAU	30	133-153	AUCUCGAGAAUGCAAAAGAGAAAA	254	131-153
AD-1290544	UCUCUUUGCAUUUCUCGAGAU	31	134-154	AAUCUCGAGAAUGCAAAAGAGAAA	255	132-154
AD-1290667	CUCUUUGCAUUUCUCGAGAU	32	135-155	AGAUCUGAGAAUGCAAAAGAGAA	256	133-155
AD-1290685	UCUUUGCAUUUCGAGAUUCGU	33	136-156	ACGAUCUGAGAAUGCAAAAGAGA	257	134-156
AD-1290695	UUUGCAUUUCGAGAUUCGU	34	138-158	AAGCGAUCUCGAGAAUGCAAAAGA	258	136-158
AD-1290653	UGCAUUUCGAGAUUCGUUAU	35	140-160	AUAAAGCGAUCUCGAGAAUGCAAA	259	138-160
AD-1290853	GCAUUUCGAGAUUCGUUAU	36	141-161	ACUAAAGCGAUCUCGAGAAUGCAA	260	139-161
AD-1290990	CAUUCUCGAGAUUCGUAGCU	37	142-162	AGCUAAAGCGAUCUCGAGAAUGCA	261	140-162
AD-1290540	CUUUAAAAAGGUUUUGCAUCAU	38	166-186	AUGAUGCAAAACCUUUUUAAAAGCG	262	164-186
AD-1290580	UUUAAAAAGGUUUUGCAUCAU	39	167-187	ACUGAUGCAAAACCUUUUUAAAAGC	263	165-187
AD-1290664	UUAAAAAGGUUUUGCAUCAGCU	40	168-188	AGCUGAUGCAAAACCUUUUUAAAAG	264	166-188
AD-1290916	UCAGCUGUGAGUCCAUUCUGAU	41	183-203	AUCAGAUCCAGCUCACAGCUGAUG	265	181-203
AD-1290938	GCUGUGAGUCCAUUCUGACAAU	42	186-206	AUUUGCAGAUCCAGCUCACAGCUG	266	184-206
AD-1290896	CUGUGAGUCCAUUCUGACAAU	43	187-207	ACUUGCAGAUCCAGCUCACAGCU	267	185-207
AD-1290914	CCAUCUGACAAAGCGAGGAAU	44	195-215	AUUUCCUCGCUUUGCAGAUCCAGC	268	193-215
AD-1290982	CAUCUGACAAAGCGAGGAAU	45	196-216	AGUUUCCUCGCUUUGCAGAUCCAGC	269	194-216

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1	Antisense sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1
AD-1290708	GGAAACUAAGGCUGAGAAAGUU	46	210-230	AACUUCUCAGCCUUAGUUUCCUC	270	208-230
AD-1290693	GAAACUAAGGCUGAGAAAGUU	47	211-231	ACACUUCUCAGCCUUAGUUUCCU	271	209-231
AD-1290942	AGACCUCUGGGUUGGCUUUCU	48	286-306	AGAAAGCCAACCCAGAGGUCUUG	272	284-306
AD-1290807	AGUAGCCUCUAGGAAGAGAAU	49	514-534	AUUCUCUCCAUAGAGGCUACUCC	273	512-534
AD-1290881	CCUCAUGGAAGAGAAAGCAGAU	50	519-539	AUCUGCUUCUCUCCAUAGAGGCU	274	517-539
AD-1290745	CUCAUGGAAGAGAAAGCAGAU	51	520-540	AAUCUGCUUCUCUCCAUAGAGGC	275	518-540
AD-1290814	AUGGAAGAGAAAGCAGAUCCUU	52	523-543	AAGGAUCUGCUUCUCUCCAUAGA	276	521-543
AD-1290900	GGAAGAGAAAGCAGAUCCUGUU	53	525-545	AACAGGAUCUGCUUCUCUCCAU	277	523-545
AD-1290964	GAAAGAGAAAGCAGAUCCUGUU	54	526-546	ACACAGGAUCUGCUUCUCUCCAU	278	524-546
AD-1290802	AUCAGCCUGGUGGACAAGUAU	55	571-591	AUACUUGUCCACCAGGCUGAUGA	279	569-591
AD-1290816	GUGGACAAAGUACCCUAAGGAU	56	580-600	AUCCUAGGGUACUUGUCCACCA	280	578-600
AD-1290821	GACAAAGUACCCUAGGAGGAU	57	583-603	AUCCUCCUAGGGUACUUGUCCA	281	581-603
AD-1290870	GAGGACUCGGAGAUAAAGGUU	58	598-618	ACACCUUAUCUCCGAGUCCUCCU	282	596-618
AD-1290984	UAAGGUUUUUGUCCACAGAGAU	59	611-631	AUCUCUGGGACAAACACCUUAUC	283	609-631
AD-1290682	AAGGUGUUUGUCCACAGAGAU	60	612-632	AAUCUCUGGGACAAACACCUUAU	284	610-632
AD-1290872	CAACUCCUGCACCGUUCUCUU	61	654-674	AAGAGAACGGUGCAGGAGUUGGA	285	652-674
AD-1290663	UCUGCUACAGACUUUUGAGAAU	62	748-768	AUUCUCAAAGUCUGUAGCAGACA	286	746-768
AD-1290627	CUGCUACAGACUUUUGAGAAU	63	749-769	ACUUCUCAAAGUCUGUAGCAGAC	287	747-769
AD-1290730	UGCUACAGACUUUUGAGAAAGU	64	750-770	ACCUUCUCAAAGUCUGUAGCAGA	288	748-770
AD-1290692	GCUACAGACUUUUGAGAAAGUU	65	751-771	AACCUUCUCAAAGUCUGUAGCAG	289	749-771
AD-1290579	CUACAGACUUUUGAGAAAGUUU	66	752-772	AAACCUUCUCAAAGUCUGUAGCA	290	750-772
AD-1290591	ACAGACUUUUGAGAAAGGUUGAU	67	754-774	AUCAACCUUCUCAAAGUCUGUAG	291	752-774
AD-1290539	CAGACUUUUGAGAAAGGUUGAUU	68	755-775	AAUCAACCUUCUCAAAGUCUGUA	292	753-775
AD-1290611	AGACUUUUGAGAAAGGUUGAUCU	69	756-776	AGAUAACCUUCUCAAAGUCUGU	293	754-776
AD-1290530	GACUUUUGAGAAAGGUUGAUCUU	70	757-777	AAGAUAACCUUCUCAAAGUCUG	294	755-777
AD-1290576	CUUUUGAGAAAGGUUGAUCUGAU	71	759-779	AUCAGAUCAACCUUCUCAAAGUC	295	757-779
AD-1290546	UUUGAGAAAGGUUGAUCUGACU	72	760-780	AGUCAGAUCAACCUUCUCAAAGU	296	758-780

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1	Antisense sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1
AD-1290823	AAGGUUGAUCUGACCCAGUUU	73	766-786	AAACUGGGUCAGAUCAACCUUUCU	297	764-786
AD-1290757	GUUGAUCUGACCCAGUUCAAU	74	769-789	AUUGAACUGGGUCAGAUCAACCU	298	767-789
AD-1290959	UUGAUCUGACCCAGUUCAAGU	75	770-790	ACUUGAACUGGGUCAGAUCAACC	299	768-790
AD-1290837	UGAUCUGACCCAGUUCAAGUU	76	771-791	AACUUGAACUGGGUCAGAUCAAC	300	769-791
AD-1290861	GAUCUGACCCAGUUCAAGUGU	77	772-792	ACACUUGAACUGGGUCAGAUCAA	301	770-792
AD-1290885	CUGACCCAGUUCAAGUGGAUU	78	775-795	AAUCCACUUGAACUGGGUCAGAU	302	773-795
AD-1290970	ACCCAGUUCAAGUGGAUCCAU	79	778-798	AUGGAUCCACUUGAACUGGGUCA	303	776-798
AD-1290962	CCAGUUCAGUGGAUCCACAU	80	780-800	AUGUGGAUCCACUUGAACUGGGU	304	778-800
AD-1290759	AGUUCAGUGGAUCCACAUUU	81	782-802	AAAUGUGGAUCCACUUGAACUGG	305	780-802
AD-1290736	UUCAAGUGGAUCCACAUUGAU	82	784-804	AUCAAUUGUGGAUCCACUUGAACU	306	782-804
AD-1290739	UCAAGUGGAUCCACAUUGAGU	83	785-805	ACUCAAUUGUGGAUCCACUUGAAC	307	783-805
AD-1290828	CAAGUGGAUCCACAUUGAGGU	84	786-806	ACCUCAAUUGUGGAUCCACUUGA	308	784-806
AD-1291001	GCAUCGGAGCAGGUGAAGAUU	85	814-834	AAUCUUCACCCUGCUCGCCGAGCGU	309	812-834
AD-1290933	CAUCGGAGCAGGUGAAGAUUGU	86	815-835	ACAUCUUCACCCUGCUCGCCGAGCG	310	813-835
AD-1290988	GAGCUCUCCAGCUGUUGUUGGU	87	919-939	ACCAAAACAGCUGGAAAGAGCUCU	311	917-939
AD-1290955	CUCUUCACGUGUUUUGGCUAU	88	922-942	AUAGCCAAACAGCUGGAAAGAGCU	312	920-942
AD-1290810	CUACGGAGACGUGGUGUUUUGU	89	939-959	ACAAACACCCAGCUCUCCCGUAGCC	313	937-959
AD-1290740	UACGGAGACGUGGUGUUUUGUU	90	940-960	AACAAACACCCAGCUCUCCCGUAGC	314	938-960
AD-1290752	CGGAGACGUGGUGUUUUGUCAU	91	942-962	AUGACAAACACCCAGCUCUCCGUA	315	940-962
AD-1290878	GGAGACGUGGUGUUUUGUCAGU	92	943-963	ACUGACAAACACCCAGCUCUCCCGU	316	941-963
AD-1290599	UGGUGUUUUGUCAGCAAGAUU	93	950-970	AAUCUUUGCUGACAAACACCCAG	317	948-970
AD-1290632	GGUGUUUUGUCAGCAAGAUUGU	94	951-971	ACAUCUUUGCUGACAAACACCCAC	318	949-971
AD-1290584	GUGUUUUGUCAGCAAGAUUGUU	95	952-972	AACAUCUUUGCUGACAAACACCCA	319	950-972
AD-1290734	UGUUUUGUCAGCAAGAUUGUGU	96	953-973	ACACAUCUUUGCUGACAAACACACC	320	951-973
AD-1290882	GUUUUGUCAGCAAGAUUGUGGU	97	954-974	ACCACAUCUUUGCUGACAAACACAC	321	952-974
AD-1290987	UUUUGUCAGCAAGAUUGUGGCU	98	955-975	AGCCACAUCUUUGCUGACAAACACA	322	953-975
AD-1290963	AAAGAUGUGGCCCAAGCACUUU	99	964-984	AAAGUGCUUGGCCCAUCUUCUUGC	323	962-984

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1	Antisense sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1
AD-1290710	UGUAUGGUCGUGAGGAAAU	100	1019-1039	AUUUCCUCACACGACCAUACAAG	324	1017-1039
AD-1290656	GUAUGGUCGUGAGGAAAGU	101	1020-1040	ACUUUCCUCACACGACCAUACAA	325	1018-1040
AD-1290890	UAUGGUCGUGAGGAAAGGU	102	1021-1041	ACUUUCCUCACACGACCAUACA	326	1019-1041
AD-1290887	UGCUCACUCGGAUGCUUUCU	103	1103-1123	AGAAAGCAUCCGAGUGGAGCAAU	327	1101-1123
AD-1290923	GAGCUGGAGACACCUUCAUU	104	1151-1171	AAUUGAAGGUGUCUCCAGCUCCC	328	1149-1171
AD-1290904	AGCUGGAGACACCUUCAUUGU	105	1152-1172	ACAUUGAAGGUGUCUCCAGCUCC	329	1150-1172
AD-1290980	CUGGAGACACCUUCAUUGCCU	106	1154-1174	AGGCAUUGAAGGUGUCUCCAGCU	330	1152-1174
AD-1290860	UGGAGACACCUUCAUUGCCUU	107	1155-1175	AAGGCAUUGAAGGUGUCUCCAGC	331	1153-1175
AD-1290969	ACCUUCAUUGCCUCCGUCUUAU	108	1162-1182	AAUGACGGAGGCAUUGAAGGUGU	332	1160-1182
AD-1290811	CCUUCAAUUGCCUCCGUCUACU	109	1163-1183	AGAUGACGGAGGCAUUGAAGGUG	333	1161-1183
AD-1290886	UUCAAUUGCCUCCGUCUACUUU	110	1165-1185	AAAGAUGACGGAGGCAUUGAAGG	334	1163-1185
AD-1290668	CAAUGCCUCCGUCUACUUCU	111	1167-1187	AUGAAGAUGACGGAGGCAUUGAA	335	1165-1187
AD-1290852	AAUGCCUCCGUCUACUUCUAGU	112	1168-1188	ACUGAAGAUGACGGAGGCAUUGA	336	1166-1188
AD-1290915	CUCCGUCUACUUCUACAGCCUUCU	113	1173-1193	AAGAGGCUAAGAUGACGGAGGC	337	1171-1193
AD-1290874	GUGCAGGAAGCACUGAGAUUU	114	1207-1227	AAAUUCACAGUGCUUCCUGCACGC	338	1205-1227
AD-1290818	UGCAGGAAGCACUGAGAUUCU	115	1208-1228	AGAAUCUCAGUGCUUCCUGCACG	339	1206-1228
AD-1290884	GCAGGAAGCACUGAGAUUCGU	116	1209-1229	ACGAAUCUCAGUGCUUCCUGCAC	340	1207-1229
AD-1290977	UGGCCUUCACAGGCUUUGAUUGU	117	1254-1274	ACAUCAAAAGCCUUCAGGCCACA	341	1252-1274
AD-1290961	CUGCAGGGCUUUGAUGGCAUU	118	1258-1278	AAUGCCAUCAAAGCCUUCAGGC	342	1256-1278
AD-1290834	CAGGGCUUUGAUGGCAUCGUU	119	1261-1281	AACGAUGCCAUCAAAGCCUUGCA	343	1259-1281
AD-1290867	GGGCUUUGAUGGCAUCGUUGU	120	1263-1283	AACACGAUGCCAUCAAAGCCUUG	344	1261-1283
AD-1290879	CUCUGCCUGUGUCCUGUGUUU	121	1409-1429	AAACACAGGACACAGGCAGAGUC	345	1407-1429
AD-1290549	CUCAGAGCAAAUAAAUUCUUCU	122	1474-1494	AGAAGAUAUUUUUUGCUCUGAGGC	346	1472-1494
AD-1290525	CAGAGCAAAUAAAUUCUUCUUCU	123	1476-1496	AAGGAAGAUUUUUUUGCUCUGAG	347	1474-1496
AD-1290622	CUCCUCUCAAUGUCUGAACUU	124	1508-1528	AAGUUCAGACAUUGAGAGGAGAA	348	1506-1528
AD-1290638	UCCUCUCAAUUGUCUGAACUGU	125	1509-1529	ACAGUUCAGACAUUGAGAGGAGA	349	1507-1529
AD-1290921	CCUCUCAAUUGUCUGAACUGCU	126	1510-1530	AGCAGUUCAGACAUUGAGAGGAG	350	1508-1530

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1	Antisense sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1
AD-1290621	CUCUCAAUGUCUGAACUGCUU	127	1511-1531	AAGCAGUUCAGACAUUGAGAGGA	351	1509-1531
AD-1290775	CUCAAUGUCUGAACUGCUCUU	128	1513-1533	AAGAGCAGUUCAGACAUUGAGAG	352	1511-1533
AD-1290748	AUUCUGAGGCGUCUGACUCUU	129	1541-1561	AAGAGUCAGAGCCUCAGGAAUGC	353	1539-1561
AD-1290865	CUGCGUUGUGCAGACUCUAUU	130	1749-1769	AAUAGAGUCUGCACAACGCAGGG	354	1747-1769
AD-1290897	UGCGUUUGGCAGACUCUAUUU	131	1750-1770	AAAUAGAGUCUGCACAACGCAGG	355	1748-1770
AD-1290989	GCGUUGUGCAGACUCUAUUUCU	132	1751-1771	AGAAUAGAGUCUGCACAACGCAG	356	1749-1771
AD-1290983	CGUUGUGCAGACUCUAUUCCU	133	1752-1772	AGGAAUAGAGUCUGCACAACGCA	357	1750-1772
AD-1290909	UUUGGCAGACUCUAUUCCCAU	134	1754-1774	AUGGGAUAGAGUCUGCACAACG	358	1752-1774
AD-1290993	UAUCCACAGCUCAGAAAGCU	135	1766-1786	AGCUUCAGCUGUGGGAAUAGA	359	1764-1786
AD-1290841	AUUCCACAGCUCAGAAAGCUU	136	1767-1787	AAGCUUCUGAGCUGUGGGAAUAG	360	1765-1787
AD-1290880	CUUGGAGCCACCUUGGAAUU	137	1938-1958	AAUCCAAAGGUGGCUCCAAGGG	361	1936-1958
AD-1290747	GGAGCCACCUUGGAAUUAUU	138	1941-1961	AUUAAUCCAAAGGUGGCUCCAA	362	1939-1961
AD-1290842	GAGCCACCUUGGAAUUAAGU	139	1942-1962	ACUAAUCCAAAGGUGGCUCCA	363	1940-1962
AD-1290911	AGCCACCUUGGAAUUAAGGU	140	1943-1963	ACCUAAUCCAAAGGUGGCUC	364	1941-1963
AD-1290926	GCCCACCUUGGAAUUAAGGU	141	1944-1964	ACCCUAAUCCAAAGGUGGCUC	365	1942-1964
AD-1291003	GGCGUGCCUCAGCCACAAAUU	142	1962-1982	AAUUGUGGCUGAGGCACGCCCU	366	1960-1982
AD-1290931	UCAGCCACAAUUGAGCCCAU	143	1970-1990	AUGGGUCACAUUUGUGGCUGAGG	367	1968-1990
AD-1290764	GGUCCGAUCUGGAACACAUUU	144	2018-2038	AUAUGUGUCCAGAUCCGACCUC	368	2016-2038
AD-1290763	GUCCGAUCUGGAACACAUUU	145	2019-2039	AAUAUGUGUCCAGAUCCGACC	369	2017-2039
AD-1290670	UCCGAUCUGGAACACAUUUU	146	2020-2040	AAUAUGUGUCCAGAUCCGACC	370	2018-2040
AD-1290712	CCGAUCUGGAACACAUUUUGU	147	2021-2041	ACAAUUGUGUCCAGAUCCGAC	371	2019-2041
AD-1290612	AUCUGGAACACAUUUUGGAAU	148	2024-2044	AUCCAAUUGUGUCCAGAUCCG	372	2022-2044
AD-1290522	UCUGGAACACAUUUUGGAAUU	149	2025-2045	AAUCCAAUUGUGUCCAGAUCC	373	2023-2045
AD-1290528	CUGGAACACAUUUUGGAAUUU	150	2026-2046	AAAUCCAAUUGUGUCCAGAU	374	2024-2046
AD-1290543	UGGAACACAUUUUGGAAUUUGU	151	2027-2047	ACAAUCCAAUUGUGUCCAG	375	2025-2047
AD-1290589	GGAACACAUUUUGGAAUUUGGU	152	2028-2048	ACCAAUCCAAUUGUGUCCAG	376	2026-2048
AD-1290800	GGGUGGUUAGGCCCUUAUAAU	153	2064-2084	AUUAAAGGCCCUUACCCACCCUA	377	2062-2084

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1	Antisense sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1
AD-1290755	GGUGGUAAGGCCUUUAUAAU	154	2065-2085	AAUUAUAAAGGCCUUACCCACCCU	378	2063-2085
AD-1290742	GUGGGUAAGGCCUUUAUAAUGU	155	2066-2086	ACAUUAUAAAGGCCUUACCCACCC	379	2064-2086
AD-1290563	GUAAGGCCUUUAUAAUGUAAAU	156	2070-2090	AUUUACAUAUAAAGGCCUUACCC	380	2068-2090
AD-1290570	AAGGCCUUUAUAAUGUAAAGAU	157	2072-2092	AUCUUUACAUAUAAAGGCCUUAC	381	2070-2092
AD-1290515	AGGCCUUUAUAAUGUAAAGAGU	158	2073-2093	ACUCUUUACAUAUAAAGGCCUUA	382	2071-2093
AD-1290556	GCCUUUAUAAUGUAAAGAGCAU	159	2075-2095	AUGCUCUUUACAUAUAAAGGCCU	383	2073-2095
AD-1290661	GCAUAUAUAAUGUAAAGGCCUUU	160	2092-2112	AAAGCCUUUACAUAUAAUGCUC	384	2090-2112
AD-1290555	AUAUAUAAUGUAAAGGCCUUUAU	161	2094-2114	AUAAAGCCUUUACAUAUAAUGC	385	2092-2114
AD-1290554	AUAUAUAAAGGCCUUUUAAGAU	162	2096-2116	AUCUAAAGCCUUUACAUAUAAU	386	2094-2116
AD-1290639	UAAUGUAAAGGCCUUUUAAGAU	163	2097-2117	ACUCUAAAGCCUUUACAUAUAAU	387	2095-2117
AD-1290618	AAUGUAAAGGCCUUUUAAGAUU	164	2098-2118	AACUCUAAAGCCUUUACAUAUAAU	388	2096-2118
AD-1290660	CCUGGAUUAAAUUUAUUGCCAUU	165	2126-2146	AAUGGCAGAUUUUAAUCCAGGUC	389	2124-2146
AD-1290551	CUGGAUUAAAUUUAUUGCCAUU	166	2127-2147	AAAUUGGCAGAUUUUAAUCCAGGU	390	2125-2147
AD-1290509	GAUUAAAUUUAUUGCCAUUUAAU	167	2130-2150	AUUAAAUUGGCAGAUUUUAAUCCA	391	2128-2150
AD-1290597	AUUAAAUUUAUUGCCAUUUAAU	168	2131-2151	AAUUAAAUUGGCAGAUUUUAAUCC	392	2129-2151
AD-1290533	AAAUUGCCAUUUUAAUUAAGCU	169	2135-2155	AGCUAAUUAUAAUUGGCAGAUUUUA	393	2133-2155
AD-1290535	AAUUGCCAUUUUAAUUAAGCUU	170	2136-2156	AAGCUAAUUAUAAUUGGCAGAUUUU	394	2134-2156
AD-1290604	AUCUGCCAUUUUAAUUAAGCUGU	171	2137-2157	ACAGCUAAUUAUAAUUGGCAGAUUU	395	2135-2157
AD-1290633	CUGCCAUUUUAAUUAAGCUGCAU	172	2139-2159	AUGCAGCUAAUUAUAAUUGGCAGAU	396	2137-2159
AD-1290741	ACGCAAUUUAUUAUUGCCAUUUUCU	173	2183-2203	AGAAAUUUGAGGCAGAUUUGCGUUA	397	2181-2203
AD-1290650	CGCAAUUUGCCAUUUUAUUCUU	174	2184-2204	AAGAAAUUUGAGGCAGAUUUGCGUU	398	2182-2204
AD-1290672	GCAAUUUGCCAUUUUAUUCUUU	175	2185-2205	AAAGAAAUUUGAGGCAGAUUUGCGU	399	2183-2205
AD-1290605	AAUCUGCCAUUUUAUUCUUCAU	176	2187-2207	AUGAAAGAAAUUUGAGGCAGAUUUGC	400	2185-2207
AD-1290573	AUCUGCCAUUUUAUUCUUCAU	177	2188-2208	AAUGAAAGAAAUUUGAGGCAGAUUG	401	2186-2208
AD-1290615	UCUGCCAUUUUAUUCUUCAUCU	178	2189-2209	AGAUGAAAGAAAUUUGAGGCAGAUU	402	2187-2209
AD-1290531	CUGCCAUUUUAUUCUUCAUCUU	179	2190-2210	AAGAUGAAAGAAAUUUGAGGCAGAU	403	2188-2210
AD-1290602	UGCCAUUUUAUUCUUCAUCUGU	180	2191-2211	ACAGAUGAAGAAAUUUGAGGCAGAU	404	2189-2211

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1	Antisense sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1
AD-1290523	GCCUCAUUUUCUUCUUCUGUU	181	2192-2212	AACAGAUGAAGAAAUAUAGGCGAG	405	2190-2212
AD-1290514	CAAUUUCUUCUUCUUCUGUCAAU	182	2196-2216	AUUUGACAGAUGAAGAAAUAUUGAG	406	2194-2216
AD-1290510	AAUUUCUUCUUCUUCUGUCAAAU	183	2197-2217	AAUUUGACAGAUGAAGAAAUAUUGA	407	2195-2217
AD-1290524	AUUUCUUCUUCUUCUGUCAAUUGU	184	2198-2218	ACAUUUGACAGAUGAAGAAAUAUUG	408	2196-2218
AD-1290836	AAUUCUGCUUUGGCUACAGAAU	185	2223-2243	AUUCUGUAGCCAAAGCAGAAUUGG	409	2221-2243
AD-1290719	AUUCUGCUUUGGCUACAGAAU	186	2224-2244	AAUUCUGUAGCCAAAGCAGAAUUG	410	2222-2244
AD-1290722	UCUGCUUUGGCUACAGAAUUAU	187	2226-2246	AUAAUUCUGUAGCCAAAGCAGAAU	411	2224-2246
AD-1290687	CUGCUUUGGCUACAGAAUUAU	188	2227-2247	AAUAAUUCUGUAGCCAAAGCAGAA	412	2225-2247
AD-1290643	UGCUGGCUACAGAAUUAUUU	189	2228-2248	AAUAAUUCUGUAGCCAAAGCAGAA	413	2226-2248
AD-1290600	GCUUGGCUACAGAAUUAUUGU	190	2229-2249	ACAAUAAUUCUGUAGCCAAAGCAG	414	2227-2249
AD-1290507	UUCUUCUUCUUCUUCUUCUUCU	191	2200-2220	AUCCAUUUGACAGAUGAAGAAAUAU	415	2198-2220
AD-1290516	GGAUUAAAUUCUGCCAUUUUAU	192	2129-2149	AUAAAUUGGCAGAUUUUUAUCCAG	416	2127-2149
AD-1290527	UGGAUUAAAUUCUGCCAUUUU	193	2128-2148	AAAAUUGGCAGAUUUUUAUCCAGG	417	2126-2148
AD-1290542	UCAUUUUCUUCUUCUUCUUCU	194	2195-2215	AUUGACAGAUGAAGAAAUAUUGAGG	418	2193-2215
AD-1290552	UUUCUUCUUCUUCUUCUUCUUCU	195	2199-2219	ACCAUUUGACAGAUGAAGAAAUAU	419	2197-2219
AD-1290557	GGCCUUUAUAAUGUAAAGAGCU	196	2074-2094	AGCUCUUUACAUAUUAUAAAGCCUU	420	2072-2094
AD-1290558	UAUAAUGUAAAGGGCUUUUAGU	197	2095-2115	ACUAAAGCCUUUUAUACAUAUUAUG	421	2093-2115
AD-1290561	AUUUUCUUCUUCUUCUUCUUCU	198	130-150	ACGAGAAUGCAAAGAGAGAAAUGC	422	128-150
AD-1290564	CCUCAUUUUCUUCUUCUUCUUCU	199	2193-2213	AGACAGAUGAAGAAAUAUUGAGGCA	423	2191-2213
AD-1290565	CUCAUUUUCUUCUUCUUCUUCU	200	2194-2214	AUGACAGAUGAAGAAAUAUUGAGGC	424	2192-2214
AD-1290574	UAAGGCCUUUAUAAUGUAAAGU	201	2071-2091	ACUUUACAUAUUAUAAAGGCCUUACC	425	2069-2091
AD-1290592	CAUAUAAUGUAAAGGGCUUUU	202	2093-2113	AAAAGCCUUUUAUACAUAUUAUUGCU	426	2091-2113
AD-1290609	UGCCAUUUAAUUAAGCUGCAU	203	2140-2160	AAUGCAGCUAAUUAUAAUUGGCAGA	427	2138-2160
AD-1290624	AUUUAUUGUGAGGAUAAAAUCU	204	2242-2262	AGAUUUUAUCCUCACAAUAAUUC	428	2240-2262
AD-1290626	GGUAAAGGCCUUUAUUAUGUAAU	205	2069-2089	AUUACAUAUUAAGGCCUUUACCCA	429	2067-2089
AD-1290635	UUCUGCUUUGGCUACAGAAU	206	2225-2245	AAAUUCUGUAGCCAAAGCAGAAU	430	2223-2245
AD-1290651	GUUCAAGUGGAUCCACAUUGU	207	783-803	ACAAUGUGGAUCCACUUGAACUG	431	781-803

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1	Antisense sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1
AD-1290654	GGGUAAGGCCUUUAAAUGUAU	208	2068-2088	AUACAUAUAAAGGCCUUUACCCAC	432	2066-2088
AD-1290655	GAUCUGGAACACAUUUGGAU	209	2023-2043	AUCCAAUAUGUUGUCCAGAUCCG	433	2021-2043
AD-1290657	UUUCUCUUUGCAUUCUCGAGU	210	132-152	ACUCGAGAAUGCAAGAGAGAAAUAU	434	130-152
AD-1290659	CAAUCUGCCUCAAUUUCUCU	211	2186-2206	AGAAGAAUUGAGGCAGAUUGCG	435	2184-2206
AD-1290665	AGAGCAAAUAAAUCUUCCUCU	212	1477-1497	AGAGGAAGAUUUUUUUGCUCUGA	436	1475-1497
AD-1290666	ACUUUGAGAAAGGUUGAUCUGU	213	758-778	ACAGAUAACCUUUCUCAAAAGUCU	437	756-778
AD-1290680	UACAGACUUUGAGAAGGUUGU	214	753-773	ACAACCUUUCUCAAAGUCUGUAGC	438	751-773
AD-1290681	UGGGUAAAGGCCUUUAUAAUGUU	215	2067-2087	AACAUAUAAGGCCUUUACCCACC	439	2065-2087
AD-1290683	UUGCAUUCUCGAGAUUCGUUU	216	139-159	AAAGCGAUUCUGAGAAUGCAAAG	440	137-159
AD-1290684	CGAUCUGGAACACAUUUUGGU	217	2022-2042	ACCAAUAUGUGUUCUCCAGAUCCGA	441	2020-2042
AD-1290702	UCUGCCAUUUAAUUAAGCUGCU	218	2138-2158	AGCAGCUAAUAAAUGGCAGAUU	442	2136-2158
AD-1290718	CGUGGUGUUUGUCAGCAAAGU	219	948-968	ACUUUGCUGACAAACACCCACGUC	443	946-968
AD-1290746	UUUGAUUGGUCUGUGAGGAAU	220	1018-1038	AUUCUCACACGACCAUAACAAGC	444	1016-1038
AD-1290750	CCCAGUAAACCUGCCAAAGAU	221	1706-1726	AUCUUUGGCAGGUUCACUGGGUG	445	1704-1726
AD-1290765	GACGUGGUGUUUGUCAGCAAU	222	946-966	AUUGCUGACAAACACCCACGUCUC	446	944-966
AD-1290778	UCAAUGCCUCCGUCUACUUCU	223	1166-1186	AGAAGAUGACGGAGGCAUUGAAG	447	1164-1186
AD-1290795	UUGCUCCACUCGGAUGCUUUU	224	1102-1122	AAAAAGCAUCCGAGUGGAGCAAUU	448	1100-1122
AD-1290796	UUUGAGCCCACCUUGGAAUUU	225	1939-1959	AAAUUCCAAGGUGGGCUCCAAGG	449	1937-1959
AD-1290803	AUCUGACAAAGCGAGGAAACUU	226	197-217	AAGUUUCCUCCGCUUGUCAGAUUG	450	195-217
AD-1290805	UGGAGCCCACCUUGGAAUUU	227	1940-1960	AUAAUCCAAGGUGGGCUCCAAG	451	1938-1960
AD-1290835	GCUCUCCACGCUUUUUGGCUU	228	921-941	AAGCCAAACAGCUGGAGAGAGCUC	452	919-941
AD-1290857	UGCCCACACGCCUGUGAUUUU	229	1852-1872	AAAUAUCACAGGCUUGGUGGCAGG	453	1850-1872
AD-1290863	AAGACCUCUGGGUUUGGCUUUU	230	285-305	AAAAGCCAAACCCAGAGGUUUUGG	454	283-305
AD-1290875	GCCCACACGCCUGUGAUUUUGU	231	1853-1873	ACAAAUACAGGCUGGUGGGCAG	455	1851-1873
AD-1290891	ACGGAGACGUGGUGUUUUGUCU	232	941-961	AGACAAACACCCACGUCUCCGUAG	456	939-961
AD-1290894	AGGUCCGAUCUGGGAACACAUU	233	2017-2037	AAUGUGUCCAGAUCCGACCUCUCC	457	2015-2037
AD-1290903	GAGUAGCCUCAUGGGAAGAGAU	234	513-533	AUCUCUCCAUAGAGGCUACUCCC	458	511-533

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1	Antisense sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1
AD-1290908	CCAGUGAACCUUGCCAAAGAAU	235	1707-1727	AUUCUUUGGCAGGUUACACUGGGU	459	1705-1727
AD-1290910	UAGGGUGGUAAGGCCUUUAU	236	2062-2082	AAUAAAGGCCUUUACCCACCCUAUA	460	2060-2082
AD-1290924	UGGGAGUAGCCUC AUGGAAGU	237	510-530	ACUUC CAUGAGGCUACUCC CAGA	461	508-530
AD-1290939	AGGUGGUAAGGCCUUUAU	238	2063-2083	AUAUAAAGGCCUUUACCCACCCUAU	462	2061-2083
AD-1290946	GGUUGAUCUGACCCAGUUAU	239	768-788	AUGAACUGGGGUCAGAUCAACCUU	463	766-788
AD-1290950	CAUCAGCCUGGUGGACAAAGU	240	570-590	AACUUGUCCACCCAGGCUUGAGAC	464	568-590
AD-1290956	AGCUGAGAUCCUACUCAGAU	241	185-205	AUGUCAGAUAGGACUCACAGCUGA	465	183-205
AD-1290971	GCUACGGAGACGUGGUGUUU	242	938-958	AAAACACCAACGUCUCUCCGUAAGCCA	466	936-958
AD-1290973	GUUGGCAGACUCUAUUCCCU	243	1753-1773	AGGGAUAAGAGUCUGCAACAGC	467	1751-1773

Table 3. Modified Sense and Antisense Strand Sequences of KHK dsRNAs

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Antisense Sequence 5' to 3'	SEQ ID NO:	mRNA target sequence	SEQ ID NO:
AD-1290652	gsusggugUfuUfGfUfGagcaaaanL96	1187	asUfscuuUfGgagacaAfaCfacaacsu	692	ACGUGGUGUUUUGUCAGCAAAAGAU	916
AD-1290731	ascsguggUfgUfUfUfGucagcaanL96	469	asUfscuuUfGgagacaAfaCfacaacsu	693	AGACGUGGUGUUUUGUCAGCAAAAG	917
AD-1290560	uscsagagCfaAfaUfUfaaauucuuL96	470	asGfsgaaGfaunnuuUfgCfucagsgsg	694	CCUCAGAGCAAAUAAUUCUUCU	918
AD-1290854	csasguncAfaGfUfGfagcaacuuL96	471	asAfsuGfagcaacUfuGfagcugsgsg	695	CCCAGUUCAGUGGAGUCCACAUU	919
AD-1290629	asgsuagcGfcAfUfUfGfagcaacuuL96	472	asCfsaaaGfagcaacUfuGfagcugsgsg	696	CAAGUAGCGCAUUUUCUUCUUCG	920
AD-1290517	gscsgcauUfuUfUfUfGfagcaacuuL96	473	asAfsauGfagcaacUfuGfagcugsgsg	697	UAGCGCAUUUUCUUCUUCUUCG	921
AD-1290526	csagcauuUfuUfUfUfGfagcaacuuL96	474	asGfsgaaGfagcaacUfuGfagcugsgsg	698	AGCGCAUUUUCUUCUUCUUCG	922
AD-1290559	gscsannuUfcUfUfUfGfagcaacuuL96	475	asAfsaaUfGgagaaGfaAfaagsgsg	699	GCGCAUUUUCUUCUUCUUCG	923
AD-1290548	csasnnuUfuUfUfUfGfagcaacuuL96	476	asGfsgaaGfagcaacUfuGfagcugsgsg	700	CGCAUUUUCUUCUUCUUCG	924
AD-1290569	ususuucUfuUfUfUfGfagcaacuuL96	477	asUfscgaGfagcaacUfuGfagcugsgsg	701	CAUUUUCUUCUUCUUCUUCG	925
AD-1290547	ususcuuUfuUfUfUfGfagcaacuuL96	478	asUfscuuGfagcaacUfuGfagcugsgsg	702	UUUUCUUCUUCUUCUUCUUCG	926
AD-1290544	uscsnnuUfgCfAfUfUfGfagcaacuuL96	479	asAfsuuUfGgagaaGfaAfaagsgsg	703	UUUCUUCUUCUUCUUCUUCG	927
AD-1290667	csusnnuGfcAfUfUfGfagcaacuuL96	480	asGfsgaaGfagcaacUfuGfagcugsgsg	704	UUUCUUCUUCUUCUUCUUCG	928
AD-1290685	uscsnnuUfuUfUfUfGfagcaacuuL96	481	asCfsgaaGfagcaacUfuGfagcugsgsg	705	UUCUUCUUCUUCUUCUUCG	929
AD-1290695	ususuGcaUfuUfUfUfGfagcaacuuL96	482	asAfsuGfagcaacUfuGfagcugsgsg	706	UCUUUGCAUUCUUCGAGAUUCG	930
AD-1290653	usgscauuUfuUfUfUfGfagcaacuuL96	483	asUfsgaaGfagcaacUfuGfagcugsgsg	707	UUUGCAUUCUUCGAGAUUCG	931
AD-1290853	gscsannuUfcGfAfUfUfGfagcaacuuL96	484	asCfsuuGfagcaacUfuGfagcugsgsg	708	UUGCAUUCUUCGAGAUUCG	932
AD-1290990	csasnnuUfgAfgUfUfGfagcaacuuL96	485	asGfsgaaGfagcaacUfuGfagcugsgsg	709	UGCAUUCUUCGAGAUUCG	933
AD-1290540	csusnnuAfaAfgUfUfGfagcaacuuL96	486	asUfsgaaGfagcaacUfuUfuaagsgsg	710	CGCUUUAAAAGGUUUGCAUCAG	934
AD-1290580	ususuAfaAfgUfUfGfagcaacuuL96	487	asCfsgaaGfagcaacUfuUfuaagsgsg	711	GCUUUAAAAGGUUUGCAUCAG	935
AD-1290664	ususuAfaAfgUfUfGfagcaacuuL96	488	asGfsgaaGfagcaacUfuUfuaagsgsg	712	CUUUAAAAGGUUUGCAUCAG	936

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Antisense Sequence 5' to 3'	SEQ ID NO:	mRNA target sequence	SEQ ID NO:
AD-1290916	uscsagcuGhuGfAfGfuccaucugaulL96	489	asUfscagAfugagucAfcAfgcugasug	713	CAUCAGCUGUGAGUCCAUUCUGAC	937
AD-1290938	gscsugugAfGfUfCfCfauucugacaunL96	490	asUfsguClagaggaCfuClacagcsug	714	CAGCUGUGAGUCCAUUCUGACAAG	938
AD-1290986	csusugugaGhuCfCfAfucugacaagunL96	491	asCfsuugUfcagaggAfcUfcacagscu	715	AGCUGUGAGUCCAUUCUGACAAGC	939
AD-1290914	cscsaucnGfAcfAfAfccagagaaunL96	492	asUfsuucUfuecgungUfcAfugaggasac	716	GUCCAUCUGACAAAGCGAGGAAC	940
AD-1290982	csasucugAfcAfAfGfagagaaaculL96	493	asGfsuunCfuecgungGhuClagaggasa	717	UCCAUCUGACAAAGCGAGGAACU	941
AD-1290708	gsgsaacUfaAfGfGfucugagaagunL96	494	asAfscunCfuecgungUfaGfmuucscu	718	GAGGAACUAAAGGCUGAGAAUG	942
AD-1290693	gsasaacUfaAfGfGfCfugagaagunL96	495	asCfsacuUfuecgungUfaGfmuucscu	719	AGGAACUAAAGGCUGAGAAUGG	943
AD-1290942	agsasacnUfuGfGfGfhuugggcuunulL96	496	asGfsaaaGfcaaacCfAfGfugucug	720	CAAGACCUCUGGGUUGGCUUUC	944
AD-1290807	asgsuagCfuCfAfUfGfagagaaunL96	497	asUfsuunCfuecgungUfcGfmuucscu	721	GGAGUAGCCUCUUGGAAGAGAAAG	945
AD-1290881	cscsuaucGfGfAfAfGfagagagaaunL96	498	asUfscugCfuecgungUfcAfugaggscu	722	AGCCUCAUGGAAGAGAACAGAU	946
AD-1290745	csuscaugGfAcfAfAfgaagcagaunL96	499	asAfscunCfuecgungUfcClagaggsc	723	GCCUCAUGGAAGAGAACAGAU	947
AD-1290814	asusgaaGfAcfAfAfccagaaucunL96	500	asAfsggaUfuecgungUfcUfuecgung	724	UCAUGGAAGAGAGAGAGAUCCUG	948
AD-1290900	gsgsaagaGfAcfAfGfCfagauccugunL96	501	asAfscagGfuecgungUfcUfuecgung	725	AUGGAAGAGAGAGAGAUCCUGUG	949
AD-1290964	gsasagagAfaGfCfAfgaucugugunL96	502	asCfsacaGfuecgungUfcCfuecgung	726	UGGAAGAGAGAGAGAGAUCCUGUG	950
AD-1290802	asusagacCfuGfGfUfGfagaaunulL96	503	asUfsacuUfuecgungUfcGfuecgung	727	UGAUCAGCCUGGUGGACAAAGUAC	951
AD-1290816	gsusggacAfaGfUfAfccuagagunL96	504	asUfscunUfagagugUfcUfuecgung	728	UGGUGGACAAAGUACCCUAGGAG	952
AD-1290821	gsascaagUfaCfCfCfuaagagagunL96	505	asUfscunCfuecgungUfcCfuecgung	729	UGGACAAAGUACCCUAGGAGGAC	953
AD-1290870	gsasggacUfcGfGfAfgaagagunulL96	506	asCfsaceUfuaucungGfAfhuecgung	730	AGGAGGACUCGGAGAUAAAGGUGU	954
AD-1290984	usasagguGhuUfUfGfhuccagagunL96	507	asUfscunUfuecgungUfcUfuecgung	731	GAUAAAGGUGUUGUCCAGAGAU	955
AD-1290682	asasggugUfuUfGfUfcccagagunulL96	508	asAfscunUfuecgungUfcUfuecgung	732	AUAAGGUGUUGUCCAGAGAU	956
AD-1290872	csasacnUfuGfCfAfccuugunulL96	509	asAfsgagAfaagugUfcGfuecgung	733	UCCAACUCCUGACCCUUGUUCUC	957
AD-1290663	uscsugcuAfcAfGfAfccuugagunulL96	510	asUfscunUfuecgungUfcUfuecgung	734	UGUCUGUACAGACUUGAGAAAG	958
AD-1290627	csusgcuAfaGfAfCfhuugagagunulL96	511	asCfsuucUfuecgungUfcUfuecgung	735	GUCUGCUACAGACUUGAGAAAGG	959
AD-1290730	usgsuacAfcAfCfUfhuugagagunulL96	512	asCfsuunCfuecgungUfcUfuecgung	736	UCUGCUACAGACUUGAGAAAGG	960
AD-1290692	gscsuacaGfAcfUfUfugagagagunulL96	513	asAfscunUfuecgungUfcUfuecgung	737	CUGCUACAGACUUGAGAAAGG	961
AD-1290579	csusacagAfcUfUfUfGfagagagunulL96	514	asAfscunUfuecgungUfcUfuecgung	738	UGCUACAGACUUGAGAAAGG	962
AD-1290591	ascagagUfuUfGfAfagagagunulL96	515	asUfscunUfuecgungUfcUfuecgung	739	CUACAGACUUGAGAAAGG	963
AD-1290539	csasagcuUfuGfAfGfagagagunulL96	516	asAfscunUfuecgungUfcUfuecgung	740	UACAGACUUGAGAAAGG	964
AD-1290611	asgsacnUfGfAfGfAfagagagunulL96	517	asGfsuucUfuecgungUfcUfuecgung	741	ACAGACUUGAGAAAGG	965
AD-1290530	gsasucnuGfAcfAfGfagagagunulL96	518	asAfscunUfuecgungUfcUfuecgung	742	CAGACUUGAGAAAGG	966
AD-1290576	csusuuugaGfAcfGfGfhuugagagunulL96	519	asUfscagUfuecgungUfcUfuecgung	743	GACUUGAGAAAGG	967
AD-1290546	usuuugagAfaGfGfUfhuugagagunulL96	520	asGfsuucUfuecgungUfcUfuecgung	744	ACUUGAGAAAGG	968
AD-1290823	asasagcuGfAcfUfUfGfagagagunulL96	521	asAfscunUfuecgungUfcUfuecgung	745	AGAAGGUGUACUUGACCCAGUUC	969
AD-1290757	gsusugcuUfuGfAfGfagagagunulL96	522	asUfscunUfuecgungUfcUfuecgung	746	AGGUUGAUUUGACCCAGUUC	970
AD-1290959	usuuugacUfGfAfCfCfagagagunulL96	523	asCfsuugUfuecgungUfcUfuecgung	747	GGUUGAUUUGACCCAGUUC	971
AD-1290837	usgsauncGfAcfCfCfagagagunulL96	524	asAfscunUfuecgungUfcUfuecgung	748	GUUGAUUUGACCCAGUUC	972
AD-1290861	gsasucugAfcCfCfAfagagagunulL96	525	asCfsacuUfuecgungUfcUfuecgung	749	UUGAUUUGACCCAGUUC	973
AD-1290885	csusagacCfaGfUfUfagagagunulL96	526	asAfscunUfuecgungUfcUfuecgung	750	AUCUACCCAGUUC	974
AD-1290970	ascsccagUfuCfAfAfagagagunulL96	527	asUfsggaUfuecgungUfcUfuecgung	751	UGACCCAGUUC	975

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Antisense Sequence 5' to 3'	SEQ ID NO:	mRNA target sequence	SEQ ID NO:
AD-1290962	cscsaguuCfAaGfUfGfauccacauL96	528	asUfsgugfGfauccacuUfgAfacuggsgsu	752	ACCCAGUUC AAGUGGAUCCACAU	976
AD-1290759	asgsnucaAfIgUfGfGfauccacauuL96	529	asAfsaugUfggauccaCfuUfgaacusgsg	753	CCAGUUC AAGUGGAUCCACAUUG	977
AD-1290736	ususcaagUfgGfAfUfccaaugauL96	530	asUfscaaUfugugaucCfaCfhugaascsu	754	AGUUC AAGUGGAUCCACAUUGAG	978
AD-1290739	uscsaaguGfgAfUfCfcaauugaguL96	531	asCfsucaAfhugugauCfcAfcuungasasc	755	GUUC AAGUGGAUCCACAUUGAGG	979
AD-1290828	csasagugGfAaUfCfCfcaauugagguL96	532	asCfscucAfauguggaUfcCfcaunugsasa	756	UUC AAGUGGAUCCACAUUGAGGG	980
AD-1291001	gscsaucgGfAaGfCfAfggugaagauL96	533	asAfsucuUfcaccugcUfcCfgaugcsgsu	757	ACGCAUCGGAGCAGGUGAAGAUG	981
AD-1290933	csasucggAfGcAfGfGfugaagauL96	534	asCfsaucUfhaccucgCfuCfcaugscsg	758	CGCAUCGGAGCAGGUGAAGAUGC	982
AD-1290988	gscsgucUfhCfCfAfGfcugnuuL96	535	asCfscaaAfcaucuggAfAfhagucscsu	759	AGGAGUCUUCACGUGUUGGCG	983
AD-1290955	csuscuncCfAaGfCfUfgnuugcuauL96	536	asUfscagCfcaacagcUfgGfagaugscsu	760	AGCUCUUCACGUGUUGGCUAC	984
AD-1290810	csusacggAfGfAfCfGfugugnuuL96	537	asCfsaaaCfaccacguCfuCfcguagcsc	761	GGCUACGGAGACGUGGUGUUUGU	985
AD-1290740	usasccgaGfAaCfGfUfggugnuuL96	538	asAfscaaAfcaaccgUfcUfcgnaugsc	762	GCUACGGAGACGUGGUGUUUGUC	986
AD-1290752	csgsaggaCfGfUfGfGfugnuugauL96	539	asUfsgacAfaacaccaCfGfUfcuccgtsua	763	UACGGAGACGUGGUGUUUGUCAG	987
AD-1290878	gsgsagacGfuGfGfUfgnuugacuL96	540	asCfsugaCfaaacaccAfcGfhuccscgsu	764	ACGGAGACGUGGUGUUUGUCAGC	988
AD-1290599	usgsuguUfhGfUfCfagcaagaauL96	541	asAfsucuUfhugcagcAfaAfaeacscsg	765	CGUGGUGUUUGUCAGCAAAAGAUG	989
AD-1290632	gsgsuguUfgUfCfAfGcaagaugL96	542	asCfsaucUfhugcugaCfaAfaacacsasc	766	GUGGUGUUUGUCAGCAAAAGAUGU	990
AD-1290584	gsgsuguuGfuCfAfGfcaagaugnuL96	543	asAfscauChunugcugAfcAfaacacsca	767	UGGUGUUUGUCAGCAAAAGAUGUG	991
AD-1290734	usgsnuugUfcAfGfCfcaaagaugnuL96	544	asCfsacaUfcnuuugcuGfAcfaaacascsc	768	GGUGUUUGUCAGCAAAAGAUGUGG	992
AD-1290882	gssuuuguCfAaGfCfAfaagaugugnuL96	545	asCfscacAfhucnuugcUfgAfaaacascsc	769	GUGUUUGUCAGCAAAAGAUGUGGC	993
AD-1290987	ususugucAfGcAfAfAfaagauggcuL96	546	asGfsccaCfauccnuugCfuGfacaacsca	770	UGUUUGUCAGCAAAAGAUGUGGCC	994
AD-1290963	asasaganGfuGfGfCfcaagcacuuL96	547	asAfsaganGfhenuggccAfcAfhucnuugsc	771	GCAAAGAUGUGGCCAAGCACUUG	995
AD-1290710	usgsuagGfuCfGfUfgugaggaauL96	548	asAfsuuncChucaacgAfcCfaucacasag	772	CUUAUUGGUCGUGUGAGGAAG	996
AD-1290656	gususaugUfcGfUfGfhugaggaauL96	549	asCfsuuncUfcucaacGfAcfauacacsasa	773	UUGAUGGUCGUGUGAGGAAGG	997
AD-1290890	usasuugGfGfUfGfUfgaggaagguL96	550	asCfscumUfcucaacaCfGfAfcuauacsca	774	UGUAUGGUCGUGUGAGGAAGGG	998
AD-1290887	usgscuccAfCfUfCfGfgaugcuuL96	551	asGfsaaaGfcauccgaGfuGfagcacasu	775	AUUGCUCACUCGGAUGCUUUUC	999
AD-1290923	gscsgcugGfAaGfAfCfaccucaaunL96	552	asAfsuugAfaagugucUfcCfagcucscsc	776	GGGAGCUGGAGACACCUUCAUUG	1000
AD-1290904	asgscuggAfGfAfCfAfcuuccaauL96	553	asCfsaanGfaagugucCfuCfcaucuscsc	777	GGAGCUGGAGACACCUUCAUUGC	1001
AD-1290980	csusggagAfcAfCfCfhuaaugcuL96	554	asGfsgcaUfhagaaguGfuChuccagscu	778	AGCUGGAGACACCUUCAUUGCCU	1002
AD-1290860	usgsgagaCfAaCfCfUfhuaugccuL96	555	asAfsggcAfhugaaggUfgUfcuccasgsc	779	GCUGGAGACACCUUCAUUGCCUC	1003
AD-1290969	ascscuncAfAaUfGfCfCuccgucanuL96	556	asAfsugaCfjggagcaUfhGfagaugsgsu	780	ACACCUCAAUGCCUCCGUCACUC	1004
AD-1290811	cscsnucaAfhGfCfCfhuccgucanuL96	557	asGfsaugAfcggaggcAfuUfgaaggsgug	781	CACCUUCAUGCCUCCGUCACUCU	1005
AD-1290886	ususcaauGfCfCfUfCfCfuecaucuuL96	558	asAfsagaUfgagggagGfcafhugaasgsg	782	CCUUCAAUGCCUCCGUCACUCUUC	1006
AD-1290668	csasaugcCfuCfCfGfhuauncuauL96	559	asUfsgaaGfauagcggAfgGfcaunugsasa	783	UUCAUGCCUCCGUCACUCUUCAG	1007
AD-1290852	asashgceUfAaCfGfUfcauuncaguL96	560	asCfsugaAfgaagcGfAfhfcaunugsasa	784	UCAAUGCCUCCGUCACUCUUCAGC	1008
AD-1290915	csusccguCfAaCfCfUfhuaucuccuL96	561	asAfsaggGfcaugaagaUfgAfcfgagsgsc	785	GCCUCCGUCACUCUUCAGCCUCUC	1009
AD-1290874	gscscagGfAaGfCfCfagagagauuL96	562	asAfsaucUfcagucUfcCfhucacsagsc	786	GCUGCAGGAAGCACUGAGAUUC	1010
AD-1290818	usgscagAfAaGfCfAfcugagauuL96	563	asGfsaanChucaugcUfhCfhucacsagsc	787	CGUGCAGGAAGCACUGAGAUUCG	1011
AD-1290884	gscsaggaAfGcAfAfcfugagauuL96	564	asCfsgaaUfcucaugCfuUfcfugcsasc	788	GUGCAGGAAGCACUGAGAUUCGG	1012
AD-1290977	usgsgccuGfCfAfGfGfGcuuugauL96	565	asCfsaucAfaagcccuGfcafhfgccascsa	789	UGUGCCUUCAGAGGCUUUGAUGG	1013
AD-1290961	csusgcagGfGfUfUfhugaugcauuL96	566	asAfsugcAfaucaaagCfcCfhugcagsgsc	790	GCCUGCAGGCUUUGAUGGCAUC	1014

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Antisense Sequence 5' to 3'	SEQ ID NO:	mRNA target sequence	SEQ ID NO:
AD-1290834	csasgggcUfuUfGfAfuGgcaucgumL96	567	asAfscaUfGgcaucaAfaGfGccugscsa	791	UGCAGGGCUUUUGAUGGCAUCGUG	1015
AD-1290867	gsgsgcuUfGfAfuGfGcaucgugumL96	568	asAfscaUfGgcaucaAfaAfgcccsug	792	CAGGGCUUUUGAUGGCAUCGUG	1016
AD-1290879	csuscuGcCfuGfuUfGfuccugugumL96	569	asAfscaUfGgcaucaAfaGfGcagagusc	793	GACUCUGCCUGUGUCUGUUC	1017
AD-1290549	csuscagaGfcAfaUfAfuuaucucumL96	570	asGfsaagAfuuaucumGfcUfGcagagusc	794	GCCUCAGAGCAAAUAAUUCUUC	1018
AD-1290525	csasagagcAfaUfAfuuaucucumL96	571	asAfsagaUfGgcaucaAfaUfGcagagusc	795	CUCAGAGCAAAUAAUUCUUCUUC	1019
AD-1290622	csusccucUfcAfaUfUfGcugagacumL96	572	asAfsaauUfGcugagacAfaUfGcagagasa	796	UUCUCCUCUAAUUGUCUGAACUG	1020
AD-1290638	uscscucUfaUfUfGfGcugagacumL96	573	asCfsaauUfGcagacUfGfGcagagasa	797	UUCUCCUCUAAUUGUCUGAACUG	1021
AD-1290921	csusccucAfaUfGfUfGcugagacumL96	574	asGfscagUfGcagacUfGfGcagagasa	798	CUCUCCUCAAUUGUCUGAACUGCU	1022
AD-1290621	csuscucaAfuGfuUfCfugagacumL96	575	asAfscaUfGgcaucaAfaUfGcagagasa	799	UCCUCUAAUGUCUGAACUGCUC	1023
AD-1290775	csuscaauGfuCfuUfGfGcagacumL96	576	asAfsagUfGgcaucaAfaUfGcagagasa	800	CUCUCAUGUCUGAACUGCUCUG	1024
AD-1290748	asusuccuGfaGfGfCfGcugacumL96	577	asAfsagUfGcagacUfGfGcagagasa	801	GCAUUCUGAGGUCUGACUCUUC	1025
AD-1290865	csuscgcuUfGfUfGfGcagacumL96	578	asAfsaagUfGcugacAfaUfGcagagasa	802	CCCUGCGUUGUCAGACUCUAAU	1026
AD-1290897	usgscguGfuGfCfAfgacucumL96	579	asAfsaauUfGcugacAfaUfGcagagasa	803	CCUGCGUUGUCAGACUCUAAU	1027
AD-1290989	gscsguugUfGfCfAfgacucumL96	580	asGfsaauUfGcagacUfGfGcagagasa	804	CUGCGUUGUCAGACUCUAAU	1028
AD-1290983	csusguugGfcAfgAfuGfGcagacumL96	581	asGfsaauUfGcagacUfGfGcagagasa	805	UGCGUUGUCAGACUCUAAU	1029
AD-1290909	usgsguGcAfgAfuGfGcagacumL96	582	asUfsgggUfGcagacUfGfGcagagasa	806	CGUUGUCAGACUCUAAU	1030
AD-1290993	usasunccCfaCfaUfGfGcagacumL96	583	asGfscuuUfGcagacUfGfGcagagasa	807	UCUAAUCCACAGUCAGAACUG	1031
AD-1290841	asusucccAfcAfgCfGcagacumL96	584	asAfsaauUfGcagacUfGfGcagagasa	808	CUAUCCACAGUCAGAACUG	1032
AD-1290880	csusuggaGfcCfCfAfgcugagumL96	585	asAfsaauUfGcagacUfGfGcagagasa	809	CCCUGGAGCCACCUUGGAAU	1033
AD-1290747	gsgsagccCfaCfCfUfGgcaucumL96	586	asUfsgggUfGcagacUfGfGcagagasa	810	UUGAGCCACCUUGGAAU	1034
AD-1290842	gsgsagccAfcCfUfUfGgcaucumL96	587	asCfsaauUfGcagacUfGfGcagagasa	811	UGGAGCCACCUUGGAAU	1035
AD-1290911	asgscccaCfcUfUfGfGcaucumL96	588	asCfsaauUfGcagacUfGfGcagagasa	812	GGAGCCACCUUGGAAU	1036
AD-1290926	gscscgaCfuUfGfGfGcaucumL96	589	asCfsaauUfGcagacUfGfGcagagasa	813	GAGCCACCUUGGAAU	1037
AD-1291003	gsgscgugCfcUfCfAfgcagacumL96	590	asAfsaauUfGcagacUfGfGcagagasa	814	AGGCGUGCCUCAGCCACAAU	1038
AD-1290931	uscsagccAfcAfaUfGfGcagacumL96	591	asUfsgggUfGcagacUfGfGcagagasa	815	CCUCAGCCACAAUUGGACCCAG	1039
AD-1290764	gsgsucggAfuCfuUfGfGcagacumL96	592	asUfsgggUfGcagacUfGfGcagagasa	816	GAGGUCGACUUGGACACAAU	1040
AD-1290763	gsgsucgaUfcUfGfGfGcagacumL96	593	asAfsaauUfGcagacUfGfGcagagasa	817	AGGUCGACUUGGACACAAU	1041
AD-1290670	uscsagcuCfuGfGfAfacacumL96	594	asAfsaauUfGcagacUfGfGcagagasa	818	GGUCCGACUUGGACACAAU	1042
AD-1290712	cscsgaucUfGfGfAfacacumL96	595	asCfsaauUfGcagacUfGfGcagagasa	819	GUCCGACUUGGACACAAU	1043
AD-1290612	asuscuGgAfaCfaUfGfGcagacumL96	596	asUfsgggUfGcagacUfGfGcagagasa	820	CGAUCUGGACACAAUUGGAAU	1044
AD-1290522	uscsuggaAfcAfcUfAfuuaucumL96	597	asAfsaauUfGcagacUfGfGcagagasa	821	GAUCUGGACACAAUUGGAAU	1045
AD-1290528	csusggaaCfaCfaUfUfGgcaucumL96	598	asAfsaauUfGcagacUfGfGcagagasa	822	AUCUGGACACAAUUGGAAU	1046
AD-1290543	usgsagacAfcAfuUfAfuuaucumL96	599	asCfsaauUfGcagacUfGfGcagagasa	823	UCUGGACACAAUUGGAAU	1047
AD-1290589	gsgsaacaCfaUfAfuUfGgcaucumL96	600	asCfsaauUfGcagacUfGfGcagagasa	824	CUGGACACAAUUGGAAU	1048
AD-1290800	gsgsguGgGfuAfuUfGfGcagacumL96	601	asUfsgggUfGcagacUfGfGcagagasa	825	UAGGUGGGAUAGGCCCUA	1049
AD-1290755	gsgsguGgUfaAfuUfGfGcagacumL96	602	asAfsaauUfGcagacUfGfGcagagasa	826	AGGUGGGAUAGGCCCUA	1050
AD-1290742	gsgsguGgUfaAfuUfGfGcagacumL96	603	asCfsaauUfGcagacUfGfGcagagasa	827	GGGUGGGAUAGGCCCUA	1051
AD-1290563	gsgsaagGcUfuUfAfuUfGgcaucumL96	604	asUfsgggUfGcagacUfGfGcagagasa	828	GGGUAAGGCCCUA	1052
AD-1290570	asasggccUfuUfAfuUfGgcaucumL96	605	asUfsgggUfGcagacUfGfGcagagasa	829	GUAAGGCCCUA	1053

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Antisense Sequence 5' to 3'	SEQ ID NO:	mRNA target sequence	SEQ ID NO:
AD-1290515	asgsgccuUfaUfAfAfuguaagacuL96	606	asCfsucUfhacauuUfaAfjgceususa	830	UAAGGCCUUUAUAUGUAAAAGAGC	1054
AD-1290556	gscscuuUfaAfUfGfhuagagacuL96	607	asUfsgcuCfhuuacauUfaUfaagccscsu	831	AGGCCUUUAUAUGUAAAAGAGCAU	1055
AD-1290661	gscsauuAfAfUfGfUfaagggcuuL96	608	asAfsagCfcuuuacaUfuAfuaugcsusc	832	GAGCAUAUAUGUAAAAGGGCUUU	1056
AD-1290555	asusauaUfGfUfAfAfagggcuuauL96	609	asUfsaaaGfccuuuafUfuuaugsgsc	833	GCAUAUAUGUAAAAGGGCUUUAG	1057
AD-1290554	asusaauGfUfaAfAfGfGfgccuuuagauL96	610	asUfscuaAfagcccuUfaCfauuausasu	834	AUAUAUGUAAAAGGGCUUUAGAG	1058
AD-1290639	usasauguAfAfAfGfGfgccuuuagauL96	611	asCfsucuAfaagcccuUfuAfcuausasa	835	UAUAUGUAAAAGGGCUUUAGAGU	1059
AD-1290618	asashguaAfAfGfGfGfuuuagauL96	612	asAfsuncUfaaagcccUfuUfacauusasu	836	AUAUGUAAAAGGGCUUUAGAGUG	1060
AD-1290660	cscsuggaUfuAfAfAfauucgccauL96	613	asAfsuagCfagauuuAfafUfccagsgusc	837	GACCUGGAUUAUAUCUGCCCAUU	1061
AD-1290551	cscsugauUfaAfAfAfucugccauuL96	614	asAfsuagCfagauuuUfaAfuccagsgsu	838	ACCUGGAUUAUAUCUGCCCAUUU	1062
AD-1290509	gsasuuafAfAfUfCfUfjcccauuauL96	615	asUfsuaaAfuggcagUfuUfhuauccsca	839	UGGAUUAUAUAUCUGCCCAUUAAU	1063
AD-1290597	asusuafAfUfUfGfGfccuuuauuL96	616	asAfsuuaAfauugcgagAfuUfhuauccsc	840	GGAUUAUAUAUCUGCCCAUUUAAU	1064
AD-1290533	asasaucnGfcCfAfUfhuauuuagcuL96	617	asGfscuaAfuaaauGfCfAfgauuususa	841	UAAAUCUGCCCAUUUAAUUAGCU	1065
AD-1290535	asasuncgCfcAfUfUfhuauuagcuL96	618	asAfsgeuAfauaauGfGfCfagauususu	842	AAAUCUGCCCAUUUAAUUAGCUG	1066
AD-1290604	asuncgcCfAfUfUfUfhuauuagcuL96	619	asCfsagCfuaauaaaUfGfGfcagauususu	843	AAUCUGCCCAUUUAAUUAGCUGC	1067
AD-1290633	cusugccaUfuUfAfAfhuuagcgcuL96	620	asUfsgcaGfcuaauaAfafUfjgcagsasu	844	AUCUGCCCAUUUAAUUAGCUGCAU	1068
AD-1290741	ascsgcaaUfcUfGfCfcuaauuicnL96	621	asGfsaaaUfhagagcaGfaUfhjgcususa	845	UAACGCAUUCUGCCCAAAUUUCU	1069
AD-1290650	csgscauCfuGfCfCfuaauuicnuL96	622	asAfsaaaUfhugagcgAfjAfhujgcgsusu	846	AACGCAUCUGCCCAAAUUUCUU	1070
AD-1290672	gscsaucUfGfCfUfUfcauuuicnuL96	623	asAfsagaAfaugagggCfAfGfauugcgusu	847	ACGCAUUCUGCCCAAAUUUCUUC	1071
AD-1290605	asasuncgCfcUfCfAfafauuucuaulL96	624	asUfsgaaGfaaaauuGfGfCfagauusgsc	848	GCAAUCUGCCCAAAUUUCUUCAU	1072
AD-1290573	asuncgcCfAfCfAfafuuuucuaulL96	625	asAfsugaAfagaauuGfGfGfcagauusug	849	CAUCUGCCCAAAUUUCUUCAUC	1073
AD-1290615	uscsugccUfcAfAfUfhuuucuaulL96	626	asGfsaugAfagaauuGfAfGfcagasusu	850	AUCUGCCCAAAUUUCUUCAUCU	1074
AD-1290531	cusugccuCfAfAfUfUfhuuucuaulL96	627	asAfsaugCfagaauuUfGfAfjgcagsasu	851	AUCUGCCCAAAUUUCUUCAUCUG	1075
AD-1290602	usgsccuAfAfUfUfUfhuuucuaulL96	628	asCfsagaUfjgaagaaaUfuGfagjgcagsa	852	UCUGCCCAAAUUUCUUCAUCUGU	1076
AD-1290523	gscscuaAfUfUfUfCfhuuucuguuL96	629	asAfsagAfugaagaaaAfUfUfagjgcagsg	853	CUGCCCAAAUUUCUUCAUCUGUC	1077
AD-1290514	csasaunuCfuUfCfAfafucugcaauL96	630	asUfsungAfcaugaAfjAfafauugsgag	854	CUCAAAUUUCUUCACUCUGUCAAAU	1078
AD-1290510	asasunucUfuCfAfUfUfcugcaauuL96	631	asAfsunGfagcaguAfAfGfaauusgsa	855	UCAUUUCUUCACUCUGUCAAAUG	1079
AD-1290524	asunucUfcAfUfUfhuuucuaulL96	632	asCfsauUfjagcauGfAfafaausug	856	CAUUUCUUCACUCUGUCAAAUGG	1080
AD-1290836	asasuncUfcUfUfUfGfhuuucagauL96	633	asUfsucUfhagccaaGfcAfgaauusgsg	857	CCAAUUCUGCUUGGCUACAGAAU	1081
AD-1290719	asusuncCfuUfGfGfcuaagaauL96	634	asAfsuncUfhagccaAfjCfagaauusug	858	CAAUUCUGCUUGGCUACAGAAUU	1082
AD-1290722	uscsugcuUfGfGfUfUfagaaunauL96	635	asUfsaauUfcuugagcCfAfAfjgcagasasu	859	AUUCUGCUUGGCUACAGAAUUUAU	1083
AD-1290687	csusgcuGfGfCfUfAfafagaauuauL96	636	asAfsaauUfcuugagCfCfAfagcagsasa	860	UUCUGCUUGGCUACAGAAUUAAU	1084
AD-1290643	usgsuugGfCfUfAfCfagaauuauuL96	637	asAfsaauAfhucugnaGfCfCfaagcagsa	861	UCUGCUUGGCUACAGAAUUAAUUG	1085
AD-1290600	gscsuncGfuAfCfAfafagaauuugulL96	638	asCfsaauAfaunuguAfjCfcaagcagsag	862	CUGCUUGGCUACAGAAUUAAUUGU	1086
AD-1290507	ususcuncAfhuCfUfhuuucagauL96	639	asUfsccaUfhucagAfhuGfagaasasu	863	AUUUCUUCACUCUGUCAAAUGGAA	1087
AD-1290516	gsgsaunAfAfAfUfUfhuuucuaulL96	640	asUfsaaaUfjgcaguUfuUfuaucssag	864	CUGGAUUAAAUCUGCCCAUUUAA	1088
AD-1290527	usgsaunAfAfAfUfUfhuuucuaulL96	641	asAfsaauUfjgcaguUfuUfauccagsg	865	CCUGGAUUAAAUCUGCCCAUUUA	1089
AD-1290542	uscsaunUfcUfUfUfCfauucuguaulL96	642	asUfsugaCfagaugaGfAfafauugsgsg	866	CCUCAUUUCUUCACUCUGUCAAA	1090
AD-1290552	ususcumCfAfUfCfUfjguuaaugguL96	643	asCfscauUfhagacaUfGfAfagaasusu	867	AAUUCUUCACUCUGUCAAAUGGA	1091
AD-1290557	gsgscuAfhuAfAfUfjguuaagagcuL96	644	asGfsuncUfhuaucuuAfufafagccscsu	868	AAGCCUUUAUAUGUAAAAGAGCA	1092

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Antisense Sequence 5' to 3'	SEQ ID NO:	mRNA target sequence	SEQ ID NO:
AD-1290558	usasaauGfuAfAfAfgggcunuaunL96	645	asCfsuaaAfggccunuaAfcAfuaaasug	869	CAUAUAUGUAAAGGGCUUUAAGA	1093
AD-1290561	asusuuucUfcUfUfUfgcauucugulL96	646	asCfsagAfauagcaafGfGfaaauugsc	870	GCAUUUUCUUCUUUGCAUUCUCGA	1094
AD-1290564	cscsucaaUfuUfUfUfucacuguculL96	647	asGfsacaGfaugaagaAfaUfugaggscsa	871	UGCCUCAUUUUCUUUAUCUGUCA	1095
AD-1290565	csuscaauUfuUfUfUfucacuguculL96	648	asUfsgacAfauagaagAfaUfugaggsc	872	GCCUCAUUUUCUUUAUCUGUCA	1096
AD-1290572	usasagccGfuUfAfUfuauguaaagunL96	649	asCfsuauAfcauuaaAfgGfuccuascsc	873	GGUAAAGCCUUUAUAUUGUAAAGA	1097
AD-1290592	csasuaaAfuGfuUfAfaagggcunuaL96	650	asAfsaagCfuccuuaAfuUfauagcsu	874	AGCAUAUAUUGUAAAGGGCUUUA	1098
AD-1290609	usgsccauUfuAfUfUfuaugcgaunL96	651	asAfsuagCfuccuuaAfaUfugagcsa	875	UCUGCCAUUAUUAUAGCUGCAUA	1099
AD-1290624	asusuaauGfuGfAfGfuaaauaunL96	652	asGfsaauUfuaucucAfcAfuaaauusc	876	GAAUAUUGUGAGGGAUAAAUAUA	1100
AD-1290626	gsgsuagGfcUfUfUfuaaauaunL96	653	asUfuaucAfuuaaagGfcCfuaacscsa	877	UGGUAAGGCCUUUAUAUUAUAAA	1101
AD-1290635	ususcugeUfuGfGfCfuacagaauunL96	654	asAfsaauCfugaagccAfaGfagaasusu	878	AAUUCUGCUUGGCUACAGAAUUA	1102
AD-1290651	gsusuaaGfuGfGfAfuaucacauunL96	655	asCfsaauGfugaagccAfcUfugaacsug	879	CAGUUCAGUGGAUCCACAUUGA	1103
AD-1290654	gsgsguaaGfGfCfUfuaaauaunL96	656	asUfsacaUfuaaagGfCfUfuaacscsc	880	GUGGUAAAGGCCUUUAUUAUUGAA	1104
AD-1290655	gsasucugGfaAfCfAfcauauugunL96	657	asUfscacAfuauugunUfcUfagaucsgg	881	CCGAUCUGGAACACAUUAUUGGAA	1105
AD-1290657	ususuucUfuUfGfCfauucucgagunL96	658	asCfsuagAfgaugcaAfaGfagaasasu	882	AUUUUCUUCUUGCAUUCUCGAGA	1106
AD-1290659	csasaucnGfcUfUfCfauuucucunL96	659	asGfsaagAfaauagGfCfAfaugscsg	883	CGCAAUCUGCCUCAUUAUUCUUA	1107
AD-1290665	asgsagcaAfaUfAfAfaucucucunL96	660	asGfsaagAfaauuaUfuUfucucsgsa	884	UCAGAGCAAAUAUUAUUCUUA	1108
AD-1290666	ascsunugAfGfAfGfuaugcagunL96	661	asCfsagaUfuaucunCfuCfaagucscu	885	AGACUUUGAGAAAGGUUGAUGA	1109
AD-1290680	usascagaCfuUfUfGfagaaggununL96	662	asCfsaacCfuaucuaAfgUfucuaugsc	886	GCUACAGACUUUGAGAAGGUUGA	1110
AD-1290681	usgsgguaAfGfGfCfhuuaaunL96	663	asAfscauUfuaagGfCfuUfaccascsc	887	GGUGGUAAAGGCCUUUAUUAUUGA	1111
AD-1290683	ususucauUfcUfCfGfagaucgucunL96	664	asAfsagGfuaucgaGfaAfuagaasag	888	CUUUGCAUUCUGGAGAUUCGCUUA	1112
AD-1290684	csgsauncGfGfAfAfCfacaunugunL96	665	asCfscauUfaugunUfcAfgaucsgsa	889	UCCGAUCUGGAACACAUUAUUGA	1113
AD-1290702	uscsugccAfuUfUfAfaunagcugunL96	666	asGfsagCfuaaauaAfuGfagcagusu	890	AAUCUGCAUUUAUUAUAGCUGCA	1114
AD-1290718	csugsugunGfuUfUfGfucagcagaunL96	667	asCfsuunGfucagcaAfcAfccagusc	891	GACGUGGUUUUGUCAGCAAGA	1115
AD-1290746	usuguanGfGfUfCfGfugugaggaunL96	668	asUfsuccUfcaacgaCfcAfuacaagsc	892	GCUUGUAUGGUGUGUGAGGAAA	1116
AD-1290750	cscscagnGfaAfCfCfugccaaunL96	669	asUfscunUfaggcagunUfcAfcugggscsg	893	CACCCAGUGAAACCUGCCAAAGAA	1117
AD-1290765	gsasegugGfuGfuUfUfugucagcaunL96	670	asUfsgucUfgacaacAfcCfagucscsc	894	GAGACGUGGUGUUUUGUCAGCAAA	1118
AD-1290778	uscsaungCfcUfCfCfugcaucunL96	671	asGfsaagAfugaggaGfGfauuagcag	895	CUUCAUGCCUCCGUGCAUCUUA	1119
AD-1290795	ususcucCfaCfUfCfugcagcunL96	672	asAfsaagCfauccgagUfgGfagcaasun	896	AAUUGUCCACUCGGAUGCUUUC	1120
AD-1290796	usugsgagCfcCfAfCfucunggaunL96	673	asAfsaunCfcaagugGfGfuccaagsg	897	CCUUGGAGCCACCUUGGAUUA	1121
AD-1290803	asuscugaCfaAfGfCfaggaacunL96	674	asAfsuunUfuccugunUfgUfcaugscsg	898	CCAUCUGACAAAGCAGGAAACUA	1122
AD-1290805	usgsugagCfcAfCfCfuaugaaunL96	675	asUfsaunUfccaagunGfGfGfuccaag	899	CUUGGAGCCACCUUGGAUUA	1123
AD-1290835	gscscunCfcAfGfCfugunugcunL96	676	asAfsagCfcaacagunGfGfagagcsc	900	GAGCUUCCAGCUGUUUGGCUA	1124
AD-1290857	usgscccaCfcAfGfCfugugaaunL96	677	asAfsaunCfagagunGfGfGfagcagsg	901	CCUUGCCACAGCCUGUGAUUUG	1125
AD-1290863	asagaccUfcUfGfGfugungcunL96	678	asAfsaagCfcaaccaGfGfGfucunsg	902	CCAAGACCUUGGUGGCUUUC	1126
AD-1290875	gscscacCfaGfCfCfugugaaunL96	679	asCfsaaaUfcaagcUfgGfugggcag	903	CUGCCACAGCCUGUGAUUUGA	1127
AD-1290891	ascsgagAfGfUfGfugunugcunL96	680	asGfsacaAfcaaccGfuCfuccgusag	904	CUACGGAGACGUGGUGUUUGUCA	1128
AD-1290894	asgsugccGfaUfCfUfugaacanL96	681	asAfsuunGfuccagaUfcGfagcscsc	905	GGAGGUCCAGUUGGAACACUA	1129
AD-1290903	gsasugagCfcUfCfAfuggaagunL96	682	asUfscueUfuccagaGfGfGfucscsc	906	GGGAGUAGCCUUAUGGAAGAGAA	1130
AD-1290908	cscsagugAfCfCfUfugccaaunL96	683	asUfscunUfuggcagUfuCfagucgsgu	907	ACCCAGUGAACCUUGCCAAAGAA	1131

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Antisense Sequence 5' to 3'	SEQ ID NO:	mRNA target sequence	SEQ ID NO:
AD-1290910	usasgggnGfGfUfAfagggccuauL96	684	asAfsuuaGfgccuuaCfcAfccuasu	908	UAUAGGGUGGGUAAAGGCCUUAUA	1132
AD-1290924	usgsaggagUfaGfCfCfucauggaagnL96	685	asCfsuucCfauaggcUfaCfuccasgsa	909	UCUGGGAGUAGCCUCAUGGAAGA	1133
AD-1290939	asgsaggugGfGfUfAfagggccuauauL96	686	asUfsauaAfggcuuaCfcCfaccuasau	910	AUAGGGUGGGUAAAGGCCUUAUA	1134
AD-1290946	gsSguugaUfcUfGfAfcccauauL96	687	asUfsgaaCfugguuaGfaUfcaacsusu	911	AAGGUUGAUCUGACCCAGUUCAA	1135
AD-1290950	csasicagCfcUfGfGfuggacaaagnL96	688	asAfsuuGfuccaccaGfGfCfugaugsac	912	GUCAUCAGCCUGGUGGACAAGUA	1136
AD-1290956	asgsuagnGfaGfUfCfcaucugacauL96	689	asUfsgucAfgauggacUfcAfcagcusgsa	913	UCAGCUGUGAGUCCAUUCUGACAA	1137
AD-1290971	gscsuacgGfaGfAfCfuggugunuuL96	690	asAfsaacAfccagucUfcCfjuaagscsc	914	UGGCUACGGAGACGUGGUGUUUG	1138
AD-1290973	gsusugugCfaGfAfCfucuaaucccuL96	691	asGfsggaAfuagagucUfGfCfacaacs gsc	915	GCGUUGUGCAGACUCUAUUCCCA	1139

Table 4. KHK Dose Screen in HepG2 cells

Duplex Name	KHK/gapdh					
	10 nM		1 nM		0.1 nM	
	mean	SD	mean	SD	mean	SD
AD-1290887.1	0.404	0.066	0.946	0.145	1.155	0.187
AD-1290629.1	0.613	0.010	1.098	0.229	1.020	0.166
AD-1290807.1	0.247	0.007	0.663	0.138	1.226	0.074
AD-1290681.1	0.990	0.171	1.179	0.170	1.183	0.178
AD-1290639.1	0.927	0.044	1.302	0.254	1.104	0.178
AD-1290597.1	0.904	0.040	1.425	0.206	1.156	0.123
AD-1290775.1	0.870	0.026	1.498	0.159	1.210	0.162
AD-1290795.1	0.182	0.023	0.526	0.119	1.005	0.106
AD-1291003.1	0.835	0.113	1.353	0.222	1.296	0.081
AD-1290903.1	0.419	0.021	1.151	0.233	0.887	0.055
AD-1290896.1	0.807	0.065	1.389	0.334	0.970	0.054
AD-1290605.1	0.675	0.077	1.474	0.345	0.989	0.083
AD-1290742.1	0.991	0.143	1.355	0.379	1.054	0.145
AD-1290554.1	0.924	0.069	1.578	0.256	1.118	0.082
AD-1290509.1	0.865	0.048	1.256	0.129	1.118	0.165
AD-1290938.1	0.482	0.044	0.772	0.164	0.990	0.327
AD-1290750.1	0.990	0.051	1.077	0.059	1.058	0.116
AD-1290659.1	0.690	0.031	0.937	0.194	0.971	0.100
AD-1290755.1	0.916	0.058	1.122	0.098	1.100	0.119
AD-1290558.1	0.888	0.034	1.064	0.214	0.850	0.035
AD-1290516.1	0.777	0.044	1.046	0.236	0.864	0.132
AD-1290621.1	0.893	0.039	0.990	0.210	0.910	0.148
AD-1290956.1	0.498	0.040	0.582	0.063	0.762	0.089
AD-1290672.1	0.814	0.034	0.828	0.073	0.826	0.210
AD-1290800.1	0.859	0.116	0.898	0.082	0.764	0.096
AD-1290555.1	0.781	0.061	0.843	0.036	0.805	0.143
AD-1290527.1	0.912	0.114	0.908	0.056	0.664	0.037
AD-1290921.1	0.920	0.045	0.896	0.102	0.741	0.082
AD-1290664.1	0.693	0.071	0.956	0.095	0.806	0.035
AD-1290924.1	0.282	0.025	0.576	0.045	0.630	0.011
AD-1290650.1	0.756	0.035	0.914	0.130	0.830	0.081
AD-1290939.1	0.829	0.027	0.873	0.030	0.804	0.128
AD-1290592.1	0.784	0.055	0.894	0.136	0.775	0.069
AD-1290551.1	0.724	0.024	0.891	0.189	0.687	0.009
AD-1290638.1	0.921	0.052	0.976	0.230	0.758	0.071
AD-1290580.1	0.410	0.017	0.702	0.116	0.741	0.112
AD-1290916.1	0.552	0.026	0.694	0.024	0.723	0.105
AD-1290741.1	0.799	0.057	0.864	0.034	0.731	0.075
AD-1290910.1	0.945	0.078	0.948	0.020	0.665	0.030
AD-1290661.1	0.985	0.065	0.937	0.064	0.665	0.011

Duplex Name	KHK/gapdh					
	10 nM		1 nM		0.1 nM	
	mean	SD	mean	SD	mean	SD
AD-1290660.1	0.901	0.159	0.936	0.022	0.912	0.032
AD-1290622.1	1.020	0.207	0.940	0.040	0.932	0.174
AD-1290540.1	0.474	0.033	0.698	0.062	0.978	0.109
AD-1290618.1	1.075	0.102	0.930	0.116	0.786	0.032
AD-1290600.1	1.072	0.213	0.901	0.055	0.953	0.133
AD-1290908.1	0.812	0.052	0.810	0.019	0.802	0.172
AD-1290665.1	0.191	0.030	0.216	0.116	0.656	0.117
AD-1290870.1	0.831	0.092	0.916	0.071	0.731	0.047
AD-1290990.1	0.698	0.020	0.687	0.036	0.785	0.075
AD-1290989.1	0.829	0.167	0.862	0.101	0.607	0.241
AD-1290987.1	0.376	0.042	0.581	0.024	0.985	0.177
AD-1290983.1	0.987	0.249	0.993	0.176	0.883	0.125
AD-1290982.1	0.949	0.138	0.846	0.054	0.866	0.052
AD-1290973.1	0.884	0.229	0.954	0.070	0.813	0.127
AD-1290971.1	0.135	0.043	0.289	0.029	0.699	0.071
AD-1290970.1	0.153	0.039	0.207	0.011	0.660	0.127
AD-1290969.1	0.140	0.034	0.221	0.017	0.608	0.113
AD-1290964.1	0.265	0.038	0.360	0.026	0.709	0.100
AD-1290963.1	0.158	0.045	0.311	0.063	0.739	0.176
AD-1290962.1	0.317	0.114	0.436	0.042	0.730	0.095
AD-1290959.1	0.157	0.044	0.295	0.014	0.835	0.044
AD-1290950.1	0.282	0.044	0.624	0.049	0.896	0.080
AD-1290946.1	0.656	0.156	0.866	0.031	0.883	0.042
AD-1290915.1	0.117	0.040	0.396	0.024	0.882	0.121
AD-1290914.1	0.676	0.046	0.689	0.038	0.862	0.102
AD-1290911.1	1.052	0.136	0.914	0.028	0.930	0.143
AD-1290900.1	0.230	0.034	0.512	0.013	0.805	0.026
AD-1290897.1	1.054	0.014	0.957	0.027	0.867	0.065
AD-1290891.1	0.534	0.134	0.675	0.016	0.853	0.068
AD-1290890.1	1.094	0.160	0.905	0.025	0.945	0.138
AD-1290886.1	0.626	0.146	0.764	0.044	0.953	0.112
AD-1290885.1	0.115	0.017	0.217	0.066	0.770	0.030
AD-1290884.1	0.133	0.025	0.264	0.014	0.783	0.120
AD-1290882.1	0.265	0.032	0.659	0.013	0.897	0.032
AD-1290881.1	0.156	0.052	0.393	0.024	0.952	0.137
AD-1290878.1	0.156	0.026	0.381	0.011	0.933	0.201
AD-1290874.1	0.135	0.006	0.371	0.010	0.827	0.127
AD-1290872.1	0.269	0.055	0.256	0.013	0.606	0.098
AD-1290865.1	0.680	0.264	0.838	0.020	0.895	0.202
AD-1290861.1	0.814	0.323	0.885	0.022	0.961	0.088
AD-1290860.1	0.169	0.022	0.641	0.031	0.957	0.032

Duplex Name	KHK/gapdh					
	10 nM		1 nM		0.1 nM	
	mean	SD	mean	SD	mean	SD
AD-1290857.1	0.656	0.179	0.921	0.068	0.990	0.068
AD-1290854.1	0.532	0.083	0.644	0.032	0.994	0.041
AD-1290853.1	0.550	0.135	0.732	0.018	0.966	0.051
AD-1290852.1	0.750	0.108	0.762	0.161	1.074	0.156
AD-1290842.1	0.887	0.182	0.748	0.049	0.982	0.039
AD-1290837.1	0.409	0.365	0.260	0.016	0.919	0.135
AD-1290828.1	0.370	0.070	0.565	0.059	0.904	0.028
AD-1290823.1	0.213	0.072	0.329	0.034	0.916	0.051
AD-1290821.1	0.198	0.043	0.363	0.012	1.036	0.111
AD-1290818.1	0.053	0.009	0.162	0.011	0.699	0.039
AD-1290816.1	0.208	0.040	0.472	0.026	0.916	0.037
AD-1290814.1	0.116	0.037	0.221	0.012	0.625	0.025
AD-1290811.1	0.120	0.031	0.291	0.023	0.830	0.034
AD-1290810.1	0.194	0.025	0.572	0.033	0.949	0.018
AD-1290802.1	0.332	0.110	0.511	0.004	0.983	0.032
AD-1290778.1	0.146	0.019	0.440	0.037	0.961	0.045
AD-1290765.1	0.086	0.017	0.141	0.010	0.647	0.020
AD-1290759.1	0.262	0.082	0.432	0.008	0.948	0.065
AD-1290757.1	0.136	0.041	0.242	0.011	0.838	0.035
AD-1290752.1	0.155	0.018	0.423	0.074	0.893	0.042
AD-1290746.1	0.123	0.013	0.598	0.099	0.970	0.125
AD-1290745.1	0.199	0.018	0.614	0.068	0.964	0.081
AD-1290740.1	0.138	0.016	0.620	0.120	0.985	0.031
AD-1290739.1	0.379	0.035	1.002	0.121	0.992	0.049
AD-1290736.1	0.525	0.046	1.239	0.176	1.017	0.173
AD-1290734.1	0.512	0.029	1.320	0.191	1.066	0.083
AD-1290731.1	0.154	0.004	0.536	0.100	1.089	0.077
AD-1290718.1	0.128	0.051	0.699	0.158	1.227	0.081
AD-1290710.1	0.237	0.082	0.841	0.138	1.133	0.125
AD-1290702.1	0.771	0.024	1.217	0.214	1.069	0.019
AD-1290695.1	0.379	0.050	0.758	0.127	0.997	0.026
AD-1290685.1	0.373	0.009	0.887	0.154	1.003	0.045
AD-1290683.1	0.363	0.013	0.741	0.104	1.030	0.056
AD-1290668.1	0.096	0.008	0.285	0.042	0.874	0.040
AD-1290667.1	0.549	0.036	0.987	0.122	1.200	0.067
AD-1290657.1	0.459	0.045	1.116	0.220	1.181	0.044
AD-1290656.1	0.591	0.104	1.197	0.190	1.231	0.021
AD-1290653.1	0.325	0.008	0.636	0.092	1.087	0.022
AD-1290652.1	0.106	0.008	0.382	0.063	1.143	0.023
AD-1290651.1	0.232	0.008	0.415	0.053	0.983	0.091
AD-1290633.1	0.943	0.033	0.882	0.084	0.898	0.126

Duplex Name	KHK/gapdh					
	10 nM		1 nM		0.1 nM	
	mean	SD	mean	SD	mean	SD
AD-1290632.1	0.406	0.154	0.773	0.099	0.866	0.099
AD-1290604.1	1.000	0.035	0.737	0.043	0.934	0.078
AD-1290599.1	0.128	0.003	0.200	0.016	0.749	0.027
AD-1290589.1	0.992	0.050	0.731	0.038	0.839	0.047
AD-1290584.1	0.222	0.012	0.362	0.031	0.830	0.037
AD-1290576.1	0.140	0.009	0.218	0.020	0.846	0.118
AD-1290569.1	0.531	0.139	0.575	0.056	0.814	0.192
AD-1290565.1	1.031	0.070	0.703	0.049	0.911	0.086
AD-1290561.1	0.400	0.039	0.640	0.106	1.109	0.180
AD-1290559.1	0.429	0.037	0.573	0.086	1.094	0.053
AD-1290557.1	0.861	0.121	0.917	0.251	1.148	0.214
AD-1290552.1	0.866	0.110	0.759	0.128	0.739	0.317
AD-1290548.1	0.427	0.040	0.436	0.041	0.854	0.037
AD-1290547.1	0.534	0.102	0.569	0.065	1.079	0.218
AD-1290546.1	0.081	0.017	0.127	0.070	0.689	0.115
AD-1290544.1	0.420	0.176	0.533	0.047	0.964	0.045
AD-1290543.1	0.798	0.127	0.855	0.085	0.973	0.049
AD-1290542.1	0.807	0.059	0.730	0.024	0.901	0.187
AD-1290528.1	0.638	0.045	0.777	0.049	1.080	0.063
AD-1290526.1	0.496	0.040	0.680	0.045	1.027	0.164
AD-1290524.1	0.886	0.029	1.005	0.038	0.998	0.132
AD-1290522.1	0.825	0.036	0.937	0.042	0.863	0.034
AD-1290515.1	0.925	0.061	0.886	0.060	0.802	0.049
AD-1290514.1	1.056	0.046	1.130	0.080	0.899	0.030
AD-1290510.1	0.794	0.058	0.921	0.052	0.869	0.073
AD-1290980.1	0.309	0.016	0.756	0.022	0.804	0.042
AD-1290933.1	0.444	0.029	0.747	0.039	0.862	0.125
AD-1290834.1	0.296	0.017	0.611	0.064	0.904	0.119
AD-1290747.1	0.839	0.068	0.831	0.135	1.002	0.093
AD-1290666.1	0.265	0.003	0.457	0.036	0.988	0.117
AD-1290612.1	0.776	0.084	0.811	0.050	0.828	0.027
AD-1290570.1	0.811	0.035	0.909	0.096	0.844	0.016
AD-1290564.1	0.956	0.026	0.910	0.053	1.112	0.182
AD-1290535.1	0.916	0.048	0.820	0.086	0.772	0.175
AD-1290517.1	0.443	0.038	0.508	0.035	0.908	0.157
AD-1291001.1	0.214	0.024	0.423	0.052	0.874	0.134
AD-1290805.1	0.927	0.033	0.863	0.094	0.948	0.152
AD-1290655.1	0.926	0.058	0.999	0.085	0.902	0.068
AD-1290574.1	0.978	0.105	0.874	0.046	0.826	0.069
AD-1290533.1	0.937	0.105	0.788	0.035	0.885	0.090
AD-1290530.1	0.127	0.007	0.230	0.022	0.731	0.057

Duplex Name	KHK/gapdh					
	10 nM		1 nM		0.1 nM	
	mean	SD	mean	SD	mean	SD
AD-1290523.1	0.997	0.162	0.713	0.015	0.937	0.168
AD-1290904.1	0.465	0.035	0.660	0.132	0.973	0.114
AD-1290796.1	0.944	0.075	0.734	0.131	0.936	0.147
AD-1290684.1	1.012	0.060	0.678	0.064	0.957	0.197
AD-1290611.1	0.201	0.009	0.224	0.023	0.781	0.084
AD-1290602.1	0.927	0.141	0.648	0.089	1.032	0.068
AD-1290563.1	0.839	0.111	0.650	0.045	1.135	0.189
AD-1290961.1	0.289	0.029	0.473	0.028	0.923	0.133
AD-1290923.1	0.137	0.005	0.280	0.038	0.771	0.071
AD-1290880.1	0.913	0.055	0.859	0.098	0.855	0.084
AD-1290712.1	0.942	0.014	0.729	0.038	0.935	0.078
AD-1290626.1	0.730	0.044	0.705	0.068	0.991	0.097
AD-1290539.1	0.121	0.012	0.166	0.041	0.609	0.026
AD-1290531.1	0.909	0.182	0.781	0.132	1.007	0.135
AD-1290670.1	0.973	0.038	0.790	0.179	1.075	0.159
AD-1290654.1	0.921	0.046	0.798	0.151	1.175	0.185
AD-1290615.1	0.918	0.026	0.772	0.081	1.243	0.213
AD-1290591.1	0.096	0.006	0.163	0.012	0.767	0.159
AD-1290879.1	0.209	0.012	0.478	0.021	0.920	0.147
AD-1290763.1	0.665	0.047	0.752	0.030	0.810	0.057
AD-1290680.1	0.092	0.013	0.198	0.018	0.759	0.050
AD-1290643.1	0.708	0.049	0.770	0.033	0.873	0.029
AD-1290573.1	0.585	0.040	0.744	0.034	0.909	0.065
AD-1290764.1	0.607	0.049	0.788	0.031	1.020	0.087
AD-1290687.1	0.646	0.032	0.894	0.092	1.038	0.155
AD-1290579.1	0.118	0.007	0.456	0.015	1.022	0.022
AD-1290977.1	0.688	0.059	0.950	0.061	1.176	0.120
AD-1290955.1	0.172	0.011	0.269	0.025	0.963	0.125
AD-1290894.1	0.864	0.038	0.804	0.051	0.997	0.068
AD-1290722.1	0.822	0.068	0.839	0.044	0.907	0.040
AD-1290692.1	0.106	0.011	0.192	0.022	0.840	0.025
AD-1290835.1	0.384	0.030	0.692	0.019	0.975	0.135
AD-1290730.1	0.246	0.020	0.491	0.022	0.990	0.131
AD-1290693.1	0.553	0.051	0.740	0.120	1.105	0.191
AD-1290682.1	0.250	0.020	0.348	0.036	0.884	0.105
AD-1290635.1	0.765	0.068	0.800	0.075	1.070	0.110
AD-1290525.1	0.128	0.019	0.203	0.019	0.958	0.069
AD-1290984.1	0.411	0.044	0.685	0.045	0.754	0.043
AD-1290942.1	0.474	0.024	0.586	0.037	0.673	0.103
AD-1290841.1	0.995	0.059	0.960	0.049	0.767	0.029
AD-1290719.1	0.887	0.047	0.789	0.043	0.913	0.113

Duplex Name	KHK/gapdh					
	10 nM		1 nM		0.1 nM	
	mean	SD	mean	SD	mean	SD
AD-1290708.1	0.751	0.032	0.794	0.046	0.980	0.136
AD-1290627.1	0.222	0.018	0.309	0.132	0.986	0.113
AD-1290624.1	0.828	0.027	0.737	0.053	0.899	0.140
AD-1290560.1	0.145	0.005	0.213	0.021	0.854	0.151
AD-1290993.1	1.013	0.140	0.825	0.053	1.298	0.137
AD-1290988.1	0.433	0.023	0.650	0.031	1.274	0.288
AD-1290863.1	0.856	0.088	0.914	0.050	0.916	0.041
AD-1290836.1	0.818	0.080	0.906	0.072	0.922	0.124
AD-1290663.1	0.247	0.019	0.496	0.025	1.019	0.180
AD-1290549.1	0.126	0.009	0.263	0.019	0.885	0.056
AD-1290931.1	1.106	0.034	0.850	0.043	1.057	0.104
AD-1290926.1	1.096	0.033	0.849	0.016	0.934	0.044
AD-1290909.1	1.023	0.042	0.776	0.065	0.935	0.089
AD-1290875.1	0.982	0.074	0.704	0.047	0.943	0.096
AD-1290867.1	1.168	0.044	0.798	0.033	1.048	0.189
AD-1290803.1	0.646	0.007	0.569	0.021	0.852	0.263
AD-1290748.1	0.830	0.098	0.901	0.126	1.229	0.126
AD-1290609.1	0.822	0.087	0.808	0.259	1.227	0.116
AD-1290556.1	0.915	0.043	0.826	0.240	1.251	0.124
AD-1290507.1	0.927	0.080	0.691	0.130	1.342	0.077
Neg ctrl	1.130	0.343	0.981	0.222	0.863	0.237
Neg ctrl	0.897	0.088	1.089	0.141	1.102	0.113
Pos ctrl	0.091	0.013	0.101	0.008	0.196	0.037

Example 3. Design, Synthesis and *In Vitro* Screening of Additional dsRNA Duplexes

Additional siRNAs were designed, synthesized, and prepared using methods known in the art and described above in Example 1.

Detailed lists of the additional unmodified KHK sense and antisense strand nucleotide sequences are shown in Table 5. Detailed lists of the modified KHK sense and antisense strand nucleotide sequences are shown in Table 6.

For transfections, Hep3b cells (ATCC, Manassas, VA) were grown to near confluence at 37°C in an atmosphere of 5% CO₂ in Eagle's Minimum Essential Medium (Gibco) supplemented with 10% FBS (ATCC) before being released from the plate by trypsinization. Transfection was carried out by adding 7.5 µl of Opti-MEM plus 0.1 µl of Lipofectamine RNAiMax per well (Invitrogen, Carlsbad CA. cat # 13778-150) to 2.5 µl of each siRNA duplex to an individual well in a 384-well plate. The mixture was then incubated at room temperature for 15 minutes. Forty µl of complete growth media without antibiotic containing ~1.5 x10⁴ Hep3b cells were then added to the siRNA

mixture. Cells were incubated for 24 hours prior to RNA purification. Single dose experiments were performed at 10 nM final duplex concentration.

Total RNA isolation was performed using DYNABEADS. Briefly, cells were lysed in 10 μ l of Lysis/Binding Buffer containing 3 μ L of beads per well and mixed for 10 minutes on an electrostatic shaker. The washing steps were automated on a Biotek EL406, using a magnetic plate support. Beads were washed (in 3 μ L) once in Buffer A, once in Buffer B, and twice in Buffer E, with aspiration steps in between. Following a final aspiration, complete 12 μ L RT mixture was added to each well, as described below.

For cDNA synthesis, a master mix of 1.5 μ l 10X Buffer, 0.6 μ l 10X dNTPs, 1.5 μ l Random primers, 0.75 μ l Reverse Transcriptase, 0.75 μ l RNase inhibitor and 9.9 μ l of H₂O per reaction were added per well. Plates were sealed, agitated for 10 minutes on an electrostatic shaker, and then incubated at 37 degrees C for 2 hours. Following this, the plates were agitated at 80 degrees C for 8 minutes.

RT-qPCR was performed as described above and relative fold change was calculated as described above.

The results of the transfection assays of the dsRNA agents listed in Tables 5 and 6 in Hep3b cells are shown in Table 7.

Table 8 provides a list of the unmodified KHK sense and antisense strand nucleotide sequences of selected dsRNA agents. Table 9 provides a list of the modified KHK sense and antisense strand nucleotide sequences of selected dsRNA agents.

Table 5. Unmodified Sense and Antisense Strand Sequences of KHK dsRNAs

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO	Range in XM_017004061.1	Antisense Sequence 5' to 3'	SEQ ID NO	Range in XM_017004061.1
AD-1423310.1	UUUGAGAAGGUUGAUCUGACU	1140	760-780	AGUCAGAUCAACCUUUCUCAAAGU	296	758-780
AD-1423311.1	GACGUGGUGUUUGUCAGCAAU	222	946-966	AUUGCUGACAAACACACGUCUC	446	944-966
AD-1423312.1	UGCAGGAAGCACUGAGAUUCU	115	1208-1228	AGAATCTCAGUGCUUCCUGCACG	1141	1206-1228
AD-1423313.1	ACAGACUUUGAGAAAGGUUGAU	67	754-774	AUCAACCUUUCUCAAAGUCUGUAG	291	752-774
AD-1423314.1	GCUACAGACUUUGAGAAAGGUU	65	751-771	AACCTUCUCAAAGUCUGUAGCAG	1142	749-771
AD-1423315.1	ACCCAGUUCAAAGUGGAUCCAU	79	778-798	AUGGAUCCACUUGAACUGGGUCA	303	776-798
AD-1423316.1	UCAGAGCAAUAUAAUCUUCCU	22	1336-1356	AGGAAGAUUUUUUUGCUCUGAGG	246	1334-1356
AD-1290665.2	AGAGCAAUAUAAUCUUCCU	212	1477-1497	AGAGGAAGAUUUUUUUGCUCUGA	436	1475-1497
AD-1423317.1	CUUUGAGAAAGGUUGAUCUGAU	71	759-779	AUCAGATCAACCUUUCUCAAAGUC	1143	757-779
AD-1423318.1	AUGGAAGAGAAAGCAGAUCCU	52	523-543	AAGGAUCUGCUUCUCUCCAUUGA	276	521-543
AD-1423319.1	GACUUUGAGAAAGGUUGAUCUU	70	757-777	AAGATCAACCUUUCUCAAAGUCUG	1144	755-777
AD-1423320.1	CUCAGAGCAAUAUAAUCUUUCU	122	1474-1494	AGAAGATUUUUUUGCUCUGAGGC	1145	1472-1494
AD-1423321.1	CUCUCCAGCUGUUUGGCUAU	88	922-942	AUAGCCAAACAGCUGGGAAGAGCU	312	920-942
AD-1423322.1	GAGCUGGAGACACCUUCAUU	104	1151-1171	AAUUGAAGGUGUCUCCAGCUCUCC	328	1149-1171
AD-1423323.1	CAUUGCCUCCGUCAUUCUUAU	111	1167-1187	AUGAAGAUAGCGGAGGCAUUGAA	335	1165-1187
AD-1423324.1	CCUUCAAUGCCUCCGUCAUUCU	109	1163-1183	AGAUGACGGAGGCAUUGAAGGUG	333	1161-1183
AD-1423325.1	CUGCUACAGACUUUUGAGAAAGU	63	749-769	ACUUCUCAAAGUCUGUAGCAGAC	287	747-769
AD-1423326.1	AAGAUGUGGCCAAGCACUUU	99	964-984	AAAGTGCUUUGGCCACAUUUUUGC	1146	962-984
AD-1423327.1	AAGGUUGAUCUGACCCAGUUU	73	766-786	AAACTGGGUCAGAUCAACCUUUCU	1147	764-786
AD-1423328.1	AAGGUGUUUGUCCACAGAUU	60	612-632	AAUCTTGGGACAAACACCUUUAU	1148	610-632
AD-1423329.1	GAAGAGAAGCAGAUCCUGUGU	54	526-546	ACACAGGAUCUGCUUUCUUCUCCA	278	524-546
AD-1423330.1	GUGUUUGUCAGCAAAGAUUUU	95	952-972	AACATCTUUGCUGACAAACACCCA	1149	950-972
AD-1423331.1	GACAAGUACCCUAAAGGAGAU	57	583-603	AUCCCTCCUUAGGGUACUUGUCCA	1150	581-603
AD-1423332.1	GUGCAGGAAGCACUGAGAUUU	114	1207-1227	AAAUCUCAGUGCUUCCUGCACGC	338	1205-1227
AD-1290878.2	GGAGACGUGGUGUUUGUCAGU	92	943-963	ACUGACAAACACACGUCUCCGU	316	941-963
AD-1423334.1	CCUCAUGGAAGAGAAGCAGAU	50	519-539	AUCUGCTUCUCUCCAUUGAGGCU	1151	517-539

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO	Range in XM	Antisense Sequence 5' to 3'	SEQ ID NO	Range in XM
AD-1423335.1	CUCCGUCACUUCAGCCUCUU	113	1173-1193	AAGAGGCUGAAGAUACGGAGGC	337	1171-1193
AD-1423336.1	GUUCAAGUGGAUCCACAUUGU	207	783-803	ACAATGTGGAUCCACUUGAACUG	1152	781-803

Table 6. Modified Sense and Antisense Strand Sequences of KHK dsRNAs

Duplex Name	Sense sequence 5' to 3'	SEQ ID NO:	Antisense sequence 5' to 3'	SEQ ID NO:	mRNA target sequence	SEQ ID NO:
AD-1423310.1	ususugagAfaGfGfUfugaucugacuL9	1153	asGfsucdAg(Agn)ucaaccUfuCfucuaaagsu	1154	ACUUUGAGAGGUUGAUCUGAC	968
AD-1423311.1	gsascgugGfuGfUfUfugucagcauL9	670	asUfsugdCu(G2p)acaacAfcCfacgucsusc	1155	GAGACGUGGUGUUUGUCAGCAA	1118
AD-1423312.1	usgscaggAfaGfCfAfcugagaucuuL9	563	asGfsaadTc(Tgn)eaagUfuCfuegcascsg	1156	CGUGCAGGAAGCACUCAGAUUUC	1011
AD-1423313.1	ascasagacUfuUfGfAfgaagguuL9	515	asUfscadAc(C2p)uuucaAfaGfucugusag	1157	CUACAGACUUUGAGAAAGGUUGA	963
AD-1423314.1	gscsuacaGfaCfUfUfugagaaguuL9	513	asAfscdTu(C2p)ucaaaUfcUfguagcsag	1158	CUGCUACAGACUUUGAGAAAGGU	961
AD-1423315.1	ascscagUfuCfAfafgugauccuL9	527	asUfsggdAu(C2p)cacuugAfaCfuggguscsa	1159	UGACCCAGUUCAGUGGAUCCA	975
AD-1423316.1	uscsagagCfaAfaUfaaauccuL9	470	asGfsgadAg(Agn)uuuuuuUfgCfucugasgs	1160	CCUCAGAGCAAUAAAUUUUCC	918
AD-1290665.2	asgsagcaAfaUfaAfaucuuccuL9	660	asGfsaggAfaaauuuUfuUfgeucugsas	884	UCAGAGCAAUAAAUUUUCCUC	1108
AD-1423317.1	csusuugaGfaAfGfGfugaucuL9	519	asUfscadGa(Tgn)caaceuUfcUfcaagcsusc	1161	GACUUUGAGAAAGGUUGAUCUGA	967
AD-1423318.1	asusggaaGfaGfAfafgcagaucuuL9	500	asAfsggdAu(C2p)ugennuUfcUfucceausgsa	1162	UCAUGGAAGAGAAAGCAGAUCCU	948
AD-1423319.1	gsascuuuGfaGfAfafgguuL9	518	asAfsgadTc(Agn)accuucUfcAfaagucsusc	1163	CAGACUUUGAGAAAGGUUGAUCU	966
AD-1423320.1	csuscagaGfcAfaAfaaauccuL9	570	asGfsaadGa(Tgn)uuuuuuGfcUfuegagsgsc	1164	GCCUCAGAGCAAUAAAUUUUCC	1018
AD-1423321.1	csuscuncCfaGfCfUfuguugetauL9	536	asUfsgadCc(Agn)aacageUfgGfaagagcsu	1165	AGCUCUCCAGCUGUUUUGGCUA	984
AD-1423322.1	gsasgeugGfaGfAfcfaccuueaauL9	552	asAfsuudGa(Agn)ggugucUfcCfagucscsc	1166	GGGAGCUGGAGACACCUUCAU	1000

Duplex Name	Sense sequence 5' to 3'	SEQ ID NO:	Antisense sequence 5' to 3'	SEQ ID NO:	mRNA target sequence	SEQ ID NO:
	6				G	
AD-1423323.1	csasagcCfuCfCfGfucacucuuL9	559	asUfsgadA(Agn)ugacggAfgGfcauugsas	1167	UUCAUAGCCUCCGUCUUAUUA	1007
AD-1423324.1	csesucaAfuGfCfCfucgucacuuL9	557	asGfsaudGa(C2p)ggaggcAfuUfgaaggsus	1168	CACCUUCAAUGCCUCCGUCUUA	1005
AD-1423325.1	csusgeuaCfaGfAfcfuuuagagaauL9	511	asCfsuudCu(C2p)aaagucUfgUfagcagsasc	1169	GUCUGCUACAGACUUAUUGAGAAAG	959
AD-1423326.1	asasagauGfuGfGfCfcaagcacuulL9	547	asAfsagdTg(C2p)uuggccAfcAfcuuiusgsc	1170	GCAAAGAUGUGGGCCAAAGCACUU	995
AD-1423327.1	asasgguuGfaUfCfUfgaccaguuuL9	521	asAfsacdTg(C2p)guacagaUfcAfacuuuscsu	1171	AGAAAGGUUGAUCUGACCCAGUU	969
AD-1423328.1	asasggugUfuUfGfUfccagagauuL9	508	asAfsuudTc(Tgn)gggacaAfaCfaccuuusasu	1172	AUAAAGGUGUUUGUCCCCAGAGAU	956
AD-1423329.1	gsasagagAfaGfCfAfgauccuguguL9	502	asCfsacdAg(G2p)aucugcUfuCfucuuuscsa	1173	UGGAAAGAGAAAGCAGAUCCUGUG	950
AD-1423330.1	gsusguuuGfuCfAfcGfcaagauguuL9	543	asAfsacdTc(Tgn)uugcugAfcAfaacacscsa	1174	UGGUGUUUGUACAGCAAAGAUGU	991
AD-1423331.1	gsascaagUfaCfCfCfuuaaggaggaauL9	505	asUfscudTc(C2p)uuagggUfaCfuugucscsa	1175	UGGACAAGUACCCUAAAGGAGGA	953
AD-1423332.1	gsusgcagGfaAfcGfCfagagagauuL9	562	asAfsaudCu(C2p)agugcuUfcCfugcagcsgsc	1176	GCGUGCAGGAAGCAGCUGAGAUU	1010
AD-1290878.2	gsgsagacGfuGfGfUfguuugucaguL96	540	asCfsugaCfaaacaccAfcGfucuuuscsu	764	ACGGAGACGUGGUGUUUUGUCAG	988
AD-1423334.1	csesucauGfgAfcGfagaagcagauL9	498	asUfscudGc(Tgn)ucucuuCfcAfuagggscsu	1177	AGCCUCAUGGAAGAGAGAGCAGA	946
AD-1423335.1	csusccguCfaUfCfUfucagccuucuuL9	561	asAfsagdGg(C2p)ugaagaUfgAfcggagsgsc	1178	GCCUCCGUCUUAUCUUCAGCCUCU	1009
AD-1423336.1	gsusucaaGfuGfGfAfuaccacuuuL9	655	asCfsaadTg(Tgn)ggauccAfcUfugaacsusg	1179	CAGUUCAAAGUGGAUCCACAUUG	1103

Table 7. KHK Single Dose Screen in Hep3b cells

Duplex Name	% Message Remaining (qPCR)
AD-1423317	9.38
AD-1423327	7.75
AD-1423336	7.70
AD-1423311	6.06
AD-1423320	21.59
AD-1423324	10.44
AD-1423329	12.28
AD-1423333	9.09
AD-1423330	8.78
AD-1423310	6.66
AD-1423314	8.66
AD-1423316	10.59
AD-1423322	18.97
AD-1423325	16.15
AD-1423334	10.71
AD-1423312	12.77
AD-1423313	9.33
AD-1423315	7.66
AD-1423318	13.43
AD-1423319	8.34
AD-1423321	11.82
AD-1423323	9.65
AD-1423326	5.15
AD-1423328	22.84
AD-1423331	13.21
AD-1423332	10.54
AD-1423335	8.60

Table 8. Unmodified Sense and Antisense Strand Sequences of KHK dsRNAs

Duplex Name	Sense sequence 5' to 3'	SEQ ID NO:	Source Name	Range in GenBank Source Name	Antisense sequence 5' to 3'	SEQ ID NO:	Range in GenBank Source Name
AD-1290757.3	GUUGAUCUGACCCAGUUCAAU	1180	XM_017004061.1_769-789_G21U_s	769-789	AUUGAACUGGGGUCAGAUCAACCU	298	767-789
AD-1290878.3	GGAGACGUGGUGUUUGUCAGU	92	XM_017004061.1_943-963_G21U_s	943-963	ACUGACAAACACCCACGUCUCCGU	316	941-963
AD-1290969.3	ACCUUCAAUGCCUCCGUCAUU	108	XM_017004061.1_1162-1182_G21U_s	1162-1182	AAUGACGGAGGCAUUGAAGGUGU	332	1160-1182
AD-1423317.2	CUUUGAGAAAGGUUGAUCUGAU	71	XM_017004061.1_759-779_G21U_s	759-779	AUCAGATCAACCUUCUCAAAGUC	1143	757-779
AD-1423327.2	AAGGUUGAUCUGACCCAGUUU	73	XM_017004061.1_766-786_G21U_s	766-786	AAACTGGGUCAGAUCAACCUUCU	1147	764-786
AD-1423336.2	GUUCAAGUGGAUCCACAUUGU	207		783-803	ACAATGTGGAUCCACUUGAACUG	1152	781-803
AD-1290599.3	UGGUGUUUGUCAGCAAAGAUU	93	XM_017004061.1_950-970_G21U_s	950-970	AAUCUUUGCUGACAAACACCACG	317	948-970
AD-1523172.1	UGGUGUUUGUCAGCAAAGAUU	93	XM_017004061.1_950-970_G21U_s	950-970	AAUCTUUGCUGACAAACACCACG	1182	948-970
AD-1290837.3	UGAUCUGACCCAGUUCAGUU	76	XM_017004061.1_771-791_G21U_s	771-791	AACUUGAACUGGGGUCAGAUCAAC	300	769-791
AD-1523173.1	UGAUCUGACCCAGUUCAGUU	76	XM_017004061.1_771-791_G21U_s	771-791	AACUTGAACUGGGGUCAGAUCAAC	1183	769-791
AD-1290884.3	GCAGGAAGCACUGAGAUUCGU	116	XM_017004061.1_1209-1229_G21U_s	1209-1229	ACGAAUCUCAGUGCUUCCUCCAC	340	1207-1229
AD-1523174.1	GCAGGAAGCACUGAGAUUCGU	116	XM_017004061.1_1209-1229_G21U_s	1209-1229	ACGAAUCUCAGUGCUUCCUCCAC	340	1207-1229
AD-1290959.3	UUGAUCUGACCCAGUUCAGUU	75	XM_017004061.1_770-790_s	770-790	ACUUGAACUGGGGUCAGAUCAACC	299	768-790
AD-1523175.1	UUGAUCUGACCCAGUUCAGUU	75	XM_017004061.1_770-790_s	770-790	ACUUGAACUGGGGUCAGAUCAACC	299	768-790
AD-1423311.2	GACGUGGUGUUUGUCAGCAU	222		946-966	AUUGCUGACAAACACCACGUCUC	446	944-966
AD-1423324.2	CCUCAAUGCCUCCGUCAUUCU	109	XM_017004061.1_1163-1183_s	1163-1183	AGAUGACGGAGGCAUUGAAGGUG	333	1161-1183
AD-1523176.1	CCUCAAUGCCUCCGUCAUUCU	109	XM_017004061.1_1163-1183_s	1163-1183	AGAUGACGGAGGCAUUGAAGGUG	333	1161-1183

Duplex Name	Sense sequence 5' to 3'	SEQ ID NO:	Source Name	Range in GenBank Source Name	Antisense sequence 5' to 3'	SEQ ID NO:	Range in GenBank Source Name
AD-1423329.2	GAAGAGAAAGCAGAUCCUGUGU	54	XM_017004061.1_526-546_C21U_s	526-546	ACACAGGAUCUGCUUCUCCUCCA	278	524-546
AD-1423333.2	GUGGUGUUUGUCAGCAAAGAU	1181	XM_005264298.1_812-830_s	810-830	AUCUTUGCUGACAAACACACGCU	1184	808-830
AD-1423330.2	GUGUUUGUCAGCAAAGAUUU	95	XM_017004061.1_952-972_G21U_s	952-972	AACATCTUUGCUGACAAACACCA	1149	950-972
AD-1523177.1	GUGUUUGUCAGCAAAGAUUU	95	XM_017004061.1_952-972_G21U_s	952-972	AACATCTUUGCUGACAAACACCA	1185	950-972
AD-1290885.3	CUGACCCAGUUCAAGUGGAUU	78	XM_017004061.1_775-795_C21U_s	775-795	AAUCCACUUGAACUGGGUCAGAU	302	773-795
AD-1523178.1	CUGACCCAGUUCAAGUGGAUU	78	XM_017004061.1_775-795_C21U_s	775-795	AAUCCACUUGAACUGGGUCAGAU	302	773-795
AD-1423334.2	CCUCAUGGAAGAGAAAGCAGAU	50	XM_017004061.1_519-539_s	519-539	AUCUGCTUCUUCUCCAUAGAGGCU	1151	517-539
AD-1523179.1	CCUCAUGGAAGAGAAAGCAGAU	50	XM_017004061.1_519-539_s	519-539	AUCUGCTUCUUCUCCAUAGAGGCU	274	517-539
AD-1523180.1	CCUCAUGGAAGAGAAAGCAGAU	50	XM_017004061.1_519-539_s	519-539	AUCUGCTUCUUCUCCAUAGAGGCU	1151	517-539
AD-1290539.3	CAGACUUUGAGAAAGGUUGAUU	68	XM_017004061.1_755-775_C21U_s	755-775	AAUCAACCUUCUCUCAAAGUCUGUA	292	753-775
AD-1523181.1	CAGACUUUGAGAAAGGUUGAUU	68	XM_017004061.1_755-775_C21U_s	755-775	AAUCAACCUUCUCUCAAAGUCUGUA	292	753-775

Table 9. Modified Sense and Antisense Strand Sequences of KHK dsRNAs

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Antisense Sequence 5' to 3'	SEQ ID NO:	mRNA Target Sequence	SEQ ID NO:
AD-1290757.3	gsusugauCfuGfAfCfccaguucauL9 6	1186	asUfsugaAfcugggucAfgAfucaacscsu	746	AGGUUGAUUCUGACCCAGUUCAG	970
AD-1290878.3	gsagsagacGfuGfGfUfguuugucaguL9 6	540	asCfsugaCfaaacaccAfcGfueuccsgsu	764	ACGGAGACGUGGUGUUUGUCAGC	988
AD-1290969.3	ascscuucAfaUfGfCfueccgucauuL9 6	556	asAfsugaCfaggagcaUfuGfaaggugsgsu	780	ACACCUUCAAUGCCUCCGUCUAC	1004
AD-1423317.2	csusugaGfaAfGfGfUfguugaucuL9 6	519	asUfscadGa(Tgn)caaccuUfcUfcaags usc	1161	GACUUUGAGAAGGUUGAUCUGAC	967
AD-1423327.2	asagsguuGfaUfCfUfgaccaguuuL9 6	521	asAfsadTg(G2p)gucagaUfcAfaccuu scsu	1171	AGAAAGGUUGAUUCUGACCCAGUUC	969

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Antisense Sequence 5' to 3'	SEQ ID NO:	mRNA Target Sequence	SEQ ID NO:
AD-1423336.2	gsusuaaGfuGfGfAfucaauuL9	655	asCfsaadTg(Tgn)ggaucAfcUfugaac susg	1179	CAGUUAAGUGGAUCCACAUAUGA	1103
AD-1290599.3	usgsuguUfuGfUfCfagcaagaauL9	541	asAfsuUfugucgacAfaAfcaccascg	765	CGUGGUGUUUGUCAGCAAGAUG	989
AD-1523172.1	usgsuguUfuGfUfCfagcaagaauL9	541	asAfsuUfugucgacAfaAfcaccascg	1188	CGUGGUGUUUGUCAGCAAGAUG	989
AD-1290837.3	usgsuauGfaCfCfCfaguucaaguL9	524	asAfsuUfagcugggUfcAfgaucasasc	748	GUUGAUCUGACCCAGUUCAGAUG	972
AD-1523173.1	usgsuauGfaCfCfCfaguucaaguL9	524	asAfsuUfagcugggUfcAfgaucasasc	1189	GUUGAUCUGACCCAGUUCAGAUG	972
AD-1290884.3	gscsaggaAfgCfAfcfugagaucguL9	564	asCfsgaaUfucucagCfuUfccugcsasc	788	GUGCAGGAAGCACUGAGAUUCGG	1012
AD-1523174.1	gscsaggaAfgCfAfcfugagaucguL9	564	asCfsgadAu(C2p)ucagugCfuUfccugc sasc	1190	GUGCAGGAAGCACUGAGAUUCGG	1012
AD-1290959.3	usugaucUfgAfcCfCfaguucaaguL9	523	asCfsuUfagcugggUfcAfgaucasasc	747	GGUUGAUCUGACCCAGUUCAGAUG	971
AD-1523175.1	usugaucUfgAfcCfCfaguucaaguL9	523	asCfsuUfagcugggUfcAfgaucasasc	1191	GGUUGAUCUGACCCAGUUCAGAUG	971
AD-1423311.2	gsascgugGfuGfUfUfugucagaauL9	670	asUfsgudCu(G2p)acaaacAfcCfaguc susc	1155	GAGACGUGGUGUUUGUCAGCAAAA	1118
AD-1423324.2	cscsuucaAfuGfCfCfucgucacuL9	557	asGfsaudGa(C2p)ggaggcAfuUfgaag gsusg	1168	CACCUUCAAUUGCCUCCGUCUUCU	1005
AD-1523176.1	cscsuucaAfuGfCfCfucgucacuL9	557	asGfsaudGa(C2p)ggaggcAfuUfgaag gsusg	1192	CACCUUCAAUUGCCUCCGUCUUCU	1005
AD-1423329.2	gsasagagAfaGfCfAfgaauucguL9	502	asCfsadAg(G2p)aucugcUfuCfucnuic scsa	1173	UGGAAGAGAAAGCAGAUCCUGUGC	950
AD-1423333.2	gsusggugUfuUfGfUfCfagcaagaauL9	468	asUfscudTu(G2p)ucgacaAfaCfaccac sgsu	1193	ACGUGGUGUUUGUCAGCAAGAAGAU	916
AD-1423330.2	gsusguuUfuCfAfgfcaagaagaauL9	543	asAfsuUfugucgAfcAfaaac scsa	1174	UGGUGUUUGUCAGCAAGAAGUGUG	991
AD-1523177.1	gsusguuUfuCfAfgfcaagaagaauL9	543	asAfsuUfugucgAfcAfaaac scsa	1194	UGGUGUUUGUCAGCAAGAAGUGUG	991
AD-1290885.3	csusgaccCfaGfUfUfcaaguggaauL9	526	asAfsuUfugucgAfcGfgucagsasu	750	AUCUGACCCAGUUCAGAAGUGGAUC	974
AD-1523178.1	csusgaccCfaGfUfUfcaaguggaauL9	526	asAfsuUfugucgAfcGfgucagsasu	1195	AUCUGACCCAGUUCAGAAGUGGAUC	974

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Antisense Sequence 5' to 3'	SEQ ID NO:	mRNA Target Sequence	SEQ ID NO:
	6		sasu			
AD-1423334.2	csucucGfGfAfGfagaagcagauL9 6	498	asUfscudGc(Tgn)ucucuuCfcAfugagg scsu	1177	AGCCUCAUGGAAGAGAAAGCAGAU	946
AD-1523179.1	csucucGfGfAfGfagaagcagauL9 6	498	asUfscudGc(U2p)ucucuuCfcAfugag gscsu	1196	AGCCUCAUGGAAGAGAAAGCAGAU	946
AD-1523180.1	csucucGfGfAfGfagaagcagauL9 6	498	asUfscudGcdTucucuuCfcAfugaggsc su	1197	AGCCUCAUGGAAGAGAAAGCAGAU	946
AD-1290539.3	csagacuUfuGfAfGfaagguugaauL9 6	516	asAfsucaAfcuucucAfaAfgucugsusa asAfsucdAa(C2p)cuucucAfaAfgucug susa	740	UACAGACUUUUGAGAAAGGUUGAUC	964
AD-1523181.1	csagacuUfuGfAfGfaagguugaauL9 6	516		1198	UACAGACUUUUGAGAAAGGUUGAUC	964

Example 4. Design, Synthesis and In Vitro Screening of Additional dsRNA Duplexes

Additional siRNAs were designed, synthesized, and prepared using the methods described above in Example 1.

Detailed lists of the additional unmodified KHK sense and antisense strand nucleotide sequences are shown in Table 10. Detailed lists of the modified KHK sense and antisense strand nucleotide sequences are shown in Table 11.

Table 10. Unmodified Sense and Antisense Strand Sequences of KHK dsRNA

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1	Antisense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1
AD-1290969	ACCUUCA AUGCCUCGUC AUU	1199	1162-1182	AAU GACGGAGGCAUU GAAGGUGU	332	1160-1182
AD-1423310	UUUGAAGAGGUUGAUCUGACU	72	760-780	AGUCAGAUCAACCUUCUCAAGU	296	758-780
AD-1423311	GACGUGGUGUUUGUCAGCAAU	222	946-966	AUUGCUGACAAAACACCACGUCUC	446	944-966
AD-1423312	UGCAGGAAGCACUGAGAUUCU	115	1208-1228	AGAATCTCAGUGCUUCCUGCACG	1141	1206-1228
AD-1423317	CUUUGAGAAAGGUUGAUCUGAU	71	759-779	AUCAGATCAACCUUCUCAAGUC	1143	757-779
AD-1423319	GACUUUGAGAAAGGUUGAUCUU	70	757-777	AAGATCAACCUUCUCAAGUCUG	1144	755-777
AD-1423323	CA AUGCCUCGUC AUUCU CAU	111	1167-1187	AUGAAGAU GACGGAGGCAUUGAA	335	1165-1187
AD-1423327	AAGGUUGAUCUGACCCAGUUU	73	766-786	AAACTGGGUCAGAUCAACCUUCU	1147	764-786
AD-1423329	GAAGAGAAAGCAGAUCCUGUGU	54	526-546	ACACAGGAUCUGCUUCUCUCCUCCA	278	524-546
AD-1423330	GUGUUUGUCAGCAAAGAUGUU	95	952-972	AACATCTUUGCUGACAAAACACCA	1149	950-972
AD-1423333	GUGGUGUUUGUCAGCAAAGAU	20	949-969	AUCUTUGCUGACAAACACCACGU	1184	947-969
AD-1423334	CCUCAUGGAAAGAGAAAGCAGAU	50	519-539	AUCUGCTUCUCUUCCAUAGAGGCU	1151	517-539
AD-1423336	GUUCAAGUGGAUCCACAUUGU	207	783-803	ACAAATGTGGAUCCACUUGAACUG	1152	781-803
AD-1523180	CCUCAUGGAAAGAGAAAGCAGAU	50	519-539	AUCUGCTUCUCUUCCAUAGAGGCU	1151	517-539
AD-1548743	UGGUGUUUGUCAGCAAAAGAUU	93	950-970	AAUCTUTGCUGACAAAACACCACG	1269	948-970
AD-	GCCUCAUGGAAAGAGAAAGCAGU	1200	518-538	ACUGCUTCUCUTCCTCCAUAGAGGCUA	1270	516-538

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1	Antisense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1
1612957						
AD-1612958	CCUCAUGGAAGAGAGCAGAU	50	519-539	ATCUGCTUCUCTUCCAUGAGGCU	1271	517-539
AD-1612963	UGGAAGAGAAAGCAGAUCCUGU	1201	524-544	ACAGGATCUGCTUCUUCUCCAUG	1272	522-544
AD-1612967	AGAGAAGCAGAUCCUGUGCGU	1202	528-548	ACGCACAGGAUCUGCUUCUCUUC	1273	526-548
AD-1612969	AGAAAGCAGAUCCUGUGCGUGU	1203	530-550	ACACGCACAGGAUCUGCUUCUCU	1274	528-550
AD-1612970	GAAGCAGAUCCUGUGCGUGGU	1204	531-551	ACCACGCACAGGAUCUGCUUCUC	1275	529-551
AD-1613059	CAGACUUUGAGAAAGGUUGAUU	68	755-775	AAUCAACCUUCTCAAAGUCUGUA	1276	753-775
AD-1613060	AGACUUUGAGAAAGGUUGAUCU	69	756-776	AGAUCAAACCUUCUCAAGUCUGU	293	754-776
AD-1613062	ACUUUGAGAAAGGUUGAUCUGU	213	758-778	ACAGAUCAACTTUCUCAAGAGUCU	1277	756-778
AD-1613070	AAGGUUGAUCUGACCCAGUUU	73	766-786	AAACTGGGUCAGAUCAACCUUCU	1147	764-786
AD-1613073	GUUGAUCUGACCCAGUUUCAAU	74	769-789	ATUGAACUGGGTCAGAUCAACCU	1278	767-789
AD-1613074	UUGAUCUGACCCAGUUUCAAGU	75	770-790	ACUUGAACUGGGUCAGAUCAACC	299	768-790
AD-1613075	UGAUCUGACCCAGUUUCAAGUU	76	771-791	AACUTGAACUGGGUCAGAUCAAC	1183	769-791
AD-1613076	GAUCUGACCCAGUUUCAAGUGU	77	772-792	ACACTUGAACUGGGUCAGAUCAA	1279	770-792
AD-1613077	AUCUGACCCAGUUUCAAGUGGU	1205	773-793	ACCACUTGAACTGGGUCAGAUCA	1280	771-793
AD-1613079	CUGACCCAGUUUCAAGUGGAUU	78	775-795	AAUCCACUUGAAACUGGGUCAGAU	302	773-795
AD-1613088	UUCAAAGUGGAUCCACAUUUGAU	82	784-804	ATCAAUGUGGATCCACUUGAACU	1281	782-804
AD-	UCAAGUGGAUCCACAUUUGAGU	83	785-805	ACUCAATGUGGAUCCACUUGAAC	1282	783-805

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1	Antisense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1
1613089						
AD-1613090	CAAGUGGAUCCACAUUGAGGU	84	786-806	ACCUCAAUGUGGAUCCACUUGAA	308	784-806
AD-1613091	AAGUGGAUCCACAUUGAGGU	1206	787-807	ACCTTCAAUGUGGAUCCACUUGA	1283	785-807
AD-1613094	UGGAUCCACAUUGAGGGCCGU	1207	790-810	ACGGCCCUCAATGUGGAUCCACU	1284	788-810
AD-1613095	GGAUCCACAUUGAGGGCCGU	1208	791-811	ACGGGCCCUCAAUUGUGGAUCCAC	1285	789-811
AD-1613237	GUUUGGCUACGGAGACGUGGU	1209	933-953	ACCACGTCUCCGUAGCCAACAG	1286	931-953
AD-1613238	UUUGGCUACGGAGACGUGGU	1210	934-954	AACACGUCUCCGUAGCCAAAACA	1287	932-954
AD-1613239	UUGGCUACGGAGACGUGGUGU	1211	935-955	ACACCACGUCUCCGUAGCCAAAC	1288	933-955
AD-1613240	UGGCUACGGAGACGUGGUGUU	1212	936-956	AACACCACGUCTCCGUAGCCAAA	1289	934-956
AD-1613241	GGCUACGGAGACGUGGUGUUU	1213	937-957	AAACACACGUCUCCGUAGCCAA	1290	935-957
AD-1613242	GCUACGGAGACGUGGUGUUUU	242	938-958	AAAACACACGTCUCCGUAGCCA	1291	936-958
AD-1613243	CUACGGAGACGUGGUGUUUGU	89	939-959	ACAAACACACGUCUCCGUAGCC	313	937-959
AD-1613244	UACGGAGACGUGGUGUUUGUU	90	940-960	AACAAACACACGUCUCCGUAGC	314	938-960
AD-1613245	ACGGAGACGUGGUGUUUGUCU	232	941-961	AGACAAACACACGUCUCCGUAG	456	939-961
AD-1613246	CGGAGACGUGGUGUUUGUCAU	91	942-962	ATGACAAACACACGUCUCCGUA	1292	940-962
AD-1613247	GGAGACGUGGUGUUUGUCAGU	92	943-963	ACUGACAAACACACGUCUCCGU	316	941-963
AD-1613254	UGGUGUUUGUCAGCAAAAGAUU	93	950-970	AAUCTUTGUGACAAACACCCAG	1269	948-970
AD-	GGUGUUUGUCAGCAAAAGAUGU	94	951-971	ACAUCUTUGCUGACAAACACCAC	1293	949-971

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1	Antisense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1
1613255						
AD-1613256	GUGUUUGUCAGCAAAGAUGUU	95	952-972	AACATCTUUGCTGACAAAACACCA	1294	950-972
AD-1613257	UGUUUUGUCAGCAAAGAUGUGU	96	953-973	ACACAUCUUUGCUGACAAACACC	320	951-973
AD-1613258	GUUUUGUCAGCAAAGAUGUGGU	97	954-974	ACCACATCUUUUGCUGACAAACAC	1295	952-974
AD-1613259	UUUGUCAGCAAAGAUGUGGCU	98	955-975	AGCCACAUCUUTGCUGACAAAACA	1296	953-975
AD-1613361	AGCUGGAGACACCUUCAAUUGU	105	1152-1172	ACAUTGAAGGUGUCUCCAGCUCC	1297	1150-1172
AD-1613362	GCUGGAGACACCUUCAAUUGCU	1214	1153-1173	AGCATUGAAGGTGUCUCCAGCUC	1298	1151-1173
AD-1613363	CUGGAGACACCUUCAAUUGCCU	106	1154-1174	AGGCAUTGAAGGUGUCUCCAGCU	1299	1152-1174
AD-1613369	ACACCUUCAAUUGCCUCCGUCU	1215	1160-1180	AGACGGAGGCATUGAAGGUGUCU	1300	1158-1180
AD-1613370	CACCUUCAAUUGCCUCCGUCAU	1216	1161-1181	ATGACGGAGGCAUUGAAGGUGUC	1301	1159-1181
AD-1613371	ACCUUCAAUUGCCUCCGUCAUU	108	1162-1182	AAUGACGGAGGCAUUGAAGGUGU	332	1160-1182
AD-1613374	UUCAAUUGCCUCCGUCAUUCUUU	110	1165-1185	AAAGAUGACGGAGGCAUUGAAGG	334	1163-1185
AD-1613377	AUUGCCUCCGUCAUUCUUCAGU	112	1168-1188	ACUGAAGAUGACGGAGGCAUUGA	336	1166-1188
AD-1613378	AUGCCUCCGUCAUUCUUCAGCU	1217	1169-1189	AGCUGAAGAUGACGGAGGCAUUG	1302	1167-1189
AD-1613395	AGCGUGCAGGAAGCACUGAGU	1218	1204-1224	ACUCAGTGCUUCUCCUGCAGCUC	1303	1202-1224
AD-1613400	GCAGGAAGCACUGAGAUUUCGU	116	1209-1229	ACGAAUUCUCAGTGCUUCUCCUGCAC	1304	1207-1229
AD-1613401	CAGGAAGCACUGAGAUUUCGGU	1219	1210-1230	ACCGAATCUCAGUGCUUCCUGCA	1305	1208-1230
AD-	UAGCCUCAUGGAAGAGAGAGCU	1220	516-536	AGCUTCTCUUCCAUGAGGCUACU	1306	514-536

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1	Antisense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1
1634353						
AD-1634354	GCCUCAUGGAAGAGAACGAGU	1200	518-538	ACUGCUTCUCUCCAUAGAGGCUA	1307	516-538
AD-1634355	CAUGGAAGAGAAAGCAGAUCCU	1221	522-542	AGGATCTGCUUCUCUCCAUAGAG	1308	520-542
AD-1634356	GGAAGAGAAAGCAGAUCCUGUU	53	525-545	AACAGGAUCUGCUUCUCUCCAU	277	523-545
AD-1634357	AGAGAAAGCAGAUCCUGGCGU	1202	528-548	ACGCACAGGAUCUGCUUCUCUUC	1273	526-548
AD-1634358	AGACUUUGAGAAAGGUUGAUCU	69	756-776	AGAUCAAACCUUCUCAAAGUCUGU	293	754-776
AD-1634359	UGAGAAGGUUGAUCUGACCCU	1222	762-782	AGGGTCAGAUCAACCUUCUCAAA	1309	760-782
AD-1634360	AGAAAGGUUGAUCUGACCCAGU	1223	764-784	ACUGGGTCAGAUCAACCUUCUCA	1310	762-784
AD-1634361	GGUUUGAUCUGACCCAGUUCAU	239	768-788	AUGAACTGGGUCAGAUCAACCUU	1311	766-788
AD-1634362	UGAUCUGACCCAGUUCAAGUU	76	771-791	AACUTGAAACUGGGUCAGAUCAAC	1183	769-791
AD-1634363	UCUGACCCAGUUCAAGUGGAU	1224	774-794	AUCCACTUGAACUGGGUCAGAU	1312	772-794
AD-1634364	UGACCCAGUUCAAGUGGAUCU	1225	776-796	AGAUCCACUUGAACUGGGUCAGA	1313	774-796
AD-1634365	CCCAGUUCAAGUGGAUCCACU	1226	779-799	AGUGGATCCACUUGAACUGGGUC	1314	777-799
AD-1634366	CCAGUUCAAAGUGGAUCCACAU	80	780-800	AUGUGGAUCCACUUGAACUGGGU	304	778-800
AD-1634367	GUGGAUCCACAUUGAGGGCCU	1227	789-809	AGGCCCTCAAUGUGGAUCCACUU	1315	787-809
AD-1634368	AGACGUGGUGUUUUGUCAGCAU	1228	945-965	AUGCTGACAAACACCACGUCUC	1316	943-965
AD-1634369	ACGUGGUGUUUUGUCAGCAAAU	21	947-967	AUUUGCTGACAAACACCACGUCU	1317	945-967
AD-	UUUGUCAGCAAAAGAUUGGCU	98	955-975	AGCCACAUCUUUUGCUGACAAACA	322	953-975

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1	Antisense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1
1634370						
AD-1634371	UGUCAGCAAGAUGUGGCCAU	1229	957-977	AUGGCCACAUCUUUGCUGACAAA	1318	955-977
AD-1634372	GCAAGAUGUGGCCAAGCACU	1230	962-982	AGUGCUTGGCCACAUCUUUGCUG	1319	960-982
AD-1634373	CUGGAGACACCUUCAUUGCCU	106	1154-1174	AGGCAUTGAAGGUGUCUCCAGCU	1299	1152-1174
AD-1634374	UGGAGACACCUUCAUUGCCUU	107	1155-1175	AAGGCATUGAAGGUGUCUCCAGC	1320	1153-1175
AD-1634375	GGAGACACCUUCAUUGCCUCU	1231	1156-1176	AGAGGCAUUGAAGGUGUCUCCAG	1321	1154-1176
AD-1634376	ACACCUUCAUUGCCUCCGUCU	1215	1160-1180	AGACGGAGGCAUUGAAGGUGUCU	1322	1158-1180
AD-1634377	CUUCAUUGCCUCCGUCUACUU	1232	1164-1184	AAGATGACGGAGGCAUUGAAGGU	1323	1162-1184
AD-1634378	UCAAUGCCUCCGUCUACUUUCU	223	1166-1186	AGAAGATGACGGAGGCAUUGAAG	1324	1164-1186
AD-1634379	AUGCCUCCGUCUACUUUCAGCU	1217	1169-1189	AGCUGAAGAUGACGGAGGCAUUG	1302	1167-1189
AD-1634380	UGCCUCCGUCUACUUUCAGCCU	1233	1170-1190	AGGCTGAAGAUGACGGAGGCAU	1325	1168-1190
AD-1634381	CCUCCGUCUACUUUCAGCCUCU	1234	1172-1192	AGAGGCTGAAGAUGACGGAGGCA	1326	1170-1192
AD-1634382	GAGGAGCGUGCAGGAAGCACU	1235	1200-1220	AGUGCUTCUCUGCACGCUCUCC	1327	1198-1220
AD-1634383	AGGAGCGUGCAGGAAGCACUU	1236	1201-1221	AAGUGCTUCCUGCACGCUCUCC	1328	1199-1221
AD-1634384	AGCGUGCAGGAAGCACUGAGU	1218	1204-1224	ACUCAGTGCUCUCCUGCACGCUC	1303	1202-1224
AD-1634385	CGUGCAGGAAGCACUGAGAUU	1237	1206-1226	AAUCTCAGUGCUUCCUGCACGC	1329	1204-1226
AD-1634386	CUUCAUUGCCUCCGUCUACUU	1238	1164-1182	AAUGACGGAGGCAUUGAAGGU	1330	1162-1182
AD-	ACCUACA AUGCCUCCGUCUACUU	1239	1162-1182	AAUGACGGAGGCAUUGAAGGUGU	1331	1160-1182

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1	Antisense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1
1634387						
AD-1634388	ACCAUCAAUGCCUCCGUCAUU	1240	1162-1182	AAUGACGGAGGCAUUGAUGGUGU	1332	1160-1182
AD-1634389	ACGUUCAAUGCCUCCGUCAUU	1241	1162-1182	AAUGACGGAGGCAUUGAACGUGU	1333	1160-1182
AD-1634390	ACAUUCAAUGCCUCCGUCAUU	1242	1162-1182	AAUGACGGAGGCAUUGAUUGUGU	1334	1160-1182
AD-1634391	CUUCAUUGCCUCCGUCAUU	1238	1164-1182	AAUGACGGAGGCAUUGAAGGU	1330	1162-1182
AD-1634392	ACCUCAAUGCCUCCGUCAUU	1239	1162-1182	AAUGACGGAGGCAUUGUAGGUGU	1331	1160-1182
AD-1634393	ACCAUCAAUGCCUCCGUCAUU	1240	1162-1182	AAUGACGGAGGCAUUGAUGGUGU	1332	1160-1182
AD-1634394	ACGUUCAAUGCCUCCGUCAUU	1241	1162-1182	AAUGACGGAGGCAUUGAACGUGU	1333	1160-1182
AD-1634395	ACAUUCAAUGCCUCCGUCAUU	1242	1162-1182	AAUGACGGAGGCAUUGAUUGUGU	1334	1160-1182
AD-1634396	GUUCAAGUGGAUCCACAUUGU	207	783-803	ACAAATGTGGAUCCACUUGAACUG	1152	781-803
AD-1634397	GUUCAAGUGGAUCCACAUUGU	207	783-803	ACAAATGTGGAUCCACUUGAACUG	1152	781-803
AD-1634398	GUUCUAGUGGAUCCACAUUGU	1243	783-803	ACAAATGTGGAUCCACUAGAACUG	1335	781-803
AD-1634399	GUUGAAGUGGAUCCACAUUGU	1244	783-803	ACAAATGTGGAUCCACUUAACUG	1336	781-803
AD-1634400	GUUAAAGUGGAUCCACAUUGU	1245	783-803	ACAAATGTGGAUCCACUUAACUG	1337	781-803
AD-1634401	GUACAAAGUGGAUCCACAUUGU	1246	783-803	ACAAATGTGGAUCCACUUGUACUG	1338	781-803
AD-1634402	AAGGUUGAUCUGACCUAGUUU	1247	766-786	AAACTAGGUCAGAUCAACCUUCU	1339	764-786
AD-1634403	AAGGUUGAUCUGACUCAGUUU	1248	766-786	AAACTGAGUCAGAUCAACCUUCU	1340	764-786
AD-	AAGUUUGAUCUGACCUAGUUU	1249	766-786	AAACTAGGUCAGAUCAACCUUCU	1341	764-786

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1	Antisense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1
1634404						
AD-1634405	AAUGUUGAUCUGACCUAGUUU	1250	766-786	AAACTAGGUCAGAUCAACAUUCU	1342	764-786
AD-1634406	AAGUUUGAUCUGACUCAGUUU	1251	766-786	AAACTGAGUCAGAUCAACUUCU	1343	764-786
AD-1634407	AAUGUUGAUCUGACUCAGUUU	1252	766-786	AAACTGAGUCAGAUCAACAUUCU	1344	764-786
AD-1634408	UGGUUUUUUGUCAGCAAAAGAUU	1253	950-970	AAUCTUTGUCUGACAAAAACCACG	1345	948-970
AD-1634409	UGGUCUUUUGUCAGCAAAAGAUU	1254	950-970	AAUCTUTGUCUGACAAAGACCACG	1346	948-970
AD-1634410	UGGAGUUUUGUCAGCAAAAGAUU	1255	950-970	AAUCTUTGUCUGACAAACUCCACG	1347	948-970
AD-1634411	UGUUGUUUUGUCAGCAAAAGAUU	1256	950-970	AAUCTUTGUCUGACAAACAACACG	1348	948-970
AD-1634412	UGCUGUUUUGUCAGCAAAAGAUU	1257	950-970	AAUCTUTGUCUGACAAACAGCACG	1349	948-970
AD-1634413	UGGUGUUUUGUCAGCAAAAGAUU	93	950-970	AAUCTUTGUCUGACAAACACCACU	1350	948-970
AD-1634414	UGGUGUUUUGUCAGCAAAAGAUU	93	950-970	AAUCTUTGUCUGACAAACACCACG	1269	948-970
AD-1634415	CCUCAUGGAAAGAGAAUUCAGAU	1258	519-539	ATCUGATUCUCTUCCAUGAGGCU	1351	517-539
AD-1634416	CCUCUUGGAAAGAGAAUUCAGAU	1259	519-539	ATCUGATUCUCTUCCAAGAGGCU	1352	517-539
AD-1634417	CCUGAUGGAAAGAGAAUUCAGAU	1260	519-539	ATCUGATUCUCTUCCAUCAGGCU	1353	517-539
AD-1634418	CCUAAUGGAAAGAGAAUUCAGAU	1261	519-539	ATCUGATUCUCTUCCAUAUAGGCU	1354	517-539
AD-1634419	CCACAUGGAAAGAGAAUUCAGAU	1262	519-539	ATCUGATUCUCTUCCAUGUGGCU	1355	517-539
AD-1634420	GACGUGGUGUUUUGUCAGCAAU	222	946-966	AUUGCUGACAAACACCACGUCUC	446	944-966
AD-	GACGUGGUGUUUUGUCAGCAAU	222	946-966	AUUGCTGACAAACACCACGUCUC	1356	944-966

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1	Antisense Sequence 5' to 3'	SEQ ID NO:	Range in XM_017004061.1
1634421						
AD-1634422	GACGUGUUUUGUCAGCAAU	222	946-966	AUUGCTGACAAAACACCACGUCUC	1356	944-966
AD-1634423	GUGGUGUUUUGUCAGCAAAAGAU	20	949-969	AUCUTUGCUGACAAACACCACGU	1184	947-969
AD-1634424	GUGGUGUUUUGUCAGUAAAGAU	1263	949-969	AUCUTUACUGACAAACACCACGU	1357	947-969
AD-1634425	GUGGUGUUUUGUCAGCAAAAGAU	20	949-969	AUCTUTGCUGACAAACACCACGU	1358	947-969
AD-1634426	GUGGAGUUUUGUCAGUAAAGAU	1264	949-969	AUCUTUACUGACAAACUCCACGU	1359	947-969
AD-1634427	GUGCUGUUUUGUCAGUAAAGAU	1265	949-969	AUCUTUACUGACAAACAGCACGU	1360	947-969
AD-1634428	GUGUUGUUUUGUCAGUAAAGAU	1266	949-969	AUCUTUACUGACAAACAACACGU	1361	947-969
AD-1634429	GUCGUGUUUUGUCAGUAAAGAU	1267	949-969	AUCUTUACUGACAAACACGACGU	1362	947-969
AD-1634430	GUUGUGUUUUGUCAGUAAAGAU	1268	949-969	AUCUTUACUGACAAACAACAACGU	1363	947-969
AD-1634431	GUGGAGUUUUGUCAGUAAAGAU	1264	949-969	AUCTUTGCUGACAAACUCCACGU	1364	947-969
AD-1634432	GUGCUGUUUUGUCAGUAAAGAU	1265	949-969	AUCTUTGCUGACAAACAGCACGU	1365	947-969
AD-1634433	GUGUUGUUUUGUCAGUAAAGAU	1266	949-969	AUCTUTGCUGACAAACAACAACGU	1366	947-969
AD-1634434	GUCGUGUUUUGUCAGUAAAGAU	1267	949-969	AUCTUTGCUGACAAACACGACGU	1367	947-969
AD-1634435	GUUGUGUUUUGUCAGUAAAGAU	1268	949-969	AUCTUTGCUGACAAACAACAACGU	1368	947-969
AD-1634436	GAAGAGAGCAGAUCCUGUGU	54	526-546	ACACAGGAUCUGCUUCUUCUCCU	1369	524-546
AD-1634437	GAAGAGAGCAGAUCCUGUGU	54	526-546	ACACAGGAUCUGCUUCUUCUCCU	1369	524-546

Table 11. Modified Sense and Antisense Strand Sequences of KHK dsRNA

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Antisense Sequence 5' to 3'	SEQ ID NO:	mRNA Target Sequence	SEQ ID NO:
AD-1290969	ascseuacAfaUfGfCfucegucagauL96	1370	asAfsugaCfaggagcaUfuGfaaggsgsu	780	ACACCUUCAAUGCCUCCGUCAU	1004
AD-1423310	ususugagAfaGfGfUfugaucugacuL96	1153	asGfsuedAg(Agn)ucaaccUfuCfuaaasgsu	1154	ACUUUGAGAAAGGUUGAUCUGAC	968
AD-1423311	gsasegugGfuGfUfUfugucagcauL96	670	asUfsugdCu(G2p)acaacAfcCfagucsu	1155	GAGACGUGGUGUUUGUCAGCAA	1118
AD-1423312	usgscaggAfaGfCfAfcugagauuL96	563	asGfsaadTc(Tgn)cagugeUfuCfuegcascsg	1156	CGUGCAGGAAGCACUCUGAGAUUC	1011
AD-1423317	csusuugaGfaAfGfGfugaucugauL96	519	asUfscadGa(Tgn)caaccUfuUfcaaaagsuc	1161	GACUUUGAGAAAGGUUGAUCUGA	967
AD-1423319	gsascuuuGfaGfAfaGfugaucuuL96	518	asAfsgadTc(Agn)accuuUfuAfaagucsu	1163	CAGACUUUGAGAAAGGUUGAUCU	966
AD-1423323	csasaugcCfuCfCfGfucaucuL96	559	asUfsgadAg(Agn)ugacggAfgGfcauugsas	1167	UUCAAUAGCCUCCGUCUUCUUA	1007
AD-1423327	asasgguuGfaUfCfUfgaccaguuL96	521	asAfsadTg(G2p)gucagaUfuAfaaccuucs	1171	AGAAAGGUUGAUCUGACCCAGUU	969
AD-1423329	gsasagagAfaGfCfAfgaucugugL96	502	asCfsadAg(G2p)aucugUfuCfucuuucs	1173	UGGAAGAGAAAGCAGAUCCUGUG	950
AD-1423330	gsusguuuGfuCfAfgfcaagauL96	543	asAfsadTc(Tgn)uugcugAfcAfaacacscsa	1174	UGGUGUUUGUCAGCAAAGAUUG	991
AD-1423333	gsusggugUfuUfGfUfcagcaagauL96	468	asUfscudTu(G2p)cugacaAfaCfaccacsgsu	1193	ACGUGGUGUUUGUCAGCAAAGA	916
AD-1423334	cscsucanGfgAfaGfagagcagauL96	498	asUfscudGc(Tgn)ucuuUfuCfAfaaggsu	1177	AGCCUCAUGGAAGAGAAAGCAGA	946
AD-1423336	gsusucaaGfuGfGfAfuaccaguuL96	655	asCfsaadTg(Tgn)ggauccAfcUfugaacsu	1179	CAGUUCAAAGUGGAUCCACAUUG	1103
AD-1523180	cscsucanGfgAfaGfagagcagauL96	498	asUfscudGedTucuuUfuCfAfaaggsu	1197	AGCCUCAUGGAAGAGAAAGCAGA	946
AD-1548743	usgsguugUfuGfUfCfagcaagauL96	541	asAfsuedTu(Tgn)gucagAfaAfaaccacsg	1482	CGUGGUGUUUGUCAGCAAAGAU	989
AD-1612957	gsescuacugGfaAfaGfagagcagauL96	1371	asdCsugdCudTcucudTcCfaugaggsusa	1483	UAGCCUCAUGGAAGAGAAAGCAG	1619

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Antisense Sequence 5' to 3'	SEQ ID NO:	mRNA Target Sequence	SEQ ID NO:
AD-1612958	cscscauaggAfAfGfagaagcagauL96	1372	asdTscudGedTucudTuCfcaugaggscsu	1484	AGCCUCAUGGAAGAGAAAGCAGA U	946
AD-1612963	usgsaagagAfAfGfagaucucguL96	1373	asdCsagdGadTcugdTuCfucuccasug	1485	CAUGGAAGAGAAAGCAGAUCCUG U	1620
AD-1612967	asgsaagagAfAfGfagaucucguL96	1374	asdCsagdGadTcugdTuCfucuccasuc	1486	GAAGAGAAAGCAGAUCCUGUGCG U	1621
AD-1612969	asgsaagagAfAfGfagaucucguL96	1375	asdCsagdGadTcugdTuCfucuccasuc	1487	AGAGAAAGCAGAUCCUGUGCGUG G	1622
AD-1612970	gsasagcagaUfCfCfugugcugguL96	1376	asdCsagdGadTcugdTuCfucuccasuc	1488	GAGAAAGCAGAUCCUGUGCGUGG G	1623
AD-1613059	csasgacuuGfAfGfagaagguauL96	1377	asdAsudAadCcuudTcAfaagucugsusa	1489	UACAGACUUUGAGAAAGGUUGAU C	964
AD-1613060	asgsaagagAfAfGfagaagguauL96	1378	asdGsaudCadAccuudCuCfaagucugsusu	1490	ACAGACUUUGAGAAAGGUUGAUC U	965
AD-1613062	ascsuuugagAfAfGfagaagguauL96	1379	asdCsagdAadCaacdTuCfcaaaagucsu	1491	AGACUUUGAGAAAGGUUGAUCUG A	1109
AD-1613070	asasgguuGfAfGfagaagguauL96	1380	asdAsacdTgdGgucadGaUfcaaacuucsu	1492	AGAAGGUUGAUCUGACCCAGUU C	969
AD-1613073	gsusgacuuGfAfGfagaagguauL96	1381	asdTsugdAadCugggdTcAfgaacaacscsu	1493	AGGUUGAUCUGACCCAGUUCAA G	970
AD-1613074	ususgacuuGfAfGfagaagguauL96	1382	asdCsudGadAcuggdTuCfagaacaacsc	1494	GGUUGAUCUGACCCAGUUCAAAG U	971
AD-1613075	usgsaagagAfAfGfagaagguauL96	1383	asdAsudTgdAacugdTcUfcaagucasu	1495	GUUGAUCUGACCCAGUUCAAAGU G	972
AD-1613076	gsasucugacCfCfAfguucagguL96	1384	asdCsacdTudGaacdGgUfcaagucasu	1496	UUGAUCUGACCCAGUUCAAAGUG G	973
AD-1613077	asusgacuuGfAfGfagaagguauL96	1385	asdCsacdTudGaacdGgUfcaagucasu	1497	UGAUCUGACCCAGUUCAAAGUGG A	1624
AD-1613079	csusgacuuGfAfGfagaagguauL96	1386	asdAsudCadCuugadAcUfgggucagusu	1498	AUCUGACCCAGUUCAAAGUGG C	974
AD-1613088	ususgacuuGfAfGfagaagguauL96	1387	asdTsacdAadGuggdTcCfcaagucasu	1499	AGUUGAAGUGGAGUCCACAUUGA G	978
AD-1613089	uscsaaguuGfAfGfagaagguauL96	1388	asdCsudAadTguggdTuCfcaagucasu	1500	GUUUGAAGUGGAGUCCACAUUGAG G	979
AD-1613090	csasgacuuGfAfGfagaagguauL96	1389	asdCsudCadAuggdGaUfcaagucasu	1501	UUCAGUGGAGUCCACAUUGAGG G	980

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Antisense Sequence 5' to 3'	SEQ ID NO:	mRNA Target Sequence	SEQ ID NO:
1613090					G	
AD-1613091	asasguggaucfCfAfcauugaggguL96	1390	asdCscdTcdAaugdGgAfuccacuusgsa	1502	UCAAAGUGGAUCCACAUGAGGG	1625
AD-1613094	usgsauccaCfAfUfugaggccguL96	1391	asdCsggdCcdCucadTgUfggaucacsu	1503	AGUGGAUCCACAUGAGGGCCG	1626
AD-1613095	gsauccacAfUfUfgaggccguL96	1392	asdCscgdGcdCucadAuGfuggaucacs	1504	GUGGAUCCACAUGAGGGCCG	1627
AD-1613237	gsuuugguAfCfGfagagggguL96	1393	asdCscadCgdTcuacdGuAfgecaacsag	1505	CUGUUUGGCUACGGAGACGUGG	1628
AD-1613238	usuuugguAfCfGfagagggguL96	1394	asdAcsdAcdGuacdCgUfagcaacsca	1506	UGUUUGGCUACGGAGACGUGGU	1629
AD-1613239	usuuugguAfCfGfagagggguL96	1395	asdCsacdCadCguacdCcGfuagcaacs	1507	GUUUGGCUACGGAGACGUGGUG	1630
AD-1613240	usgsuacgGfAfGfagagggguL96	1396	asdAscadCcdAeugdTcCfugagcaasa	1508	UUUGGCUACGGAGACGUGGUGU	1631
AD-1613241	gsuacggAfGfAfegugguuuL96	1397	asdAsacdAcdCagudCuCfegagccsa	1509	UUGGCUACGGAGACGUGGUGUU	1632
AD-1613242	gsuacggAfCfGfugguuuuuL96	1398	asdAasadCadCcaegdTcUfegagccsa	1510	UGGCUACGGAGACGUGGUGUUU	1138
AD-1613243	csuacggAfCfGfugguuuuuL96	1399	asdCsacdAcdAccadGuCfuecgagccsc	1511	GGCUACGGAGACGUGGUGUUUG	985
AD-1613244	usaseggagAfCfGfugguuuuuL96	1400	asdAscadAadCaccadCgUfuecgagccsc	1512	GGCUACGGAGACGUGGUGUUUG	986
AD-1613245	ascsggagAfCfGfugguuuuuL96	1401	asdGscadAadAcacedAcGfueccgusag	1513	CUACGGAGACGUGGUGUUUGUC	1128
AD-1613246	csuagagAfCfGfugguuuuuL96	1402	asdTsgadCadAacacdCaCfueccgusag	1514	UACGGAGACGUGGUGUUUGUCA	987
AD-1613247	gsuagagAfCfGfugguuuuuL96	1403	asdCsugdAcdAaacadCcAfegueccgsu	1515	ACGGAGACGUGGUGUUUGUCAG	988
AD-1613254	usgsuuguuGfUfCfagcaagaauL96	1404	asdAsuedTudTgcugdAcAfaacaccscg	1516	CGUGGUGUUUGUCAGCAAGAU	989
AD-1613255	gsuuguuGfUfCfAfcaagaauL96	1405	asdCsaudCudTugudGaCfaaacaccsc	1517	GUGGUGUUUGUCAGCAAGAU	990
AD-1613256	gsuuguuGfUfCfAfcaagaauL96	1406	asdAscadTcdTugudTgAfaaacaccsc	1518	UGGUGUUUGUCAGCAAGAU	991

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Antisense Sequence 5' to 3'	SEQ ID NO:	mRNA Target Sequence	SEQ ID NO:
AD-1613257	usgsuunugucAfGfCfaagaugugul96	1407	asdCsacdAudCuunugdCuGfacaacascsc	1519	GGUUUUUGUCAGCAAAAGAUGUG	992
AD-1613258	gsusuunugcaGfCfAfaagaugugul96	1408	asdCsacdCadTcuunudGcUfgacaacsasc	1520	GUGUUUUUGUCAGCAAAAGAUGUGG	993
AD-1613259	ususuugucagCfAfAfagaugugugul96	1409	asdGscddAcdAucnuuTgCfugacaacsca	1521	UGUUUUUGUCAGCAAAAGAUGUGGC	994
AD-1613361	asgsucugagAfCfAfccuucuuagul96	1410	asdCsaudTgdAaggudGuCfuccagcuscsc	1522	GGAGCUGGAGACACCUUCAAUG	1001
AD-1613362	gscsuugagaCfAfCfcuucuuagul96	1411	asdGscadTudGaaggdTgUfuccagcusc	1523	GAGCUGGAGACACCUUCAAUGC	1633
AD-1613363	csusggagacAfCfCfuucuuagccul96	1412	asdGsgcdAudTgaagdGuGfuccagcscsu	1524	AGCUGGAGACACCUUCAAUGCC	1002
AD-1613369	ascaccuucAfAfUfgccuccgucul96	1413	asdGsacdGgdAggcadTuGfaaggugscsu	1525	AGACACCUUCAAUGCCUCCGUC	1634
AD-1613370	csascuucAfUfGfccuccgucul96	1414	asdTsgadCgdGaggcdAuUfgaaggugscsu	1526	GACACCUUCAAUGCCUCCGUC	1635
AD-1613371	ascscuucAfUfGfccuccgucanuL96	1415	asdAsugdAcdGgaggdCaUfugaaggugsu	1527	ACACCUUCAAUGCCUCCGUC	1004
AD-1613374	ususcuaugCfUfCfcuucuuuL96	1416	asdAsagdAudGacggdAgGfcauugaasg	1528	CCUCAAUGCCUCCGUC	1006
AD-1613377	asasugccucCfGfUfcauucuuL96	1417	asdCsugdAadGaugadCgGfaggcauugsa	1529	UCAAUGCCUCCGUC	1008
AD-1613378	asusgcuucGfUfCfauucuuL96	1418	asdGscudGadAgaugdAcGfaggcauug	1530	CAAUGCCUCCGUC	1636
AD-1613395	asgscgugcaGfGfAfagcacugagul96	1419	asdCsucdAgdTgcuudCcUfgcacguscsc	1531	GGAGCGUGCAGGAAGCACUGAG	1637
AD-1613400	gscsaggaagCfAfCfugagaauugul96	1420	asdCsagdAudCucagdTgCfuuccgcsasc	1532	GUGCAGGAAGCACUGAGAUUCG	1012
AD-1613401	csasggaagCfCfUfagagaauugul96	1421	asdCscgdAadTcucadGuGfuccuugscsa	1533	UGCAGGAAGCACUGAGAUUCGG	1638
AD-1634353	usasgcuCfAfUfGfGfaagagaagul96	1422	asGfscdTc(Tgn)cuuccaUfgAfggcuascu	1534	AGUAGCCUCAUGGAAGAGAGAGC	1639
AD-1634354	gscseucaUfgGfAfafagaagcagul96	1423	asCfsugdCu(Tgn)cuuccCfaUfgaggcsus	1535	UAGCCUCAUGGAAGAGAGAGCAG	1619
AD-	csasuggaAfGfAfGfagcagaucul96	1424	asGfsgdTc(Tgn)gcnuuCuUfccaugsag	1536	CUCAUGGAAGAGAGAGAGAUCC	1640

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Antisense Sequence 5' to 3'	SEQ ID NO:	mRNA Target Sequence	SEQ ID NO:
1634355					U	
AD-1634356	gsgsaagaGfaAfGfCfagaucuccuL96	501	asAfscadGg(Agn)ucugcuUfcUfcuuccsas	1537	AUGGAAGAGAGCAGAUCCUGU	949
AD-1634357	asgsaagaGfcAfGfAfuccugugcgL96	1425	asCfsgcdAc(Agn)ggauCuGfcUfucucusus	1538	GAAGAGAAAGCAGAUCCUGUGCG	1621
AD-1634358	asgsaacuuUfgAfGfAfagguuGaucuL96	517	asGfsaudCa(Agn)ccuucuCfaAfagucugs	1539	ACAGACUUUGAGAAAGGUUGAUC	965
AD-1634359	usgsaagaGfgUfUfGfaucugaccuL96	1426	asGfsggdTc(Agn)gaucuaCfcUfucucasasa	1540	UUUGAGAAAGGUUGAUCUGACCCC	1641
AD-1634360	asgsaaggUfuGfAfUfucugaccagL96	1427	asCfsugdGg(Tgn)cagaucAfaCfcuucscsa	1541	UGAGAAAGGUUGAUCUGACCCCAG	1642
AD-1634361	gsgsuugaUfcUfGfAfccagguuL96	687	asUfsgadAc(Tgn)ggguCaGfaUfcaaccsus	1542	AAGGUUGAUCUGACCCCAGUUA	1135
AD-1634362	usgsaucuGfaCfCfCfaguucaagL96	524	asAfscudTg(Agn)acugggUfcAfgaucasas	1543	GUUGAUCUGACCCCAGUUAAGU	972
AD-1634363	uscsugacCfcAfGfUfucaguggaL96	1428	asUfscdAc(Tgn)ugaacuGfgGfucagasus	1544	GAUCUGACCCCAGUUAAGUGGA	1643
AD-1634364	usgsaaccAfgUfUfCfaaguggaucL96	1429	asGfsaudCc(Agn)cuugaaCfuGfggucasgs	1545	UCUGACCCCAGUUAAGUGGAUC	1644
AD-1634365	csccscaguUfcAfAfGfuggaucacL96	1430	asGfsugdGa(Tgn)ccacuGfaAfucgggsus	1546	GACCCAGUUAAGUGGAUCCAC	1645
AD-1634366	csccsaguCfaAfGfUfugaucacacL96	528	asUfsgudGg(Agn)uccacuUfgAfacugggs	1547	ACCCAGUUAAGUGGAUCCACA	976
AD-1634367	gsusggaucCfcAfCfAfugagggccuL96	1431	asGfsgcdCc(Tgn)caaugUfgAfuccacsus	1548	AAGUGGAUCCACAUGAGGGCC	1646
AD-1634368	asgsaaguGfgUfGfUfugucagcauL96	1432	asUfsgcdTg(Agn)caacaCfcAfegucscsc	1549	GGAGACGUGGUUUUGUCAGCA	1647
AD-1634369	ascsugugUfgUfUfUfugacagcauL96	469	asUfsuudGc(Tgn)gacaaaCfaCfcacgscsu	1550	AGACGUGGUUUUGUCAGCAAA	917
AD-1634370	usususucAfgCfAfafagugggcuL96	546	asGfscdAc(Agn)ucuuuGfuGfacaasas	1551	UGUUUGUCAGCAAAAGAUUGGC	994
AD-1634371	usgsucagCfaAfAfGfuguggccuL96	1433	asUfsggdCc(Agn)caucuUfgCfugacasas	1552	UUUGUCAGCAAAAGAUUGGGCCA	1648
AD-1634372	gscsaagaAfuGfUfGfcccagcacuL96	1434	asGfsugdCu(Tgn)ggccacAfuCfuugcsus	1553	CAGCAAAAGAUUGGGCCAAGCAC	1649

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Antisense Sequence 5' to 3'	SEQ ID NO:	mRNA Target Sequence	SEQ ID NO:
AD-1634373	csusggagAfeAfcCfcfucaaugccuL96	554	asGfsgdAu(Tgn)gaagguGfuCfuceagsgs u	1554	AGCUGGAGACACCUUCA AUGCC U	1002
AD-1634374	usgsaggAcfAfcCfcfucaaugccuL96	555	asAfsaggdCa(Tgn)ugaaggUfgUfuceagsgs c	1555	GCUGGAGACACCUUCA AUGCCU C	1003
AD-1634375	gsgsagacAfeCfcUfufcaaugccuL96	1435	asGfsagdGc(Agn)uugaagGfuGfucuccsas g	1556	CUGGAGACACCUUCA AUGCCUC C	1650
AD-1634376	ascsaccuUfeAfaUfGCCUccguL96	1436	asGfsacdGg(Agn)ggcauuGfaAfgguguscs u	1557	AGACACCUUCA AUGCCUCCGUC A	1634
AD-1634377	csusucAAUfgCfcUfGCCUcauuL96	1437	asAfsagdTg(Agn)cggaggCfaUfugaagsgs u	1558	ACCUUCA AUGCCUCCGUC AU CU U	1651
AD-1634378	uscsaaagCfcUfCfcfucauuL96	671	asGfsaadGa(Tgn)gacgggGfgCfaauugasas g	1559	CUUCA AUGCCUCCGUC AU CU A	1119
AD-1634379	asusgccuCfcGfuCfcauuL96	1438	asGfiscudGa(Agn)gaugacGfgAfggcausus g	1560	CAAUGCCUCCGUC AU CU UUCAGC C	1636
AD-1634380	usgsccuCfcUfCfAfucauuL96	1439	asGfsgdTg(Agn)agaugaCfgGfaggcasus u	1561	AAUGCCUCCGUC AU CU UUCAGCC U	1652
AD-1634381	cscsuecgUfcAfUfCfucauuL96	1440	asGfsagdTg(Tgn)gaagauGfaCfaggagsgs a	1562	UGCCUCCGUC AU CU UUCAGCCUC U	1653
AD-1634382	gsasggagCfcUfGfCfaggagcauL96	1441	asGfsugdCu(Tgn)ccugcaCfcCfuccucscsc c	1563	GGGAGGAGCGUGCAGGAAGCAC U	1654
AD-1634383	asgsaggCfcUfGfCfaggagcauL96	1442	asAfsugdGc(Tgn)uccugcAfcGfuccucscs c	1564	GGAGGAGCGUGCAGGAAGCACU G	1655
AD-1634384	asgsccugCfaGfGfAfgcauL96	1443	asCfsudAg(Tgn)gcuuccUfgCfaccucscsc u	1565	GGAGCGUGCAGGAAGCACUGAG A	1637
AD-1634385	csgsugcaGfgAfAfgfcauL96	1444	asAfsudTc(Agn)gugcuCfcUfgcaagsgs u	1566	AGCGUGCAGGAAGCACUGAGAU U	1656
AD-1634386	csusucAAUfGfCfuccuL96	1445	asdAsugdAcdGaggdCaUfugaagsgsu	1567	ACCUUCA AUGCCUCCGUC AU C C	1657
AD-1634387	ascscuacAAUfGfCfuccuL96	1446	asdAsugdAcdGaggdCaUfugaagsgsu	1568	ACACCUUCA AUGCCUCCGUC AU C C	1004
AD-1634388	ascscuacAAUfGfCfuccuL96	1447	asdAsugdAcdGaggdCaUfugaagsgsu	1569	ACACCUUCA AUGCCUCCGUC AU C C	1004
AD-1634389	ascsguacAAUfGfCfuccuL96	1448	asdAsugdAcdGaggdCaUfugaagsgsu	1570	ACACCUUCA AUGCCUCCGUC AU C C	1004
AD-1634390	ascsaucAAUfGfCfuccuL96	1449	asdAsugdAcdGaggdCaUfugaagsgsu	1571	ACACCUUCA AUGCCUCCGUC AU C C	1004

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Antisense Sequence 5' to 3'	SEQ ID NO:	mRNA Target Sequence	SEQ ID NO:
1634390					C	
AD-1634391	csusucAfaUfGfCfuccgucanuL96	1450	asAfsugaCfggagggaUfuGfaagsgsu	1572	ACCUUCAAUGCCUCCGUCAC	1657
AD-1634392	ascscuacAfaUfGfCfuccgucanuL96	1451	asAfsugaCfggagggaUfuGfuaggsgsu	1573	ACACCUUCAAUGCCUCCGUCAC	1004
AD-1634393	ascseaucAfaUfGfCfuccgucanuL96	1452	asAfsugaCfggagggaUfuGfauggsgsu	1574	ACACCUUCAAUGCCUCCGUCAC	1004
AD-1634394	ascsguucAfaUfGfCfuccgucanuL96	1453	asAfsugaCfggagggaUfuGfaacgsgsu	1575	ACACCUUCAAUGCCUCCGUCAC	1004
AD-1634395	ascsaucAfaUfGfCfuccgucanuL96	1454	asAfsugaCfggagggaUfuGfaaugsgsu	1576	ACACCUUCAAUGCCUCCGUCAC	1004
AD-1634396	gsusueaaguGfGfAfuccacauuL96	1455	asdCsaadTg(Tgn)ggandCcAfcUfugaacsu	1577	CAGUUCAAAGUGGAUCCACAUUG	1103
AD-1634397	gsusueaaguGfGfAfuccacauuL96	1455	asdCsaadTg(Tgn)ggandCcAfcUfugaacsu	1578	CAGUUCAAAGUGGAUCCACAUUG	1103
AD-1634398	gsusueaGfuGfGfAfuccacauuL96	1456	asCfsaadTg(Tgn)ggauccAfcUfagaacsug	1579	CAGUUCAAAGUGGAUCCACAUUG	1103
AD-1634399	gsusugaaGfuGfGfAfuccacauuL96	1457	asCfsaadTg(Tgn)ggauccAfcUfugaacsug	1580	CAGUUCAAAGUGGAUCCACAUUG	1103
AD-1634400	gsusuaaaGfuGfGfAfuccacauuL96	1458	asCfsaadTg(Tgn)ggauccAfcUfuaaacsug	1581	CAGUUCAAAGUGGAUCCACAUUG	1103
AD-1634401	gsusacaaGfuGfGfAfuccacauuL96	1459	asCfsaadTg(Tgn)ggauccAfcUfuguacsug	1582	CAGUUCAAAGUGGAUCCACAUUG	1103
AD-1634402	asasguuugaUfCfUfGaccuaguuuL96	1460	asdAsaadTadGgucadGaUfcaacuuu	1583	AGAAGGUUGAUCUGACCCAGUU	969
AD-1634403	asasguuugaUfCfUfGaccuaguuuL96	1461	asdAsaadTadAgucadGaUfcaacuuu	1584	AGAAGGUUGAUCUGACCCAGUU	969
AD-1634404	asasguuugaUfCfUfGaccuaguuuL96	1462	asdAsaadTadGgucadGaUfcaacuuu	1585	AGAAGGUUGAUCUGACCCAGUU	969
AD-1634405	asasguuugaUfCfUfGaccuaguuuL96	1463	asdAsaadTadGgucadGaUfcaacuuu	1586	AGAAGGUUGAUCUGACCCAGUU	969
AD-1634406	asasguuugaUfCfUfGaccuaguuuL96	1464	asdAsaadTadAgucadGaUfcaacuuu	1587	AGAAGGUUGAUCUGACCCAGUU	969
AD-1634407	asasguuugaUfCfUfGaccuaguuuL96	1465	asdAsaadTadAgucadGaUfcaacuuu	1588	AGAAGGUUGAUCUGACCCAGUU	969

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Antisense Sequence 5' to 3'	SEQ ID NO:	mRNA Target Sequence	SEQ ID NO:
AD-1634408	usgsuuuUfuGfUfCfagcaaaagauL96	1466	asAfsudTu(Tgn)gcugacAfaAfaaccascg	1589	CGUGGUGUUUGUCAGCAAAAGAU G	989
AD-1634409	usgsuenuUfuGfUfCfagcaaaagauL96	1467	asAfsudTu(Tgn)gcugacAfaAfgaccascg	1590	CGUGGUGUUUGUCAGCAAAAGAU G	989
AD-1634410	usgsaguUfuGfUfCfagcaaaagauL96	1468	asAfsudTu(Tgn)gcugacAfaAfcuaccascg	1591	CGUGGUGUUUGUCAGCAAAAGAU G	989
AD-1634411	usgsuuguUfuGfUfCfagcaaaagauL96	1469	asAfsudTu(Tgn)gcugacAfaAfcacacascg	1592	CGUGGUGUUUGUCAGCAAAAGAU G	989
AD-1634412	usgsuenuUfuGfUfCfagcaaaagauL96	1470	asAfsudTu(Tgn)gcugacAfaAfcagcascg	1593	CGUGGUGUUUGUCAGCAAAAGAU G	989
AD-1634413	usgsuguUfuGfUfCfagcaaaagauL96	541	asAfsudTu(Tgn)gcugacAfaAfcaccascu	1594	CGUGGUGUUUGUCAGCAAAAGAU G	989
AD-1634414	usgsuguuuGfUfCfagcaaaagauL96	1404	asdAsudTu(Tgn)gcugdAcAfaAfcaccascg	1595	CGUGGUGUUUGUCAGCAAAAGAU G	989
AD-1634415	cscsucauggAfAfGfagaucaagauL96	1471	asdTscudGadTucuedTuCfcauagaggscsu	1596	AGCCUCAUGGAAAGAGAAAGCAGA U	946
AD-1634416	cscsucuuuggAfAfGfagaucaagauL96	1472	asdTscudGadTucuedTuCfcaagaggscsu	1597	AGCCUCAUGGAAAGAGAAAGCAGA U	946
AD-1634417	cscsuauuggAfAfGfagaucaagauL96	1473	asdTscudGadTucuedTuCfcaucaggscsu	1598	AGCCUCAUGGAAAGAGAAAGCAGA U	946
AD-1634418	cscsuauuggAfAfGfagaucaagauL96	1474	asdTscudGadTucuedTuCfcauuaggscsu	1599	AGCCUCAUGGAAAGAGAAAGCAGA U	946
AD-1634419	cscsacauuggAfAfGfagaucaagauL96	1475	asdTscudGadTucuedTuCfcauaggscsu	1600	AGCCUCAUGGAAAGAGAAAGCAGA U	946
AD-1634420	gsascguuGfuGfUfUfugcagcaauL96	670	asUfsugdCudGacaaacAfcCfagcucsuc	1601	GAGACGUGGUGUUUGUCAGCAA A	1118
AD-1634421	gsascguuGfuGfUfUfugcagcaauL96	670	asUfsudGc(Tgn)gacaaacAfcCfagcucsuc	1602	GAGACGUGGUGUUUGUCAGCAA A	1118
AD-1634422	gsascguuGfuGfUfUfugcagcaauL96	670	asUfsugdTG(Agn)caaacAfcCfagcucsuc	1603	GAGACGUGGUGUUUGUCAGCAA A	1118
AD-1634423	gsusggguUfuUfGfUfcagcaaaagauL96	468	asUfscudTudGeugacaAfaCfaccacsgsu	1604	ACGUGGUGUUUGUCAGCAAAAGA U	916
AD-1634424	gsusggguUfuUfGfUfcaguaaaagauL96	1476	asUfscudTudAcugacaAfaCfaccacsgsu	1605	ACGUGGUGUUUGUCAGCAAAAGA U	916
AD-	gsusggguUfuUfGfUfcagcaaaagauL96	468	asUfscdTu(Tgn)gcugacaAfaCfaceacsgsu	1606	ACGUGGUGUUUGUCAGCAAAAGA	916

Duplex Name	Sense Sequence 5' to 3'	SEQ ID NO:	Antisense Sequence 5' to 3'	SEQ ID NO:	mRNA Target Sequence	SEQ ID NO:
1634425					U	
AD-1634426	gsusggagUfuUfGfUfcaguaaagauL96	1477	asUfscudTudAcugacaAfaCfuaccacsgsu	1607	ACGUGGUGUUUGUCAGCAAAAGA	916
AD-1634427	gsusgcugUfuUfGfUfcaguaaagauL96	1478	asUfscudTudAcugacaAfaCfagcacsgsu	1608	ACGUGGUGUUUGUCAGCAAAAGA	916
AD-1634428	gsusguugUfuUfGfUfcaguaaagauL96	1479	asUfscudTudAcugacaAfaCfaacacsgsu	1609	ACGUGGUGUUUGUCAGCAAAAGA	916
AD-1634429	gsuscgugUfuUfGfUfcaguaaagauL96	1480	asUfscudTudAcugacaAfaCfacgacsgsu	1610	ACGUGGUGUUUGUCAGCAAAAGA	916
AD-1634430	gsusugugUfuUfGfUfcaguaaagauL96	1481	asUfscudTudAcugacaAfaCfacaacsgsu	1611	ACGUGGUGUUUGUCAGCAAAAGA	916
AD-1634431	gsusggagUfuUfGfUfcaguaaagauL96	1477	asUfscdTtu(Tgn)gcugacaAfaCfuaccacsgsu	1612	ACGUGGUGUUUGUCAGCAAAAGA	916
AD-1634432	gsusgcugUfuUfGfUfcaguaaagauL96	1478	asUfscdTtu(Tgn)gcugacaAfaCfagcacsgsu	1613	ACGUGGUGUUUGUCAGCAAAAGA	916
AD-1634433	gsusguugUfuUfGfUfcaguaaagauL96	1479	asUfscdTtu(Tgn)gcugacaAfaCfaacacsgsu	1614	ACGUGGUGUUUGUCAGCAAAAGA	916
AD-1634434	gsuscgugUfuUfGfUfcaguaaagauL96	1480	asUfscdTtu(Tgn)gcugacaAfaCfacgacsgsu	1615	ACGUGGUGUUUGUCAGCAAAAGA	916
AD-1634435	gsusugugUfuUfGfUfcaguaaagauL96	1481	asUfscdTtu(Tgn)gcugacaAfaCfacaacsgsu	1616	ACGUGGUGUUUGUCAGCAAAAGA	916
AD-1634436	gsasagagAfaGfCfAfgauceugugL96	502	asdCsacdAgdGaucudGeUfucucucscsu	1617	UGGAAGAGAAAGCAGAUCCUGUG	950
AD-1634437	gsasagagAfaGfCfAfgauceugugL96	502	asCfsacadGg(Agn)ueugcUfuCfucucscsu	1618	UGGAAGAGAAAGCAGAUCCUGUG	950

Example 5. Design, Synthesis and In Vitro Screening of Additional dsRNA Duplexes

Based on the *in vitro* analyses, structure-active relationship (SAR) analyses were performed. In particular, additional duplexes were designed, synthesized, and assayed.

siRNAs were designed, synthesized, and prepared using the methods described above. *In vitro* screening assays in Hep3B and PCH cells with these siRNAs were performed as described above.

Detailed lists of the unmodified KHK sense and antisense strand nucleotide sequences are shown in Table 12. Detailed lists of the modified KHK sense and antisense strand nucleotide sequences are shown in Table 13.

For transfections, cells (ATCC, Manassas, VA) were grown to near confluence at 37°C in an atmosphere of 5% CO₂ in Eagle's Minimum Essential Medium (Gibco) supplemented with 10% FBS (ATCC) before being released from the plate by trypsinization. Transfection was carried out by adding 7.5 µl of Opti-MEM plus 0.1 µl of Lipofectamine RNAiMax per well (Invitrogen, Carlsbad CA, cat # 13778-150) to 2.5 µl of each siRNA duplex to an individual well in a 384-well plate. The mixture was then incubated at room temperature for 15 minutes. Forty µl of complete growth media without antibiotic containing $\sim 1.5 \times 10^4$ cells were then added to the siRNA mixture. Cells were incubated for 24 hours prior to RNA purification. Single dose experiments were performed at 10, 1 and 0.1 nM final duplex concentration.

Total RNA isolation was performed using DYNABEADS. Briefly, cells were lysed in 10µl of Lysis/Binding Buffer containing 3 µL of beads per well and mixed for 10 minutes on an electrostatic shaker. The washing steps were automated on a Biotek EL406, using a magnetic plate support. Beads were washed (in 3µL) once in Buffer A, once in Buffer B, and twice in Buffer E, with aspiration steps in between. Following a final aspiration, complete 12µL RT mixture was added to each well, as described below.

For cDNA synthesis, a master mix of 1.5µl 10X Buffer, 0.6µl 10X dNTPs, 1.5µl Random primers, 0.75µl Reverse Transcriptase, 0.75µl RNase inhibitor and 9.9µl of H₂O per reaction were added per well. Plates were sealed, agitated for 10 minutes on an electrostatic shaker, and then incubated at 37 degrees C for 2 hours. Following this, the plates were agitated at 80 degrees C for 8 minutes.

RT-qPCR was performed as described above and relative fold change was calculated as described above. The results of the transfection assays of the dsRNA agents listed in Tables 12 and 13 in Hep3B cells are shown in Table 14. The results of the transfection assays of the dsRNA agents listed in Tables 12 and 13 in primary cynomolgus hepatocytes (PCH) are shown in Table 15.

For Dual-Glo® Luciferase assay, cells (ATCC, Manassas, VA) were grown to near confluence at 37°C in an atmosphere of 5% CO₂ in Eagle's Minimum Essential Medium (Gibco) supplemented with 10% FBS (ATCC) before being released from the plate by trypsinization. Dual-Glo® Luciferase constructs were generated in the psiCHECK2 plasmid containing the human KHK genomic sequence. Each dual-luciferase plasmid was co-transfected with siRNA (Tables 12 and 13)

into approximately 2×10^4 cells using Lipofectamine 2000 (Invitrogen, Carlsbad CA. cat # 11668-019). For each well of a 96 well plate, 0.5 μ l of Lipofectamine was added to 100 ng of plasmid vector and a single siRNA (Tables 12 and 13) in 14.8 μ l of Opti-MEM and allowed to complex at room temperature for 15 minutes. The mixture was then added to the cells which were resuspended in 80 μ l of fresh complete media. Cells were incubated for 24 hours before luciferase was measured. Single dose experiments were performed at 10, 1 and 0.1 nM final duplex concentration.

Forty-eight hours after the siRNAs were transfected, Firefly (transfection control) and Renilla (fused to KHK target sequence) luciferase were measured. First, media was removed from cells. Then Firefly luciferase activity was measured by adding 75 μ l of Dual-Glo® Luciferase Reagent equal to the culture medium volume to each well and mix. The mixture was incubated at room temperature for 30 minutes before luminescence (500 nm) was measured on a Spectramax (Molecular Devices) to detect the Firefly luciferase signal. Renilla luciferase activity was measured by adding 75 μ l of room temperature Dual-Glo® Stop & Glo® Reagent to each well and the plates were incubated for 10-15 minutes before luminescence was again measured to determine the Renilla luciferase signal. The Dual-Glo® Stop & Glo® Reagent, quenches the firefly luciferase signal and sustains luminescence for the Renilla luciferase reaction. siRNA activity was determined by normalizing the Renilla (KHK) signal to the Firefly (control) signal within each well. The magnitude of siRNA activity was then assessed relative to cells that were transfected with the same vector but were not treated with siRNA or were treated with a non-targeting siRNA. All transfections were done in quadruplicates.

Table 16 shows the Dual-Glo® Luciferase assay results of a single dose screen in cells transfected with the indicated agents in Tables 12 and 13.

Table 12. Unmodified Sense and Antisense Strand Sequences of KHK dsRNA

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Range in XM_017004061.1	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	Range in XM_017004061.1
AD-1290507.2	UUCUUCACUCUGUCAAAUGGAU	1658	2200-2220	AUCCAUUUUGACAGAUAGAAAGAAU	415	2198-2220
AD-1290509.2	GAUUA AAAUCUGCCAUUUAAU	167	2130-2150	AUUAAAUGGCAGAUUUUAAUCCA	391	2128-2150
AD-1290510.2	AAUUUCUUCACUCUGUCAAAUU	183	2197-2217	AAUUUGACAGAUAGAAAUUUGA	407	2195-2217
AD-1290514.2	CAAUUUCUUCACUCUGUCAAAU	182	2196-2216	AUUUGACAGAUAGAAAUUUGAG	406	2194-2216
AD-1290515.2	AGCCUUUAUAAUGUAAAAGAGU	158	2073-2093	ACUCUUUACAUUAUAAAGGCCUUA	382	2071-2093
AD-1290516.2	GGAUUA AAAUCUGCCAUUUAAU	192	2129-2149	AUAAAUGGCAGAUUUUAAUCCAG	416	2127-2149
AD-1290522.2	UCUGGAACACAUAAUUGGAUUU	149	2025-2045	AAUCCAAUAUGUGUUCAGAUUC	373	2023-2045
AD-1290523.2	GCCUCAAUUUCUUCACUCUGUU	181	2192-2212	AACAGAUAGAAAUUAGGCAG	405	2190-2212
AD-1290524.2	AUUUCUUCACUCUGUCAAAUGU	184	2198-2218	ACAUUUGACAGAUAGAAAUUUG	408	2196-2218
AD-1290527.2	UGGAUUA AAAUCUGCCAUUUU	193	2128-2148	AAAUGGCAGAUUUUAAUCCAGG	417	2126-2148
AD-1290528.2	CUGGAACACAUAAUUGGAUUU	150	2026-2046	AAAUUCCAAUAUGUGUUCAGAU	374	2024-2046
AD-1290531.2	CUGCCUCAAUUUCUUCACUCUU	179	2190-2210	AAGAUGAAGAAAUUGAGGCAGAU	403	2188-2210
AD-1290533.2	AAAUUCUGCCAUUUUAAUUAAGCU	169	2135-2155	AGCUAAUUAUAAUGGCAGAUUUUA	393	2133-2155
AD-1290535.2	AAUCUGCCAUUUUAAUUAAGCUU	170	2136-2156	AAGCUAAUUAUAAUGGCAGAUUUU	394	2134-2156
AD-1290539.5	CAGACUUUUGAGAAAGGUUGAUU	68	755-775	AAUCAACCUUCUCAAAGUCUGUA	292	753-775
AD-1290542.2	UCAAUUUUCUUCACUCUGUCAAU	194	2195-2215	AUUGACAGAUAGAAAUUUGAGG	418	2193-2215
AD-1290543.2	UGGAACACAUAAUUGGAUUUGU	151	2027-2047	ACAAUUCCAAUAUGUGUUCAGGA	375	2025-2047
AD-1290551.2	CUGGAUU AAAAUUCUGCCAUUU	166	2127-2147	AAAUUGGCAGAUUUUAAUCCAGGU	390	2125-2147
AD-1290552.2	UUUCUUCACUCUGUCAAAUGGU	195	2199-2219	ACCAUUUGACAGAUAGAAAGAAUU	419	2197-2219
AD-1290554.2	AUAUGUAAAGGGCUUUUAGAU	162	2096-2116	AUCUAAAGCCUUUACAUUAUUAU	386	2094-2116
AD-1290555.2	AUAUAAUGUAAAGGGCUUUUAU	161	2094-2114	AUAAAGCCCUUUACAUUAUUAUGC	385	2092-2114
AD-1290556.2	GCCUUUAUAUGUAAAGAGCAU	159	2075-2095	AUGCUCUUUACAUUAUAAAGGCCU	383	2073-2095
AD-1290557.2	GGCCUUUAUAUGUAAAGAGCU	196	2074-2094	AGCUCUUUACAUUAUAAAGGCCUU	420	2072-2094
AD-1290558.2	UAUAAUGUAAAGGGCUUUUAGU	197	2095-2115	ACUAAAGCCCUUUACAUUAUUAUG	421	2093-2115
AD-1290563.2	GUAAGGCCUUUAUAUGUAAAU	156	2070-2090	AUUUACAUUAUAAAGGCCUUACCC	380	2068-2090
AD-1290564.2	CCUCAAUUUUCUUCACUCUGUCU	199	2193-2213	AGACAGAUAGAAAUUUGAGGCA	423	2191-2213

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Range in XM_017004061.1	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	Range in XM_017004061.1
AD-1290565.2	CUCAAUUUCUUCACUCUGUCAU	200	2194-2214	AUGACAGAUAGAAAGAAUUGAGGC	424	2192-2214
AD-1290570.2	AAGGCCUUUAUAAUGUAAAGAU	157	2072-2092	AUCUUUACAUAUUAAGGCCUUAC	381	2070-2092
AD-1290573.2	AUCUGCCUCAAUUUCUUCAUU	177	2188-2208	AAUGAAAGAAUUGAGGCAGAUUG	401	2186-2208
AD-1290574.2	UAAGGCCUUUAUAAUGUAAAGU	201	2071-2091	ACUUUACAUAUUAAGGCCUUACC	425	2069-2091
AD-1290584.2	GUGUUUUGUCAGCAAGAUUGUU	95	952-972	AACAUCUUUGCUGACAAACACCA	319	950-972
AD-1290589.2	GGAACACAUUUUGGAUUUGGU	152	2028-2048	ACCAAUUCCAAUUAUGUGUUCAG	376	2026-2048
AD-1290592.2	CAUAUAUGUAAAGGCCUUUU	202	2093-2113	AAAGCCUUUACAUAUAUUGCU	426	2091-2113
AD-1290597.2	AUUAUUUUGUGCCAUUUAAUU	168	2131-2151	AAUUAAAUGGCAGAUUUAAUCC	392	2129-2151
AD-1290599.7	UGGUGUUUUGUCAGCAAGAUU	93	950-970	AAUCUUUUGCUGACAAACACACG	317	948-970
AD-1290600.2	GCUUGGCUACAGAAUUAUUUGU	190	2229-2249	ACAAUAAUUCUGUAGCCAAAGCAG	414	2227-2249
AD-1290602.2	UGCCUCAUUUCUUCACUCUGU	180	2191-2211	ACAGAUAGAAGAAUUGAGGCAGA	404	2189-2211
AD-1290604.2	AUCUGCCAUUUAAUUAAGCUGU	171	2137-2157	ACAGCUAAUUAUUAUGGCAGAUUU	395	2135-2157
AD-1290605.2	AAUCUGCCUCAUUUCUUCAUU	176	2187-2207	AUGAAGAAUUUGAGGCAGAUUUGC	400	2185-2207
AD-1290609.2	UGCCAUUUAAUUAGCUGCAUU	203	2140-2160	AAUGCAGCUAAUUAUUAUGGCAGA	427	2138-2160
AD-1290611.3	AGACUUUUGAGAAAGGUUGAUCU	69	756-776	AGAUCAAACCUUCUCAAAGUCUGU	293	754-776
AD-1290612.2	AUCUGGAACACAUUUUGGAAU	148	2024-2044	AUCCCAAUAUGUGUUCACAGAUUG	372	2022-2044
AD-1290615.2	UCUGCCUCAUUUCUUCACUCU	178	2189-2209	AGAUGAAGAAAUUGAGGCAGAUU	402	2187-2209
AD-1290618.2	AAUGUAAAGGCCUUUAGAGUU	164	2098-2118	AACUCUAAAGCCUUUACAUAU	388	2096-2118
AD-1290624.2	AUUUUUGAGGGAUAAAUCU	204	2242-2262	AGAUUUUAUCCUCACAAUAAUUC	428	2240-2262
AD-1290626.2	GGUAGGCCUUUAUUAUGUAAU	205	2069-2089	AUUACAUAUUAAGGCCUUUACCCA	429	2067-2089
AD-1290633.2	CUGCCAUUUAAUUAGCUGCAU	172	2139-2159	AUGCAGCUAAUUAUUAUGGCAGAU	396	2137-2159
AD-1290635.2	UUCUGCUUGGCUACAGAAUUU	206	2225-2245	AAUUCUGUAGCCAAAGCAGAAUU	430	2223-2245
AD-1290639.2	UAUUGUAAAGGCCUUUAGAGU	163	2097-2117	ACUCUAAAGCCUUUACAUAUA	387	2095-2117
AD-1290643.2	UGCUGGCUACAGAAUUAUUU	189	2228-2248	AAUAAUUCUGUAGCCAAAGCAGA	413	2226-2248
AD-1290650.2	CGCAAUCUGCCUCAUUUCUU	174	2184-2204	AAGAAAUUGAGGCAGAUUGCGUU	398	2182-2204
AD-1290651.2	GUUCAAGUGGAUCCACAUUGU	207	783-803	ACAAUGUGGAUCCACUUGAACUG	431	781-803
AD-1290654.2	GGGUAAGGCCUUUAUUAUGUUAU	208	2068-2088	AUACAUAUUAAGGCCUUUACCCAC	432	2066-2088

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Range in XM_017004061.1	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	Range in XM_017004061.1
AD-1290655.2	GAUCUGGAACACAUUUUGGAU	209	2023-2043	AUCCAAU AUGUGUUCCAGAUCCG	433	2021-2043
AD-1290659.2	CAAUUCUGCCUCAAUUUCUUCU	211	2186-2206	AGAAGAAUUGAGGCAGAUUGCG	435	2184-2206
AD-1290660.2	CCUGGAUUAAAUCUGCCAUAU	165	2126-2146	AAUGGCAGAUUUUAAUCCAGGUC	389	2124-2146
AD-1290661.2	GCAUAUAUGUAAAGGGCUUU	160	2092-2112	AAAGCCUUUACAUAUAUAGCUC	384	2090-2112
AD-1290666.2	ACUUUGAGAAAGGUUGAUCUGU	213	758-778	ACAGAUCAACCUUUCUCAAAGUCU	437	756-778
AD-1290670.2	UCCGAUCUGGAACACAUUUU	146	2020-2040	AAUAUUGUGUUCCAGAUCCGACC	370	2018-2040
AD-1290672.2	GCAUCUGCCUCAAUUUCUUCU	175	2185-2205	AAAGAAAUUGAGGCAGAUUGCGU	399	2183-2205
AD-1290681.2	UGGGUAAAGGCCUUUAAUUGUU	215	2067-2087	AACAUAUAAGGCCUUUACCCACC	439	2065-2087
AD-1290684.2	CGAUCUGGAACACAUUUUGGU	217	2022-2042	ACCAUAUUGUGUUCCAGAUCCGGA	441	2020-2042
AD-1290687.2	CUGCUUGGCUACAGAAUUAUU	188	2227-2247	AAUAUUUCUGUAGCCAAAGCAGAA	412	2225-2247
AD-1290702.2	UCUGCCAUAUUAAUAGCUGCU	218	2138-2158	AGCAGCUAAUUAUUGGCAGAUU	442	2136-2158
AD-1290712.2	CCGAUCUGGAACACAUUUUGU	147	2021-2041	ACAAUAUUGUUUCCAGAUCCGAC	371	2019-2041
AD-1290719.2	AUUCUGCUUGGCUACAGAAUU	186	2224-2244	AAUUCUGUAGCCAAAGCAGAAUUG	410	2222-2244
AD-1290722.2	UCUGCUUGGCUACAGAAUUAU	187	2226-2246	AUAAUUCUGUAGCCAAAGCAGAAU	411	2224-2246
AD-1290741.2	ACGCAAUUCUGCCUCAAUUUCU	173	2183-2203	AGAAAUUGAGGCAGAUUUGCGUUA	397	2181-2203
AD-1290742.2	GUGGGUAAAGGCCUUUAAUUGU	155	2066-2086	ACAUUAUAAGGCCUUUACCCACCC	379	2064-2086
AD-1290747.2	GGAGCCACCUUGGAAUUAUU	138	1941-1961	AUUAUUUCCAAAGGUGGGCUCCAA	362	1939-1961
AD-1290750.2	CCCAGUGAACCCUGCCAAAGAU	221	1706-1726	AUCUUUUGGCAGGUUCACUGGGUG	445	1704-1726
AD-1290755.2	GGUGGGUAAAGGCCUUUAAUUAU	154	2065-2085	AAUUAUAAGGCCUUUACCCACCCU	378	2063-2085
AD-1290763.2	GUCCGAUCUGGAACACAUUAU	145	2019-2039	AAUAUGUGUUCCAGAUCCGACCUC	369	2017-2039
AD-1290764.2	GGUCCGAUCUGGAACACAUUAU	144	2018-2038	AUAUGUGUUCCAGAUCCGACCUC	368	2016-2038
AD-1290796.2	UUGGAGCCACCUUGGAAUUAU	225	1939-1959	AAAUCCAAAGGUGGGCUCCAAAGG	449	1937-1959
AD-1290800.2	GGGUGGGUAAAGGCCUUUAAUUAU	153	2064-2084	AUUAUAAGGCCUUUACCCACCCUA	377	2062-2084
AD-1290805.2	UGGAGCCACCUUGGAAUUAUUAU	227	1940-1960	AUAAUUAAGGUGGGCUCCAAAG	451	1938-1960
AD-1290836.2	AAUUCUGCUUGGCUACAGAAU	185	2223-2243	AUUCUGUAGCCAAAGCAGAAUUGG	409	2221-2243
AD-1290837.5	UGAUCUGACCCAGUUAAGUU	76	771-791	AACUUGAACUGGGGUCAGAUCAAC	300	769-791
AD-1290841.2	AUUCACACAGCUCAGAAAGCUU	136	1767-1787	AAGCUUCUGAGCUGUGGGAAUAG	360	1765-1787

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Range in XM_017004061.1	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	Range in XM_017004061.1
AD-1290842.2	GAGCCACCCUUGGAAUUAAGU	139	1942-1962	ACUUAUUAUCCAAAGGUGGGCUCCA	363	1940-1962
AD-1290857.2	UGCCCCACAGCCUGUGAUUUU	229	1852-1872	AAAUAACACAGGUGGUGGGCAGG	453	1850-1872
AD-1290865.2	CUGCGUUGUGCAGACUCUAUU	130	1749-1769	AAUAGAGUCUGCACAACGCAGGG	354	1747-1769
AD-1290875.2	GCCCACCAGCCUGUGAUUUGU	231	1853-1873	ACAAAUCACAGGCUUGGGGCAG	455	1851-1873
AD-1290880.2	CUUGGAGCCCCACCUUGGAAUU	137	1938-1958	AAUUCCAAAGGUGGGCUCCAAGGG	361	1936-1958
AD-1290884.5	GCAGGAAGCACUGAGAUUCGU	116	1209-1229	ACGAUUCUCAGUGCUUCCUGCAC	340	1207-1229
AD-1290885.5	CUGACCCAGUUAAGUGGAUU	78	775-795	AAUCCACUUGAACUGGGGUCAGAU	302	773-795
AD-1290894.2	AGGUCCGAUCUGGAACACAUU	233	2017-2037	AAUGUGUCCAGAUCCGGACCUC	457	2015-2037
AD-1290897.2	UGCGUUGUGCAGACUCUAUUU	131	1750-1770	AAUAGAGUCUGCACAACGCAGG	355	1748-1770
AD-1290908.2	CCAGUGAACCCUGCCAAAGAAU	235	1707-1727	AUUCUUUUGGCAGGUUCACUGGGU	459	1705-1727
AD-1290909.2	UUUGCAGACUCUAUUCUCAU	134	1754-1774	AUGGGAUAGAGUCUGCACAACG	358	1752-1774
AD-1290910.2	UAGGGUGGUAAGGCCUUAUU	236	2062-2082	AAUAGGCCUUAACCCACCCUAUA	460	2060-2082
AD-1290911.2	AGCCCACCUUGGAAUUAAGGU	140	1943-1963	ACCUUAAUUAUCCAAAGGUGGCUC	364	1941-1963
AD-1290926.2	GCCCACCUUGGAAUUAAGGGU	141	1944-1964	ACCCUAAUUAUCCAAAGGUGGCUC	365	1942-1964
AD-1290931.2	UCAGCCACAAUUGUGACCCAU	143	1970-1990	AUGGGUCACAUUUGUGGGCUGAGG	367	1968-1990
AD-1290939.2	AGGGUGGGUAAGGCCUUAUAU	238	2063-2083	AUAUAAAGGCCUUAACCCACCCUAU	462	2061-2083
AD-1290969.7	ACCUUCAUAGCCUCCGUCUAU	108	1162-1182	AAUGACGGAGGCAUUGAAGGUGU	332	1160-1182
AD-1290971.3	GCUACGGAGACGUGGUGUUUU	242	938-958	AAACACACACGUCUCCGUAGCCA	466	936-958
AD-1290973.2	GUUGGCAGACUCUAUUCUU	243	1753-1773	AGGGAAUAGAGUCUGCACAACGC	467	1751-1773
AD-1290983.2	CGUUGGCAGACUCUAUUCUU	133	1752-1772	AGGAAUAGAGUCUGCACAACGCA	357	1750-1772
AD-1290989.2	GCGUUGUGCAGACUCUAUUCU	132	1751-1771	AGAAUAGAGUCUGCACAACGCAG	356	1749-1771
AD-1290993.2	UAUCCCCACAGCUCAGAAAGCU	135	1766-1786	AGCUUCUGAGCUGUGGGGAUAGA	359	1764-1786
AD-1291003.2	GCGUGCCUCAGCCACAAAUU	142	1962-1982	AAUUUGUGGCUGAGGCACGCCCCU	366	1960-1982
AD-1423312.3	UGCAGGAAGCACUGAGAUUCU	115	1208-1228	AGAAATCTCAGUGCUUCCUGCACG	1141	1206-1228
AD-1423319.3	GACUUUGAGAAGGUUGAUUCU	70	757-777	AAGATCAACCUUCUCUCAAAGUCUG	1144	755-777
AD-1423336.7	GUUCAAGUGGAUCCACAUUGU	207	783-803	ACAATGTGAUCCACAUUAAACUG	1152	781-803
AD-1548743.7	UGGUGUUUGUCAGCAAAAGAUU	93	950-970	AAUCTUTGCUGACAAACACCCAG	1269	948-970

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Range in XM_017004061.1	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	Range in XM_017004061.1
AD-1612957.2	GCCUCAUGGAAGAGAACAGU	1200	518-538	ACUGCUTCUCUTCCAUAGAGCUA	1270	516-538
AD-1612963.2	UGGAAGAGAAAGCAGAUCCUGU	1201	524-544	ACAGGATCUGCTUCUCUUCUCCAU	1272	522-544
AD-1612969.2	AGAAGCAGAUCCUGUGCGUGU	1203	530-550	ACACGCACAGGAUCUGCUUCUCU	1274	528-550
AD-1613059.2	CAGACUUUGAGAAAGGUUGAUU	68	755-775	AAUCAACCUUCTCAAAGUCUGUA	1276	753-775
AD-1613060.2	AGACUUUGAGAAAGGUUGAUUCU	69	756-776	AGAUCAAACCUUCUCUCAAAGUCUGU	293	754-776
AD-1613061.1	GACUUUGAGAAAGGUUGAUUCU	70	757-777	AAGATCAAACCUUCUCUCAAAGUCUG	1696	755-777
AD-1613062.2	ACUUUGAGAAAGGUUGAUUCUGU	213	758-778	ACAGAUCAACTUCUCUCAAAGUCU	1277	756-778
AD-1613072.1	GGUUGAUCUGACCCAGUUCAU	239	768-788	ATGAACTGGGUCAGAUCAACCUU	1697	766-788
AD-1613075.2	UGAUCUGACCCAGUUCUAGUU	76	771-791	AACTGAAACUGGGUCAGAUCAAC	1183	769-791
AD-1613079.2	CUGACCCAGUUCUAGUGAUU	78	775-795	AAUCCACUUGAACUGGGUCAGAU	302	773-795
AD-1613087.1	GUUCAAGUGGAUCCACAUUGU	207	783-803	ACAATGTGAUCCACUUGAAACUG	1152	781-803
AD-1613094.2	UGGAUCCACAUUGAGGGCCGU	1207	790-810	ACGGCCUCAAATGUGGAUCCACU	1284	788-810
AD-1613242.2	GCUACGGAGACGUGGUGUUUU	242	938-958	AAACACACACGTCUCCGUAGCCA	1291	936-958
AD-1613254.2	UGGUGUUUGUCAGCAAAAGAUU	93	950-970	AAUCTUTGUCUGACAAACACCCACG	1269	948-970
AD-1613256.2	GUGUUUGUCAGCAAAAGAUUU	95	952-972	AACATCTUUGCTGACAAACACCA	1294	950-972
AD-1613371.3	ACCUUCAAGCCUCCGUCAUU	108	1162-1182	AAUGACGGAGGCAUUGAAGGUGU	332	1160-1182
AD-1613400.2	GCAGGAAGCACUGAGAUUCGU	116	1209-1229	ACGAAUCUCAGTGCUCUCCUGCAC	1304	1207-1229
AD-1684592.1	GUAGCCUCAUGGAAGAGAAAGU	1659	515-535	ACUUCUCUCCAUAGAGGCUACUC	1698	513-535
AD-1684593.1	AGCCUCAUGGAAGAGAAAGCAU	1660	517-537	AUGCTUCUCUCCAUAGAGGCUAC	1699	515-537
AD-1684594.1	CUCAUGGAAGAGAAAGCAGAUU	51	520-540	AAUCTGCUUCUCUCCAUAGAGGC	1700	518-540
AD-1684595.1	UCAUGGAAGAGAAAGCAGAUUCU	1661	521-541	AGAUCUGCUUCUCUCCAUAGAGG	1701	519-541
AD-1684596.1	AUGGAAGAGAAAGCAGAUCCUU	52	523-543	AAGGAUCUGCUUCUCUCCAUAGA	276	521-543
AD-1684597.1	AAGAGAAAGCAGAUCCUGUGCU	1662	527-547	AGCACAGGAUCUGCUUCUCCUCC	1702	525-547
AD-1684598.1	GAGAAAGCAGAUCCUGUGCGUU	1663	529-549	AACGCACAGGAUCUGCUUCUCCU	1703	527-549
AD-1684599.1	AAGCAGAUCCUGUGCGUGGGU	1664	532-552	ACCCACGCACAGGAUCUGCUUCU	1704	530-552
AD-1684600.1	AAGCAGAUCCUGUGCGUGGGU	1664	532-552	ACCCACGCACAGGAUCUGCUUCU	1704	530-552
AD-1684601.1	AGCAGAUCCUGUGCGUGGGGU	1665	533-553	ACCCACGCACAGGAUCUGCUUC	1705	531-553

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Range in XM_017004061.1	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	Range in XM_017004061.1
AD-1684602.1	AGCAGAUCCUGUGCGGGGU	1665	533-553	ACCCACGCACAGGAUCUGCUUC	1705	531-553
AD-1684603.1	GCAGAUCCUGUGCGGGGU	1666	534-554	AGCCCCACGCACAGGAUCUGCUU	1706	532-554
AD-1684604.1	CAGAUCCUGUGCGGGGU	1667	535-555	AAGCCCCACGCACAGGAUCUGCU	1707	533-555
AD-1684605.1	AGAUCCUGUGCGGGGU	1668	536-556	AUAGCCCCACGCACAGGAUCUGC	1708	534-556
AD-1684606.1	CAGACUUUGAGAGGUUGAUU	68	755-775	AAUCAACCUUUCTCAAAGUCUGUG	1709	753-775
AD-1684607.1	CAGACUUUGAGAGGUUGAUU	68	755-775	AAUCAACCUUUCTCAAAGUCUGCU	1710	753-775
AD-1684608.1	CAGACUUUGAGAGGUUGAUU	1669	755-775	UAUCAACCUUUCTCAAAGUCUGCU	1711	753-775
AD-1684609.1	GACUUUGAGAGGUUGAUU	1670	757-775	AAUCAACCUUUCTCAAAGUCUG	1712	755-775
AD-1684610.1	GACUUUGAGAGGUUGAUU	70	757-777	AAGATCAAACCUUUCTCAAAGUCUG	1696	755-777
AD-1684611.1	UUUGAGAGGUUGAUUCUGU	1671	760-778	ACAGAUCAACCTUUCUCAAAGU	1713	758-778
AD-1684612.1	ACUUUAAGAGGUUGAUUCUGU	1672	758-778	ACAGAUCAACCTUUCUCAAAGUCU	1714	756-778
AD-1684613.1	UUUGAGAGGUUGAUUCUGACCU	1673	761-781	AGGUCAGAUCAACCUUUCUCAAAG	1715	759-781
AD-1684614.1	GAGAGGUUGAUUCUGACCCAU	1674	763-783	AUGGGUCAGAUCAACCUUUCUCAA	1716	761-783
AD-1684615.1	GAGGUUGAUUCUGACCCAGUU	1675	765-785	AACUGGGUCAGAUCAACCUUUCUC	1717	763-785
AD-1684616.1	AGGUUGAUUCUGACCCAGUUUCU	1676	767-787	AGAACUGGGUCAGAUCAACCUUUC	1718	765-787
AD-1684617.1	UGAUCUGACCCAGUUCAAGUU	76	771-791	AACUTGAACUGGGUCAGAUCAAGC	1719	769-791
AD-1684618.1	UGAUCUGACCCAGUUCAAGUU	76	771-791	AACUTGAACUGGGUCAGAUCAAGC	1720	769-791
AD-1684619.1	UGAUCUGACCCAGUUCAAGUA	1677	771-791	UACUTGAACUGGGUCAGAUCAAGC	1721	769-791
AD-1684620.1	AUCUGACCCAGUUCAAGUU	1678	773-791	AACUTGAACUGGGUCAGAUCAAGC	1722	771-791
AD-1684621.1	GACCCAGUUCAAGUGGAUCCU	1679	777-797	AGGATCCACUUUGAACUGGGUCAG	1723	775-797
AD-1684622.1	ACCCAGUUCAAGUGGAUCCAU	79	778-798	AUGGAUCCACUUUGAACUGGGUCA	303	776-798
AD-1684623.1	CAGUUCAAGUGGAUCCACAUU	23	781-801	AAUGTGAUCCACUUUGAACUGGG	1724	779-801
AD-1684624.1	AGUUCAAGUGGAUCCACAUUU	81	782-802	AAUGUGGAUCCACUUUGAACUGG	305	780-802
AD-1684625.1	AGUGGAUCCACAUUGAGGGCU	1680	788-808	AGCCCUCAAUGUGGAUCCACUUG	1725	786-808
AD-1684626.1	UGGAUCCACAUUGAGGGCCGU	1207	790-810	ACGGCCCUCAAUGUGGAUCCACU	1726	788-810
AD-1684627.1	GAUCCACAUUGAGGGCCGGAU	1681	792-812	AUCCGGCCCUCAAUGUGGAUCCA	1727	790-812
AD-1684628.1	AUCCACAUUGAGGGCCGGAU	1682	793-813	AUUCGGCCCUCAAUGUGGAUCC	1728	791-813

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Range in XM_017004061.1	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	Range in XM_017004061.1
AD-1684629.1	GAGACGUGGUGUUUGUCAGCU	1683	944-964	AGCUGACAAACACACACGUCUCCG	1729	942-964
AD-1684630.1	CGUGGUGUUUGUCAGCAAAGU	219	948-968	ACUUTGCUGACAAACACACCGUC	1730	946-968
AD-1684631.1	UUUGUCAGCAAAGAUUGGCGU	1684	956-976	AGGCCACAUCUUUGCUGACAAAC	1731	954-976
AD-1684632.1	GUUCAGCAAAGAUUGGCGCAAU	1685	958-978	AUUGGCCACAUCUUUGCUGACAA	1732	956-978
AD-1684633.1	UCAGCAAAGAUUGGCGCAAAGU	1686	959-979	ACUUGGCCACAUCUUUGCUGACA	1733	957-979
AD-1684634.1	CAGCAAAGAUUGGCGCAAAGCU	1687	960-980	AGCUTGGCCACAUCUUUGCUGAC	1734	958-980
AD-1684635.1	AGCAAAGAUUGGCGCAAAGCAU	1688	961-981	AUGTUGGCCACAUCUUUGCUGA	1735	959-981
AD-1684636.1	GAGACACCUUCAAGCCUCCU	1689	1157-1177	AGGAGGCAUUGAAGGUGUCUCCA	1736	1155-1177
AD-1684637.1	AGACACCUUCAAGCCUCCGU	1690	1158-1178	ACGGAGGCAUUGAAGGUGUCUCC	1737	1156-1178
AD-1684638.1	GACACCUUCAAGCCUCCGUU	1691	1159-1179	AACGGAGGCAUUGAAGGUGUCUC	1738	1157-1179
AD-1684639.1	CCUUCAAUGCCUCCGUCAUCU	109	1163-1183	AGAUGACGGAGGCAUUGAAGGUG	333	1161-1183
AD-1684640.1	GCCUCCGUCAUCUUCAGCCUU	1692	1171-1191	AAGGCUGAAGAUACGGAGGCAU	1739	1169-1191
AD-1684641.1	CUCCGUCAUCUUCAGCCUUCU	113	1173-1193	AAGAGGCUGAAGAUACGGAGGC	337	1171-1193
AD-1684642.1	GGAGCGUGCAGGAAGCACUGU	1693	1202-1222	ACAGTGUUCCUGCACGCUCUCC	1740	1200-1222
AD-1684643.1	GAGCGUGCAGGAAGCACUGAU	1694	1203-1223	AUCAGUGCUUCCUGCACGCUCU	1741	1201-1223
AD-1684644.1	GCGUGCAGGAAGCACUGAGAU	1695	1205-1225	AUCUCAGUGCUUCCUGCACGCUC	1742	1203-1225
AD-1684645.1	GUGCAGGAAGCACUGAGAUUU	114	1207-1227	AAUUCACAGUGCUUCCUGCACGC	338	1205-1227
AD-1684646.1	CCCAGUGAACCCUGCCAAAGAU	221	1706-1726	ATCUTUGGCAGGUUACACUGGGUG	1743	1704-1726
AD-1684647.1	CCAGUGAACCCUGCCAAAGAAU	235	1707-1727	ATUCTUTGGCAGGUUACACUGGGU	1744	1705-1727
AD-1684648.1	CUGCGUUGUGCAGACUCUAUU	130	1749-1769	AAUAGAGUCUGCACAAACGCAGGG	354	1747-1769
AD-1684649.1	UGCGUUGUGCAGACUCUAUUU	131	1750-1770	AAAUAGAGUCUGCACAAACGCAGG	355	1748-1770
AD-1684650.1	GCGUUGUGCAGACUCUAUUUCU	132	1751-1771	AGAATAGAGUCTGCACAACGCAG	1745	1749-1771
AD-1684651.1	CGUUGUGCAGACUCUAUUCCU	133	1752-1772	AGGAUUAGAGUCUGCACAAACGCA	357	1750-1772
AD-1684652.1	GUUUGCAGACUCUAUUCCCU	243	1753-1773	AGGGAATAGAGTCUGCACAAACGC	1746	1751-1773
AD-1684653.1	UUUGCAGACUCUAUUCCCAU	134	1754-1774	ATGGGAUUAGAGUCUGCACAAACG	1747	1752-1774
AD-1684654.1	UAUUCCACAGCUCACAGAGCU	135	1766-1786	AGCUTCTGAGCTGUGGGAUAGA	1748	1764-1786
AD-1684655.1	AUUCCACAGCUCACAGAGCUU	136	1767-1787	AAGCTUCUGAGCUGUGGGAUAG	1749	1765-1787

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Range in XM_017004061.1	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	Range in XM_017004061.1
AD-1684656.1	UGCCCACCAAGCCUGUGAUUUU	229	1852-1872	AAATCACAAGGCGUGGCGCAGG	1750	1850-1872
AD-1684657.1	GCCCACCAAGCCUGUGAUUUU	231	1853-1873	ACAAAUACACAGGCGUGGCGCAG	455	1851-1873
AD-1684658.1	CUUGGAGCCACCCUUGGAAUU	137	1938-1958	AAUCCAAAGGUGGCGUCCAAAGG	361	1936-1958
AD-1684659.1	UUGGAGCCACCCUUGGAAUUU	225	1939-1959	AAAUTCAAAGGTGGGCUCCAAAG	1751	1937-1959
AD-1684660.1	UGGAGCCACCCUUGGAAUUU	227	1940-1960	ATAATUCCAAGGUGGCGUCCAAAG	1752	1938-1960
AD-1684661.1	GGAGCCACCCUUGGAAUUU	138	1941-1961	ATUAAU'TCCAAGGUGGCGUCCAA	1753	1939-1961
AD-1684662.1	GAGCCACCCUUGGAAUUU	139	1942-1962	ACUUAATUCCAAGGUGGCGUCCAA	1754	1940-1962
AD-1684663.1	AGCCACCCUUGGAAUUU	140	1943-1963	ACCUTAAUCCAAAGGUGGCGUCC	1755	1941-1963
AD-1684664.1	GCCACCCUUGGAAUUU	141	1944-1964	ACCCUAAAUCCAAAGGUGGCGUC	1756	1942-1964
AD-1684665.1	GGCGUGCCUCAGCCACAAUU	142	1962-1982	AAUUTGTGGCUGAGGCACGCCCU	1757	1960-1982
AD-1684666.1	UCAGCCACAAUUGAGCCAU	143	1970-1990	ATGGGUCACAUTUUGGCGUAGG	1758	1968-1990
AD-1684667.1	AGGUCCGAUCUGGAACACAUU	233	2017-2037	AAUGTGUCCAGAUCCGACCUCC	1759	2015-2037
AD-1684668.1	GGUCCGAUCUGGAACACAUU	144	2018-2038	ATAUGUGUCCAGAUCCGACCUCC	1760	2016-2038
AD-1684669.1	GUCCGAUCUGGAACACAUU	145	2019-2039	AAUATGTGUCCAGAUCCGACCU	1761	2017-2039
AD-1684670.1	UCCGAUCUGGAACACAUU	146	2020-2040	AAUAUGUGUCCAGAUCCGACCU	370	2018-2040
AD-1684671.1	CCGAUCUGGAACACAUU	147	2021-2041	ACAATATGUGUTCCAGAUCCGAC	1762	2019-2041
AD-1684672.1	CGAUCUGGAACACAUU	217	2022-2042	ACCAUAUGUGUTCCAGAUCCGGA	1763	2020-2042
AD-1684673.1	GAUCUGGAACACAUU	209	2023-2043	ATCCAAT AUGUGUCCAGAUCCG	1764	2021-2043
AD-1684674.1	AUCUGGAACACAUU	148	2024-2044	ATUCCAAUAUGTGUCCAGAUCCG	1765	2022-2044
AD-1684675.1	UCUGGAACACAUU	149	2025-2045	AAUCCAAUAUGUGUCCAGAUCC	373	2023-2045
AD-1684676.1	CUGGAACACAUU	150	2026-2046	AAAUTCCAAUAUGUGUCCAGAU	1766	2024-2046
AD-1684677.1	UGGAACACAUU	151	2027-2047	ACAATUCCAAUAUGUGUCCAGAU	1767	2025-2047
AD-1684678.1	GGAACACAUU	152	2028-2048	ACCAAUTCCAAUAUGUGUCCAG	1768	2026-2048
AD-1684679.1	UAGGGUGGUAAGGCCUUAU	236	2062-2082	AAUAAGGCCUUAACCCACCCUUA	460	2060-2082
AD-1684680.1	AGGGUGGUAAGGCCUUAU	238	2063-2083	ATAUAAGGCCUTACCCACCCUUA	1769	2061-2083
AD-1684681.1	GGGUGGUAAGGCCUUAU	153	2064-2084	ATUATAAGGCCUUAACCCACCCU	1770	2062-2084
AD-1684682.1	GGUGGUAAGGCCUUAU	154	2065-2085	AAUUAUAAGGCCUUAACCCACCCU	378	2063-2085

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Range in XM_017004061.1	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	Range in XM_017004061.1
AD-1684683.1	GUGGGUAAAGGCCUUUAUAAUGU	155	2066-2086	ACAUTATAAGGCCUUUACCCACCC	1771	2064-2086
AD-1684684.1	UGGGUAAAGGCCUUUAUAAUGUU	215	2067-2087	AACATUAUAAGGCCUUUACCCACC	1772	2065-2087
AD-1684685.1	GGGUAAGGCCUUUAUAAUGUAAU	208	2068-2088	ATACAUTAAAGGCCUUUACCCAC	1773	2066-2088
AD-1684686.1	GGUAAAGGCCUUUAUAAUGUAAU	205	2069-2089	ATUACATUAUAAGGCCUUUACCCA	1774	2067-2089
AD-1684687.1	GUAAGGCCUUUAUAAUGUAAA	156	2070-2090	ATUUACAUUAUAAGGCCUUUACCC	1775	2068-2090
AD-1684688.1	UAAAGGCCUUUAUAAUGUAAAGU	201	2071-2091	ACUUTACAUUATAAGGCCUUUACC	1776	2069-2091
AD-1684689.1	AAGGCCUUUAUAAUGUAAAGAU	157	2072-2092	ATCUTUACAUUAUAAGGCCUUUAC	1777	2070-2092
AD-1684690.1	AGGCCUUUAUAAUGUAAAGAGU	158	2073-2093	ACUCTUTACAUTAAUAAAGGCCUUA	1778	2071-2093
AD-1684691.1	GGCCUUUAUAAUGUAAAGAGCU	196	2074-2094	AGCUCUTUACATUAUAAGGCCUU	1779	2072-2094
AD-1684692.1	GCCUUUAUAAUGUAAAGAGCAU	159	2075-2095	ATGCTCTUUACAUUAUAAGGCCU	1780	2073-2095
AD-1684693.1	GCAUUAUAAUGUAAAGGCCUUU	160	2092-2112	AAAGCCUUUACAUUAUAUAGCUC	384	2090-2112
AD-1684694.1	CAUUAUAAUGUAAAGGCCUUU	202	2093-2113	AAAGCCUUUACAUUAUAUAGCU	426	2091-2113
AD-1684695.1	AUAUAUAAUGUAAAGGCCUUU	161	2094-2114	ATAAAGCCCUUACAUUAUAUAGC	1781	2092-2114
AD-1684696.1	UAUAUAAUGUAAAGGCCUUUAGU	197	2095-2115	ACUAAAGCCCUUACAUUAUAUAG	1782	2093-2115
AD-1684697.1	AUAUGUAAAGGCCUUUAGAU	162	2096-2116	ATCUAAAGCCCTUUACAUUAUAU	1783	2094-2116
AD-1684698.1	UAUAUGUAAAGGCCUUUAGAGU	163	2097-2117	ACUCTAAAGCCCUUACAUUAUA	1784	2095-2117
AD-1684699.1	AAUGUAAAGGCCUUUAGAGUU	164	2098-2118	AACUCUAAAGCCCUUUAUUAUUAU	388	2096-2118
AD-1684700.1	CCUGGAUUAAAUCUGCCAUU	165	2126-2146	AAUGGCAGAUUUAUUAUUAUUAU	1785	2124-2146
AD-1684701.1	CUGGAUUAAAUCUGCCAUUU	166	2127-2147	AAUUGGCAGAUUUAUUAUUAUUA	1786	2125-2147
AD-1684702.1	UGGAUUAAAUCUGCCAUUUU	193	2128-2148	AAAATGGCAGATUUUAUUAUUAU	1787	2126-2148
AD-1684703.1	GGAUUAAAUCUGCCAUUUUAU	192	2129-2149	ATAAAUGGCAGAUUUUAUUAUUA	1788	2127-2149
AD-1684704.1	GAUUAUAAUCUGCCAUUUUAU	167	2130-2150	ATUAAATGGCAGAUUUUAUUAUUA	1789	2128-2150
AD-1684705.1	AUUAAAUCUGCCAUUUUAUUAU	168	2131-2151	AAUUAAAUGGCAGAUUUUAUUAU	392	2129-2151
AD-1684706.1	AAUUCUGCCAUUUUAUUAUUAU	169	2135-2155	AGCUAATUAAATGGCAGAUUUUA	1790	2133-2155
AD-1684707.1	AUUCUGCCAUUUUAUUAUUAU	170	2136-2156	AAGCTAAUUAUUAUUAUUAUUAU	1791	2134-2156
AD-1684708.1	AUCUGCCAUUUUAUUAUUAUUA	171	2137-2157	ACAGCUAAUUAUUAUUAUUAUUA	395	2135-2157
AD-1684709.1	UCUGCCAUUUUAUUAUUAUUAU	218	2138-2158	AGCAGCTAAUUAUUAUUAUUAUUA	1792	2136-2158

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Range in XM_017004061.1	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	Range in XM_017004061.1
AD-1684710.1	CUGCCAUUUAAUAGCUGCAU	172	2139-2159	ATGCAGCUAAUTAAUUGGCAGAU	1793	2137-2159
AD-1684711.1	UGCCAUUUAAUAGCUGCAUU	203	2140-2160	A AUGCAGCUAATUAAUUGGCAGA	1794	2138-2160
AD-1684712.1	ACGCAAUCUGCCUCAUUUCU	173	2183-2203	AGAAAUTGAGGCAGAUUUGCGUUA	1795	2181-2203
AD-1684713.1	CGCAAUCUGCCUCAUUUCUU	174	2184-2204	AAGAAATUGAGGCAGAUUUGCGUU	1796	2182-2204
AD-1684714.1	GCAAUCUGCCUCAUUUCUUU	175	2185-2205	AAAGAAAUGAGGCAGAUUGCGU	399	2183-2205
AD-1684715.1	CAAUCUGCCUCAUUUCUUU	211	2186-2206	AGAAAGAAUUGAGGCAGAUUGCG	435	2184-2206
AD-1684716.1	AUCUGCCUCAUUUCUUCAU	176	2187-2207	ATGAAGAAUUGAGGCAGAUUGC	1797	2185-2207
AD-1684717.1	AUCUGCCUCAUUUCUUCAUU	177	2188-2208	AAUGAAAGAAUUGAGGCAGAUUG	1798	2186-2208
AD-1684718.1	UCUGCCUCAUUUCUUCAUUCU	178	2189-2209	AGAUGAAAGAAUUGAGGCAGAUU	1799	2187-2209
AD-1684719.1	CUGCCUCAUUUCUUCAUUCU	179	2190-2210	AAGATGAAGAAUUGAGGCAGAU	1800	2188-2210
AD-1684720.1	UGCCUCAUUUCUUCAUUCUGU	180	2191-2211	ACAGAUAGAAAUUGAGGCAGAG	404	2189-2211
AD-1684721.1	GCCUCAUUUCUUCAUUCUGUU	181	2192-2212	AACAGATGAAGAAUUGAGGCAG	1801	2190-2212
AD-1684722.1	CCUCAUUUCUUCAUUCUGUCU	199	2193-2213	AGACAGAUAGAAAUUGAGGCAG	423	2191-2213
AD-1684723.1	CUCAUUUCUUCAUUCUGUCAU	200	2194-2214	ATGACAGAUAGAAAUUGAGGC	1802	2192-2214
AD-1684724.1	UCAUUUCUUCAUUCUGUCAAU	194	2195-2215	ATUGACAGAUAGAAAUUGAGG	1803	2193-2215
AD-1684725.1	CAAUUUCUUCAUUCUGUCAAAU	182	2196-2216	ATUUGACAGAUAGAAAUUGAG	1804	2194-2216
AD-1684726.1	AAUUUCUUCAUUCUGUCAAAU	183	2197-2217	AAUUTGACAGATGAAGAAAUUGA	1805	2195-2217
AD-1684727.1	AUUUCUUCAUUCUGUCAAAUGU	184	2198-2218	ACAUTUGACAGAUAGAAAUUG	1806	2196-2218
AD-1684728.1	UUUCUUCAUUCUGUCAAAUGGU	195	2199-2219	ACCATUTGACAGAUAGAAAUU	1807	2197-2219
AD-1684729.1	UUCUUCAUUCUGUCAAAUGGAU	191	2200-2220	ATCCAUTUGACAGAUAGAAAUU	1808	2198-2220
AD-1684730.1	AAUUCUGCUUGGCUACAGAAU	185	2223-2243	ATUCTGTAGCCAAGCAGAAUUGG	1809	2221-2243
AD-1684731.1	AUUCUGCUUGGCUACAGAAU	186	2224-2244	AAUUCUGUAGCCAAGCAGAAUUG	410	2222-2244
AD-1684732.1	UUUCUGCUUGGCUACAGAAU	206	2225-2245	AAAUTCTGUAGCCAAGCAGAAU	1810	2223-2245
AD-1684733.1	UCUGCUUGGCUACAGAAU	187	2226-2246	ATAATUCUGUAGCCAAGCAGAAU	1811	2224-2246
AD-1684734.1	CUGCUUGGCUACAGAAU	188	2227-2247	AAUAAUTCUGUAGCCAAGCAGAA	1812	2225-2247
AD-1684735.1	UGCUUGGCUACAGAAU	189	2228-2248	AAUAAATUCUGTAGCCAAGCAG	1813	2226-2248
AD-1684736.1	GCUUGGCUACAGAAU	190	2229-2249	ACAATAAUUCUGUAGCCAAGCAG	1814	2227-2249

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Range in XM_017004061.1	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	Range in XM_017004061.1
AD-1684737.1	AUUUUUGAGGAAUAAAUCU	204	2242-2262	AGAUTUTAUCCCTCACAAUAAUUC	1815	2240-2262

Table 13. Modified Sense and Antisense Strand Sequences of KHK dsRNA

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	mRNA target sequence	SEQ ID NO.
AD-1290507.2	ususcucAfuCfUfGfucaaauggaL96	1816	asUfsccaUfugagagAfuGfaagaasasu	863	AUUUCUUCAUCUGUCAAAUGGAA	1087
AD-1290509.2	gsasuuuaaAfaUfCfUfGccauuaaL96	615	asUfsuaaAfuggcagaUfuUfuaucscsa	839	UGGAUUAAAUCUGCCAUUUAA	1063
AD-1290510.2	asasuuucUfuCfAfuUfGfucuaaaL96	631	asAfsuuuGfacagagAfaGfaaausgsa	855	U	1079
AD-1290514.2	csasaauuUfuUfCfAfuUfGfucuaaaL96	630	asUfsuugAfcagagaAfgAfaauugsas	854	UCAUUUUCUUCUUCUGUCAAAUG	1078
AD-1290515.2	asgsgecuUfaUfAfaUfGfuaaaagagL96	606	asCfsucuUfucaauuaUfaAfggcccusasa	830	CUCAUUUUCUUCUUCUGUCAAAU	1054
AD-1290516.2	gsgsaauaAfaUfUfCfUfGfucccauuuL96	640	asUfsaaaUfggcagauUfuUfaauccsasg	864	UAAAGCCUUUAUAAAUGUAAAAGAG	1088
AD-1290522.2	uscsuggaAfcAfcAfuUfGfuaauggaaL96	597	asAfsuucCfaauaugUfuUfcccagatusc	821	GAUCUGGAACACAUAAUUGGAAU	1045
AD-1290523.2	gscscucaAfuUfUfCfuaucuguuL96	629	asAfsuucCfaauaugUfuUfcccagatusc	853	CUGCCUCAUUUCUUCUUCUUCUGUC	1077
AD-1290524.2	asusuucUfcAfuUfCfuguaaagL96	632	asAfsuucCfaauaugUfuUfcccagatusc	856	CAUUUCUUCUUCUUCUUCUUCUUCUG	1080
AD-1290527.2	usgsaauAfaUfAfuUfGfuaauggaaL96	641	asAfsuucCfaauaugUfuUfcccagatusc	865	CCUGGAUUAAAUCUGCCAUUUA	1089
AD-1290528.2	csusggaAfaUfAfuUfGfuaauggaaL96	598	asAfsuucCfaauaugUfuUfcccagatusc	822	AUCUGGAACACAUAAUUGGAAU	1046
AD-1290531.2	csusgecuCfaAfuUfUfGfuaauggaaL96	627	asAfsuucCfaauaugUfuUfcccagatusc	851	AUCUGCCUCAUUUCUUCUUCUUCUG	1075
AD-1290533.2	asasaucUfcAfuUfUfGfuaauggaaL96	617	asAfsuucCfaauaugUfuUfcccagatusc	841	UAAAUCUGCCAUUUAUUUAAUAGCU	1065
AD-1290535.2	asasucgCfcAfuUfUfGfuaauggaaL96	618	asAfsuucCfaauaugUfuUfcccagatusc	842	AAAUCUGCCAUUUAUUUAAUAGCU	1066
AD-1290539.5	csasgacuUfuGfAfuUfGfuaauggaaL96	516	asAfsuucCfaauaugUfuUfcccagatusc	740	UACAGACUUUGAGAGAGGUUGAU	964
AD-1290542.2	uscsaauUfcUfUfCfuaucuguaaL96	642	asUfsugaCfagaagaaGfaAfaauugsgsg	866	CCUCAUUUUCUUCUUCUUCUUCUUCU	1090
AD-1290543.2	usgsaaccAfcAfuUfAfuUfGfuaauggaaL96	599	asCfsaauUfcccuaauUfuUfGfuaauggaaL96	823	UCUGGAACACAUAAUUGGAAUUG	1047
AD-1290551.2	csusggaUfaAfaUfAfuUfGfuaauggaaL96	614	asAfsaauUfcccuaauUfuUfGfuaauggaaL96	838	ACCUGGAUUAAAUCUGCCAUUU	1062
AD-1290552.2	ususuucUfaUfUfCfUfGfuaauggaaL96	643	asCfsaauUfcccuaauUfuUfGfuaauggaaL96	867	AAUUCUUCUUCUUCUUCUUCUUCUUCU	1091
AD-1290554.2	asusaauUfaAfaUfGfuaauggaaL96	610	asUfsuucCfaauaugUfuUfGfuaauggaaL96	834	AUUAUUGUAAAAGGGCUUUAGA	1058

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	mRNA target sequence	SEQ ID NO.
AD-1290555.2	asusauaaUfgUfAfAfagggcuuuauL96	609	asUfsaaaGfcccuuuaCfaUfuauausgc	833	GCAUAUAAUGUAAAAGGGCUUUA G	1057
AD-1290556.2	gscscuuUfaAfUfGfuuaagagcauL96	607	asUfsgcuCfuuuacauUfaUfaagcscsu	831	AGCCCUUAUAUGUAAAAGAGCA U	1055
AD-1290557.2	gsgscuuAfuAfAfUfguaaagagcuL96	644	asGfscueUfuuaacauAfuAfagcccsusu	868	AAGGCCUUUAUAUGUAAAAGAGC A	1092
AD-1290558.2	usasuaauGfuAfAfAgggcuuuaguL96	645	asCfsuaaAfgcccuuuAfcAfuuausug	869	CAUAUAUGUAAAAGGGCUUUAAG A	1093
AD-1290563.2	gsusaaggCfcUfUfAfuaaaguuaauL96	604	asUfsuuaCfauuuaaGfgCfcuuacsc	828	GGUAAGGCCUUUAUAUGUAAA G	1052
AD-1290564.2	cscscuaUfuUfCfUfucaucugcuL96	647	asGfsacaGfaugaagaAfaUfugaggsca	871	UGCCUCAAUUUCUUCAUCUGUCA G	1095
AD-1290565.2	csuscauUfuCfUfUfcaucugcuL96	648	asUfsgacAfgaugaagAfaAfuugagsgsc	872	GCCUCAAUUUCUUCAUCUGUCA G	1096
AD-1290570.2	asasggccUfuAfUfAfauaagaauL96	605	asUfscuuUfacuuuAfaGfgccuusc	829	GUAGGCCUUUAUAUGUAAAAGA G	1053
AD-1290573.2	asuscgcCfuCfAfAfuuuucuaauL96	625	asAfsugaAfgaauugAfgGfcagausus	849	CAAUCUGCCUCAAUUUCUUCAUC G	1073
AD-1290574.2	usasaggcCfuUfAfUfaaunguaaaguL96	649	asCfsuuAfcuuuaAfgGfcuuacsc	873	GGUAAGGCCUUUAUAUGUAAAAG A	1097
AD-1290584.2	gsusguuuGfuCfAfGfcaagauguL96	543	asAfscauCfuungcugAfcAfaacacsc	767	UGGUGUUUGUCAGCAAAAGAUGU G	991
AD-1290589.2	gsgsaacaCfaUfAfUfuggaauugguL96	600	asCfscaaUfucaauaUfgUfgnuccsag	824	CUGGAACACAUAAUUGGAAUUGG G	1048
AD-1290592.2	csasuaaAfuGfUfAfagggcuuuuL96	650	asAfsaagCfccuuuacAfuUfauaugscsu	874	AGCAUAUAUGUAAAGGGCUUU A	1098
AD-1290597.2	asusuaaaAfuCfUfGfcauuuaauuL96	616	asAfsuuaAfauggcagAfuUfuuaauscsc	840	GGAUUAAAUCUGCCCAUUUAAU U	1064
AD-1290599.7	usgsguguUfuGfUfCfagcaagaauL96	541	asAfsucuUfugcugacAfaAfcaccascg	765	CGUGGUGUUUGUCAGCAAAAGAU G	989
AD-1290600.2	gscsuuugCfuAfCfAfgaauuauguL96	638	asCfsaauAfauuuuguAfgCfcaagcsag	862	CUGCUUGGCUACAGAAUUAUUGU G	1086
AD-1290602.2	usgscuacAfaUfUfUfcauucugcuL96	628	asCfsagaUfgaagaauUfuGfagcagsga	852	UCUGCCUCAAUUUCUUCUUCUGUGU G	1076
AD-1290604.2	asuscgcCfaUfUfUfuaaauagcuguL96	619	asCfsageUfaauuaaUfgGfcaagausus	843	AAAUUCUGCCAUUAUUAUAGCUGC G	1067
AD-1290605.2	asascugCfcUfCfAfauuucuaauL96	624	asUfsgaaGfaaauugaGfgCfagaungsc	848	GCAUUCUGCCCAAUUUCUUCUUAU G	1072
AD-1290609.2	usgscuauUfuAfAfUfuaugcgaauL96	651	asAfsugcAfgcuaauAfaAfuaggcagsga	875	UCUGCCAUUAUUAUAGCUGCAUA G	1099
AD-1290611.3	asgsacuUfgAfGfAfagguugaauL96	517	asGfsaucAfaccuuuCfaAfaugucsgsu	741	ACAGACUUUGAGAAAGGUUGAUC U	965

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	mRNA target sequence	SEQ ID NO.
AD-1290612.2	asuscggAfaCfAfCfaauuuggaauL96	596	asUfuuccAfauaugugUfuCfcagaucsg	820	CGAUCUGGAACACAUAUUGGAAU	1044
AD-1290615.2	uscsugccUfcAfAfUfuucnucauclL96	626	asGfsaugAfagaaaauGfaGfgcagasuu	850	AAUCUGCCUCAAUUUUCUCAUCU	1074
AD-1290618.2	asasuguaAfaGfGfGfccccuugaguL96	612	asAfsuicUfaaaagcccUfuUfacaauasau	836	AUAAUGUAAAAGGGCUUUUAGAGU G	1060
AD-1290624.2	asusuauuGfuGfAfGfGaauaaaaauclL96	652	asGfsauuUfuauuceucAfcAfauaauusuc	876	GAAUUAAUUGUGAGGAUAAAAAUC A	1100
AD-1290626.2	gsgsuuagGfcCFUfUfauaaugaauL96	653	asUfsuacAfuaauaagGfcCfuuaaccsa	877	UGGGUAAGGCCUUUAUAAUGUAA A	1101
AD-1290633.2	csusgccAUfuUfAfAfuaageucauL96	620	asUfsgcaGfcauaauaAfaUfggcagsasu	844	AUCUGCCAUUUAAUUAAGCUGC AU	1068
AD-1290635.2	uususegcUfuGfGfCfuacagaauuL96	654	asAfsauuCfuguagccAfaGfcagaasuu	878	AAUUCUGCUUGGCUACAGAAUUA U	1102
AD-1290639.2	usasauGuAfaAFgGfGfccccuagaguL96	611	asCfsucuAfaagcccuUfuAfcanuuasua	835	UAUAAUGUAAAGGGCUUUUAGAG U	1059
AD-1290643.2	usgsuugGfceUfAfCfagaaunuauL96	637	asAfsauaAfuucuguaGfcCfaagcausga	861	UCUGCUUGGCUACAGAAUUAUUG	1085
AD-1290650.2	csgscaaUCfuGfCfCfcaaanuucuuL96	622	asAfsгааАфуu gaggc Afг Afuugcgсsu	846	AACGCAUCUGCCUCAAUUUCUU	1070
AD-1290651.2	gsusueaaGfuGfGfAfuaccauugulL96	655	asCfsaanGfuggauccAfeUfugaacsug	879	CAGUUC AAGUGGAUCCACA UUGA	1103
AD-1290654.2	gsgsguaaGfgCfCfUfuuaauuguauL96	656	asUfsacaUfuuaaaggCfeUfuaccssasc	880	GUGGUAAAGGCCUUUAUAAUGUA A	1104
AD-1290655.2	gsasuucGfAfCfAfcaauuuggalL96	657	asUfsecaAfuauguuUfcCfagaucsgsg	881	CCGAUCUGGAACACAUAUUGGAA	1105
AD-1290659.2	csasaucGfcCfUfCfcaanuucuuL96	659	asGfsaagAfauuugagGfcAfgaunsgcsg	883	CGCAAUCUGCCUCAAUUUCUUA	1107
AD-1290660.2	cscsuggaUfuAfAfAfaucugccaauL96	613	asAfsuggCfagaunuuAfaUfecaggсsuc	837	GACCUGGAUUA AAAUCUGCCA UU	1061
AD-1290661.2	gscsauuAfaUfGfUfuaagggcuuulL96	608	asAfsageCfcuuuacaUfuAfuauгсsuc	832	GAGCAUUA AUGUAAAGGGCUU U	1056
AD-1290666.2	ascsuuugAfgAfAfGfguuaucuL96	661	asCfsagaUfcaaacuuCfuCfaaагссу	885	AGACUUUGAGAAGGUUGAUCUG A	1109
AD-1290670.2	uscscgauCfuGfGfAfacaauuuL96	594	asAfsauaUfguuuccAfgAfucggассc	818	GGUCCGAUCUGGAACACAUAUUG	1042
AD-1290672.2	gscsaucUfgCfCfUfcaanuucuuL96	623	asAfsagaAfaauaggCfAfgaunгссgu	847	ACGCAUUCUGCCUCAAUUUCUUC	1071
AD-1290681.2	usgsgguaAfgCfCfCfuuaauuguuL96	663	asAfscauUfauaaggCfuUfacccассc	887	GGUGGGUAAAGGCCUUUAUAAUGU A	1111
AD-1290684.2	csgsauCuGfgAfAfCfacaauuugulL96	665	asCfscaaUfauguuuCfeAfgaucгсgsa	889	UCCGAUCUGGAACACAUAUUGGA	1113
AD-1290687.2	csusguuGfgCfUfAfcaagaauuuL96	636	asAfsuaaUfucuguaCfeAfagcagsasa	860	UUCUGCUUGGCUACAGAAUUAU	1084
AD-1290702.2	uscsugccAfuUfuUfAfaauuagcuL96	666	asGfscagCfuauuuaaAfuGfgcagasuu	890	AAUCUGCCAUUUAUUAUAGCUGCA	1114
AD-1290712.2	cscsgaucUfgGfAfafcaauuugulL96	595	asCfsaauAfuguuucCfaGfaucгсgsac	819	GUCCGAUCUGGAACACAUAUUGG	1043
AD-1290719.2	asusucuCfuUfgGfGfcaagaauL96	634	asAfsuucUfguagccaAfgCfagaauusg	858	CAAUUCUGCUUGGCUACAGAAU	1082
AD-1290722.2	uscsugcuUfgGfCfUfacagaauuuL96	635	asUfsaaUfеугuagcCfaAfgcagasuu	859	AUUCUGCUUGGCUACAGAAUUAU	1083

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	mRNA target sequence	SEQ ID NO.
AD-1290741.2	ascsgcaaUfcUfGfCfcucaauuuuL96	621	asGfsaaaUfugaggaGfaUfugcgusasa	845	UAACGCAAUUCUGGCCUCAAUUUUCU	1069
AD-1290742.2	gsusggguAfaGfGfCfcuuaauaauL96	603	asCfsauuAfuuaaggeCufuAfcceacsesc	827	GGGUGGGUAAGGCCUUAUAUAAG	1051
AD-1290747.2	gsgsagccCfaCfCfUfuggaauuaauL96	586	asUfsuaaUfuuccaaggUfgGfgcuucsasa	810	UUGGAGCCCAACCUUGGAAUUAAG	1034
AD-1290750.2	cscscaguGfaAfCfCfugcceaaauL96	669	asUfscuuUfggcaggUfCfAfcugggsuus	893	CACCCAGUGAACCUGCCAAAGAA	1117
AD-1290755.2	gsgsugggUfaAfGfGfCfcuuuaauuL96	602	asAfsuuaUfaagggcuUfaCfccaccscsu	826	AGGGUGGGUAAGGCCUUAUAUAU	1050
AD-1290763.2	gsuuccgaUfeUFGfGfaacacauuuL96	593	asAfsuauGfuguuuccaGfaUfcggacscsu	817	AGGUCCGAUCUGGAAACACAUAUU	1041
AD-1290764.2	gsgsuuccgAfuCFUfGfGfaacacauuL96	592	asUfsaugUfguuuccagAfuCfGggaccscuc	816	GAGGUCCGAUCUGGAAACACAUAU	1040
AD-1290796.2	usugggagCfcCfAfCfcuuggaauuuL96	673	asAfsauuCfcaaggUgGfgCfuccaasgsg	897	CCUUGGAGCCCCACCUUGGAAUUA	1121
AD-1290800.2	gsgsguggGfuAfAfGfGfcuuuaauL96	601	asUfsuauAfagggcuuAfcCfcaccscusa	825	UAGGGUGGGUAAGGCCUUAUAUA	1049
AD-1290805.2	usgsgagcCfcAfCfCfuuggaauuuL96	675	asUfsaaUufccaaagGfgGfucccasag	899	CUUGGAGCCCACCUUGGAAUUAUA	1123
AD-1290836.2	asasuucUgfeUfUfGfGfcuacagaL96	633	asUfsucuGfuagccaaGfcAfgaauusgsg	857	CCAUAUCUGCUUGGCUACAGAAU	1081
AD-1290837.5	usgsaucuGfaCfCfCfaguucaaguuL96	524	asAfsceuGfaacuggGfCfAfgaucasac	748	GUUGAUCUGACCCAGUUCAGUG	972
AD-1290841.2	asusuccAfcAfGfCfcucagaaguuL96	584	asAfsgcUfCugagcuGfuGfggaausas	808	CUAUUCCCACAGCUCAGAGCUG	1032
AD-1290842.2	gsasgcccAfcCfUfUfugaaauaagL96	587	asCfsuuaAfuuccaagGfuGfggcuucsca	811	UGGAGCCCACCUUGGAAUUAAGG	1035
AD-1290857.2	usgscecaCfcAfGfCfcugugauuuL96	677	asAfsaaUCfacagcuGfgUfgggeasgsg	901	CCUGCCCACCAAGCCUGUGAUUUG	1125
AD-1290865.2	csusgcuUfgUfGfCfagacucuaL96	578	asAfsuagAfgucugaCfaAfcgcagsgsg	802	CCCUGCGUUGGCGAGACUCUAU	1026
AD-1290875.2	gscscacCfaGfCfCfugugauuugL96	679	asCfsaaaUfcaacaggeUfgGfugggcsasg	903	CUGCCCACCAAGCCUGUGAUUUGA	1127
AD-1290880.2	csusuggaGfcCfCfAfcuugaaauL96	585	asAfsuucCfaagguaggGfcUfccaaagsgsg	809	CCCUUGGAGCCCACCUUGGAAU	1033
AD-1290884.5	gscsaggaAfgCfAfCfugagaucguL96	564	asCfsgaaUfcuacugCfuUfccugcsasc	788	GUGCAGGAAGCACUGAGAUUCGG	1012
AD-1290885.5	csusgaccCfaGfUfUfcaagugaaL96	526	asAfsuccAfcuugaacUfgGfgucagsasu	750	AUCUGACCCAGUUCAGUGGAUC	974
AD-1290894.2	asgsguccGfaUfCfUfuggaacaaL96	681	asAfsuguGfuuccagaUfcGfgaceuscsc	905	GGAGUCCGAUCUGGAACACAUA	1129
AD-1290897.2	usgsgcuGfuGfCfAfgacucuaauL96	579	asAfsauaGfagucagCfcAfagcaasgsg	803	CCUGCGUUGGCGAGACUCUAUUC	1027
AD-1290908.2	cscsagugAfaCfCfUfgcgcaagaauL96	683	asUfsucuUfugcgaggUfuCfagucgsgs	907	ACCCAGUGAACCUGCCAAAGAA	1131
AD-1290909.2	usugugccAfgAfCfUfcauucccauL96	582	asUfsgggAfauagaguCfuGfcacaascs	806	CGUUGGCGAGACUCUAUCCCCAC	1030
AD-1290910.2	usasggguGfgGfUfAfagggcuauuL96	684	asAfsuaaGfgccuuacCfcAfcceuasusa	908	UAUAGGGUGGGUAAGGCCUUAU	1132
AD-1290911.2	asgscccaCfcUfUfGfgaauuaagguL96	588	asCfscuuAfaauccaaGfgUfgggcuscsc	812	GGAGCCCACCUUGGAAUUAAGGG	1036
AD-1290926.2	gscscacCfuUfGfGfaauuaaggguL96	589	asCfscuuAfaauccaAfgGfugggcuscsc	813	GAGCCCACCUUGGAAUUAAGGGC	1037

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	mRNA target sequence	SEQ ID NO.
AD-1290931.2	uscsagccAfcAfAfAfugagaccuL96	591	asUfsgggUfcacauuuGfuGfgcugagsg	815	CCUCAGCCACAAAUGUGACCCAG	1039
AD-1290939.2	asgsggugGfgUfAfAfAggcccuaauL96	686	asUfsauaAfgggccuaCfcCfaccuusasu	910	AUAGGGUGGGUAAAGGCCUUAUA	1134
AD-1290969.7	ascscuucAfaUfGfCfcuaccgucuuL96	556	asAfsugaCfaggagcaUfuGfaaggusgs	780	ACACCUUCAAUGCCUCCGUCUAUC	1004
AD-1290971.3	gscsuacgGfaGfAfCfuggguguuuL96	690	asAfsaacAfccacgucUfcCfugagcsca	914	UGGCUACGGAGACGUGGUGUUU	1138
AD-1290973.2	gsusugugCfaGfAfCfucuaucuuL96	691	asGfsggaAfuagagucUfgCfacaacgsc	915	GCGUUGUGCAGACUCUAUUCCCA	1139
AD-1290983.2	csgsuugGfcAfGfAfucuaucuuL96	581	asGfsgaaUfagagucUfCfacaacgscsa	805	UGCGUUGUGCAGACUCUAUUCCC	1029
AD-1290989.2	gscsguugUfgCfAfGfAcucuaucuuL96	580	asGfssauAfgagucUfCfacaacgscasg	804	CUGCGUUGUGCAGACUCUAUUCC	1028
AD-1290993.2	usasuuiccCfaCfAfGfAcuagaaguuL96	583	asGfscuuCfugagucUfgGfagaauasgsa	807	UCUAUUCCCCACAGCUCAGAGAAGCU	1031
AD-1291003.2	gsgsgugCfcUfCfAfGfAcacaaauuL96	590	asAfsuuuGfuggcugaGfgCfagccscsu	814	AGGGCGUGCCUCAGCCACACAAUG	1038
AD-1423312.3	usgscaggAfaGfCfAfucgagaucuuL96	563	asGfsaadTc(Tgn)caugeUfuCfugca	1156	CGUGCAGGAAGCACUCUGAGAUCG	1011
AD-1423319.3	gsascuuuGfaGfAfAfggugaucuuL96	518	asAfsadTc(Agn)accuucUfcAfaagu	1163	CAGACUUUGAGAAAGGUUGAUCU	966
AD-1423336.7	gsusueaaGfuGfGfAfuccacauuL96	655	asCfsaadTg(Tgn)ggauccAfcUfugaac	1179	CAGUUAAGUGGAUCCACAUUGA	1103
AD-1548743.7	usgsguguUfuGfUfCfagcaagaauL96	541	asAfsuudTg(Tgn)gcugacAfaAfcacca	1482	CGUGGUGUUUGUCAGCAAAAGAU	989
AD-1612957.2	gscscucaugGfAfAfagagaagcaguuL96	1371	asdCsugdCudTcuudTcCfaugaggcs	1483	UAGCCUCAUGGAAGAGAAGCAGA	1619
AD-1612963.2	usgsgaagagAfaGfAgagaucucuuL96	1373	asdCsagdGadTcuugdTuCfucuuccasu	1485	CAUGGAAGAGAAGCAGAUCCUGU	1620
AD-1612969.2	asgsaagcagAfUfCfugugcguguuL96	1375	asdCsacdGcdAcaggdAuCfugcuucus	1487	AGAGAAGCAGAUCCUGUGCGUGG	1622
AD-1613059.2	csasgacuuuGfAfGfAgagguuagaauL96	1377	asdAsuudAadCcuudTcAfaagucugs	1489	UACAGACUUUGAGAAAGGUUGAU	964
AD-1613060.2	asgsacuunugAfGfAfagguuagaucuuL96	1378	asdGsaudCadAccuudCuCfaagucus	1490	ACAGACUUUGAGAAAGGUUGAUC	965
AD-1613061.1	gsasecuuugaGfAfAfagguuagaucuuL96	1817	asdAsgadTcdAaccudTcUfcaaaucsu	1859	CAGACUUUGAGAAAGGUUGAUCU	966
AD-1613062.2	ascsuuugagAfAfGfAgguuagaucuuL96	1379	asdCsagdAudCaaccdTcUfcaaaagusc	1491	AGACUUUGAGAAAGGUUGAUCUG	1109

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	mRNA target sequence	SEQ ID NO.
AD-1613072.1	gsgsuugaueUfGfAfeccegaucuuL96	1818	asdTsgadAcdTgggudCaGfaucacacsu	1860	AAGGUUGAUCUGACCCAGUUCAA	1135
AD-1613075.2	usgsaucugaCfCfCfaguucaaguL96	1383	asdAscudTgdAcuagdGgUfcagaucaas	1495	GUUGAUCUGACCCAGUUCAAAGUG	972
AD-1613079.2	csusgaccaGfUfUfcaaguggaauL96	1386	asdAsuudCadCuugadAcUfeggucags	1498	AUCUGACCCAGUUCAAAGUGGAUC	974
AD-1613087.1	gsusucaaaguGfGfAfuccacaauL96	1455	asdCsaadTgdTggandCcAfeuuagaacsu	1861	CAGUUCAAAGUGGAUCCACAUUGA	1103
AD-1613094.2	usgsauccaCfAfUfugaggccguL96	1391	asdCsggdCcdCucaadTgUfggauccasc	1503	AGUGGAUCCACAUUGAGGGCCGG	1626
AD-1613242.2	gscsuacggaGfAfCfuggguguuuuL96	1398	asdAsaadCadCcaagdTcUfcguagasc	1510	UGGCUACGGAGACGUGGUGUUU	1138
AD-1613254.2	usgsuguuuGfUfCfagcaagaauL96	1404	asdAsuudTudTgcugdAcAfaacaccasc	1516	CGUGGUGUUUGUCAGCAAAAGAU	989
AD-1613256.2	gsusguuuuGfAfGfcaagaauL96	1406	asdAscadTcdTuugdTGfAfaaacacsc	1518	UGGUGUUUGUCAGCAAAAGAU	991
AD-1613371.3	ascseuucaaUfGfCfuccgucuuL96	1415	asdAsugdAcdGgaggdCaUfugaaggus	1527	ACACCUUCA AUGCCUCCGUCUAUC	1004
AD-1613400.2	gscsaggaagCfAfCfugagaauL96	1420	asdCsgadAudCucagdTGfCfuuccugcs	1532	GUGCAGGAAGCACUGAGAUUCGG	1012
AD-1684592.1	gsusagccUfcAfUfGfagaagaauL96	1819	asCfsuudCudCuuccauGfaGfgcuacsu	1862	GAGUAGCCUCAUGGAAGAGAAAGC	2008
AD-1684593.1	asgscuacAfUfGfAfagagaagcauL96	1820	asUfsgcdTudCucuuccAfUfGfaggcuasa	1863	GUAGCCUCAUGGAAGAGAAAGCAG	2009
AD-1684594.1	csuscaugGfaAfGfAfgaagcagaauL96	499	asAfsuudTgdCuuccuUfcCfaugagsg	1864	GCCUCAUGGAAGAGAAAGCAGAUUC	947
AD-1684595.1	uscsauaggAfaGfAfGfagcagaauL96	1821	asGfsaudCudGcuuccUfcCfaugagsg	1865	CCUCAUGGAAGAGAAAGCAGAUUC	2010
AD-1684596.1	asusggaaGfaGfAfAfgcagaauL96	500	asAfsaggdAudCugcuuccUfcUfucaus	1866	UCAUGGAAGAGAAAGCAGAUUCUG	948
AD-1684597.1	asasgagaAfgCfAfGfaucceugcuL96	1822	asGfscadCadGgaucugCfuUfcuucc	1867	GGAAGAGAAAGCAGAUUCUGUGCG	2011
AD-1684598.1	gsasgaagCfaGfAfUfcugugcgguL96	1823	asAfsagdCadCaggauUfgCfuuccu	1868	AAGAGAAAGCAGAUUCUGUGCGUG	2012
AD-1684599.1	asasgcagauCfCfUfugugcgguL96	1824	asdCsccdAcdGcaadGgAfucugcuus	1869	AGAAGCAGAUUCUGUGCGUGGGG	2013

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	mRNA target sequence	SEQ ID NO.
AD-1684600.1	asasgcagAfuCfCfUfugcguggguL96	1825	csu asCfsecaCfgecacaggAfuCfugcuusc asdCsecdCadCgcacdAgGfaucugc usc	1870 1871 1872	AGAAGCAGAUCCUGUGCGUGGGG GAAGCAGAUCCUGUGCGUGGGG GAAGCAGAUCCUGUGCGUGGGG	2013 2014 2014
AD-1684601.1	asgsagauCfcUfGfUfugcguggguL96	1826	asGfscedCc(Agn)cegeacaGfgAfucug csusu	1873	AAGCAGAUCCUGUGCGUGGGGCU	2015
AD-1684602.1	asgsagauCfcUfGfUfugcguggguL96	1827	asAfsgecdCcdCacgcacAfgGfaucugsc su	1874	AGCAGAUCCUGUGCGUGGGGCUA	2016
AD-1684603.1	asgsagauCfcUfGfUfugcguggguL96	1828	asUfsagdcCdCcaagcaCfaGfauucug sc	1875	GCAGAUCCUGUGCGUGGGGCUAG	2017
AD-1684604.1	asgsagauCfcUfGfUfugcguggguL96	1829	asdAsucdAadCcuucdTcAfaagucugs usc	1876	UACAGACUUUGAGAAAGGUUGAU	964
AD-1684605.1	asgsagauCfcUfGfUfugcguggguL96	1830	asdAsucdAadCcuucdTcAfaagucugs csu	1877	UACAGACUUUGAGAAAGGUUGAU	964
AD-1684606.1	asgsagauCfcUfGfUfugcguggguL96	1831	usdAsucdAadCcuucdTcAfaagucugs csu	1878	UACAGACUUUGAGAAAGGUUGAU	964
AD-1684607.1	asgsagauCfcUfGfUfugcguggguL96	1832	asdAsgadTc(Agn)accudTcUfcAfaag ucsu	1879 1880	CAGACUUUGAGAAAGGUUGAU CAGACUUUGAGAAAGGUUGAU	2018 966
AD-1684608.1	asgsagauCfcUfGfUfugcguggguL96	1833	asdCsagdTc(Agn)accudTcUfcAfaag ucsu	1881	ACUUUGAGAAAGGUUGAU	2019
AD-1684609.1	asgsagauCfcUfGfUfugcguggguL96	1834	asdCsagdTc(Agn)accudTcUfcAfaag ucsu	1882	AGACUUUGAGAAAGGUUGAU	1109
AD-1684610.1	asgsagauCfcUfGfUfugcguggguL96	1835	asGfsagdTc(Agn)accudTcUfcAfaag ucsu	1883	CUUUGAGAAAGGUUGAU	2020
AD-1684611.1	asgsagauCfcUfGfUfugcguggguL96	1836	asUfsagdTc(Agn)accudTcUfcAfaag ucsu	1884	UUGAGAAAGGUUGAU	2021
AD-1684612.1	asgsagauCfcUfGfUfugcguggguL96	1837	asAfsagdTc(Agn)accudTcUfcAfaag ucsu	1885	GAGAAAGGUUGAU	2022
AD-1684613.1	asgsagauCfcUfGfUfugcguggguL96	1838	asGfsagdTc(Agn)accudTcUfcAfaag ucsu	1886	GAGAAAGGUUGAU	2023
AD-1684614.1	asgsagauCfcUfGfUfugcguggguL96	1839	asAfsagdTc(Agn)accudTcUfcAfaag ucsu	1887	GUUGAUCUGACCCAGU	972
AD-1684615.1	asgsagauCfcUfGfUfugcguggguL96	1840	asAfsagdTc(Agn)accudTcUfcAfaag ucsu	1888	GUUGAUCUGACCCAGU	972

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	mRNA target sequence	SEQ ID NO.
AD-1684619.1	usgsaucugaCfCfCfaguucaagual96	1839	csu usdAscudTgdAacugdGgUfcagaucac csu	1889	GUUGAUCUGACCCAGUUCAAAGUG	972
AD-1684620.1	asuscugaCfCfCfaguucaagual96	1840	asAscudTgdAacugdGgUfcagaucac g	1890	UGAUCUGACCCAGUUCAAAGUG	2024
AD-1684621.1	gsascccaGfuUfCfAfaguggaucual96	1841	asGfsgdTcdCacuugaAfcUfjggucsa sg	1891	CUGACCCAGUUCAAAGUGGAUCCA	2025
AD-1684622.1	ascscagUfuCfAfafuggaucual96	527	asUfsggdAudCcauugAfaCfugggus csa	1892	UGACCCAGUUCAAAGUGGAUCCAC	975
AD-1684623.1	csasguucAfaGfuUfGfaguccaauul96	471	asAfsugdTgdGauccacUfuGfaucugsg sg	1893	CCCAGUUCAAAGUGGAUCCACAUU	919
AD-1684624.1	asgsuicaAfgUfGfGfauccaauul96	529	asAfsaudGudGauccaCfuUfgaacugsg sg	1894	CCAGUUCAAAGUGGAUCCACAUUUG	977
AD-1684625.1	asgsuggaUfcCfAfCfaungaggcual96	1842	asGfscddCudCaauugGfaUfccacusu sg	1895	CAAGUGGAUCCACAUAUAGGGGCC	2026
AD-1684626.1	usgsaucCfaCfAfUfagaggccgual96	1843	asCfsggcCfcauugUfgGfauccacsu sa	1896	AGUGGAUCCACAUAUAGGGCCCGG	1626
AD-1684627.1	gsasuccaCfaUfUfGfagggccggaual96	1844	asUfscddGgdCccucaaUfgUfjggauusc sa	1897	UGGAUCCACAUAUAGGGGCCGGAA	2027
AD-1684628.1	asuscacAfuUfGfAfgggccggaual96	1845	asUfsuedCgdGccucaaAfuGfuggaunc sc	1898	GGAUCCACAUAUAGGGGCCGGAAC	2028
AD-1684629.1	gsasgacUfgGfUfGfuuugucagcual96	1846	asGfscudGadCaacacCfaCfugucucscs g	1899	CGGAGACGUGGUGUUGUCAGCA	2029
AD-1684630.1	csgsugguGfuUfUfGfucagcaagual96	667	asCfsuudTgdCugacaaAfcAfccacgsu sc	1900	GACGUGGUGUUGUCAGCAAAAG A	1115
AD-1684631.1	usugucaGfcAfaAfgaugggccual96	1847	asGfsgcdCadCauuuuGfcUfgacaasa sc	1901	GUUUGUCAGCAAAAGAUGUGGCCA	2030
AD-1684632.1	gsuscagcAfaAfgAfgugggccaual96	1848	asUfsugdGcdCacauuUfuGfugacsa sa	1902	UUGUCAGCAAAAGAUGUGGCCAAG	2031
AD-1684633.1	uscsagcaAfaGfAfuUfgugggccaual96	1849	asCfsuudGgdCcauucUfuUfjgucgasc sa	1903	UGUCAGCAAAAGAUGUGGCCAAGC	2032
AD-1684634.1	csasgcaaAfgAfuUfGfugggccaagual96	1850	asGfscudTgdGccacauCfuUfugucgsa sc	1904	GUCAGCAAAAGAUGUGGCCAAGCA	2033
AD-1684635.1	asgscaaaGfaUfGfUfugggccaagual96	1851	asUfsgcdTudGgccacaUfcUfuugucsg sa	1905	UCAGCAAAAGAUGUGGCCAAGCAC	2034
AD-1684636.1	gsasgacaCfcUfUfCfaungccuccual96	1852	asGfsgadGgdCauugaaGfgUfjgucusc sc	1906	UGGAGACACCUUCAUAGCCUCCG	2035

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	mRNA target sequence	SEQ ID NO.
AD-1684637.1	asgsaacCfuUfCfAfaugccuccuL96	1853	sa asCfsggdAgdGcauugaAfgGfugucucsc	1907	GGAGACACCUUCAAUGCCUCCGU	2036
AD-1684638.1	gsasacacUfuCfAfAfaugccuccuL96	1854	usc asAfsggdGadGgcauugaAfaGfugucusc	1908	GAGACACCUUCAAUGCCUCCGU	2037
AD-1684639.1	cscsuucaAfuGfCfCfuccuuccuL96	557	usc asGfsaudGadCggaggcAfuUfgaaggsusc	1909	CACCUUCAAUGCCUCCGUCAUCU	1005
AD-1684640.1	gscscuccGfuCfAfUfuccuagccuL96	1855	su asAfsggdCudGgaugAfcGfagggsa	1910	AUGCCUCCGUCAUCUUCAGCCUC	2038
AD-1684641.1	csuscguCfaUfCfUfuccuagccuL96	561	gsc asAfsggdGadCugaagaUfgAfcaggags	1911	GCCUCCGUCAUCUUCAGCCUCUC	1009
AD-1684642.1	gsgsagcgUfgCfAfGfaggaagccuL96	1856	sc asCfsagdTgdCuuccugCfaCfgeuccsu	1912	GAGGAGCGUGCAGGAAGCACUGA	2039
AD-1684643.1	gsasgcguGfcAfGfGfaagcagauL96	1857	su asUfscadGudGcuuccuGfcAfcgeucsc	1913	AGGAGCGUGCAGGAAGCACUGAG	2040
AD-1684644.1	gscsgugcAfgGfAfAfgcagagauL96	1858	sc asUfscudCadGugcuucChuGfcacgcsu	1914	GAGCGUGCAGGAAGCACUGAGAU	2041
AD-1684645.1	gsusgcagGfaAfGfCfagcagauL96	562	sc asAfsaudCudCagucuuUfcCfugcacsg	1915	GCGUGCAGGAAGCACUGAGAUUC	1010
AD-1684646.1	cscscaguGfaAfCfCfugccaaagauL96	669	usc asdTscudTudGgcagdGuUfcacugggs	1916	CACCCAGUGAACCUGCCAAAGAA	1117
AD-1684647.1	cscsagugAfaCfCfUfgccaaagauL96	683	gsu asdTsudTudTggcadGgUfucacuggs	1917	ACCCAGUGAACCUGCCAAAGAAA	1131
AD-1684648.1	csusgcguUfgUfGfCfagacucuaL96	578	gsg asdAsuadGadGueugdCaCfaacgcags	1918	CCCUGCGUUGUGCAGACUCUAUU	1026
AD-1684649.1	usgscguGfuGfCfAfgacucuaL96	579	gsg asdAsaudAgdAgnucudGcAfcacgcags	1919	CCUGCGUUGUGCAGACUCUAUUUC	1027
AD-1684650.1	gscsguugUfgCfAfGfagacucuaL96	580	sg asdGsaadTadGagucdTgCfacaagcsa	1920	CUGCGUUGUGCAGACUCUAUUCC	1028
AD-1684651.1	csgsuuugGfcAfGfAfcuauuccuL96	581	csa asdGsgadAudAgagudCuGfcaacaags	1921	UGCGUUGUGCAGACUCUAUUCCCC	1029
AD-1684652.1	gsusugugCfaGfAfCfucuaauccuL96	691	sc asdGsggdAadTagagdTcUfgcacaacsg	1922	GCGUUGUGCAGACUCUAUUCCCCA	1139
AD-1684653.1	usugugcAfgAfCfUfcauauccuL96	582	csg asdTsggdGadAuagadGuCfugcacaas	1923	CGUUGUGCAGACUCUAUUCCCCAC	1030

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	mRNA target sequence	SEQ ID NO.
AD-1684654.1	usasuuccCfaCfAfGfcuagaaguuL96	583	asdGscudTcdTgagedTgUfgggaauas gsa	1924	UCUAUUCACACAGCUCAGAAAGCU	1031
AD-1684655.1	asusucccAfcAfGfCfucagaaguuL96	584	asdAsgedTudCugagdCuGfugggaauas asg	1925	CUAUUCACACAGCUCAGAAAGCUG	1032
AD-1684656.1	usgscccaCfcAfGfCfugugaauuuL96	677	asdAsaadTcdAcaggdCuGfuggggcas gsg	1926	CCUGCCCCACAGCCUGUGAUUUUG	1125
AD-1684657.1	gscscacCfaGfCfCfugugaauuuL96	679	asdCsaadAudCacagdGcUfgggggcs asg	1927	CUGCCCCACAGCCUGUGAUUUUGA	1127
AD-1684658.1	csusuggaGfcCfcAfccuuggaauuL96	585	asdAsuudCcdAaggudGgGfucccaags gsg	1928	CCCUGGAGCCCCACCUUGGAAUU	1033
AD-1684659.1	usugggagCfcCfcAfCfcuuggaauuL96	673	asdAsaudTcdCaaggdTgGfgucccaasg sg	1929	CCUUGGAGCCCCACCUUGGAAUUA	1121
AD-1684660.1	usgsagacCfcAfCfCfugugaauuuL96	675	asdTsaadTudCcaagdGuGfgucccasa sg	1930	CUUGGAGCCCCACCUUGGAAUUA	1123
AD-1684661.1	gsgagaccCfaCfcUfUfggaauuaaL96	586	asdTsuadAudTccaadGgUfgggcuacs asa	1931	UUGGAGCCCCACCUUGGAAUUAAG	1034
AD-1684662.1	gsasgcccAfcCfcUfUfggaauuaaL96	587	asdCsnuadAadTuccadAgGfugggcuacs csa	1932	UGGAGCCCCACCUUGGAAUUAAGG	1035
AD-1684663.1	asgscccaCfcUfUfGfgaauuaagguL96	588	asdCscudTadAuuuccdAaGfuggggcuacs csc	1933	GGAGCCCCACCUUGGAAUUAAGGG	1036
AD-1684664.1	gscscacCfcUfGfGfaauuaagguL96	589	asdCscudTadAuuuccdCaAfgggggcs usc	1934	GAGCCCCACCUUGGAAUUAAGGGC	1037
AD-1684665.1	gsgscgugCfcUfcAfGgcacaaauL96	590	asdAsuudTgdTggcudGaGfgcacgcs csu	1935	AGGGCGUGCCUCAGCCACAAAUUG	1038
AD-1684666.1	uscsagccAfcAfAfAfugugacccauL96	591	asdTsggdGudCacaudTuGfuggcgugas gsg	1936	CCUCAGCCACAAAUUGUGACCCAG	1039
AD-1684667.1	asgsugccGfaUfcUfUfggaacacauuL96	681	asdAsugdTgdTuccadGaUfcggaccus csc	1937	GGAGGUCCGAUCUGGGAACACAUUA	1129
AD-1684668.1	gsgsucgAfuCfcUfGfgaacacauuL96	592	asdTsaudGudGuuuccdAgAfucggaccs usc	1938	GAGGUCCGAUCUGGGAACACAUUAU	1040
AD-1684669.1	gsusegaUfcUfGfGfaacacauuL96	593	asdAsuadTgdTguuuccdCaGfaucggacs csu	1939	AGGUCCGAUCUGGGAACACAUUAU	1041
AD-1684670.1	uscscgauCfuGfGfAfacacauuL96	594	asdAsaudAudGuguuuccdCcAfgaucggacs csc	1940	GGUCCGAUCUGGGAACACAUUAUUG	1042
AD-1684671.1	cscsgaucUfgGfAfAfcacauuugnuL96	595	asdCsaadTadTgugudTcCfagaucgggsa	1941	GUCCGAUCUGGGAACACAUUAUUGG	1043

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	mRNA target sequence	SEQ ID NO.
AD-1684672.1	csgsaucuGfgAfAfCfacauauugguL96	665	sc asdCscadAudAugudTuCfcagaucgs gsa	1942	UCCGAUCUGGAACACAUUUUGGA	1113
AD-1684673.1	gsasucugGfaAfCfAfcuaauuggauL96	657	asdTscadAadTaugudGuUfcccagaucs gsg	1943	CCGAUCUGGAACACAUUUUGGAA	1105
AD-1684674.1	asusucuggAfaCfAfCfaauuuggaauL96	596	asdTsuedCadAuaugdTuUfuccagaucs csg	1944	CGAUCUGGAACACAUUUUGGAAU	1044
AD-1684675.1	uscsuggaAfcAfCfAfuauuuggaauL96	597	asdAsuudCedAuaudGuGfuuccagas usc	1945	GAUCUGGAACACAUUUUGGAAU U	1045
AD-1684676.1	csusggaaCfaCfAfUfaauuuggaauuL96	598	asdAsaudTcdCaauadTuUfguuccagsa su	1946	AUCUGGAACACAUUUUGGAAU G	1046
AD-1684677.1	usgsugaacAfcAfUfAfuuggaauuL96	599	asdCsaadTudCcaudAuGfuguuccas gsa	1947	UCUGGAACACAUUUUGGAAUUG G	1047
AD-1684678.1	gsgsaacaCfaUfAfUfuggaauuL96	600	asdCscadAudTccadTaUfguuccesa sg	1948	CUGGAACACAUUUUGGAAUUGG G	1048
AD-1684679.1	usasggguGfgGfUfAfagccuauuL96	684	asdAsuadAgdGccuudAcCfcaccuas usa	1949	UAUAGGGUGGGUAAGGCCCUU A	1132
AD-1684680.1	asgsugguGfgUfAfAfgccuauuL96	686	asdTsaudAadGgccudTaCfccaccusa su	1950	AUAGGGUGGGUAAGGCCCUU A	1134
AD-1684681.1	gsugsuggGfgUfAfGfgccuauuL96	601	asdTsaudTadAggccuTaAfccaccsu sa	1951	UAGGGUGGGUAAGGCCCUU U	1049
AD-1684682.1	gsugsuggUfaAfGfGfccuauuL96	602	asdAsuudAudAagcdCuUfaccaccs csu	1952	AGGGUGGGUAAGGCCCUU G	1050
AD-1684683.1	gsusggguAfaGfGfCfcuauuauL96	603	asdCsaudTadTaagcdCcUfuaccaccsc sc	1953	GGGUGGGUAAGGCCCUU U	1051
AD-1684684.1	usgsgguaAfgGfCfCfuauuauuL96	663	asdAscudTudAuaagdGcCfuuaaccasc sc	1954	GGUGGGUAAGGCCCUU A	1111
AD-1684685.1	gsugsuaaGfgCfCfUfuauuauuL96	656	asdTsaudAudTaaadGgCfcuuaaccsa sc	1955	GUGGGUAAGGCCCUU A	1104
AD-1684686.1	gsugsuaagGfcCfUfUfauaauuL96	653	asdTsaudCadTuaadAgGfcuuaaccsc sa	1956	UGGGUAAGGCCCUU A	1101
AD-1684687.1	gsusaaggCfcUfUfAfuauuauuL96	604	asdTsaudAcadAuaudAaGfgccuuaacs csc	1957	GGGUAAGGCCCUU G	1052
AD-1684688.1	usasaggcCfuUfAfUfaauuauuL96	649	asdCsaudTadCaauadTaAfggcuuaacs sc	1958	GGUAAGGCCCUU A	1097

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	mRNA target sequence	SEQ ID NO.
AD-1684689.1	asasggccUfuAfAfUfaugaagagauL96	605	asdTscudTudAcauudAuAfagccuusasc	1959	GUAAAGCCUUUAUAAAUGUAAAAGA G	1053
AD-1684690.1	asgsgecuUfaAfAfAfugaagagauL96	606	asdCsucdTudTacaudTaUfaaggccusasa	1960	UAAGGCCUUUAUAAUGUAAAAGAG C	1054
AD-1684691.1	gsgsccuuAfuAfAfUfugaagagcuL96	644	asdGscudCudTuacadTuAfuaaggccsusu	1961	AAGGCCUUUAUAAUGUAAAAGAGC A	1092
AD-1684692.1	gscscuuuUfaAfUfGfuaaagagcauL96	607	asdTsgcdTcdTuuacdAuUfauaaggcscsu	1962	AGGCCUUUAUAAUGUAAAAGAGCA U	1055
AD-1684693.1	gscsauuAfaUfGfUfaaagggecuuL96	608	asdAsagdCcdCuuaadCaUfuauaugcsusc	1963	GAGCAUUAUAAUGUAAAGGGCUU U	1056
AD-1684694.1	csasuaaAfuGfUfAfaagggecuuuL96	650	asdAaadGcdCcuudAcAfuaauaugscsu	1964	AGCAUUAUAAUGUAAAGGGCUU A	1098
AD-1684695.1	asusauaUfgUfAfAfaggggecuuuL96	609	asdTsaadAgdCceudTaCfauuauaugsc	1965	GCAUUAUAAUGUAAAGGGCUUUA G	1057
AD-1684696.1	usasuauGfuAfAfAfggggecuuaguL96	645	asdCsuadAadGcccdTuAfcuuuauasusg	1966	CAUUAUUGUAAAGGGCUUUAAG A	1093
AD-1684697.1	asusaugUfaAfAfGfggecuuagauL96	610	asdTscudAadAgcccdTuUfacuuuauasusu	1967	AUAUAAUGUAAAGGGCUUUAAGA G	1058
AD-1684698.1	usasauguAfaAfGfGfgecuuagaguL96	611	asdCsucdTadAagecdCuUfuacuuasusa	1968	UAUAUGUAAAGGGCUUUAAGAG U	1059
AD-1684699.1	asasuuaAfaGfGfGfgecuuagaguL96	612	asdAseudCudAaagcdCcUfuuuacuuasu	1969	AUAUUGUAAAGGGCUUUAAGAGU G	1060
AD-1684700.1	cscsuggaUfuAfAfAfaucuggecauL96	613	asdAstu gdGcdAgaudTuAfauccaggsusc	1970	GACCUGGAUUAUAAUUCUGCCA UU	1061
AD-1684701.1	csusggauUfaAfAfAfucuggecauuuL96	614	asdAasadGgdCagaudTuUfaauccagsgsu	1971	ACCUGGAUUAUAAUUCUGCCA UUU	1062
AD-1684702.1	usgsgauAfaAfAfUfuggecauuuuL96	641	asdAasadTgdGcagadTuUfuauuccasgsg	1972	CCUGGAUUAUAAUUCUGCCA UUUA	1089
AD-1684703.1	gsgsauuaAfaAfUfCfuggecauuuuL96	640	asdTsaadAudGgeagdAuUfuuaauecsasg	1973	CUGGAUUAUAAUUCUGCCA UUUAA	1088
AD-1684704.1	gsasuuuaAfaUfCfUfgecauuuuauL96	615	asdTsuadAadTggcadGaUfuuuauecsasa	1974	UGGAUUAUAAUUCUGCCA UUUAAU	1063
AD-1684705.1	asusuaaaAfuCfUfGfgecauuuuauL96	616	asdAsuudAadAuggcdAgAfuuuuauascsc	1975	GGAUUAUAAUUCUGCCA UUUAAU	1064
AD-1684706.1	asasaucGfcCfAfUfuuaauuagcuL96	617	asdGscudAadTuuaadTgGfcagauuusasc	1976	UAAAUUCUGCCA UUUAAUUAAGCU	1065

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	mRNA target sequence	SEQ ID NO.
AD-1684707.1	asasucugCfcAfUfUfuaauuagcuuL96	618	usa asdAsgcdTadAuuadAuGfgcagaauus usu	1977	AAAUCUGCCCAUUUAAUUAGCUG	1066
AD-1684708.1	asusucgeCfaUfUfUfuaauuagcugul96	619	usu asdCsagdCudAuuadAaUfggcagaus usu	1978	AAAUCUGCCCAUUUAAUUAGCUGC	1067
AD-1684709.1	uscsugccAfuUfUfAfaauuagcugcuL96	666	usu asdGscadGedTaaudAaAfuggcagag usu	1979	AAUCUGCCCAUUUAAUUAGCUGCA	1114
AD-1684710.1	csusgccAfuUfAfaAfauiagcugcauL96	620	asu asdTsgcdAgdCuauadTaAfauggcags asu	1980	AUCUGCCCAUUUAAUUAGCUGCAU	1068
AD-1684711.1	usgsccauUfuAfaUfuagcugcauL96	651	gsa asdAsugdCadGcuadTuAfauggcas gsa	1981	UCUGCCCAUUUAAUUAGCUGCAUA	1099
AD-1684712.1	ascsgcaaUfcUfGfCfcucauuuL96	621	usa asdGsaadAudTgaggdCaGfaungcgus usa	1982	UAAACGCAAUUCUGCCCUCAAUUUCU	1069
AD-1684713.1	csgscaauCfuGfCfCfcauuuL96	622	usu asdAsgadAadTugagdGcAfgaungcgs usu	1983	AACGCAAUUCUGCCCUCAAUUUCUU	1070
AD-1684714.1	gscsaauUfgCfCfUfcauuuL96	623	gsu asdAsagdAadAuugadGgCfagaungcs gsu	1984	ACGCAAUUCUGCCCUCAAUUUCUUC	1071
AD-1684715.1	csasaucUgcCfUfCfauuuL96	659	csg asdGsaadGadAauugdAgGfcaagaung csg	1985	CGCAAUUCUGCCCUCAAUUUCUUA	1107
AD-1684716.1	asasucugCfcUfCfAfauuuL96	624	gsc asdTsgadAgdAaaudGaGfgcagaauus gsc	1986	GCAAUUCUGCCCUCAAUUUCUUAU	1072
AD-1684717.1	asusucgcCfuCfAfAfuuuuL96	625	usg asdAsugdAadGaaadTgAfggcagaus usg	1987	CAAUCUGCCCUCAAUUUCUUAUC	1073
AD-1684718.1	uscsugccUfcAfaUfufuucuaucul96	626	usu asdGsaudGadAgaadTuGfaggcagag usu	1988	AAUCUGCCCUCAAUUUCUUAUCU	1074
AD-1684719.1	csusgccuCfaAfUfUfucuaucuuL96	627	asu asdAsgadTgdAgaadAuUfgaggcags asu	1989	AUCUGCCCUCAAUUUCUUAUCUG	1075
AD-1684720.1	usgsccucAfaUfUfUfucuaucugul96	628	gsa asdCsagdAudGaagadAaUfugaggcas gsa	1990	UCUGCCCUCAAUUUCUUAUCUGU	1076
AD-1684721.1	gscscucaAfuUfUfCfucaucugul96	629	asg asdAscadGadTgaagdAaAfuaggcs asg	1991	CUGCCCUCAAUUUCUUAUCUGUC	1077
AD-1684722.1	cscscaaaUfuUfCfUfucuaucugul96	647	csa asdGsacdAgdAugaadGaAfaungaggs csa	1992	UGCCCUCAAUUUCUUAUCUGUCA	1095
AD-1684723.1	csuscaauUfuCfUfUfcaucugul96	648	gsc asdTsgadCadGaugadAgAfaungaggs gsc	1993	GCCCUCAAUUUCUUAUCUGUCA	1096

Duplex Name	Sense Strand Sequence 5' to 3'	SEQ ID NO.	Antisense Strand Sequence 5' to 3'	SEQ ID NO.	mRNA target sequence	SEQ ID NO.
AD-1684724.1	uscsauuUfcUfUfCfaucugucaauL96	642	asdTsugdAcdAgaugdAaGfaaauugasg	1994	CCUCAUUUUCUUCUUCUGUCAAA	1090
AD-1684725.1	csasauuUfcUfCfAfucugucaauL96	630	asdTsugdGadCagaudGaAfgaaauugs	1995	CUCAUUUUCUUCUUCUGUCAAAU	1078
AD-1684726.1	asasuuuUfcUfCfAfufcugucaauL96	631	asdAsuudTgdAcaagdTaGafagaaauus	1996	UCAUUUUCUUCUUCUGUCAAAUG	1079
AD-1684727.1	asusuuuUfcUfCfAfufcugucaauL96	632	asdCsaudTudGacagdAuGfaagaaus	1997	CAAUUUUCUUCUUCUGUCAAAUGG	1080
AD-1684728.1	usuuuuUfcUfCfAfufcugucaauL96	643	asdCsaudTudTgacagdGaUfgaagaaasu	1998	AAUUUUCUUCUUCUGUCAAAUGGA	1091
AD-1684729.1	usuuuuUfcUfCfAfufcugucaauL96	639	asdTsccdAudTugacdAgAfugaagaas	1999	AUUUUCUUCUUCUGUCAAAUGGAA	1087
AD-1684730.1	asuuuuUfcUfCfAfufcugucaauL96	633	asdTsuedTgdTagccdAaGfcagaausg	2000	CCAAUUUCUUCUUCUGGCUACAGAAU	1081
AD-1684731.1	asuuuuUfcUfCfAfufcugucaauL96	634	asdAsuudCudGuagcdCaAfcagaaus	2001	CAAUUUCUUCUUCUGGCUACAGAAUU	1082
AD-1684732.1	usuuuuUfcUfCfAfufcugucaauL96	654	asdAsaudTcdTguagcdCcAfcagaaasu	2002	AAUUUCUUCUUCUGGCUACAGAAUUA	1102
AD-1684733.1	usuuuuUfcUfCfAfufcugucaauL96	635	asdTsaudTudCugudGcCfaagcagasa	2003	AUUUCUUCUUCUGGCUACAGAAUUAU	1083
AD-1684734.1	csuuuuUfcUfCfAfufcugucaauL96	636	asdAsuudAudTcugudAgCfcaagcags	2004	UUCUGCUUCUGGCUACAGAAUUAU	1084
AD-1684735.1	usuuuuUfcUfCfAfufcugucaauL96	637	asdAsaudAadTucudTaGfccaagcags	2005	UCUGCUUCUGGCUACAGAAUUAUUG	1085
AD-1684736.1	gscuuuuUfcUfCfAfufcugucaauL96	638	asdCsaudTadAuucudGuAfgccaagcs	2006	CUGCUUCUGGCUACAGAAUUAUUGU	1086
AD-1684737.1	asuuuuUfcUfCfAfufcugucaauL96	652	asdGsaudTudTaucudTcAfcuaaauus	2007	GAAUUUUUGUGAGGAUUAUUAUC	1100

Table 14. KHK Single Dose Screen in Hep3b Cells

	10 nM		1 nM		0.1 nM	
Duplex ID	Average % message remaining	STDEV	Average % message remaining	STDEV	Average % message remaining	STDEV
AD-1290635.2	98.30	12.80	109.90	0.00	133.00	0.00
AD-1684641.1	25.30	0.00	51.50	14.40	18.60	10.60
AD-1684620.1	7.20	2.70	11.30	0.70	10.10	2.10
AD-1684619.1	6.60	1.50	13.70	3.60	17.90	2.90
AD-1684610.1	7.60	1.60	15.40	3.70	25.00	7.40
AD-1684617.1	7.60	1.40	13.30	5.40	12.50	4.00
AD-1613079.2	9.70	2.20	36.70	8.80	33.60	5.70
AD-1684618.1	5.60	0.70	13.00	4.60	9.50	1.60
AD-1684622.1	8.30	2.50	14.00	2.30	17.60	4.50
AD-1684607.1	8.30	0.90	14.40	2.70	12.10	2.10
AD-1684614.1	7.80	1.50	22.00	7.60	23.30	7.70
AD-1613059.2	8.50	0.50	11.70	1.40	11.80	1.50
AD-1613075.2	6.90	0.70	16.00	4.90	19.60	6.80
AD-1613061.1	5.90	2.20	8.00	2.50	10.50	6.10
AD-1684608.1	10.20	2.80	19.20	3.00	18.80	6.80
AD-1684624.1	16.50	3.50	31.80	5.70	50.70	12.80
AD-1423319.3	9.20	0.70	14.40	2.10	14.90	1.60
AD-1684606.1	8.10	2.00	12.40	2.20	14.10	4.40
AD-1684609.1	8.40	1.20	17.00	2.90	14.00	4.00
AD-1684616.1	15.20	2.90	29.70	8.40	31.50	3.00
AD-1613060.2	13.60	1.70	27.00	1.90	29.80	9.50
AD-1613087.1	16.80	2.90	35.50	6.30	39.80	10.40
AD-1290539.5	12.30	2.80	18.30	2.90	21.70	2.50
AD-1290885.5	17.50	5.90	41.70	7.50	63.60	1.40
AD-1613062.2	12.10	2.10	24.10	4.90	28.60	9.00
AD-1684611.1	14.70	3.70	22.30	2.40	26.50	6.10
AD-1684623.1	18.60	3.60	31.90	3.00	59.60	13.80
AD-1612969.2	15.40	4.00	30.40	10.90	52.70	6.80
AD-1613256.2	8.30	1.20	23.60	6.70	33.40	3.80
AD-1423312.3	5.70	2.30	20.50	5.50	16.00	5.80
AD-1548743.7	14.60	2.40	24.20	2.30	34.60	8.10
AD-1684596.1	21.40	8.00	20.40	0.70	24.30	6.00
AD-1423336.7	10.90	1.50	32.80	3.40	36.60	5.80
AD-1612963.2	12.30	4.10	26.50	5.90	28.70	7.10
AD-1290611.3	15.60	3.80	32.40	7.40	54.20	10.00
AD-1613254.2	11.60	2.20	20.70	4.50	24.00	2.80
AD-1684612.1	11.70	1.00	19.50	2.70	31.70	9.10
AD-1684645.1	14.90	2.80	28.80	6.70	35.70	4.70
AD-1684621.1	21.20	6.50	59.50	12.40	42.00	9.10

	10 nM		1 nM		0.1 nM	
Duplex ID	Average % message remaining	STDEV	Average % message remaining	STDEV	Average % message remaining	STDEV
AD-1290837.5	17.70	6.20	49.70	7.60	69.90	15.10
AD-1684598.1	37.30	9.50	67.00	19.00	66.40	10.90
AD-1684638.1	23.00	6.60	47.50	13.90	40.40	7.20
AD-1290599.7	11.00	1.20	18.60	3.30	40.00	5.00
AD-1613400.2	7.80	1.70	19.10	7.80	23.00	2.20
AD-1684615.1	17.50	3.20	41.00	2.90	52.70	6.40
AD-1684630.1	14.20	1.30	45.40	10.30	51.20	10.00
AD-1613072.1	43.70	14.40	72.70	6.50	86.70	11.40
AD-1684632.1	17.50	5.60	36.80	7.70	53.40	3.40
AD-1613242.2	11.60	2.60	28.40	9.80	35.20	8.90
AD-1684605.1	53.80	6.00	72.00	8.60	102.80	17.40
AD-1684594.1	16.70	3.90	27.10	4.20	35.80	9.10
AD-1612957.2	14.90	5.10	29.60	7.40	25.90	6.30
AD-1290971.3	13.60	2.40	37.60	9.50	36.90	12.60
AD-1684595.1	29.60	9.90	49.80	12.20	52.40	9.80
AD-1613371.3	14.20	4.40	27.70	5.80	32.10	2.80
AD-1684593.1	20.10	5.10	32.70	10.70	39.60	13.90
AD-1684639.1	13.50	4.50	35.10	6.50	39.90	2.30
AD-1613094.2	16.80	5.20	38.70	4.90	58.50	17.50
AD-1684597.1	30.30	3.00	61.00	14.40	48.90	4.70
AD-1290563.2	50.40	7.90	92.60	14.00	95.40	26.70
AD-1684599.1	41.60	13.60	66.40	17.20	66.80	14.50
AD-1684640.1	17.80	3.60	50.90	10.60	62.70	11.10
AD-1290584.2	32.10	9.80	70.00	11.80	76.10	20.40
AD-1684627.1	20.10	10.50	54.00	12.10	71.60	11.20
AD-1290969.7	18.50	5.40	31.80	7.00	34.30	5.10
AD-1290651.2	51.80	11.50	100.80	20.90	117.60	24.10
AD-1684628.1	17.40	7.00	26.80	5.30	34.10	6.40
AD-1290884.5	20.80	7.20	37.60	7.60	39.00	5.00
AD-1684633.1	25.60	5.90	52.30	3.50	77.80	17.00
AD-1684637.1	31.90	10.90	55.00	9.20	68.60	17.60
AD-1684629.1	38.00	5.90	86.00	13.60	91.70	16.40
AD-1684635.1	32.60	4.30	87.20	14.10	45.90	4.10
AD-1684613.1	43.20	9.20	84.20	23.20	75.90	26.30
AD-1684604.1	47.30	8.80	78.10	15.50	83.00	11.40
AD-1290666.2	28.30	8.10	62.20	16.50	74.10	11.60
AD-1684634.1	39.90	11.00	76.80	9.60	86.20	17.40
AD-1684600.1	70.30	11.40	101.80	5.30	63.80	22.40
AD-1684644.1	68.00	19.10	159.30	17.60	131.10	15.50
AD-1684643.1	96.80	16.70	130.10	23.00	140.40	19.50

	10 nM		1 nM		0.1 nM	
Duplex ID	Average % message remaining	STDEV	Average % message remaining	STDEV	Average % message remaining	STDEV
AD-1684601.1	92.10	22.20	136.00	33.00	115.30	33.70
AD-1684626.1	35.10	7.20	65.30	10.50	66.90	5.70
AD-1684642.1	72.30	18.80	116.80	22.20	124.30	8.60
AD-1684592.1	68.50	13.90	120.10	23.20	85.70	6.80
AD-1684636.1	52.00	18.10	88.40	34.10	87.30	10.60
AD-1684603.1	133.70	13.10	143.80	21.30	128.00	22.60
AD-1684631.1	114.50	35.20	163.20	10.70	162.80	24.90
AD-1684625.1	74.60	12.90	121.80	25.30	105.40	20.30
AD-1290523.2	38.30	4.50	44.10	3.20	49.20	15.10
AD-1684602.1	91.40	21.30	151.40	24.60	110.60	24.70
AD-1290570.2	113.50	16.00	137.90	22.90	94.90	11.30
AD-1684666.1	116.20	5.80	109.50	14.40	143.90	23.60
AD-1290865.2	58.40	13.50	64.50	10.30	77.90	7.80
AD-1290589.2	92.60	17.80	108.80	5.90	113.00	7.50
AD-1684681.1	111.40	18.20	129.40	13.10	131.70	21.70
AD-1684689.1	148.40	36.10	91.30	3.00	122.40	27.70
AD-1684708.1	51.20	10.40	83.10	17.60	93.00	21.90
AD-1290557.2	118.30	12.80	76.90	5.70	125.20	33.40
AD-1290515.2	106.60	14.40	116.50	20.20	98.10	9.30
AD-1290741.2	109.20	9.20	119.20	28.90	144.10	20.80
AD-1684713.1	91.70	14.60	84.70	7.90	116.30	17.60
AD-1290650.2	89.60	6.80	75.90	10.30	123.80	18.30
AD-1290897.2	54.80	10.60	81.70	22.90	75.20	24.00
AD-1290556.2	123.30	14.80	92.50	13.30	115.10	12.00
AD-1290750.2	93.70	13.30	95.10	14.20	100.10	12.50
AD-1684714.1	98.00	6.20	136.70	24.30	118.10	12.60
AD-1290654.2	102.80	15.70	119.50	14.80	134.00	32.20
AD-1290909.2	91.20	10.30	108.90	34.40	81.90	22.00
AD-1684674.1	96.60	21.20	118.40	19.30	112.90	27.70
AD-1684712.1	46.90	8.60	88.20	13.40	75.30	13.50
AD-1290796.2	111.90	12.00	119.70	14.30	171.60	18.40
AD-1290612.2	65.20	11.20	94.10	16.20	87.40	11.00
AD-1290633.2	106.60	11.10	94.20	9.50	97.00	23.00
AD-1684691.1	142.10	25.10	112.20	13.20	129.20	9.80
AD-1290659.2	79.40	14.80	103.40	10.30	120.70	13.50
AD-1684686.1	107.60	17.70	129.20	33.80	108.30	23.50
AD-1290604.2	60.90	12.20	64.30	15.40	76.30	16.10
AD-1290574.2	121.10	5.80	122.10	15.40	128.60	12.90
AD-1290609.2	87.60	13.30	111.90	17.40	91.70	17.20
AD-1290911.2	134.00	15.60	65.80	14.70	82.30	16.50

	10 nM		1 nM		0.1 nM	
Duplex ID	Average % message remaining	STDEV	Average % message remaining	STDEV	Average % message remaining	STDEV
AD-1290615.2	110.30	11.00	127.90	11.60	158.20	13.00
AD-1684710.1	95.20	12.40	103.60	33.60	117.10	10.50
AD-1684709.1	89.50	19.50	81.20	18.80	92.00	6.10
AD-1290533.2	91.20	19.70	104.90	13.90	99.00	13.30
AD-1684671.1	78.00	7.50	102.80	18.70	98.50	11.20
AD-1684650.1	108.50	3.10	127.80	12.40	118.90	14.50
AD-1684711.1	109.10	20.40	116.90	21.40	106.80	24.30
AD-1684670.1	73.90	14.70	104.70	17.20	127.80	8.90
AD-1684692.1	96.10	16.30	113.50	17.10	103.70	8.30
AD-1290939.2	112.00	10.60	108.90	18.70	101.00	11.20
AD-1684662.1	113.70	21.40	115.40	20.80	117.00	19.60
AD-1684700.1	97.00	21.20	99.20	20.90	65.60	13.10
AD-1290742.2	120.00	18.60	140.80	26.00	97.10	12.40
AD-1684715.1	85.70	18.20	72.70	18.50	120.60	8.70
AD-1290894.2	102.60	11.70	125.50	28.90	149.60	44.30
AD-1684718.1	112.50	13.00	122.40	22.90	136.80	18.20
AD-1290702.2	112.80	29.70	73.50	8.90	80.50	18.40
AD-1684688.1	106.50	25.50	124.40	36.40	123.10	16.60
AD-1684690.1	110.50	5.50	94.50	13.40	106.60	11.50
AD-1684672.1	94.00	12.20	91.00	4.70	98.10	9.30
AD-1684684.1	124.60	21.80	134.40	17.30	121.20	11.40
AD-1684723.1	122.90	4.90	137.70	20.30	142.70	35.90
AD-1684651.1	121.50	44.40	94.60	19.10	107.00	15.50
AD-1684683.1	86.10	5.00	122.80	16.60	91.60	12.10
AD-1290973.2	135.00	19.60	121.30	17.90	129.00	27.10
AD-1290857.2	106.00	12.00	105.00	22.10	89.90	13.10
AD-1684649.1	61.80	9.50	90.40	9.30	67.00	31.50
AD-1290516.2	106.50	19.40	84.40	15.50	70.60	6.80
AD-1290554.2	71.60	21.20	72.80	12.90	71.10	20.50
AD-1290509.2	115.50	16.80	112.90	19.60	92.90	15.10
AD-1290660.2	132.60	30.90	135.00	21.70	98.20	28.10
AD-1684698.1	116.30	8.30	111.20	6.20	90.70	25.00
AD-1290670.2	122.20	6.90	135.80	24.50	150.90	20.40
AD-1684673.1	101.80	11.20	103.80	5.00	105.40	30.20
AD-1684646.1	148.30	19.10	159.50	17.50	128.30	21.40
AD-1290597.2	109.30	23.60	97.80	15.50	109.10	34.10
AD-1290573.2	71.20	7.50	88.60	4.80	93.50	6.40
AD-1684707.1	88.20	7.50	94.50	13.40	91.10	19.00
AD-1684722.1	102.60	11.40	147.30	34.10	162.60	1.40
AD-1290639.2	88.00	11.40	74.20	8.40	83.20	11.10

	10 nM		1 nM		0.1 nM	
Duplex ID	Average % message remaining	STDEV	Average % message remaining	STDEV	Average % message remaining	STDEV
AD-1290551.2	100.60	27.30	74.50	19.50	105.80	31.00
AD-1684655.1	146.00	14.60	127.60	21.40	109.60	18.60
AD-1684678.1	148.20	38.60	144.00	24.60	160.70	11.20
AD-1290800.2	129.20	17.20	141.00	10.40	119.30	16.10
AD-1684726.1	83.90	6.80	95.10	21.20	153.80	21.30
AD-1290764.2	85.70	9.50	100.30	16.60	89.50	14.40
AD-1290672.2	90.20	14.50	108.20	6.50	122.60	29.80
AD-1684685.1	158.00	23.20	147.70	27.30	131.50	17.80
AD-1290528.2	17.30	2.30	26.80	4.40	35.90	7.40
AD-1684696.1	83.80	15.70	87.80	20.90	56.60	13.20
AD-1290836.2	120.80	24.10	138.00	20.80	153.80	22.50
AD-1684682.1	99.50	7.40	121.50	22.20	102.10	19.30
AD-1684659.1	61.20	13.60	89.50	3.40	102.00	18.30
AD-1684669.1	101.90	15.80	114.60	19.50	112.10	24.30
AD-1684704.1	115.60	9.50	143.60	36.20	111.10	34.60
AD-1684716.1	83.10	11.60	87.30	7.90	106.30	22.40
AD-1684699.1	106.50	14.40	111.70	29.80	64.20	17.80
AD-1290510.2	112.30	18.30	137.60	27.30	155.40	21.70
AD-1290531.2	87.20	9.20	113.60	33.80	125.10	21.60
AD-1684703.1	101.00	14.00	104.40	15.90	81.80	17.40
AD-1290910.2	96.60	6.80	96.30	35.70	123.50	13.10
AD-1684705.1	98.30	15.30	108.60	32.30	96.40	21.30
AD-1290618.2	109.80	9.20	117.20	13.60	72.30	17.00
AD-1684668.1	95.50	5.80	105.80	16.30	103.00	8.00
AD-1684701.1	61.40	12.80	59.40	11.60	81.70	15.50
AD-1290542.2	110.40	18.30	120.10	23.60	110.00	3.90
AD-1290626.2	92.50	9.90	95.20	10.10	105.00	8.60
AD-1684724.1	98.40	8.20	106.50	12.10	144.80	26.30
AD-1290535.2	131.60	18.00	137.80	13.30	127.70	33.60
AD-1290558.2	129.70	41.60	107.30	30.00	61.90	12.50
AD-1684647.1	118.10	43.70	124.50	25.80	94.60	17.50
AD-1290763.2	91.60	6.90	121.20	18.40	105.70	16.10
AD-1684677.1	94.50	18.30	97.10	22.20	103.50	4.00
AD-1684658.1	115.10	25.50	108.90	16.00	126.20	12.60
AD-1684687.1	92.20	17.60	107.40	15.70	104.80	11.50
AD-1684719.1	97.00	5.10	121.20	5.20	106.00	10.70
AD-1290681.2	130.40	12.30	120.30	17.30	113.50	18.10
AD-1684653.1	133.20	34.50	112.90	7.20	94.80	25.20
AD-1290841.2	166.20	35.70	140.10	1.50	147.10	15.70
AD-1290687.2	83.90	6.80	140.00	15.70	138.80	12.90

	10 nM		1 nM		0.1 nM	
Duplex ID	Average % message remaining	STDEV	Average % message remaining	STDEV	Average % message remaining	STDEV
AD-1290592.2	75.50	4.00	63.30	22.80	53.40	4.00
AD-1290522.2	86.40	5.50	102.50	18.10	95.70	11.40
AD-1290880.2	125.50	24.70	94.30	11.10	126.00	12.60
AD-1684693.1	56.90	19.40	53.80	7.10	46.50	6.60
AD-1684679.1	96.50	11.30	111.50	11.40	115.70	21.40
AD-1290555.2	102.60	12.20	59.80	6.50	74.00	33.30
AD-1684648.1	64.70	25.60	86.20	8.10	69.90	28.10
AD-1684725.1	97.40	10.30	109.20	10.50	143.70	21.00
AD-1684706.1	37.50	4.70	46.80	16.60	55.10	14.90
AD-1684663.1	111.70	15.50	118.30	30.30	86.10	35.10
AD-1684702.1	100.20	11.00	79.80	12.00	81.80	10.10
AD-1291003.2	110.40	24.90	108.30	14.50	122.30	20.40
AD-1684664.1	110.20	5.00	117.70	22.00	98.80	7.20
AD-1684697.1	58.70	13.20	66.60	14.80	62.10	15.80
AD-1290514.2	89.80	6.40	108.60	7.20	151.30	18.10
AD-1290989.2	93.40	7.70	101.00	18.70	110.30	13.70
AD-1684657.1	90.30	11.70	98.80	16.00	99.70	29.30
AD-1684654.1	128.30	24.50	109.50	22.10	105.60	33.40
AD-1684695.1	106.60	19.70	91.90	14.50	58.70	7.60
AD-1290712.2	78.60	8.50	126.00	31.80	96.20	13.60
AD-1290931.2	144.80	16.70	127.50	23.50	120.60	18.50
AD-1684729.1	117.20	9.80	134.20	14.70	138.70	25.30
AD-1290805.2	87.90	18.00	94.50	33.50	102.90	20.50
AD-1290755.2	117.00	13.30	124.90	28.50	125.00	29.10
AD-1290527.2	124.10	2.80	76.20	21.60	92.30	31.20
AD-1684652.1	102.00	14.00	96.20	28.30	72.30	18.50
AD-1290507.2	107.20	18.20	118.90	22.10	145.70	41.10
AD-1290747.2	119.20	36.80	103.60	5.30	102.40	14.10
AD-1290926.2	104.90	20.70	105.00	24.10	85.60	16.00
AD-1290983.2	93.70	26.10	136.80	26.50	117.40	15.60
AD-1684680.1	119.70	9.90	115.70	20.40	112.70	18.00
AD-1290605.2	82.10	14.20	96.30	22.40	90.80	9.80
AD-1290842.2	147.60	23.00	145.10	24.30	151.50	27.20
AD-1290565.2	90.90	12.90	107.40	14.80	162.30	28.00
AD-1290661.2	81.70	18.70	82.70	7.80	73.00	24.20
AD-1684667.1	41.60	3.10	54.00	5.90	61.80	5.20
AD-1290684.2	85.00	8.00	92.90	11.80	101.60	7.90
AD-1290524.2	114.60	17.20	143.40	15.60	139.30	26.90
AD-1290655.2	142.20	24.00	128.40	16.50	136.10	21.10
AD-1684660.1	110.20	18.10	134.30	16.20	122.60	20.30

	10 nM		1 nM		0.1 nM	
Duplex ID	Average % message remaining	STDEV	Average % message remaining	STDEV	Average % message remaining	STDEV
AD-1684656.1	87.70	37.40	75.00	26.10	76.20	25.20
AD-1684676.1	37.60	2.80	58.60	12.60	72.40	5.00
AD-1684727.1	104.30	31.00	110.10	20.50	117.50	12.10
AD-1684665.1	115.00	28.50	115.70	16.40	105.90	4.90
AD-1290993.2	126.50	14.30	107.50	12.10	98.50	26.30
AD-1684721.1	84.80	4.40	115.10	9.00	144.20	10.10
AD-1290543.2	41.90	8.40	52.50	9.70	54.00	10.30
AD-1290719.2	102.80	11.70	107.60	10.40	136.50	13.40
AD-1290602.2	97.50	7.70	111.60	23.90	116.30	21.10
AD-1290564.2	51.40	1.80	55.70	6.00	75.50	15.00
AD-1684737.1	96.80	16.70	111.80	9.20	105.40	18.20
AD-1684694.1	63.70	21.10	65.10	20.50	72.20	15.80
AD-1290875.2	116.90	11.10	123.80	27.30	72.10	27.80
AD-1684732.1	99.40	14.40	91.50	17.70	138.80	7.00
AD-1684717.1	49.00	11.30	101.40	15.10	104.80	3.30
AD-1290908.2	118.70	7.20	117.70	15.60	97.80	14.70
AD-1684720.1	86.00	2.70	90.20	15.90	112.10	6.60
AD-1290552.2	98.50	16.80	121.20	17.10	137.80	29.70
AD-1684728.1	101.60	25.20	113.60	20.10	136.80	29.60
AD-1684731.1	137.20	10.40	126.20	11.10	142.60	2.40
AD-1290722.2	137.00	19.70	166.40	13.80	170.50	18.70
AD-1684730.1	130.20	30.50	117.60	15.60	117.80	9.00
AD-1684736.1	128.90	12.90	137.40	13.70	135.60	30.10
AD-1684733.1	169.30	14.60	170.60	26.10	178.70	11.10
AD-1684661.1	31.60	6.40	41.70	8.40	48.80	15.50
AD-1684734.1	80.20	13.20	65.20	20.10	85.00	20.90
AD-1684735.1	114.70	26.20	94.40	18.00	119.80	18.20
AD-1290600.2	120.90	18.80	101.00	13.30	118.60	9.70
AD-1290624.2	130.50	13.50	141.60	27.20	115.50	17.40
AD-1290643.2	111.40	14.00	62.10	21.50	114.00	21.40
AD-1684675.1	94.00	21.20	89.60	10.90	84.00	7.70

Table 15. KHK Single Dose Screen in PCH Cells

	10 nM		1 nM		0.1 nM	
Duplex ID	Average % message remaining	STDEV	Average % message remaining	STDEV	Average % message remaining	STDEV
AD-1290635.2	23.50	10.50	0.00	0.00	21.60	5.20
AD-1684641.1	0.00	0.00	0.00	0.00	6.00	0.20
AD-1684620.1	1.00	0.10	1.70	0.50	3.20	0.30

	10 nM		1 nM		0.1 nM	
Duplex ID	Average % message remaining	STDEV	Average % message remaining	STDEV	Average % message remaining	STDEV
AD-1684619.1	1.30	0.10	2.00	0.10	2.80	0.30
AD-1684610.1	2.00	0.60	2.10	0.20	4.20	0.50
AD-1684617.1	1.70	0.10	2.10	0.40	3.00	0.50
AD-1613079.2	1.40	0.40	2.30	0.20	3.90	1.00
AD-1684618.1	1.00	0.30	2.30	0.30	3.40	0.60
AD-1684622.1	1.80	0.20	2.40	0.20	4.20	0.80
AD-1684607.1	1.60	0.10	2.50	0.40	5.60	0.80
AD-1684614.1	2.10	0.70	2.60	0.30	4.30	0.30
AD-1613059.2	1.90	0.40	2.70	0.40	5.10	0.20
AD-1613075.2	1.10	0.30	2.70	0.30	3.50	0.20
AD-1613061.1	1.90	0.70	2.80	0.30	5.00	0.80
AD-1684608.1	2.10	0.30	2.80	0.20	6.10	1.10
AD-1684624.1	1.70	0.20	2.80	1.00	7.00	1.30
AD-1423319.3	1.90	0.40	2.90	0.80	4.90	0.70
AD-1684606.1	2.00	0.30	3.10	0.20	5.80	0.80
AD-1684609.1	2.00	0.30	3.10	0.30	5.50	0.60
AD-1684616.1	2.20	0.50	3.10	0.80	5.20	1.40
AD-1613060.2	2.00	0.70	3.30	0.20	6.30	1.40
AD-1613087.1	1.50	0.20	3.30	0.10	5.30	0.70
AD-1290539.5	2.50	0.10	3.80	0.10	6.20	0.70
AD-1290885.5	2.00	0.40	3.90	0.60	6.30	0.90
AD-1613062.2	2.80	0.40	3.90	0.10	6.90	0.80
AD-1684611.1	2.00	0.20	4.00	0.80	7.70	0.80
AD-1684623.1	3.10	0.30	4.00	0.80	7.90	1.80
AD-1612969.2	3.90	0.40	4.70	0.60	11.30	1.20
AD-1613256.2	3.60	0.40	4.70	1.10	7.20	1.00
AD-1423312.3	3.60	1.70	4.80	0.90	7.60	2.20
AD-1548743.7	4.40	1.30	4.90	0.30	9.30	1.90
AD-1684596.1	4.40	0.60	4.90	0.70	13.40	3.90
AD-1423336.7	2.40	0.70	5.00	1.30	8.00	2.30
AD-1612963.2	4.40	0.70	5.00	0.30	12.50	1.60
AD-1290611.3	2.60	0.70	5.20	1.10	12.60	3.50
AD-1613254.2	3.50	1.00	5.20	1.40	9.80	2.60
AD-1684612.1	3.40	1.00	5.30	0.90	9.60	0.40
AD-1684645.1	3.00	0.60	5.50	1.20	6.20	0.40
AD-1684621.1	3.10	0.40	5.80	0.10	12.10	3.10
AD-1290837.5	2.50	0.60	5.90	0.80	13.90	1.50
AD-1684598.1	4.60	1.10	6.00	0.70	14.80	2.90
AD-1684638.1	4.00	1.30	6.30	1.10	8.60	1.80
AD-1290599.7	3.70	1.00	6.50	1.10	11.80	1.80
AD-1613400.2	4.50	1.30	6.60	1.40	10.30	2.40

Duplex ID	10 nM		1 nM		0.1 nM	
	Average % message remaining	STDEV	Average % message remaining	STDEV	Average % message remaining	STDEV
AD-1684615.1	2.70	0.80	6.60	1.10	13.00	1.90
AD-1684630.1	4.00	1.70	6.70	1.30	9.60	1.70
AD-1613072.1	3.30	1.00	6.90	0.70	12.30	1.80
AD-1684632.1	4.10	1.50	7.00	1.30	8.00	1.10
AD-1613242.2	5.10	2.20	7.10	1.20	9.20	2.30
AD-1684605.1	7.30	1.30	7.60	0.90	17.10	1.90
AD-1684594.1	6.70	1.00	7.70	1.20	15.60	2.10
AD-1612957.2	5.00	0.80	7.80	1.80	14.00	1.10
AD-1290971.3	6.20	1.90	8.10	1.50	12.80	2.00
AD-1684595.1	5.90	0.70	8.20	2.20	18.90	1.30
AD-1613371.3	4.40	1.10	8.80	1.00	9.60	1.10
AD-1684593.1	6.30	0.80	8.80	1.10	12.00	2.50
AD-1684639.1	5.70	1.90	8.80	1.70	19.10	5.30
AD-1613094.2	6.90	1.20	9.70	0.90	19.90	4.60
AD-1684597.1	5.70	1.00	9.70	1.60	22.40	2.80
AD-1290563.2	17.60	5.00	9.80	0.00	27.40	8.90
AD-1684599.1	4.90	1.80	9.90	1.80	19.80	2.70
AD-1684640.1	6.40	2.70	10.10	1.50	18.20	4.00
AD-1290584.2	5.50	2.50	10.40	1.30	15.80	3.80
AD-1684627.1	5.90	1.70	12.30	1.00	21.60	3.70
AD-1290969.7	6.70	2.40	12.60	4.00	16.80	5.60
AD-1290651.2	3.90	1.10	13.30	1.50	24.70	4.10
AD-1684628.1	9.10	2.40	13.30	0.20	18.50	2.20
AD-1290884.5	5.40	1.60	13.60	1.70	22.20	5.90
AD-1684633.1	8.20	3.80	14.20	0.90	27.10	5.90
AD-1684637.1	7.80	3.50	15.10	2.00	23.00	2.60
AD-1684629.1	5.80	1.90	16.90	3.20	24.00	1.40
AD-1684635.1	12.10	2.70	17.10	1.20	27.50	7.70
AD-1684613.1	7.10	2.10	18.20	3.80	35.50	5.20
AD-1684604.1	11.80	0.40	19.90	0.60	41.60	2.50
AD-1290666.2	10.00	3.00	20.80	4.80	37.00	2.30
AD-1684634.1	10.00	4.00	22.70	4.00	37.30	6.30
AD-1684600.1	11.60	1.90	27.90	0.80	53.10	5.40
AD-1684644.1	15.60	4.80	28.80	3.10	55.40	19.80
AD-1684643.1	12.20	4.20	30.20	2.80	41.90	4.30
AD-1684601.1	16.00	2.10	31.20	3.80	60.10	6.00
AD-1684626.1	21.50	6.40	31.60	5.10	60.50	16.20
AD-1684642.1	13.50	4.60	35.50	5.20	56.50	8.40
AD-1684592.1	21.80	1.90	35.70	5.00	59.70	6.20
AD-1684636.1	11.30	4.50	38.10	6.60	59.60	14.00
AD-1684603.1	22.70	4.00	51.50	2.10	77.80	11.40

	10 nM		1 nM		0.1 nM	
Duplex ID	Average % message remaining	STDEV	Average % message remaining	STDEV	Average % message remaining	STDEV
AD-1684631.1	21.40	7.60	53.80	9.50	68.00	7.30
AD-1684625.1	12.80	4.50	54.20	7.70	67.50	14.20
AD-1290523.2	68.70	17.50	67.80	25.20	105.40	19.60
AD-1684602.1	37.60	3.30	69.00	5.10	99.90	5.60
AD-1290570.2	113.90	17.40	74.40	15.30	118.80	10.50
AD-1684666.1	114.80	4.60	75.40	12.40	99.60	7.20
AD-1290865.2	90.60	6.20	76.50	35.10	107.90	14.00
AD-1290589.2	133.30	30.50	77.30	8.40	120.40	23.60
AD-1684681.1	118.30	35.00	80.70	18.10	115.30	14.10
AD-1684689.1	145.00	30.40	82.20	13.40	100.00	21.80
AD-1684708.1	85.20	12.90	83.50	7.60	89.10	5.30
AD-1290557.2	143.10	27.50	85.40	13.60	142.40	27.30
AD-1290515.2	146.90	30.00	85.90	15.30	152.80	28.10
AD-1290741.2	77.20	17.70	86.30	19.50	88.50	16.50
AD-1684713.1	81.30	21.10	86.80	14.00	89.80	15.00
AD-1290650.2	70.10	15.20	87.00	13.50	93.80	15.50
AD-1290897.2	84.50	12.20	88.50	35.40	98.20	8.90
AD-1290556.2	130.10	24.90	88.60	21.40	149.90	29.90
AD-1290750.2	41.60	15.10	89.20	24.30	131.10	34.80
AD-1684714.1	84.20	10.00	89.20	7.70	80.10	8.10
AD-1290654.2	117.30	18.70	89.50	16.40	107.40	13.50
AD-1290909.2	79.50	5.30	89.50	12.00	87.40	12.00
AD-1684674.1	109.80	18.20	89.60	26.20	94.20	6.20
AD-1684712.1	75.20	12.40	89.70	6.10	87.70	10.50
AD-1290796.2	94.60	12.30	90.70	8.80	104.30	13.60
AD-1290612.2	141.60	32.40	90.80	5.60	116.90	22.40
AD-1290633.2	92.10	16.50	90.80	4.20	91.90	11.20
AD-1684691.1	130.90	21.50	90.80	10.80	147.30	22.50
AD-1290659.2	77.40	11.60	91.50	10.90	83.40	8.80
AD-1684686.1	115.30	23.00	91.80	23.80	132.80	20.30
AD-1290604.2	102.20	21.70	92.60	11.90	91.50	11.60
AD-1290574.2	118.10	16.60	93.80	4.40	138.30	11.10
AD-1290609.2	76.10	7.50	93.90	12.10	79.40	4.90
AD-1290911.2	83.20	10.90	94.10	22.60	85.00	20.70
AD-1290615.2	83.40	11.20	94.90	16.30	87.60	9.90
AD-1684710.1	83.80	5.80	95.20	11.00	89.50	7.60
AD-1684709.1	74.10	5.00	95.40	15.30	91.70	6.20
AD-1290533.2	60.80	2.90	96.00	21.40	98.10	5.80
AD-1684671.1	109.90	24.30	96.10	27.80	114.60	15.80
AD-1684650.1	88.00	6.10	96.50	24.20	100.70	11.50
AD-1684711.1	74.10	6.90	97.00	3.80	91.30	7.20

	10 nM		1 nM		0.1 nM	
Duplex ID	Average % message remaining	STDEV	Average % message remaining	STDEV	Average % message remaining	STDEV
AD-1684670.1	87.20	10.00	97.30	28.90	90.90	5.20
AD-1684692.1	141.10	33.00	97.50	14.20	136.30	32.50
AD-1290939.2	122.30	10.60	98.30	11.70	128.50	6.70
AD-1684662.1	99.20	17.30	98.60	8.40	100.00	20.40
AD-1684700.1	99.30	9.10	98.60	9.60	106.60	10.90
AD-1290742.2	129.20	16.80	98.90	12.20	128.20	17.60
AD-1684715.1	93.70	10.90	98.90	10.10	100.70	9.00
AD-1290894.2	68.90	12.30	99.60	29.10	80.80	16.30
AD-1684718.1	83.00	3.60	99.60	5.80	96.10	14.40
AD-1290702.2	82.00	17.20	100.60	20.70	90.80	15.10
AD-1684688.1	126.60	29.80	100.60	9.30	144.00	31.80
AD-1684690.1	156.10	29.90	101.30	11.40	156.50	25.20
AD-1684672.1	119.50	27.80	101.40	23.10	125.10	34.20
AD-1684684.1	109.90	17.40	102.00	9.20	116.50	8.10
AD-1684723.1	89.40	12.20	102.40	7.90	107.30	6.20
AD-1684651.1	77.60	7.90	102.50	16.10	86.80	14.20
AD-1684683.1	122.10	20.10	102.50	12.50	135.40	19.70
AD-1290973.2	66.80	15.60	103.80	13.80	93.70	11.40
AD-1290857.2	92.30	5.20	103.90	6.10	105.60	6.90
AD-1684649.1	78.90	6.80	103.90	27.90	103.80	11.00
AD-1290516.2	89.30	12.20	105.20	7.00	107.80	12.00
AD-1290554.2	101.40	2.80	105.20	10.30	102.20	6.50
AD-1290509.2	93.00	10.80	105.40	4.20	113.40	8.80
AD-1290660.2	101.60	7.50	105.40	4.70	98.80	6.00
AD-1684698.1	105.40	4.50	105.60	11.70	110.20	7.20
AD-1290670.2	88.70	6.50	106.10	15.30	94.50	10.60
AD-1684673.1	88.30	5.20	106.10	2.50	94.50	11.50
AD-1684646.1	68.80	21.90	106.60	19.00	127.30	25.00
AD-1290597.2	105.80	10.00	107.40	3.40	110.00	12.20
AD-1290573.2	97.40	12.60	107.90	15.20	92.20	10.80
AD-1684707.1	86.40	2.60	108.00	4.80	98.50	11.00
AD-1684722.1	96.60	11.70	108.00	12.10	96.90	8.80
AD-1290639.2	106.10	7.10	108.40	8.50	103.50	6.20
AD-1290551.2	111.70	7.50	109.50	7.80	104.80	7.70
AD-1684655.1	91.50	9.00	109.50	7.40	94.60	5.10
AD-1684678.1	91.10	9.20	109.50	5.60	88.50	3.60
AD-1290800.2	107.10	7.30	109.60	10.90	93.70	8.50
AD-1684726.1	104.90	16.30	109.60	14.60	114.50	8.20
AD-1290764.2	77.50	7.80	110.10	17.00	93.00	12.00
AD-1290672.2	99.10	10.80	110.70	9.90	104.30	13.40
AD-1684685.1	133.70	29.90	110.70	29.30	128.50	32.50

	10 nM		1 nM		0.1 nM	
Duplex ID	Average % message remaining	STDEV	Average % message remaining	STDEV	Average % message remaining	STDEV
AD-1290528.2	45.40	4.40	110.80	15.30	84.60	13.70
AD-1684696.1	114.00	11.70	111.00	5.70	120.50	6.60
AD-1290836.2	118.10	8.10	111.70	12.30	123.80	4.70
AD-1684682.1	111.90	18.40	111.80	9.50	124.20	10.20
AD-1684659.1	97.90	4.90	111.90	8.60	99.50	10.20
AD-1684669.1	64.50	9.70	111.90	15.10	81.40	7.10
AD-1684704.1	108.80	8.60	112.00	6.30	97.30	6.70
AD-1684716.1	102.80	16.80	112.00	22.40	98.40	12.60
AD-1684699.1	103.80	5.50	112.40	6.40	105.30	13.70
AD-1290510.2	99.80	10.70	112.70	7.50	115.90	10.10
AD-1290531.2	113.00	19.70	113.00	27.70	118.50	20.40
AD-1684703.1	85.30	9.20	113.40	14.70	107.50	6.00
AD-1290910.2	109.50	15.50	113.50	20.80	133.70	28.50
AD-1684705.1	94.20	4.80	113.50	8.20	113.00	5.90
AD-1290618.2	113.70	12.60	114.20	7.30	103.40	5.70
AD-1684668.1	74.50	13.50	114.20	6.00	84.80	9.70
AD-1684701.1	92.50	14.90	114.30	10.30	105.10	6.80
AD-1290542.2	104.10	14.20	114.40	10.00	123.10	10.40
AD-1290626.2	119.70	13.70	114.40	15.00	144.90	14.70
AD-1684724.1	107.40	11.70	114.40	19.80	121.90	13.70
AD-1290535.2	90.80	4.90	114.60	14.70	101.60	7.00
AD-1290558.2	109.40	6.40	114.90	15.30	115.40	12.00
AD-1684647.1	99.40	27.50	114.90	19.80	136.90	32.80
AD-1290763.2	75.90	7.30	115.50	16.90	111.20	14.60
AD-1684677.1	91.30	8.80	115.50	15.40	95.80	18.60
AD-1684658.1	92.50	14.90	116.50	15.90	109.20	12.60
AD-1684687.1	114.50	18.10	116.90	13.90	132.30	10.30
AD-1684719.1	102.40	6.30	117.20	11.70	96.70	8.20
AD-1290681.2	107.00	9.00	117.60	11.00	117.40	4.40
AD-1684653.1	80.70	3.20	117.70	17.10	81.80	9.30
AD-1290841.2	75.10	4.00	118.00	11.00	85.70	4.70
AD-1290687.2	107.70	12.90	118.20	6.40	124.20	4.50
AD-1290592.2	119.00	9.20	118.30	4.30	120.60	11.50
AD-1290522.2	118.50	37.70	118.50	20.40	136.80	37.60
AD-1290880.2	96.70	19.90	118.70	21.80	110.10	20.90
AD-1684693.1	114.30	7.70	118.70	10.70	116.50	13.10
AD-1684679.1	117.20	20.30	118.80	6.80	126.50	13.80
AD-1290555.2	125.00	8.30	118.90	4.70	113.50	16.10
AD-1684648.1	81.50	12.40	119.10	21.00	95.30	6.60
AD-1684725.1	114.50	12.10	119.50	17.20	127.60	7.20
AD-1684706.1	89.90	9.20	119.60	27.40	124.10	22.90

	10 nM		1 nM		0.1 nM	
Duplex ID	Average % message remaining	STDEV	Average % message remaining	STDEV	Average % message remaining	STDEV
AD-1684663.1	82.10	7.70	120.20	13.70	84.40	10.90
AD-1684702.1	98.10	2.80	120.40	5.00	107.50	3.20
AD-1291003.2	85.70	8.50	120.50	8.30	95.90	9.20
AD-1684664.1	87.30	9.50	120.70	17.50	98.60	17.10
AD-1684697.1	86.40	5.20	121.00	8.60	109.80	7.60
AD-1290514.2	110.00	18.00	121.20	8.80	125.50	8.40
AD-1290989.2	88.80	3.60	121.60	11.60	110.00	12.50
AD-1684657.1	82.50	2.60	121.60	14.20	104.60	5.40
AD-1684654.1	81.10	4.50	121.80	15.10	101.60	2.30
AD-1684695.1	103.90	12.30	122.10	6.90	105.10	10.90
AD-1290712.2	122.10	28.40	122.40	10.60	114.50	28.30
AD-1290931.2	82.00	3.10	122.40	14.10	89.10	11.20
AD-1684729.1	104.60	9.20	123.10	7.70	123.50	12.60
AD-1290805.2	101.60	3.30	123.20	9.40	100.50	5.90
AD-1290755.2	120.80	13.20	123.60	3.30	110.50	19.00
AD-1290527.2	105.70	3.50	123.80	6.20	116.20	6.30
AD-1684652.1	81.80	9.60	123.80	14.40	91.50	12.50
AD-1290507.2	119.00	5.80	124.40	10.90	119.80	5.30
AD-1290747.2	91.90	6.10	124.50	3.30	102.50	17.60
AD-1290926.2	74.50	8.60	125.30	8.90	92.90	15.90
AD-1290983.2	88.30	10.80	125.70	4.10	96.00	6.30
AD-1684680.1	105.10	11.90	125.90	2.90	126.30	18.10
AD-1290605.2	99.20	7.80	126.50	19.90	107.40	14.50
AD-1290842.2	100.80	20.90	127.20	11.10	105.20	14.70
AD-1290565.2	104.90	15.40	127.30	19.20	120.90	17.40
AD-1290661.2	115.40	2.60	127.70	5.70	116.60	9.50
AD-1684667.1	79.60	10.90	129.10	19.10	93.80	5.00
AD-1290684.2	100.20	19.10	129.20	10.90	111.00	9.40
AD-1290524.2	114.10	8.60	129.40	21.20	134.10	19.90
AD-1290655.2	84.20	4.60	129.90	7.20	91.70	2.40
AD-1684660.1	106.80	17.30	130.10	13.70	119.80	14.80
AD-1684656.1	94.10	9.30	130.40	15.20	90.80	14.70
AD-1684676.1	125.80	31.60	130.70	10.10	141.50	42.50
AD-1684727.1	112.30	11.80	130.80	15.60	134.10	10.20
AD-1684665.1	82.50	19.00	131.30	9.90	103.40	6.40
AD-1290993.2	81.50	10.60	132.90	17.10	96.40	5.80
AD-1684721.1	118.30	29.70	133.40	22.80	129.60	16.70
AD-1290543.2	117.30	33.60	133.80	5.80	134.30	21.30
AD-1290719.2	125.50	4.70	134.50	18.60	135.30	13.50
AD-1290602.2	122.90	13.50	135.30	23.70	117.30	12.20
AD-1290564.2	105.80	15.20	136.20	13.00	109.20	11.40

Duplex ID	10 nM		1 nM		0.1 nM	
	Average % message remaining	STDEV	Average % message remaining	STDEV	Average % message remaining	STDEV
AD-1684737.1	139.10	33.20	136.40	12.50	142.70	28.20
AD-1684694.1	113.60	7.10	136.60	11.80	118.50	7.50
AD-1290875.2	100.10	5.10	138.20	5.60	104.20	4.30
AD-1684732.1	115.40	13.50	139.80	6.40	131.10	6.80
AD-1684717.1	119.30	16.20	140.00	30.80	120.10	24.90
AD-1290908.2	96.80	28.00	140.10	27.80	147.20	37.70
AD-1684720.1	124.30	14.00	140.50	23.90	120.80	14.90
AD-1290552.2	123.10	4.70	142.50	18.90	137.50	12.20
AD-1684728.1	128.40	15.80	143.40	23.80	139.10	18.30
AD-1684731.1	131.10	12.90	147.20	5.60	148.60	29.20
AD-1290722.2	121.90	13.20	147.80	22.40	124.10	19.20
AD-1684730.1	144.30	31.10	150.10	41.90	121.70	5.50
AD-1684736.1	132.70	21.70	151.10	19.90	144.20	15.80
AD-1684733.1	130.50	19.30	151.20	22.00	141.30	22.00
AD-1684661.1	117.60	34.20	151.80	0.00	134.50	29.30
AD-1684734.1	140.80	29.20	153.70	37.90	150.30	28.10
AD-1684735.1	147.10	29.80	154.10	1.60	159.80	22.20
AD-1290600.2	130.70	35.00	160.60	27.90	150.40	19.70
AD-1290624.2	150.80	32.00	161.90	26.00	151.90	33.80
AD-1290643.2	139.30	26.20	163.80	27.20	160.60	26.00
AD-1684675.1	116.00	28.80	NA	0.00	130.20	26.80

Table 16. KHK Single Dose Screen (Dual-Luciferase Assay)

Duplex Name	RLuc/FLuc		RLuc/FLuc		RLuc/FLuc	
	10 nM		1 nM		0.1 nM	
	Avg (%)	SD (%)	Avg (%)	SD (%)	Avg (%)	SD (%)
AD-1290635.2	27.55	4.72	75.07	12.04	82.87	2.65
AD-1684641.1	110.35	9.02	108.94	4.27	110.57	4.47
AD-1684620.1	49.87	8.22	58.56	6.05	70.53	11.50
AD-1684619.1	52.62	8.75	75.71	10.40	80.49	2.91
AD-1684610.1	37.56	5.38	67.47	3.80	80.31	4.72
AD-1684617.1	55.49	13.45	70.80	1.77	75.55	1.72
AD-1613079.2	53.10	14.44	59.41	4.50	81.54	6.24
AD-1684618.1	55.17	9.77	69.69	5.23	72.30	5.02
AD-1684622.1	63.23	13.55	78.66	4.27	89.31	3.28
AD-1684607.1	58.97	7.60	72.73	7.51	76.63	5.82
AD-1684614.1	64.70	10.39	80.88	8.02	79.18	5.68
AD-1613059.2	51.21	4.83	77.16	7.06	74.45	6.20
AD-1613075.2	60.08	8.05	77.04	7.40	83.17	6.93
AD-1613061.1	33.86	3.11	66.45	5.22	75.37	1.85
AD-1684608.1	57.25	9.23	78.62	6.26	78.71	3.21
AD-1684624.1	79.54	24.34	87.68	11.58	90.36	3.70
AD-1423319.3	36.18	4.92	71.09	4.29	81.57	7.77
AD-1684606.1	54.06	6.46	69.09	8.66	81.86	3.98
AD-1684609.1	50.63	11.26	69.42	5.35	75.07	4.46
AD-1684616.1	68.70	8.45	83.79	6.71	90.02	5.65
AD-1613060.2	66.82	13.96	88.93	7.79	85.14	3.13
AD-1613087.1	74.02	4.74	88.43	10.42	86.90	7.15
AD-1290539.5	54.13	8.10	76.99	5.02	77.45	2.84
AD-1290885.5	61.23	8.10	86.40	22.40	86.33	2.17
AD-1613062.2	41.02	9.84	61.06	10.45	78.05	7.96
AD-1684611.1	28.66	7.54	68.17	4.16	73.93	11.62
AD-1684623.1	70.49	21.68	78.20	8.68	93.68	4.29
AD-1612969.2	82.38	14.04	98.61	3.54	88.83	5.84
AD-1613256.2	63.57	23.77	80.73	3.90	85.86	7.48
AD-1423312.3	78.78	18.49	89.56	6.87	93.64	11.24
AD-1548743.7	60.42	7.72	80.40	4.82	87.16	5.21
AD-1684596.1	66.99	3.42	89.91	18.17	93.12	9.16
AD-1423336.7	55.41	10.18	75.06	10.07	81.43	5.09
AD-1612963.2	68.21	8.77	90.00	8.17	89.11	10.05
AD-1290611.3	72.79	17.88	87.65	5.54	89.02	6.88
AD-1613254.2	60.32	9.01	93.11	8.72	91.19	7.21
AD-1684612.1	57.05	5.54	68.77	6.05	77.64	4.46
AD-1684645.1	94.74	17.21	100.78	3.85	97.29	4.48
AD-1684621.1	70.57	13.92	96.48	4.17	102.25	8.16
AD-1290837.5	75.64	11.34	87.27	7.07	89.95	5.79

Duplex Name	RLuc/FLuc		RLuc/FLuc		RLuc/FLuc	
	10 nM		1 nM		0.1 nM	
	Avg (%)	SD (%)	Avg (%)	SD (%)	Avg (%)	SD (%)
AD-1684598.1	82.26	9.02	100.74	8.99	95.70	14.97
AD-1684638.1	90.83	19.35	99.80	1.21	88.22	5.61
AD-1290599.7	81.02	16.64	88.84	3.66	96.80	4.47
AD-1613400.2	78.98	6.10	101.81	4.90	97.90	11.65
AD-1684615.1	67.00	20.89	97.66	10.46	88.82	5.13
AD-1684630.1	92.58	21.02	102.41	5.76	95.70	6.29
AD-1613072.1	74.57	8.15	92.03	6.87	101.02	3.25
AD-1684632.1	123.67	22.63	120.79	8.89	111.58	5.69
AD-1613242.2	78.42	23.84	97.73	5.29	91.80	1.46
AD-1684605.1	100.37	8.25	97.95	10.50	93.62	9.84
AD-1684594.1	72.68	15.57	112.86	9.89	96.08	5.44
AD-1612957.2	84.90	22.12	94.33	10.29	95.29	8.77
AD-1290971.3	90.45	5.32	92.69	5.86	100.99	5.05
AD-1684595.1	67.25	5.15	83.63	8.61	97.72	8.62
AD-1613371.3	84.73	8.63	93.73	5.20	92.88	3.87
AD-1684593.1	95.59	10.06	105.09	8.84	99.26	9.30
AD-1684639.1	111.42	26.90	100.56	13.89	100.10	10.09
AD-1613094.2	109.88	20.02	106.26	7.18	91.52	4.75
AD-1684597.1	87.17	18.25	98.70	10.75	97.29	11.97
AD-1290563.2	57.60	6.91	70.25	6.46	93.86	10.89
AD-1684599.1	95.44	9.63	99.22	5.79	96.16	3.23
AD-1684640.1	68.26	5.61	95.79	2.54	102.60	4.75
AD-1290584.2	61.38	5.41	94.01	8.50	94.05	2.24
AD-1684627.1	90.44	15.14	92.95	9.50	93.69	9.49
AD-1290969.7	81.86	22.36	100.31	15.03	104.51	10.34
AD-1290651.2	97.29	8.97	93.94	5.58	90.64	2.47
AD-1684628.1	99.71	21.99	94.37	8.89	95.59	1.56
AD-1290884.5	89.60	2.17	98.52	11.66	105.58	5.25
AD-1684633.1	124.09	6.72	124.21	8.35	126.12	7.08
AD-1684637.1	87.99	25.10	99.86	3.94	98.08	2.65
AD-1684629.1	96.24	14.82	108.74	6.76	98.94	1.93
AD-1684635.1	115.43	19.21	110.59	14.86	111.51	5.28
AD-1684613.1	77.44	17.90	86.13	7.31	96.31	11.48
AD-1684604.1	126.73	12.80	104.44	9.66	88.10	9.76
AD-1290666.2	77.77	7.66	85.66	5.31	91.09	7.78
AD-1684634.1	101.54	9.42	112.46	7.92	102.84	8.33
AD-1684600.1	92.36	15.27	102.10	14.83	98.62	7.39
AD-1684644.1	94.78	12.14	105.73	11.26	91.40	7.74
AD-1684643.1	134.90	25.23	106.06	3.63	114.45	5.37
AD-1684601.1	109.99	17.91	106.64	6.25	93.03	6.35
AD-1684626.1	105.90	5.90	97.95	4.84	97.84	3.22

Duplex Name	RLuc/FLuc		RLuc/FLuc		RLuc/FLuc	
	10 nM		1 nM		0.1 nM	
	Avg (%)	SD (%)	Avg (%)	SD (%)	Avg (%)	SD (%)
AD-1684642.1	121.11	34.83	118.91	13.95	106.61	2.62
AD-1684592.1	93.35	12.76	103.28	10.86	103.22	9.57
AD-1684636.1	101.15	23.41	102.25	10.70	108.30	10.50
AD-1684603.1	105.78	12.89	103.83	10.25	94.04	10.93
AD-1684631.1	88.92	2.51	98.87	14.74	103.10	3.82
AD-1684625.1	98.13	10.61	116.53	26.66	103.80	4.63
AD-1290523.2	36.07	3.49	83.69	18.88	78.13	21.59
AD-1684602.1	108.47	14.10	109.97	12.29	100.25	5.84
AD-1290570.2	69.96	7.85	86.80	14.21	101.61	7.01
AD-1684666.1	77.63	4.44	85.12	7.88	89.66	10.91
AD-1290865.2	67.01	0.58	88.22	11.34	96.40	4.28
AD-1290589.2	67.56	4.89	85.24	5.97	97.93	8.15
AD-1684681.1	86.44	3.20	88.04	8.65	103.81	12.28
AD-1684689.1	49.57	6.76	86.48	5.18	90.62	11.35
AD-1684708.1	23.03	1.62	33.48	7.99	57.59	11.14
AD-1290557.2	94.58	3.42	98.87	10.22	103.18	8.22
AD-1290515.2	48.39	6.21	70.61	2.16	86.52	1.87
AD-1290741.2	62.89	8.45	108.61	21.31	83.31	16.19
AD-1684713.1	25.62	2.85	56.78	8.85	73.15	15.46
AD-1290650.2	45.96	4.20	75.32	14.73	88.04	15.00
AD-1290897.2	91.50	12.78	99.78	4.12	95.69	6.37
AD-1290556.2	46.60	6.23	72.83	12.88	95.77	2.43
AD-1290750.2	100.69	11.17	112.50	12.75	98.54	9.04
AD-1684714.1	28.09	1.61	63.87	15.58	58.74	14.71
AD-1290654.2	59.38	5.24	82.45	5.68	92.90	11.63
AD-1290909.2	79.81	7.84	85.50	1.84	99.95	6.60
AD-1684674.1	38.19	5.91	68.84	4.29	86.91	7.62
AD-1684712.1	27.74	1.92	51.61	7.17	81.25	10.84
AD-1290796.2	90.91	8.26	93.92	11.82	98.49	8.90
AD-1290612.2	42.68	2.55	66.55	14.42	68.94	7.63
AD-1290633.2	50.34	3.85	73.42	11.49	83.99	10.78
AD-1684691.1	66.75	8.42	91.12	4.34	97.18	11.63
AD-1290659.2	29.24	3.16	58.78	1.46	83.51	13.24
AD-1684686.1	55.60	5.55	81.33	10.32	90.49	12.00
AD-1290604.2	30.50	1.61	58.09	12.94	75.45	12.12
AD-1290574.2	62.06	4.41	79.92	5.27	89.83	8.75
AD-1290609.2	27.15	4.45	50.65	5.55	73.67	12.54
AD-1290911.2	96.37	7.95	93.75	11.00	96.22	5.42
AD-1290615.2	51.72	2.67	70.39	15.92	77.60	16.60
AD-1684710.1	42.53	5.32	73.27	11.74	68.13	11.94
AD-1684709.1	58.70	4.19	79.18	25.68	86.01	19.30

Duplex Name	RLuc/FLuc		RLuc/FLuc		RLuc/FLuc	
	10 nM		1 nM		0.1 nM	
	Avg (%)	SD (%)	Avg (%)	SD (%)	Avg (%)	SD (%)
AD-1290533.2	47.59	4.90	68.99	11.94	77.30	6.48
AD-1684671.1	47.59	1.95	61.26	3.20	82.05	10.96
AD-1684650.1	46.11	8.10	76.50	10.07	82.83	4.08
AD-1684711.1	25.37	2.16	39.63	9.66	66.61	6.31
AD-1684670.1	61.98	4.96	79.82	3.32	86.14	2.50
AD-1684692.1	51.68	5.44	73.68	5.82	94.81	6.71
AD-1290939.2	79.47	12.39	91.84	15.17	102.79	10.83
AD-1684662.1	92.36	5.74	89.87	6.57	98.46	7.31
AD-1684700.1	49.06	2.35	66.17	5.75	80.59	11.96
AD-1290742.2	97.05	12.34	108.91	9.16	98.27	8.80
AD-1684715.1	39.93	3.07	71.43	4.49	66.16	5.22
AD-1290894.2	69.53	5.96	86.15	6.51	89.41	8.71
AD-1684718.1	38.19	2.50	56.43	6.04	89.12	4.16
AD-1290702.2	63.45	4.81	94.75	15.47	93.98	25.50
AD-1684688.1	31.21	4.38	62.76	5.56	71.36	5.67
AD-1684690.1	37.78	7.44	65.65	6.32	81.53	5.19
AD-1684672.1	50.47	5.26	77.82	8.07	89.96	7.10
AD-1684684.1	34.84	3.57	66.09	6.84	81.50	13.30
AD-1684723.1	35.25	2.97	68.48	5.60	65.99	9.83
AD-1684651.1	70.03	6.39	85.13	4.79	94.44	5.75
AD-1684683.1	54.95	5.39	77.78	7.33	95.72	7.28
AD-1290973.2	98.50	6.54	92.81	14.03	98.60	4.58
AD-1290857.2	87.52	2.70	96.73	5.63	99.17	2.18
AD-1684649.1	72.47	0.92	84.56	8.23	89.82	2.21
AD-1290516.2	26.76	0.49	42.76	4.24	59.84	6.99
AD-1290554.2	61.58	4.05	88.87	14.21	74.37	3.21
AD-1290509.2	73.11	5.62	99.31	14.02	101.98	16.69
AD-1290660.2	54.56	9.39	83.38	0.31	86.16	6.94
AD-1684698.1	49.13	6.23	101.74	19.35	58.63	21.67
AD-1290670.2	70.45	5.20	85.30	12.39	83.73	9.68
AD-1684673.1	54.65	6.25	78.09	7.36	92.77	10.76
AD-1684646.1	88.86	5.66	109.84	2.99	100.07	6.89
AD-1290597.2	64.33	3.82	104.86	17.05	78.64	14.59
AD-1290573.2	21.93	2.25	51.90	11.20	61.08	10.20
AD-1684707.1	25.65	1.98	47.58	11.42	58.67	13.41
AD-1684722.1	42.02	2.86	72.20	13.41	91.03	17.74
AD-1290639.2	65.65	8.85	106.60	6.21	80.86	3.84
AD-1290551.2	37.93	4.95	63.38	4.48	69.08	10.49
AD-1684655.1	82.73	4.01	88.85	9.58	98.35	13.91
AD-1684678.1	71.26	6.57	96.82	5.79	98.92	5.96
AD-1290800.2	81.68	8.76	95.82	8.76	99.82	11.38

Duplex Name	RLuc/FLuc		RLuc/FLuc		RLuc/FLuc	
	10 nM		1 nM		0.1 nM	
	Avg (%)	SD (%)	Avg (%)	SD (%)	Avg (%)	SD (%)
AD-1684726.1	28.47	1.78	45.62	14.88	47.10	11.51
AD-1290764.2	67.56	8.24	67.75	7.72	79.61	6.78
AD-1290672.2	42.65	3.57	64.81	14.49	73.51	15.34
AD-1684685.1	52.36	4.45	80.46	8.33	90.09	6.80
AD-1290528.2	40.22	5.18	55.62	6.12	74.10	6.88
AD-1684696.1	36.27	4.80	43.87	3.17	104.26	16.60
AD-1290836.2	78.37	9.59	84.56	11.22	101.22	23.26
AD-1684682.1	80.66	18.04	114.19	18.74	92.36	3.20
AD-1684659.1	80.80	5.53	92.64	9.37	100.32	4.86
AD-1684669.1	61.93	5.52	72.55	4.18	83.30	4.78
AD-1684704.1	73.43	3.74	102.98	4.47	82.11	11.96
AD-1684716.1	49.39	6.90	78.93	10.67	88.70	8.71
AD-1684699.1	32.13	1.49	49.17	12.29	88.94	7.66
AD-1290510.2	29.78	2.09	61.76	7.12	57.41	3.23
AD-1290531.2	30.64	2.31	61.41	11.62	88.80	10.45
AD-1684703.1	29.94	4.56	48.74	5.70	64.27	5.80
AD-1290910.2	78.87	4.68	83.35	7.19	102.58	9.62
AD-1684705.1	84.81	5.73	78.46	14.78	108.49	29.28
AD-1290618.2	38.80	2.21	91.85	24.03	70.60	14.74
AD-1684668.1	82.61	3.09	85.84	5.55	102.22	13.23
AD-1684701.1	33.37	3.20	59.65	10.73	79.48	7.48
AD-1290542.2	25.33	4.70	75.56	5.50	43.19	10.83
AD-1290626.2	42.99	7.92	66.24	9.90	78.99	6.15
AD-1684724.1	25.49	3.64	41.90	10.84	75.17	17.57
AD-1290535.2	39.61	4.59	86.53	3.83	75.49	9.54
AD-1290558.2	52.87	4.30	77.41	14.99	88.24	18.29
AD-1684647.1	63.31	20.44	88.14	11.46	99.17	9.42
AD-1290763.2	76.79	3.45	91.24	4.92	100.24	8.61
AD-1684677.1	49.89	7.84	62.12	3.31	80.47	5.14
AD-1684658.1	61.99	9.91	82.39	6.38	93.13	3.41
AD-1684687.1	56.84	10.02	73.94	6.08	90.30	8.39
AD-1684719.1	21.60	1.78	54.66	6.44	49.60	12.61
AD-1290681.2	70.01	13.50	102.05	13.79	97.11	8.26
AD-1684653.1	77.63	3.92	90.78	7.67	107.04	10.77
AD-1290841.2	102.02	12.88	92.72	10.43	92.89	8.78
AD-1290687.2	24.79	5.58	47.49	9.56	54.96	7.96
AD-1290592.2	42.32	3.00	63.61	7.19	81.99	13.27
AD-1290522.2	63.08	8.25	80.77	2.61	89.07	3.72
AD-1290880.2	86.62	8.68	84.96	10.84	112.23	7.89
AD-1684693.1	33.57	4.76	72.88	8.53	56.56	8.52
AD-1684679.1	63.98	10.81	81.92	8.14	99.47	7.56

Duplex Name	RLuc/FLuc		RLuc/FLuc		RLuc/FLuc	
	10 nM		1 nM		0.1 nM	
	Avg (%)	SD (%)	Avg (%)	SD (%)	Avg (%)	SD (%)
AD-1290555.2	29.21	2.95	57.32	7.73	76.70	14.67
AD-1684648.1	57.07	4.43	72.65	5.51	90.63	6.01
AD-1684725.1	37.50	5.23	60.12	13.34	75.61	7.15
AD-1684706.1	34.25	5.45	66.03	7.18	61.51	7.34
AD-1684663.1	100.81	7.18	100.10	13.78	98.87	4.95
AD-1684702.1	27.84	1.80	55.04	5.17	62.99	6.59
AD-1291003.2	99.82	7.41	90.75	6.78	96.81	11.67
AD-1684664.1	98.11	1.83	95.21	12.95	100.40	8.82
AD-1684697.1	63.74	8.80	90.40	16.93	79.86	15.55
AD-1290514.2	25.53	1.05	39.72	6.89	59.21	5.46
AD-1290989.2	80.25	6.00	95.06	4.87	94.19	9.09
AD-1684657.1	85.45	4.39	92.61	11.75	107.59	8.01
AD-1684654.1	93.92	6.75	95.83	4.68	99.57	13.80
AD-1684695.1	40.77	3.71	87.34	16.28	65.10	12.55
AD-1290712.2	76.80	6.49	89.36	6.93	97.09	5.67
AD-1290931.2	74.20	8.48	91.78	7.74	93.55	7.40
AD-1684729.1	32.72	5.04	71.92	14.70	63.69	5.82
AD-1290805.2	85.12	3.08	83.71	7.55	90.13	4.27
AD-1290755.2	82.43	5.17	101.69	9.25	96.50	4.82
AD-1290527.2	35.84	2.68	72.84	6.30	61.60	13.91
AD-1684652.1	85.57	2.57	95.34	9.86	91.15	4.65
AD-1290507.2	29.99	3.00	86.33	6.23	57.42	9.02
AD-1290747.2	93.73	11.80	93.12	7.86	93.91	7.92
AD-1290926.2	105.81	5.23	93.36	5.15	101.13	11.67
AD-1290983.2	83.97	2.62	84.46	5.64	102.69	8.80
AD-1684680.1	75.84	12.82	88.75	9.33	92.50	2.09
AD-1290605.2	71.92	10.68	111.52	16.71	79.13	8.92
AD-1290842.2	104.49	5.65	91.21	5.53	95.02	7.94
AD-1290565.2	34.69	2.42	75.14	21.84	83.67	22.69
AD-1290661.2	47.11	5.63	82.93	15.48	77.74	26.12
AD-1684667.1	50.51	6.46	74.42	2.87	89.86	7.71
AD-1290684.2	61.88	5.00	86.54	7.60	91.09	8.89
AD-1290524.2	55.34	5.89	100.08	30.59	97.04	35.30
AD-1290655.2	55.60	8.94	79.31	8.29	86.56	4.09
AD-1684660.1	90.30	7.72	90.68	6.87	89.53	4.84
AD-1684656.1	99.30	6.66	87.28	5.54	93.70	10.20
AD-1684676.1	42.60	3.34	64.98	4.82	81.15	8.48
AD-1684727.1	34.77	9.34	62.64	16.13	56.10	7.77
AD-1684665.1	88.07	7.37	85.96	2.62	96.42	4.35
AD-1290993.2	126.19	4.37	103.72	5.04	100.36	8.22
AD-1684721.1	30.93	4.69	73.02	5.08	74.51	8.53

Duplex Name	RLuc/FLuc		RLuc/FLuc		RLuc/FLuc	
	10 nM		1 nM		0.1 nM	
	Avg (%)	SD (%)	Avg (%)	SD (%)	Avg (%)	SD (%)
AD-1290543.2	60.43	2.14	78.76	1.16	86.30	3.38
AD-1290719.2	72.55	5.47	106.96	11.38	89.56	13.94
AD-1290602.2	36.81	5.78	75.60	6.07	63.11	4.79
AD-1290564.2	46.18	1.47	88.84	15.84	89.88	12.30
AD-1684737.1	19.91	2.75	65.84	2.75	50.34	9.86
AD-1684694.1	37.30	6.64	65.54	8.09	68.75	11.54
AD-1290875.2	88.36	6.67	87.65	4.57	95.91	11.39
AD-1684732.1	21.92	1.86	70.21	17.18	48.70	2.36
AD-1684717.1	20.14	3.23	53.41	2.38	49.49	5.05
AD-1290908.2	69.14	8.90	91.09	8.96	105.33	6.07
AD-1684720.1	25.19	1.57	65.20	9.13	55.67	9.89
AD-1290552.2	60.07	5.86	110.60	5.95	68.03	4.85
AD-1684728.1	32.65	4.26	60.26	10.61	81.39	13.63
AD-1684731.1	71.00	4.39	97.76	10.63	103.47	10.13
AD-1290722.2	56.44	2.77	96.22	25.60	84.59	1.63
AD-1684730.1	55.45	5.72	103.19	33.31	94.48	30.63
AD-1684736.1	22.63	1.19	55.13	6.21	63.03	19.64
AD-1684733.1	31.22	2.64	74.74	15.23	80.11	13.22
AD-1684661.1	88.94	5.85	86.32	8.94	96.70	2.89
AD-1684734.1	24.44	1.34	55.52	4.03	41.46	7.30
AD-1684735.1	27.36	1.31	62.50	9.06	50.38	6.57
AD-1290600.2	63.33	8.27	96.26	30.33	114.38	17.93
AD-1290624.2	34.72	1.33	92.38	34.13	71.36	13.25
AD-1290643.2	31.00	3.54	63.18	15.27	67.58	13.33
AD-1684675.1	43.08	8.00	63.69	6.05	73.37	3.64

Example 6: Effects of siRNA –GalNAC Conjugates in Non-Human Primates

The effect of candidates identified from the *in vitro* studies described above, duplexes AD-1613062, AD-1613073, AD-1613242, AD-1613243, AD-1613246, AD-1613247, AD-1613400, AD-1634397, AD-1634424, and AD-1634425, were further investigated for their effectiveness in non-human primates. Specifically, a single dose of 3 mg/kg of AD-1613062, AD-1613073, AD-1613242, AD-1613243, AD-1613246, AD-1613247, AD-1613400, AD-1634397, AD-1634424, or AD-1634425 was subcutaneously administered to cynomolgous monkeys. Sera and tissue samples were collected at Days 29, 50, and 78 post-dose.

mRNA was extracted from liver tissue by a magnetic bead-based extraction method using the NucleoMag RNA kit by Macherey-Nagel. cDNA was generated using Applied Biosystems SuperScript IV VILO master mix. Taqman probe-based qPCR was used to quantify KHK mRNA which was normalized to the geometric mean of two housekeeping genes, ARL6IP4 and PPIB.

Targeted quantitation of KHK protein in cynomolgus monkey liver was performed via liquid chromatography coupled to mass spectrometer (LC-MS) using parallel reaction monitoring (PRM) in positive ion mode. The signature peptide sequence selected for quantitation was HLGFSQAGEALR (UniProtKB - A0A2K5V1R8-1, amino acid positions 198-209).

Figure 2 shows the effect of administration of a single 3 mg/kg dose of the selected duplexes on the level of KHK mRNA and protein at Day 29 post-dose.

Figure 3 shows the effect of administration of a single 3 mg/kg dose of the selected duplexes on the level of KHK mRNA at Day 50 post-dose.

Figure 4 shows the effect of administration of a single 3 mg/kg dose of the selected duplexes on the level of KHK mRNA at Day 78 post-dose.

The data demonstrate that the indicated agents, *e.g.*, AD-1613400 and AD-1613243, are effective in durably and potently inhibiting KHK mRNA and protein expression.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments and methods described herein. Such equivalents are intended to be encompassed by the scope of the following claims.

We claim:

1. A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of ketohexokinase (KHK) in a cell, wherein said dsRNA comprises a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises a region of complementarity to an mRNA encoding KHK, and wherein the region of complementarity comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the antisense nucleotide sequences in any one of Tables 2, 3, 5, 6, and 8-13.
2. The dsRNA agent of claim 1, wherein the dsRNA agent comprises a sense strand comprising at least 15 contiguous nucleotides differing by no more than three nucleotides from any one of the nucleotide sequences of the sense strands in any one of Tables 2, 3, 5, 6, and 8-13 and an antisense strand comprising at least 15 contiguous nucleotides differing by no more than three nucleotides from any one of the nucleotide sequences of the antisense strands in any one of Tables 2, 3, 5, 6, and 8-13.
3. The dsRNA agent of claim 1, wherein the dsRNA agent comprises a sense strand comprising at least 15 contiguous nucleotides differing by no more than two nucleotides from any one of the nucleotide sequences of the sense strands in any one of Tables 2, 3, 5, 6, and 8-13 and an antisense strand comprising at least 15 contiguous nucleotides differing by no more than two nucleotides from any one of the nucleotide sequences of the antisense strands in any one of Tables 2, 3, 5, 6, and 8-13.
4. The dsRNA agent of claim 1, wherein the dsRNA agent comprises a sense strand comprising at least 15 contiguous nucleotides differing by no more than one nucleotide from any one of the nucleotide sequences of the sense strands in any one of Tables 2, 3, 5, 6, and 8-13 and an antisense strand comprising at least 15 contiguous nucleotides differing by no more than one nucleotide from any one of the nucleotide sequences of the antisense strands in any one of Tables 2, 3, 5, 6, and 8-13.
5. The dsRNA agent of claim 1, wherein the dsRNA agent comprises a sense strand comprising a nucleotide sequence selected from the group consisting of any one of the nucleotide sequences of the sense strands in any one of Tables 2, 3, 5, 6, and 8-13 and an antisense strand comprising a nucleotide sequence selected from the group consisting of any one of the nucleotide sequences of the antisense strands in any one of Tables 2, 3, 5, 6, and 8-13.
6. A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of ketohexokinase (KHK) in a cell, wherein said dsRNA comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than three nucleotides from any one of the nucleotide sequence of nucleotides 120-162; 164-188; 181-207; 193-217; 209-231; 283-306; 508-546; 568-603; 596-632;

640-674; 746-806; 806-835; 917-942; 936-084; 1016-1041; 1100-1123; 1149-1175; 1160-1193; 1205-1229; 1252-1283; 1334-1356; 1407-1429; 1472-1497; 1506-1533; 1539-1561; 1704-1727; 1747-1787; 1850-1873; 1936-1964; 1960-1990; 2015-2048; 2060-2095; 2090-2118; 2124-2160; 2181-2200; 2221-2262 of SEQ ID NO: 1, and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than three nucleotides from the corresponding nucleotide sequence of SEQ ID NO:2.

7. A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of ketohexokinase (KHK) in a cell, wherein said dsRNA comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than three nucleotides from any one of the nucleotide sequence of nucleotides 517-539; 521-543; 524-546; 517-546; 581-603; 610-632; 747-769; 749-771; 752-774; 755-777; 757-779; 758-780; 764-786; 776-798; 781-803; 747-803; 920-942; 941-963; 944-966; 950-972; 962-984; 920-984; 1149-1171; 1161-1183; 1165-1187; 1171-1193; 1149-1193; 1205-1227; 1206-1228; 1205-1228; 1334-1356; 1472-1494; 1475-1497; 1472-1497 of SEQ ID NO: 1, and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than three nucleotides from the corresponding nucleotide sequence of SEQ ID NO:2.

8. A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of ketohexokinase (KHK) in a cell, wherein said dsRNA comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than three nucleotides from any one of the nucleotide sequence of nucleotides 517-539; 524-546; 517-546; 753-775; 757-779; 753-779; 764-786; 767-789; 768-790; 769-791; 764-791; 773-795; 781-803; 773-803; 753-803; 808-830; 937-959; 941-963; 944-966; 941-966; 948-970; 950-972; 948-972; 1160-1182; 1161-1183; 1160-1183; and 1207-1229 of SEQ ID NO: 1, and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than three nucleotides from the corresponding nucleotide sequence of SEQ ID NO:2.

9. The dsRNA agent of any one of claims 1-8, wherein the antisense strand comprises at least 15 contiguous nucleotides differing by no more than three nucleotides from any one of the antisense strand nucleotide sequences of a duplex selected from the group consisting of AD-1613400; AD-1613243; AD-1290757.3; AD-1290878.3; AD-1290969.3; AD-1423317.2; AD-1423327.2; AD-1423336.2; AD-1290599.3; AD-1523172.1; AD-1290837.3; AD-1523173.1; AD-1290884.3; AD-1523174.1; AD-1290959.3; AD-1523175.1; AD-1423311.2; AD-1423324.2; AD-1523176.1; AD-1423329.2; AD-1423333.2; AD-1423330.2; AD-1523177.1; AD-1290885.3; AD-1523178.1; AD-1423334.2; AD-1523179.1; AD-1523180.1; AD-1290539.3; and AD-1523181.1.

10. A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of ketohexokinase (KHK) in a cell, wherein said dsRNA comprises a sense strand and an antisense

strand forming a double stranded region, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than three nucleotides from any one of the nucleotide sequence of nucleotides 495-517, 492-517, 500-529, 514-551, 517-539, 524-546, 517-548, 614-643, 625-647, 625-660, 642-664, 642-672, 753-811, 754-780, 762-791, 764-786, 772-800, 781-803, 805-827, 808-830, 809-831, 792-838, 931-982, 944-966, 947-969, 948-970, 948-982, 1011-1035, 1021-1043, 1019-1050, 1063-1091, 1150-1192, 1152-1176, 1160-1192, 1160-1182, 1162-1184, 1198-1230, 1198-1221, and 1202-1230 of SEQ ID NO: 1, and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than three nucleotides from the corresponding nucleotide sequence of SEQ ID NO:2.

11. A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of ketohexokinase (KHK) in a cell, wherein said dsRNA comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than three nucleotides from any one of the nucleotide sequence of nucleotides 513-556, 753-813, 936-981, 1155-1193, 1200-1229, 1704-1727, 1747-1787, 1850-1873, 1936-1964, 1960-1990, 1936-1990, 2015-2048, 2060-2095, 2090-2118, 2060-2118, 2124-2160, 2181-2220, 2221-2249, 2181-2249, 2240-2262, 2221-2262, and 2181-2262 of SEQ ID NO: 1, and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than three nucleotides from the corresponding nucleotide sequence of SEQ ID NO:2.

12. A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of ketohexokinase (KHK) in a cell, wherein said dsRNA comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than three nucleotides from the nucleotide sequence of nucleotides 1207-1229 or 937-959 of SEQ ID NO: 1, and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than three nucleotides from the corresponding nucleotide sequence of SEQ ID NO:2.


13. The dsRNA agent of claim 12, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than three nucleotides from the nucleotide sequence of nucleotides 1207-1229 of SEQ ID NO: 1, and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than three nucleotides from the corresponding nucleotide sequence of SEQ ID NO:2.

14. The dsRNA agent of any one of claims 1-13, wherein the dsRNA agent comprises at least one modified nucleotide.


15. The dsRNA agent of any one of claims 1-14, wherein substantially all of the nucleotides of the sense strand; substantially all of the nucleotides of the antisense strand comprise a modification; or substantially all of the nucleotides of the sense strand and substantially all of the nucleotides of the antisense strand comprise a modification.
16. The dsRNA agent of any one of claims 1-15, wherein all of the nucleotides of the sense strand comprise a modification; all of the nucleotides of the antisense strand comprise a modification; or all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand comprise a modification.
17. The dsRNA agent of any one of claims 14-16, wherein at least one of the modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3'-terminal deoxythymidine (dT) nucleotide, a 2'-O-methyl modified nucleotide, a 2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2'-amino-modified nucleotide, a 2'-O-allyl-modified nucleotide, 2'-C-alkyl-modified nucleotide, 2'-hydroxly-modified nucleotide, a 2'-methoxyethyl modified nucleotide, a 2'-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5'-phosphate, a nucleotide comprising a 5'-phosphate mimic, a nucleotide comprising a 2' phosphate, a thermally destabilizing nucleotide, a glycol modified nucleotide (GNA), a nucleotide comprising a 2' phosphate, and a 2-O-(N-methylacetamide) modified nucleotide; and combinations thereof.
18. The dsRNA agent of any one of claims 14-16, wherein the modifications on the nucleotides are selected from the group consisting of LNA, HNA, CeNA, 2'-methoxyethyl, 2'-O-alkyl, 2'-O-allyl, 2'-C-allyl, 2'-fluoro, 2'-deoxy, 2'-hydroxyl, and glycol; and combinations thereof.
19. The dsRNA agent of any one of claims 14-16, wherein at least one of the modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 2'-O-methyl modified nucleotide, a 2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, a glycol modified nucleotide (GNA), a nucleotide comprising a 2' phosphate, a vinyl-phosphonate nucleotide; and combinations thereof.

20. The dsRNA agent of any one of claims 14-16, wherein at least one of the modifications on the nucleotides is a thermally destabilizing nucleotide modification.
21. The dsRNA agent of claim 20, wherein the thermally destabilizing nucleotide modification is selected from the group consisting of an abasic modification; a mismatch with the opposing nucleotide in the duplex; and destabilizing sugar modification, a 2'-deoxy modification, an acyclic nucleotide, an unlocked nucleic acids (UNA), and a glycerol nucleic acid (GNA).
22. The dsRNA agent of any one of claims 1-21, wherein the double stranded region is 19-30 nucleotide pairs in length.
23. The dsRNA agent of claim 22, wherein the double stranded region is 19-25 nucleotide pairs in length.
24. The dsRNA agent of claim 22, wherein the double stranded region is 19-23 nucleotide pairs in length.
25. The dsRNA agent of claim 22, wherein the double stranded region is 23-27 nucleotide pairs in length.
26. The dsRNA agent of claim 22, wherein the double stranded region is 21-23 nucleotide pairs in length.
27. The dsRNA agent of any one of claims 1-26, wherein each strand is independently no more than 30 nucleotides in length.
28. The dsRNA agent of any one of claims 1-27, wherein the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
29. The dsRNA agent of any one of claims 1-28, wherein the region of complementarity is at least 17 nucleotides in length.
30. The dsRNA agent of any one of claims 1-29, wherein the region of complementarity is between 19 and 23 nucleotides in length.
31. The dsRNA agent of any one of claims 1-30, wherein the region of complementarity is 19 nucleotides in length.

32. The dsRNA agent of any one of claims 1-31, wherein at least one strand comprises a 3' overhang of at least 1 nucleotide.
33. The dsRNA agent of any one of claims 1-31, wherein at least one strand comprises a 3' overhang of at least 2 nucleotides.
34. The dsRNA agent of any one of claims 1-33, further comprising a ligand.
35. The dsRNA agent of claim 34, wherein the ligand is conjugated to the 3' end of the sense strand of the dsRNA agent.
36. The dsRNA agent of claim 34 or 35, wherein the ligand is an N-acetylgalactosamine (GalNAc) derivative.
37. The dsRNA agent of any one of claims 34-36, wherein the ligand is one or more GalNAc derivatives attached through a monovalent, bivalent, or trivalent branched linker.
38. The dsRNA agent of claim 36 or 37, wherein the ligand is



39. The dsRNA agent of claim 38, wherein the dsRNA agent is conjugated to the ligand as shown in the following schematic



and, wherein X is O or S.

40. The dsRNA agent of claim 39, wherein the X is O.

41. The dsRNA agent of any one of claims 1-40, wherein the dsRNA agent further comprises at least one phosphorothioate or methylphosphonate internucleotide linkage.

42. The dsRNA agent of claim 41, wherein the phosphorothioate or methylphosphonate internucleotide linkage is at the 3'-terminus of one strand.

43. The dsRNA agent of claim 42, wherein the strand is the antisense strand.

44. The dsRNA agent of claim 42, wherein the strand is the sense strand.

45. The dsRNA agent of claim 41, wherein the phosphorothioate or methylphosphonate internucleotide linkage is at the 5'-terminus of one strand.

46. The dsRNA agent of claim 45, wherein the strand is the antisense strand.

47. The dsRNA agent of claim 45, wherein the strand is the sense strand.

48. The dsRNA agent of claim 41, wherein the phosphorothioate or methylphosphonate internucleotide linkage is at the both the 5'- and 3'-terminus of one strand.

49. The dsRNA agent of claim 48, wherein the strand is the antisense strand.

50. The dsRNA agent of any one of claims 1-49, wherein the base pair at the 1 position of the 5'-end of the antisense strand of the duplex is an AU base pair.

51. A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of ketohexokinase (KHK) in a cell, or a pharmaceutically acceptable salt thereof, comprising a sense strand and an antisense strand forming a double stranded region, wherein

a) the nucleotide sequence of the sense strand differs by no more than 4 bases from the nucleotide sequence 5'-gscsaggaagCfAfCfugagauucgu-3' and the nucleotide sequence of the antisense strand differs by no more than 4 bases from the nucleotide sequence 5'-asdCsgadAudCucagdTgCfuuccugcsasc-3',

wherein a, g, c and u are 2'-O-methyl (2'-OMe) A, G, C, and U; Cf and Uf are 2'-deoxy-2'-fluoro (2'-F) C and U; dC, dA, and dT are 2'-deoxy C, A, and T; and s is a phosphorothioate linkage; or

b) the nucleotide sequence of the sense strand differs by no more than 4 bases from the nucleotide sequence 5'-csusacggagAfCfGfugguguuugu-3' and the nucleotide sequence of the antisense strand differs by no more than 4 bases from the nucleotide sequence 5'-asdCsaadAcdAccacdGuCfuccguagscsc -3',

wherein a, g, c and u are 2'-O-methyl (2'-OMe) A, G, C, and U; Cf and Uf are 2'-deoxy-2'-fluoro (2'-F) C and U; dC, dA, and dG are 2'-deoxy C, A, and G; and s is a phosphorothioate linkage.

52. The dsRNA agent of claim 51, wherein

a) the nucleotide sequence of the sense strand differs by no more than 3 bases from the nucleotide sequence 5'-gscsaggaagCfAfCfugagauucgu-3' and the nucleotide sequence of the antisense strand differs by no more than 3 bases from the nucleotide sequence 5'-asdCsgadAudCucagdTgCfuuccugcsasc-3',

wherein a, g, c and u are 2'-O-methyl (2'-OMe) A, G, C, and U; Cf and Uf are 2'-deoxy-2'-fluoro (2'-F) C and U; dC, dA, and dT are 2'-deoxy C, A, and T; and s is a phosphorothioate linkage; or

b) the nucleotide sequence of the sense strand differs by no more than 3 bases from the nucleotide sequence 5'-csusacggagAfCfGfugguguuugu-3' and the nucleotide sequence of the antisense strand differs by no more than 3 bases from the nucleotide sequence 5'-asdCsaadAcdAccacdGuCfuccguagscsc -3',

wherein a, g, c and u are 2'-O-methyl (2'-OMe) A, G, C, and U; Cf and Uf are 2'-deoxy-2'-fluoro (2'-F) C and U; dC, dA, and dG are 2'-deoxy C, A, and G; and s is a phosphorothioate linkage.

53. The dsRNA agent of claim 51, wherein

a) the nucleotide sequence of the sense strand differs by no more than 2 bases from the nucleotide sequence 5'-gscsaggaagCfAfCfugagauucgu-3' and the nucleotide sequence of the antisense strand differs by no more than 2 bases from the nucleotide sequence 5'-asdCsgadAudCucagdTgCfuuccugcsasc-3',

wherein a, g, c and u are 2'-O-methyl (2'-OMe) A, G, C, and U; Cf and Uf are 2'-deoxy-2'-fluoro (2'-F) C and U; dC, dA, and dT are 2'-deoxy C, A, and T; and s is a phosphorothioate linkage; or

b) the nucleotide sequence of the sense strand differs by no more than 2 bases from the nucleotide sequence 5'-csusacggagAfCfGfugguguuugu-3' and the nucleotide sequence of the antisense strand differs by no more than 2 bases from the nucleotide sequence 5'-asdCsaadAcdAccacdGuCfuccguagscsc-3',

wherein a, g, c and u are 2'-O-methyl (2'-OMe) A, G, C, and U; Cf and Uf are 2'-deoxy-2'-fluoro (2'-F) C and U; dC, dA, and dG are 2'-deoxy C, A, and G; and s is a phosphorothioate linkage.

54. The dsRNA agent of claim 51, wherein

a) the nucleotide sequence of the sense strand differs by no more than 1 base from the nucleotide sequence 5'-gscsaggaagCfAfCfugagauucgu-3' and the nucleotide sequence of the antisense strand differs by no more than 1 base from the nucleotide sequence 5'-asdCsgadAudCucagdTgCfuuccugcsasc-3',

wherein a, g, c and u are 2'-O-methyl (2'-OMe) A, G, C, and U; Cf and Uf are 2'-deoxy-2'-fluoro (2'-F) C and U; dC, dA, and dT are 2'-deoxy C, A, and T; and s is a phosphorothioate linkage; or

b) the nucleotide sequence of the sense strand differs by no more than 1 base from the nucleotide sequence 5'-csusacggagAfCfGfugguguuugu-3' and the nucleotide sequence of the antisense strand differs by no more than 1 base from the nucleotide sequence 5'-asdCsaadAcdAccacdGuCfuccguagscsc-3',

wherein a, g, c and u are 2'-O-methyl (2'-OMe) A, G, C, and U; Cf and Uf are 2'-deoxy-2'-fluoro (2'-F) C and U; dC, dA, and dG are 2'-deoxy C, A, and G; and s is a phosphorothioate linkage.

55. The dsRNA agent of claim 51, wherein

a) the nucleotide sequence of the sense strand comprises the nucleotide sequence 5'-gscsaggaagCfAfCfugagauucgu-3' and the nucleotide sequence of the antisense strand comprises the nucleotide sequence 5'-asdCsgadAudCucagdTgCfuuccugcsasc-3',

wherein a, g, c and u are 2'-O-methyl (2'-OMe) A, G, C, and U; Cf and Uf are 2'-deoxy-2'-fluoro (2'-F) C and U; dC, dA, and dT are 2'-deoxy C, A, and T; and s is a phosphorothioate linkage; or

b) the nucleotide sequence of the sense strand comprises the nucleotide sequence 5'-csusacggagAfCfGfugguguugu-3' and the nucleotide sequence of the antisense strand comprises the nucleotide sequence 5'-asdCsaadAcdAccacdGuCfuccguagscsc-3',

wherein a, g, c and u are 2'-O-methyl (2'-OMe) A, G, C, and U; Cf and Uf are 2'-deoxy-2'-fluoro (2'-F) C and U; dC, dA, and dG are 2'-deoxy C, A, and G; and s is a phosphorothioate linkage.


56. The dsRNA agent of any one of claims 50-55, further comprising a ligand.

57. The dsRNA agent of claim 56, wherein the ligand is conjugated to the 3' end of the sense strand of the dsRNA agent.


58. The dsRNA agent of claim 56 or 57, wherein the ligand is an N-acetylgalactosamine (GalNAc) derivative.

59. The dsRNA agent of any one of claims 56-58, wherein the ligand is one or more GalNAc derivatives attached through a monovalent, bivalent, or trivalent branched linker.

60. The dsRNA agent of claim 58 or 59, wherein the ligand is



61. The dsRNA agent of claim 60, wherein the dsRNA agent is conjugated to the ligand as shown in the following schematic



and, wherein X is O or S.

62. The dsRNA agent of claim 61, wherein the X is O.

63. A cell containing the dsRNA agent of any one of claims 1-62.

64. A pharmaceutical composition for inhibiting expression of a gene encoding ketohexokinase (KHK) comprising the dsRNA agent of any one of claims 1-62.

65. The pharmaceutical composition of claim 64, wherein dsRNA agent is in an unbuffered solution.

66. The pharmaceutical composition of claim 65, wherein the unbuffered solution is saline or water.

67. The pharmaceutical composition of claim 64, wherein said dsRNA agent is in a buffer solution.

68. The pharmaceutical composition of claim 67, wherein the buffer solution comprises acetate, citrate, prolamine, carbonate, or phosphate or any combination thereof.

69. The pharmaceutical composition of claim 68, wherein the buffer solution is phosphate buffered saline (PBS).

70. A method of inhibiting expression of a ketohexokinase (KHK) gene in a cell, the method comprising contacting the cell with the dsRNA agent of any one of claims 1-62, or the pharmaceutical composition of any one of claims 64-69, thereby inhibiting expression of the KHK gene in the cell.
71. The method of claim 70, wherein the cell is within a subject.
72. The method of claim 71, wherein the subject is a human.
73. The method of claim 71 or 72, wherein the subject has a KHK-associated disorder.
74. The method of claim 73, wherein the KHK-associated disorder is a liver disease selected from the group consisting of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
75. The method of claim 73, wherein the KHK-associated disorder is dyslipidemia selected from the group consisting of hyperlipidemia, high LDL cholesterol, low HDL cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia, adipocyte dysfunction, visceral adipose deposition, obesity, and metabolic syndrome.
76. The method of claim 73, wherein the KHK-associated disorder is a disorder of glycemic control selected from the group consisting of insulin resistance, type 2 diabetes, and glucose intolerance.
77. The method of claim 73, wherein the KHK-associated disorder is a cardiovascular disease selected from the group consisting of hypertension and endothelial cell dysfunction.
78. The method of claim 73, wherein the KHK-associated disorder is a kidney disease selected from the group consisting of acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, and chronic kidney disease.
79. The method of claim 73, wherein the KHK-associated disorder is hyperuricemia.
80. The method of claim 73, wherein the KHK-associated disorder is gout.
81. The method of any one of claims 56-66, wherein contacting the cell with the dsRNA agent inhibits the expression of KHK by at least 50%, 60%, 70%, 80%, 90%, or 95%.

82. The method of any one of claims 70-81, wherein inhibiting expression of KHK decreases KHK protein level in serum of the subject by at least 50%, 60%, 70%, 80%, 90%, or 95%.
83. A method of treating a subject having a disease or disorder that would benefit from reduction in ketohexokinase (KHK) expression, comprising administering to the subject a therapeutically effective amount of the dsRNA agent of any one of claims 1-62 or the pharmaceutical composition of any one of claims 64-69, thereby treating the subject having the disorder that would benefit from reduction in KHK expression.
84. A method of preventing at least one symptom in a subject having a disorder that would benefit from reduction in ketohexokinase (KHK) expression, comprising administering to the subject a prophylactically effective amount of the dsRNA agent of any one of claims 1-62 or the pharmaceutical composition of any one of claims 64-69, thereby preventing at least one symptom in the subject having the disorder that would benefit from reduction in KHK expression.
85. The method of claim 83 or 84, wherein the disorder is a KHK-associated disorder.
86. The method of claim 85, wherein the KHK-associated disorder is a liver disease selected from the group consisting of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
87. The method of claim 85, wherein the KHK-associated disorder is dyslipidemia selected from the group consisting of hyperlipidemia, high LDL cholesterol, low HDL cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia, adipocyte dysfunction, visceral adipose deposition, obesity, and metabolic syndrome.
88. The method of claim 85, wherein the KHK-associated disorder is a disorder of glycemic control selected from the group consisting of insulin resistance, type 2 diabetes, and glucose intolerance.
89. The method of claim 85, wherein the KHK-associated disorder is a cardiovascular disease selected from the group consisting of hypertension and endothelial cell dysfunction.
90. The method of claim 85, wherein the KHK-associated disorder is a kidney disease selected from the group consisting of acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, and chronic kidney disease.

91. The method of claim 85, wherein the KHK-associated disorder is hyperuricemia.
92. The method of claim 85, wherein the KHK-associated disorder is gout.
93. The method of any one of claims 83-92, wherein the subject is human.
94. The method of claim 93, wherein the subject has or is prone to compromised renal function.
95. The method of any one of claims 83-94, wherein the administration of the dsRNA agent to the subject causes a decrease in one or more serum lipid and/or a decrease in KHK protein accumulation.
96. The method of any one of claims 83-95, wherein the administration of the dsRNA agent to the subject causes a decrease in fructose metabolism.
97. The method of any one of claims 83-96, wherein the dsRNA agent is administered to the subject at a dose of about 0.01 mg/kg to about 50 mg/kg.
98. The method of any one of claims 83-97, wherein the dsRNA agent is administered to the subject subcutaneously.
99. The method of any one of claims 83-98, further comprising determining the level of KHK in a sample(s) from the subject.
100. The method of claim 99, wherein the level of KHK in the subject sample(s) is a KHK protein level in a blood or serum sample(s).
101. The method of claim 83-100, further comprising determining a level of fructose metabolism in a sample(s) from the subject.
102. The method of claim 83-101, further comprising determining a level of uric acid in a sample(s) from the subject.
103. The method of claim 83-102, further comprising determining a level of serum lipid in a sample(s) from the subject.
104. The method of any one of claims 83-103, further comprising administering to the subject an additional therapeutic agent for treatment of a KHK-associated disorder.

105. A kit comprising the dsRNA agent of any one of claims 1-62 or the pharmaceutical composition of any one of claims 64-69.

106. A vial comprising the dsRNA agent of any one of claims 1-62 or the pharmaceutical composition of any one of claims 64-69.

107. A syringe comprising the dsRNA agent of any one of claims 1-62 or the pharmaceutical composition of any one of claims 64-69.

108. An RNA-induced silencing complex (RISC) comprising an antisense strand of any of the dsRNA agents of claims 1-62.




FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4

SEQUENCE LISTING

<110> ALNYLAM PHARMACEUTICALS, INC.
 NOETZLI, Leila
 MCININCH, James D.
 TREMBLAY, Frederic
 SCHLEGEL, Mark K.
 CASTORENO, Adam

<120> KETOHEXOKINASE (KHK) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

<130> 121301-14720

<140>

<141>

<150> 63/280,668

<151> 2021-11-18

<150> 63/223,581

<151> 2021-07-20

<150> 63/154,005

<151> 2021-02-26

<160> 2041

<170> PatentIn version 3.5

<210> 1

<211> 2283

<212> DNA

<213> Homo sapiens

<400> 1

ggggcggggc ggggccgccg cgaccgcggg cttcaggcag ggctgcagat gcgaggccca 60

gctgtacctc gcgtgtcccg ggtcgggagt cggagacgca ggtgcaggag agtgcggggc 120

aagtagcgca ttttctcttt gcattctcga gatcgcttag ccgcgcttta aaaaggtttg 180

catcagctgt gagtccatct gacaagcgag gaaactaagg ctgagaagtg ggaggcgttg 240

ccatctgcag gcccaggcaa cctgctacgg gaagaccggg gaccaagacc tctgggttgg 300

ctttcctaga cccgctcggg tcttcgggtg tcgagaggaa gggccctgct cttttcgttc 360

cctgcacccc tggccgctgc aggtggctcc ctggaggagg agctccacg cggaggagga 420

gccagggcag ctgggagcgg ggacaccatc ctcttgata agaggcagag gccgggagga 480

accccgtagcag ccgggcgggc aggaagctct gggagtagcc tcatggaaga gaagcagatc	540
ctgtgcgtgg ggctagtggg gctggacgtc atcagcctgg tggacaagta ccctaaggag	600
gactcggaga taaggtgttt gtcccagaga tggcagcgcg gaggcaacgc gtccaactcc	660
tgcaccgttc tctccctgct cggagcccc tgtgccttca tgggctcaat ggctcctggc	720
catgttgctg agagcctgcc agatgtgtct gctacagact ttgagaaggt tgatctgacc	780
cagttcaagt ggatccacat tgagggccgg aacgcacgag agcaggtgaa gatgctgcag	840
cggatagacg cacacaacac caggcagcct ccagagcaga agatccgggt gtccgtggag	900
gtggagaagc cacgagagga gctcttccag ctgtttggct acggagacgt ggtgtttgtc	960
agcaaagatg tggccaagca cttgggggttc cagtcagcag aggaagcctt gaggggcttg	1020
tatggtcgtg tgaggaaagg ggctgtgctt gtctgtgcct gggctgagga gggcgccgac	1080
gccctgggcc ctgatggcaa attgctccac tcggatgctt tcccgccacc ccgcgtggtg	1140
gatacactgg gagctggaga caccttcaat gcctccgtca tcttcagcct ctcccagggg	1200
aggagcgtgc aggaagcact gagattcggg tgccaggtgg ccggcaagaa gtgtggcctg	1260
cagggccttg atggcatcgt gtgagagcag gtgccggctc ctacacacc atggagacta	1320
ccattgcggc tgcacgcct tctcccctcc atccagcctg gcgtccaggt tgccctgttc	1380
aggggacaga tgcaagctgt ggggaggact ctgcctgtgt cctgtgttcc ccacagggag	1440
aggctctggg gggatggctg ggggatgcag agcctcagag caaataaatc ttcctcagag	1500
ccagcttctc ctctcaatgt ctgaactgct ctggctgggc attcctgagg ctctgactct	1560
tcgatcctcc ctcttttgtt ccattcccc aattaacctc tccgccaggg cccagaggag	1620
gggctgcctg ggctagagca gcgagaagtg ccctgggctt gccaccagct ctgccctggc	1680
tggggaggac actcgggtgc ccacaccag tgaacctgcc aaagaaaccg tgagagctct	1740
tcggggccct gcgttgtgca gactctattc ccacagctca gaagctggga gtccacaccg	1800
ctgagctgaa ctgacaggcc agtggggggc aggggtgcgc ctctctgcc ctgcccacca	1860
gcctgtgatt tgatgggggtc ttcatgtgcc agaaatacct cctcccgtg actgccccag	1920
agcctgaaag tctcaccctt ggagcccacc ttggaattaa gggcgtgcct cagccacaaa	1980

tgtgaccag gatacagagt gttgctgtcc tcaggaggt ccatctgga acacatattg	2040
gaattggggc caactccaat atagggtggg taaggcctta taatgtaaag agcatataat	2100
gtaaagggt ttagagttag acagacctgg attaaaatct gccatttaat tagctgcata	2160
tcaccttagg gtacagcact taacgcaatc tgcctcaatt tcttcatctg tcaaatggaa	2220
ccaattctgc ttggctacag aattattgtg aggataaaat catatataaa atgcccagca	2280
tga	2283

<210> 2

<211> 2283

<212> DNA

<213> Homo sapiens

<400> 2

tcatgctggg cattttatat atgattttat cctcacaata attctgtagc caagcagaat	60
tggttcatt tgacagatga agaaattgag gcagattgcg ttaagtgtg taccctaagg	120
tgatatgcag ctaattaaat ggcagatttt aatccaggtc tgtctcactc taaagccctt	180
tacattatat gctctttaca ttataaggcc ttaccaccc tatattggag ttggcccaa	240
ttccaatatg tgttccagat cggacctccc tgaggacagc aacactctgt atcctgggtc	300
acatttgtgg ctgaggcacg cccttaattc caaggtgggc tccaagggtg agactttcag	360
gctctggggc agtcagcggg aggaggtatt tctggacaat gaagaccca tcaaatcaca	420
ggctgggtggg cagggcagag gaggcgcacc cctgcccccc actggcctgt cagttcagct	480
cagcgggtgtg gactcccagc ttctgagctg tgggaataga gtctgcacaa cgcaggggcc	540
cgaagagctc tcacggtttc tttggcaggt tctgggtg tggggcaccg agtgcctcc	600
ccagccaggg cagagctggt ggcaagcca gggcacttct cgctgctcta gccaggcag	660
cccctcctct gggcctgggc ggagagggtta atttggggaa tggacacaaa gagggaggat	720
cgaagagtca gagcctcagg aatgccagc cagagcagtt cagacattga gaggagaagc	780
tggctctgag gaagatttat ttgctctgag gctctgcatc cccagccat ccccccagag	840
cctctccctg tggggaacac aggacacagg cagagtcctc cccacagctt gcatctgtcc	900

cctgaacagg gcaacctgga cgccaggctg gatggagggg agaaggcgat gcagccgcaa	960
tggtagtctc catggtgtgt gaggagccgg cacctgctct cacacgatgc catcaaagcc	1020
ctgcaggcca cacttcttgc cggccacctg gcacccgaat ctcagtgtt cctgcacgt	1080
cctcccctgg gagaggctga agatgacgga ggcattgaag gtgtctccag ctcccagtgt	1140
atccaccacg cggggtggcg ggaaagcatc cgagtggagc aatttgccat cagggccag	1200
ggcgtcggcg ccctcctcag cccaggcaca gacaagcaca gcccctttcc tcacacgacc	1260
atacaagccc ctcaaggctt cctctgctga ctggaacccc aagtgttgg ccacatcttt	1320
gctgacaaac accacgtctc cgtagccaaa cagctggaag agctcctctc gtggcttctc	1380
cacctccacg gacacccgga tcttctgctc tggaggctgc ctggtgttgt gtgcgtctat	1440
ccgctgcagc atcttcacct gtcctgatgc gttccggccc tcaatgtgga tccacttgaa	1500
ctgggtcaga tcaaccttct caaagtctgt agcagacaca tctggcaggc tctcagcaac	1560
atggccagga gccattgagc ccatgaaggc acagggggct ccgagcaggg agagaacggt	1620
gcaggagttg gacgcgttgc ctccgcgtg ccatctctgg gacaaacacc ttatctccga	1680
gtcctcctta gggacttgt ccaccaggct gatgacgtcc agcaccacta gcccacgca	1740
caggatctgc ttctcttcca tgaggctact cccagagctt cctgcccgcc cggctgacgg	1800
ggttcctccc ggcctctgcc tcttatccag gaggatggtg tccccgctcc cagctgccct	1860
ggctcctcct ccgcgtggga gtcctcctc caggagacca cctgcagcgg ccagggtgc	1920
agggaacgaa aggagcaggg cccttcctcg cgacaccga agaccgagc gggcttagga	1980
aagccaaccc agaggtcttg gtccccggtc ttcccgtagc aggttgctg ggcctgcaga	2040
tggcaacgcc tcccacttct cagccttagt ttctctgctt gtcagatgga ctcacagctg	2100
atgcaaacct ttttaaagcg cggctaagcg atctcgagaa tgcaaagaga aaatgcgcta	2160
cttgccccgc actctcctgc acctgcgtct ccgactcccg acccgggaca cgcgaggtac	2220
agctgggcct cgcatctgca gccctgcctg aagcccgcgg tcgcggcggc cccgccccgc	2280
ccc	2283

<211> 2397

<212> DNA

<213> Homo sapiens

<400> 3

aggcagggct gcagatgcga ggcccagctg tacctcgcgt gtcccgggtc gggagtcgga	60
gacgcaggtg caggagagtg cggggcaagt agcgcatttt ctctttgcat tctcgagatc	120
gcttagccgc gctttaaaaa ggtttgcata agctgtgagt ccatctgaca agcgaggaaa	180
ctaaggctga gaagtgggag gcgttgccat ctgcaggccc aggcaacctg ctacgggaag	240
accggggacc aagacctctg ggttggcttt cctagacctg ctcgggtctt cgggtgtcgc	300
gaggaagggc cctgctcctt tcgttccttg caccctggc cgctgcaggt ggctccctgg	360
aggaggagct cccacgcgga ggaggagcca gggcagctgg gagcggggac accatcctcc	420
tggataagag gcagaggccg ggaggaacct cgtcagccgg gcgggcagga agctctggga	480
gtagcctcat ggaagagaag cagatcctgt gcgtggggct agtggtgctg gacgtcatca	540
gcctggtgga caagtacctt aaggaggact cggagataag gtgtttgtcc cagagatggc	600
agcgcggagg caacgcgtcc aactcctgca ccgttctctc cctgctcgga gccccctgtg	660
ccttcatggg ctcaatggct cctggccatg ttgctgactt cctggtggcc gacttcaggc	720
ggcggggcgt ggacgtgtct caggtggcct ggcagagcaa gggggacacc cccagctcct	780
gctgcatcat caacaactcc aatggcaacc gtaccattgt gctccatgac acgagcctgc	840
cagatgtgtc tgctacagac tttgagaagg ttgatctgac ccagttcaag tggatccaca	900
ttgagggccg gaacgcatcg gagcaggtga agatgctgca gcggaatagac gcacacaaca	960
ccaggcagcc tccagagcag aagatccggg tgtccgtgga ggtggagaag ccacgagagg	1020
agctcttcca gctgtttggc tacggagacg tgggtgtttgt cagcaaagat gtggccaagc	1080
acttgggggt ccagtcagca gaggaagcct tgaggggctt gtatggctct gtgaggaaag	1140
gggctgtgct tgtctgtgcc tgggctgagg agggcgccga cgccctgggc cctgatggca	1200
aattgctcca ctcggatgct ttcccggcac ccgcgtggt ggatacactg ggagctggag	1260
acaccttcaa tgcctccgtc atcttcagcc tctcccaggg gaggagcgtg caggaagcac	1320
tgagattcgg gtgccaggtg gccggcaaga agtgtggcct gcagggcttt gatggcatcg	1380

tgtgagagca ggtgccggct cctcacacac catggagact accattgcgg ctgcatcgcc	1440
ttctcccctc catccagcct ggcgtccagg ttgccctggt caggggacag atgcaagctg	1500
tggggaggac tctgcctgtg tcctgtgttc cccacaggga gaggctctgg ggggatggct	1560
gggggatgca gagcctcaga gcaaataaat cttcctcaga gccagcttct cctctcaatg	1620
tctgaactgc tctggctggg cattcctgag gctctgactc ttcgatcctc cctctttgtg	1680
tccattcccc aaattaacct ctccgcccag gccagagga ggggctgcct gggctagagc	1740
agcgagaagt gccctgggct tgccaccagc tctgccctgg ctggggagga cactcggtgc	1800
cccacacca gtgaacctgc caaagaaacc gtgagagctc ttcggggccc tgcgttgtgc	1860
agactctatt cccacagctc agaagctggg agtccacacc gctgagctga actgacaggc	1920
cagtgggggg caggggtgcg cctcctctgc cctgcccacc agcctgtgat ttgatggggt	1980
cttcattgtc cagaaatacc tcctcccgct gactgcccc aagcctgaaa gtctcacctt	2040
tggagcccac cttggaatta agggcgtgcc tcagccacaa atgtgacca ggatacagag	2100
tggtgctgtc ctcagggagg tccgatctgg aacacatatt ggaattgggg ccaactccaa	2160
tatagggtgg gtaaggcctt ataatgtaaa gagcatataa tgtaaagggc tttagagtga	2220
gacagacctg gattaaaatc tgccatttaa ttagctgcat atcaccttag ggtacagcac	2280
ttaacgcaat ctgcctcaat ttcttcatct gtcaaaggga accaattctg cttggctaca	2340
gaattattgt gaggataaaa tcatatataa aatgccagc atgatgcctg atgtgta	2397

<210> 4

<211> 2397

<212> DNA

<213> Homo sapiens

<400> 4

tacacatcag gcatcatgct gggcatttta tatatgattt taccctcaca ataattctgt	60
agccaagcag aattggttcc atttgacaga tgaagaaatt gaggcagatt gcgttaagtg	120
ctgtacccta aggtgatatg cagctaatta aatggcagat tttaatccag gtctgtctca	180
ctctaaagcc ctttacatta tatgctcttt acattataag gccttaccba ccctatatgt	240

gagttggccc caattccaat atgtgttcca gatcggacct ccctgaggac agcaacactc	300
tgtatcctgg gtcacatttg tggctgaggc acgcccttaa ttccaaggtg ggctccaagg	360
gtgagacttt caggctctgg ggcagtcagc gggaggaggt atttctggac aatgaagacc	420
ccatcaaadc acaggctggg gggcagggca gaggaggcgc acccctgccc cccactggcc	480
tgtcagttca gctcagcggg gtggactccc agcttctgag ctgtgggaat agagtctgca	540
caacgcaggg ccccgaagag ctctcacggg ttctttggca ggttcactgg gtgtggggca	600
ccgagtgtcc tccccagcca gggcagagct ggtggcaagc ccagggcact tctcgctgct	660
ctagcccagg cagccccctc tctgggcctg ggcggagagg ttaatttggg gaatggacac	720
aaagaggagg gatcgaagag tcagagcctc aggaatgccc agccagagca gttcagacat	780
tgagaggaga agctggctct gaggaagatt tatttgctct gaggctctgc atccccagc	840
catccccca gagcctctcc ctgtggggaa cacaggacac aggcagagtc ctccccacag	900
cttgcatctg tcccctgaac agggcaacct ggacgccagg ctggatggag gggagaaggc	960
gatgcagccg caatggtagt ctccatggg tgtgaggagc cggcacctgc tctcacacga	1020
tgccatcaaa gccctgcagg ccacacttct tgccggccac ctggcacccg aatctcagtg	1080
cttcctgcac gtcctcccc tgggagaggc tgaagatgac ggaggcattg aaggtgtctc	1140
cagctcccag tgtatccacc acgcgggggtg gcgggaaagc atccgagtgg agcaatttgc	1200
catcagggcc cagggcgtcg gcgccctcct cagcccaggc acagacaagc acagcccctt	1260
tcctcacacg accatacaag cccctcaagg cttcctctgc tgactggaac cccaagtgt	1320
tggccacatc tttgctgaca aacaccacgt ctccgtagcc aaacagctgg aagagctcct	1380
ctcgtggctt ctccacctcc acggacaccc ggatcttctg ctctggaggc tgcctggtgt	1440
tgtgtgcgtc tatccgtgc agcatcttca cctgctccga tgcgttccgg ccctcaatgt	1500
ggatccactt gaactgggtc agatcaacct tctcaaagtc tgtagcagac acatctggca	1560
ggctcgtgtc atggagcaca atggtacggg tgccattgga gttgttgatg atgcagcagg	1620
agctgggggt gtcccccttg ctctgccagg ccacctgaga cacgtccacg ccccgccgcc	1680
tgaagtcggc caccaggaag tcagcaacat ggccaggagc cattgagccc atgaaggcac	1740

agggggctcc gagcaggag agaacggtgc aggagttagga cgcgttgctt ccgcgctgcc	1800
atctctggga caaacacctt atctccgagt cctccttagg gtacttgtcc accaggctga	1860
tgacgtccag caccactagc cccacgcaca ggatctgctt ctcttccatg aggctactcc	1920
cagagcttcc tgcccggccg gctgacgggg ttctctccgg cctctgcctc ttatccagga	1980
ggatggtgtc cccgctccca gctgccctgg ctctctctcc gcgtgggagc tcctcctcca	2040
gggagccacc tgcagcggcc aggggtgcag ggaacgaaag gagcagggcc cttcctcgcg	2100
acacccgaag acccgagcgg gtctaggaaa gccaacccag aggtcttggt ccccggtctt	2160
cccgtagcag gttgcctggg cctgcagatg gcaacgcctc ccacttctca gccttagttt	2220
cctcgcttgt cagatggact cacagctgat gcaaaccttt ttaaagcgcg gctaagcgat	2280
ctcgagaatg caaagagaaa atgcgctact tgccccgcac tctcctgcac ctgcgtctcc	2340
gactcccgac ccgggacacg cgaggtacag ctgggcctcg catctgcagc cctgcct	2397

<210> 5

<211> 2397

<212> DNA

<213> Homo sapiens

<400> 5

aggcagggtc gcagatgcga ggcccagctg tacctcgcgt gtcccgggtc gggagtcgga	60
gacgcagggtg caggagagtg cggggcaagt agcgcatttt ctctttgcat tctcgagatc	120
gcttagccgc gctttaaaaa ggtttgcata agctgtgagt ccatctgaca agcgaggaaa	180
ctaaggctga gaagtgggag gcgttgccat ctgcaggccc aggcaacctg ctacgggaag	240
accggggacc aagacctctg ggttggcttt cctagacctg ctcgggtctt cgggtgtcgc	300
gaggaagggc cctgctcctt tcgttccttg caccctggc cgctgcaggt ggctccctgg	360
aggaggagct cccacgcgga ggaggagcca gggcagctgg gagcggggac accatcctcc	420
tggataagag gcagaggccg ggaggaacct cgtcagccgg gcgggcagga agctctggga	480
gtagcctcat ggaagagaag cagatcctgt gcgtggggct agtggtgctg gacgtcatca	540
gcctgggtgga caagtaccct aaggaggact cggagataag gtgtttgtcc cagagatggc	600
agcgcggagg caacgcgtcc aactcctgca ccgttctctc cctgctcgga gcccctgtg	660

ccttcatggg ctcaatggct cctggccatg ttgctgattt tgtcctggat gacctccgcc	720
gctatttctgt ggacctacgc tacacagtct ttcagaccac aggctccgtc cccatcgcca	780
cggatcatcat caacgaggcc agtggttagcc gcaccatcct atactatgac aggagcctgc	840
cagatgtgtc tgctacagac tttgagaagg ttgatctgac ccagttcaag tggatccaca	900
ttgagggccg gaacgcatcg gagcaggtga agatgctgca gcggatagac gcacacaaca	960
ccaggcagcc tccagagcag aagatccggg tgtccgtgga ggtggagaag ccacgagagg	1020
agctcttcca gctgtttggc tacggagacg tgggtgttgt cagcaaagat gtggccaagc	1080
acttgggggtt ccagtcagca gaggaagcct tgaggggctt gtatggctgt gtgaggaaag	1140
gggctgtgct tgtctgtgcc tgggctgagg agggcgccga cgccctgggc cctgatggca	1200
aattgctcca ctcggtatgt tttccgccac cccgcgtggt ggatacactg ggagctggag	1260
acaccttcaa tgcctccgtc atcttcagcc tctcccaggg gaggagcgtg caggaagcac	1320
tgagattcgg gtgccaggtg gccggcaaga agtgtggcct gcagggcttt gatggcatcg	1380
tgtgagagca ggtgccggct cctcacacac catggagact accattgcgg ctgcatcgcc	1440
ttctcccctc catccagcct ggcgtccagg ttgccctgtt caggggacag atgcaagctg	1500
tggggaggac tctgcctgtg tcctgtgttc cccacaggga gaggctcttg ggggatggct	1560
gggggatgca gagcctcaga gcaaataaat cttcctcaga gccagcttct cctctcaatg	1620
tctgaactgc tctggctggg cattcctgag gctctgactc ttcgatcctc cctctttgtg	1680
tccattcccc aaattaacct ctccgccag gccagagga ggggctgcct gggctagagc	1740
agcgagaagt gccctgggct tgccaccagc tctgccctgg ctggggagga cactcggtgc	1800
cccacaccca gtgaacctgc caaagaaacc gtgagagctc ttcggggccc tgcgttgtgc	1860
agactctatt cccacagctc agaagctggg agtccacacc gctgagctga actgacaggc	1920
cagtgggggg caggggtgcg cctcctctgc cctgcccacc agcctgtgat ttgatggggt	1980
cttcattgtc cagaaatacc tcctcccgct gactgcccc aagcctgaaa gtctcacctt	2040
tggagcccac cttggaatta agggcgtgcc tcagccacaa atgtgacca ggatacagag	2100
tgttgctgtc ctgaggagg tccgatctgg aacacatatt ggaattgggg ccaactccaa	2160

tatagggtgg gtaaggcctt ataatgtaaa gagcatataa tgtaaagggc tttagagtga	2220
gacagacctg gattaaaaatc tgccatttaa ttagctgcat atcaccttag ggtacagcac	2280
ttaacgcaat ctgcctcaat ttcttcatct gtcaaagga accaattctg cttggctaca	2340
gaattattgt gaggataaaa tcatatataa aatgcccagc atgatgcctg atgtgta	2397

<210> 6

<211> 2397

<212> DNA

<213> Homo sapiens

<400> 6

tacacatcag gcatcatgct gggcatttta tatatgattt tatkctcaca ataattctgt	60
agccaagcag aattggttcc atttgacaga tgaagaaatt gaggcagatt gcgttaagtg	120
ctgtacccta aggtgatatg cagctaatta aatggcagat tttaatccag gtctgtctca	180
ctctaaagcc ctttacatta tatgctcttt acattataag gccttaccba ccctatatattg	240
gagttggccc caattccaat atgtgtttcca gatcggacct ccctgaggac agcaaacactc	300
tgtatcctgg gtcacatttg tggctgaggc acgcccttaa ttccaaggtg ggctccaagg	360
gtgagacttt caggctctgg ggcagtcagc gggaggaggt atttctggac aatgaagacc	420
ccatcaaadc acaggctggg gggcagggca gaggaggcgc acccctgccc cccactggcc	480
tgtcagttca gctcagcggg gtggactccc agcttctgag ctgtgggaat agagtctgca	540
caacgcaggg ccccgaagag ctctcacggg ttctttggca ggttcactgg gtgtggggca	600
ccgagtgtcc tccccagcca gggcagagct ggtggcaagc ccagggcact tctcgtctgt	660
ctagcccagg cagcccctcc tctgggcctg ggcggagagg ttaatttggg gaatggacac	720
aaagagggag gatcgaagag tcagagcctc aggaatgccc agccagagca gttcagacat	780
tgagaggaga agctggctct gaggaagatt tatttgctct gaggctctgc atccccagc	840
catccccca gagcctctcc ctgtggggaa cacaggacac aggcagagtc ctccccacag	900
cttgcatctg tcccctgaac agggcaacct ggacgccagg ctggatggag gggagaaggc	960
gatgcagccg caatggtagt ctccatggtg tgtgaggagc cggcacctgc tctcacacga	1020

tgccatcaaa gccctgcagg ccacacttct tgccggccac ctggcaccgc aatctcagtg	1080
cttcctgcac gtcctctccc tgggagaggc tgaagatgac ggaggcattg aaggtgtctc	1140
cagctcccag tgtatccacc acgcgggggtg gcgggaaagc atccgagtgg agcaatttgc	1200
catcagggcc cagggcgtcg gcgccctcct cagcccaggc acagacaagc acagcccctt	1260
tcctcacacg accatacaag cccctcaagg cttcctctgc tgactggaac cccaagtgtc	1320
tggccacatc tttgctgaca aacaccacgt ctccgtagcc aaacagctgg aagagctcct	1380
ctcgtggctt ctccacctcc acggacaccc ggatcttctg ctctggaggc tgcctggtgt	1440
tgtgtgcgtc tatccgctgc agcatcttca cctgctccga tgcgttccgg ccctcaatgt	1500
ggatccactt gaactgggtc agatcaacct tctcaaagtc tgtagcagac acatctggca	1560
ggctcctgtc atagtatagg atggtgcggc taccactggc ctcgttgatg atgaccgtgg	1620
cgatggggac ggagcctgtg gtctgaaaga ctgtgtagcg taggtccaca gaatagcggc	1680
ggaggtcatc caggacaaaa tcagcaacat ggccaggagc cattgagccc atgaaggcac	1740
agggggctcc gagcagggag agaacggtgc aggagttaga cgcgttgcct ccgcgctgcc	1800
atctctggga caaacacctt atctccgagt cctccttagg gtacttgtcc accaggctga	1860
tgacgtccag caccactagc cccacgcaca ggatctgctt ctcttccatg aggctactcc	1920
cagagcttcc tgcccgcgcg gctgacgggg ttctctccgg cctctgcctc ttatccagga	1980
ggatgggtgtc cccgctccca gctgccctgg ctctcctcc gcgtgggagc tcctcctcca	2040
gggagccacc tgcagcggcc aggggtgcag ggaacgaaag gagcagggcc cttcctcgcg	2100
acacccgaag acccgagcgg gtctaggaaa gccaacccag aggtcttggt ccccggtctt	2160
cccgtagcag gttgcctggg cctgcagatg gcaacgcctc ccacttctca gccttagttt	2220
cctcgcttgt cagatggact cacagctgat gcaaaccctt ttaaagcgcg gctaagcgat	2280
ctcgagaatg caaagagaaa atgcgctact tgccccgcac tctcctgcac ctgcgtctcc	2340
gactccccgac ccgggacacg cgaggtacag ctgggcctcg catctgcagc cctgcct	2397

<210> 7

<211> 1590

<212> DNA

<213> Mus musculus

<400> 7

gagggagaga acgcttgctt ctgtgctccg cctgcgaagg cgaagtttct gttgccagac	60
tgtgctagtc cgggtggtcc agggctctgca gcaggcgcag agggatcgga aaggcgatgc	120
attactagtg cgctttcgct ttgacagctg aggcggaaaa gtgagagggc ctgccattgg	180
ccgggctagg taaccacccc ttgcaaagca gaaagctccc tgcgggagga gttctgcacg	240
cagaggagga gccaaagtag ccagtgagaa gttgggacac ggtcctccag tagataagag	300
gcagagccca gcaggaaccc cctctgcttg cgggtaggaa gcttggggag cagcctcatg	360
gaagagaagc agatcctgtg cgtggggctg gtggtgctgg acatcatcaa tgtggtggac	420
aaatacccag aggaagacac ggatcgcagg tgcctgtccc agagatggca gcgtggaggc	480
aacgcatcca actcctgcac tgtcctttcc ttgcttgag cccgctgtgc cttcatgggc	540
tctttggccc ctggccacgt tgccgatttt gtcctggatg acctccgcca acattctgtg	600
gacttacgat atgtggctct tcagaccgag ggctccatcc ccacttctac agtcatcatc	660
aacgaggcca gcggcagccg caccattctg cacgcctaca gcttcctggt ggctgacttc	720
aggcagaggg gcgtggatgt gtctcaagtg acttggcaga gccagggaga tacccttgc	780
tcttgctgca tcgtcaacaa ctccaatggc tcccgtacca ttatactcta cgacacgaac	840
ctgccagatg tgtctgctaa ggactttgag aaggctgatc tgacccggtt caagtggatc	900
cacattgagg gccggaatgc atcggaacag gtgaagatgc tgcagcggat agaggagcac	960
aatgccaagc agcctctgcc acagaaggc cgggtgtcgg tggagataga gaagccccgt	1020
gaggagctct tccagttgtt tagctatggt gaggtggtgt ttgtcagcaa agatgtggcc	1080
aagcacctgg ggttccagtc agcagtggag gccctgaggg gcttgtacag tcgagtgaag	1140
aaaggggcta cgcttgctctg tgcctgggct gaggaggggtg ccgatgccct gggccccgat	1200
ggtcagctgc tccactcaga tgccttccca ccgccccgag tagtagacac tcttggggct	1260
ggagacacct tcaatgcctc tgtcatcttc agcctctcga agggaaacag catgcaagag	1320
gccctgagat tcgggtgcc a ggtggctggc aagaagtgtg gcttgcaggg gtttgatggc	1380
attgtgtgag aggcaagcgg caccagctcg atacctcaga ggctggcacc atgcctgcc	1440

ctgccttctc tacttcctcc agcttagcat ccagctgccca ttccccggca ggtgtgggat	1500
gtgggacagc ctctgtctgt gtctgcgtct ctgtatacct atctcctctc tgcagatacc	1560
tggagcaaataaatcttccc ctgagccagc	1590

<210> 8

<211> 1590

<212> DNA

<213> Mus musculus

<400> 8

gctggctcag gggaagattt atttgctcca ggtatctgca gagaggagat aggtatacag	60
agacgcagac acagacagag gctgtccac atccacacc tgccggggaa tggcagctgg	120
atgctaagct ggaggaagta gagaaggcag tggcaggcat ggtgccagcc tctgaggtat	180
cgagctgggtg ccgcttgctt ctcacacaat gccatcaaac ccctgcaagc cacacttctt	240
gccagccacc tggcacccga atctcagggc ctcttgcatt ctgtttccct tcgagaggct	300
gaagatgaca gaggcattga aggtgtctcc agccccaaga gtgtctacta ctcggggcgg	360
tgggaaggca tctgagtgga gcagctgacc atcggggccc agggcatcgg caccctcctc	420
agcccaggca cagacaagcg tagccccctt cttcactcga ctgtacaagc ccctcagggc	480
ctccactgct gactggaacc ccaggtgctt ggccacatct ttgctgacaa acaccacctc	540
accatagcta aacaactgga agagctcctc acggggcttc tctatctcca ccgacacccg	600
gaccttctgt ggagaggct gcttggcatt gtgctcctct atccgctgca gcatcttcac	660
ctgttccgat gcattccggc cctcaatgtg gatccacttg aaccgggtca gatcgacctt	720
ctcaaagtcc ttagcagaca catctggcag gttcgtgtcg tagagtataa tggtagggga	780
gccattggag ttgttgacga tgcagcaaga gcaaggggta tctccctggc tctgccaagt	840
cacttgagac acatccacgc ccctctgcct gaagtcagcc accaggaagc tgtaggcgtg	900
cagaatgggtg cggctgccgc tggcctcgtt gatgatgact gtagaagtgg ggatggagcc	960
ctcggctctga aggaccacat atcgtaagtc cacagaatgt tggcggagggt catccaggac	1020
aaaatcggca acgtggccag gggccaaaga gcccatgaag gcacagcggg ctccaagcaa	1080

ggaaaggaca gtgcaggagt tggatgcgtt gcctccacgc tgccatctct gggacaggca	1140
cctgcgatcc gtgtcttcct ctgggtatct gtccaccaca ttgatgatgt ccagcaccac	1200
cagccccacg cacaggatct gcttctcttc catgaggctg ctccccaagc ttcctaccg	1260
caagcagagg gggttcctgc tgggctctgc ctcttatcta ctggaggacc gtgtcccaac	1320
ttctcactgg ctaccttggc tcctcctctg cgtgcagaac tcctcccgca gggagctttc	1380
tgctttgcaa ggggtgggtta cctagcccgg ccaatggcag gccctctcac ttttccgcct	1440
cagctgtcaa agcgaaagcg cactagtaat gcatcgcctt tccgatccct ctgcgcctgc	1500
tgagaccct ggaccacccg gactagcaca gtctggcaac agaaacttcg ctttcgcagg	1560
cggagcacag aagcaagcgt tctctccctc	1590

<210> 9

<211> 1307

<212> DNA

<213> Rattus norvegicus

<400> 9

gtgagagggt ctgccattgg ccggactagg taaccaaacc ctcgcaacag cagaaagcac	60
cctgcgggag gagctccgca ggcagaggag gagccagggt agcccctgag aagttgggac	120
acggtcctgc ggtagataag agacagagtc tagcaggaat cccctccgct tgcgggtagg	180
aagcttgggg agcagcctca tggaagagaa gcagatcctg tgcgtggggc tgggtggtgt	240
ggacatcatc aatgtgggtgg acaaataccc agaggaagac acggatcgca ggtgcctatc	300
ccagagatgg cagcgtggag gcaacgcgtc caactcctgc actgtgcttt ccttgctcgg	360
agcccgtgt gccttcatgg gctcgtggc ccatggccat gttgccgact tcctggtggc	420
cgacttcagg cggaggggtg tggatgtgtc tcaagtggcc tggcagagcc agggagatac	480
cccttgctcc tgctgcatcg tcaacaactc caatggctcc cgtaccatta ttctctacga	540
cacgaacctg ccagatgtgt ctgctaagga ctttgagaag gtcgatctga cccggttcaa	600
gtggatccac attgagggcc ggaatgcac ggaacaggta aagatgctac agcggataga	660
acagtacaat gccacgcagc ctctgcagca gaaggtccgg gtgtccgtgg agatagagaa	720
gccccgagag gaactcttcc agctgttcgg ctatggagag gtggtgtttg tcagcaaaga	780

tgtggccaag cacctggggt tccggtcagc aggggaggcc ctgaagggct tgtacagtcg	840
tgtgaagaaa ggggctacgc tcatctgtgc ctgggctgag gagggagccg atgccctggg	900
ccccgacggc cagctgctcc actcagatgc cttcccacca ccccgagtag tagacactct	960
cggggctgga gacaccttca atgcctctgt catcttcagc ctctccaagg gaaacagcat	1020
gcaggaggcc ctgagattcg ggtgccaggt ggctggcaag aagtgtggct tgcaggggtt	1080
tgatggcatt gtgtgagaga tgagcgggtg gaggtagcag ctcgacacct cagaggctgg	1140
caccactgcc tgccattgcc ttcttcattt catccagcct ggcgctctggc tgcccagttc	1200
cctgggccag tgtaggctgt ggaacgggtc tttctgtctc ttctctgcag acacctggag	1260
caaataaatc ttcccctgag ccaaaaaaaaa aaaaaaaaaa aaaaaaa	1307

<210> 10

<211> 1307

<212> DNA

<213> Rattus norvegicus

<400> 10

tttttttttt tttttttttt tttttggctc aggggaagat ttatttgctc caggtgtctg	60
cagagaagag acagaaagac ccgttcaca gcctacactg gcccaggga ctgggcagcc	120
agacgccagg ctggatgaaa tgaagaaggc aatggcaggc agtggtgcca gcctctgagg	180
tgctgagctg ctacctcca ccgctcatct ctacacaaat gccatcaaac ccctgcaagc	240
cacacttctt gccagccacc tggcacccga atctcagggc ctcttgcctg ctgtttccct	300
tggagaggct gaagatgaca gaggcattga aggtgtctcc agccccgaga gtgtctacta	360
ctcggggtgg tgggaaggca tctgagtgga gcagctggcc gtcggggccc agggcatcgg	420
ctccctctc agcccaggca cagatgagcg tagccccctt cttcacacga ctgtacaagc	480
ccttcagggc ctcccctgct gaccggaacc ccagggtgctt ggccacatct ttgctgacaa	540
acaccacctc tccatagccg aacagctgga agagttcctc tcggggcttc tctatctcca	600
cggacacccg gaccttctgc tgcagaggct gcgtggcatt gtactgttct atccgctgta	660
gcatctttac ctgttccgat gcattccggc cctcaatgtg gatccacttg aaccgggtca	720

gatcgacctt ctcaaagtcc ttagcagaca catctggcag gttcgtgtcg tagagaataa	780
tggtacggga gccattggag ttgttgacga tgcagcagga gcaaggggta tctccctggc	840
tctgccaggc cacttgagac acatccacac ccctccgcct gaagtcggcc accaggaagt	900
cggcaacatg gccatgggcc agcgagccca tgaaggcaca gcgggctccg agcaaggaaa	960
gcacagtgca ggagttggac gcgttgccct caccgtgcc a tctctgggat aggcacctgc	1020
gatccgtgtc ttcctctggg tatttgtcca ccacattgat gatgtccagc accaccagcc	1080
ccacgcacag gatctgcttc tcttccatga ggctgctccc caagcttcct acccgcaagc	1140
ggaggggatt cctgctagac tctgtctctt atctaccgca ggaccgtgtc ccaacttctc	1200
aggggctacc ctggctcctc ctctgcctgc ggagctcctc ccgcagggtg ctttctgctg	1260
ttgcgagggt ttggttacct agtccggcca atggcagacc ctctcac	1307

<210> 11

<211> 2416

<212> DNA

<213> *Macaca fascicularis*

<400> 11

ggggccgggc agccgcgacc acggtcttca ggcagggtg cagatgcagg cccagctcta	60
cctcgcggggt ccagggtcgg gagtccgaga cgcagggtga gcagagggcg gggcacgtag	120
cgcattttcca gcgcattttc tctttgcatt ctcgagatcg cttagccgcg ctttagaagg	180
gtttgcatca gtc ccgagtc catctgacaa gcgaggaaac tgaggctgag aagtgggagg	240
cgttgccatc tgcaggccca ggcaacctgc tacgggaaga ccgggggcca agacctccgg	300
gttggctttc ccaggccagc ttgggtcttc ggggtgtcggg agcaaaggcc cagctccttt	360
cgtttcctgc acccctcgcc gctgcagggtg gctccccgga ggaggagctc ccacgcggag	420
gaggagccag ggcagctggg agcgaggaca ccatcctcct ggataacagg cagaggccgg	480
gaggaacccg tcagtcgggc gggcaggaag ctctgggatc agcctcatgg aagagaagca	540
gatcctgtgc gtggggctag tgggtgctgga cgtcatcagc ctggtggaca agtaccctaa	600
ggaggactca gagataaggt gcttgtccca gagatggcaa cgcggaggca acgcgtccaa	660
ctcctgcacc gttctctccc tgctcggagc cccctgtgcc ttcattgggct caatggcccc	720

tggccatgtt gctgacttcc tgggtggccga cttcaggcgg cgggggtgtgg acgtgtctca	780
ggtggcctgg cagagcaagg gggacacccc cagctcctgc tgcacatca acaactccaa	840
tggcaaccgt accattgtgc tccatgacac gagcctgcca gatgtgtctg ctacggactt	900
tgagaagggt gatctgaccc agttcaagt gatccacatt gagggccgga atgcatcgga	960
gcaggatgaag atgctgcagc ggatagacgc gcacaacacc aggcagcctc cagagcagaa	1020
gatccgggtg tccgtggagg tggagaagcc acaagaggag ctctttcagc tgtttggtta	1080
cggagacgtg gtgtttgtca gcaaagatgt ggccaagcac ttgggggttcc agtcagcagg	1140
ggaagccctg aggggcttgt atggctgtgt gaggaaagg gctgtgcttg tctgtgcctg	1200
ggctgaggag ggcgccgacg ccctgggccc tgatggcaaa ctgatccact cggatgcttt	1260
cccgccaccc cgcgtgggtgg ataccctggg ggctggagac accttcaatg cctccgtcat	1320
cttcagcctc tcccagggga ggagcgtgca ggaagcactg agattcggat gccagggtggc	1380
cggcaagaag tgtggccagc agggctttga tggcatcgtg tcagagccgg tgcggtagga	1440
ggtgccggct ccccgcacac tatggaggct gacattgcgg ctgcatcgcc ttctcccctc	1500
catccagcct ggcatccagg ttgccctgct caggggacag atgcaggctg tggggaggac	1560
tccgcctgtg tcctgtgttc cccacacgtc tctccctgca gaggcctcaga gcgaataaat	1620
cttctcggga gccagcttcc cctggcagct tctgtcctcg atgtctgaac tgctctggct	1680
gggcattcct gaggctctga ctctccagtc ctccctcctc gtgtgcattc cccaaattaa	1740
cctctccacc caggcccaga ggaggggctg cctgggctat agcagcaaga agtgccccag	1800
gcttgccgcc agctctgccc tggctgggga ggacactcag tgccccatac ccagcgaacc	1860
tgccaaagaa ccagaagcca tgagagctct ttggggccct gcgttgtgca gactctattc	1920
ccatagctca gaagctggga gtccacacgg ctgagccaaa ctgacaggcc agtggggggc	1980
gaggggggtg ggcgcctcct ctgccctgcc caccagcctg tgatttggtg gcgtctttgt	2040
tgtccaaaaa tatctcctcc cgctgactgc cccagagcct gaaagtctca cccgtggagc	2100
ccaccttgga attaagggga tgcctcagcc acaaatgtga cccaagatag agtgttgtcc	2160
tcagggaggt cggatctgga acacatattg gaattggggc caactccaat atagagtgga	2220

taaggcctta taatgtaaag agcacataag gtaaagggct ttagagtcag acagacctag	2280
attcaaatct gccatttaat tagctgcatg tcacctgagg gtacagcgct taacacaatc	2340
cgcctcaatt tcttcatctg tcaaattggag ccaattctgc ctggctacag aattattgcg	2400
aggataaaaat catgta	2416

<210> 12

<211> 2416

<212> DNA

<213> *Macaca fascicularis*

<400> 12

tacatgattt tatcctcgca ataattctgt agccaggcag aattggctcc atttgacaga	60
tgaagaaatt gaggcggatt gtgttaagcg ctgtaccctc aggtgacatg cagctaatta	120
aatggcagat ttgaatctag gtctgtctga ctctaaagcc ctttacctta tgtgctcttt	180
acattataag gccttatcca ctctatattg gagttggccc caattccaat atgtgttcca	240
gatccgacct ccctgaggac aacctctat cttgggtcac atttgtggct gaggcattccc	300
cttaattcca aggtgggctc cacgggtgag actttcaggc tctggggcag tcagcgggag	360
gagatatttt tggacaacaa agacgccacc aaatcacagg ctggtgggca gggcagagga	420
ggcgccccac cccctcgccc cccactggcc tgtcagtttg gctcagccgt gtggactccc	480
agcttctgag ctatgggaat agagtctgca caacgcaggg ccccaaagag ctctcatggc	540
ttctgggttct ttggcagggt cgctgggtat ggggcactga gtgtcctccc cagccagggc	600
agagctggcg gcaagcctgg ggcacttctt gctgctatag cccaggcagc ccctcctctg	660
ggcctgggtg gagagggtta tttggggaat gcacacgagg agggaggact ggagagtcag	720
agcctcagga atgcccagcc agagcagttc agacatcgag gacagaagct gccaggggaa	780
gctggctccg aggaagattt attcgctctg aggctctgca gggagagacg tgtggggaac	840
acaggacaca ggcggagtcc tccccacagc ctgcatctgt cccctgagca gggcaacctg	900
gatgccaggc tggatggagg ggagaaggcg atgcagccgc aatgtcagcc tccatagtgt	960
gcggggagcc ggcacctcct accgcaccgg ctctgacacg atgcatcaa agccctgctg	1020

gccacacttc ttgccggcca cctggcatcc gaatctcagt gcttcctgca cgctcctccc	1080
ctgggagagg ctgaagatga cggaggcatt gaaggtgtct ccagcccca gggatatccac	1140
cacgcgggggt ggcgggaaag catccgagtg gatcagtttg ccatcagggc ccagggcgtc	1200
ggcgccctcc tcagcccagg cacagacaag cacagcccct ttcctcacac gaccatacaa	1260
gcccctcagg gcttcccctg ctgactggaa cccaagtgc ttggccacat ctttgctgac	1320
aaacaccacg tctccgtagc caaacagctg aaagagctcc tcttgtggct tctccacctc	1380
cacggacacc cggatcttct gctctggagg ctgcctgggt ttgtgcgcgt ctatccgctg	1440
cagcatcttc acctgctccg atgcattccg gccctcaatg tggatccact tgaactgggt	1500
cagatcaacc ttctcaaagt ccgtagcaga cacatctggc aggctcgtgt catggagcac	1560
aatggtacgg ttgccattgg agttgttgat gatgcagcag gagctggggg tgtccccctt	1620
gctctgccag gccacctgag acacgtccac accccgccgc ctgaagtcgg ccaccaggaa	1680
gtcagcaaca tggccagggg ccattgagcc catgaaggca cagggggctc cgagcaggga	1740
gagaacggtg caggagttag acgcgttgcc tccgcgttgcc catctctggg acaagcacct	1800
tatctctgag tcctccttag ggtacttgct caccaggctg atgacgtcca gcaccactag	1860
ccccacgcac aggatctgct tctcttccat gaggtgatc ccagagcttc ctgcccggcc	1920
gactgacggg ttctctccgg cctctgcctg ttatccagga ggatggtgtc ctcgctccca	1980
gctgccctgg ctctcctcc gcgtgggagc tcctcctccg gggagccacc tgcagcggcg	2040
aggggtgcag gaaacgaaag gagctgggcc tttgctcccg acaccgaag acccaagctg	2100
gcctgggaaa gccaaaccgg aggtcttgcc cccggctctt cccgtagcag gttgcctggg	2160
cctgcagatg gcaacgcctc ccacttctca gcctcagttt cctcgcttgt cagatggact	2220
cggagctgat gcaaaccctt ctaaagcgcg gctaagcgat ctcgagaatg caaagagaaa	2280
atgcgctgga aatgcgctac gtgccccgcc ctctgctgca cctgcgtctc ggactcccga	2340
ccctggaccc gcgaggtaga gctgggcctg catctgcagc cctgcctgaa gaccgtggtc	2400
gcggctgccc ggcccc	2416

<400> 13
000

<210> 14
<211> 16
<212> PRT
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown:
RFGF peptide sequence"

<400> 14
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
1 5 10 15

<210> 15
<211> 11
<212> PRT
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown:
RFGF analogue sequence"

<400> 15
Ala Ala Leu Leu Pro Val Leu Leu Ala Ala Pro
1 5 10

<210> 16
<211> 13
<212> PRT
<213> Human immunodeficiency virus 1

<400> 16
Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Pro Pro Gln
1 5 10

<210> 17
<211> 16
<212> PRT
<213> Drosophila sp.

<400> 17
Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys
1 5 10 15

<210> 18
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 18
cuuacgcuga guacuucgat t 21

<210> 19
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 19
ucgaaguacu cagcguaagt t 21

<210> 20
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 20

gugguguuug ucagcaaaga u

21

<210> 21

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 21

acgugguguu ugucagcaaa u

21

<210> 22

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 22

ucagagcaaa uaaauccuucc u

21

<210> 23

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 23

caguucaagu ggauccacau u

21

<210> 24

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 24
aguagcgcau uuucucuuug u 21

<210> 25
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 25
gcgcauuuuc ucuuugcauu u 21

<210> 26
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 26
cgcauuuucu cuuugcauuc u 21

<210> 27
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 27
gcacuuuucuc uuugcauucu u 21

<210> 28
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 28
cauuuucucu uugcauucuc u 21

<210> 29
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 29
uuuucucuuu gcuuucucga u 21

<210> 30
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 30
uucucuuugc auucucgaga u 21

<210> 31
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 31

ucucuuugca uucucgagau u

21

<210> 32

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 32

cucuuugcau ucucgagau u

21

<210> 33

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 33

ucuuugcauu cucgagaucg u

21

<210> 34

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 34

uuugcauucu cgagaucgcu u 21

<210> 35
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 35
ugcauucucg agaucgcuua u 21

<210> 36
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 36
gcauucucga gaucgcuuag u 21

<210> 37
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 37
cauucucgag aucgcuuagc u 21

<210> 38
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 38
 cuuuaaaaag guuugcauca u 21

<210> 39
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 39
 uuuaaaaagg uuugcaucag u 21

<210> 40
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 40
 uuaaaaaggu uugcaucagc u 21

<210> 41
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 41
 ucagcuguga guccaucuga u 21

<210> 42
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 42
gcugugaguc caucugacaa u 21

<210> 43
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 43
cugugagucc aucugacaag u 21

<210> 44
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 44
ccaucugaca agcgaggaaa u 21

<210> 45
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 45

caucugacaa gcgaggaaac u

21

<210> 46

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 46

ggaaacuaag gcugagaagu u

21

<210> 47

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 47

gaaacuaagg cugagaagug u

21

<210> 48

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 48

agaccucugg guuggcuuuc u

21

<210> 49

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 49
aguagccuca uggaagagaa u 21

<210> 50
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 50
ccucauggaa gagaagcaga u 21

<210> 51
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 51
cucauggaag agaagcagau u 21

<210> 52
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 52
auggaagaga agcagauccu u 21

<210> 53
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 53
ggaagagaag cagauccugu u 21

<210> 54
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 54
gaagagaagc agauccugug u 21

<210> 55
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 55
aucagccugg uggacaagua u 21

<210> 56
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 56

guggacaagu acccuaagga u

21

<210> 57

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 57

gacaaguacc cuaaggagga u

21

<210> 58

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 58

gaggacucgg agauaaggug u

21

<210> 59

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 59

uaagguguuu gucccagaga u 21

<210> 60
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 60
aagguguuug ucccagagau u 21

<210> 61
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 61
caacuccugc accguucucu u 21

<210> 62
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 62
ucugcuacag acuuugagaa u 21

<210> 63
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 63
 cugcuacaga cuuugagaag u 21

 <210> 64
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 64
 ugcucacagac uuugagaagg u 21

 <210> 65
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 65
 gcuacagacu uugagaaggu u 21

 <210> 66
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 66
 cuacagacuu ugagaagguu u 21

<210> 67
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 67
acagacuuug agaagguuga u 21

<210> 68
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 68
cagacuuuga gaagguugau u 21

<210> 69
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 69
agacuuugag aagguugauc u 21

<210> 70
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 70

gacuuugaga agguugaucu u

21

<210> 71

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 71

cuuugagaag guugaucuga u

21

<210> 72

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 72

uuugagaagg ugaucugac u

21

<210> 73

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 73

aagguugauc ugacccaguu u

21

<210> 74

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 74
guugaucuga cccagucaa u 21

<210> 75
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 75
uugaucugac ccagucaag u 21

<210> 76
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 76
ugaucugacc cagucaagu u 21

<210> 77
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 77
gaucugaccc aguucaagug u 21

<210> 78
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 78
cugacccagu ucaaguggau u 21

<210> 79
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 79
accaguuca aguggaucca u 21

<210> 80
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 80
ccaguucaag uggauccaca u 21

<210> 81
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 81

aguucaagug gauccacauu u

21

<210> 82

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 82

uucaagugga uccacauuga u

21

<210> 83

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 83

ucaaguggau ccacauugag u

21

<210> 84

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 84

caaguggauc cacauugagg u 21

<210> 85

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 85

gcaucggagc aggugaagau u 21

<210> 86

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 86

caucggagca ggugaagau u 21

<210> 87

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 87

gagcucuucc agcuguuugg u 21

<210> 88

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 88
cucuuccagc uguuuggcua u 21

<210> 89
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 89
cuacggagac gugguguuug u 21

<210> 90
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 90
uacggagacg ugguguuugu u 21

<210> 91
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 91
cggagacgug guguuuguca u 21

<210> 92
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 92
ggagacgugg uguuugucag u 21

<210> 93
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 93
ugguguuugu cagcaaagau u 21

<210> 94
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 94
gguguuuguc agcaaagau u 21

<210> 95
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 95

guguuuguca gcaaagaugu u

21

<210> 96

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 96

uguuugucag caaagaugug u

21

<210> 97

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 97

guuugucagc aaagaugugg u

21

<210> 98

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 98

uuugucagca aagauguggc u

21

<210> 99

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 99
aaagaugugg ccaagcacuu u 21

<210> 100
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 100
uguauggucg ugugaggaaa u 21

<210> 101
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 101
guauggucgu gugaggaaag u 21

<210> 102
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 102
uauggucgug ugaggaaagg u 21

<210> 103
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 103
ugcuccacuc ggaugcuuuc u 21

<210> 104
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 104
gagcuggaga caccuucuu u 21

<210> 105
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 105
agcuggagac accuucuaug u 21

<210> 106
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 106

cuggagacac cuucaaugcc u

21

<210> 107

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 107

uggagacacc uucaaugccu u

21

<210> 108

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 108

accuucaaug ccuccgucau u

21

<210> 109

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 109

ccuucaaugc cuccgucauc u 21

<210> 110
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 110
uucaaugccu ccgucaucuu u 21

<210> 111
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 111
caaugccucc gucaucuca u 21

<210> 112
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 112
aaugccuccg ucaucuucag u 21

<210> 113
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 113
 cuccgucauc uucagccucu u 21

<210> 114
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 114
 gugcaggaag cacugagauu u 21

<210> 115
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 115
 ugcaggaagc acugagauuc u 21

<210> 116
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 116
 gcaggaagca cugagauucg u 21

<210> 117
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 117
uggccugcag ggcuuugaug u 21

<210> 118
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 118
cugcagggcu uugauggcau u 21

<210> 119
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 119
cagggcuuug auggcaucgu u 21

<210> 120
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 120

gggcuuugau ggcaucgugu u

21

<210> 121

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 121

cucugccugu guccuguguu u

21

<210> 122

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 122

cucagagcaa auaaaucuuc u

21

<210> 123

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 123

cagagcaau aaauucuuccu u

21

<210> 124

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 124
cuccucucaa ugucugaacu u 21

<210> 125
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 125
uccucucaau gucugaacug u 21

<210> 126
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 126
ccucucaaug ucugaacugc u 21

<210> 127
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 127
cucucaaugu cugaacugcu u 21

<210> 128
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 128
cucaaugucu gaacugcucu u 21

<210> 129
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 129
auuccugagg cucugacucu u 21

<210> 130
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 130
cugcguugug cagacucuau u 21

<210> 131
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 131

ugcguugugc agacucuauu u

21

<210> 132

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 132

gcguugugca gacucuauuc u

21

<210> 133

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 133

cguugugcag acucuauucc u

21

<210> 134

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 134

uugugcagac ucuaauuccca u 21

<210> 135
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 135
uauucccaca gcucagaagc u 21

<210> 136
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 136
auucccacag cucagaagcu u 21

<210> 137
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 137
cuuggagccc accuuggaau u 21

<210> 138
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 138
 ggagcccacc uuggaauuaa u 21

 <210> 139
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 139
 gagcccaccu uggaauuaag u 21

 <210> 140
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 140
 agcccaccuu ggaauuaagg u 21

 <210> 141
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 141
 gcccaccuug gaauuaaggg u 21

<210> 142
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 142
ggcgugccuc agccacaaau u 21

<210> 143
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 143
ucagccacaa augugaccca u 21

<210> 144
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 144
gguccgaucu ggaacacaua u 21

<210> 145
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 145

guccgaucug gaacacauau u

21

<210> 146

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 146

uccgaucugg aacacauauu u

21

<210> 147

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 147

ccgaucugga acacauauug u

21

<210> 148

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 148

aucuggaaca cauauuggaa u

21

<210> 149

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 149
ucuggaacac auauuggaau u 21

<210> 150
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 150
cuggaacaca uauuggaauu u 21

<210> 151
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 151
uggaacacau auuggaauug u 21

<210> 152
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 152
ggaacacaua uuggauugg u 21

<210> 153
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 153
ggguggguuaa ggccuuauaa u 21

<210> 154
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 154
gguggguuaag gccuuauaa u 21

<210> 155
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 155
guggguuaagg ccuuauaaug u 21

<210> 156
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 156

guaaggccuu auaauguaaa u

21

<210> 157

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 157

aaggccuuau aauguaaaga u

21

<210> 158

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 158

aggccuuaua auguaaagag u

21

<210> 159

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 159

gccuuauaaau guaaagagca u 21

<210> 160
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 160
gcuaauaaug uaaaggcguu u 21

<210> 161
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 161
auauaaugua aaggcuuua u 21

<210> 162
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 162
auaauguaaa gggcuuuaga u 21

<210> 163
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 163
 uaauguaaag ggcuuuagag u 21

 <210> 164
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 164
 aauguaaagg gcuuuagagu u 21

 <210> 165
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 165
 ccuggauuaa aaucugccau u 21

 <210> 166
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 166
 cuggauuaaa aucugccauu u 21

<210> 167
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 167
gauuaaaauc ugccauuuuaa u 21

<210> 168
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 168
auuaaaau cu gccauuuuaa u 21

<210> 169
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 169
aaaucugcca uuuaauuagc u 21

<210> 170
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 170

aaucugccau uuaauuagcu u

21

<210> 171

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 171

aucugccauu uaauuagcug u

21

<210> 172

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 172

cugccauuuu auuagcugca u

21

<210> 173

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 173

acgcaaucug ccucauuuc u

21

<210> 174

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 174
cgcaaucugc cucauuucu u 21

<210> 175
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 175
gcaaucugcc ucauuucu u 21

<210> 176
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 176
aaucugccuc aauuucuca u 21

<210> 177
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 177
aucugccuca auuucuucau u 21

<210> 178
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 178
ucugccucaa uuucuucauc u 21

<210> 179
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 179
cugccucaau uucuucauc u 21

<210> 180
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 180
ugccucaauu ucuucaucg u 21

<210> 181
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 181

gccucaauuu cuucaucugu u

21

<210> 182

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 182

caauuucuuc aucugucaaa u

21

<210> 183

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 183

aaauucuuca ucugucaaa u

21

<210> 184

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 184

auuucuucau cugucaaaug u 21

<210> 185
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 185
aauucugcuu ggcuacagaa u 21

<210> 186
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 186
auucugcuug gcuacagaau u 21

<210> 187
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 187
ucugcuuggc uacagaauua u 21

<210> 188
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 188
 cugcuuggcu acagaauuau u 21

 <210> 189
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 189
 ugcuuaggcua cagaauuuau u 21

 <210> 190
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 190
 gcuuggcuac agaauuuauug u 21

 <210> 191
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 191
 uucuucaucu gucaaaugga u 21

<210> 192
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 192
ggauuaaaaau cugccauuuu u 21

<210> 193
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 193
uggauuaaaa ucugccauuu u 21

<210> 194
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 194
ucaauuucuu caucugucuu u 21

<210> 195
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 195

uuucuucauc ugucaaaugg u

21

<210> 196

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 196

ggccuuauaa uguaaaagagc u

21

<210> 197

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 197

uauaauguuaa agggcuuuag u

21

<210> 198

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 198

auuuucucuu ugcauucucg u

21

<210> 199

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 199
ccucaauuuc uucaucuguc u 21

<210> 200
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 200
cucaauuucu ucaucuguca u 21

<210> 201
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 201
uaaggccuua uaauguaaag u 21

<210> 202
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 202
cauaaaaugu aaagggcuuu u 21

<210> 203
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 203
ugccauuuuaa uuagcugcau u 21

<210> 204
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 204
auuaauuguga ggauaaaauc u 21

<210> 205
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 205
gguaaggccu uauaauguaa u 21

<210> 206
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 206

uucugcuugg cuacagaauu u

21

<210> 207

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 207

guucaagugg auccacauug u

21

<210> 208

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 208

ggguaaggcc uuauaaugua u

21

<210> 209

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 209

gaucuggaac acauauugga u 21

<210> 210
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 210
uuucucuuug cauucucgag u 21

<210> 211
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 211
caaucugccu caauuucuuc u 21

<210> 212
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 212
agagcaaaaua aaucuuccuc u 21

<210> 213
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 213
 acuuugagaa gguugaucug u 21

 <210> 214
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 214
 uacagacuuu gagaagguug u 21

 <210> 215
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 215
 uggguaaggc cuuauaangu u 21

 <210> 216
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 216
 uugcauucuc gagaucgcuu u 21

<210> 217
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 217
cgaucuggaa cacauauugg u 21

<210> 218
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 218
ucugccauuu aauuagcugc u 21

<210> 219
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 219
cgugguguuu gucagcaaag u 21

<210> 220
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 220

uuguauagguc gugugaggaa u

21

<210> 221

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 221

cccagugaac cugccaaaga u

21

<210> 222

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 222

gacguggugu uugucagcaa u

21

<210> 223

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 223

ucaaugccuc cgucaucuuc u

21

<210> 224

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 224
uugcuccacu cggaugcuuu u 21

<210> 225
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 225
uuggagccca ccuuggaauu u 21

<210> 226
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 226
aucugacaag cgaggaaacu u 21

<210> 227
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 227
uggagccac cuuggaauua u 21

<210> 228
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 228
gcucuuccag cuguuuggcu u 21

<210> 229
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 229
ugcccaccag ccugugauuu u 21

<210> 230
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 230
aagaccucug gguuggcuuu u 21

<210> 231
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 231

gcccaccagc cugugauuug u

21

<210> 232

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 232

acggagacgu gguguuuguc u

21

<210> 233

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 233

agguccgauc uggaacacau u

21

<210> 234

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 234

gaguagccuc auggaagaga u 21

<210> 235
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 235
ccagugaacc ugccaaagaa u 21

<210> 236
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 236
uagggugggu aaggccuuau u 21

<210> 237
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 237
ugggaguagc cucauggaag u 21

<210> 238
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 238
 agggugggua aggccuuaua u 21

<210> 239
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 239
 gguugaucug acccaguuca u 21

<210> 240
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 240
 caucagccug guggacaagu u 21

<210> 241
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 241
 agcugugagu ccaucugaca u 21

<210> 242
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 242
gcuacggaga cgugguguuu u 21

<210> 243
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 243
guugugcaga cucuauuccc u 21

<210> 244
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 244
aucuuugcug acaaacacca cgu 23

<210> 245
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 245

auuugcugac aaacaccacg ucu

23

<210> 246

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 246

aggaagauuu auuugcucug agg

23

<210> 247

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 247

aauguggauc cacuugaacu ggg

23

<210> 248

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 248

acaaagagaa aaugcgcuac uug

23

<210> 249

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 249
aaaugcaaag agaaaaugcg cua 23

<210> 250
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 250
agaaugcaaa gagaaaaugc gcu 23

<210> 251
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 251
aagaaugcaa agagaaaaug cgc 23

<210> 252
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 252
agagaaugca aagagaaaau gcg 23

<210> 253
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 253
aucgagaaug caaagagaaa aug 23

<210> 254
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 254
aucucgagaa ugcaaagaga aaa 23

<210> 255
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 255
aaucucgaga augcaaagag aaa 23

<210> 256
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 256

agaucucgag aaugcaaaga gaa

23

<210> 257

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 257

acgaucucga gaaugcaaag aga

23

<210> 258

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 258

aagcgaucuc gagaaugcaa aga

23

<210> 259

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 259

auaagcgauc ucgagaaugc aaa 23

<210> 260

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 260

acuaagcgau cucgagaugc caa 23

<210> 261

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 261

agcuaagcga ucucgagaau gca 23

<210> 262

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 262

augaugcaaa ccuuuuuuuu gcg 23

<210> 263

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 263
 acugaugcaa accuuuuuuaa agc 23

<210> 264
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 264
 agcugaugca aaccuuuuuaa aag 23

<210> 265
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 265
 aucagauugga cucacagcug aug 23

<210> 266
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 266
 auugucagau ggacucacag cug 23

<210> 267
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 267
acuugucaga uggacucaca gcu 23

<210> 268
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 268
auuuccucgc uugucagau gac 23

<210> 269
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 269
aguuuccucg cuugucagau gga 23

<210> 270
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 270

aacuucucag ccuaguuuuc cuc

23

<210> 271

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 271

acacuucuca gccuaguuu ccu

23

<210> 272

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 272

agaaagccaa cccagagguc uug

23

<210> 273

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 273

auucucuucc augaggcuac ucc

23

<210> 274

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 274
aucugcuucu cuuccaugag gcu 23

<210> 275
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 275
aaucugcuuc ucuuccauga ggc 23

<210> 276
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 276
aaggaucugc uucucuucca uga 23

<210> 277
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 277
aacaggaucu gcuucucuuc cau 23

<210> 278
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 278
acacaggauc ugcucucuu cca 23

<210> 279
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 279
auacuugucc accaggcuga uga 23

<210> 280
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 280
auccuuaggg uacuugucca cca 23

<210> 281
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 281

auccuccuua ggguacuugu cca

23

<210> 282

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 282

acaccuuauu uccgaguuccu ccu

23

<210> 283

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 283

aucucuggga caaacaccuu auc

23

<210> 284

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 284

aaucucuggg acaaacaccu uau 23

<210> 285

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 285

aagagaacgg ugcaggaguu gga 23

<210> 286

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 286

auucucaaaag ucuguagcag aca 23

<210> 287

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 287

acuucucaaa gucuguagca gac 23

<210> 288

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 288
 accuucucua agucuguagc aga 23

<210> 289
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 289
 aaccuucua aagucuguag cag 23

<210> 290
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 290
 aaaccuucuc aaagucugua gca 23

<210> 291
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 291
 aucaaccuuc ucaaagucug uag 23

<210> 292
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 292
aaucaaccuu cucaaagucu gua

23

<210> 293
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 293
agaucaaccu ucucuaaguc ugu

23

<210> 294
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 294
aagaucaacc uucucuaagu cug

23

<210> 295
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 295

aucagaucaa ccuucucaaa guc

23

<210> 296

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 296

agucagauca accuucucaa agu

23

<210> 297

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 297

aaacuggguc agaucaaccu ucu

23

<210> 298

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 298

auugaacugg gucagaucaa ccu

23

<210> 299

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 299
acuugaacug ggucagauca acc 23

<210> 300
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 300
aacuugaacu gggucagauca aac 23

<210> 301
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 301
acacuugaac ugguccagau caa 23

<210> 302
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 302
aauccacuug aacuggguca gau 23

<210> 303
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 303
auggauccac uugaacuggg uca 23

<210> 304
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 304
auguggaucc acuugaacug ggu 23

<210> 305
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 305
aaaugggau ccacuugaac ugg 23

<210> 306
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 306

aucaaugugg auccacuuga acu

23

<210> 307

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 307

acucaaugug gauccacuug aac

23

<210> 308

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 308

accucaaugu ggauccacuu gaa

23

<210> 309

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 309

aaucuucacc ugcuccgaug cgu 23

<210> 310
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 310
acaucuucac cugcuccgau gcg 23

<210> 311
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 311
accaaacagc uggaagagcu ccu 23

<210> 312
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 312
auagccaaac agcuggaaga gcu 23

<210> 313
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 313
acaaacacca cgucuccgua gcc

23

<210> 314
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 314
aacaacacc acgucuccgu agc

23

<210> 315
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 315
augacaaaca ccacgucucc gua

23

<210> 316
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 316
acugacaaac accacgucuc cgu

23

<210> 317
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 317
aaucuuugcu gacaaacacc acg

23

<210> 318
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 318
acaucuuugc ugacaaacac cac

23

<210> 319
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 319
aacaucuuug cugacaaaca cca

23

<210> 320
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 320

acacauuuu gcugacaaac acc

23

<210> 321

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 321

accacauuu ugcugacaaa cac

23

<210> 322

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 322

agccacauu ugcugacaa aca

23

<210> 323

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 323

aaagugcuug gccacauuu ugc

23

<210> 324

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 324
auuuccucac acgaccuac aag 23

<210> 325
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 325
acuuuccuca cacgaccuaa caa 23

<210> 326
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 326
accuuuccuc acacgaccu aca 23

<210> 327
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 327
agaaagcauc cgaguggagc aaau
23

<210> 328
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 328
aaauugaaggu gucuccagcu ccc
23

<210> 329
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 329
acauugaagg ugucuccagc ucc
23

<210> 330
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 330
aggcauugaa ggugucucca gcu
23

<210> 331
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 331

aaggcauuga aggugucucc agc

23

<210> 332

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 332

aaugacggag gcauugaagg ugu

23

<210> 333

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 333

agaugacgga ggcauugaag gug

23

<210> 334

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 334

aaagaugacg gaggcauuga agg 23

<210> 335

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 335

augaagauga cggaggcauu gaa 23

<210> 336

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 336

acugaagaug acggaggcau uga 23

<210> 337

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 337

aagaggcuga agaugacgga ggc 23

<210> 338

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 338
aaaucucagu gcuuccugca cgc 23

<210> 339
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 339
agaauucucag ugcuccugc acg 23

<210> 340
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 340
acgaaucau ggcuccug cac 23

<210> 341
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 341
acaucaaagc ccugcaggcc aca 23

<210> 342
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 342
aaugccauga aagcccugca ggc

23

<210> 343
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 343
aacgaugcca ucaaagcccu gca

23

<210> 344
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 344
aacacgaugc cauaaagcc cug

23

<210> 345
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 345

aaacacagga cacaggcaga guc

23

<210> 346

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 346

agaagauua uuugcucuga ggc

23

<210> 347

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 347

aaggaagauu uauuugcucu gag

23

<210> 348

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 348

aaguucagac auugagagga gaa

23

<210> 349

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 349
acaguucaga cauugagagg aga 23

<210> 350
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 350
agcaguucag acauugagag gag 23

<210> 351
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 351
aagcaguuca gacauugaga gga 23

<210> 352
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 352
aagagcaguu cagacauuga gag 23

<210> 353
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 353
aagagucaga gccucaggaa ugc 23

<210> 354
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 354
aaauagagucu gcacaacgca ggg 23

<210> 355
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 355
aaauagaguc ugcacaacgc agg 23

<210> 356
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 356

agaauagagu cugcacaacg cag

23

<210> 357

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 357

aggaauagag ucugcacaac gca

23

<210> 358

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 358

augggaauag agucugcaca acg

23

<210> 359

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 359

agcuucugag cugugggaau aga 23

<210> 360

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 360

aagcuucuga gcugugggaa uag 23

<210> 361

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 361

aaauccaagg ugggcuccaa ggg 23

<210> 362

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 362

auuaauucca aggugggcuc caa 23

<210> 363

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 363
acuuauuucc aaggugggcu cca

23

<210> 364
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 364
accuuauuuc caaggugggc ucc

23

<210> 365
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 365
acccuuauuu ccaagguggg cuc

23

<210> 366
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 366
aauuuguggc ugaggcacgc ccu

23

<210> 367
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 367
augggucaca uuuguggcug agg

23

<210> 368
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 368
auauguguuc cagaucggac cuc

23

<210> 369
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 369
aaauauguguu ccagaucgga ccu

23

<210> 370
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 370

aaauaugugu uccagaucgg acc

23

<210> 371

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 371

acaauaugug uuccagaucg gac

23

<210> 372

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 372

auuccaauau guguuccaga ucg

23

<210> 373

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 373

aaauccaaua uguguuccag auc

23

<210> 374

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 374
aaaauccaau auguguucca gau 23

<210> 375
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 375
acaauuccaa uauguguucc aga 23

<210> 376
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 376
accaauucca auauguguuc cag 23

<210> 377
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 377
auuauaaggc cuuacccacc cua 23

<210> 378
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 378
aauuauaagg ccuuaccac ccu 23

<210> 379
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 379
acauuauaag gccuuacca ccc 23

<210> 380
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 380
auuuacauua uaaggccuua ccc 23

<210> 381
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 381

aucuuuacau uauaaggccu uac

23

<210> 382

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 382

acucuuuaca uuauaaggcc uua

23

<210> 383

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 383

augcucuuua cauuauaagg ccu

23

<210> 384

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 384

aaagcccuuu acauuauaug cuc 23

<210> 385

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 385

auaaagcccu uuacauuaua ugc 23

<210> 386

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 386

aucuaaagcc cuuuacauua uau 23

<210> 387

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 387

acucuaaagc ccuuuacauu aua 23

<210> 388

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 388
aacucuaaag cccuuuacau uau

23

<210> 389
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 389
aauggcagau uuuauuccag guc

23

<210> 390
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 390
aaauggcaga uuuuaucca ggu

23

<210> 391
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 391
auuuauuggc agauuuuau cca

23

<210> 392
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 392
aauuuaaugg caguuuuuaa ucc

23

<210> 393
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 393
agcuaauuaa auggcagauu uua

23

<210> 394
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 394
aagcuaauua aauggcagau uuu

23

<210> 395
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 395

acagcuaauu aaauggcaga uuu

23

<210> 396

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 396

augcagcuaa uuaaauggca gau

23

<210> 397

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 397

agaaaauagag gcagauugcg uua

23

<210> 398

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 398

aagaaauuga ggcagauugc guu

23

<210> 399

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 399
aaagaaaug aggcagauug cgu 23

<210> 400
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 400
augaagaaau ugaggcagau ugc 23

<210> 401
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 401
aaugaagaaa uugaggcaga uug 23

<210> 402
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 402
agaugaagaa auugaggcag auu 23

<210> 403
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 403
aagaugaaga aaugaggca gau 23

<210> 404
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 404
acagaugaag aaauaggc aga 23

<210> 405
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 405
aacagaugaa gaaauagg cag 23

<210> 406
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 406

auuugacaga ugaagaaau gag

23

<210> 407

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 407

aaauugacag augaagaaau uga

23

<210> 408

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 408

acaauugaca gaugaagaaa uug

23

<210> 409

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 409

auucuguagc caagcagaau ugg 23

<210> 410

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 410

aaucuguag ccaagcagaa uug 23

<210> 411

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 411

aaaauucugu agccaagcag aa 23

<210> 412

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 412

aaaaauucug uagccaagca gaa 23

<210> 413

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 413
aaauaaauucu guagccaagc aga

23

<210> 414
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 414
acaauaaauuc uguagccaag cag

23

<210> 415
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 415
auccauuuga cagaugaaga aa

23

<210> 416
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 416
auaaauggca gauuuuaauc cag

23

<210> 417
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 417
aaaauaggcag auuuuaaucc agg

23

<210> 418
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 418
auugacagau gaagaaauug agg

23

<210> 419
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 419
accuuugac agaugaagaa auu

23

<210> 420
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 420

agcucuuuac auuauaaggc cuu

23

<210> 421

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 421

acuaaaagccc uuuacauuau aug

23

<210> 422

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 422

acgagaaugc aaagagaaaa ugc

23

<210> 423

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 423

agacagauga agaaauugag gca

23

<210> 424

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 424
augacagaug aagaaauuga ggc 23

<210> 425
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 425
acuuuacauu auaaggccuu acc 23

<210> 426
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 426
aaaagcccuu uacauuauau gcu 23

<210> 427
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 427
aaugcagcua auuaaauggc aga 23

<210> 428
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 428
agauuuuauuc cucacaauaa uuc 23

<210> 429
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 429
auuacauuau aaggccuuac cca 23

<210> 430
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 430
aaaauucugua gccaagcaga auu 23

<210> 431
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 431

acaaugugga uccacuugaa cug

23

<210> 432

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 432

auacauuaua aggccuuacc cac

23

<210> 433

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 433

auccaauaug uguuccagau cgg

23

<210> 434

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 434

acucgagaau gcaaagagaa aaU 23

<210> 435

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 435

agaagaaauu gaggcagauu gcg 23

<210> 436

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 436

agaggaagau uuauuugcuc uga 23

<210> 437

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 437

acagaucaac cuucucuaag ucu 23

<210> 438

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 438
acaaccuucu caaagucugu agc

23

<210> 439
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 439
aacauuauaa ggccuuaccc acc

23

<210> 440
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 440
aaagcgaucu cgagaaugca aag

23

<210> 441
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 441
accaauaugu guuccagauc gga

23

<210> 442
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 442
agcagcuaau uaaauggcag auu

23

<210> 443
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 443
acuuugcuga caaacaccac guc

23

<210> 444
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 444
auuccucaca cgaccauaca agc

23

<210> 445
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 445

aucuuuggca gguucacugg gug

23

<210> 446

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 446

auugcugaca aacaccacgu cuc

23

<210> 447

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 447

agaagaugac ggaggcauug aag

23

<210> 448

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 448

aaaagcaucc gaguggagca auu

23

<210> 449

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 449
aaaauccaag gugggcucca agg 23

<210> 450
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 450
aaguuuccuc gcuugucaga ugg 23

<210> 451
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 451
aauuuuccaa ggugggcucc aag 23

<210> 452
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 452
aagccaaaca gcuggaagag cuc 23

<210> 453
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 453
aaaaucacag gcuggugggc agg 23

<210> 454
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 454
aaaagccaac ccagaggucu ugg 23

<210> 455
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 455
acaaaucaca ggcugguggg cag 23

<210> 456
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 456

agacaaacac cacgucuccg uag

23

<210> 457

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 457

aauguguucc agaucggacc ucc

23

<210> 458

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 458

aucucuucca ugaggcuacu ccc

23

<210> 459

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 459

auucuuuggc agguucacug ggu 23

<210> 460
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 460
aauaaggccu uacccacccu aua 23

<210> 461
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 461
acuuccauga ggcucacucc aga 23

<210> 462
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 462
auauaaggcc uuacccaccc uau 23

<210> 463
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 463
 augaacuggg ucagaucaac cuu 23

 <210> 464
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 464
 aacuugucca ccaggcugau gac 23

 <210> 465
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 465
 augucagaug gacucacagc uga 23

 <210> 466
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 466
 aaaacaccac gucuccguag cca 23

<210> 467
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 467
agggaauaga gucugcaciaa cgc

23

<210> 468
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 468
gugguguuug ucagcaaaga u

21

<210> 469
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 469
acgugguguu ugucagcaaa u

21

<210> 470
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 470

ucagagcaaa uaaauccuucc u

21

<210> 471

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 471

caguucaagu ggauccacau u

21

<210> 472

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 472

aguagcgcau uuucucuuug u

21

<210> 473

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 473

gcgcuuuuuc uuuugcauu u

21

<210> 474

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 474
cgcauuuucu cuuugcauuc u 21

<210> 475
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 475
gcauuuucuc uuugcauucu u 21

<210> 476
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 476
cauuuucucu uugcauucuc u 21

<210> 477
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 477
uuuucucuuu gcauucucga u 21

<210> 478
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 478
uucucuuugc auucucgaga u 21

<210> 479
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 479
ucucuuugca uucucgagau u 21

<210> 480
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 480
cucuuugcau ucucgagau u 21

<210> 481
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 481

ucuuugcauu cucgagaucg u

21

<210> 482

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 482

uuugcauucu cgagaucgcu u

21

<210> 483

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 483

ugcauucucg agaucgcuua u

21

<210> 484

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 484

gcauucucga gaucgcuuag u 21

<210> 485

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 485

cauucucgag aucgcuuagc u 21

<210> 486

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 486

cuuuaaaaag guuugcauca u 21

<210> 487

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 487

uuuaaaaagg uuugcaucag u 21

<210> 488

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 488
uuaaaaaggu uugcaucagc u 21

<210> 489
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 489
ucagcuguga guccaucuga u 21

<210> 490
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 490
gcugugaguc caucugacaa u 21

<210> 491
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 491
cugugagucc aucugacaag u 21

<210> 492
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 492
ccaucugaca agcgaggaaa u 21

<210> 493
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 493
caucugacaa gcgaggaaac u 21

<210> 494
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 494
ggaaacuaag gcugagaagu u 21

<210> 495
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 495

gaaacuaagg cugagaagug u

21

<210> 496

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 496

agaccucugg guuggcuuuc u

21

<210> 497

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 497

aguagccuca uggaagagaa u

21

<210> 498

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 498

ccucauggaa gagaagcaga u

21

<210> 499

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 499
cucauggaag agaagcagau u 21

<210> 500
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 500
auggaagaga agcagauccu u 21

<210> 501
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 501
ggaagagaag cagauccugu u 21

<210> 502
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 502
gaagagaagc agauccugug u 21

<210> 503
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 503
aucagccugg uggacaagua u 21

<210> 504
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 504
guggacaagu acccuaagga u 21

<210> 505
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 505
gacaaguacc cuaaggagga u 21

<210> 506
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 506

gaggacucgg agauaaggug u

21

<210> 507

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 507

uaagguguuu gucccagaga u

21

<210> 508

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 508

aagguguuug ucccagagau u

21

<210> 509

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 509

caacuccugc accguucucu u 21

<210> 510

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 510

ucugcuacag acuuugagaa u 21

<210> 511

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 511

cugcuacaga cuuugagaag u 21

<210> 512

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 512

ugcuacagac uuugagaagg u 21

<210> 513

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 513
 gcuacagacu uugagaaggu u 21

<210> 514
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 514
 cuacagacuu ugagaagguu u 21

<210> 515
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 515
 acagacuuug agaagguuga u 21

<210> 516
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 516
 cagacuuuga gaagguugau u 21

<210> 517
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 517
agacuuugag aagguugauc u 21

<210> 518
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 518
gacuuugaga agguugaucu u 21

<210> 519
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 519
cuuugagaag guugaucuga u 21

<210> 520
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 520

uuugagaagg ugaucugac u

21

<210> 521

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 521

aagguugauc ugacccaguu u

21

<210> 522

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 522

guugaucuga cccaguucaa u

21

<210> 523

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 523

uugaucugac ccaguucaag u

21

<210> 524

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 524
ugaucugacc caguucaagu u 21

<210> 525
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 525
gaucugaccc aguucaagug u 21

<210> 526
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 526
cugacccagu ucaaguggau u 21

<210> 527
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 527
accaguuca aguggaucca u 21

<210> 528
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 528
ccaguucaag uggauccaca u 21

<210> 529
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 529
aguucaagug gauccacauu u 21

<210> 530
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 530
uucaagugga uccacauuga u 21

<210> 531
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 531

ucaaguggau ccacauugag u

21

<210> 532

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 532

caaguggauc cacauugagg u

21

<210> 533

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 533

gcaucggagc aggugaagau u

21

<210> 534

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 534

caucggagca ggugaagaug u 21

<210> 535

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 535

gagcucuucc agcuguuugg u 21

<210> 536

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 536

cucuuccagc uguuuggcua u 21

<210> 537

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 537

cuacggagac gugguguuug u 21

<210> 538

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 538
uacggagacg ugguguuuugu u 21

<210> 539
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 539
cggagacgug guguuuguca u 21

<210> 540
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 540
ggagacgugg uguuuugucag u 21

<210> 541
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 541
ugguguuuugu cagcaaagau u 21

<210> 542
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 542
gguguuuguc agcaaagaug u 21

<210> 543
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 543
guguuuguca gcaaagaugu u 21

<210> 544
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 544
uguuugucag caaagaugug u 21

<210> 545
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 545

guuugucagc aaagaugugg u

21

<210> 546

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 546

uuugucagca aagauguggc u

21

<210> 547

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 547

aaagaugugg ccaagcacuu u

21

<210> 548

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 548

uguauggucg ugugaggaaa u

21

<210> 549

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 549
guauggucgu gugaggaaag u 21

<210> 550
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 550
uauggucgug ugaggaaagg u 21

<210> 551
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 551
ugcuccacuc ggaugcuuuc u 21

<210> 552
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 552
gagcuggaga caccuucaau u 21

<210> 553
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 553
agcuggagac accuucraag u 21

<210> 554
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 554
cuggagacac cuucaaugcc u 21

<210> 555
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 555
uggagacacc uucaaugccu u 21

<210> 556
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 556

accuucaaug ccuccgucau u

21

<210> 557

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 557

ccuucaaugc cuccgucauc u

21

<210> 558

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 558

uucaaugccu ccgucaucuu u

21

<210> 559

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 559

caaugccucc gucaucuca u 21

<210> 560

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 560

aaugccuccg ucaucuucag u 21

<210> 561

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 561

cuccgucauc uucagccucu u 21

<210> 562

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 562

gugcaggaag cacugagauu u 21

<210> 563

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 563
 ugcaggaagc acugagauuc u 21

 <210> 564
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 564
 gcaggaagca cugagauucg u 21

 <210> 565
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 565
 uggccugcag ggcuuugaug u 21

 <210> 566
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 566
 cugcagggc uugauggcau u 21

<210> 567
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 567
cagggcuuug auggcaucgu u 21

<210> 568
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 568
gggcuuugau ggcaucgugu u 21

<210> 569
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 569
cucugccugu guccuguguu u 21

<210> 570
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 570

cucagagcaa auaaaucuuc u

21

<210> 571

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 571

cagagcaaaau aaauucuuccu u

21

<210> 572

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 572

cuccucucaa ugucugaacu u

21

<210> 573

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 573

uccucucaau gucugaacug u

21

<210> 574

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 574
ccucucaaug ucugaacugc u 21

<210> 575
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 575
cucucaaugu cugaacugcu u 21

<210> 576
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 576
cucaaugucu gaacugcucu u 21

<210> 577
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 577
auuccugagg cucugacucu u 21

<210> 578
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 578
cugcguugug cagacucua u 21

<210> 579
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 579
ugcguugugc agacucua u 21

<210> 580
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 580
gcguugugca gacucua u 21

<210> 581
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 581

cguugugcag acucuauucc u

21

<210> 582

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 582

uugugcagac ucuauuccca u

21

<210> 583

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 583

uauucccaca gcucagaagc u

21

<210> 584

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 584

auucccacag cucagaagcu u 21

<210> 585

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 585

cuuggagccc accuuggaau u 21

<210> 586

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 586

ggagcccacc uuggaauuaa u 21

<210> 587

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 587

gagcccaccu uggaauuaag u 21

<210> 588

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 588
agcccaccuu ggaauuaagg u 21

<210> 589
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 589
gcccaccuug gaauuaaggg u 21

<210> 590
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 590
ggcgugccuc agccacaaau u 21

<210> 591
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 591
ucagccacaa augugaccca u 21

<210> 592
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 592
gguccgaucu ggaacacaua u 21

<210> 593
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 593
guccgaucug gaacacauau u 21

<210> 594
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 594
uccgaucugg aacacauauu u 21

<210> 595
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 595

ccgaucugga acacauauug u

21

<210> 596

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 596

aucuggaaca cauauuggaa u

21

<210> 597

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 597

ucuggaacac auauuggaau u

21

<210> 598

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 598

cuggaacaca uauuggaauu u

21

<210> 599

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 599
uggaacacau auuggaauug u 21

<210> 600
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 600
ggaacacaua uuggaauugg u 21

<210> 601
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 601
ggguggguuaa ggccuuauaa u 21

<210> 602
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 602
gguggguaag gccuuauaa u 21

<210> 603
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 603
guggguaagg ccuuauaaug u 21

<210> 604
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 604
guaaggccuu auaauguaaa u 21

<210> 605
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 605
aaggccuuau aauguaaaga u 21

<210> 606
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 606

aggccuuaua auguaaagag u

21

<210> 607

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 607

gccuuauaa u guaaagagca u

21

<210> 608

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 608

gcuaauaaug uaaagggcuu u

21

<210> 609

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 609

auauaaugua aaggguuuu u 21

<210> 610
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 610
auaauguaaa ggguuuuaga u 21

<210> 611
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 611
uaauguaaag ggcuuuagag u 21

<210> 612
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 612
aauguaaaagg gcuuuagagu u 21

<210> 613
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 613
 ccuggauuaa aaucugccau u 21

<210> 614
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 614
 cuggauuaaa aucugccauu u 21

<210> 615
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 615
 gauuaaaauc ugccauuuua u 21

<210> 616
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 616
 auuaaaau cu gccauuuuuu u 21

<210> 617
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 617
aaaucugcca uuuaauuagc u 21

<210> 618
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 618
aaucugccau uuauuuagcu u 21

<210> 619
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 619
aucugccauu uaauuagcug u 21

<210> 620
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 620

cugccauuuu auuagcugca u

21

<210> 621

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 621

acgcaaucug ccucauuuuc u

21

<210> 622

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 622

cgcaaucugc cucauuuucu u

21

<210> 623

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 623

gcaaucugcc ucauuuucu u

21

<210> 624

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 624
aaucugccuc aauuucuca u 21

<210> 625
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 625
aucugccuca auuucucau u 21

<210> 626
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 626
ucugccucaa uuucucauc u 21

<210> 627
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 627
cugccucaau uucucaucu u 21

<210> 628
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 628
ugccucaauu ucuucaucug u 21

<210> 629
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 629
gccucaauuu cuucaucugu u 21

<210> 630
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 630
caauuucuuc aucugucaaa u 21

<210> 631
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 631

aaauucuuca ucugucaaa u

21

<210> 632

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 632

auuucuuc au cugucaaaug u

21

<210> 633

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 633

aaauucugcuu ggcuaacagaa u

21

<210> 634

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 634

auucugcuug gcuacagaau u 21

<210> 635
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 635
ucugcuuggc uacagaauua u 21

<210> 636
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 636
cugcuuggcu acagaauuau u 21

<210> 637
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 637
ugcuuggcua cagaauuuau u 21

<210> 638
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 638
 gcuuggcuac agaauuuauug u 21

<210> 639
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 639
 uucuucaucu gucaaaugga u 21

<210> 640
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 640
 ggauuaaaau cugccauuuu u 21

<210> 641
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 641
 uggauuaaaa ucugccauuu u 21

<210> 642
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 642
ucaauuucuu caucugucua u 21

<210> 643
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 643
uuucuucauc ugucaaaugg u 21

<210> 644
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 644
ggccuuauaa uguaaaagagc u 21

<210> 645
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 645

uauaauguaa agggcuuuag u

21

<210> 646

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 646

auuuucucuu ugcauucug u

21

<210> 647

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 647

ccucaauuuc uucaucuguc u

21

<210> 648

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 648

cucaauuucu ucaucuguca u

21

<210> 649

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 649
uaaggccuua uaauguaaag u 21

<210> 650
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 650
cauauaaugu aaagggcuuu u 21

<210> 651
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 651
ugccauuuuaa uuagcugcau u 21

<210> 652
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 652
auuauuguga ggauaaaauc u 21

<210> 653
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 653
gguaaggccu uauaauguaa u 21

<210> 654
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 654
uucugcuugg cuacagaauu u 21

<210> 655
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 655
guucaagugg auccacauug u 21

<210> 656
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 656

ggguaaggcc uuauaauga u

21

<210> 657

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 657

gaucuggaac acauauugga u

21

<210> 658

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 658

uuucucuuug cauucucgag u

21

<210> 659

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 659

caaucugccu caauuucuuc u 21

<210> 660

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 660

agagcaaaaua aaucuuccuc u 21

<210> 661

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 661

acuuugagaa gguugaucug u 21

<210> 662

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 662

uacagacuuu gagaagguug u 21

<210> 663

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 663
 uggguaaggc cuuauaaugu u 21

 <210> 664
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 664
 uugcauucuc gagaucgcuu u 21

 <210> 665
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 665
 cgaucuggaa cacauauugg u 21

 <210> 666
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 666
 ucugccauuu aauuagcugc u 21

<210> 667
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 667
cgugguguuu gucagcaaag u 21

<210> 668
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 668
uuguaugguc gugugaggaa u 21

<210> 669
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 669
cccagugaac cugccaaaga u 21

<210> 670
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 670

gacguggugu uugucagcaa u

21

<210> 671

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 671

ucaaugccuc cgucaucuuc u

21

<210> 672

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 672

uugcuccacu cggaugcuuu u

21

<210> 673

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 673

uuggagccca ccuuggaauu u

21

<210> 674

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 674
aucugacaag cgaggaaacu u 21

<210> 675
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 675
uggagcccac cuuggaauua u 21

<210> 676
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 676
gcucuuccag cuguuuggcu u 21

<210> 677
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 677
ugcccaccag ccugugauuu u 21

<210> 678
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 678
aagaccucug gguuggcuuu u 21

<210> 679
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 679
gcccaccagc cugugauuug u 21

<210> 680
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 680
acggagacgu gguguuuguc u 21

<210> 681
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 681

agguccgauc uggaacacau u

21

<210> 682

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 682

gaguagccuc auggaagaga u

21

<210> 683

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 683

ccagugaacc ugccaaagaa u

21

<210> 684

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 684

uagggugggu aaggccuuau u 21

<210> 685
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 685
ugggaguagc cucauggaag u 21

<210> 686
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 686
agggugggua aggccuuaua u 21

<210> 687
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 687
gguugaucug acccaguuca u 21

<210> 688
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 688
 caucagccug guggacaagu u 21

<210> 689
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 689
 agcugugagu ccaucugaca u 21

<210> 690
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 690
 gcuacggaga cgugguguuu u 21

<210> 691
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 691
 guugugcaga cucuauuccc u 21

<210> 692
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 692
aucuuugcug acaaacacca cgu 23

<210> 693
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 693
auuugcugac aaacaccacg ucu 23

<210> 694
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 694
aggaagauuu auuugcucug agg 23

<210> 695
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 695

aauguggauc cacuugaacu ggg

23

<210> 696

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 696

acaaagagaa aaugcgcuac uug

23

<210> 697

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 697

aaaugcaaag agaaaaugcg cua

23

<210> 698

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 698

agaaugcaaa gagaaaaugc gcu

23

<210> 699

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 699
aagaaugcaa agagaaaaug cgc 23

<210> 700
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 700
agagaaugca aagagaaaau gcg 23

<210> 701
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 701
aucgagaug caaagagaaa aug 23

<210> 702
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 702
aucucgagaa ugcaaagaga aaa 23

<210> 703
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 703
aaucucgaga augcaaagag aaa 23

<210> 704
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 704
agaucucgag aaugcaaaga gaa 23

<210> 705
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 705
acgaucucga gaaugcaaag aga 23

<210> 706
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 706

aagcgaucuc gagaaugcaa aga

23

<210> 707

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 707

auaagcgauc ucgagaaugc aaa

23

<210> 708

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 708

acuaagcgau cucgagaug caa

23

<210> 709

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 709

agcuaagcga ucucgagaau gca 23

<210> 710

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 710

augaugcaaa ccuuuuuuaa gcg 23

<210> 711

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 711

acugaugcaa accuuuuuua agc 23

<210> 712

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 712

agcugaugca aaccuuuuua aag 23

<210> 713

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 713
 aucagaugga cucacagcug aug 23

<210> 714
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 714
 auugucagau ggacucacag cug 23

<210> 715
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 715
 acuugucaga uggacucaca gcu 23

<210> 716
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 716
 auuuccucgc uugucagaug gac 23

<210> 717
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 717
aguuuccucg cuugucagau gga

23

<210> 718
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 718
aacuucucag ccuaguuuc cuc

23

<210> 719
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 719
acacuucuca gccuaguuu ccu

23

<210> 720
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 720

agaaagccaa cccagagguc uug

23

<210> 721

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 721

auucucuucc augaggcuac ucc

23

<210> 722

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 722

aucugcuucu cuuccaugag gcu

23

<210> 723

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 723

aaucugcuuc ucuuccauga ggc

23

<210> 724

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 724
aaggaucugc uucucuucca uga 23

<210> 725
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 725
aacaggaucu gcuucucuuc cau 23

<210> 726
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 726
acacaggauc ugcucucuu cca 23

<210> 727
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 727
auacuugucc accaggcuga uga 23

<210> 728
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 728
auccuuaggg uacuugucca cca 23

<210> 729
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 729
auccuccuua gggacuugu cca 23

<210> 730
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 730
acaccuuaucc uccgaguccu ccu 23

<210> 731
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 731

aucucuggga caaacaccuu auc

23

<210> 732

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 732

aaucucuggg acaaaccu uau

23

<210> 733

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 733

aagagaacgg ugcaggaguu gga

23

<210> 734

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 734

auucucaaaag ucuguagcag aca 23

<210> 735
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 735
acuucucaaa gucuguagca gac 23

<210> 736
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 736
accuucucaa agucuguagc aga 23

<210> 737
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 737
aaccuucuca aagucuguag cag 23

<210> 738
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 738
aaaccuucuc aaagucugua gca

23

<210> 739
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 739
aucaaccuuc ucaaagucug uag

23

<210> 740
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 740
aaucaaccuu cucaaagucu gua

23

<210> 741
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 741
agaucaaccu ucucuaaguc ugu

23

<210> 742
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 742
aagaucaacc uucucuaagu cug

23

<210> 743
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 743
aucagaucaa ccuucuaaa guc

23

<210> 744
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 744
agucagauca accuucuaa agu

23

<210> 745
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 745

aaacuggguc agaucaaccu ucu

23

<210> 746

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 746

auugaacugg gucagaucaa ccu

23

<210> 747

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 747

acuugaacug ggucagauca acc

23

<210> 748

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 748

aacuugaacu gggucagauc aac

23

<210> 749

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 749
acacuugaac ugggucagau caa 23

<210> 750
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 750
aauccacuug aacuggguca gau 23

<210> 751
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 751
auggauccac uugaacuggg uca 23

<210> 752
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 752
auguggaucc acuugaacug ggu 23

<210> 753
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 753
aaaugggau ccacuugaac ugg 23

<210> 754
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 754
aucaaugugg auccacuuga acu 23

<210> 755
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 755
acucaaugug gauccacuug aac 23

<210> 756
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 756

accucaaugu ggauccacuu gaa

23

<210> 757

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 757

aaucuucacc ugcuccgaug cgu

23

<210> 758

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 758

acaucuucac cugcuccgau gcg

23

<210> 759

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 759

accaaacagc uggaagagcu ccu 23

<210> 760

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 760

auagccaaac agcuggaaga gcu 23

<210> 761

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 761

acaaacacca cgucuccgua gcc 23

<210> 762

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 762

aacaaacacc acgucuccgu agc 23

<210> 763

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 763
augacaaaca ccacgucucc gua

23

<210> 764
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 764
acugacaaac accacgucuc cgu

23

<210> 765
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 765
aaucuuugcu gacaaacacc acg

23

<210> 766
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 766
acaucuuugc ugacaaacac cac

23

<210> 767
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 767
aacaucuuug cugacaaaca cca

23

<210> 768
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 768
acacauuuu gcugacaaac acc

23

<210> 769
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 769
accacauuu ugcugacaaa cac

23

<210> 770
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 770

agccacaucu uugcugacaa aca

23

<210> 771

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 771

aaagugcuug gccacaucuu ugc

23

<210> 772

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 772

auuuccucac acgaccuac aag

23

<210> 773

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 773

acuuuccuca cacgaccuaa caa

23

<210> 774

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 774
accuuuccuc acacgaccu aca 23

<210> 775
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 775
agaaagcauc cgaguggagc aa 23

<210> 776
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 776
aaugaaggu guccagcu ccc 23

<210> 777
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 777
acauugaagg ugucuccagc ucc 23

<210> 778
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 778
aggcauugaa ggugucucca gcu 23

<210> 779
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 779
aaggcauuga aggugucc agc 23

<210> 780
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 780
aaugacggag gcauugaagg ugu 23

<210> 781
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 781

agaugacgga ggcaugaag gug

23

<210> 782

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 782

aaaugacg gaggauga agg

23

<210> 783

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 783

augaauga cggaggcau gaa

23

<210> 784

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 784

acugaaugacgaggagcau uga 23

<210> 785

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 785

aagaggcuga agaugacgga ggc 23

<210> 786

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 786

aaucucagu gcuuccugca cgc 23

<210> 787

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 787

agaucucag ugcuccugc acg 23

<210> 788

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 788
acgaaucuca gugcuuccug cac

23

<210> 789
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 789
acaucaaagc ccugcaggcc aca

23

<210> 790
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 790
aaugccauca aagcccugca ggc

23

<210> 791
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 791
aacgaugcca ucaaagcccu gca

23

<210> 792
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 792
aacacgaugc caucaaagcc cug 23

<210> 793
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 793
aaacacagga cacaggcaga guc 23

<210> 794
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 794
agaagauua uuugcucuga ggc 23

<210> 795
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 795

aaggaagauu uauuugcucu gag

23

<210> 796

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 796

aaguucagac auugagagga gaa

23

<210> 797

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 797

acaguucaga cauugagagg aga

23

<210> 798

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 798

agcaguucag acauugagag gag

23

<210> 799

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 799
aagcaguuca gacauugaga gga 23

<210> 800
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 800
aagagcaguu cagacauuga gag 23

<210> 801
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 801
aagagucaga gccucaggaa ugc 23

<210> 802
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 802
aauagagucu gcacaacgca ggg 23

<210> 803
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 803
aaauagaguc ugcacaacgc agg 23

<210> 804
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 804
agaauagagu cugcacaacg cag 23

<210> 805
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 805
aggaaauagag ucugcacaac gca 23

<210> 806
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 806

augggaauag agucugcaca acg

23

<210> 807

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 807

agcuucugag cugugggaau aga

23

<210> 808

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 808

aagcuucuga gcugugggaa uag

23

<210> 809

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 809

aauuccaagg ugggcuccaa ggg 23

<210> 810

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 810

auuaauucca aggugggcuc caa 23

<210> 811

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 811

acuaauucc aaggugggcu cca 23

<210> 812

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 812

accuaauuc caaggugggc ucc 23

<210> 813

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 813
acccuuaauu ccaagguggg cuc

23

<210> 814
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 814
aauuuguggc ugaggcacgc ccu

23

<210> 815
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 815
augggucaca uuuguggcug agg

23

<210> 816
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 816
auauguguuc cagaucggac cuc

23

<210> 817
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 817
aaauauguu ccagaucgga ccu

23

<210> 818
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 818
aaauaugugu uccagaucgg acc

23

<210> 819
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 819
acaauaugug uuccagaucg gac

23

<210> 820
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 820

auuccaauau guguuccaga ucg

23

<210> 821

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 821

aaauccaaua uguguuccag auc

23

<210> 822

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 822

aaaauccaau auguguucca gau

23

<210> 823

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 823

acaauuccaa uauguguucc aga

23

<210> 824

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 824
accaaaucca auauguguuc cag 23

<210> 825
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 825
auuauaaggc cuuaccacc cua 23

<210> 826
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 826
aauuauaagg ccuaccac ccu 23

<210> 827
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 827
acauuauaag gccuuaccca ccc 23

<210> 828
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 828
auuuacauua uaaggccuua ccc 23

<210> 829
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 829
aucuuuacau uauaaggccu uac 23

<210> 830
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 830
acucuuuaca uuauaaggcc uua 23

<210> 831
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 831

augcucuuua cauuauaagg ccu

23

<210> 832

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 832

aaagcccuuu acauuauaug cuc

23

<210> 833

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 833

auaaagcccu uuacauuaua ugc

23

<210> 834

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 834

aucuaaaagcc cuuuacauua uau 23

<210> 835
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 835
acucuaaaagc ccuuuacauu aua 23

<210> 836
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 836
aacucuaaaag cccuuuacau uau 23

<210> 837
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 837
aauggcagau uuuuauccag guc 23

<210> 838
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 838
aaauggcaga uuuuaaucca ggu

23

<210> 839
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 839
auuaaauggc agauuuuaau cca

23

<210> 840
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 840
aaauaaaugg cagauuuuaa ucc

23

<210> 841
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 841
agcuauuaa auggcagauu uua

23

<210> 842
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 842
aagcuaauua aauggcagau uuu

23

<210> 843
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 843
acagcuaauu aaauggcaga uuu

23

<210> 844
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 844
augcagcuaa uuaaauggca gau

23

<210> 845
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 845

agaaaauugag gcagauugcg uua

23

<210> 846

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 846

aagaaaauuga ggcagauugc guu

23

<210> 847

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 847

aaagaaaauug aggagauug cgu

23

<210> 848

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 848

augaagaaaau ugaggcagau ugc

23

<210> 849

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 849
aaugaagaaa uugaggcaga uug 23

<210> 850
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 850
agaugaagaa auugaggcag auu 23

<210> 851
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 851
aagaugaaga aaugaggca gau 23

<210> 852
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 852
acagaugaag aaauugaggc aga 23

<210> 853
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 853
aacagaugaa gaaauugagg cag 23

<210> 854
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 854
auuugacaga ugaagaaau gag 23

<210> 855
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 855
aauuugacag augaagaaau uga 23

<210> 856
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 856

acaauugaca gaugaagaaa uug

23

<210> 857

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 857

auucuguagc caagcagaau ugg

23

<210> 858

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 858

aaauucuguag ccaagcagaa uug

23

<210> 859

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 859

auaauucugu agccaagcag aaau 23

<210> 860

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 860

aaauauucug uagccaagca gaa 23

<210> 861

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 861

aaauauuucu guagccaagc aga 23

<210> 862

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 862

acaauauuuc uguagccaag cag 23

<210> 863

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 863
 auccauuuga cagaugaaga aaau
 23

<210> 864
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 864
 auaaauggca gauuuuaauc cag
 23

<210> 865
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 865
 aaaauggcag auuuuaaucc agg
 23

<210> 866
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 866
 auugacagau gaagaaauug agg
 23

<210> 867
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 867
accauuugac agaugaagaa auu

23

<210> 868
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 868
agcucuuuac auuauaaggc cuu

23

<210> 869
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 869
acuaaagccc uuuacauuau aug

23

<210> 870
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 870

acgagaaugc aaagagaaaa ugc

23

<210> 871

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 871

agacagauga agaaauugag gca

23

<210> 872

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 872

augacagaug aagaaauuga ggc

23

<210> 873

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 873

acuuuacauu auaaggccuu acc

23

<210> 874

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 874
aaaagcccuu uacauuauau gcu 23

<210> 875
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 875
aaugcagcua auuaaauggc aga 23

<210> 876
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 876
agauuuuauuc cucacaauaa uuc 23

<210> 877
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 877
auuacauuau aaggccuuac cca 23

<210> 878
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 878
aaaauucugua gccaaagcaga auu 23

<210> 879
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 879
acaauugugga uccacuugaa cug 23

<210> 880
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 880
auacauuaua aggccuuacc cac 23

<210> 881
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 881

auccaauaug uguuccagau cgg

23

<210> 882

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 882

acucgagaau gcaaagagaa aa

23

<210> 883

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 883

agaagaaau gaggcagauu gcg

23

<210> 884

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 884

agaggaagau uuauuuugcuc uga 23

<210> 885

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 885

acagaucaac cuucucuaag ucu

23

<210> 886

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 886

acaaccuucu caaagucugu agc

23

<210> 887

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 887

aacauuauaa ggccuuaccc acc

23

<210> 888

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 888
aaagcgaucu cgagaaugca aag

23

<210> 889
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 889
accaauaugu guuccagauc gga

23

<210> 890
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 890
agcagcuaau uaaauggcag auu

23

<210> 891
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 891
acuuugcuga caaacaccac guc

23

<210> 892
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 892
auuccucaca cgaccuaca agc

23

<210> 893
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 893
aucuuuggca gguucacugg gug

23

<210> 894
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 894
auugcugaca aacaccacgu cuc

23

<210> 895
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 895

agaagaugac ggaggcauug aag

23

<210> 896

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 896

aaaagcaucc gaguggagca auu

23

<210> 897

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 897

aaauuccaag gugggcucca agg

23

<210> 898

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 898

aaguuccuc gcuugucaga ugg

23

<210> 899

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 899
auaauuccaa ggugggcucc aag 23

<210> 900
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 900
aagccaaaca gcuggaagag cuc 23

<210> 901
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 901
aaaaucacag gcuggugggc agg 23

<210> 902
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 902
aaaagccaac ccagaggucu ugg 23

<210> 903
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 903
acaaaucaca ggcugguggg cag 23

<210> 904
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 904
agacaaacac cacgucuccg uag 23

<210> 905
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 905
aauguguucc agaucggacc ucc 23

<210> 906
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 906

aucucuucca ugaggcuacu ccc

23

<210> 907

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 907

auucuuuggc agguucacug ggu

23

<210> 908

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 908

aaauaaggccu uaccacccu aua

23

<210> 909

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 909

acuuccauga ggcuacucucc aga 23

<210> 910

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 910

auauaaggcc uuacccaccc uau

23

<210> 911

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 911

augaacuggg ucagaucaac cuu

23

<210> 912

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 912

aacuugucca ccaggcugau gac

23

<210> 913

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 913
 augucagaug gacucacagc uga 23

 <210> 914
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 914
 aaaacaccac gucuccguag cca 23

 <210> 915
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 915
 agggaaauaga gucugcacao cgc 23

 <210> 916
 <211> 23
 <212> RNA
 <213> Homo sapiens

 <400> 916
 acgugguguu ugucagcaaa gau 23

 <210> 917
 <211> 23
 <212> RNA
 <213> Homo sapiens

<400> 917
agacguggug uuugucagca aag 23

<210> 918
<211> 23
<212> RNA
<213> Homo sapiens

<400> 918
ccucagagca aaauaaucuu ccu 23

<210> 919
<211> 23
<212> RNA
<213> Homo sapiens

<400> 919
cccaguucac guggauccac auu 23

<210> 920
<211> 23
<212> RNA
<213> Homo sapiens

<400> 920
caaguagcgc auuuucucuu ugc 23

<210> 921
<211> 23
<212> RNA
<213> Homo sapiens

<400> 921
uagcgcauuu ucucuuugca uuc 23

<210> 922
<211> 23
<212> RNA
<213> Homo sapiens

<400> 922
agcgcauuuu cucuuugcau ucu 23

<210> 923
<211> 23
<212> RNA
<213> Homo sapiens

<400> 923
gcgcacuuuuc ucuuugcauu cuc 23

<210> 924
<211> 23
<212> RNA
<213> Homo sapiens

<400> 924
cgcauuuucu cuuugcauuc ucg 23

<210> 925
<211> 23
<212> RNA
<213> Homo sapiens

<400> 925
cauuuucucu uugcauucuc gag 23

<210> 926
<211> 23
<212> RNA
<213> Homo sapiens

<400> 926
uuuucucuuu gcauucucga gau 23

<210> 927
<211> 23
<212> RNA
<213> Homo sapiens

<400> 927
uuucucuuug cauucucgag auc 23

<210> 928
<211> 23
<212> RNA
<213> Homo sapiens

<400> 928
uucucuuugc auucucgaga ucg 23

<210> 929
<211> 23
<212> RNA
<213> Homo sapiens

<400> 929
ucucuuugca uucucgagau cgc 23

<210> 930
<211> 23
<212> RNA
<213> Homo sapiens

<400> 930
ucuuugcauu cucgagaucg cuu 23

<210> 931
<211> 23
<212> RNA
<213> Homo sapiens

<400> 931
uuugcauucu cgagaucgcu uag 23

<210> 932
<211> 23
<212> RNA
<213> Homo sapiens

<400> 932
uugcauucuc gagaucgcuu agc 23

<210> 933
<211> 23
<212> RNA
<213> Homo sapiens

<400> 933
ugcauucucg agaucgcuua gcc 23

<210> 934

<211> 23
<212> RNA
<213> Homo sapiens

<400> 934
cgcuuuaaaa agguuugcau cag 23

<210> 935
<211> 23
<212> RNA
<213> Homo sapiens

<400> 935
gcuuuaaaaa gguuugcauc agc 23

<210> 936
<211> 23
<212> RNA
<213> Homo sapiens

<400> 936
cuuuaaaaag guuugcauca gcu 23

<210> 937
<211> 23
<212> RNA
<213> Homo sapiens

<400> 937
caucagcugu gaguccaucu gac 23

<210> 938
<211> 23
<212> RNA
<213> Homo sapiens

<400> 938
cagcugugag uccaucugac aag 23

<210> 939
<211> 23
<212> RNA
<213> Homo sapiens

<400> 939

agcugugagu ccaucugaca agc 23

<210> 940
<211> 23
<212> RNA
<213> Homo sapiens

<400> 940
guccaucuga caagcgagga aac 23

<210> 941
<211> 23
<212> RNA
<213> Homo sapiens

<400> 941
uccaucugac aagcgaggaa acu 23

<210> 942
<211> 23
<212> RNA
<213> Homo sapiens

<400> 942
gaggaaacua aggcugagaa gug 23

<210> 943
<211> 23
<212> RNA
<213> Homo sapiens

<400> 943
aggaaacuaa ggcugagaag ugg 23

<210> 944
<211> 23
<212> RNA
<213> Homo sapiens

<400> 944
caagaccucu gggguuggcuu ucc 23

<210> 945
<211> 23

<212> RNA	
<213> Homo sapiens	
<400> 945	
ggaguagccu cauggaagag aag	23
<210> 946	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 946	
agccucaugg aagagaagca gau	23
<210> 947	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 947	
gccucaugga agagaagcag auc	23
<210> 948	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 948	
ucauggaaga gaagcagauc cug	23
<210> 949	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 949	
auggaagaga agcagauccu gug	23
<210> 950	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 950	
uggaagagaa gcagauccug ugc	23

<210> 951
<211> 23
<212> RNA
<213> Homo sapiens

<400> 951
ucaucagccu gguggacaag uac 23

<210> 952
<211> 23
<212> RNA
<213> Homo sapiens

<400> 952
ugguggacaa guaccuaag gag 23

<210> 953
<211> 23
<212> RNA
<213> Homo sapiens

<400> 953
uggacaagua cccuaaggag gac 23

<210> 954
<211> 23
<212> RNA
<213> Homo sapiens

<400> 954
aggaggacuc ggagauaagg ugu 23

<210> 955
<211> 23
<212> RNA
<213> Homo sapiens

<400> 955
gauaaggugu uugucccaga gau 23

<210> 956
<211> 23
<212> RNA

<213> Homo sapiens	
<400> 956	
auaagguguu ugucccagag aug	23
<210> 957	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 957	
uccaacuccu gcaccguucu cuc	23
<210> 958	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 958	
ugucugcuac agacuuugag aag	23
<210> 959	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 959	
gucugcuaca gacuuugaga agg	23
<210> 960	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 960	
ucugcuacag acuuugagaa ggu	23
<210> 961	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 961	
cugcuacaga cuuugagaag guu	23

<210> 962
<211> 23
<212> RNA
<213> Homo sapiens

<400> 962
ugcuacagac uuugagaagg uug 23

<210> 963
<211> 23
<212> RNA
<213> Homo sapiens

<400> 963
cuacagacuu ugagaagguu gau 23

<210> 964
<211> 23
<212> RNA
<213> Homo sapiens

<400> 964
uacagacuuu gagaagguug auc 23

<210> 965
<211> 23
<212> RNA
<213> Homo sapiens

<400> 965
acagacuuug agaagguuga ucu 23

<210> 966
<211> 23
<212> RNA
<213> Homo sapiens

<400> 966
cagacuuuga gaagguugau cug 23

<210> 967
<211> 23
<212> RNA
<213> Homo sapiens

<400> 967
gacuuugaga agguugaucu gac 23

<210> 968
<211> 23
<212> RNA
<213> Homo sapiens

<400> 968
acuuugagaa gguugaucug acc 23

<210> 969
<211> 23
<212> RNA
<213> Homo sapiens

<400> 969
agaagguuga ucugaccag uuc 23

<210> 970
<211> 23
<212> RNA
<213> Homo sapiens

<400> 970
agguugaucu gaccaguuuc aag 23

<210> 971
<211> 23
<212> RNA
<213> Homo sapiens

<400> 971
gguugaucug acccaguuca agu 23

<210> 972
<211> 23
<212> RNA
<213> Homo sapiens

<400> 972
guugaucuga cccaguucaa gug 23

<210> 973
<211> 23
<212> RNA
<213> Homo sapiens

<400> 973
uugaucugac ccaguucaag ugg 23

<210> 974
<211> 23
<212> RNA
<213> Homo sapiens

<400> 974
aucugaccca guucaagugg auc 23

<210> 975
<211> 23
<212> RNA
<213> Homo sapiens

<400> 975
ugacccaguu caaguggauc cac 23

<210> 976
<211> 23
<212> RNA
<213> Homo sapiens

<400> 976
acccaguuca aguggaucca cau 23

<210> 977
<211> 23
<212> RNA
<213> Homo sapiens

<400> 977
ccaguucaag uggauccaca uug 23

<210> 978
<211> 23
<212> RNA
<213> Homo sapiens

<400> 978
aguucaagug gauccacauu gag 23

<210> 979
<211> 23
<212> RNA
<213> Homo sapiens

<400> 979
guucaagugg auccacauug agg 23

<210> 980
<211> 23
<212> RNA
<213> Homo sapiens

<400> 980
uucagugga uccacauuga ggg 23

<210> 981
<211> 23
<212> RNA
<213> Homo sapiens

<400> 981
acgcaucgga gcaggugaag aug 23

<210> 982
<211> 23
<212> RNA
<213> Homo sapiens

<400> 982
cgcaucggag caggugaaga ugc 23

<210> 983
<211> 23
<212> RNA
<213> Homo sapiens

<400> 983
aggagcucuu ccagcuguuu ggc 23

<210> 984

<211> 23
<212> RNA
<213> Homo sapiens

<400> 984
agcucuucca gcuguuuggc uac 23

<210> 985
<211> 23
<212> RNA
<213> Homo sapiens

<400> 985
ggcuacggag acgugguguu ugu 23

<210> 986
<211> 23
<212> RNA
<213> Homo sapiens

<400> 986
gcuacggaga cgugguguuu guc 23

<210> 987
<211> 23
<212> RNA
<213> Homo sapiens

<400> 987
uacggagacg ugguguuugu cag 23

<210> 988
<211> 23
<212> RNA
<213> Homo sapiens

<400> 988
acggagacgu gguguuuguc agc 23

<210> 989
<211> 23
<212> RNA
<213> Homo sapiens

<400> 989

cgugguguuu gucagcaaag aug 23

<210> 990
<211> 23
<212> RNA
<213> Homo sapiens

<400> 990
gugguguuug ucagcaaaga ugu 23

<210> 991
<211> 23
<212> RNA
<213> Homo sapiens

<400> 991
ugguguuugu cagcaaagau gug 23

<210> 992
<211> 23
<212> RNA
<213> Homo sapiens

<400> 992
gguguuuguc agcaaagau ugg 23

<210> 993
<211> 23
<212> RNA
<213> Homo sapiens

<400> 993
guguuuguca gcaaagaugu ggc 23

<210> 994
<211> 23
<212> RNA
<213> Homo sapiens

<400> 994
uguuugucag caaagaugug gcc 23

<210> 995
<211> 23

<212> RNA	
<213> Homo sapiens	
<400> 995	
gcaaagaugu ggccaagcac uug	23
<210> 996	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 996	
cuuguauggu cgugugagga aag	23
<210> 997	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 997	
uuguaugguc gugugaggaa agg	23
<210> 998	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 998	
uguauggucg ugugaggaaa ggg	23
<210> 999	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 999	
auugcuccac ucggaugcuu ucc	23
<210> 1000	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1000	
gggagcugga gacaccuua aug	23

<210> 1001
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1001
ggagcuggag acaccucaa ugc 23

<210> 1002
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1002
agcuggagac accucaaug ccu 23

<210> 1003
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1003
gcuggagaca ccucaaugc cuc 23

<210> 1004
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1004
acaccucaa ugccuccguc auc 23

<210> 1005
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1005
caccucaaau gccuccguca ucu 23

<210> 1006
<211> 23
<212> RNA

<213> Homo sapiens	
<400> 1006	
ccuucaaugc cuccgucauc uuc	23
<210> 1007	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1007	
uucaaugccu ccgucaucuu cag	23
<210> 1008	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1008	
ucaaugccuc cgucaucuuc agc	23
<210> 1009	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1009	
gccuccguca ucuucagccu cuc	23
<210> 1010	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1010	
gcgugcagga agcacugaga uuc	23
<210> 1011	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1011	
cgugcaggaa gcacugagau ucg	23

<210> 1012
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1012
gugcaggaag cacugagauu cgg 23

<210> 1013
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1013
uguggccugc agggcuuuga ugg 23

<210> 1014
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1014
gccugcaggg cuuugauggc auc 23

<210> 1015
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1015
ugcagggcuu ugauggcauc gug 23

<210> 1016
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1016
cagggcuuug auggcaucgu gug 23

<210> 1017
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1017
gacucugccu guguccugug uuc 23

<210> 1018
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1018
gccucagagc aaauaaaucu ucc 23

<210> 1019
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1019
cucagagcaa auaaaucuuc cuc 23

<210> 1020
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1020
uucuccucuc aaugucugaa cug 23

<210> 1021
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1021
ucuccucuca augucugaac ugc 23

<210> 1022
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1022
cuccucucaa ugucugaacu gcu 23

<210> 1023
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1023
uccucucaau gucugaacug cuc 23

<210> 1024
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1024
cucucaaugu cugaacugcu cug 23

<210> 1025
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1025
gcauuccuga ggcucugacu cuu 23

<210> 1026
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1026
cccugcguug ugcagacucu auu 23

<210> 1027
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1027
ccugcguugu gcagacucua uuc 23

<210> 1028
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1028
cugcguugug cagacucuau ucc 23

<210> 1029
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1029
ugcguugugc agacucuauu ccc 23

<210> 1030
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1030
cguugugcag acucuauucc cac 23

<210> 1031
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1031
ucuauuccca cagcucagaa gcu 23

<210> 1032
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1032
cuauucccac agcucagaag cug 23

<210> 1033
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1033
cccuuggagc ccaccuugga auu 23

<210> 1034

<211> 23
<212> RNA
<213> Homo sapiens

<400> 1034
uuggagccca ccuuggaauu aag 23

<210> 1035
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1035
uggagcccac cuuggaauua agg 23

<210> 1036
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1036
ggagcccacc uuggaauuaa ggg 23

<210> 1037
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1037
gagcccaccu uggaauuaag ggc 23

<210> 1038
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1038
agggcgugcc ucagccacaa aug 23

<210> 1039
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1039

ccucagccac aaaugugacc cag 23

<210> 1040

<211> 23

<212> RNA

<213> Homo sapiens

<400> 1040

gagguccgau cuggaacaca uau 23

<210> 1041

<211> 23

<212> RNA

<213> Homo sapiens

<400> 1041

agguccgauc uggaacacau auu 23

<210> 1042

<211> 23

<212> RNA

<213> Homo sapiens

<400> 1042

gguccgaucu ggaacacaua uug 23

<210> 1043

<211> 23

<212> RNA

<213> Homo sapiens

<400> 1043

guccgaucug gaacacauau ugg 23

<210> 1044

<211> 23

<212> RNA

<213> Homo sapiens

<400> 1044

cgaucuggaa cacauauugg aaU 23

<210> 1045

<211> 23

<212> RNA	
<213> Homo sapiens	
<400> 1045	
gaucuggaac acauauugga auu	23
<210> 1046	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1046	
aucuggaaca cauauuggaa uug	23
<210> 1047	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1047	
ucuggaacac auauuggaau ugg	23
<210> 1048	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1048	
cuggaacaca uauuggaauu ggg	23
<210> 1049	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1049	
uagggugggu aaggccuuau aa	23
<210> 1050	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1050	
agggugggua aggccuuaua aug	23

<210> 1051
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1051
ggguggguuaa ggccuuauaa ugu 23

<210> 1052
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1052
ggguaaggcc uuauaaugua aag 23

<210> 1053
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1053
guaaggccuu auaauguaaa gag 23

<210> 1054
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1054
uaaggccuua uaauguaaag agc 23

<210> 1055
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1055
aggccuuaua auguaaagag cau 23

<210> 1056
<211> 23
<212> RNA

<213> Homo sapiens	
<400> 1056	
gagcauauaa uguaaagggc uuu	23
<210> 1057	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1057	
gcuaauaaug uaaagggcuu uag	23
<210> 1058	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1058	
auauaaugua aagggcuuuu gag	23
<210> 1059	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1059	
uauaauguaa agggcuuuag agu	23
<210> 1060	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1060	
auaauguaaa gggcuuuaga gug	23
<210> 1061	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1061	
gaccuggauu aaaaucugcc auu	23

<210> 1062
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1062
accuggauua aaaucugcca uuu 23

<210> 1063
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1063
uggauuaaaa ucugccauuu aa 23

<210> 1064
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1064
ggauuaaaa cuGCCauuu auu 23

<210> 1065
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1065
uaaaaucugc cauuuaauua gcu 23

<210> 1066
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1066
aaaauCugcc auuuauuag cug 23

<210> 1067
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1067
aaaucugcca uuuaauuagc ugc 23

<210> 1068
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1068
aucugccauu uaauuagcug cau 23

<210> 1069
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1069
uaacgcaauc ugccucaauu ucu 23

<210> 1070
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1070
aacgcaaucu gccucaauuu cuu 23

<210> 1071
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1071
acgcaaucug ccucauuuuc uuc 23

<210> 1072
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1072
gcaaucugcc ucaauuucuu cau 23

<210> 1073
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1073
caaucugccu caauuucuuc auc 23

<210> 1074
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1074
aaucugccuc aaauucuuca ucu 23

<210> 1075
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1075
aucugccuca auuucuuc au cug 23

<210> 1076
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1076
ucugccuca uuuucucauc ugu 23

<210> 1077
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1077
cugccucaau uucuucauc guc 23

<210> 1078
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1078
cucaauuucu ucaucuguca aaau 23

<210> 1079
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1079
ucaauuucuu caucugucuu aug 23

<210> 1080
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1080
caauuucuu aucugucuu ugg 23

<210> 1081
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1081
ccaauucugc uggcuacag aaau 23

<210> 1082
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1082
caauucugcu uggcuacaga aaau 23

<210> 1083
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1083
auucugcuug gcuacagaau uau 23

<210> 1084

<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1084	
uucugcuugg cuacagaauu auu	23
<210> 1085	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1085	
ucugcuuggc uacagaauua uug	23
<210> 1086	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1086	
cugcuuggcu acagaauuau ugu	23
<210> 1087	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1087	
auuucuucan cugucaaaug gaa	23
<210> 1088	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1088	
cuggauuaaa aucugccauu uaa	23
<210> 1089	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1089	

ccuggauuaa aaucugccau uua 23

<210> 1090

<211> 23

<212> RNA

<213> Homo sapiens

<400> 1090

ccucaauuuc uucaucuguc aaa 23

<210> 1091

<211> 23

<212> RNA

<213> Homo sapiens

<400> 1091

aaauucuuca ucugucuuu gga 23

<210> 1092

<211> 23

<212> RNA

<213> Homo sapiens

<400> 1092

aaaggccuuau aauguaaaga gca 23

<210> 1093

<211> 23

<212> RNA

<213> Homo sapiens

<400> 1093

cauauaaugu aaaggcuuu aga 23

<210> 1094

<211> 23

<212> RNA

<213> Homo sapiens

<400> 1094

gcauuuucuc uuugcauucu cga 23

<210> 1095

<211> 23

<212> RNA	
<213> Homo sapiens	
<400> 1095	
ugccucaauu ucuucaucug uca	23
<210> 1096	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1096	
gccucaauuu cuucaucugu caa	23
<210> 1097	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1097	
gguaaggccu uauaauguaa aga	23
<210> 1098	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1098	
agcauauaa uuaaagggc uua	23
<210> 1099	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1099	
ucugccauuu aaauagcugc aua	23
<210> 1100	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1100	
gaauuauugu gaggauaaaa uca	23

<210> 1101
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1101
uggguaaggc cuuauaangu aaa 23

<210> 1102
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1102
aauucugcuu ggcuacagaa uua 23

<210> 1103
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1103
caguucaagu ggauccacau uga 23

<210> 1104
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1104
guggguaagg ccuuauaauug uaa 23

<210> 1105
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1105
ccgaucugga acacauauug gaa 23

<210> 1106
<211> 23
<212> RNA

<213> Homo sapiens	
<400> 1106	
auuuucucuu ugcauucucg aga	23
<210> 1107	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1107	
cgcaaucugc cucaauuucu uca	23
<210> 1108	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1108	
ucagagcaaa uaaauucuucc uca	23
<210> 1109	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1109	
agacuuugag aagguugauc uga	23
<210> 1110	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1110	
gcuacagacu uugagaaggu uga	23
<210> 1111	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1111	
gguggguaag gccuuuaau gua	23

<210> 1112
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1112
cuuugcauuc ucgagaucgc uua 23

<210> 1113
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1113
uccgaucugg aacacauauu gga 23

<210> 1114
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1114
aaucugccau uuaauuagcu gca 23

<210> 1115
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1115
gacguggugu uugucagcaa aga 23

<210> 1116
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1116
gcuuguaugg ucgugugagg aaa 23

<210> 1117
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1117
cacccaguga accugccaaa gaa 23

<210> 1118
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1118
gagacguggu guuugucagc aaa 23

<210> 1119
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1119
cuucaaugcc uccgucaucu uca 23

<210> 1120
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1120
aauugcucca cucggaugcu uuc 23

<210> 1121
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1121
ccuuggagcc caccuuggaa uua 23

<210> 1122
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1122
ccaucugaca agcgaggaaa cua 23

<210> 1123
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1123
cuuggagccc accuuggaau uaa 23

<210> 1124
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1124
gagcucuucc agcuguuugg cua 23

<210> 1125
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1125
ccugcccacc agccugugau uug 23

<210> 1126
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1126
ccaagaccuc ugguuuggcu uuc 23

<210> 1127
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1127
cugcccacca gccugugauu uga 23

<210> 1128
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1128
cuacggagac gugguguuug uca 23

<210> 1129
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1129
ggagguccga ucuggaacac aua 23

<210> 1130
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1130
gggaguagcc ucauggaaga gaa 23

<210> 1131
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1131
accagugaa ccugccaaag aaa 23

<210> 1132
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1132
uauagggugg guaaggccuu aua 23

<210> 1133
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1133
ucugggagua gccucaugga aga 23

<210> 1134

<211> 23
<212> RNA
<213> Homo sapiens

<400> 1134
auaggguagg uaaggccuua uaa 23

<210> 1135
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1135
aagguugauc ugacccaguu caa 23

<210> 1136
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1136
gucaucagcc ugguggacaa gua 23

<210> 1137
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1137
ucagcuguga guccaucuga caa 23

<210> 1138
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1138
uggcuacgga gacguggugu uug 23

<210> 1139
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1139

gcguugugca gacucuauuc cca

23

<210> 1140

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1140

uuugagaagg uugaucugac u

21

<210> 1141

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1141

agaatctcag ugcuccugc acg

23

<210> 1142

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1142
aacctucuca aagucuguag cag 23

<210> 1143
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1143
aucagatcaa ccuucucaaa guc 23

<210> 1144
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1144
aagatcaacc uucucuaagu cug 23

<210> 1145
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1145

agaagatuua uuugcucuga ggc

23

<210> 1146

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1146

aaagtgcuug gccacauuu ugc

23

<210> 1147

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1147

aaactggguc agaucaaccu ucu

23

<210> 1148
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1148
aauctctggg acaaacaccu uau 23

<210> 1149
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1149
aacatctuug cugacaaaca cca 23

<210> 1150
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1150

aucctccuua gggacuugu cca

23

<210> 1151

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1151

aucugctucu cuuccaugag gcu

23

<210> 1152

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1152

acaatgtgga uccacuugaa cug

23

<210> 1153

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1153
uuugagaagg uugaucugac u

21

<210> 1154
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1154
agucagauca accuucucuaa agu

23

<210> 1155
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1155
auugcugaca aacaccacgu cuc

23

<210> 1156
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic

oligonucleotide"

<400> 1156
agaatctcag ugcuccugc acg 23

<210> 1157
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1157
aucaaccuuc ucaaagucug uag 23

<210> 1158
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1158
aacctucuca aagucuguag cag 23

<210> 1159
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1159

auggauccac uugaacuggg uca 23

<210> 1160
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1160
aggaagauuu auuugcucug agg 23

<210> 1161
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1161
aucagatcaa ccuucucaaa guc 23

<210> 1162
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1162
aaggaucugc uucucuucca uga 23

<210> 1163
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1163
aagatcaacc uucucaaagu cug 23

<210> 1164
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1164
agaagatuua uuugcucuga ggc 23

<210> 1165
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1165
auagccaaac agcuggaaga gcu 23

<210> 1166
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1166
aaaugaaggu guccagcu ccc

23

<210> 1167
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1167
augaauga cggaggcauu gaa

23

<210> 1168
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1168
agaugacgga ggcaugaag gug

23

<210> 1169
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1169
acuucuaaa gucuguagca gac

23

<210> 1170
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1170
aaagtgcuug gccacauuu ugc

23

<210> 1171
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1171
aaactggguc agaucaaccu ucu

23

<210> 1172
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1172
aauctctggg acaaacaccu uau 23

<210> 1173
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1173
acacaggau cugcuucucuu cca 23

<210> 1174
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1174
aacatctuug cugacaaaca cca 23

<210> 1175
<211> 23

<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1175
aucctccuua ggguacuugu cca 23

<210> 1176
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1176
aaaucucagu gcuuccugca cgc 23

<210> 1177
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1177
aucugctucu cuuccaugag gcu 23

<210> 1178
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1178
aagaggcuga agaugacgga ggc

23

<210> 1179
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1179
acaatgtgga uccacuugaa cug

23

<210> 1180
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1180
guugaucuga cccaguucaa u

21

<210> 1181
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1181

gugguguuuug ucagcaaaga u

21

<210> 1182

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1182

aaactuugcu gacaaacacc acg

23

<210> 1183

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1183

aacutgaacu gggucagauc aac

23

<210> 1184

<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1184
aucutugcug acaaacacca cgu 23

<210> 1185
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1185
aacatcuuug cugacaaaca cca 23

<210> 1186
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1186
guugaucuga cccaguucuaa u 21

<210> 1187
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1187
gugguguuuug ucagcaaaga u

21

<210> 1188
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1188
aauctuugcu gacaaacacc acg

23

<210> 1189
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1189

aacutgaacu gggucagauc aac 23

<210> 1190

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1190

acgaaucuca gugcuuccug cac 23

<210> 1191

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1191

acuugaacug ggucagauca acc 23

<210> 1192

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1192

agaugacgga ggcauugaag gug 23

<210> 1193

<211> 23

<212> DNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1193
aucutugcug acaaacacca cgu 23

<210> 1194
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1194
aacatcuuug cugacaaaca cca 23

<210> 1195
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1195
aauccacuug aacuggguca gau 23

<210> 1196
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1196

aucugcuucu cuuccaugag gcu

23

<210> 1197

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1197

aucugctucu cuuccaugag gcu

23

<210> 1198

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1198

aaucaaccuu cucaaagucu gua

23

<210> 1199

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1199
 accuuc~~aa~~ug ccuccgu~~cau~~ u 21

<210> 1200
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1200
 gccucaugga agagaagcag u 21

<210> 1201
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1201
 uggaagagaa gcagauccug u 21

<210> 1202
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1202
 agagaagcag auccugugcg u 21

<210> 1203
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1203
agaagcagau ccugugcgug u 21

<210> 1204
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1204
gaagcagauc cugugcgugg u 21

<210> 1205
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1205
aucugaccca guucaagugg u 21

<210> 1206
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1206
aaguggaucc acauugaggg u 21

<210> 1207
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1207
uggauccaca uugagggccg u 21

<210> 1208
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1208
ggauccacau ugagggccg u 21

<210> 1209
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1209
guuuggcuac ggagacgugg u 21

<210> 1210
<211> 21

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1210
uuuggcuacg gagacguggu u 21

<210> 1211
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1211
uuggcuacgg agacguggug u 21

<210> 1212
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1212
uggcuacgga gacguggugu u 21

<210> 1213
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1213
ggcuacggag acgugguguu u 21

<210> 1214
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1214
gcuggagaca ccuucaaugc u 21

<210> 1215
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1215
acaccucaa ugccuccguc u 21

<210> 1216
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1216
caccucaaau gccuccguca u 21

<210> 1217
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1217
augccuccgu caucuucagc u 21

<210> 1218
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1218
agcgugcagg aagcacugag u 21

<210> 1219
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1219
caggaagcac ugagauucgg u 21

<210> 1220
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1220
uagccucaug gaagagaagc u 21

<210> 1221
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1221
cauggaagag aagcagauc u 21

<210> 1222
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1222
ugagaagguu gaucugaccc u 21

<210> 1223
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1223
agaagguuga ucugacccag u 21

<210> 1224
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1224
 ucugaccag uucaagugga u 21

<210> 1225
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1225
 ugaccaguu caaguggauc u 21

<210> 1226
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1226
 cccaguucaa guggauccac u 21

<210> 1227
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1227
 guggauccac auugagggcc u 21

<210> 1228
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1228
agacguggug uuugucagca u 21

<210> 1229
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1229
ugucagcaaa gauguggcca u 21

<210> 1230
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1230
gcaaagaugu ggccaagcac u 21

<210> 1231
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1231
ggagacaccu ucaaugccuc u 21

<210> 1232
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1232
cuucaaugcc uccgucaucu u 21

<210> 1233
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1233
ugccuccguc aucuucagcc u 21

<210> 1234
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1234
ccuccgucau cuucagccuc u 21

<210> 1235
<211> 21

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1235
gaggagcgug caggaagcac u 21

<210> 1236
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1236
aggagcgugc aggaagcacu u 21

<210> 1237
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1237
cgugcaggaa gcacugagau u 21

<210> 1238
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1238
cuucaaugcc uccgucauu 19

<210> 1239
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1239
accuacaaug ccuccgucau u 21

<210> 1240
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1240
accucaaug ccuccgucau u 21

<210> 1241
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1241
acguucaaug ccuccgucau u 21

<210> 1242
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1242
acauucaaug ccuccgucau u 21

<210> 1243
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1243
guucuagugg auccacauug u 21

<210> 1244
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1244
guugaagugg auccacauug u 21

<210> 1245
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1245
guuaaagugg auccacauug u 21

<210> 1246
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1246
guacaagugg auccacauug u 21

<210> 1247
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1247
aagguugauc ugaccuaguu u 21

<210> 1248
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1248
aagguugauc ugacucaguu u 21

<210> 1249
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 1249	
aaguuugauc ugaccuaguu u	21
<210> 1250	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 1250	
aauguugauc ugaccuaguu u	21
<210> 1251	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 1251	
aaguuugauc ugacucaguu u	21
<210> 1252	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 1252	
aauguugauc ugacucaguu u	21

<210> 1253
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1253
ugguuuuugu cagcaaagau u 21

<210> 1254
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1254
uggucuuugu cagcaaagau u 21

<210> 1255
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1255
uggaguuugu cagcaaagau u 21

<210> 1256
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1256
uguuguuuugu cagcaaagau u 21

<210> 1257
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1257
ugcuguuuugu cagcaaagau u 21

<210> 1258
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1258
ccucauggaa gagaaucaga u 21

<210> 1259
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1259
ccucuuggaa gagaaucaga u 21

<210> 1260
<211> 21

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1260
ccugauggaa gagaaucaga u 21

<210> 1261
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1261
ccuaauggaa gagaaucaga u 21

<210> 1262
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1262
ccacauggaa gagaaucaga u 21

<210> 1263
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1263
gugguguuug ucaguaaaga u 21

<210> 1264
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1264
guggaguuug ucaguaaaga u 21

<210> 1265
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1265
gugcuguuug ucaguaaaga u 21

<210> 1266
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1266
guguuguuug ucaguaaaga u 21

<210> 1267
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1267
gucguguuug ucaguaaaga u

21

<210> 1268
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1268
guuguguuug ucaguaaaga u

21

<210> 1269
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1269
aauctutgcu gacaaacacc acg

23

<210> 1270
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1270

acugcutcuc utccaugagg cua

23

<210> 1271

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1271

atcugctucu ctuccaugag gcu

23

<210> 1272

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1272

acaggatcug ctucucuucc aug

23

<210> 1273
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1273
acgcacagga ucugcuucuc uuc

23

<210> 1274
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1274
acacgcacag gaucugcuuc ucu

23

<210> 1275
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1275
accacgcaca ggaucugcuu cuc

23

<210> 1276
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1276

aaucaaccuu ctcaaagucu gua

23

<210> 1277

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1277

acagaucaac ctucucuaag ucu

23

<210> 1278

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1278

atugaacugg gtcagaucaa ccu

23

<210> 1279

<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1279
acactugaac ugggucagau caa 23

<210> 1280
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1280
accacutgaa ctgggucaga uca 23

<210> 1281
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic

oligonucleotide"

<400> 1281
atcaaugugg atccacuuga acu 23

<210> 1282
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1282
acucaatgug gauccacuug aac 23

<210> 1283
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1283
accctcaaug uggauccacu uga 23

<210> 1284
<211> 23
<212> DNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1284
acggcccuca atguggaucc acu 23

<210> 1285
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1285
accggcccuc aauguggauc cac 23

<210> 1286
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1286
accacgtcuc cguagccaaa cag 23

<210> 1287
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1287
aaccacgucu ccguagccaa aca

23

<210> 1288
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1288
acaccacguc uccguagcca aac

23

<210> 1289
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1289
aacaccacgu ctccguagcc aaa

23

<210> 1290
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1290

aaacaccacg ucuccguagc caa

23

<210> 1291

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1291

aaaacaccac gtcuccguag cca

23

<210> 1292

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1292

atgacaaaca ccacgucucc gua

23

<210> 1293

<211> 23

<212> DNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1293
acaucutugc ugacaaacac cac

23

<210> 1294
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1294
aacatctuug ctgacaaaca cca

23

<210> 1295
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1295
accacatcuu ugcugacaaa cac

23

<210> 1296
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1296
agccacaucu utgcugacaa aca 23

<210> 1297
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1297
acautgaagg ugucuccagc ucc 23

<210> 1298
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1298
agcatugaag gtgucuccag cuc

23

<210> 1299
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1299
aggcautgaa ggugucucca gcu

23

<210> 1300
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1300
agacggaggc atugaaggug ucu

23

<210> 1301
<211> 23
<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1301

atgacggagg caugaaggu guc

23

<210> 1302

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1302

agcugaagau gacggaggca uug

23

<210> 1303

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1303

acucagtgcu uccugcacgc ucc

23

<210> 1304

<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1304
acgaaucuca gtgcuuccug cac 23

<210> 1305
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1305
accgaatcuc agugcuuccu gca 23

<210> 1306
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic

oligonucleotide"

<400> 1306

agcutctcuu ccaugaggcu acu

23

<210> 1307

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1307

acugcutcuc uucaugagg cua

23

<210> 1308

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1308

aggatctgcu ucucuuccau gag

23

<210> 1309

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1309
agggtcagau caaccuucuc aaa

23

<210> 1310
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1310
acugggtcag aucaaccuuc uca

23

<210> 1311
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1311
augaactggg ucagaucaac cuu

23

<210> 1312
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1312
auccactuga acugggucag auc 23

<210> 1313
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1313
agauccacuu gaacuggguc aga 23

<210> 1314
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1314

aguggatcca cuugaacugg guc

23

<210> 1315

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1315

aggccctcaa uguggaucca cuu

23

<210> 1316

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1316

augctgacaa acaccacguc ucc

23

<210> 1317

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1317
auuugctgac aaacaccacg ucu 23

<210> 1318
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1318
auggccacau cuuugcugac aaa 23

<210> 1319
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1319
agugcutggc cacaucuuug cug 23

<210> 1320
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1320

aaggcatuga aggugucc agc

23

<210> 1321

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1321

agaggcauug aaggugucuc cag

23

<210> 1322

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1322

agacggaggc auugaaggug ucu

23

<210> 1323

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1323
aagatgacgg aggcauugaa ggu

23

<210> 1324
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1324
agaagatgac ggaggcauug aag

23

<210> 1325
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1325
aggctgaaga ugacggaggc auu

23

<210> 1326
<211> 23
<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1326

agaggctgaa gaugacggag gca

23

<210> 1327

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1327

agugcutccu gcacgcuccu ccc

23

<210> 1328

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1328
aagugctucc ugcacgcucc ucc 23

<210> 1329
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1329
aauctcagug cuuccugcac gcu 23

<210> 1330
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1330
aaugacggag gcauugaagg u 21

<210> 1331
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1331
aaugacggag gcauuguagg ugu 23

<210> 1332
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1332
aaugacggag gcauugaugg ugu

23

<210> 1333
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1333
aaugacggag gcauugaacg ugu

23

<210> 1334
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1334
aaugacggag gcauugaaug ugu

23

<210> 1335
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1335

acaatgtgga uccacuagaa cug

23

<210> 1336

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1336

acaatgtgga uccacuucaa cug

23

<210> 1337

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1337

acaatgtgga uccacuuuuaa cug

23

<210> 1338
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1338
acaatgtgga uccacuugua cug 23

<210> 1339
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1339
aaactagguc agaucaaccu ucu 23

<210> 1340
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1340

aaactgaguc agaucaaccu ucu

23

<210> 1341

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1341

aaactagguc agaucaaacu ucu

23

<210> 1342

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1342

aaactagguc agaucaacau ucu

23

<210> 1343

<211> 23

<212> DNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1343
aaactgaguc agaucaaacu ucu 23

<210> 1344
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1344
aaactgaguc agaucaacau ucu 23

<210> 1345
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1345
aauctutgcu gacaaaaacc acg 23

<210> 1346
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1346
aauctutgcu gacaaagacc acg 23

<210> 1347
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1347
aauctutgcu gacaaacucc acg 23

<210> 1348
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1348
aauctutgcu gacaaacaac acg

23

<210> 1349
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1349
aauctutgcu gacaaacagc acg

23

<210> 1350
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1350
aauctutgcu gacaaacacc acu

23

<210> 1351
<211> 23
<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1351

atcugatucu ctuccaugag gcu

23

<210> 1352

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1352

atcugatucu ctuccaagag gcu

23

<210> 1353

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1353
atcugatucu ctuccaucag gcu 23

<210> 1354
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1354
atcugatucu ctuccauuag gcu 23

<210> 1355
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1355
atcugatucu ctuccaugug gcu 23

<210> 1356
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1356

auugctgaca aacaccacgu cuc

23

<210> 1357

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1357

aucutuacug acaaacacca cgu

23

<210> 1358

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1358

auctutgcug acaaacacca cgu

23

<210> 1359

<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1359
aucutuacug acaaacucca cgu 23

<210> 1360
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1360
aucutuacug acaaacagca cgu 23

<210> 1361
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic

oligonucleotide"

<400> 1361
aucutuacug acaaacaaca cgu 23

<210> 1362
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1362
aucutuacug acaaacacga cgu 23

<210> 1363
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1363
aucutuacug acaaacacaa cgu 23

<210> 1364
<211> 23
<212> DNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 1364
 auctutgcug acaaacucca cgu 23

<210> 1365
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 1365
 auctutgcug acaaacagca cgu 23

<210> 1366
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 1366
 auctutgcug acaaacaaca cgu 23

<210> 1367
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1367
auctutgcug acaaacacga cgu 23

<210> 1368
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1368
auctutgcug acaaacacaa cgu 23

<210> 1369
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1369

acacaggauc ugcuuucucu ccu 23

<210> 1370
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1370
accuucuaug ccuccgucau u 21

<210> 1371
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1371
gccucaugga agagaagcag u 21

<210> 1372
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1372
ccucauggaa gagaagcaga u 21

<210> 1373
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1373
 uggaagagaa gcagauccug u 21

<210> 1374
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1374
 agagaagcag auccugugcg u 21

<210> 1375
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1375
 agaagcagau ccugugcgug u 21

<210> 1376
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1376
 gaagcagau cugugcgugg u 21

<210> 1377
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1377
cagacuuuga gaagguugau u 21

<210> 1378
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1378
agacuuugag aagguugauc u 21

<210> 1379
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1379
acuuugagaa gguugaucug u 21

<210> 1380
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1380

aagguugauc ugacccaguu u

21

<210> 1381

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1381

guugaucuga cccaguucaa u

21

<210> 1382

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1382

uugaucugac ccaguucaag u

21

<210> 1383

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1383

ugaucugacc caguucaagu u

21

<210> 1384

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1384
gaucugaccc aguucaagug u 21

<210> 1385
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1385
aucugaccca guucaagugg u 21

<210> 1386
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1386
cugacccagu ucaaguggau u 21

<210> 1387
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1387
uucaagugga uccacauuga u 21

<210> 1388
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1388
ucaaguggau ccacauugag u 21

<210> 1389
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1389
caaguggauc cacauugagg u 21

<210> 1390
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1390
aaguggaucc acauugaggg u 21

<210> 1391
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1391

uggauccaca uugagggccg u

21

<210> 1392

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1392

ggauccacau ugagggccgg u

21

<210> 1393

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1393

guuuggcuac ggagacgugg u

21

<210> 1394

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1394

uuuggcuacg gagacguggu u 21

<210> 1395
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1395
uuggcuacgg agacguggug u 21

<210> 1396
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1396
uggcuacgga gacguggugu u 21

<210> 1397
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1397
ggcuacggag acgugguguu u 21

<210> 1398
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1398
gcuacggaga cgugguguuu u 21

<210> 1399
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1399
cuacggagac gugguguuug u 21

<210> 1400
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1400
uacggagacg ugguguuugu u 21

<210> 1401
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1401
acggagacgu gguguuuguc u 21

<210> 1402
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1402
cggagacgug guguuuguca u 21

<210> 1403
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1403
ggagacgugg uguuugucag u 21

<210> 1404
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1404
ugguguuugu cagcaaagau u 21

<210> 1405
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1405

gguguuuguc agcaaagaug u

21

<210> 1406

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1406

guguuuguca gcaaagaugu u

21

<210> 1407

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1407

uguuugucag caaagaugug u

21

<210> 1408

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1408

guuugucagc aaagaugugg u

21

<210> 1409

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1409
uuugucagca aagaugggc u 21

<210> 1410
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1410
agcuggagac accucaaug u 21

<210> 1411
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1411
gcuggagaca ccucaaugc u 21

<210> 1412
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1412
cuggagacac cuucaaugcc u 21

<210> 1413
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1413
acaccucaa ugccuccguc u 21

<210> 1414
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1414
caccucaaau gccuccguca u 21

<210> 1415
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1415
accucaaug ccuccgucau u 21

<210> 1416
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1416

uucaaugccu ccgucaucu u

21

<210> 1417

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1417

aaugccuccg ucaucuucag u

21

<210> 1418

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1418

augccuccgu caucuucagc u

21

<210> 1419

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1419

agcgugcagg aagcacugag u 21

<210> 1420
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1420
gcaggaagca cugagauucg u 21

<210> 1421
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1421
caggaagcac ugagauucgg u 21

<210> 1422
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1422
uagccucaug gaagagaagc u 21

<210> 1423
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1423
 gccucaugga agagaagcag u 21

 <210> 1424
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1424
 cauggaagag aagcagauc u 21

 <210> 1425
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1425
 agagaagcag auccugugcg u 21

 <210> 1426
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1426
 ugagaagguu gaucugaccc u 21

<210> 1427
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1427
agaagguuga ucugaccag u 21

<210> 1428
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1428
ucugaccag uucaagugga u 21

<210> 1429
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1429
ugaccaguu caaguggauc u 21

<210> 1430
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1430

cccaguucaa guggauccac u

21

<210> 1431

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1431

guggauccac auugagggcc u

21

<210> 1432

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1432

agacguggug uuugucagca u

21

<210> 1433

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1433

ugucagcaaa gauguggcca u

21

<210> 1434

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1434
gcaaagaugu ggccaagcac u 21

<210> 1435
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1435
ggagacaccu ucaaugccuc u 21

<210> 1436
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1436
acaccuucaa ugccuccguc u 21

<210> 1437
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1437
cuucaaugcc uccgucaucu u 21

<210> 1438
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1438
augccuccgu caucuucagc u 21

<210> 1439
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1439
ugccuccguc aucuucagcc u 21

<210> 1440
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1440
ccuccgucau cuucagccuc u 21

<210> 1441
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1441

gaggagcgug caggaagcac u

21

<210> 1442

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1442

aggagcgugc aggaagcacu u

21

<210> 1443

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1443

agcgugcagg aagcacugag u

21

<210> 1444

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1444

cgugcaggaa gcacugagau u 21

<210> 1445
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1445
cuucaaugcc uccgucauu 19

<210> 1446
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1446
accuacaaug ccuccgucau u 21

<210> 1447
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1447
accaucaaug ccuccgucau u 21

<210> 1448
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1448
 acguucaaug ccuccgucau u 21

<210> 1449
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1449
 acauucaaug ccuccgucau u 21

<210> 1450
 <211> 19
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1450
 cuucaaugcc uccgucauu 19

<210> 1451
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1451
 accuacaug ccuccgucau u 21

<210> 1452
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1452
accaucaaug ccuccgucau u 21

<210> 1453
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1453
acguucaaug ccuccgucau u 21

<210> 1454
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1454
acauucaaug ccuccgucau u 21

<210> 1455
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1455

guucaagugg auccacauug u

21

<210> 1456

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1456

guucuagugg auccacauug u

21

<210> 1457

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1457

guugaagugg auccacauug u

21

<210> 1458

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1458

guuaaagugg auccacauug u

21

<210> 1459

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1459
guacaagugg auccacauug u 21

<210> 1460
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1460
aagguugauc ugaccuaguu u 21

<210> 1461
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1461
aagguugauc ugacucaguu u 21

<210> 1462
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1462
aaguuugauc ugaccuaguu u 21

<210> 1463
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1463
aauguugauc ugaccuaguu u 21

<210> 1464
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1464
aaguuugauc ugacucaguu u 21

<210> 1465
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1465
aauguugauc ugacucaguu u 21

<210> 1466
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1466

ugguuuuugu cagcaaagau u

21

<210> 1467

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1467

uggucuuugu cagcaaagau u

21

<210> 1468

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1468

uggaguuugu cagcaaagau u

21

<210> 1469

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1469

uguuguuuugu cagcaaagau u 21

<210> 1470
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1470
ugcuguuuugu cagcaaagau u 21

<210> 1471
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1471
ccucauggaa gagaaucaga u 21

<210> 1472
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1472
ccucuuggaa gagaaucaga u 21

<210> 1473
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1473
 ccugauggaa gagaaucaga u 21

 <210> 1474
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1474
 ccuaauggaa gagaaucaga u 21

 <210> 1475
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1475
 ccacauggaa gagaaucaga u 21

 <210> 1476
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1476
 gugguguuug ucaguaaaga u 21

<210> 1477
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1477
guggaguuug ucaguaaaga u 21

<210> 1478
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1478
gugcuguuug ucaguaaaga u 21

<210> 1479
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1479
guguuguuug ucaguaaaga u 21

<210> 1480
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1480

gucguguuug ucaguaaaga u

21

<210> 1481

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1481

guuguguuug ucaguaaaga u

21

<210> 1482

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1482

aauctutgcu gacaaacacc acg

23

<210> 1483

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1483
acugcutcuc utccaugagg cua

23

<210> 1484
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1484
atcugctucu ctuccaugag gcu

23

<210> 1485
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1485
acaggatcug ctucucuucc aug

23

<210> 1486
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1486

acgcacagga ucugcuucuc uuc

23

<210> 1487

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1487

acacgcacag gaucugcuuc ucu

23

<210> 1488

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1488

accacgcaca ggaucugcuu cuc

23

<210> 1489

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1489
aaucaaccuu ctcaaagucu gua

23

<210> 1490
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1490
agaucaaccu ucucuaaguc ugu

23

<210> 1491
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1491
acagaucaac ctucucuaag ucu

23

<210> 1492
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1492
aaactggguc agaucaaccu ucu 23

<210> 1493
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1493
atugaacugg gtcagaucaa ccu 23

<210> 1494
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1494
acuugaacug ggucagauca acc 23

<210> 1495
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1495

aacutgaacu gggucagauc aac

23

<210> 1496

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1496

acactugaac ugggucagau caa

23

<210> 1497

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1497

accacutgaa ctgggucaga uca

23

<210> 1498
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1498
aauccacuug aacuggguca gau

23

<210> 1499
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1499
atcaaugugg atccacuuga acu

23

<210> 1500
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1500
acucaatgug gauccacuug aac

23

<210> 1501
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1501
accucaaugu ggauccacuu gaa

23

<210> 1502
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1502
accctcaaug uggauccacu uga

23

<210> 1503
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1503
acggcccuca atguggaucc acu 23

<210> 1504
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1504
accggcccuc aauguggauc cac 23

<210> 1505
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1505
accacgtcuc cguagccaaa cag 23

<210> 1506
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1506
aaccacgucu ccguagccaa aca 23

<210> 1507
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1507
acaccacguc uccguagcca aac

23

<210> 1508
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1508
aacaccacgu ctccguagcc aaa

23

<210> 1509
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1509
aaacaccacg ucuccguagc caa

23

<210> 1510
<211> 23

<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1510
aaaacaccac gtcuccguag cca 23

<210> 1511
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1511
acaaacacca cgucuccgua gcc 23

<210> 1512
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1512
aacaacacc acgucuccgu agc 23

<210> 1513
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1513
agacaaacac cacgucuccg uag

23

<210> 1514
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1514
atgacaaaca ccacgucucc gua

23

<210> 1515
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1515
acugacaaac accacgucuc cgu

23

<210> 1516
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1516

aauctutgcu gacaaacacc acg

23

<210> 1517

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1517

acaucutugc ugacaaacac cac

23

<210> 1518

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1518

aacatctuug ctgacaaaca cca

23

<210> 1519

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1519
acacaucuuu gcugacaaac acc

23

<210> 1520
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1520
accacatcuu ugcugacaaa cac

23

<210> 1521
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1521
agccacaucu utgcugacaa aca

23

<210> 1522
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1522
acautgaagg ugucuccagc ucc 23

<210> 1523
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1523
agcatugaag gtgucuccag cuc 23

<210> 1524
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1524
aggcautgaa ggugucucca gcu

23

<210> 1525
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1525
agacggaggc atugaaggug ucu

23

<210> 1526
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1526
atgacggagg cauugaaggu guc

23

<210> 1527
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1527
aaugacggag gcauugaagg ugu 23

<210> 1528
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1528
aaaugacg gaggc auuga agg 23

<210> 1529
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1529
acugaaug acggaggcau uga 23

<210> 1530
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1530
agcugaagau gacggaggca uug 23

<210> 1531
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1531
acucagtgcu uccugcacgc ucc

23

<210> 1532
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1532
acgaaucuca gtgcuuccug cac

23

<210> 1533
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1533
accgaatcuc agugcuuccu gca

23

<210> 1534
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1534
agcutctcuu ccaugaggcu acu

23

<210> 1535
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1535
acugcutcuc uucaugagg cua

23

<210> 1536
<211> 23
<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1536

aggatctgcu ucucuuccau gag

23

<210> 1537

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1537

aacaggau cu gcuucucuuc cau

23

<210> 1538

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1538

acgcacagga ucugcuucuc uuc

23

<210> 1539

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1539
agaucaaccu ucucuaaguc ugu

23

<210> 1540
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1540
agggtcagau caaccuucuc aaa

23

<210> 1541
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1541
acugggtcag aucaaccuuc uca

23

<210> 1542
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1542
augaactggg ucagaucaac cuu

23

<210> 1543
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1543
aacutgaacu gggucagauc aac

23

<210> 1544
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1544

auccactuga acugggucag auc 23

<210> 1545
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1545
agauccacuu gaacuggguc aga 23

<210> 1546
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1546
aguggatcca cuugaacugg guc 23

<210> 1547
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1547
auguggaucc acuugaacug ggu 23

<210> 1548
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1548
aggccctcaa uguggaucca cuu 23

<210> 1549
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1549
augctgacaa acaccacguc ucc 23

<210> 1550
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1550

auuugctgac aaacaccacg ucu

23

<210> 1551

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1551

agccacaucu uugcugacaa aca

23

<210> 1552

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1552

auggccacau cuuugcugac aaa

23

<210> 1553

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1553
agugcutggc cacaucuuug cug 23

<210> 1554
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1554
aggcautgaa ggugucucca gcu 23

<210> 1555
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1555
aaggcatuga aggugucucc agc 23

<210> 1556
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1556
agaggcauug aaggugucuc cag 23

<210> 1557
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1557
agacggaggc auugaaggug ucu 23

<210> 1558
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1558
aagatgacgg aggcauugaa ggu 23

<210> 1559
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1559
agaagatgac ggaggcauug aag

23

<210> 1560
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1560
agcugaagau gacggaggca uug

23

<210> 1561
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1561
aggctgaaga ugacggaggc auu

23

<210> 1562
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1562
agaggctgaa gaugacggag gca 23

<210> 1563
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1563
agugcutccu gcacgcuccu ccc 23

<210> 1564
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1564
aagugctucc ugcacgcucc ucc 23

<210> 1565
<211> 23

<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1565
acucagtgcu uccugcacgc ucc 23

<210> 1566
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1566
aauctcagug cuuccugcac gcu 23

<210> 1567
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1567
aaugacggag gc auugaagg u 21

<210> 1568
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1568
aaugacggag gcauuguagg ugu

23

<210> 1569
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1569
aaugacggag gcauugaugg ugu

23

<210> 1570
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1570
aaugacggag gcauugaacg ugu

23

<210> 1571
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1571
aaugacggag gcauugaaug ugu 23

<210> 1572
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1572
aaugacggag gcauugaagg u 21

<210> 1573
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1573
aaugacggag gcauuguagg ugu 23

<210> 1574
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1574
aaugacggag gcauugaugg ugu 23

<210> 1575
<211> 23

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1575
aaugacggag gcauugaacg ugu

23

<210> 1576
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1576
aaugacggag gcauugaaug ugu

23

<210> 1577
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1577
acaatgtgga uccacuugaa cug

23

<210> 1578
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1578
acaatgtgga uccacuugaa cug 23

<210> 1579
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1579
acaatgtgga uccacuagaa cug 23

<210> 1580
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1580
acaatgtgga uccacuucaa cug 23

<210> 1581
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1581
acaatgtgga uccacuuuaa cug 23

<210> 1582
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1582
acaatgtgga uccacuugua cug 23

<210> 1583
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1583
aaactagguc agaucaaccu ucu

23

<210> 1584
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1584
aaactgaguc agaucaaccu ucu

23

<210> 1585
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1585
aaactagguc agaucaaacu ucu

23

<210> 1586
<211> 23
<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1586

aaactagguc agaucaacau ucu

23

<210> 1587

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1587

aaactgaguc agaucaaacu ucu

23

<210> 1588

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1588
aaactgaguc agaucaacau ucu 23

<210> 1589
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1589
aauctutgcu gacaaaaacc acg 23

<210> 1590
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1590
aauctutgcu gacaaagacc acg 23

<210> 1591
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1591

aauctutgcu gacaaacucc acg

23

<210> 1592

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1592

aauctutgcu gacaaacaac acg

23

<210> 1593

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1593

aauctutgcu gacaaacagc acg

23

<210> 1594

<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1594
aauctutgcu gacaaacacc acu 23

<210> 1595
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1595
aauctutgcu gacaaacacc acg 23

<210> 1596
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic

oligonucleotide"

<400> 1596
atcugatucu ctuccaugag gcu 23

<210> 1597
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1597
atcugatucu ctuccaagag gcu 23

<210> 1598
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1598
atcugatucu ctuccaucag gcu 23

<210> 1599
<211> 23
<212> DNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1599
atcugatucu ctuccauuag gcu 23

<210> 1600
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1600
atcugatucu ctuccaugug gcu 23

<210> 1601
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1601
auugcugaca aacaccacgu cuc 23

<210> 1602
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1602
auugctgaca aacaccacgu cuc

23

<210> 1603
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1603
auugctgaca aacaccacgu cuc

23

<210> 1604
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1604

aucutugcug acaaacacca cgu

23

<210> 1605

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1605

aucutuacug acaaacacca cgu

23

<210> 1606

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1606

auctutgcug acaaacacca cgu

23

<210> 1607

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1607
aucutuacug acaaacucca cgu

23

<210> 1608
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1608
aucutuacug acaaacagca cgu

23

<210> 1609
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1609
aucutuacug acaaacaaca cgu

23

<210> 1610
<211> 23

<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1610
aucutuacug acaaacacga cgu 23

<210> 1611
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1611
aucutuacug acaaacacaa cgu 23

<210> 1612
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1612
auctutgcug acaaacucca cgu 23

<210> 1613
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1613
auctutgcug acaaacagca cgu 23

<210> 1614
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1614
auctutgcug acaaacaaca cgu 23

<210> 1615
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1615

auctutgcug acaaacacga cgu

23

<210> 1616

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1616

auctutgcug acaaacacaa cgu

23

<210> 1617

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1617

acacaggauc ugcuuucuuu ccu

23

<210> 1618

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1618
acacaggauc ugcuuucuu ccu 23

<210> 1619
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1619
uagccucaug gaagagaagc aga 23

<210> 1620
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1620
cauggaagag aagcagauc ugu 23

<210> 1621
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1621
gaagagaagc agauccugug cgu 23

<210> 1622
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1622
agagaagcag auccugugcg ugg 23

<210> 1623
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1623
gagaagcaga uccugugcgu ggg 23

<210> 1624
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1624
ugaucugacc caguucaagu gga 23

<210> 1625
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1625
ucaaguggau ccacauugag ggc 23

<210> 1626
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1626
aguggaucca cauugagggc cgg 23

<210> 1627
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1627
guggauccac auugagggcc gga 23

<210> 1628
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1628
cuguuuggcu acggagacgu ggu 23

<210> 1629

<211> 23
<212> RNA
<213> Homo sapiens

<400> 1629
uguuuggcua cggagacgug gug 23

<210> 1630
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1630
guuuggcuac ggagacgugg ugu 23

<210> 1631
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1631
uuuggcuacg gagacguggu guu 23

<210> 1632
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1632
uuggcuacgg agacguggug uuu 23

<210> 1633
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1633
gagcuggaga caccuucgau gcc 23

<210> 1634
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1634

agacaccuuc aaugccuccg uca 23

<210> 1635

<211> 23

<212> RNA

<213> Homo sapiens

<400> 1635

gacaccuua augccuccgu cau 23

<210> 1636

<211> 23

<212> RNA

<213> Homo sapiens

<400> 1636

caaugccucc gucaucuca gcc 23

<210> 1637

<211> 23

<212> RNA

<213> Homo sapiens

<400> 1637

ggagcgugca ggaagcacug aga 23

<210> 1638

<211> 23

<212> RNA

<213> Homo sapiens

<400> 1638

ugcaggaagc acugagauuc ggg 23

<210> 1639

<211> 23

<212> RNA

<213> Homo sapiens

<400> 1639

aguagccuca uggaagagaa gca 23

<210> 1640

<211> 23

<212> RNA	
<213> Homo sapiens	
<400> 1640	
cucauggaag agaagcagau ccu	23
<210> 1641	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1641	
uuugagaagg uugaucugac cca	23
<210> 1642	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1642	
ugagaagguu gaucugaccc agu	23
<210> 1643	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1643	
gaucugaccc aguucaagug gau	23
<210> 1644	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1644	
ucugacccag uucaagugga ucc	23
<210> 1645	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1645	
gaccaguuuc aaguggaucc aca	23

<210> 1646
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1646
aaguggaucc acauugaggg ccg 23

<210> 1647
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1647
ggagacgugg uguuugucag caa 23

<210> 1648
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1648
uuugucagca aagauguggc caa 23

<210> 1649
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1649
cagcaaagau guggccaagc acu 23

<210> 1650
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1650
cuggagacac cuucaaugcc ucc 23

<210> 1651
<211> 23
<212> RNA

<213> Homo sapiens	
<400> 1651	
accuucaaug ccuccgucau cuu	23
<210> 1652	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1652	
aaugccuccg ucaucuucag ccu	23
<210> 1653	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1653	
ugccuccguc aucuucagcc ucu	23
<210> 1654	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1654	
gggaggagcg ugcaggaagc acu	23
<210> 1655	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1655	
ggaggagcgu gcaggaagca cug	23
<210> 1656	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1656	
agcgugcagg aagcacugag auu	23

<210> 1657
<211> 21
<212> RNA
<213> Homo sapiens

<400> 1657
accuucaaug ccuccgucau c

21

<210> 1658
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1658
uucuucaucu gucaaaugga u

21

<210> 1659
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1659
guagccucau ggaagagaag u

21

<210> 1660
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1660
agccucaugg aagagaagca u

21

<210> 1661
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1661
ucauggaaga gaagcagauc u 21

<210> 1662
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1662
aagagaagca gauccugugc u 21

<210> 1663
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1663
gagaagcaga uccugugcgu u 21

<210> 1664
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1664
 aagcagaucc ugugcguggg u 21

 <210> 1665
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1665
 agcagauccu gugcgugggg u 21

 <210> 1666
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1666
 gcagauccug ugcguggggc u 21

 <210> 1667
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1667
 cagauccugu gcguggggcu u 21

<210> 1668
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1668
agauccugug cguggggcua u 21

<210> 1669
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1669
cagacuuuga gaagguugau a 21

<210> 1670
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1670
gacuuugaga agguugauu 19

<210> 1671
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1671
uuugagaagg ugaucugu 19

<210> 1672
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1672
acuuuaagaa gguugaucug u 21

<210> 1673
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1673
uugagaaggu ugaucugacc u 21

<210> 1674
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1674
gagaagguug aucugaccca u 21

<210> 1675
<211> 21

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1675
gaagguugau cugacccagu u 21

<210> 1676
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1676
agguugaucu gaccagauuc u 21

<210> 1677
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1677
ugaucugacc caguucaagu a 21

<210> 1678
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1678
aucugaccca guucaaguu 19

<210> 1679
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1679
gaccaguuuc aaguggaucc u 21

<210> 1680
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1680
aguggaucca cauugagggc u 21

<210> 1681
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1681
gauccacauu gagggccgga u 21

<210> 1682
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1682
auccacauug agggccggaa u 21

<210> 1683
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1683
gagacguggu guuugucagc u 21

<210> 1684
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1684
uugucagcaa agauguggcc u 21

<210> 1685
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1685
gucagcaaag auguggccaa u 21

<210> 1686
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1686
ucagcaaaga uguggccaag u 21

<210> 1687
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1687
cagcaaagau guggccaagc u 21

<210> 1688
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1688
agcaaagau ugccaagca u 21

<210> 1689
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1689
 gagacaccuu caaugccucc u 21

<210> 1690
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1690
 agacaccuuc aaugccuccg u 21

<210> 1691
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1691
 gacaccuua augccuccgu u 21

<210> 1692
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1692
 gccuccguca ucuucagccu u 21

<210> 1693
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1693
ggagcgugca ggaagcacug u

21

<210> 1694
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1694
gagcgugcag gaagcacuga u

21

<210> 1695
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1695
gcgugcagga agcacugaga u

21

<210> 1696
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1696

aagatcaacc utcucaaagu cug

23

<210> 1697

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1697

atgaactggg ucagaucaac cuu

23

<210> 1698

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1698

acuucucuuc caugaggcua cuc

23

<210> 1699

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 1699
 augctucucu uccaugaggc uac 23

<210> 1700
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 1700
 aauctgcuuc ucuuccauga ggc 23

<210> 1701
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1701
 agaucugcuu cucuuccaug agg 23

<210> 1702
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1702
agcacaggau cugcuucucu ucc 23

<210> 1703
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1703
aacgcacagg aucugcuucu cuu 23

<210> 1704
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1704
accacgcac aggaucugcu ucu 23

<210> 1705
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1705
accccacgca caggaucugc uuc 23

<210> 1706
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1706
agccccacgc acaggaucug cuu 23

<210> 1707
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1707
aagccccacg cacaggaucu gcu 23

<210> 1708
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1708
auagccccac gcacaggauc ugc 23

<210> 1709
<211> 23
<212> DNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1709
aaucaaccuu ctcaaagucu gug 23

<210> 1710
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1710
aaucaaccuu ctcaaagucu gcu 23

<210> 1711
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1711
uaucaaccuu ctcaaagucu gcu 23

<210> 1712
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1712
aaucaaccuu ctcaaagucu g 21

<210> 1713
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1713
acagaucaac ctucucuaag u 21

<210> 1714
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 1714
 acagaucaac ctucuuaaag ucu 23

<210> 1715
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1715
 aggucagauc aaccuucua aag 23

<210> 1716
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1716
 augggucaga ucaaccuucu caa 23

<210> 1717
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1717
 aacuggguca gaucaaccuu cuc 23

<210> 1718
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1718
agaacugggu cagaucaacc uuc

23

<210> 1719
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1719
aacutgaacu gggucagauc agc

23

<210> 1720
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1720
aacutgaacu gggucagauc acu

23

<210> 1721
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1721
uacutgaacu gggucagauc acu 23

<210> 1722
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1722
aacutgaacu gggucagauc g 21

<210> 1723
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1723
aggatccacu ugaacugggu cag 23

<210> 1724
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1724
aaugtggau cacuugaacu ggg 23

<210> 1725
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1725
agcccucaau guggauccac uug 23

<210> 1726
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1726
acggcccuca auguggaucc acu 23

<210> 1727
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1727
auccggcccu caauguggau cca 23

<210> 1728
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1728
auuccggccc ucaaugugga ucc 23

<210> 1729
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1729
agcugacaaa caccacgucu ccg 23

<210> 1730
<211> 23

<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1730
acuutgcuga caaacaccac guc 23

<210> 1731
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1731
aggccacauc uuugcugaca aac 23

<210> 1732
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1732
auuggccaca uuuugcuga caa 23

<210> 1733
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1733
acuuggccac aucuuugcug aca

23

<210> 1734
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1734
agcutggcca caucuugcu gac

23

<210> 1735
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1735
augctuggcc acaucuugc uga

23

<210> 1736
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1736

aggaggcauu gaaggugucu cca

23

<210> 1737

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1737

acggaggcau ugaagguguc ucc

23

<210> 1738

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1738

aacggaggca uugaaggugu cuc

23

<210> 1739

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1739

aaggcugaag augacggagg cau 23

<210> 1740
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1740
acagtgcuuc cugcacgcuc cuc 23

<210> 1741
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1741
aucagugcuu ccugcacgcu ccu 23

<210> 1742
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1742
aucucagugc uuccugcacg cuc 23

<210> 1743
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1743
atcutuggca gguucacugg gug 23

<210> 1744
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1744
atuctutggc agguucacug ggu 23

<210> 1745
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1745

agaatagagu ctgcacaacg cag

23

<210> 1746

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1746

agggaataga gtcugcaciaa cgc

23

<210> 1747

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1747

atgggaauag agucugcaca acg

23

<210> 1748

<211> 23

<212> DNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1748
agcutctgag ctgugggaau aga

23

<210> 1749
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1749
aagctucuga gcugugggaa uag

23

<210> 1750
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1750
aaaatcacag gcuggugggc agg

23

<210> 1751
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1751
aaautccaag gtgggcucca agg 23

<210> 1752
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1752
ataatuccaa ggugggcucc aag 23

<210> 1753
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1753
atuaautcca aggugggcuc caa

23

<210> 1754
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1754
acuaaatucc aaggugggcu cca

23

<210> 1755
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1755
accutaauuc caaggugggc ucc

23

<210> 1756
<211> 23
<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1756

accctuaauu ccaagguggg cuc

23

<210> 1757

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1757

aaautgtggc ugaggcacgc ccu

23

<210> 1758

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1758
atgggucaca utuguggcug agg 23

<210> 1759
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1759
aaugtgtucc agaucggacc ucc 23

<210> 1760
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1760
atauguguuc cagaucggac cuc 23

<210> 1761
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1761

aauatgtguu ccagaucgga ccu

23

<210> 1762

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1762

acaatatgug utccagaucg gac

23

<210> 1763

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1763

accaauaugu gtuccagauc gga

23

<210> 1764

<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1764
atccaataug uguuccagau cgg 23

<210> 1765
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1765
atuccaauau gtguuccaga ucg 23

<210> 1766
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic

oligonucleotide"

<400> 1766

aaautccaau atguguucca gau

23

<210> 1767

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1767

acaatuccaa uauguguucc aga

23

<210> 1768

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1768

accaautcca atauguguuc cag

23

<210> 1769

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1769
atauaaggcc utaccacccc uau 23

<210> 1770
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1770
atuataaggc ctuaccacc cua 23

<210> 1771
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1771
acautataag gccuaccca ccc 23

<210> 1772
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1772
aacatuauaa ggccuuaccc acc 23

<210> 1773
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1773
atacautaua aggccuuacc cac 23

<210> 1774
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1774
atuacatuau aaggccuuac cca

23

<210> 1775
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1775
atuuacauua uaaggccuua ccc

23

<210> 1776
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1776
acuutacauu ataaggccuu acc

23

<210> 1777
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1777
atcutuacau uauaaggccu uac

23

<210> 1778
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1778
acuctutaca utauaaggcc uua

23

<210> 1779
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1779

agcucutuac atuauaaggc cuu

23

<210> 1780

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1780

atgctctuua cauuaaagg ccu

23

<210> 1781

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1781

ataaagcccu utacauuaua ugc

23

<210> 1782

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1782
acuaaaagccc utuacauuau aug

23

<210> 1783
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1783
atcuaaaagcc ctuuacauua uau

23

<210> 1784
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1784
acuctaaagc ccuuuacauu aua

23

<210> 1785
<211> 23

<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1785
aauggcagau utuaauccag guc 23

<210> 1786
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1786
aaauggcaga utuuaucca ggu 23

<210> 1787
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1787
aaaatggcag atuuuaaucc agg 23

<210> 1788
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1788
ataaauggca gauuuuaauc cag 23

<210> 1789
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1789
atuaaatggc agauuuuaau cca 23

<210> 1790
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1790

agcuaatuaa atggcagauu uua

23

<210> 1791

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1791

aagctaauua aauggcagau uuu

23

<210> 1792

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1792

agcagctaau uaaauggcag auu

23

<210> 1793
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1793
atgcagcuaa utaaauggca gau 23

<210> 1794
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1794
aaugcagcua atuaaauggc aga 23

<210> 1795
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1795

agaaautgag gcagauugcg uua

23

<210> 1796

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1796

aagaaatuga ggcagauugc guu

23

<210> 1797

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1797

atgaagaaau ugaggcagau ugc

23

<210> 1798

<211> 23

<212> DNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1798
aaugaagaaa utgaggcaga uug

23

<210> 1799
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1799
agaugaagaa atugaggcag auu

23

<210> 1800
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1800
aagatgaaga aaugaggca gau

23

<210> 1801
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1801
aacagatgaa gaaauugagg cag

23

<210> 1802
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1802
atgacagaug aagaaauuga ggc

23

<210> 1803
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1803
atugacagau gaagaaauug agg

23

<210> 1804
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1804
atuugacaga ugaagaaau gag

23

<210> 1805
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1805
aaautgacag atgaagaaau uga

23

<210> 1806
<211> 23
<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1806

acautugaca gaugaagaaa uug

23

<210> 1807

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1807

accatutgac agaugaagaa auu

23

<210> 1808

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1808
atccautuga cagaugaaga aaau
23

<210> 1809
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1809
atuctgtagc caagcagaau ugg
23

<210> 1810
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1810
aaautctgua gccaagcaga auu
23

<210> 1811
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1811

ataatucugu agccaagcag aa

23

<210> 1812

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1812

aaaaautcug uagccaagca gaa

23

<210> 1813

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1813

aaaatucu gtagccaagc aga

23

<210> 1814

<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1814
acaataauuc uguagccaag cag 23

<210> 1815
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1815
agaututau ctcacaauaa uuc 23

<210> 1816
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1816
uucuucaucu gucaaaugga u 21

<210> 1817
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1817
gacuuugaga agguugaucu u 21

<210> 1818
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1818
gguugaucug acccaguuca u 21

<210> 1819
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1819
guagccucau ggaagagaag u 21

<210> 1820
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1820

agccucaugg aagagaagca u

21

<210> 1821

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1821

ucauggaaga gaagcagauc u

21

<210> 1822

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1822

aagagaagca gauccugugc u

21

<210> 1823

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1823

gagaagcaga uccugugcgu u

21

<210> 1824

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1824
aagcagaucc ugugcguggg u 21

<210> 1825
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1825
aagcagaucc ugugcguggg u 21

<210> 1826
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1826
agcagauccu gugcgugggg u 21

<210> 1827
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1827
agcagauccu gugcgugggg u 21

<210> 1828
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1828
gcagauccug ugcguggggc u 21

<210> 1829
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1829
cagauccugu gcguggggcu u 21

<210> 1830
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1830
agauccugug cguggggcua u 21

<210> 1831
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1831

cagacuuuga gaagguugau a

21

<210> 1832

<211> 19

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1832

gacuuugaga agguugauu

19

<210> 1833

<211> 19

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1833

uuugagaagg ugaucugu

19

<210> 1834

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1834

acuuuaagaa gguugaucug u 21

<210> 1835

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1835

uugagaaggu ugaucugacc u 21

<210> 1836

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1836

gagaagguug aucugaccca u 21

<210> 1837

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1837

gaagguugau cugacccagu u 21

<210> 1838

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1838
 agguugaucu gaccaguuc u 21

 <210> 1839
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1839
 ugaucugacc caguucaagu a 21

 <210> 1840
 <211> 19
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1840
 aucugacca guucaaguu 19

 <210> 1841
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1841
 gaccaguuc aaguggaucc u 21

<210> 1842
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1842
aguggaucca cauugagggc u 21

<210> 1843
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1843
uggauccaca uugagggccg u 21

<210> 1844
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1844
gauccacauu gagggccgga u 21

<210> 1845
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1845

auccacauug agggccggaa u

21

<210> 1846

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1846

gagacguggu guuugucagc u

21

<210> 1847

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1847

uugucagcaa agaugggcc u

21

<210> 1848

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1848

gucagcaaag auguggccaa u

21

<210> 1849

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1849
ucagcaaaga uguggccaag u 21

<210> 1850
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1850
cagcaaagau guggccaagc u 21

<210> 1851
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1851
agcaaagau uggccaagca u 21

<210> 1852
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1852
gagacaccuu caaugccucc u 21

<210> 1853
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1853
agacaccuuc aaugccuccg u 21

<210> 1854
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1854
gacaccuuca augccuccgu u 21

<210> 1855
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1855
gccuccguca ucuucagccu u 21

<210> 1856
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1856

ggagcgugca ggaagcacug u

21

<210> 1857

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1857

gagcgugcag gaagcacuga u

21

<210> 1858

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1858

gcgugcagga agcacugaga u

21

<210> 1859

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1859
aagatcaacc utcucaaagu cug

23

<210> 1860
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1860
atgaactggg ucagaucaac cuu

23

<210> 1861
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1861
acaatgtgga uccacuugaa cug

23

<210> 1862
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1862
acuucucuuc caugaggcua cuc

23

<210> 1863
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1863
augctucucu uccaugaggc uac

23

<210> 1864
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1864
aauctgcuuc ucuuccauga ggc

23

<210> 1865
<211> 23

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1865
agaucugcuu cucuuccaug agg 23

<210> 1866
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1866
aaggauugc uucucuucca uga 23

<210> 1867
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1867
agcacaggau cugcuucucu ucc 23

<210> 1868
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1868
aacgcacagg aucugcuucu cuu 23

<210> 1869
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1869
acccacgcac aggaucugcu ucu 23

<210> 1870
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1870
acccacgcac aggaucugcu ucu 23

<210> 1871
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1871
accccacgca caggaucugc uuc 23

<210> 1872
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1872
accccacgca caggaucugc uuc 23

<210> 1873
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1873
agccccacgc acaggaucug cuu 23

<210> 1874
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1874
aagccccacg cacaggaucu gcu 23

<210> 1875
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1875
auagccccac gcacaggauc ugc 23

<210> 1876
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1876
aaucaaccuu ctcaaagucu gug 23

<210> 1877
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1877
aaucaaccuu ctcaaagucu gcu 23

<210> 1878
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1878
uaucaaccuu ctcaaagucu gcu

23

<210> 1879
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1879
aaaucaaccuu ctcaaagucu g

21

<210> 1880
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1880
aagatcaacc utcucaaagu cug

23

<210> 1881
<211> 21
<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1881

acagaucaac ctucucaaaag u

21

<210> 1882

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1882

acagaucaac ctucuuaaaag ucu

23

<210> 1883

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1883

aggucagauc aaccuucuca aag

23

<210> 1884

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1884
augggucaga ucaaccuucu caa 23

<210> 1885
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1885
aacuggguca gaucaaccuu cuc 23

<210> 1886
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1886
agaacugggu cagaucaacc uuc 23

<210> 1887
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1887
aacutgaacu gggucagauc agc

23

<210> 1888
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1888
aacutgaacu gggucagauc acu

23

<210> 1889
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1889
uacutgaacu gggucagauc acu

23

<210> 1890
<211> 21

<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1890
aacutgaacu gggucagauc g 21

<210> 1891
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1891
aggatccacu ugaacugggu cag 23

<210> 1892
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1892
auggauccac uugaacuggg uca 23

<210> 1893
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1893
aaugtggau cacuugaacu ggg 23

<210> 1894
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1894
aaaugggau ccacuugaac ugg 23

<210> 1895
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1895
agcccucaau guggauccac uug 23

<210> 1896
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1896

acggcccua auguggaucc acu

23

<210> 1897

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1897

auccggcccu caauguggau cca

23

<210> 1898

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1898

auuccggccc ucaaugugga ucc

23

<210> 1899

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1899

agcugacaaa caccacgucu ccg 23

<210> 1900
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1900
acuutgcuga caaacaccac guc 23

<210> 1901
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1901
aggccacauc uuugcugaca aac 23

<210> 1902
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1902
auuggccaca ucuuugcuga caa 23

<210> 1903
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1903
acuuggccac aucuuugcug aca

23

<210> 1904
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1904
agcutggcca caucuuugcu gac

23

<210> 1905
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1905
augctuggcc acaucuuugc uga

23

<210> 1906
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1906
aggaggcauu gaaggugucu cca

23

<210> 1907
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1907
acggaggcau ugaagguguc ucc

23

<210> 1908
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1908
aacggaggca uugaaggugu cuc

23

<210> 1909
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1909
agaugacgga ggcauugaag gug

23

<210> 1910
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1910
aaggcugaag augacggagg cau

23

<210> 1911
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1911
aagaggcuga agaugacgga ggc

23

<210> 1912
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1912
acagtgcuuc cugcacgcuc cuc 23

<210> 1913
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1913
aucagugcuu ccugcacgcu ccu 23

<210> 1914
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1914
aucucagugc uuccugcacg cuc 23

<210> 1915
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1915
aaaucucagu gcuuccugca cgc 23

<210> 1916
<211> 23
<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1916

atcutuggca gguucacugg gug

23

<210> 1917

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1917

atuctutggc agguucacug ggu

23

<210> 1918

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1918

aaugagucu gcacaacgca ggg

23

<210> 1919

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1919
aaauagaguc ugcacaacgc agg 23

<210> 1920
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1920
agaatagagu ctgcacaacg cag 23

<210> 1921
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1921
aggaaauagag ucugcacaac gca 23

<210> 1922
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1922
agggaataga gtcugcaciaa cgc

23

<210> 1923
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1923
atgggaauag agucugcaca acg

23

<210> 1924
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1924

agcutctgag ctgugggaau aga

23

<210> 1925

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1925

aagctucuga gcugugggaa uag

23

<210> 1926

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1926

aaaatcacag gcuggugggc agg

23

<210> 1927

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1927
acaaaucaca ggcugguggg cag 23

<210> 1928
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1928
aaauccaagg ugggcuccaa ggg 23

<210> 1929
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1929
aaautccaag gtgggcucca agg 23

<210> 1930
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1930

ataatuccaa ggugggcucc aag

23

<210> 1931

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1931

atuaautcca aggugggcuc caa

23

<210> 1932

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1932

acuaaatucc aaggugggcu cca

23

<210> 1933

<211> 23

<212> DNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1933
accutaauc caaggugggc ucc

23

<210> 1934
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1934
accctuaauu ccaagguggg cuc

23

<210> 1935
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1935
aaautgtggc ugaggcacgc ccu

23

<210> 1936
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1936
atgggucaca utuguggcug agg 23

<210> 1937
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1937
aaugtgtucc agaucggacc ucc 23

<210> 1938
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1938
atauguguuc cagaucggac cuc 23

<210> 1939
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1939
aauatgtguu ccagaucgga ccu 23

<210> 1940
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1940
aaaauaugugu uccagaucgg acc 23

<210> 1941
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1941

acaatatgug utccagaucg gac

23

<210> 1942

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1942

accaauaugu gtuccagauc gga

23

<210> 1943

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1943

atccaataug uguuccagau cgg

23

<210> 1944

<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1944
atuccaauau gtguuccaga ucg 23

<210> 1945
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1945
aaauccaaua uguguuccag auc 23

<210> 1946
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1946
aaautccaau atguguucca gau 23

<210> 1947
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1947
acaatuccaa uauguguucc aga 23

<210> 1948
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1948
accaautcca atauguguuc cag 23

<210> 1949
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1949

aaauaaggccu uacccacccu aua

23

<210> 1950

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1950

atauaaggcc utacccaccc uau

23

<210> 1951

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1951

atuataaggc ctuaccacc cua

23

<210> 1952

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1952
aauuauaagg ccuuaccac ccu 23

<210> 1953
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1953
acautataag gccuuacca ccc 23

<210> 1954
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1954
aacatuauaa ggccuuaccc acc 23

<210> 1955
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1955

atacautaua aggccuuacc cac

23

<210> 1956

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1956

atuacatuau aaggccuuac cca

23

<210> 1957

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1957

atuuacauua uaaggccuua ccc

23

<210> 1958
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1958
acuutacauu ataaggccuu acc 23

<210> 1959
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1959
atcutuacau uauaaggccu uac 23

<210> 1960
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1960

acuctutaca utauaaggcc uua

23

<210> 1961

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1961

agcucutuac atuauaaggc cuu

23

<210> 1962

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1962

atgctctuua cauuauaagg ccu

23

<210> 1963

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1963
aaagccuuu acauuauaug cuc

23

<210> 1964
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1964
aaaagccuu uacauuauau gcu

23

<210> 1965
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1965
ataaagcccu utacauuaua ugc

23

<210> 1966
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1966

acuaaaagccc utuacauuau aug

23

<210> 1967

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1967

atcuaaagcc ctuuacauua uau

23

<210> 1968

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1968

acuctaaagc ccuuuacauu aua

23

<210> 1969

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1969
aacucuaaag cccuuuacau uau

23

<210> 1970
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1970
aauggcagau utuaauccag guc

23

<210> 1971
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1971
aaauggcaga utuuaucca ggu

23

<210> 1972
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1972
aaaatggcag atuuuaaucc agg 23

<210> 1973
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1973
ataaauggca gauuuuaauc cag 23

<210> 1974
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1974
atuaaatggc agauuuuaau cca

23

<210> 1975
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1975
aauuuaaugg cagauuuuaa ucc

23

<210> 1976
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1976
agcuaatuaa atggcagauu uua

23

<210> 1977
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1977
aagctaauua aauggcagau uuu

23

<210> 1978
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1978
acagcuaauu aaauggcaga uuu

23

<210> 1979
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1979
agcagctaa uaaauggcag auu

23

<210> 1980
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1980

atgcagcuaa utaaauggca gau

23

<210> 1981

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1981

aaugcagcua atuaaauggc aga

23

<210> 1982

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1982

agaaautgag gcagauugcg uua

23

<210> 1983
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1983
aagaaatuga ggcagauugc guu 23

<210> 1984
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1984
aaagaaaauug aggcagauug cgu 23

<210> 1985
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1985
agaagaaaau gaggcagauu gcg 23

<210> 1986
<211> 23
<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1986

atgaagaaau ugaggcagau ugc

23

<210> 1987

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1987

aaugaagaaa utgaggcaga uug

23

<210> 1988

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1988
agaugaagaa atugaggcag auu 23

<210> 1989
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1989
aagatgaaga aaugaggca gau 23

<210> 1990
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1990
acagaugaag aaauaggc aga 23

<210> 1991
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic

oligonucleotide"

<400> 1991
aacagatgaa gaaauugagg cag 23

<210> 1992
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1992
agacagauga agaaauugag gca 23

<210> 1993
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1993
atgacagaug aagaaauuga ggc 23

<210> 1994
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1994
atugacagau gaagaaauug agg

23

<210> 1995
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1995
atuugacaga ugaagaaauu gag

23

<210> 1996
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1996
aaautgacag atgaagaaau uga

23

<210> 1997
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1997
acautugaca gaugaagaaa uug

23

<210> 1998
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1998
accatutgac agaugaagaa auu

23

<210> 1999
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1999

atccautuga cagaugaaga aa

23

<210> 2000

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 2000

atuctgtagc caagcagaau ugg

23

<210> 2001

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2001

aaucuguag ccaagcagaa uug

23

<210> 2002

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 2002
aaautctgua gccaaagcaga auu 23

<210> 2003
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 2003
ataatucugu agccaagcag aaau 23

<210> 2004
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 2004
aauaautcug uagccaagca gaa 23

<210> 2005
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 2005

aaauaatucu gtagccaagc aga

23

<210> 2006

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 2006

acaataauuc uguagccaag cag

23

<210> 2007

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 2007

agaututauc ctcaaaauaa uuc

23

<210> 2008
<211> 23
<212> RNA
<213> Homo sapiens

<400> 2008
gaguagccuc auggaagaga agc 23

<210> 2009
<211> 23
<212> RNA
<213> Homo sapiens

<400> 2009
guagccucau ggaagagaag cag 23

<210> 2010
<211> 23
<212> RNA
<213> Homo sapiens

<400> 2010
ccucauggaa gagaagcaga ucc 23

<210> 2011
<211> 23
<212> RNA
<213> Homo sapiens

<400> 2011
ggaagagaag cagauccugu gcg 23

<210> 2012
<211> 23
<212> RNA
<213> Homo sapiens

<400> 2012
aagagaagca gauccugugc gug 23

<210> 2013
<211> 23
<212> RNA
<213> Homo sapiens

<400> 2013
agaagcagau ccugugcgug ggg 23

<210> 2014
<211> 23
<212> RNA
<213> Homo sapiens

<400> 2014
gaagcagauc cugugcgugg ggc 23

<210> 2015
<211> 23
<212> RNA
<213> Homo sapiens

<400> 2015
aagcagauc ugugcguggg gcu 23

<210> 2016
<211> 23
<212> RNA
<213> Homo sapiens

<400> 2016
agcagauc cu gugcgugggg cua 23

<210> 2017
<211> 23
<212> RNA
<213> Homo sapiens

<400> 2017
gcagaucug ugcguggggc uag 23

<210> 2018
<211> 21
<212> RNA
<213> Homo sapiens

<400> 2018
cagacuuuga gaagguugau c 21

<210> 2019

<211> 21
<212> RNA
<213> Homo sapiens

<400> 2019
acuuugagaa gguugaucug a 21

<210> 2020
<211> 23
<212> RNA
<213> Homo sapiens

<400> 2020
cuuugagaag guugaucuga ccc 23

<210> 2021
<211> 23
<212> RNA
<213> Homo sapiens

<400> 2021
uugagaaggu ugaucugacc cag 23

<210> 2022
<211> 23
<212> RNA
<213> Homo sapiens

<400> 2022
gagaagguug aucugaccca guu 23

<210> 2023
<211> 23
<212> RNA
<213> Homo sapiens

<400> 2023
gaagguugau cugacccagu uca 23

<210> 2024
<211> 21
<212> RNA
<213> Homo sapiens

<400> 2024

ugaucugacc caguucaagu g 21

<210> 2025

<211> 23

<212> RNA

<213> Homo sapiens

<400> 2025

cugacccagu ucaaguggau cca 23

<210> 2026

<211> 23

<212> RNA

<213> Homo sapiens

<400> 2026

caaguggauc cacauugagg gcc 23

<210> 2027

<211> 23

<212> RNA

<213> Homo sapiens

<400> 2027

uggauccaca uugagggccg gaa 23

<210> 2028

<211> 23

<212> RNA

<213> Homo sapiens

<400> 2028

ggauccacau ugagggccgg aac 23

<210> 2029

<211> 23

<212> RNA

<213> Homo sapiens

<400> 2029

cggagacgug guguuuguca gca 23

<210> 2030

<211> 23

<212> RNA	
<213> Homo sapiens	
<400> 2030	
guuugucagc aaagaugugg cca	23
<210> 2031	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 2031	
uugucagcaa agaugggcc aag	23
<210> 2032	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 2032	
ugucagcaaa gaugggccca agc	23
<210> 2033	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 2033	
gucagcaaag auguggccaa gca	23
<210> 2034	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 2034	
ucagcaaaga uguggccaag cac	23
<210> 2035	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 2035	
uggagacacc uucaaugccu ccg	23

<210> 2036
<211> 23
<212> RNA
<213> Homo sapiens

<400> 2036
ggagacaccu ucaaugccuc cgu 23

<210> 2037
<211> 23
<212> RNA
<213> Homo sapiens

<400> 2037
gagacaccuu caaugccucc guc 23

<210> 2038
<211> 23
<212> RNA
<213> Homo sapiens

<400> 2038
augccuccgu caucuucagc cuc 23

<210> 2039
<211> 23
<212> RNA
<213> Homo sapiens

<400> 2039
gaggagcgug caggaagcac uga 23

<210> 2040
<211> 23
<212> RNA
<213> Homo sapiens

<400> 2040
aggagcgugc aggaagcacu gag 23

<210> 2041
<211> 23
<212> RNA

<213> Homo sapiens

<400> 2041

gagcgugcag gaagcacuga gau

23